FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Wolf, EJ Cooper, MSRA DiGiovine, CP Boninger, ML Guo, SF AF Wolf, EJ Cooper, MSRA DiGiovine, CP Boninger, ML Guo, SF TI Using the absorbed power method to evaluate effectiveness of vibration absorption of selected seat cushions during manual wheelchair propulsion SO MEDICAL ENGINEERING & PHYSICS LA English DT Article DE wheelchair; vibration; seat cushions ID WHOLE-BODY VIBRATION; DISCOMFORT; SUSPENSION; PREDICTION; EXPOSURE AB Although wheelchair users are frequently subjected to oscillatory and shock vibrations, little research has been conducted to assess the whole-body vibration exposure of wheelchair users. The purpose of this study was to determine if selected wheelchair cushions alter potentially harmful whole-body vibrations transferred to wheelchair users. Thirty-two participants, who use wheelchairs as their primary mode of mobility, contributed to this study. Four of the most commonly prescribed wheelchair cushions were selected. Participants were asked to propel their wheelchair over a simulated activities of daily living (ADL) course while acceleration and force data were recorded. A repeated measures ANOVA showed no significant differences between the different cushions for the total averaged absorbed power (p = 0.190), the 50 mm curb drop (p = 0.234), or the rumble strip (p = 0.143). A repeated measure ANOVA for the peak curb drop absorbed power revealed a significant difference in the cushions = 0.043). The cushions that were most effective in this testing appear to be the Invacare Pindot and the Varilite Solo. Not only did those cushions appear to have the lowest values much of the time but also they did not display the highest values. When comparing results from a similar study, absorbed power appears to be as effective in determining vibration effects in the time domain as the methods in the ISO 2631 Standard. (C) 2004 Published by Elsevier Ltd on behalf of IPEM. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151R1, Vet Affairs Rehabil Res & Dev Ctr, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol & Bioengn, Pittsburgh, PA USA. Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. Assist Technol Unit, Chicago, IL USA. Univ Illinois, Dept Disabil & Human Dev, Chicago, IL USA. RP Cooper, MSRA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151R1, Vet Affairs Rehabil Res & Dev Ctr, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu RI DiGiovine, Carmen/E-2982-2011 OI Wolf, Erik/0000-0002-6353-7978; Boninger, Michael/0000-0001-6966-919X NR 23 TC 4 Z9 4 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1350-4533 J9 MED ENG PHYS JI Med. Eng. Phys. PD NOV PY 2004 VL 26 IS 9 BP 799 EP 806 DI 10.1016/j.medengphy.2004.06.005 PG 8 WC Engineering, Biomedical SC Engineering GA 879WJ UT WOS:000225749600012 PM 15564117 ER PT J AU El-Shewy, HM Kelly, FL Barki-Harrington, L Luttrell, LM AF El-Shewy, HM Kelly, FL Barki-Harrington, L Luttrell, LM TI Ectodomain shedding-dependent transactivation of epidermal growth factor receptors in response to insulin-like growth factor type I SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID PROTEIN-COUPLED RECEPTORS; EGF RECEPTOR; TYROSINE KINASE; SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORT; ACTIVATION; CELLS; PHOSPHORYLATION; ADHESION; PATHWAYS AB Diverse extracellular stimuli activate the ERK1/2 MAPK cascade by transactivating epidermal growth factor (EGF) receptors. Here, we have examined the role of EGF receptors in IGF-I-stimulated ERK1/2 activation in several cultured cell lines. In human embryonic kidney 293 cells, IGF-I triggered proteolysis of heparin binding (HB)-EGF, increased tyrosine autophosphorylation of EGF receptors, stimulated EGF receptor inhibitor (AG1478)-sensitive ERK1/2 phosphorylation, and promoted EGF receptor endocytosis. In a mixed culture system that employed IGF-I receptor null murine embryo fibroblasts (MEFs) (R- cells) to detect paracrine signals produced by MEFs expressing the human IGF-I receptor (R+ cells), stimulation of R+ cells provoked rapid activation of green fluorescent protein-tagged ERK2 in cocultured R- cells. The R- cell response was abolished by either the broad-spectrum matrix metalloprotease inhibitor batimastat or by AG1478, indicating that it resulted from the proteolytic generation of an EGF receptor ligand from adjacent R+ cells. These data suggest that the paracrine production of EGF receptor ligands leading to EGF receptor transactivation is a general property of IGF-I receptor signaling. In contrast, the contribution of transactivated EGF receptors to IGF-I-stimulated downstream events, such as ERK1/2 activation, varies in a cell type-dependent manner. C1 Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,816 Clin Sci Bldg,POB 250624, Charleston, SC 29425 USA. EM luttrell@musc.edu FU NIDDK NIH HHS [DK58283] NR 53 TC 38 Z9 39 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD NOV PY 2004 VL 18 IS 11 BP 2727 EP 2739 DI 10.1210/me.2004-0174 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 865VP UT WOS:000224732600010 PM 15272055 ER PT J AU McMillan, PJ Peskind, E Raskind, MA Leverenz, JB AF McMillan, PJ Peskind, E Raskind, MA Leverenz, JB TI Increased galanin receptor occupancy in Alzheimer's disease SO NEUROBIOLOGY OF AGING LA English DT Article DE Alzheimer's disease; galanin; GTP; slice-binding assay; receptor occupancy ID VITRO AUTORADIOGRAPHIC ANALYSIS; RAT VENTRAL HIPPOCAMPUS; CENTRAL-NERVOUS-SYSTEM; HUMAN BASAL FOREBRAIN; BINDING-SITES; MESSENGER-RNA; NUCLEUS BASALIS; NEUROENDOCRINE PEPTIDE; ACETYLCHOLINE-RELEASE; PARKINSONS-DISEASE AB Increased galanin (GAL) may be associated with the cognitive deficits characteristic of Alzheimer's disease (AD). However, both increased and decreased GAL receptor density has been reported in AD brain. Previous studies indicate pre-treatment with guanine nucleotides displaces endogenous GAL from GAL receptors (GALR), providing an indirect measurement of GALR occupancy. In addition, pre-treatment with guanine nucleotides may provide a more accurate measurement of GALR density since it would avoid the masking of GALRs by residual binding of endogenous GAL. Thus, in the present study, we examined the influence of pre-treatment with guanine nucleotides on 125I-GAL binding in multiple regions of normal and AD brain. Our results indicate that GTP pre-treatment enhances GAL binding in specific regions in normal and AD brain. In addition, our results suggest an increase in the number of GALRs occupied by endogenous GAL in the deep layers of the frontal cortex and the lateral hypothalamus of AD subjects compared to normal subjects. The regional differences in GALR density and receptor occupancy between normal and AD subjects may play a role in the cognitive disturbances associated with the disease. (C) 2004 Elsevier Inc. All rights reserved. C1 Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci & Neurol, Seattle, WA 98195 USA. RP Leverenz, JB (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. EM leverenz@u.washington.edu NR 45 TC 16 Z9 16 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD NOV-DEC PY 2004 VL 25 IS 10 BP 1309 EP 1314 DI 10.1016/j.neurobiolaging.2004.01.004 PG 6 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 864UY UT WOS:000224659600007 PM 15465628 ER PT J AU Studer, RK AF Studer, RK TI Nitric oxide decreases IGF-1 receptor function in vitro; glutathione depletion enhances this effect in vivo SO OSTEOARTHRITIS AND CARTILAGE LA English DT Article DE insulin-like growth factor receptor; nitric oxide; IGF-1 resistance; arthritis ID GROWTH-FACTOR RECEPTOR; ARTICULAR CHONDROCYTES; INHIBITION; CARTILAGE; OSTEOARTHRITIS; NITROSYLATION; INFLAMMATION; EXPRESSION; APOPTOSIS; SYNTHASE AB Insulin-like growth factor-1 (IGF) helps maintain healthy articular cartilage; however, arthritic cartilage becomes less responsive to the anabolic actions of IGF. We previously showed that high concentrations of nitric oxide (NO) decrease IGF receptor tyrosine phosphorylation and response to IGF in intact chondrocytes. The current studies evaluate direct effects of NO on IGF receptor kinase (IGF-RK) in vitro. NO from Snitroso-N-acetyl-D,L-penicillamine (SNAP) or 1-hydroxy-2-oxo-3-(N-3-methyl-aminopropyl)-3-methyl-1-triazene (NOC-7) inhibits IGF-RK auto-and substrate phosphorylation in a dose and time dependent manner. There is a linear correlation between inhibition of auto- and substrate phosphorylation (r(2) = 0.98). Increasing either dithiothreitol or reduced glutathione (GSH) content of the phosphorylation buffer to protect thiol groups blocks NO inhibition of IGF-RK substrate phosphorylation. Increased S-nitrosylation of cysteines in IGF-RK after exposure to SNAP suggests that NO may react with sulfhydryl groups, form S-nitrosothiols, which may result in functional modifications. NO blockade of IGF-1 stimulated proteoglycan synthesis in intact cells is enhanced when chondrocyte glutathione is depleted. The in vitro system shows that there can be direct effects of NO on IGF-RK that modify receptor function; the intact cell studies suggest that the mechanisms identified in vitro may be important in intact chondrocyte insensitivity to IGF-1 in cells exposed to NO. (C) 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved. C1 Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, VA Med Ctr,Ferguson Lab,VA Pittsburgh Healthcare, Pittsburgh, PA 15240 USA. RP Studer, RK (reprint author), Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, VA Med Ctr,Ferguson Lab,VA Pittsburgh Healthcare, 151-U,Univ Dr C, Pittsburgh, PA 15240 USA. EM rstuder@pitt.edu NR 30 TC 14 Z9 15 U1 0 U2 0 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD NOV PY 2004 VL 12 IS 11 BP 863 EP 869 DI 10.1016/j.joca.2004.07.005 PG 7 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 871FX UT WOS:000225116300002 PM 15501401 ER PT J AU Rosenfeld, B Roth, AJ Gandhi, S Penson, D AF Rosenfeld, B Roth, AJ Gandhi, S Penson, D TI Differences in health-related quality of life of prostate cancer patients based on stage of cancer SO PSYCHO-ONCOLOGY LA English DT Article ID RADICAL PROSTATECTOMY; FUNCTIONAL ASSESSMENT; HOSPITAL ANXIETY; DEPRESSION SCALE; MEN; VALIDATION; RADIATION; OUTCOMES; BOTHER AB Background: Understanding medical factors that influence quality of life for men with prostate cancer is an important goal. This study analysed the relationship between cancer stage and quality of life, including measures of physical and psychological well-being. Method: A secondary analysis of data from 341 ambulatory men with prostate cancer. The Functional Assessment of Cancer Therapy (FACT)-Prostate version, Urinary Function Subscale of UCLA Prostate Cancer Index, and Hospital Anxiety and Depression Scale (HADS), were administered during their clinic visit. Stage of disease and treatment history was obtained from clinic records. Patients were categorized into localised (T1-T2, N0, M0, n = 186), locally advanced (T3-T4, N0, M0, n = 92), and metastatic (T3-T4, N1-3 or Ma-c, n = 63) disease. Differences in quality of life based on stage were examined using multivariate analyses controlling for age, treatment type, time since diagnosis, co-morbidities, and urinary function. Results: Stage of prostate cancer was significantly associated with most FACT scales (Physical, Functioning, Social) and summary scores (Treatment Outcomes Index, FACT total score). However, no significant associations were observed between stage of cancer and psychological symptoms of depression or anxiety. This association remained significant even after controlling for the influence of illness co-morbidity, urinary functioning, time since diagnosis, age, and type of treatment. Conclusions: Higher cancer stage appears to be associated with poorer quality of life in prostate cancer and this association does not appear to be simply a function of the symptoms and disability that accompany advanced disease. These results have implications for understanding the impact of progression of prostate cancer on patients' health-related quality of life. Copyright (C) 2004 John Wiley Sons, Ltd. C1 Fordham Univ, Dept Psychol, Bronx, NY 10458 USA. Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, New York, NY USA. AstraZeneca, Hlth Econ & Outcomes Res, Wilmington, DE USA. VA Puget Sound HCS, Urol Sect, Seattle, WA USA. Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. RP Rosenfeld, B (reprint author), Fordham Univ, Dept Psychol, 441 E Fordham Rd, Bronx, NY 10458 USA. EM Rosenfeld@fordham.edu NR 24 TC 42 Z9 42 U1 0 U2 5 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9249 J9 PSYCHO-ONCOL JI Psycho-Oncol. PD NOV PY 2004 VL 13 IS 11 BP 800 EP 807 DI 10.1002/pon.797 PG 8 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 874JZ UT WOS:000225348000005 PM 15386638 ER PT J AU Hughes, RB Robinson-Whelen, S Taylor, HB Swedlund, N Nosek, MA AF Hughes, RB Robinson-Whelen, S Taylor, HB Swedlund, N Nosek, MA TI Enhancing self-esteem in women with physical disabilities SO REHABILITATION PSYCHOLOGY LA English DT Article ID DEPRESSIVE SYMPTOMS; SOCIAL CONNECTEDNESS; RHEUMATOID-ARTHRITIS; MULTIPLE-SCLEROSIS; CHRONIC ILLNESS; HEALTH-STATUS; OLDER ADULTS; SHORT-FORM; MEDIATOR; SUPPORT AB Objective: To determine the efficacy of a 6-week self-esteem group intervention for women with disabilities. Design: Random assignment to either center for independent living (CIL) services or CIL. services plus a self-esteem intervention, with pre- and-posttest. Participants: Women with physical disabilities (N 102, 51 per group). Setting: Five CILs-in 5 different states. Outcome measures: Self-esteem, self-efficacy, social connectedness, and depression. Results: Participants in the intervention group showed significantly greater improvement on self-esteem (effect sizes [ES] =.88 and.81),. self-efficacy (ES.60), and depression (ES =.59). Groups did not differ significantly on social, connectedness (ES =.32). Conclusion: Women with physical disabilities may benefit from a self-esteem group intervention., C1 Baylor Coll Med, Ctr Res Women Disabil, Dept Phys Med & Rehabil, Houston, TX 77046 USA. Houston Vet Affairs Med Ctr, Rehabil Res & Dev Serv, Houston, TX USA. RP Hughes, RB (reprint author), Baylor Coll Med, Ctr Res Women Disabil, Dept Phys Med & Rehabil, 3440 Richmond Ave,Suite B, Houston, TX 77046 USA. EM rhughes@bcm.tmc.edu NR 51 TC 14 Z9 16 U1 1 U2 3 PU EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0090-5550 J9 REHABIL PSYCHOL JI Rehabil. Psychol. PD NOV PY 2004 VL 49 IS 4 BP 295 EP 302 DI 10.1037/0090-5550.49.4.295 PG 8 WC Psychology, Clinical; Rehabilitation SC Psychology; Rehabilitation GA 874OR UT WOS:000225360200004 ER PT J AU Mohr, PE Cheng, CM Claxton, K Conley, RR Feldman, JJ Hargreaves, WA Lehman, AF Lenert, LA Mahmoud, R Marder, SR Neumann, PJ AF Mohr, PE Cheng, CM Claxton, K Conley, RR Feldman, JJ Hargreaves, WA Lehman, AF Lenert, LA Mahmoud, R Marder, SR Neumann, PJ TI The heterogeneity of schizophrenia in disease states SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; outcome assessment; prognosis; treatment costs ID POSITIVE-NEGATIVE DICHOTOMY; HEALTH STATES; SYMPTOMS; MODEL; RISPERIDONE; PREFERENCES; DEPRESSION; OUTCOMES; SCALE AB Previous presentation: Some of the contents of this paper have been previously presented at the 16th Annual Meeting of the International Society for Technology Assessment in Health Care June 20, 2000 in the Hague, Netherlands and at the 21st Annual Meeting of the Society for Medical Decision Making as a poster on October 3, 1999 in Reno, NV. Background: Studies of schizophrenia treatment often oversimplify the array of health outcomes among patients. Our objective was to derive a set of disease states for schizophrenia using the Positive and Negative Symptom Assessment Scale (PANSS) that captured the heterogeneity of symptom responses. Methods: Using data from a 1-year clinical trial that collected PANSS scores and costs on schizophrenic patients (N = 663), we conducted a k-means cluster analyses on PANSS scores for items in five factor domains. Results of the cluster analysis were compared with a conceptual framework of disease states developed by an expert panel. Final disease states were defined by combining our conceptual framework with the empirical results. We tested its utility by examining the influence of disease state on treatment costs and prognosis. Results: Analyses led to an eight-state framework with varying levels of positive, negative, and cognitive impairment. The extent of hostile/aggressive symptoms and mood disorders correlated with severity of disease states. Direct treatment costs for schizophrenia vary significantly across disease states (F = 27.47, df = 7, p<0.0001), and disease state at baseline was among the most important predictors of treatment outcomes. Conclusion: The disease states we describe offer a useful paradigm for understanding the links between symptom profiles and outcomes. (C) 2003 Elsevier B.V. All rights reserved. C1 Ctr Medicare, ORDI, REG, DBR, Baltimore, MD 21244 USA. PacifiCare, Med Informat, Cypress, CA 90630 USA. Univ York, Dept Econ, York YO10 5DD, N Yorkshire, England. Maryland Psychiat Res Ctr, Baltimore, MD 21228 USA. Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA. Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA. Univ Calif San Diego, Sch Med, Hlth Serv Res & Dev, San Diego, CA 92103 USA. Janssen Pharmaceut Prod LP, Med Dev, Titusville, NJ USA. VA Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Ctr Medicaid Serv, ORDI, REG, DBR, Baltimore, MD 21244 USA. RP Mohr, PE (reprint author), Ctr Medicare, ORDI, REG, DBR, Mail Stop C3-19-07 7500,Secur Blvd, Baltimore, MD 21244 USA. EM pmohr@cms.hhs.gov NR 29 TC 27 Z9 32 U1 1 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD NOV 1 PY 2004 VL 71 IS 1 BP 83 EP 95 DI 10.1016/j.schres.2003.11.008 PG 13 WC Psychiatry SC Psychiatry GA 859BW UT WOS:000224238100010 PM 15374576 ER PT J AU Carrion-Baralt, JR Fuentes-Rivera, Z Schmeidler, J Silverman, JM AF Carrion-Baralt, JR Fuentes-Rivera, Z Schmeidler, J Silverman, JM TI A case-control study of the seasonality effects on schizophrenic births on a tropical island SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; seasonality; etiology; risk factors; Puerto Rico ID BIPOLAR DISORDER AB A substantial body of evidence from dozens of studies in many different countries suggests an excess number of individuals with schizophrenia are born in winter months. The presence of a seasonality effect in regions with year-round warm climate, however, has rarely been examined. The major purpose of this project was to better understand if the seasonality effect on schizophrenic births that has been reported in other, mostly cold regions of the Northern Hemisphere, also can be detected in a warm, tropical climate. We set out to study birth months as risk factors, quantifying the risk for being born with schizophrenia for every month of the winter season in terms of incidence rate ratios (IRRs) in the central region of Puerto Rico. We also analyzed climatic data in order to determine if there was any correlation between the rate of schizophrenic births (n = 7 10) to births in the general population (n = 101,248) and average rainfall and temperature for every month of the year in our period of study (January 1932-December 1967). Our results suggest that the risk of developing schizophrenia is 36.5% higher for people born in February than for people born in the other months of the year (95% C.I. = 6.6-74.8%). We also found correlations between the rate of schizophrenic to control births for any given month, and rainfall 4 months earlier (r = 0.66, p = 0.010), and temperature 5 months earlier (r = 0.64, p = 0.013) that remained significant after correcting for multiple comparisons. (C) 2003 Elsevier B.V. All rights reserved. C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. Mental Hlth Ctr, Cayey, PR 00736 USA. Bronx Vet Affairs Med Ctr, Bronx, NY 10468 USA. RP Silverman, JM (reprint author), Mt Sinai Sch Med, Dept Psychiat, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA. EM jeremy.silverman@mssm.edu NR 14 TC 3 Z9 5 U1 2 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD NOV 1 PY 2004 VL 71 IS 1 BP 145 EP 153 DI 10.1016/j.schres.2003.11.004 PG 9 WC Psychiatry SC Psychiatry GA 859BW UT WOS:000224238100016 PM 15374582 ER PT J AU Weinstein, PR Hong, S Sharp, FR AF Weinstein, PR Hong, S Sharp, FR TI Molecular identification of the ischemic penumbra SO STROKE LA English DT Article; Proceedings Paper CT 24th Princeton Conference on Cerebrovascular Disease CY APR 02-04, 2004 CL Baltimore, MD SP Amer Heart Assoc, Amer Stroke Assoc, Stroke Council, Astra Zeneca Pharmaceut, Centocor Inc, Janssen Ortho McNeil Johnson & Johnson, Mitsubishi Pharma, NINDS, Bristol Myers Squibb, Sanofi Synthelabo DE brain edema; blood flow; energy metabolism; magnetic resonance imaging; protein synthesis; stroke, ischemic ID CEREBRAL-ARTERY OCCLUSION; APPARENT DIFFUSION-COEFFICIENT; HSP70 MESSENGER-RNA; MAGNETIC-RESONANCE SPECTROSCOPY; TRANSIENT FOCAL ISCHEMIA; IN-SITU HYBRIDIZATION; HEAT-SHOCK-PROTEIN; C-FOS; RAT HEAT-SHOCK-PROTEIN-70; BLOOD-FLOW AB Review of results of experimental and clinical studies indicates that the penumbra of physiologically impaired but potentially salvageable tissue surrounding the central core of focal cerebral ischemia that develops shortly after onset of major conducting vessel occlusion is complex and dynamic with severity and duration thresholds for hypoxic stress and injury that are specific to tissue site, cell type, molecular pathway or gene expression investigated and efficiency of collateral or residual flow and reperfusion. Imaging methods that have been utilized in vivo to identify penumbra and predict response to reperfusion and other protective therapies include magnetic resonance spectroscopy, diffusion- and perfusion-MRI as well as positron emission tomography. However, resolution of focal lesions characterized by lactic acidosis or cellular edema does not predict tissue survival, and imaging thresholds for resuscitation after reperfusion have not been determined experimentally. HSP-70 stress protein induction represents an endogenous protective mechanism that occurs in penumbra but not core neurones. A robust protective effect has been demonstrated during focal ischemia in transgenic mice overexpressing HSP-70 perhaps by suppressing early cytochrome c release. Delayed manganese mediated striatal neurodegeneration can be detected with T I MRI after brief episodes of transient focal ischemia. Future studies may define endogenous cytotoxic and cytoprotective molecular penumbras that can be exploited to improve outcome after temporary focal ischemia. C1 Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, Dept Neurol Surg, San Francisco, CA USA. Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA. RP Weinstein, PR (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,M 779, San Francisco, CA 94143 USA. EM weinsteinp@neurosurg.ucsf.edu NR 31 TC 65 Z9 72 U1 1 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD NOV PY 2004 VL 35 IS 11 SU 1 BP 2666 EP 2670 DI 10.1161/01.STR.0000144052.10644.ed PG 5 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 867PP UT WOS:000224854800016 PM 15486332 ER PT J AU Shen, WT Kebebew, E Clark, OH Duh, QY AF Shen, WT Kebebew, E Clark, OH Duh, QY TI Reasons for conversion from laparoscopic to open or hand-assisted adrenalectomy: Review of 261 laparoscopic adrenalectomies from 1993 to 2003 SO WORLD JOURNAL OF SURGERY LA English DT Article; Proceedings Paper CT Annual Meeting of the International-Association-of-Endocrine-Surgeons CY JUN 14-17, 2004 CL Uppsala, SWEDEN SP Int Assoc Endocrine Surg ID OPEN CHOLECYSTECTOMY; SURGERY AB Over the past decade, laparoscopic adrenalectomy has become the operation of choice for resecting adrenal tumors. However, few reported data exist regarding the reasons for conversion from laparoscopic to open or hand-assisted adrenalectomy. We retrospectively reviewed the records of 261 consecutive laparoscopic adrenalectomies performed by one surgeon between 1993 and 2003. Laparoscopic adrenalectomy could not be completed in 8 of the 261 patients (3%); four of the operations were converted to hand-assisted laparoscopic adrenalectomy and four to open adrenalectomy. The reasons for the conversion were as follows: In three patients the tumor was too adherent to surrounding structures to be resected laparoscopically; in three patients the tumor was found to have malignant features during laparoscopy, and the operation was converted to achieve proper resection margins; in two patients the tumors were too large (15 and 1.6 cm, respectively) to be safely removed laparoscopically. The eight resected tumors included three pheochromocytomas, one myelolipoma, one angiomyolipoma, one solitary fibrous tumor, one liposarcoma, and one metastatic hepatocellular carcinoma. There were no cases in which conversion was required emergently for bleeding or other intraoperative catastrophes. All eight of the tumors removed were at least 5 cm in size (range 5-16 cm). The mean length of hospitalization was 4.4 days (range 3-8 days). C1 San Francisco Vet Affairs Med Ctr, Surg Serv 112, San Francisco, CA 94121 USA. Univ Calif San Francisco, Mt Zion Med Ctr, Dept Surg, San Francisco, CA 94143 USA. RP Duh, QY (reprint author), San Francisco Vet Affairs Med Ctr, Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA. NR 12 TC 39 Z9 39 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0364-2313 J9 WORLD J SURG JI World J.Surg. PD NOV PY 2004 VL 28 IS 11 BP 1176 EP 1179 DI 10.1007/s00268-004-7620-0 PG 4 WC Surgery SC Surgery GA 874TL UT WOS:000225372600021 PM 15490056 ER PT J AU Xu, GY Kane, DJ Faller, LD Farley, RA AF Xu, GY Kane, DJ Faller, LD Farley, RA TI The role of loop 6/7 in folding and functional performance of Na,K-ATPase SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID SARCOPLASMIC-RETICULUM CA2+-ATPASE; SITE-DIRECTED MUTAGENESIS; TRANSMEMBRANE SEGMENTS 6; CYTOPLASMIC LOOP; ALPHA-SUBUNIT; RENAL NA,K-ATPASE; COORDINATING RESIDUES; GASTRIC H+,K+-ATPASE; CATION OCCLUSION; CA2+ BINDING AB Alanine substitutions were made for 15 amino acids in the cytoplasmic loop between transmembrane helices 6 and 7 (L6/7) of the human alpha(1)-subunit of Na,K-ATPase. Most mutations reduced Na,K-ATPase activity by less than 50%; however, the mutations R834A, R837A, and R848A reduced Na,K-ATPase activity by 75, 89, and 66%, respectively. Steady-state phosphoenzyme formation from ATP was reduced in mutants R834A, R837A, and R848A, and R837A also had a faster E2P-->E-2 dephosphorylation rate compared with the wild-type enzyme. Effects of L6/7 mutations on the phosphorylation domain of the protein were also demonstrated by O-18 exchange, which showed that intrinsic rate constants for P-i binding and/or reaction with the protein were altered. Although most L6/7 mutations had no effect on the interaction of Na+ or K+ with Na,K-ATPase, the E825A, E828A, R834A, and R837A mutations reduced the apparent affinity of the enzyme for both Na+ and K+ by 1.5-3-fold. 1-Bromo-2,4,6-tris(methylisothiouronium) benzene (Br-TITU3+), a competitive antagonist of Rb+ and Na+ occlusion (Hoving, S., Bar-Shimon, M., Tijmes, J.J., Goldschleger, R., Tal, D. M., and Karlish, S.J.D. (1995) J. Biol. Chem. 270, 29788-29793), was used to test whether charged residues in L6/7 are involved in binding monovalent cations and cation antagonists. Br-TITU3+ inhibited ouabain binding to wild type Na, K-ATPase with an IC50 of 30 muM. Ouabain binding to the E825A, E828A, R834A, or R837A mutants was still inhibited by Br-TITU3+, indicating that Br-TITU3+ does not bind to charged residues in L6/7. This observation makes it unlikely that L6/7 functions as a cytoplasmic cation binding site in Na,K-ATPase, and together with the effects of L6/7 mutations on phosphate interactions with the enzyme suggests that L6/7 is important in stabilizing the phosphorylation domain and its relationship to the ion binding sites of the protein. C1 Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, Los Angeles, CA 90033 USA. Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA. Univ Calif Los Angeles, CURE, Digest Dis Res Ctr, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. RP Farley, RA (reprint author), Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, 1333 San Pablo St,MMR 250, Los Angeles, CA 90033 USA. EM rfarley@usc.edu FU NIDDK NIH HHS [DK52802]; NIGMS NIH HHS [GM28673] NR 37 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD OCT 29 PY 2004 VL 279 IS 44 BP 45594 EP 45602 DI 10.1074/jbc.M408147200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 865IC UT WOS:000224694900038 PM 15322120 ER PT J AU Ishiyama, M Ramabadran, RS Sekiguchi, K Sakata, Y DeFreitas, G Carabello, BA Mann, DL AF Ishiyama, M Ramabadran, RS Sekiguchi, K Sakata, Y DeFreitas, G Carabello, BA Mann, DL TI Hemodynamic overload provokes accelerated cardiac decompensation in DARE mice that lack TNF AU-rich elements SO CIRCULATION LA English DT Meeting Abstract CT 77th Scientific Meeting of the American-Heart-Association CY NOV 07-10, 2004 CL New Orleans, LA SP Amer Heart Assoc C1 Baylor Coll Med, VA Med Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 26 PY 2004 VL 110 IS 17 SU S MA 22 BP 7 EP 7 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 866OT UT WOS:000224783500023 ER PT J AU Colston, JT de la Rosa, SD Strader, JR Anderson, MA Freeman, GL AF Colston, JT de la Rosa, SD Strader, JR Anderson, MA Freeman, GL TI H2O2 activates Nox4 through phospholipase A(2)-dependent arachidonic acid production in adult cardiac fibroblasts SO CIRCULATION LA English DT Meeting Abstract CT 77th Scientific Meeting of the American-Heart-Association CY NOV 07-10, 2004 CL New Orleans, LA SP Amer Heart Assoc C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 26 PY 2004 VL 110 IS 17 SU S MA 421 BP 89 EP 90 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 866OT UT WOS:000224783500422 ER PT J AU Zhang, P Guccione, JM Nicholas, SI Walker, JC Crawford, PC Shamal, A Saloner, D Wallace, AW Ratcliffe, MB AF Zhang, P Guccione, JM Nicholas, SI Walker, JC Crawford, PC Shamal, A Saloner, D Wallace, AW Ratcliffe, MB TI Effect of Dor procedure in the left ventricle with dyskinetic anterior wall on ventricular volume, chamber stiffness, and function SO CIRCULATION LA English DT Meeting Abstract CT 77th Scientific Meeting of the American-Heart-Association CY NOV 07-10, 2004 CL New Orleans, LA SP Amer Heart Assoc C1 Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. Univ Calif Berkeley, Berkeley, CA 94720 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 26 PY 2004 VL 110 IS 17 SU S MA 489 BP 103 EP 104 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 866OT UT WOS:000224783500490 ER PT J AU Saam, T Takaya, N Polissar, NL Hatsukami, TS Yuan, C AF Saam, T Takaya, N Polissar, NL Hatsukami, TS Yuan, C TI Identification of early hemorrhage with magnetic resonance imaging is highly associated with markers of plaque vulnerability and patients' symptom status SO CIRCULATION LA English DT Meeting Abstract CT 77th Scientific Meeting of the American-Heart-Association CY NOV 07-10, 2004 CL New Orleans, LA SP Amer Heart Assoc C1 Univ Washington, Seattle, WA 98195 USA. Mt Whisper Light Stat Consulting, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 26 PY 2004 VL 110 IS 17 SU S MA 1190 BP 248 EP 248 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 866OT UT WOS:000224783501348 ER PT J AU Zahid, M Sonel, AF Saba, S Good, CB AF Zahid, M Sonel, AF Saba, S Good, CB TI Perioperative risk of noncardiac surgery associated with aortic stenosis SO CIRCULATION LA English DT Meeting Abstract CT 77th Scientific Meeting of the American-Heart-Association CY NOV 07-10, 2004 CL New Orleans, LA SP Amer Heart Assoc C1 VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 26 PY 2004 VL 110 IS 17 SU S MA 1718 BP 360 EP 360 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 866OT UT WOS:000224783502035 ER PT J AU Teerlink, JR Massie, BM Cleland, JG Tzivoni, D Rainisio, M Frey, A AF Teerlink, JR Massie, BM Cleland, JG Tzivoni, D Rainisio, M Frey, A CA RITZ-1 Investigators TI The relationship between hypotension and renal dysfunction during tezosentan treatment for acute decompensated heart failure: An analysis of the randomized interventions with TeZosentan (RITZ-1) trial SO CIRCULATION LA English DT Meeting Abstract CT 77th Scientific Meeting of the American-Heart-Association CY NOV 07-10, 2004 CL New Orleans, LA SP Amer Heart Assoc C1 Univ Calif San Francisco, San Francisco VAMC, San Francisco, CA 94143 USA. Univ Hull, Castle Hill Hosp, Kingston Upon Hull, Yorks, England. Shaare Zedek Med Ctr, Jerusalem, Israel. Actelion Pharm Ltd, Allschwil, Switzerland. RI Teerlink, John/D-2986-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 26 PY 2004 VL 110 IS 17 SU S MA 2409 BP 514 EP 514 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 866OT UT WOS:000224783502728 ER PT J AU Teerlink, JR Cleland, JG Massie, BM Tzivoni, D Frey, A AF Teerlink, JR Cleland, JG Massie, BM Tzivoni, D Frey, A CA RITZ-1 Investigators TI Treatments for acute decompensated heart failure have significant international variations: An analysis of the randomized interventions with TeZosentan (RITZ-1) trial SO CIRCULATION LA English DT Meeting Abstract CT 77th Scientific Meeting of the American-Heart-Association CY NOV 07-10, 2004 CL New Orleans, LA SP Amer Heart Assoc C1 Univ Calif San Francisco, San Francisco VAMC, San Francisco, CA 94143 USA. Univ Hull, Castle Hill Hosp, Kingston Upon Hull, Yorks, England. Shaare Zedek Med Ctr, Jerusalem, Israel. Actelion Pharm Ltd, Allschwil, Switzerland. RI Teerlink, John/D-2986-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 26 PY 2004 VL 110 IS 17 SU S MA 2426 BP 518 EP 518 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 866OT UT WOS:000224783502745 ER PT J AU Abraham, WT Trupp, RJ Mehra, MR Lawless, CE Mitchell, JE Le Jemtel, TH Smart, FW Bijou, R O'Connor, CM Yancy, CW Massie, BM Silver, MA Packer, M AF Abraham, WT Trupp, RJ Mehra, MR Lawless, CE Mitchell, JE Le Jemtel, TH Smart, FW Bijou, R O'Connor, CM Yancy, CW Massie, BM Silver, MA Packer, M TI A multivariate impedance cardiography composite scare can predict the occurrence of major heart failure events: the PREDICT study SO CIRCULATION LA English DT Meeting Abstract CT 77th Scientific Meeting of the American-Heart-Association CY NOV 07-10, 2004 CL New Orleans, LA SP Amer Heart Assoc C1 Ohio State Univ, Ctr Heart, Columbus, OH 43210 USA. Ochsner Clin Fdn, New Orleans, LA USA. DuPage Med Grp, Chicago, IL USA. Suny Downstate Med Ctr, New York, NY USA. Albert Einstein Hosp, New York, NY USA. Texas Heart Inst, Houston, TX 77025 USA. Columbia Presbyterian Med Ctr, New York, NY 10032 USA. Duke Univ, Med Ctr, Durham, NC USA. Univ Texas, SW Med Ctr, Dallas, TX USA. San Francisco VA Med Ctr, San Francisco, CA USA. Advocate Christ Med Ctr, Chicago, IL USA. Columbia Presbyterian Med Ctr, New York, NY 10032 USA. NR 0 TC 7 Z9 7 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 26 PY 2004 VL 110 IS 17 SU S MA 2775 BP 597 EP 597 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 866OT UT WOS:000224783503229 ER PT J AU Go, AS Yang, JR Ackerson, LM Lepper, KL Massie, BM Robbins, S Shlipalk, MG AF Go, AS Yang, JR Ackerson, LM Lepper, KL Massie, BM Robbins, S Shlipalk, MG TI Chronic kidney disease is the strongest predictor of developing anemia in heart failure: The kaiser permanente CHF cohort study SO CIRCULATION LA English DT Meeting Abstract CT 77th Scientific Meeting of the American-Heart-Association CY NOV 07-10, 2004 CL New Orleans, LA SP Amer Heart Assoc C1 Kaiser Permanente No Calif, Oakland, CA USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Amgen Inc, Thousand Oaks, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 26 PY 2004 VL 110 IS 17 SU S MA 3344 BP 722 EP 723 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 866OT UT WOS:000224783503792 ER PT J AU Baruch, L Gage, B Persson, M Zabalgoitia, M Juul-Moller, S Labrovitz, A Horrow, J AF Baruch, L Gage, B Persson, M Zabalgoitia, M Juul-Moller, S Labrovitz, A Horrow, J TI Which is the most accurate stroke prediction scheme in atrial fibrillation patients treated with anticoagulants? A comparison of 5 risk stratification schemes SO CIRCULATION LA English DT Meeting Abstract CT 77th Scientific Meeting of the American-Heart-Association CY NOV 07-10, 2004 CL New Orleans, LA SP Amer Heart Assoc C1 Bronx Vet Adm Med Ctr, Bronx, NY USA. Washington Univ, Sch Med, St Louis, MO 63130 USA. AstraZeneca R&D Molndal, Molndal, Sweden. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. Univ Hosp, Malmo, Sweden. St Louis Univ Hosp, St Louis, MO USA. AstraZeneca, Wilmington, DE USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 26 PY 2004 VL 110 IS 17 SU S MA 3616 BP 783 EP 784 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 866OT UT WOS:000224783504193 ER PT J AU Peterson, PN Safley, D Vaglio, J Masoudi, FA Reid, KJ Spertus, JA Rumsfeld, JS AF Peterson, PN Safley, D Vaglio, J Masoudi, FA Reid, KJ Spertus, JA Rumsfeld, JS TI The impact of diabetes on one-year health status outcomes following acute coronary syndromes SO CIRCULATION LA English DT Meeting Abstract CT 77th Scientific Meeting of the American-Heart-Association CY NOV 07-10, 2004 CL New Orleans, LA SP Amer Heart Assoc C1 Univ Colorado, Denver, CO 80202 USA. Univ Missouri, Kansas City, MO 64110 USA. Univ Kansas, Kansas City, KS USA. UMKC, Mid Amer Heart Inst, Kansas City, KS USA. Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 26 PY 2004 VL 110 IS 17 SU S MA 3619 BP 784 EP 784 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 866OT UT WOS:000224783504196 ER PT J AU Deswal, A Petersen, NJ Urbauer, DL Beyth, R Debakey, ME AF Deswal, A Petersen, NJ Urbauer, DL Beyth, R Debakey, ME TI Impact of race on the quality of outpatient care for heart failure SO CIRCULATION LA English DT Meeting Abstract CT 77th Scientific Meeting of the American-Heart-Association CY NOV 07-10, 2004 CL New Orleans, LA SP Amer Heart Assoc C1 VA Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 26 PY 2004 VL 110 IS 17 SU S MA 3691 BP 798 EP 799 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 866OT UT WOS:000224783504258 ER PT J AU Aronow, H Samaha, FF Kimmel, SE Williams, M Roche, D AF Aronow, H Samaha, FF Kimmel, SE Williams, M Roche, D TI Increasing statin dose is associated with a stepwise decline in long-term all-cause mortality SO CIRCULATION LA English DT Meeting Abstract CT 77th Scientific Meeting of the American-Heart-Association CY NOV 07-10, 2004 CL New Orleans, LA SP Amer Heart Assoc C1 Philadelphia VA Med Ctr, Philadelphia, PA USA. Hosp Univ Penn, Philadelphia, PA 19104 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 26 PY 2004 VL 110 IS 17 SU S MA 3783 BP 819 EP 819 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 866OT UT WOS:000224783504348 ER PT J AU Koybasi, S Senkal, CE Sundararaj, K Spassieva, S Bielawski, J Osta, W Day, TA Jiang, JC Jazwinski, SM Hannun, YA Obeid, LM Ogretmen, B AF Koybasi, S Senkal, CE Sundararaj, K Spassieva, S Bielawski, J Osta, W Day, TA Jiang, JC Jazwinski, SM Hannun, YA Obeid, LM Ogretmen, B TI Defects in cell growth regulation by C-18 : 0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID TANDEM MASS-SPECTROMETRY; TELOMERASE ACTIVITY; ENDOGENOUS CERAMIDE; INDUCED APOPTOSIS; LAG1; YEAST; INHIBITION; GENERATION; ACTIVATION; CANCER AB In this study, endogenous long chain ceramides were measured in 32 human head and neck squamous cell carcinoma (HNSCC) and 10 nonsquamous head and neck carcinoma tumor tissues, as compared with adjacent noncancerous tissues, by liquid chromatography/mass spectroscopy. Interestingly, only one specific ceramide, C-18:0-ceramide, was selectively down-regulated in the majority of HNSCC tumor tissues. On the other hand, in nonsquamous tumor tissues, this selectivity for C-18-ceramide was not detected. These data suggested the hypotheses that decreased levels of C-18-ceramide might impart a growth advantage to HNSCC cells and that increased generation of C-18-ceramide may be involved in the inhibition of growth. These roles were examined by reconstitution of C-18-ceramide at physiologically relevant concentrations in UM-SCC-22A cells ( squamous cell carcinoma of hypopharynx) via overexpression of mammalian upstream regulator of growth and differentiation factor 1 (mUOG1), a mouse homologue of longevity assurance gene 1 (mLAG1), which has been shown to specifically induce the generation of C-18-ceramide. Liquid chromatography/mass spectroscopy analysis showed that overexpression of the mLAG1/mUOG1 resulted in increased levels of only C-18:0-ceramide by similar to2-fold, i.e. concentrations similar to those of normal head and neck tissues. Importantly, increased generation of C-18-ceramide by mLAG1/mUOG1 inhibited cell growth (similar to70-80%), which mechanistically involved the modulation of telomerase activity and induction of apoptotic cell death by mitochondrial dysfunction. In conclusion, this study demonstrates, for the first time, a biological role for LAG1 and C-18-ceramide in the regulation of growth of HNSCC. C1 Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA. Abant Izzet Baysal Univ, Izzet Baysal Med Fac, Dept Otolaryngol, Bolu, Turkey. RP Ogretmen, B (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. EM ogretmen@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [CA-097132, CA-88932]; NIA NIH HHS [AG-16583, AG06168] NR 34 TC 116 Z9 122 U1 0 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD OCT 22 PY 2004 VL 279 IS 43 BP 44311 EP 44319 DI 10.1074/jbc.M406920200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 862QJ UT WOS:000224505600012 PM 15317812 ER PT J AU Shelkovnikov, S Gonick, HC AF Shelkovnikov, S Gonick, HC TI Peroxynitrite but not nitric oxide donors destroys epinephrine: HPLC measurement and rat aorta contractility SO LIFE SCIENCES LA English DT Article DE epinephrine; nitric oxide; peroxynitrite; rat; aorta; contraction ID ESSENTIAL-HYPERTENSION; GUANYLATE-CYCLASE; PULMONARY-ARTERY; NITROGEN-OXIDES; RELAXATION; CATECHOLAMINES; NOREPINEPHRINE; INHIBITION; ADRENALINE; NITRATION AB Nitric oxide (INTO) and peroxynitrite (ONOO) have been reported to destroy catecholamines. We compared the ability of NO donors and peroxynitrite to decompose epinephrine in both chemical and pharmacological experiments. Epinephrine (1 muM) was incubated with NO donors (SNAP and MAHMA NONOate) and ONOO at a concentration of 0.1 mM in phosphate buffer (pH 7.4; 0.1 M) or Krebs solution for 10 minutes at 37 degreesC. HPLC revealed that the concentration of epinephrine in the presence of NO donors was unaltered. In contrast, peroxynitrite decreased epinephrine concentration more than 20 fold. Similar relationships were obtained in the study of rat thoracic aorta ring contraction. The contractile activity (EC50) of epinephrine in control solutions and after incubation of NE with NO donors did not change. EC50 was measured at 8-10 nM in control solutions and after preincubation with NO donors. However when epinephrine was preincubated with peroxynitrite, no contractile effect was evoked. Therefore, under these experimental conditions peroxynitrite, but not NO donors, was capable of destroying epinephrine. (C) 2004 Elsevier Inc. All rights reserved. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Nephrol Sect, Med & Res Sect, Los Angeles, CA 90073 USA. RP Shelkovnikov, S (reprint author), Univ Calif Irvine, Dept Pharmacol, MSRII,Room 350C, Irvine, CA 92697 USA. EM shelkovnikov@pcmagic.net NR 25 TC 20 Z9 22 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0024-3205 J9 LIFE SCI JI Life Sci. PD OCT 22 PY 2004 VL 75 IS 23 BP 2765 EP 2773 DI 10.1016/j.lfs.2004.04.044 PG 9 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 859SE UT WOS:000224287400003 PM 15464828 ER PT J AU Bibbins-Domingo, K Lin, F Vittinghof, E Barrett-Connor, E Grady, D Shlipak, MG AF Bibbins-Domingo, K Lin, F Vittinghof, E Barrett-Connor, E Grady, D Shlipak, MG TI Renal insufficiency as an independent predictor of mortality among women with heart failure SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID ESTROGEN/PROGESTIN REPLACEMENT; CREATININE CLEARANCE; SURVIVAL; DISEASE; TRIAL; DYSFUNCTION; OUTCOMES; THERAPY; RISK AB OBJECTIVES We sought to explore the association between renal insufficiency and mortality among women with heart failure (HF) and to evaluate this risk by the presence of preserved or depressed systolic function. BACKGROUND Although HF is common in older women, little is known about their risk factors for mortality. METHODS This prospective cohort study retrospectively analyzed data from the Heart and Estrogen/ progestin Replacement Study (HERS). Of the 2,763 women in HERS, 702 had HF. Renal function was categorized as creatinine clearance (CrCl) >60 ml/min, 40 to 60 ml/min, and <40 ml/min. We used proportional hazards models to evaluate the association between renal insufficiency and mortality. RESULTS Over a mean 5.8 years, 228 women with HF died (32%). Renal insufficiency was strongly associated with mortality, even after adjustment for co-morbid conditions, systolic function, and medications (adjusted hazard ratio [HR] 1.53, 95% confidence interval [CI] 1.09 to 2.16 for CrCl 40 to 60 ml/min; adjusted HR 2.40, 95% CI 1.60 to 3.62 for CrCl <40 ml/min). Preserved or depressed systolic function did not modify the association between renal insufficiency and mortality risk, but the use of angiotensin-converting enzyme (ACE) inhibitors did modify this risk (ACE users: adjusted HR = 0.9, 95% CI 0.6 to 1.6; ACE nonusers: adjusted HR 2.1, 95% CI 1.3 to 3.2; p = 0.02 for interaction). Compared with other risk factors for mortality, renal insufficiency had the highest population attributable risk (27%). CONCLUSIONS Renal insufficiency was a major predictor of mortality among women with HF and preserved or depressed systolic function. This risk was attenuated by the use of ACE inhibitors. (C) 2004 by the American College of Cardiology Foundation. C1 Univ Calif San Francisco, San Francisco Gen Hosp, Div Gen Internal Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA. Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94143 USA. RP Bibbins-Domingo, K (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Div Gen Internal Med, Box 1364, San Francisco, CA 94143 USA. EM bibbinsk@medicine.ucsf.edu NR 28 TC 45 Z9 50 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD OCT 19 PY 2004 VL 44 IS 8 BP 1593 EP 1600 DI 10.1016/j.jacc.2004.07.040 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 863PJ UT WOS:000224573700009 PM 15489091 ER PT J AU Beer, TM Garzotto, M Henner, WD Eilers, KM Wersinger, EM AF Beer, TM Garzotto, M Henner, WD Eilers, KM Wersinger, EM TI Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer SO BRITISH JOURNAL OF CANCER LA English DT Article DE docetaxel; calcitriol; vitamin D; prostate cancer; chemotherapy AB Recently, completed phase III studies demonstrated a survival benefit for a fixed number of cycles of docetaxel-containing chemotherapy treatment of androgen-independent prostate cancer (AIPC). Management of patients who respond well to initial chemotherapy for AIPC remains ill-defined. We previously reported that in a select group of such patients, retreatment with the same regimen was feasible and was associated with quality of life gains. Here, we report that multiple cycles of such intermittent chemotherapy are feasible. We prospectively tested intermittent chemotherapy in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) <4 ng ml(-1) (22% of the 37 patients who were initially treated with this regimen). Chemotherapy was suspended until a rise in PSA &GE;50% and 1 ng ml(-1). The median duration of the first treatment holiday was 20 weeks (13-74 weeks) and all patients retained sensitivity to retreatment. Four patients were eligible for a second chemotherapy holiday, and the median duration was 21 weeks (17-28 weeks). Two patients elected to take a third chemotherapy holiday, which lasted 10 and 28 weeks. The median time to treatment failure was 26.5 months (95% CI 23.6-29.4 months), and the median survival is 41 months (95% CI 33.7-48.3 months). Multiple cycles of intermittent chemotherapy interrupted by clinically meaningful treatment holidays are feasible in a subset of AIPC patients treated with this docetaxel-containing regimen. Intermittent chemotherapy for AIPC is feasible and deserves further study. C1 Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97207 USA. Portland VA Med Ctr, Portland, OR 97207 USA. RP Beer, TM (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Mail Code CR145,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM beert@ohsu.edu FU NCRR NIH HHS [M01 RR000334, 3M01RR00334-33S2] NR 5 TC 36 Z9 37 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0007-0920 J9 BRIT J CANCER JI Br. J. Cancer PD OCT 18 PY 2004 VL 91 IS 8 BP 1425 EP 1427 DI 10.1038/sj.bjc.6602198 PG 3 WC Oncology SC Oncology GA 861JJ UT WOS:000224412500003 PM 15467765 ER PT J AU Luttrell, DK Luttrell, LM AF Luttrell, DK Luttrell, LM TI Not so strange bedfellows: G-protein-coupled receptors and Src family kinases SO ONCOGENE LA English DT Review DE G-protein-coupled receptor; focal adhesion kinase; epidermal growth factor; mitogen-activated protein kinase; receptor crosstalk ID GROWTH-FACTOR RECEPTOR; SMOOTH-MUSCLE-CELLS; FOCAL ADHESION KINASE; DEPENDENT TYROSINE KINASE; C-SRC; EGF RECEPTOR; ANGIOTENSIN-II; MAP KINASE; BETA-ARRESTIN; LYSOPHOSPHATIDIC ACID AB Src family nonreceptor tyrosine kinases are an integral component of the signal transduction apparatus employed by growth factor receptor tyrosine kinases. As such, their role in cellular growth control and malignant transformation has been the subject of intensive investigation. In contrast, classical G-protein-coupled receptor ( GPCR) signaling involves activation of second messenger-regulated serine/threonine kinases or ion channels, and is primarily involved in neurotransmission and the short-term regulation of intermediary metabolism. Over the past decade, this strictly dichotomous model of transmembrane signaling has been challenged by the discovery that GPCRs also exert control over cellular growth, proliferation, and differentiation, and do so by stimulating tyrosine phosphorylation cascades. Several mechanisms, from the direct association of Src family kinases with GPCRs or receptor-associated proteins, to the transactivation of receptor tyrosine kinases and focal adhesion complexes by G-protein-mediated signals, permit GPCRs to activate Src family kinases. Conversely, Src activity plays a central role in controlling GPCR trafficking and effects on cell proliferation and cytoskeletal rearrangement. It is now clear that GPCRs and Src family kinases do not belong to separate, exclusive clubs. Rather, these strange bedfellows are intimately involved in multilayered forms of crosstalk that influence a host of cellular processes. C1 Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Mol Biol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,816 CSB,POB 250624, Charleston, SC 29425 USA. EM luttrell@musc.edu FU NIDDK NIH HHS [DK55524, DK58283, DK64353] NR 103 TC 134 Z9 135 U1 1 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 J9 ONCOGENE JI Oncogene PD OCT 18 PY 2004 VL 23 IS 48 BP 7969 EP 7978 DI 10.1038/sj.onc.1208162 PG 10 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA 863JR UT WOS:000224558300007 PM 15489914 ER PT J AU Kovacs, TOG Lee, CQ Chiu, YL Pilmer, BL Metz, DC AF Kovacs, TOG Lee, CQ Chiu, YL Pilmer, BL Metz, DC TI Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID GASTROESOPHAGEAL-REFLUX DISEASE; ESOMEPRAZOLE AB Background: Some patients requiring acid suppression may be unable to take oral medications. Aim: To compare the gastric acid inhibition effects of lansoprazole 30 mg administered either intravenous or orally in erosive oesophagitis patients. Methods: The study included 87 Helicobacter pylori-negative patients with erosive oesophagitis. Each patient received 7 days of lansoprazole 30 mg orally prior to being randomized in a 3:1 fashion to intravenously lansoprazole 30 mg or intravenously placebo for 7 days. Basal acid output and pentagastrin-stimulated acid output were measured on days 8, 9 and 15. Results: Median pentagastrin-stimulated acid output was 7.2 mmol/h after 7 days of oral lansoprazole. The median pentagastrin-stimulated acid output increased to 7.6 mmol/h after 7 days of intravenous lansoprazole compared with 26.9 mmol/h after intravenous placebo (P < 0.001). Conclusions: Lansoprazole 30 mg administered intravenous was equivalent to the 30 mg oral capsule in gastric acid suppression. Intravenous proton pump inhibitor therapy represents an important treatment option for those with acid-related diseases who are unable to take oral medications. C1 VA Greater Los Angeles Healthcare Syst, Cure Digest Dis Res Ctr, CURE Clin, Los Angeles, CA 90073 USA. TAP Pharmaceut Prod Inc, Lake Forest, IL USA. Abbott Labs, Abbott Pk, IL 60064 USA. Univ Penn, Philadelphia, PA 19104 USA. RP Kovacs, TOG (reprint author), VA Greater Los Angeles Healthcare Syst, Cure Digest Dis Res Ctr, CURE Clin, 11301 Wilshire Blvd,Bldg 115,Room 212, Los Angeles, CA 90073 USA. EM tkovacs@mednet.ucla.edu NR 13 TC 11 Z9 11 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD OCT 15 PY 2004 VL 20 IS 8 BP 883 EP 889 DI 10.1111/j.1365-2036.2004.02188.x PG 7 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 861UO UT WOS:000224444300008 PM 15479360 ER PT J AU Kwiatkowski, BA Ragoczy, T Ehly, J Schubach, WH AF Kwiatkowski, BA Ragoczy, T Ehly, J Schubach, WH TI Identification and cloning of a novel chromatin-associated protein partner of Epstein-Barr nuclear protein 2 SO EXPERIMENTAL CELL RESEARCH LA English DT Article DE Epstein-Barr virus; EBNA2; Parallel Sister Chromatids Protein; wings apart-like ID VIRUS NUCLEAR ANTIGEN-2; BINDING-PROTEIN; DROSOPHILA-MELANOGASTER; ACIDIC DOMAIN; COMPLEX; TRANSCRIPTION; ORGANIZATION; LOCALIZATION; ARCHITECTURE; ACTIVATION AB In a screen for binding partners of the Epstein-Barr virus transformation-related protein EBNA2, we cloned a novel, evolutionarily conserved protein showing similarity to the Drosophila Parallel Sister Chromatids Protein (PASC). We have named this protein "Friend of EBNA2" (FOE). Human FOE encodes a protein of 1227 amino acids with a functional bipartite nuclear localization signal, an arginine-rich motif, a putative nuclear export signal as well as with three highly acidic regions and a predicted coiled-coil domain. FOE and EBNA2 coimmunoprecipitate from lymphocyte nuclear extracts. RNA and protein blots show that FOE is expressed in all human tissues. FOE is a nuclear protein with the bulk of the protein associated with the insoluble nuclear fraction biochemically defined as the nuclear matrix. Indirect immunofluorescence and dynamic imaging studies suggest that FOE associates with transcriptionally active nuclear subregions in interphase cells and concentrates at the ends of formed chromosomes during mitosis. (C) 2004 Elsevier Inc. All rights reserved. C1 VA Puget Sound Hlth Care Syst, Dept Med, Div Oncol, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. RP Schubach, WH (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Div Oncol, S-111-ONC,1660 S Columbian Way, Seattle, WA 98108 USA. EM wschu@u.washington.edu FU NCI NIH HHS [CA82459] NR 33 TC 7 Z9 9 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4827 J9 EXP CELL RES JI Exp. Cell Res. PD OCT 15 PY 2004 VL 300 IS 1 BP 223 EP 233 DI 10.1016/j.yexcr.2004.06.028 PG 11 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 858YH UT WOS:000224228200021 PM 15383329 ER PT J AU Loftis, JM Hauser, P AF Loftis, JM Hauser, P TI The phenomenology and treatment of interferon-induced depression SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Review DE hepatitis C; multiple sclerosis; cancer; interferon; depression; cytokines ID CHRONIC HEPATITIS-C; CHRONIC VIRAL-HEPATITIS; MULTIPLE-SCLEROSIS; ALPHA-INTERFERON; PSYCHIATRIC-SYMPTOMS; ANXIETY SYMPTOMS; ALFA-INTERFERON; CANCER-PATIENTS; PHASE-III; IFN-ALPHA AB Interferon (IFN)-alpha, IFN-beta, and IFN-gamma are currently available for the treatment of malignancies, viral infections (e.g., hepatitis C virus), multiple sclerosis (MS), and skin conditions. In addition to their therapeutic effects, IFNs commonly cause various side effects. Most common among the side effects of IFN are "flu-like" symptoms such as chills, fever, and muscle soreness. However, IFN can also cause significant neuropsychiatric side effects, particularly symptoms of depression. A literature search was conducted in order to summarize current information on (1) the frequency, characteristics, and risk factors of IFN-induced depression, (2) possible biochemical mechanisms associated with IFN-induced depression, and (3) the treatment strategies for IFN-induced depression. Review of the literature suggests that symptoms of depression induced by IFN therapy, in particular IFN-alpha therapy, are common and can limit the treatment utility, often necessitating discontinuation of TFN therapy or the use of psychopharmacologic agents. Depression is also a suspected side effect of therapy with IFN-beta and IFN-gamma; however, the association has not been as convincingly confirmed. Importantly, IFNs affect neurochemical pathways putatively involved in the etiology of depression. While these depressive side effects usually resolve after the completion of IFN therapy, they can persist or reappear with dose escalations. It is recommended that health care providers, patients and their families be informed about the potential risk of the psychiatric disturbances that can occur with IFN-a therapy. Screening and monitoring, ideally using symptom rating scales for depression, and early antidepressant treatment intervention appear necessary to optimize IFN therapy for the majority of patients. (C) 2004 Elsevier B.V. All rights reserved. C1 Portland VA Med Ctr P3MHAdm, NW Hepatitis C Resources Ctr, Psychiat Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR USA. Portland VA Med Ctr, JENS Lab, Portland, OR USA. Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR USA. RP Hauser, P (reprint author), Portland VA Med Ctr P3MHAdm, NW Hepatitis C Resources Ctr, Psychiat Behav Hlth & Clin Neurosci Div, 3710 SW US Veterans Hosp Rd, Portland, OR 97239 USA. EM loftisj@ohsu.edu; peter.hauser2@med.va.gov NR 74 TC 123 Z9 127 U1 4 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD OCT 15 PY 2004 VL 82 IS 2 BP 175 EP 190 DI 10.1016/j.jad.2004.04.002 PG 16 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 870IQ UT WOS:000225051200002 PM 15488246 ER PT J AU Yao, JK Cheng, P AF Yao, JK Cheng, P TI Determination of multiple redox-active compounds by high-performance liquid chromatography with coulometric multi-electrode array system SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES LA English DT Article DE Coulometric multi-electrode array system; redox-active compounds ID DEPENDENT METABOLIC SEROTYPES; RATS; FEMALE AB Studies of the antioxidant defense system and the related metabolic pathways are often complicated by cumbersome analytical methods, which require separate and multi-step extraction and chemical reaction procedures. Further, assaying multiple parameters is limited because of the usual small sample amounts. High-performance liquid chromatography coupled with a coulometric multi-electrode array system provides us high specificity and sensitivity to measure electrochemically oxidizable compounds in biological samples. In contrast to previously reported methods with two columns in series and a complex gradient elution profile, we have developed an automated procedure to simultaneously measure multiple redox-active low-molecular weight compounds that utilizes a single column with a simplified binary gradient profile. No other chemical reactions are necessary. In order to reduce the running time and yet achieve a reproducible retention time by the auto sampler injection, our gradient elution profile was modified to produce a shorter equilibration time, stable retention time, and a reduced cost per test. (C) 2004 Elsevier B.V. All rights reserved. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15213 USA. RP Yao, JK (reprint author), VA Pittsburgh Healthcare Syst, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM jkyao@pitt.edu FU NIMH NIH HHS [MH 58141] NR 13 TC 12 Z9 12 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1570-0232 J9 J CHROMATOGR B JI J. Chromatogr. B PD OCT 15 PY 2004 VL 810 IS 1 BP 93 EP 100 DI 10.1016/j.jchromb.2004.07.021 PG 8 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 855YE UT WOS:000224010000012 PM 15358312 ER PT J AU Giri, S Rattan, R Singh, AK Singh, I AF Giri, S Rattan, R Singh, AK Singh, I TI The 15-deoxy-delta 12,14-prostaglandin J(2) inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-kappa B-p300 pathway independent of peroxisome proliferator-activated receptor gamma SO JOURNAL OF IMMUNOLOGY LA English DT Article ID NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); CYCLOPENTENONE PROSTAGLANDINS; PROINFLAMMATORY CYTOKINES; NEGATIVE REGULATION; PROTEIN-KINASE; BETA-SUBUNIT; GLIAL-CELLS AB Ligands for peroxisome proliferator-activated receptor gamma (PPARgamma), such as 15-deoxy-12,14-PGJ(2) (15d-PGJ(2)), have been proposed as a new class of anti-inflammatory compounds because 15d-PGJ(2) was able to inhibit the induction of inflammatory response genes such as inducible NO synthase (MOS) and TNF (TNF-alpha) in a PPAR-dependent manner in various cell types. In primary astrocytes, the anti-inflammatory effects (inhibition of TNF-alpha, IL-1beta, IL-6, and iNOS gene expression) of 15d-PGJ(2) are observed to be independent of PPARgamma. Overexpression (wild-type and dominant-negative forms) of PPARgamma and its antagonist (GW9662) did not alter the 15d-PGJ(2)-induced inhibition of LPS/IFN-gamma-mediated iNOS and NF-kappaB activation. The 15d-PGJ(2) inhibited the inflammatory response by inhibiting IkappaB kinase activity, which leads to the inhibition of degradation of IkappaB and nuclear translocation of p65, thereby regulating the NF-kappaB pathway. Moreover, 15d-PGJ2 also inhibited the LPS/IFN-gamma-induced PI3K-Akt pathway. The 15d-PGJ2 inhibited the recruitment of p300 by NF-kappaB (p65) and down-regulated the p300-mediated induction of iNOS and NF-kappaB luciferase reporter activity. Coexpression of constitutive active Akt and PI3K (p110) reversed the 15d-PGJ(2)-mediated inhibition of p300-induced iNOS and NF-kappaB luciferase activity. This study demonstrates that 15d-PGJ(2) suppresses inflammatory response by inhibiting NF-kappaB signaling at multiple steps as well as by inhibiting the PI3K/Akt pathway independent of dPPARgamma in primary astrocytes. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. Ralph Johnson Vet Affairs Med Ctr, Dept Pathol & Lab Med, Charleston, SC 29425 USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, 316 Clin Sci Bldg, Charleston, SC 29425 USA. EM singhi@musc.edu FU NINDS NIH HHS [NS-22576, NS-34741, NS-37766, NS-40144, NS-40810] NR 60 TC 102 Z9 106 U1 0 U2 4 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD OCT 15 PY 2004 VL 173 IS 8 BP 5196 EP 5208 PG 13 WC Immunology SC Immunology GA 861BX UT WOS:000224392200051 PM 15470065 ER PT J AU Subramanian, S West, RB Corless, CL Ou, WB Rubin, BP Chu, KM Leung, SY Yuen, ST Zhu, S Hernandez-Boussard, T Montgomery, K Nielsen, TO Patel, RM Goldblum, JR Heinrich, MC Fletcher, JA van de Rijn, M AF Subramanian, S West, RB Corless, CL Ou, WB Rubin, BP Chu, KM Leung, SY Yuen, ST Zhu, S Hernandez-Boussard, T Montgomery, K Nielsen, TO Patel, RM Goldblum, JR Heinrich, MC Fletcher, JA van de Rijn, M TI Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles SO ONCOGENE LA English DT Article DE GIST; KIT; PDGFRA; mutations; microarray; gene expression ID OF-FUNCTION MUTATIONS; SIGNAL-TRANSDUCTION; C-KIT; ERM PROTEINS; CANCER; IMATINIB; SITE; MICROARRAYS; MODULATION; APOPTOSIS AB Most GISTs require oncogenic activation of the KIT or PDGFRA receptor tyrosine kinase proteins, and the genomic mechanisms of oncogene activation are heterogeneous. Notably, the kinase mutation type correlates with both tumor biology and imatinib response. For example, GISTs with KIT exon 11 mutations are typically gastric and have excellent imatinib response, whereas those with KIT exon 9 mutations generally arise in the small bowel and are less responsive to imatinib. To identify genes that might contribute to these biological differences, we carried out gene expression profiling of 26 GISTs with known KIT and PDGFRA mutational status. Expression differences were then evaluated further by RNA in situ hybridization, immunohistochemistry, and immunoblotting. Unsupervised hierarchical clustering grouped tumors with similar mutations together, but the distinction between the different groups was not absolute. Differentially expressed genes included ezrin, p70S6K, and PKCs, which are known to have key roles in KIT or PDGFRA signaling, and which might therefore contribute to the distinctive clinicopathological features in GISTs with different mutation types. These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated. C1 Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA. Oregon Hlth & Sci Univ, OHSU Canc Inst, Dept Pathol, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Washington, Med Ctr, Dept Anat Pathol, Seattle, WA 98195 USA. Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China. Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China. Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94305 USA. Vancouver Gen Hosp, Dept Pathol, Vancouver, BC V5Z 1M9, Canada. Vancouver Gen Hosp, Genet Pathol Evaluat Ctr, Vancouver, BC, Canada. Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA. Oregon Hlth & Sci Univ, OHSU Canc Inst, Dept Med, Portland, OR 97201 USA. RP van de Rijn, M (reprint author), Stanford Univ, Med Ctr, Dept Pathol, L-235,300 Pasteur Dr, Stanford, CA 94305 USA. EM mrijn@stanford.edu RI Chu, Kent/C-4251-2009; Yuen , Siu /K-6311-2014; Leung, Suet Yi/C-4340-2009 FU NCI NIH HHS [CA85129] NR 47 TC 95 Z9 98 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 J9 ONCOGENE JI Oncogene PD OCT 14 PY 2004 VL 23 IS 47 BP 7780 EP 7790 DI 10.1038/sj.onc.1208056 PG 11 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA 860GX UT WOS:000224331600004 PM 15326474 ER PT J AU Arancio, O Zhang, HP Chen, X Lin, C Trinchese, F Puzzo, D Liu, SM Hegde, A Yan, SF Stern, A Luddy, JS Lue, LF Walker, DG Roher, A Buttini, M Mucke, L Li, WY Schmidt, AM Kindy, M Hyslop, PA Stern, DM Du Yan, SS AF Arancio, O Zhang, HP Chen, X Lin, C Trinchese, F Puzzo, D Liu, SM Hegde, A Yan, SF Stern, A Luddy, JS Lue, LF Walker, DG Roher, A Buttini, M Mucke, L Li, WY Schmidt, AM Kindy, M Hyslop, PA Stern, DM Du Yan, SS TI RAGE potentiates A beta-induced perturbation of neuronal function in transgenic mice SO EMBO JOURNAL LA English DT Article DE neuroinflammation; neuronal degeneration; NF-kappa B activation; synaptic plasticity ID NF-KAPPA-B; AMYLOID-PRECURSOR-PROTEIN; ALZHEIMERS-DISEASE; OXIDANT STRESS; SYNAPTIC PLASTICITY; PLAQUE-FORMATION; GENE-EXPRESSION; RECEPTOR; ACTIVATION; PEPTIDE AB Receptor for Advanced Glycation Endproducts (RAGE), a multiligand receptor in the immunoglobulin superfamily, functions as a signal-transducing cell surface acceptor for amyloid-beta peptide (Abeta). In view of increased neuronal expression of RAGE in Alzheimer's disease, a murine model was developed to assess the impact of RAGE in an Ab-rich environment, employing transgenics (Tgs) with targeted neuronal overexpression of RAGE and mutant amyloid precursor protein (APP). Double Tgs (mutant APP (mAPP)/RAGE) displayed early abnormalities in spatial learning/memory, accompanied by altered activation of markers of synaptic plasticity and exaggerated neuropathologic findings, before such changes were found in mAPP mice. In contrast, Tg mice bearing a dominant-negative RAGE construct targeted to neurons crossed with mAPP animals displayed preservation of spatial learning/memory and diminished neuropathologic changes. These data indicate that RAGE is a cofactor for Abeta-induced neuronal perturbation in a model of Alzheimer's-type pathology, and suggest its potential as a therapeutic target to ameliorate cellular dysfunction. C1 Columbia Univ, Coll Phys & Surg, Taub Inst Alzheimers Dis & Aging Brain, Dept Pathol, New York, NY 10032 USA. Columbia Univ, Coll Phys & Surg, Dept Surg, New York, NY 10032 USA. NYU, Sch Med, Dementia Res Ctr,nathan Kline Inst, Dept Psychiat Physiol & Neurosci, New York, NY USA. NYU, Dept Neurol, New York, NY USA. Wake Forest Univ, Bowman Gray Sch Med, Dept Neurobiol & Anat, Winston Salem, NC USA. Sun Hlth Res Inst, Sun City, AZ USA. Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. Eli Lilly & Co, Dept Neurosci, Indianapolis, IN 46285 USA. Med Univ S Carolina, Inst Neurosci, Dept Physiol & Neurosci, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. Med Coll Georgia, Sch Med, Augusta, GA 30912 USA. RP Du Yan, SS (reprint author), Columbia Univ, Coll Phys & Surg, Taub Inst Alzheimers Dis & Aging Brain, Dept Pathol, 630 W 168th St, New York, NY 10032 USA. EM sdy1@columbia.edu OI PUZZO, Daniela/0000-0002-9542-2251 FU CSR NIH HHS [IIRG-00-2076]; NIA NIH HHS [AG17490, 1KO7AG00959, AG16223, AG18345, AG60901, K07 AG000959, P01 AG017490, R01 AG018345] NR 36 TC 185 Z9 195 U1 0 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0261-4189 J9 EMBO J JI Embo J. PD OCT 13 PY 2004 VL 23 IS 20 BP 4096 EP 4105 DI 10.1038/sj.emboj.7600415 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 867BG UT WOS:000224816500018 PM 15457210 ER PT J AU O'Connell, JB Maggard, MA Ko, CY AF O'Connell, JB Maggard, MA Ko, CY TI Colon cancer survival rates with the new American Joint Committee on cancer sixth edition staging SO JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID RECTAL-CANCER; COLORECTAL-CANCER; LYMPH-NODES; HIGH-RISK; NUMBER; PROGNOSIS AB Background: The recently revised American Joint Committee on Cancer (AJCC) sixth edition cancer staging system increased the stratification within colon cancer stages II and III defined by the AJCC fifth edition system. Using nationally representative Surveillance, Epidemiology, and End Results (SEER) data, we compared survival rates associated with colon cancer stages defined according to both AJCC systems. Methods: Using SEER data (from January 1, 1991, through December 31, 2000), we identified 119 363 patients with colon adenocarcinoma and included all patients in two analyses by stages defined by AJCC fifth and sixth edition systems. Tumors were stratified by SEER's "extent of disease" and "number of positive [lymph] nodes" coding schemes. Kaplan-Meier analyses were used to compare overall and stage-specific 5-year survival. All statistical tests were two-sided. Results: Overall 5-year survival was 65.2%. According to stages defined by the AJCC fifth edition system, 5-year stage-specific survivals were 93.2% for stage I, 82.5% for stage II, 59.5% for stage III, and 8.1% for stage IV. According to stages defined by the AJCC sixth edition system, 5-year stage-specific survivals were 93.2% for stage I, 84.7% for stage IIa, 72.2% for stage IIb, 83.4% for stage IIIa, 64.1 % for stage IIIb, 44.3 % for stage IIIc, and 8.1 % for stage IV. Under the sixth edition system, 5-year survival was statistically significantly better for patients with stage IIIa colon cancer (83.4%) than for patients with stage IIb disease (72.2%) (P<.001). Conclusions: The AJCC sixth edition system for colon cancer stratifies survival more distinctly than the fifth edition system by providing more substages. The association of stage IIIa colon cancer with statistically Significantly better survival than stage IIb in the new system may reflect current clinical practice, in which stage III patients receive chemotherapy but stage II patients generally do not. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Hosp, Dept Surg, Los Angeles, CA USA. RP O'Connell, JB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave,Rm 72-215 CHS, Los Angeles, CA 90095 USA. EM jbocjboc@hotmail.com NR 17 TC 746 Z9 781 U1 2 U2 21 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 J NATL CANCER I JI J. Natl. Cancer Inst. PD OCT 6 PY 2004 VL 96 IS 19 BP 1420 EP 1425 DI 10.1093/jnci/djh275 PG 6 WC Oncology SC Oncology GA 859YM UT WOS:000224304300008 PM 15467030 ER PT J AU Terasawa, T Blackmore, CC Bent, S Kohlwes, RJ AF Terasawa, T Blackmore, CC Bent, S Kohlwes, RJ TI Systematic review: Computed tomography and ultrasonography to detect acute appendicitis in adults and adolescents SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID SUSPECTED ACUTE APPENDICITIS; ABDOMINAL SONOGRAPHY; DIAGNOSTIC-TESTS; HELICAL CT; US; METAANALYSIS; ACCURACY; ULTRASOUND; DECISION; PATIENT AB Background: Although clinicians commonly use computed tomography or ultrasonography to diagnose acute appendicitis, the accuracy of these imaging tests remains unclear. Purpose: To review the diagnostic accuracy of computed tomography and ultrasonography in adults and adolescents with suspected acute appendicitis. Data Sources: The authors used MEDLINE, EMBASE, bibliographies, review articles, textbooks, and expert opinion to retrieve English- and non-English-language articles published from 1966 to December 2003. Study Selection: The authors included prospective studies evaluating computed tomography or ultrasonography followed by surgical confirmation or clinical follow-up in patients at least 14 years of age with suspected appendicitis. Data Extraction: One assessor (for non-English-language studies) or 2 assessors (for English-language studies) independently reviewed each article to abstract relevant study characteristics and results. Data Synthesis: Twelve computed tomography studies and 14 ultrasonography studies met inclusion criteria. Computed tomography had an overall sensitivity of 0.94 (95% Cl, 0.91 to 0.95), a specificity of 0.95 (Cl, 0.93 to 0.96), a positive likelihood ratio of 13.3 (Cl, 9.9 to 17.9), and a negative likelihood ratio of 0.09 (Cl, 0.07 to 0.12). Ultrasonography had an overall sensitivity of 0.86 (Cl, 0.83 to 0.88), a specificity of 0.81 (Cl, 0.78 to 0.84), a positive likelihood ratio of 5.8 (Cl, 3.5 to 9.5), and a negative likelihood ratio of 0.19 (Cl, 0.13 to 0.27). Verification bias and inappropriate blinding of reference standards were noted in all of the included studies. Limitations: The summary assessment of the diagnostic accuracy for both tests was limited by the small number of studies, heterogeneity among study samples, and poor methodologic quality in the original studies. Conclusions: Computed tomography is probably more accurate than ultrasonography for diagnosing appendicitis in adults and adolescents. Prospective studies that apply gold standard diagnostic testing to all study participants would more reliably estimate the true diagnostic accuracy of these tests. C1 San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Washington, Harborview Med Ctr, Seattle, WA 98195 USA. RP Terasawa, T (reprint author), Nagoya Natl Hosp, Dept Clin Res & Hematol, Naka Ku, 4-1-1 Sannomaru, Nagoya, Aichi 4600001, Japan. EM terasawa@nnh.hosp.go.jp FU AHRQ HHS [K08-HS11291]; NCCIH NIH HHS [1 K08-AT001338-01] NR 45 TC 143 Z9 149 U1 0 U2 5 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD OCT 5 PY 2004 VL 141 IS 7 BP 537 EP 546 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 862CR UT WOS:000224467800006 PM 15466771 ER PT J AU Snow, V Barry, P Fihn, SD Gibbons, RJ Owens, DK Williams, SV Mottur-Pilson, C Weiss, KB AF Snow, V Barry, P Fihn, SD Gibbons, RJ Owens, DK Williams, SV Mottur-Pilson, C Weiss, KB CA Amer Coll of Physicians TI Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: A clinical practice guideline from the American College of Physicians SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID ASSOCIATION TASK-FORCE; HIGH-RISK PATIENTS; MYOCARDIAL-INFARCTION; CARDIOVASCULAR EVENTS; ANTIPLATELET THERAPY; CHOLESTEROL LEVELS; RANDOMIZED TRIALS; SILENT ISCHEMIA; HEART-FAILURE; DOUBLE-BLIND AB In 1999, the American College of Physicians (ACP), then the American College of Physicians-American Society of Internal Medicine, and the American College of Cardiology/American Heart Association (ACC/AHA) developed joint guidelines on the management of patients with chronic stable angina. The ACC/AHA then published an updated guideline in 2002, which ACP recognized as a scientifically valid review of the evidence and background paper. This ACP guideline summarizes the recommendations of the 2002 ACC/AHA updated guideline and underscores the recommendations most likely to be important to physicians seeing patients in the primary care setting. This guideline is the second of 2 that provide guidance on the management of patients with chronic stable angina. This document covers treatment and follow-up of symptomatic patients who have not had an acute myocardial infarction or revascularization procedure in the previous 6 months. Sections addressing asymptomatic patients are also included. Asymptomatic refers to patients with known or suspected coronary disease based on a history or electrocardiographic evidence of previous myocardial infarction, coronary angiography, or abnormal results on noninvasive tests. A previous guideline covered diagnosis and risk stratification for symptomatic patients who have not had an acute myocardial infarction or revascularization procedure in the previous 6 months and asymptomatic patients with known or suspected coronary disease based on a history or electrocardiographic evidence of previous myocardial infarction, coronary angiography, or abnormal results on noninvasive tests. C1 Amer Coll Physicians, Philadelphia, PA 19106 USA. Univ Penn, Philadelphia, PA 19104 USA. Merck Inst Aging & Hlth, Washington, DC USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Mayo Clin, Rochester, MN USA. Vet Affairs Hlth Care Syst, Palo Alto, CA USA. Edward Hines Jr Vet Adm Hosp, Chicago, IL USA. Northwestern Univ, Chicago, IL 60611 USA. RP Snow, V (reprint author), Amer Coll Physicians, 192 N Independence Mall W, Philadelphia, PA 19106 USA. EM vincenza@mail.acponline.org NR 27 TC 37 Z9 48 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD OCT 5 PY 2004 VL 141 IS 7 BP 562 EP 567 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 862CR UT WOS:000224467800009 PM 15466774 ER PT J AU Gemma, C Stellwagen, H Fister, M Coultrap, SJ Mesches, MH Browning, MD Bickford, PC AF Gemma, C Stellwagen, H Fister, M Coultrap, SJ Mesches, MH Browning, MD Bickford, PC TI Rosiglitazone improves contextual fear conditioning in aged rats SO NEUROREPORT LA English DT Article DE aging; contextual fear conditioning; IL-1 beta memory; PPAR gamma agonists; rosiglitazone ID ACTIVATED-RECEPTOR-GAMMA; LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; ANTIINFLAMMATORY DRUGS; INFLAMMATORY PROCESSES; EXPRESSION; AGONISTS; INSULIN; BETA; PATHOGENESIS AB Experimental, clinical, and epidemiologic studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) are beneficial in Alzheimer's disease and other neuroinflammatory processes. One possible mechanism is an interaction with peroxisome proliferator-activated receptors (PPARs). We examined the effect of a specific PPARgamma agonist, rosiglitazone, on contextual fear conditioning in aged rats. Male rats (20-months-old) were administered rosiglitazone in the diet for 2 months prior to behavioral testing. Young control and aged rats fed rosiglitazone froze significantly more than did the aged control rats in a hippocampal-dependent fear conditioning task. Rosiglitazone had no effect hippocampal interleukin-1beta levels, markers of oxidative damage, and NMDA receptor expression. Therefore, activation of PFARgamma prevented age-related deficits in hippocampal function. C1 Univ S Florida, Dept Neurosurg, Ctr Excellence Aging & Brain Repair, Tampa, FL 33612 USA. James A Haley Vet Hosp, Tampa, FL 33612 USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA. Denver VA Med Ctr, Denver, CO 80220 USA. RP Bickford, PC (reprint author), Univ S Florida, Dept Neurosurg, Ctr Excellence Aging & Brain Repair, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA. EM pbickfor@hsc.usf.edu RI Bickford, Paula/J-5970-2012 OI Bickford, Paula/0000-0001-9657-7725; Gemma, Carmelina/0000-0002-4480-0056 FU NIA NIH HHS [AG04418] NR 25 TC 13 Z9 13 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0959-4965 J9 NEUROREPORT JI Neuroreport PD OCT 5 PY 2004 VL 15 IS 14 BP 2255 EP 2259 DI 10.1097/00001756-200410050-00023 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 871NW UT WOS:000225141400023 PM 15371745 ER PT J AU Fleischmann, J Liu, H Wu, CP AF Fleischmann, J Liu, H Wu, CP TI Polyadenylation of ribosomal RNA by Candida albicans also involves the small subunit SO BMC MOLECULAR BIOLOGY LA English DT Article ID ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; POLYMERASE SWITCH; YEAST; RDNA AB Background: Candida albicans is a polymorphic fungus causing serious infections in immunocompromised patients. It is capable of shifting from yeast to germinating forms such as hypha and pseudohypha in response to a variety of signals, including mammalian serum. We have previously shown that some of the large 25S components of ribosomal RNA in Candida albicans get polyadenylated, and this process is transiently intensified shortly after serum exposure just prior to the appearance of germination changes. Results: We now present data that this process also involves the small 18S subunit of ribosomal RNA in this organism. Unlike the large 25S subunit, polyadenylation sites near the 3' end are more variable and no polyadenylation was found at the reported maturation site of 18S. Similar to 25S, one or more polyadenylated mature sized 18S molecules get intensified transiently by serum just prior to the appearance of hypha. Conclusions: The transient increase in polyadenylation of both the large and the small subunits of ribosomal RNA just prior to the appearance of hypha, raises the possibility of a role in this process. C1 Univ Calif Los Angeles, Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Dent, Dept Oral Biol & Med, Los Angeles, CA 90095 USA. RP Fleischmann, J (reprint author), Univ Calif Los Angeles, Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jfl@ucla.edu; biye@ucla.edu; hivictorwu@yahoo.com NR 14 TC 12 Z9 14 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1471-2199 J9 BMC MOL BIOL JI BMC Mol. Biol. PD OCT 4 PY 2004 VL 5 AR 17 DI 10.1186/1471-2199-5-17 PG 6 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 862AK UT WOS:000224461100001 PM 15461824 ER PT J AU Johansen, KL AF Johansen, KL TI Treatment of hypogonadism in men with chronic kidney disease SO ADVANCES IN CHRONIC KIDNEY DISEASE LA English DT Article DE testosterone; androgens; hypogonadism; chronic kidney disease; end-stage renal disease ID TESTOSTERONE TRANSDERMAL SYSTEM; CLINICAL-RESEARCH-CENTER; CORONARY-ARTERY-DISEASE; CHRONIC-RENAL-FAILURE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; RANDOMIZED CONTROLLED-TRIAL; PITUITARY-TESTICULAR AXIS; BONE-MINERAL DENSITY; NANDROLONE DECANOATE; REPLACEMENT THERAPY AB Hypogonadism is common among men with chronic kidney disease, but few studies have directly assessed the effects of testosterone replacement in this population. Limited information suggests that androgen replacement may improve libido and sexual function among men who are frankly hypogonadal. However, the threshold for normal sexual function is in the lower end of the normal range. Increasing serum testosterone above this level does not appear to have beneficial effects on sexual functioning. On the other hand, at least among healthy men, the dose-response curve for anabolic effects of testosterone administration appears to extend to testosterone levels on the high end of the normal range or above. Small studies have suggested that androgen treatment has anabolic effects among end-stage renal disease patients, even in the absence of hypogonadism. Androgens have potential side effects, and some preinitiation and subsequent assessment and monitoring are recommended to minimize these adverse effects. Recommendations for healthy older men appear to be reasonable for patients with chronic kidney disease. More research is needed to measure the effects of androgen therapy on various symptoms of hypogonadism as well as on overall quality of life, physical functioning, and survival among patients with chronic kidney disease. (C) 2004 by the National Kidney Foundation, Inc. C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Div Nephrol, Nephrol Sect, 111J,4150 Clement St, San Francisco, CA 94121 USA. EM johanse@itsa.ucsf.edu NR 71 TC 14 Z9 17 U1 0 U2 2 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 1548-5595 J9 ADV CHRONIC KIDNEY D JI Adv. Chronic Kidney Dis. PD OCT PY 2004 VL 11 IS 4 BP 348 EP 356 DI 10.1053/j.ackd.2004.07.006 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 868FQ UT WOS:000224899900005 PM 15492971 ER PT J AU Brennan, FX Stromberg, MF AF Brennan, FX Stromberg, MF TI Ethanol consumption improves avoidance learning in rats: role of deprivation interval SO ALCOHOL LA English DT Article DE ethanol; escape/avoidance; rats; stress ID RESPONSE-INDEPENDENT COCAINE; NUCLEUS-ACCUMBENS; ALCOHOL; STRESS; PERFORMANCE; REDUCTION; MICE; REINFORCEMENT; PREFERENCE; INCREASES AB Voluntary oral self-administration of ethanol in rats has been used to model ethanol consumption and abuse in human beings, with contradictory results. The purpose of the current study was to assess the effect of voluntary ethanol consumption on acquisition of a lever press escape/avoidance task in rats. Male Wistar rats were exposed to ethanol in a limited-access procedure, and either 1 day or 10 days after their last ethanol exposure, animals received a 4-h lever press escape/avoidance session. Control animals were not exposed to ethanol at any time. Animals in the 1-day ethanol-deprivation group performed significantly better than did the other two groups with respect to avoidance responding. There were no group differences in number of lever presses during a safety period, a measure of anxiety. Further, we obtained a significant negative correlation between behavioral performance and change in ethanol consumption after the escape/avoidance session, as well as a significant positive correlation between baseline ethanol consumption and avoidance performance. Results are discussed in terms of the potential neural mediators of the improved avoidance effect in animals in the 1-day ethanol-deprivation group. (c) 2005 Elsevier Inc. All rights reserved. C1 Philadelphia VA Med Ctr, Med Res Serv 151, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Psychiat, Treatment Res Ctr, Philadelphia, PA 19104 USA. RP Brennan, FX (reprint author), Philadelphia VA Med Ctr, Med Res Serv 151, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM Brennan_F@mail.trc.upenn.edu FU NIAAA NIH HHS [AA-00228] NR 28 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0741-8329 J9 ALCOHOL JI Alcohol PD OCT-NOV PY 2004 VL 34 IS 2-3 BP 159 EP 164 DI 10.1016/j.alcohol.2004.07.011 PG 6 WC Substance Abuse; Pharmacology & Pharmacy; Toxicology SC Substance Abuse; Pharmacology & Pharmacy; Toxicology GA 908BO UT WOS:000227762400008 PM 15902909 ER PT J AU Sonnenberg, A AF Sonnenberg, A TI Trials on reflux disease - the role of acid secretion and inhibition SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article; Proceedings Paper CT Symposium on Critical Evidence on Gastric Acid Reflux and Barretts Oesophagus CY 2003 CL Marbella, SPAIN ID HELICOBACTER-PYLORI INFECTION; RANDOMIZED CONTROLLED-TRIAL; GASTROESOPHAGEAL-REFLUX; GASTRIC-ACID; EROSIVE ESOPHAGITIS; APPROPRIATE CONTROLS; BARRETTS-ESOPHAGUS; SYMPTOM RELIEF; CORPUS GASTRITIS; PEPSIN-SECRETION AB The importance of gastric acid in the pathophysiology of gastro-oesophageal reflux disease is substantiated by the extraordinary therapeutic success of acid inhibition in the management of the disease. The influence of many risk factors for gastro-oesophageal reflux disease is also mediated through their effect on gastric acid secretion and acid reflux. Helicobacter pylori reduces the risk of gastro-oesophageal reflux disease by causing corpus gastritis and reducing gastric acid output. The geographical and temporal trends of H. pylori infection in human populations and its influence on gastric acid secretion are responsible for much of the apparent epidemiology of gastro-oesophageal reflux disease. On average, intra-oesophageal exposure to acid is higher in patients who respond poorly to antisecretory medication. It also tends to increase with increasing severity of reflux disease. However, gastric acid secretion and intra-oesophageal acid exposure vary markedly in reflux patients. The degrees of gastric or intra-oesophageal acidity do not allow the prediction of the presence or severity of gastro-oesophageal reflux disease in the individual subject. The many clinical trials on gastro-oesophageal reflux disease indicate that the reflux of gastric acid constitutes an essential mechanism in the development of this disease, but that additional and partly unknown risk factors must contribute to its aetiology and promote its occurrence in the individual patient. C1 Portland VA Med Ctr, Gastroenterol Sect, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Portland, OR USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Gastroenterol Sect, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 41 TC 3 Z9 4 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD OCT PY 2004 VL 20 SU 5 BP 2 EP 8 DI 10.1111/j.1365-2036.2004.02131.x PG 7 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 858CH UT WOS:000224167300002 PM 15456457 ER PT J AU Sonnenberg, A AF Sonnenberg, A TI Anti-reflux surgery and endoluminal therapies SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article; Proceedings Paper CT Symposium on Critical Evidence on Gastric Acid Reflux and Barretts Oesophagus CY 2003 CL Marbella, SPAIN ID GASTROESOPHAGEAL-REFLUX DISEASE; LAPAROSCOPIC NISSEN FUNDOPLICATION; BARRETTS-ESOPHAGUS; FOLLOW-UP; TOUPET FUNDOPLICATION; RADIOFREQUENCY ENERGY; SURGICAL THERAPY; CONTROLLED TRIAL; GERD; ADENOCARCINOMA AB In the short term, fundoplication and antisecretory medication are equally effective in the management of gastro-oesophageal reflux disease. However, over the long term, the fundoplication wrap tends to become loose, and many surgical patients continue to take antisecretory medication after surgery. The operation is technically complex and takes a long time to learn. Inexperience of the individual surgeon is a major factor contributing to the occurrence of postsurgical complications. Fundoplication does not prevent the occurrence of Barrett's oesophagus nor its progression to oesophageal adenocarcinoma. There is no evidence to suggest that the procedure is less costly or more cost-effective than long-term maintenance therapy with antisecretory medications, especially if surgical failures and postsurgical complications are taken into account. Fundoplication represents an alternative to medical therapy in patients with gastro-oesophageal reflux disease who cannot or do not want to be on long-term maintenance therapy with antisecretory medication. Endoluminal procedures, such as radiofrequency ablation, endoscopic suturing and injection at the gastro-oesophageal junction, work only in mild forms of reflux disease. They fail to provide complete relief of reflux symptoms and do not heal erosive oesophagitis. All endoluminal procedures would have to undergo major technological improvements before they could become comparable with fundoplication or antisecretory therapy. C1 Portland VA Med Ctr, Gastroenterol Sect, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Portland, OR USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Gastroenterol Sect, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 34 TC 4 Z9 4 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD OCT PY 2004 VL 20 SU 5 BP 81 EP 88 DI 10.1111/j.1365-2036.2004.02130.x PG 8 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 858CH UT WOS:000224167300014 PM 15456469 ER PT J AU Ezekiel, F Chao, L Kornak, J Du, AT Cardenas, V Truran, D Jagust, W Chui, H Miller, B Yaffe, K Schuff, N Weiner, M AF Ezekiel, F Chao, L Kornak, J Du, AT Cardenas, V Truran, D Jagust, W Chui, H Miller, B Yaffe, K Schuff, N Weiner, M TI Comparisons between global and focal brain atrophy rates in normal aging and Alzheimer disease boundary shift integral versus tracing of the entorhinal cortex and hippocampus SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE dementia; boundary shift integral; serial MRI; longitudinal; normal aging; Alzheimer disease ID COGNITIVE IMPAIRMENT; MRI; AD; PROGRESSION; VOLUMETRY; DEMENTIA; DECLINE AB The objectives of this study were to (1) compare atrophy rates associated with normal aging and Alzheimer disease (AD) using the semi-automated Boundary Shift Integral (BSI) method and manual tracing of the entorhinal cortex (ERC) and hippocampus and (2) calculate power of BSI vs. ERC and hippocampal volume changes for clinical trials in AD. We quantified whole brain and ventricular BSI atrophy rates and ERC and hippocampal atrophy rates from longitudinal MRI data in 20 AD patients and 22 age-matched healthy controls. All methods revealed significant brain atrophy in controls and AD patients. AD patients had approximately 2.5 times greater whole brain BSI atrophy rates and more than 5 times greater ERC and hippocampal atrophy rates than controls. ERC and hippocampal atrophy rates were higher in both groups than whole brain BSI atrophy rates, but lower than ventricular BSI atrophy rates. Effect size and power calculations suggest that ERC and hippocampal measurements may be more sensitive than ventricular or whole brain BSI for detecting AD progression and the potential effects of disease modifying agents. Logistic regression analysis revealed that combined rates of ERC and ventricular BSI were the best explanatory variables for classifying AD from controls. C1 San Francisco VA Med Ctr, Magnet Resonance Unit, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif Berkeley, Inst Neurosci, Berkeley, CA 94720 USA. Univ So Calif, Dept Neurol, Los Angeles, CA 90089 USA. RP Weiner, M (reprint author), San Francisco VA Med Ctr, Magnet Resonance Unit, 114M,4150 Clement St, San Francisco, CA 94121 USA. EM mweiner@itsa.ucsf.edu FU NIA NIH HHS [P01 AG012435, P01 AG12435, P50 AG023501, R01 AG010897, R01 AG10897] NR 28 TC 44 Z9 45 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD OCT-DEC PY 2004 VL 18 IS 4 BP 196 EP 201 PG 6 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 882HM UT WOS:000225930000008 PM 15592130 ER PT J AU Graham, DP Cully, JA Snow, AL Massman, P Doody, R AF Graham, DP Cully, JA Snow, AL Massman, P Doody, R TI The Alzheimer's disease assessment scale - Cognitive subscale - Normative data for older adult controls SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE Alzheimer disease; assessment; dementia ID PERFORMANCE; POPULATION; PREDICTORS; EDUCATION; VALIDITY; TRIALS AB The Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-cog) is commonly used to assess cognitive dysfunction in individuals with Alzheimer disease and other dementias. The purpose of this study was to provide non-native scores for the ADAS-cog 11 individual items and total score, as well for delayed recall errors, using normal, elderly volunteers. The ADAS-cog was administered to 124, non-cognitively impaired volunteers ages 55 to 89, with 10 to 21 years of education. The mean total ADAS-cog score was five. The ADAS-cog error score was not associated with education in this highly educated group, and was positively correlated (P < 0.001) with the age of the participant. Age stratified ADAS-cog normative data are reported for the ADAS-cog total and the delayed recall error score. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Ultizat Studies Hlth Serv, Houston, TX 77030 USA. Baylor Coll Med, Vet Affairs S Cent MIRECC, Houston, TX 77030 USA. Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. Univ Houston, Dept Psychol, Houston, TX 77004 USA. Baylor Coll Med, Rush Alzheimers Dis Ctr, Houston, TX 77030 USA. RP Graham, DP (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Ultizat Studies Hlth Serv, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM david.graham@med.va.gov RI Graham, David /J-1158-2014 FU NIA NIH HHS [AGO P50 8664] NR 27 TC 24 Z9 28 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD OCT-DEC PY 2004 VL 18 IS 4 BP 236 EP 240 PG 5 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 882HM UT WOS:000225930000015 PM 15592137 ER PT J AU Beer, TM Garzotto, M Katovic, NM AF Beer, TM Garzotto, M Katovic, NM TI High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS LA English DT Article DE prostate cancer; chemotherapy; carboplatin; calcitriol; vitamin D ID SQUAMOUS-CELL CARCINOMA; VITAMIN-D ANALOGS; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; 1,25-DIHYDROXYVITAMIN D-3; ANTITUMOR-ACTIVITY; PLATINUM DRUGS; IN-VITRO; HUMAN KERATINOCYTES; OVARIAN-CARCINOMA; CLINICAL-TRIALS AB Calcitriol acts synergistically with carboplatin in preclinical models of adenocarcinoma of the prostate. The authors sought to test high-dose oral calcitriol in combination with carboplatin in patients with metastatic androgen-independent prostate cancer. Seventeen patients received oral calcitriol (0.5 mug/kg) on day 1 and intravenous carboplatin (AUC 7 or AUC 6 in patients with prior radiation) on day 2, repeated every 4 weeks. PSA response was the primary end point and was defined as a 50% reduction confirmed 4 weeks later. Palliative response (2-point reduction or normalization of pain on the present pain intensity [PPI] scale without increased analgesic consumption) was also examined. One of 17 patients (6%, 95% CI, 0-28) achieved a confirmed PSA response. Four patients (24%, 95% CI, 7-49) had PSA reductions ranging from 24 to 38%. Of the 15 patients with a PPI greater than or equal to 1 point on entry, 3 (18%, 95% CI, 4-48) met criteria for palliative response. Treatment-related toxicity was mild and generally similar to that expected with single-agent carboplatin. Despite encouraging preclinical evidence, the addition of oral calcitriol to carboplatin in this study was not associated with an increase in the response rate when compared with the reported activity of carboplatin alone. C1 Oregon Hlth Sci Univ, Dept Med, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR USA. RP Beer, TM (reprint author), Oregon Hlth Sci Univ, Dept Med, Mail Code L586,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM beert@ohsu.edu FU NCRR NIH HHS [3M01RR00334-33S2] NR 60 TC 24 Z9 25 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-3732 J9 AM J CLIN ONCOL-CANC JI Am. J. Clin. Oncol.-Cancer Clin. Trials PD OCT PY 2004 VL 27 IS 5 BP 535 EP 541 DI 10.1097/01.coc.0000136020.27904.9c PG 7 WC Oncology SC Oncology GA 860JC UT WOS:000224337500021 PM 15596926 ER PT J AU Faigel, DO Sonnenberg, A Lieberman, DA AF Faigel, DO Sonnenberg, A Lieberman, DA TI Virtual Colonoscopy is not safer: Procedure- and screening program-related mortality of colonoscopy versus CT colonography SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 69th Annual Scientific Meeting of the American-College-of-Gastroentrology CY OCT 29-NOV 03, 2004 CL Orlando, FL SP Amer Coll Gastroentrol C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2004 VL 99 IS 10 SU S MA 978 BP S322 EP S322 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 862GW UT WOS:000224479700972 ER PT J AU Pisegna, JR Karlstadt, RG Oh, D Graepel, J Dorr, MB AF Pisegna, JR Karlstadt, RG Oh, D Graepel, J Dorr, MB TI Preoperative IV pantoprazole (IVP) decreases gastric volume (GV) and acid output (GAO) and increases pH in elective surgery patients SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 69th Annual Scientific Meeting of the American-College-of-Gastroentrology CY OCT 29-NOV 03, 2004 CL Orlando, FL SP Amer Coll Gastroentrol C1 Univ Calif Los Angeles, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Wyeth Pharmaceut, Collegeville, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2004 VL 99 IS 10 SU S MA 118 BP S40 EP S40 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 862GW UT WOS:000224479700118 ER PT J AU Qureshi, W Willingham, F Anand, BS AF Qureshi, W Willingham, F Anand, BS TI Localizing the lesion by capsule endoscopy: Newer techniques in improving accuracy SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 69th Annual Scientific Meeting of the American-College-of-Gastroentrology CY OCT 29-NOV 03, 2004 CL Orlando, FL SP Amer Coll Gastroentrol C1 Baylor Coll Med, Houston, TX 77030 USA. VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2004 VL 99 IS 10 SU S MA 202 BP S67 EP S67 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 862GW UT WOS:000224479700202 ER PT J AU Hutt, E Reznickova, N Morgenstern, N Frederickson, E Kramer, AM AF Hutt, E Reznickova, N Morgenstern, N Frederickson, E Kramer, AM TI Improving care for nursing home-acquired pneumonia in a managed care environment SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID CONTROLLED TRIAL; RESIDENTS; FACILITIES; GUIDELINES; IMPROVEMENT; INFLUENZA; MORTALITY; PROGRAM; VACCINATION; PREVENTION AB Objective: To characterize care of nursing home residents who became ill with nursing home-acquired pneumonia (NHAP) in a group-model, nonprofit HMO, and to pilot-test a strategy to implement evidence-based NHAP care guidelines. Study Design: Medical record review and intervention pilot test. Methods: Nursing home medical records of 78 patients who developed NHAP in 6 homes where the HMO contracts for Medicare services were reviewed for demographics, functional status, comorbidity, NHAP severity, care processes, and guideline compliance. The intervention, combining organizational change (facilitating immunization and providing appropriate emergency antibiotics) and education (quarterly in-services for nursing and aide staff), was pilot-tested for 7 months in I facility. Measures of baseline and intervention guideline adherence at that facility were compared with Fisher's exact test. Results: Among the patients with NHAP, 83% had a response from their physician in less than 8 hours, 82% were treated with an antibiotic that met spectrum recommendations, and 74% were able to swallow were treated with oral antibiotics. However, few patients had documentation of influenza and pneumococcal vaccination; less than half the direct care staff had been vaccinated; and nursing assessments were incomplete for 23%. At the pilot-test facility, improvement was seen in influenza vaccination (14% to 52%, P = .01) and use of the most appropriate antibiotics (47% to 85%; P = .03). The guideline adherence score improved from 52% to 63% (P = .04). Conclusion: Use of a multidisciplinary, multifaceted intervention resulted in improvement in quality of care for nursing home residents who become ill with pneumonia. C1 Denver VAMC, Program Improve Qual Life & Care Vet LTC, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Div Hlth Care Policy & Res, Denver, CO USA. Kaiser Permanente, Denver, CO USA. RP Hutt, E (reprint author), Denver VAMC, Program Improve Qual Life & Care Vet LTC, 151,1055 Clermont St, Denver, CO 80220 USA. EM evelyn.hutt@uchsc.edu NR 27 TC 9 Z9 9 U1 0 U2 4 PU AMER MED PUBLISHING, M W C COMPANY PI JAMESBURG PA 241 FORSGATE DR, STE 102, JAMESBURG, NJ 08831 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD OCT PY 2004 VL 10 IS 10 BP 681 EP 686 PG 6 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 862QA UT WOS:000224504600006 PM 15521159 ER PT J AU Nagami, GT AF Nagami, GT TI Ammonia production and secretion by S3 proximal tubule segments from acidotic mice: role of ANG II SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE ammonia transport; ammoniagenesis; acid-base physiology; losartan ID CHRONIC METABOLIC-ACIDOSIS; RAT NEPHRON SEGMENTS; ANGIOTENSIN-II; PERFUSED INVITRO; EXCRETION; MICROPUNCTURE; MEMBRANE AB ANG II has potent effects on ammonia production and secretion rates by the proximal tubule and is found in substantial concentrations in the lumen of the proximal tubule in vivo. Because our previous studies demonstrated that acid loading enhanced the stimulatory effects of ANG II on ammonia production and secretion by S2 proximal tubule segments, we examined the effect of ANG II on ammonia production and secretion by isolated, perfused S3 segments from nonacidotic control mice and acidotic mice given NH(4)Cl for 7 days. In the absence of ANG II, ammonia production and secretion rates were no different in S3 segments from acidotic and control mice. By contrast, when ANG II was present in the luminal perfusion solution, ammonia production and secretion rates were stimulated, in a losartan-inhibitable manner, to a greater extent in S3 segments from acidotic mice. Ammonia secretion rates in S3 segments were largely inhibited by perfusion with a low-sodium solution containing amiloride in the presence or absence of ANG II. These results demonstrated that isolated, perfused mouse S3 proximal tubule segments produce and secrete ammonia, that NH(4)Cl-induced acidosis does not affect the basal rates of ammonia production and secretion, and that ANG II, added to the luminal fluid, stimulates ammonia production and secretion to a greater extent in S3 segments from acidotic mice. These findings suggest that S3 segments, in the presence of ANG II, can contribute to the enhanced renal excretion that occurs with acid loading. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Med Serv, Nephrol Sect 111L, Los Angeles, CA 90073 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Nagami, GT (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Med Serv, Nephrol Sect 111L, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 31 TC 18 Z9 18 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD OCT PY 2004 VL 287 IS 4 BP F707 EP F712 DI 10.1152/ajprenal.00189.2003 PG 6 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 851CZ UT WOS:000223664300014 PM 15345494 ER PT J AU Adler, LE Olincy, A Cawthra, EM McRae, KA Harris, JG Nagamoto, HT Waldo, MC Hall, MH Bowles, A Woodward, L Randal, R Freedman, R AF Adler, LE Olincy, A Cawthra, EM McRae, KA Harris, JG Nagamoto, HT Waldo, MC Hall, MH Bowles, A Woodward, L Randal, R Freedman, R TI Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID NEUROPHYSIOLOGICAL EVIDENCE; STIMULATION INTERVAL; ANTIPSYCHOTIC-DRUGS; EVOKED-RESPONSES; SUPPRESSION; CLOZAPINE; RELATIVES; DEFICITS; NORMALIZATION; HABITUATION AB Objective: Sensory gating deficits found in schizophrenia can be assessed by using a paired auditory stimulus paradigm to measure auditory evoked response, The ratio of the P50 response amplitude of the second or test stimulus to that of the first or conditioning stimulus is expressed as a percentage. Normal subjects generally suppress the second response and typically have ratios of less than 40%. Subjects with schizophrenia and half their first-degree relatives have deficits in sensory gating, with P50 ratios that are generally greater than 50%. Treatment with typical neuroleptics does not reverse this deficit. However, previous studies have shown that treatment with clozapine, an atypical neuroleptic, ameliorates this deficit in clinically responsive patients. This study sought to determine whether other atypical neuroleptics improve P50 ratios. Method: P50 evoked potential recordings were obtained from 132 patients with schizophrenia and 177 healthy comparison subjects. Eighty-eight patients were being treated with atypical neuroleptics (clozapine [N=26], olanzapine [N=31], risperidone [N=22], and quetiapine [N=9]). Thirty-four patients were taking typical neuroleptics, and 10 were unmedicated. Results: Healthy subjects exhibited P50 suppression that was significantly better than the schizophrenia patients receiving typical neuroleptics (mean=19.8% [SD= 21.0%] versus 110.1% [SD=87.9%]). Patients receiving atypical neuroleptics had a mean P50 ratio that fell between these two means (mean=70.4%, SD=53.7%). When patients treated with different atypical neuroleptics were compared, only the clozapine group had mean P50 ratios that were in the normal range. All other groups exhibited auditory P50 response inhibition that was significantly poorer than that of the healthy subjects. Conclusions: Improvement in P50 gating appears to be greatest in patients treated with clozapine. C1 Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA. Denver VA Med Ctr, Denver, CO USA. RP Waldo, MC (reprint author), Univ Colorado, Hlth Sci Ctr, Box C268-26,4200 E 9th Ave, Denver, CO 80262 USA. EM merilyne.waldo@uchsc.edu RI Hall, Mei-Hua/A-3674-2008 OI Hall, Mei-Hua/0000-0002-4558-7023 FU NIMH NIH HHS [5R01-MH-50787, 5R0-MH-38321, 2K02-MH-01121] NR 46 TC 128 Z9 137 U1 3 U2 4 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD OCT PY 2004 VL 161 IS 10 BP 1822 EP 1828 DI 10.1176/appi.ajp.161.10.1822 PG 7 WC Psychiatry SC Psychiatry GA 859OY UT WOS:000224279000016 PM 15465979 ER PT J AU Rosen, J Mulsant, BH Bruce, ML Mittal, V Fox, D AF Rosen, J Mulsant, BH Bruce, ML Mittal, V Fox, D TI Actors' portrayals of depression to test interrater reliability in clinical trials SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID STUDENTS AB Objective: This study determined if actors could portray depressed patients to establish the interrater reliability of raters using the Hamilton Depression Rating Scale (HDRS). Method: Actors portrayed depressed patients using scripts derived from HDRS assessments obtained at three points during treatment. Four experienced raters blindly viewed videotapes of two patients and two actors. They guessed if each interviewee was a patient or an actor and rated the certainty of their guesses. For each interview, they also rated the realism of the portrayal and completed the HDRS. Results: Experienced raters could not distinguish actors and patients better than chance and were equally certain of their right and wrong guesses. Actors and patients received high scores on the realism of their portrayals. The HDRS scores of the actor-patient pairs were correlated. Conclusions: Actors can effectively portray depressed patients. Future studies will determine if actors can accurately portray patients with anxiety and psychosis. C1 Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. Univ Pittsburgh, Katz Grad Sch Business, Pittsburgh, PA 15260 USA. VA Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. Cornell Univ, Weill Med Coll, White Plains, NY USA. Fox Learning Syst Inc, Bridgeville, PA USA. RP Mulsant, BH (reprint author), 3811 O Hara St, Pittsburgh, PA 15213 USA. EM mulsantbh@upmc.edu FU AHRQ HHS [HS-11976]; NIA NIH HHS [AG-19088]; NIMH NIH HHS [MH-61639, MH-01634, MH-01613, MH-52247] NR 9 TC 5 Z9 5 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD OCT PY 2004 VL 161 IS 10 BP 1909 EP 1911 DI 10.1176/appi.ajp.161.10.1909 PG 3 WC Psychiatry SC Psychiatry GA 859OY UT WOS:000224279000027 PM 15465990 ER PT J AU Wang, EA Lee, MH Wang, MC Lee, HY AF Wang, EA Lee, MH Wang, MC Lee, HY TI Iatrogenic left iliac-caval fistula: Imaging and endovascular treatment SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article ID LUMBAR-DISK SURGERY; ARTERIOVENOUS-FISTULAS; AORTOCAVAL; ANATOMY C1 Olive View UCLA Med Ctr, Dept Radiol, Sylmar, CA 91342 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Imaging Serv, Los Angeles, CA USA. RP Lee, MH (reprint author), Olive View UCLA Med Ctr, Dept Radiol, 14445 Olive View Dr, Sylmar, CA 91342 USA. EM marglee@ucla.edu NR 8 TC 4 Z9 6 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD OCT PY 2004 VL 183 IS 4 BP 1032 EP 1034 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 858UJ UT WOS:000224217200026 PM 15385299 ER PT J AU Weinrieb, RM O'Brien, CP AF Weinrieb, RM O'Brien, CP TI A case report of naltrexone for alcoholism in a liver transplant recipient: Side effects and safety SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID DEPENDENCE; NALOXONE; PAIN C1 Univ Penn, Treatment & Evaluat Ctr, Dept Psychiat, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Mental Illness Res & Educ Ctr, Philadelphia, PA USA. RP Weinrieb, RM (reprint author), Univ Penn, Treatment & Evaluat Ctr, Dept Psychiat, 3440 Market St,Suite 370, Philadelphia, PA 19104 USA. EM Weinrieb_B@mail.trc.upenn.edu NR 9 TC 5 Z9 5 U1 1 U2 1 PU BRUNNER-ROUTLEDGE PI PHILADELPHIA PA 325 CHESTNUT ST, 8TH FL, PHILADELPHIA, PA 19106 USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PD OCT-DEC PY 2004 VL 13 IS 5 BP 495 EP 497 DI 10.1080/10550490490512870 PG 3 WC Substance Abuse SC Substance Abuse GA 875AW UT WOS:000225393000007 PM 15764427 ER PT J AU Maggard, MA Zingmond, D O'Connell, JB Ko, CY AF Maggard, MA Zingmond, D O'Connell, JB Ko, CY TI What proportion of patients with an ostomy (for diverticulitis) get reversed? SO AMERICAN SURGEON LA English DT Article; Proceedings Paper CT Annual Meeting of the Southern California Chapter of the American-College-of-Surgeons CY JAN 16-18, 2004 CL Santa Barbara, CA SP Amer Coll Surg, SO Calif Chapter ID QUALITY-OF-LIFE; COLOSTOMY CLOSURE; COMPLICATIONS; MORBIDITY; SURGERY; IMPACT AB A common operation for patients with complicated sigmoid diverticulitis is resection and placement of an ostomy (Hartmann procedure). This population-based study examines that proportion of ostomates who undergo reversal. In the California inpatient file, patients admitted for acute diverticulitis in 1995 were identified, including a subset that had surgical resection. Data regarding receipt of ostomy were obtained (4-year follow-up). Demographics and clinical data (procedure, ostomy reversal, time to reversal, comorbidity score, and complications) were collected. In 1995, 11,582 admissions for diverticulitis occurred in California. Of these, 24.2 per cent (n = 2808) underwent surgery at admission; 88.9 per cent were sigmoid/left colectomies; and 41.7 per cent had a Hartmann procedure. Patients with ostomies were older (P = 0.0004) and male (P = 0.03). Median comobidity score was the same for patients with or without an ostomy. Of the 1176 patients who had the Hartmann procedure, 65 per cent underwent reversal (mean 143 days). A larger proportion of men than women had their ostomies reversed (74.5% vs 55.9%, respectively, P < 0.0001). Median comorbidity scores for both groups were low, 0 for those reversed and 1 for nonreversed. Our study shows that although the majority of patients had their ostomies reversed, over 35 per cent did not at 4-year follow-up. Further studies are required to evaluate how this rate may be improved. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA. W Los Angeles Vet Adm, Dept Surg, Los Angeles, CA USA. W Los Angeles Vet Adm, Dept Gen Internal Med, Los Angeles, CA USA. RP Maggard, MA (reprint author), 911 Broxton Ave,3rd Floor, Los Angeles, CA 90024 USA. NR 13 TC 53 Z9 53 U1 0 U2 0 PU SOUTHEASTERN SURGICAL CONGRESS PI ATLANTA PA 141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA SN 0003-1348 J9 AM SURGEON JI Am. Surg. PD OCT PY 2004 VL 70 IS 10 BP 928 EP 931 PG 4 WC Surgery SC Surgery GA 862CW UT WOS:000224468300023 PM 15529854 ER PT J AU Harris, BS Jay, PY Rackley, MS Izumo, S O'Brien, TX Gourdie, RG AF Harris, BS Jay, PY Rackley, MS Izumo, S O'Brien, TX Gourdie, RG TI Transcriptional regulation of cardiac conduction system development: 2004 FASEB Cardiac Conduction System Minimeeting, Washington, DC SO ANATOMICAL RECORD PART A-DISCOVERIES IN MOLECULAR CELLULAR AND EVOLUTIONARY BIOLOGY LA English DT Article; Proceedings Paper CT FASEB Experimental Biology Meeting CY APR, 2004 CL Washington, DC SP FASEB DE heart conduction system; Nkx2-5; Purkinje fibers; development; atrioventricular block ID CONGENITAL HEART-DISEASE; HOLT-ORAM-SYNDROME; PURKINJE-FIBERS; NEURAL CREST; T-GENE; MESODERM FORMATION; NKX2.5 MUTATIONS; SKELETAL-MUSCLE; EMBRYONIC HEART; BOX GENE AB The development of the complex network of specialized cells that form the atrioventricular conduction system (AVCS) during cardiac morphogenesis occurs by progressive recruitment within a multipotent cardiomyogenic lineage. Understanding the molecular control of this developmental process has been the focus of recent research. Transcription factors representative of multiple subfamilies have been identified and include members of zinc-finger subfamilies (GATA4, GATA6 HF-1b), skeletal muscle transcription factors (MyoD), T-box genes (Tbx5), and also homeodomain transcription factors (Msx2 and Nkx2.5). Mutations in some of these transcription factors cause congenital heart disease and are associated with cardiac abnormalities, including deficits within the AVCS. Mouse models that closely phenocopy known human heart disease provide powerful tools for the study of molecular effectors of AVCS development. Indeed, investigations of the Nkx2.5 haploinsufficient mouse have shown that peripheral Purkinje fibers are significantly underrepresented. This piece of data corroborates our previous work showing in chick, mouse, and humans that Nkx2.5 is elevated in the differentiating AVCS relative to adjacent working ventricular myocardial tissues. Using the chick embryo as a model, we show that this elevation of Nkx2.5 is transient in the network of conduction cells comprising the peripheral Purkinje fiber system. Functional studies using defective adenoviral constructs, which disrupt the normal variation in level of this gene, result in perturbations of Purkinje fiber phenotype. Thus, the precise spatiotemporal regulation of Nkx2.5 levels during development may be required for the progressive emergence of gene expression patterns specific to differentiated Purkinje fiber cells. Published 2004 Wiley-Liss, Inc.dagger. C1 Med Univ S Carolina, Dept Anat & Cell Biol, Charleston, SC 29425 USA. Med Univ S Carolina, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. Washington Univ, Sch Med, Dept Pediat, Dev Biol Unit, St Louis, MO 63110 USA. Med Univ S Carolina, Ralph H Johnson Dept Vet Affairs Med Ctr, Med Res Serv, Charleston, SC 29425 USA. Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02215 USA. RP Harris, BS (reprint author), Med Univ S Carolina, Dept Anat & Cell Biol, 171 Ashley Ave, Charleston, SC 29425 USA. EM harrisbs@musc.edu FU NHLBI NIH HHS [HL56728, HL36059]; NICHD NIH HHS [HD39946] NR 61 TC 6 Z9 7 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0003-276X J9 ANAT REC PART A JI Anat. Rec. Part A PD OCT PY 2004 VL 280A IS 2 BP 1036 EP 1045 DI 10.1002/ar.a.20101 PG 10 WC Anatomy & Morphology SC Anatomy & Morphology GA 860JF UT WOS:000224337800014 PM 15368344 ER PT J AU Shelburne, SA Musher, DM Hulten, K Ceasar, H Lu, MY Bhaila, I Hamill, RJ AF Shelburne, SA Musher, DM Hulten, K Ceasar, H Lu, MY Bhaila, I Hamill, RJ TI In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID VANCOMYCIN PLUS RIFAMPIN; PROSPECTIVE MULTICENTER; BACTERICIDAL ACTIVITY; ENDOCARDITIS; INFECTIONS; THERAPY; GENTAMICIN; SUSCEPTIBILITY; EPIDEMIOLOGY; MANAGEMENT AB This study employs time-kill techniques to examine the most common drug combinations used in the therapy of methicillin-resistant Staphylococcus aureus (MRSA) infections, vancomycin plus either gentamicin or rifampin. Community-associated MRSA were more likely to be synergistically inhibited by combinations of vancomycin and gentamicin versus vancomycin alone compared to inhibition associated with hospital-acquired strains. C1 Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. Baylor Coll Med, Infect Dis Sect, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Infect Dis Sect, Dept Pediat, Houston, TX 77030 USA. RP Hamill, RJ (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM richard.hamill@med.va.gov OI Hulten, Kristina/0000-0001-7446-157X NR 32 TC 46 Z9 46 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD OCT PY 2004 VL 48 IS 10 BP 4016 EP 4019 DI 10.1128/AAC.48.10.4016-4019.2004 PG 4 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 858UH UT WOS:000224217000055 PM 15388469 ER PT J AU Vartanian, JG Carvalho, AL Yueh, B Priante, AVM de Melo, RL Correia, LM Kohler, HF Toyota, J Kowalski, ISG Kowalski, LP AF Vartanian, JG Carvalho, AL Yueh, B Priante, AVM de Melo, RL Correia, LM Kohler, HF Toyota, J Kowalski, ISG Kowalski, LP TI Long-term quality-of-life evaluation after head and neck cancer treatment in a developing country SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID EUROPEAN ORGANIZATION; VALIDATION; OUTCOMES AB Objective: To evaluate the long-term quality of life of patients treated for head and neck cancer at a single institution in a developing country. Design: Cross-sectional analysis of a consecutive series of patients. Setting: Tertiary cancer center hospital in Brazil. Patients: Eligible subjects included patients treated between 1974 and 1999 for head and neck carcinoma who had a minimum disease-free survival of 2 years and who completed a Portuguese version of the University of Washington Quality of Life (UW-QOL) questionnaire. Main Outcome Measures: Descriptive analyses of the results and comparisons of the scores for each UW-QOL domain, stratified by tumor site, were performed using nonparametric tests. Results: Findings from 344 patients were analyzed. Of the study population, 140 (41%) had survived 2 to 5 years, 125 (36%) had survived 5 to 10 years, and 79 (23%) had survived more than 10 years since treatment. Primary tumor sites were in the oral cavity in 43.3% of cases, the oropharynx in 20.9%, the larynx in 32.0%, and the hypopharynx in 3.8%. In terms of treatment, 33.1% underwent surgery alone; 16.9%, radiotherapy alone; and 50% underwent combined treatment. Overall, 78.5% of the patients classified their own health as good or excellent. Stratified analysis showed that impairment in chewing and swallowing was more common in patients with oral and oropharyngeal tumors than in those with larynx and hypopharynx tumors, and speech impairment was more frequently related to patients with larynx and hypopharynx tumors than to those with oral and oropharynx tumors. In all tumor sites, the composite scores were significantly worse in advanced tumors than early stage tumors, but the use of combined treatment had the greatest negative impact on quality-of-life scores, after we adjusted for T and N stage with multivariable analyses (P<.001). Conclusions: The Portuguese version of the UW-QOL questionnaire was an effective tool to evaluate quality of life in a Brazilian population. Although many patients reported some limitations, most reported a good to excellent long-term quality of life. C1 Hosp Canc AC Camargo, Dept Otolaryngol Head & Neck Surg, BR-01509900 Sao Paulo, Brazil. Univ Washington, Vet Affairs Puget Sound Healthcare Syst, Seattle, WA 98195 USA. Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. RP Kowalski, LP (reprint author), Hosp Canc AC Camargo, Dept Otolaryngol Head & Neck Surg, Rua Professor Antonio Prudente 211, BR-01509900 Sao Paulo, Brazil. EM lp_kowalski@uol.com.br RI Francisco, Suely/D-9065-2014; Kowalski, Luiz/D-1701-2012; Carvalho, Andre/C-1185-2011; Vartanian, Jose/B-4470-2015; Carvalho, Andre/S-7053-2016; Kowalski, Ivonete/E-3040-2017 OI Kowalski, Luiz/0000-0001-5865-9308; Carvalho, Andre/0000-0001-7214-6402; Carvalho, Andre/0000-0001-7214-6402; Kowalski, Ivonete/0000-0001-6043-0924; Yueh, Bevan/0000-0003-1380-1053; Kowalski, Luiz Paulo/0000-0002-0481-156X NR 13 TC 53 Z9 57 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD OCT PY 2004 VL 130 IS 10 BP 1209 EP 1213 DI 10.1001/archotol.130.10.1209 PG 5 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 860OT UT WOS:000224353600014 PM 15492171 ER PT J AU Sassi, RB Brambilla, P Hatch, JP Nicoletti, MA Mallinger, AG Frank, E Kupfer, DJ Keshavan, MS Soares, JC AF Sassi, RB Brambilla, P Hatch, JP Nicoletti, MA Mallinger, AG Frank, E Kupfer, DJ Keshavan, MS Soares, JC TI Reduced left anterior cingulate volumes in untreated bipolar patients SO BIOLOGICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT 57th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 16-18, 2002 CL PHILADELPHIA, PA SP Soc Biol Psychiat DE affective disorders; bipolar disorder; cingulate; mood disorders; MRI; neuroimaging ID POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL BLOOD-FLOW; SUBGENUAL PREFRONTAL CORTEX; MAJOR DEPRESSIVE DISORDER; SEASONAL AFFECTIVE-DISORDER; BRAIN GLUCOSE-METABOLISM; IN-VIVO; MOOD DISORDERS; FUNCTIONAL NEUROANATOMY; COGNITIVE IMPAIRMENT AB Background: Functional and morphologic abnormalities of the cingulate cortex have been reported in mood disorder patients. To examine the involvement of anatomic abnormalities of the cingulate in bipolar disorder, we measured the volumes of this structure in untreated and lithium-treated bipolar patients and healthy contrl subjects, using magnetic resonance imaging. Methods: the volume of gray matter at the right and left anterior and posteriorcingulate cortices were measured in 11 bipolar patientsnot taking any psychotropic medications (aged 38 +/-11 years, 5 women), 16 bipolar patients treated with lithium monotherapy (aged 33 +/- 11 years, 7 women), and 39 healthy control subjects (aged 37 +/- 10 years, 14 women). Volumetric measurements were made with T1-weighted control MRI images, with 1.5 mm-thick slices. at 1.5T, and were done blindly. Results: Using analysis of covariance with age and intracranial volume as covariates, we found that untreated bipolar patients had decreased left anterior cingulate with age and intracranial volume compared with healthy control subjects [2.4 +/- .3cm(3) and 2.9 +/- .6cm(3), respectively, F(1.58) = 6.4, p = 0.42] and compared with the lithium-treated patients [3.3 +/- .5cm(3) : F(1.58) = 11.7, p = .003]. The cingulate volumes in lithium-treated patients were not significantly different from those of healthy control subjects. Conclusion: Our findings indicate that anatomic abnormalities in left anterior cingulate are present in bipolar patients. Furthermore our results suggest that lithium treatment might influence cingulate volumes in bipolar patients, which could possibly reflect postulated neuroprotective effects of lithium. C1 Univ Texas, Hlth Sci Ctr, Div Mood & Anxiety Disorders, Dept Psychiat, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. Audie L Murphy Div, San Antonio, TX 78229 USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA. Univ Sao Paulo, Inst Psychiat, Dept Psychiat, Sch Med, Sao Paulo, Brazil. Univ Pavia, Sch Med, IRCCS, Dept Psychiat, I-27100 Pavia, Italy. RP Soares, JC (reprint author), Univ Texas, Hlth Sci Ctr, Div Mood & Anxiety Disorders, Dept Psychiat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM soares@uthscsa.edu RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 FU NIMH NIH HHS [MH 01736, MH 29618, MH 30915] NR 88 TC 128 Z9 130 U1 5 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD OCT 1 PY 2004 VL 56 IS 7 BP 467 EP 475 DI 10.1016/j.biopsych.2004.07.005 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 857JV UT WOS:000224113400001 PM 15450781 ER PT J AU Kilbourne, AM Cornelius, JR Han, XY Pincus, HA Shad, M Salloum, I Conigliaro, J Haas, GL AF Kilbourne, AM Cornelius, JR Han, XY Pincus, HA Shad, M Salloum, I Conigliaro, J Haas, GL TI Burden of general medical conditions among individuals with bipolar disorder SO BIPOLAR DISORDERS LA English DT Article DE aging; bipolar disorder; comorbidity; diabetes mellitus; metabolic syndrome; substance-related disorders ID CARE; PREVALENCE; SUBSTANCE; LITHIUM; IMPACT; COSTS; ABUSE AB Objective: Treatment of coexisting medical comorbidities may reduce the risk of adverse outcomes among patients with bipolar disorder. We determined the prevalence of general medical conditions in a population-based sample of patients diagnosed with bipolar disorder in the Veterans Administration (VA). Methods: We conducted a cross-sectional study of patients (n = 4310) diagnosed with bipolar disorder in fiscal year 2001 receiving care at VA facilities located within the mid-Atlantic region. General medical conditions were assessed using ICD-9 codes, and we compared the prevalence of each condition in our bipolar sample with national data on the VA patient population. Results: The mean age was 53 (SD = 13), 10% were women, and 12% African-American. The mean age of the VA national patient population was higher (58 years). The most prevalent conditions among patients with bipolar disorder included cardiovascular (e.g. hypertension, 35%), endocrine (e.g. hyperlipidemia, 23%; diabetes, 17%), and alcohol use disorder (25%). When compared with national data, the prevalence of diabetes was higher in the bipolar cohort than in the national cohort (17.2% versus 15.6%; p = 0.0035). Hepatitis C was more common in the bipolar group than the national cohort (5.9% versus 1.1%; p < 0.001). Lower back pain (15.4% versus 10.6%; p < 0.0001) and pulmonary conditions (e.g. COPD: 10.6% versus 9.4%; p = 0.005) were also more prevalent among the bipolar cohort than the VA national cohort. Conclusions: Individuals with bipolar disorder possess a substantial burden of general medical comorbidity, and are occurring at an earlier age than in the general VA patient population, suggesting the need for earlier detection and treatment for patients with bipolar disorder. C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA. RAND Univ Pittsburgh Hlth Inst, Pittsburgh, PA USA. RP Kilbourne, AM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr C, Pittsburgh, PA 15240 USA. EM amy.kilbourne@med.va.gov FU NIMH NIH HHS [MH30915] NR 21 TC 186 Z9 192 U1 2 U2 5 PU BLACKWELL MUNKSGAARD PI COPENHAGEN PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD OCT PY 2004 VL 6 IS 5 BP 368 EP 373 DI 10.1111/j.1399-5618.2004.00138.x PG 6 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 855TD UT WOS:000223996200003 PM 15383128 ER PT J AU McNeil, MR Hula, WD Matthews, CT Doyle, PJ Fossett, TRD AF McNeil, MR Hula, WD Matthews, CT Doyle, PJ Fossett, TRD TI Auditory comprehension and visual-manual tracking dual-task performance in aphasia: Preliminary findings SO BRAIN AND LANGUAGE LA English DT Meeting Abstract ID ATTENTION C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Pittsburgh, PA 15260 USA. EM mcneil@pitt.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0093-934X J9 BRAIN LANG JI Brain Lang. PD OCT PY 2004 VL 91 IS 1 BP 31 EP 32 DI 10.1016/j.bandl.2004.06.019 PG 2 WC Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental SC Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology GA 861TZ UT WOS:000224442800014 ER PT J AU Singh, I Paintlia, AS Khan, M Stanislaus, R Paintlia, MK Haq, E Singh, AK Contreras, MA AF Singh, I Paintlia, AS Khan, M Stanislaus, R Paintlia, MK Haq, E Singh, AK Contreras, MA TI Impaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment SO BRAIN RESEARCH LA English DT Article DE peroxisome; experimental autoimmune encephalomyelitis; statin; neuroinflammation ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; X-LINKED ADRENOLEUKODYSTROPHY; BETA-OXIDATION ENZYMES; RAT-LIVER PEROXISOMES; NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; CHAIN FATTY-ACIDS; MULTIPLE-SCLEROSIS; LEWIS RATS; REDUCTASE INHIBITOR AB Peroxisomes are ubiquitous subcellular organelles and abnormality in their biogenesis and specific gene defects leads to fatal demyelinating disorders. We report that neuroinflammatory disease in brain of experimental autoimmune encephalomyelitis (EAE) rats decreased the peroxisomal functions. Degradation of very long chain fatty acids decreased by 47% and resulted in its accumulation (C26:0, 40%). Decreased activity (66% of control) of dihydroxyacetonephosphate acyltransferase (DHAP-AT), first enzyme in plasmalogens biosynthesis, resulted in decreased levels of plasmalogens (16-30%). Catalase activity, a peroxisomal enzyme, was also reduced (37%). Gene microarray analysis of EAE spinal cord showed significant decrease in transcripts encoding peroxisomal proteins including catalase (folds 3.2; p<0.001) and DHAP-AT (folds 2.6; p<0.001). These changes were confirmed by quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis, suggesting that decrease of peroxisomal functions in the central nervous system will have negative consequences for myelin integrity and repair because these lipids are major constituents of myelin. However, lovastatin (a cholesterol lowering and anti-inflammatory drug) administered during EAE induction provided protection against loss/down-regulation of peroxisomal functions. Attenuation of induction of neuro inflammatory mediators by statins in cultured brain cells [J. Clin. Invest. 100 (1997) 2671-2679], and in central nervous system of EAE animals and thus the EAE disease [J. Neurosci. Res. 66 (2001) 155-162] and the studies described here indicate that inflammatory mediators have a marked negative effect on peroxisomal functions and thus on myelin assembly and that these effects can be prevented by treatment with statins. These observations are of importance because statins are presently being tested as therapeutic agents against a number of neuroinflammatory demyelinating diseases. (C) 2004 Elsevier B.V All rights reserved. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA. EM singhi@musc.edu OI Paintlia, Ajaib/0000-0003-4525-5333; Haq, Ehtishamul/0000-0002-4195-0606 FU NINDS NIH HHS [NS 37766, NS 22576, NS 34741, NS 40144, NS 40810] NR 62 TC 41 Z9 43 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD OCT 1 PY 2004 VL 1022 IS 1-2 BP 1 EP 11 DI 10.1016/j.brainres.2004.06.059 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 856GL UT WOS:000224033600001 PM 15353207 ER PT J AU Hussein, MR Hassan, HI AF Hussein, MR Hassan, HI TI Alterations of p53, Bcl-2, and hMSH2 protein expression in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas in the Upper Egypt SO CANCER BIOLOGY & THERAPY LA English DT Article DE p53; Bcl-2; hMSH2; breast cancer ID RADIAL GROWTH-PHASE; CUTANEOUS MALIGNANT MELANOMAS; ULTRAVIOLET-B IRRADIATION; TUMOR-SUPPRESSOR GENE; MICROSATELLITE INSTABILITY; OVARIAN-CANCER; IMMUNOHISTOCHEMICAL EXPRESSION; CELL-LINES; MUTATIONS; ACCUMULATION AB Background: Tumorigenesis involves alterations in the tumor suppressor genes (p53), protooncogenes (Bcl-2) and housekeeping genes [human MutS homologue-2 (hMSH2)]. We hypothesized that mammary carcinogenesis involves interactions among p53, Bcl-2 and hMSh2 proteins. In the Upper Egypt, the clinicopathologic features and genetic changes during mammary carcinogenesis are unknown. Methods: To test our hypothesis and to examine these issues, 53 mastectomy specimens, each entailing normal breast, benign proliferative breast disease (BPBD), duct carcinoma in situ (DCIS) and infiltrating ductal carcinoma (IDC) were immunostained for p53, Bcl-2 and hMSH2 protein expression. Results: The average age incidence of ductal carcinomas was 43.2 +/- 7.06 years. The tumors were common in the left than right side (1.2:1, respectively, p > 0.05). Infiltrating ductal carcinoma of non-specific type was the most common histologic type. Examination of the average weighted scores in the normal breast, BPBD, DCIS and IDC, respectively, showed: (1) significant upregulation of p53 proteins (0.00 +/- 0.00, 0.00 +/- 0.00, 6.25 +/- 2.42, 6.62 +/- 2.15, p = 0.001), (2) insignificant downregulation of Bcl-2 (6.67 +/- 1.33, 5.17 +/- 2.20, 4.79 +/- 2.27 and 4.42 +/- 2.83, p = 0.37), and (3) significant downregulotion of hMSH2 (11.3 +/- 0.75, 10.70 +/- 1.27, 7.11 +/- 1.50 and 7.0 +/- 1.33, p = 0.0006). There were insignificant negative correlations between p53 and both Bcl-2 (r = -0.20, p > 0.05) and hMSH2 (r = -0.15, p > 0.05) protein expression. Conclusions: In the Upper Egypt: (1) breast cancer had similar clinicopathologic features to those in the high risk regions, and (2) alterations of the p53, Bcl-2 and hMSH2 proteins occur during mammary carcinogenesis. C1 Assiut Univ, Fac Med, Dept Pathol, Assiut, Egypt. Univ Wisconsin, Sch Med, William S Middleton Mem Vet Hosp, Madison, WI 53705 USA. RP Hussein, MR (reprint author), Assiut Univ, Fac Med, Dept Pathol, Assiut, Egypt. EM mrh17@swissinfo.org NR 35 TC 17 Z9 18 U1 0 U2 0 PU LANDES BIOSCIENCE PI GEORGETOWN PA 810 SOUTH CHURCH STREET, GEORGETOWN, TX 78626 USA SN 1538-4047 J9 CANCER BIOL THER JI Cancer Biol. Ther. PD OCT PY 2004 VL 3 IS 10 BP 983 EP 988 PG 6 WC Oncology SC Oncology GA 903QI UT WOS:000227440300021 PM 15467428 ER PT J AU Kazhdan, I Marciniak, RA AF Kazhdan, I Marciniak, RA TI Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) SO CANCER GENE THERAPY LA English DT Article DE breast cancer; death receptor 4; tumor targeting; hTERT promoter ID NF-KAPPA-B; REVERSE-TRANSCRIPTASE PROMOTER; C-FLIP EXPRESSION; PROSTATE-CANCER; MEDIATED APOPTOSIS; DEATH RECEPTOR; DECOY RECEPTORS; DOWN-REGULATION; GENE-THERAPY; GLIOMA-CELLS AB Breast cancer cells are generally resistant to induction of apoptosis by treatment with tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL). In this study, we demonstrate that both TRAIL-sensitive and TRAIL-resistant breast cancer cell lines can be efficiently killed by overexpression of the TRAIL receptor, death receptor 4 (DR4). The extent of cell death depended on the strength of the promoter driving DR4 expression. When driven by the strong CMV promoter, expression of DR4 killed over 90% of cells in five out of six cell lines tested in the absence of exogenous TRAIL. When driven by the relatively weak tumor-specific hTERT promoter, DR4 was less effective alone, but sensitized cells to killing by TRAIL. The extent of TRAIL sensitization depended on the magnitude of hTERT promoter activity. MCF-7 cells were relatively resistant to the action of DR4. We compared expression of the genes involved in transduction and execution of the death receptor-initiated apoptotic stimuli between MCF-7 and DR4-sensitive cell lines. We confirmed that in the panel of cell lines, MCF-7 was the only line deficient in expression of caspase 3. Bcl-2 and FLIP proteins, implicated in suppression of TRAIL-induced apoptosis, were expressed at a higher level. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Kazhdan, I (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kazhdan@uthscsa.edu FU NCI NIH HHS [5 K12 CA01723-10] NR 40 TC 13 Z9 14 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0929-1903 J9 CANCER GENE THER JI Cancer Gene Ther. PD OCT PY 2004 VL 11 IS 10 BP 691 EP 698 DI 10.1038/sj.cgt.7700747 PG 8 WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity; Research & Experimental Medicine GA 857CA UT WOS:000224091900004 PM 15354201 ER PT J AU Selander, KS Li, L Watson, L Merrell, M Dahmen, H Heinrich, PC Muller-Newen, G Harris, KW AF Selander, KS Li, L Watson, L Merrell, M Dahmen, H Heinrich, PC Muller-Newen, G Harris, KW TI Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy SO CANCER RESEARCH LA English DT Article ID GROWTH-FACTOR; TISSUE INHIBITOR; CARCINOMA-CELLS; EGF RECEPTOR; INTERLEUKIN-6 RECEPTOR; EXPRESSION; PROTEIN; FAMILY; SRC; LINES AB The cytokine receptor gp130 is the common signaling subunit of receptors used by the interleukin (IL)-6 cytokine family. gp130 is widely expressed in breast cancer cell lines and primary tumors. The role of gp130 in breast cancer in vivo is unknown. To study the effect of gp130 inhibition in breast cancer, endogenous gp130 signaling in breast cancer cell lines was blocked with a dominant-negative gp130 protein (DN gp130). DN gp130 inhibited constitutive Stat3 activation in breast cancer cells. Both gp130 and epidermal growth factor receptor (EGFR) have been implicated in constitutive Stat3 activation in breast cancer. There are known physical and functional interactions between gp130 and EGFR. Consistent with this, we show that DN gp130 inhibits signaling downstream of the EGFR in breast cancer cells. The effect of DN gp130 on breast cancer in vivo was assessed with an orthotopic nude mouse model. DN gp130 MDA-231 cells had markedly decreased engraftment, size, and metastasis compared with control cells. These results are particularly striking considering that DN gp130-expressing breast cancer cells grow faster in vitro. We hypothesized that DN gp130 expression results in inhibition of invasion and metastasis in vivo. Marked angiogenesis was present in tumors from control animals and was absent in tumors from DN gp130 animals. We additionally show that tissue inhibitor of metalloproteinase-3, an inhibitor of tumor invasion and angiogenesis, is up-regulated in both MDA-231 DN gp130 cells and tumors. These results, in light of the availability of several potential pharmacological inhibitors of gp130, suggest novel approaches to breast cancer therapy. C1 Univ Alabama, Div Hematol Oncol, Dept Med, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Rhein Westfal TH Aachen, Inst Biochem, Aachen, Germany. RP Harris, KW (reprint author), Univ Alabama, Div Hematol Oncol, Dept Med, WTI 520-D,1530 3rd Ave S, Birmingham, AL 35294 USA. EM kevin.harris@ccc.uab.edu NR 40 TC 54 Z9 56 U1 1 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD OCT 1 PY 2004 VL 64 IS 19 BP 6924 EP 6933 DI 10.1158/0008-5472.CAN-03-2516 PG 10 WC Oncology SC Oncology GA 859UC UT WOS:000224292400016 PM 15466183 ER PT J AU Unni, E Sun, SH Nan, BC McPhaul, MJ Cheskis, B Mancini, MA Marcelli, M AF Unni, E Sun, SH Nan, BC McPhaul, MJ Cheskis, B Mancini, MA Marcelli, M TI Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence SO CANCER RESEARCH LA English DT Article ID PROSTATE-CANCER CELLS; MEMBRANE PROGESTIN RECEPTOR; EPIDERMAL-GROWTH-FACTOR; PROTEIN-KINASE; PHOSPHORYLATION SITES; ESTROGEN-RECEPTOR; TYROSINE KINASE; CARCINOMA-CELLS; MAMMARY-TUMORS; SEX STEROIDS AB A cure for prostate cancer (CaP) will be possible only after a complete understanding of the mechanisms causing this disease to progress from androgen dependence to androgen independence. To carry on a careful characterization of the phenotypes of CaP cell lines before and after acquisition of androgen independence, we used two human CaP LNCaP sublines: LNCaPnan, which is androgen dependent (AD), and LNCaP-HP, which is androgen independent (AI). In AD LNCaPnan cells, dihydrotestosterone (DHT) stimulated in an androgen receptor (AR)-dependent way a phosphorylation signaling pathway involving steroid receptor coactivator (Src)-mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)-1/2-ERK-1/2-cAMP-response element binding-protein (CREB). Activation of this pathway was associated with increased [H-3]thymidine incorporation and resistance to apoptosis. Use of dominant-negative forms of MEK-1/2 and CREB demonstrated in LNCap(nan) cells that DHT induced [H-3]thymidiine incorporation through a thus far unidentified molecule activated downstream of NIEK-1/2, and antiapoptosis through phosphorylation of the transcription factor CREB. In contrast, in AI LNCaP-HP cells, the Src-MEK-1/2-ERK-1/2-CREB pathway was constitutively active. Because it was not further stimulated by addition of DHT, no increase of [3 H]thymidine incorporation or apoptosis resistance was demonstrated in LNCaP-HP cells. Additional experiments showed that Src and the scaffold protein MNAR coimmunoprecipitated with AR, indicating a role for Src as an apical molecule in the Sre-MEK-1/2-ERK-1/2-CREB pathway. Interestingly, differences between the two cell lines were that in LNCaP-HP cells presence of an AI phenotype and lack of response to DHT were associated with constitutive activation of the protein kinase Src and interaction among Src, AR, and MNAR. In contrast, in LNCaPnan cells, presence of an AD phenotype and ability to respond to DHT were associated with DHT-dependent activation of Src kinase activity and interaction among Src, AR, and MNAR. Intriguingly, in LNCaPnan cells, we found that transcription through the prototypical CREB-responsive promoter c-fos could be induced in a DHT-dependent way, and this action was inhibited by the AR antagonist Casodex and MEK-1 inhibitor PD98059. In contrast, transcription through the PSA P/E promoter, a prototypical AR-dependent promoter directly activated by agonist, was obliterated only by Casodex. Additional experiments with genital skin fibroblasts derived from patients with a variety of AR abnormalities indicated that nongenotropic AR signaling does not depend on an intact DNA-binding domain or on the ability of AR to translocate to the nucleus. The results suggest the following: (1) Constitutive activation of the Src-MEK-1/2-ERK-1/2-CREB pathway is associated with the AI phenotype observed in LNCaP-HP cells. (2) Activation of the Src-MEK-1/2-ERK-1/2-CREB pathway is DHT dependent in AD LNCaPnan cells. (3) DHT activation of this pathway is associated with induction of [H-3]thymidine incorporation by a molecule activated downstream of MEK-1/2 and of antiapoptosis through activation of the transcription factor CREB in AD LNCaPnan cells. (4) AR regulates transcription either directly upon ligand binding and nuclear translocation or indirectly through kinase pathways leading to activation of downstream transcription factors. (5) Nuclear translocation and ability of the DNA-binding domain of AR to interact with DNA are not prerequisites for nongenotropic AR activity. C1 Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. VA Med Ctr, Houston, TX USA. Wyeth Pharmaceut, Womens Hlth Res Inst, Dept Cell Biol, Collegeville, PA USA. RP Marcelli, M (reprint author), 2002 Holcombe Blvd, Houston, TX 77030 USA. EM marcelli@bcm.tmc.edu FU NIDDK NIH HHS [DK03892, DK 55622] NR 70 TC 163 Z9 169 U1 1 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD OCT 1 PY 2004 VL 64 IS 19 BP 7156 EP 7168 DI 10.1158/0008-5472.CAN-04-1121 PG 13 WC Oncology SC Oncology GA 859UC UT WOS:000224292400047 PM 15466214 ER PT J AU Nield, M Hoo, GS Roper, J Santiago, S AF Nield, M Hoo, GS Roper, J Santiago, S TI Pursed-lips breathing decreases dyspnea and improves health-related quality of life in 4-group randomized, controlled study SO CHEST LA English DT Meeting Abstract CT CHEST 2004 Conference CY OCT 23-28, 2004 CL Seattle, WA C1 W LA VA, VA Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2004 VL 126 IS 4 SU S BP 805S EP 805S PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 865VF UT WOS:000224731400315 ER PT J AU Lock, BJ Dransfield, MT AF Lock, BJ Dransfield, MT TI Factors influencing the rate of lung cancer resection in a veteran population SO CHEST LA English DT Meeting Abstract CT CHEST 2004 Conference CY OCT 23-28, 2004 CL Seattle, WA C1 Univ Alabama, Birmingham, AL USA. Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2004 VL 126 IS 4 SU S BP 913S EP 914S PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 865VF UT WOS:000224731400647 ER PT J AU Gerson, LB Groeneveld, PW Triadafilopoulos, G AF Gerson, Lauren B. Groeneveld, Peter W. Triadafilopoulos, George TI Cost-Effectiveness Model of Endoscopic Screening and Surveillance in Patients With Gastroesophageal Reflux Disease SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID HIGH-GRADE DYSPLASIA; QUALITY-OF-LIFE; SPECIALIZED INTESTINAL METAPLASIA; ARGON PLASMA COAGULATION; BARRETTS-ESOPHAGUS; PHOTODYNAMIC THERAPY; FOLLOW-UP; GASTRIC CARDIA; CANCER-RISK; GASTROINTESTINAL-ENDOSCOPY AB Background & Aims: Endoscopic screening and periodic surveillance for patients with Barrett's esophagus has been shown to be cost-effective in patients with esophageal dysplasia, with treatment for esophageal cancer limited to esophagectomy. Most gastroenterologists refer patients with high-grade dysplasia for esophagectomy, and effective endoscopic therapies are available for nonoperative patients with esophageal cancer. The cost-effectiveness of screening strategies that incorporate these nonsurgical treatment modalities has not been determined. Methods: We designed a Markov model to compare lifetime costs and life expectancy for a cohort of 50-year-old men with chronic reflux symptoms. We compared 10 clinical strategies incorporating combinations of screening and surveillance protocols (no screening, screening with periodic surveillance for both dysplastic and nondysplastic Barrett's esophagus, or periodic surveillance for dysplasia only), treatment for high-grade dysplasia (esophagectomy or intensive surveillance), and treatment for cancer (esophagectomy or surgical and endoscopic treatment options). Results: Screening and surveillance of patients with both dysplastic and nondysplastic Barrett's esophagus followed by esophagectomy for surgical candidates with high-grade dysplasia or esophageal cancer and endoscopic therapy for cancer patients who were not operative candidates cost $12,140 per life-year gained compared to no screening. Other screening strategies, including strategies that had no endoscopic treatment options, were either less effective at the same cost, or equally effective at a higher cost. Conclusions: The cost-effectiveness of screening and subsequent surveillance of patients with dysplastic as well as nondysplastic Barrett's esophagus followed by endoscopic or surgical therapy in patients who develop cancer compares favorably to many widely accepted screening strategies for cancer. C1 [Gerson, Lauren B.; Triadafilopoulos, George] Stanford Univ, Sch Med, Div Gastroenterol, Stanford, CA 94305 USA. [Triadafilopoulos, George] VA Palo Alto Hlth Care Syst, Gastroenterol Sect, Palo Alto, CA USA. [Groeneveld, Peter W.] Philadelphia VA Med Ctr, Sect Primary Care & Consultat Med, Philadelphia, PA USA. [Groeneveld, Peter W.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Groeneveld, Peter W.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Gerson, LB (reprint author), Stanford Univ, Div Gastroenterol & Hepatol, A149, Stanford, CA 94305 USA. EM lgerson@stanford.edu FU Wellcome Institute for Digestive Health FX Dr. Gerson was supported by a Glaxo Wellcome Institute for Digestive Health Healthcare Advancement Award. NR 89 TC 58 Z9 59 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD OCT PY 2004 VL 2 IS 10 BP 868 EP 879 DI 10.1053/S1542-3565(04)00394-5 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA V19KV UT WOS:000208072200006 PM 15476150 ER PT J AU Lipsky, BA Berendt, AR Deery, HG Embil, JM Joseph, WS Karchmer, AW LeFrock, JL Lew, DP Mader, JT Norden, C Tan, JS AF Lipsky, BA Berendt, AR Deery, HG Embil, JM Joseph, WS Karchmer, AW LeFrock, JL Lew, DP Mader, JT Norden, C Tan, JS TI Diagnosis and treatment of diabetic foot infections SO CLINICAL INFECTIOUS DISEASES LA English DT Review ID COLONY-STIMULATING FACTOR; SOFT-TISSUE INFECTIONS; RESISTANT STAPHYLOCOCCUS-AUREUS; PERIPHERAL VASCULAR-DISEASE; ARTERIAL OCCLUSIVE DISEASE; LOWER-EXTREMITY INFECTIONS; CUTANEOUS OXYGEN-TENSION; TOE BLOOD-PRESSURE; OPEN-LABEL TRIAL; TERM-FOLLOW-UP C1 Univ Washington, Sch Med, Med Serv, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med, Div Gen Med, Seattle, WA 98108 USA. Nuffield Orthopaed Ctr, Bone Infect Unit, Oxford OX3 7LD, England. No Michigan Infect Dis, Petoskey, MI USA. Univ Manitoba, Dept Med, Infect Dis Sect, Winnipeg, MB, Canada. Vet Affairs Med Ctr, Dept Primary Care, Sect Podiatry, Coatesville, PA USA. Harvard Univ, Sch Med, Div Infect Dis, Dept Med, Boston, MA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dimens Dosing Syst, Sarasota, FL USA. Univ Geneva Hosp, Dept Med, Infect Dis Serv, Geneva, Switzerland. Univ Texas, Med Branch, Dept Internal Med, Inst Marine Biomed, Galveston, TX 77550 USA. Univ Texas, Med Branch, Dept Orthopaed & Rehabil, Galveston, TX 77550 USA. New Jersey Sch Dent & Med, Dept Med, Camden, NJ USA. Cooper Hosp Univ Med Ctr, Camden, NJ USA. Summa Hlth Syst, Dept Internal Med, Akron, OH USA. NE Ohio Univ, Coll Med, Akron, OH USA. RP Lipsky, BA (reprint author), Univ Washington, Sch Med, Med Serv, Vet Affairs Puget Sound Hlth Care Syst, S-111-GIMC,1600 S Columbian Way, Seattle, WA 98108 USA. EM Benjamin.Lipsky@med.va.gov RI Lipsky, Benjamin/B-4645-2013 OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 297 TC 445 Z9 469 U1 7 U2 42 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2004 VL 39 IS 7 BP 885 EP 910 DI 10.1086/424846 PG 26 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 904JE UT WOS:000227491600001 PM 15472838 ER PT J AU Hamner, MB Robert, S Frueh, BC AF Hamner, MB Robert, S Frueh, BC TI Treatment-resistant posttraumatic stress disorder: Strategies for intervention SO CNS SPECTRUMS LA English DT Review ID TREATMENT-REFRACTORY DEPRESSION; PLACEBO-CONTROLLED STUDY/; COMBAT-RELATED PTSD; DOUBLE-BLIND; OPEN-LABEL; SERTRALINE TREATMENT; CONTROLLED-TRIAL; COMPENSATION-SEEKING; ADJUNCTIVE THERAPY; PSYCHOTIC FEATURES AB The mainstay of treatment for chronic posttraumatic stress disorder (PTSD) is a combination of psychotherapy and medication treatments. The first-line medications for PTSD are antidepressants, with two selective serotonin reuptake inhibitors (sertraline and paroxetine) currently Food and Drug Administration-indicated for PTSD. However, many patients do not have an adequate response to antidepressants, therefore, combinations with other antidepressants or with other classes of psychotropic medication are often utilized to enhance the therapeutic response. Other agents that have been used include mood stabilizers, anti-adrenergics, anxiolytics, and atypical antipsychotics. The heterogeneity of symptom clusters in PTSD as well as the complex Psychiatric comorbidities (eg, with depression or substance abuse) further support the notion that combinations of medications may be needed. TO date, there is a paucity of data to support specific strategies for augmenting antidepressants in PTSD. This review will address representative existing studies and discuss several potential pharmacologic strategies for patients suffering from treatment refractory PTSD. C1 Ralph H Johnson VA Med Ctr, Mental Hlth Serv 116, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, PTSD Clin Treatment Team, Charleston, SC 29401 USA. Ralph H Johnson VA Med Ctr, Psychiat Res Sect, Charleston, SC 29401 USA. RP Hamner, MB (reprint author), Ralph H Johnson VA Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM hamnermb@musc.edu NR 124 TC 45 Z9 47 U1 5 U2 9 PU M B L COMMUNICATIONS, INC PI NEW YORK PA 333 HUDSON ST, 7TH FLOOR, NEW YORK, NY 10013 USA SN 1092-8529 J9 CNS SPECTRUMS JI CNS Spectr. PD OCT PY 2004 VL 9 IS 10 BP 740 EP 752 PG 13 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 895VL UT WOS:000226891800010 PM 15448585 ER PT J AU Majeski, EI Widener, CE Basile, J AF Majeski, EI Widener, CE Basile, J TI Hypertension and dementia: Does blood pressure control favorably affect cognition? SO CURRENT HYPERTENSION REPORTS LA English DT Article ID ISOLATED SYSTOLIC HYPERTENSION; HEALTH INITIATIVE MEMORY; ELDERLY PROGRAM SHEP; ALZHEIMER-DISEASE; POSTMENOPAUSAL WOMEN; VASCULAR DEMENTIA; CONTROLLED-TRIAL; DIETARY-INTAKE; RISK; IMPAIRMENT AB Dementia and aging are not synonymous. Dementia is a progressive deterioration in cognitive and social and/or occupational functions that can eventually impair a patients ability to live independently. Alzheimer's disease is the most common form of dementia. Vascular dementis, responsible for up to 15% of all diagnosed cases, is the second most common form of dementia. Hypertension remains a significant risk factor for vascular dementia. The optimal level of blood pressure control for the prevention of dementia and whether one particular class of antihypertensive drug is more beneficial than another remains uncertain. C1 Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Majeski, EI (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA. EM Jan.Basile@med.va.gov NR 30 TC 5 Z9 5 U1 3 U2 5 PU CURRENT SCIENCE INC PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1522-6417 J9 CURR HYPERTENS REP JI Curr. Hypertens. Rep. PD OCT PY 2004 VL 6 IS 5 BP 357 EP 362 DI 10.1007/s11906-004-0054-0 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 991HJ UT WOS:000233802800006 PM 15341687 ER PT J AU Levin, BE Routh, VH Kang, L Sanders, NM Dunn-Meynell, AA AF Levin, BE Routh, VH Kang, L Sanders, NM Dunn-Meynell, AA TI Perspectives in diabetes - Neuronal glucosensing what do we know after 50 years? SO DIABETES LA English DT Article ID SENSITIVE K+ CHANNELS; FOS-LIKE IMMUNOREACTIVITY; PANCREATIC BETA-CELLS; OBESE ZUCKER RATS; LOWER BRAIN-STEM; HYPOTHALAMIC NEURONS; FOOD-INTAKE; EXTRACELLULAR GLUCOSE; ARCUATE NUCLEUS; POTASSIUM CHANNELS AB Glucosensing neurons are specialized cells that use glucose as a signaling molecule to alter their action potential frequency in response to variations in ambient glucose levels. Glucokinase (GK) appears to be the primary regulator of most neuronal glucosensing, but other regulators almost certainly exist. Glucose-excited neurons increase their activity when glucose levels rise, and most use GK and an ATP-sensitive K+ channel as the ultimate effector of glucose-induced signaling. Glucose-inhibited (GI) neurons increase their activity at low glucose levels. Although many use GK, it is unclear what the final pathway of GI neuronal glucosensing is. Glucosensing neurons are located in brain sites and respond to and integrate a variety of hormonal, metabolic, transmitter, and peptide signals involved in the regulation of energy homeostasis and other biological functions. Although it is still uncertain whether daily fluctuations in blood glucose play a specific regulatory role in these physiological functions, it is clear that large decreases in glucose availability stimulate food intake and counterregulatory responses that restore glucose levels to sustain cerebral function. Finally, glucosensing is altered in obesity and after recurrent bouts of hypoglycemia, and this altered sensing may contribute to the adverse outcomes of these conditions. Thus, although much is known, much remains to be learned about the physiological function of brain glucosensing neurons. C1 NJ Hlth Care Syst, Neurol Serv 127C, Dept Vet Affairs, E Orange, NJ 07018 USA. Univ Med & Dent New Jersey, Sch Med, Dept Neurol & Neurosci, Newark, NJ 07103 USA. Univ Med & Dent New Jersey, Sch Med, Dept Pharmacol & Physiol, Newark, NJ 07103 USA. VA Puget Sound Hlth Care Syst, Metab Endocrinol Serv, Seattle, WA USA. RP Levin, BE (reprint author), NJ Hlth Care Syst, Neurol Serv 127C, Dept Vet Affairs, 385 Tremont Ave, E Orange, NJ 07018 USA. EM levin@umdnj.edu NR 96 TC 263 Z9 268 U1 0 U2 12 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD OCT PY 2004 VL 53 IS 10 BP 2521 EP 2528 DI 10.2337/diabetes.53.10.2521 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 857KU UT WOS:000224116100001 PM 15448079 ER PT J AU Hollander, PA Blonde, L Rowe, R Mehta, AE Milburn, JL Hershon, KS Chiasson, JL Levin, SR AF Hollander, PA Blonde, L Rowe, R Mehta, AE Milburn, JL Hershon, KS Chiasson, JL Levin, SR CA Exubera Phase III Study Grp TI Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes - Results of a 6-month, randomized, comparative trial SO DIABETES CARE LA English DT Article; Proceedings Paper CT 61st Annual Meeting of the American-Diabetes-Association CY JUN 22-26, 2001 CL PHILADELPHIA, PA SP Amer Diabetes Assoc ID MICROVASCULAR COMPLICATIONS; BLOOD-GLUCOSE; MELLITUS; PROGRESSION; GLYCEMIA; NIDDM; RISK AB OBJECTIVE- Glycerine control using inhaled, dry-powder insulin plus a single injection of long-acting insulin was compared with a conventional regimen in patients with type 2 diabetes, which was previously managed with at least two daily insulin injections. RESEARCH DESIGN AND METHODS - Patients were randomized to 6 months' treatment with either premeal inhaled insulin plus a bedtime dose of Ultralente (n = 149) or at least two daily injections of subcutaneous insulin (mixed regular/NPH insulin; n = 150). The primary efficacy end point was the change in HbA(1C) from baseline to the end of study. RESULTS- HbA(1c) decreased similarly in the inhaled (-0.7%) and subcutaneous (-0.6%) insulin groups (adjusted treatment group difference: -0.07%, 95% CI-0.32 to 0.17). HbA(1c), <7.0% was achieved in more patients receiving inhaled (46.9%) than subcutaneous (31.7%) insulin (odds ratio 2.27, 95% CI 1.24-4.14). Overall hypoglycemia (events per subject-month) was slightly lower in the inhaled (1.4 events) than in the subcutaneous (1.6 events) insulin group (risk ratio 0.89, 95% CI 0.82-0.97), with no difference in severe events. Other adverse events, with the exception of increased cough in the inhaled insulin group, were similar. No difference in pulmonary function testing was seen. Further studies are underway to assess tolerability in the longer term. Insulin antibody binding increased more in the inhaled insulin group. Treatment satisfaction was greater in the inhaled insulin group. CONCLUSION- inhaled insulin appears to be effective, well tolerated, and well accepted in patients with type 2 diabetes and provides glycemic control comparable to a conventional subcutaneous regimen. C1 Baylor Univ, Med Ctr, Endocrinol Ctr, Dallas, TX 75246 USA. Ochsner Clin & Alton Ochsner Med Fdn, New Orleans, LA USA. Dalhousie Univ, Dept Med, Div Endocrinol, Halifax, NS, Canada. Cleveland Clin Fdn, Cleveland, OH 44195 USA. N Texas Hlth Care Associates, Irving, TX USA. N Shore Diabet & Endocrine Associates, New Hyde Pk, NY USA. Univ Montreal, Res Ctr, Dept Med, Ctr Hosp, Montreal, PQ, Canada. W Los Angeles VA Med Ctr, Los Angeles, CA USA. RP Hollander, PA (reprint author), Baylor Univ, Med Ctr, Endocrinol Ctr, 3600 Gaston Ave,Wadley Tower, Dallas, TX 75246 USA. NR 28 TC 153 Z9 158 U1 0 U2 7 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2004 VL 27 IS 10 BP 2356 EP 2362 DI 10.2337/diacare.27.10.2356 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 857KQ UT WOS:000224115700011 PM 15451900 ER PT J AU Egede, LE Poston, ME AF Egede, LE Poston, ME TI Racial/ethnic differences in leisure-time physical activity levels among individuals with diabetes SO DIABETES CARE LA English DT Article ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; ADULTS C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Dept Med, 135 Cannon St,Suite 403,POB 250837, Charleston, SC 29425 USA. EM egedel@musc.edu FU AHRQ HHS [5K08HS11418] NR 11 TC 15 Z9 15 U1 1 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2004 VL 27 IS 10 BP 2493 EP 2494 DI 10.2337/diacare.27.10.2493 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 857KQ UT WOS:000224115700034 PM 15451923 ER PT J AU Lieber, CS AF Lieber, CS TI The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role SO DRUG METABOLISM REVIEWS LA English DT Review DE microsomal ethanol oxidizing system; CYP2E1; alcohol dehydrogenase; nonalcoholic steatohepatitis; nonalcoholic fatty liver disease ID FRAGMENT-LENGTH-POLYMORPHISM; BLOOD-ALCOHOL CONCENTRATIONS; RAT-LIVER MICROSOMES; HUMAN CYP2E1 GENE; CYTOCHROME-P450 2E1; LUNG-CANCER; NONALCOHOLIC STEATOHEPATITIS; ACETONE METABOLISM; HEPATIC MICROSOMES; FATTY LIVER AB Oxidation of ethanol via alcohol dehydrogenase (ADH) explains various metabolic effects of ethanol but does not account for the tolerance. This fact, as well as the discovery of the proliferation of the smooth endoplasmic reticulum (SER) after chronic alcohol consumption, suggested the existence of an additional pathway which was then described by Lieber and DeCarli, namely the microsomal ethanol oxidizing system (MEOS), involving cytochrome P450. The existence of this system was initially challenged but the effect of ethanol on liver microsomes was confirmed by Remmer and his group. After chronic ethanol consumption, the activity of the MEOS increases, with an associated rise in cytochrome P450, especially CYP2E1, most conclusively shown in alcohol dehydrogenase negative deer mice. There is also cross-induction of the metabolism of other drugs, resulting in drug tolerance. Furthermore, the conversion of hepatotoxic agents to toxic metabolites increases, which explains the enhanced susceptibility of alcoholics to the adverse effects of various xenobiotics, including industrial solvents. CYP2E1 also activates some commonly used drugs (such as acetaminophen) to their toxic metabolites, and promotes carcinogenesis. In addition, catabolism of retinol is accelerated resulting in its depletion. Contrasting with the stimulating effects of chronic consumption, acute ethanol intake inhibits the metabolism of other drugs. Moreover, metabolism by CYP2E1 results in a significant release of free radicals which, in turn, diminishes reduced glutathione (GSH) and other defense systems against oxidative stress which plays a major pathogenic role in alcoholic liver disease. CYP1A2 and CYP3A4, two other perivenular P450s, also sustain the metabolism of ethanol, thereby contributing to MEOS activity and possibly liver injury. CYP2E1 has also a physiologic role which comprises gluconeogenesis from ketones, oxidation of fatty acids, and detoxification of xenobiotics other than ethanol. Excess of these physiological substrates (such as seen in obesity and diabetes) also leads to CYP2E1 induction and nonalcoholic fatty liver disease (NAFLD), which includes nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH), with pathological lesions similar to those observed in alcoholic steatohepatitis. Increases of CYP2E1 and its mRNA prevail in the perivenular zone, the area of maximal liver damage. CYP2E1 up-regulation was also demonstrated in obese patients as well as in rat models of obesity and NASH. Furthermore, NASH is increasingly recognized as a precursor to more severe liver disease, sometimes evolving into "cryptogenic" cirrhosis. The prevalence of NAFLD averages 20% and that of NASH 2% to 3% in the general population, making these conditions the most common liver diseases in the United States. Considering the pathogenic role that up-regulation of CYP2E1 also plays in alcoholic liver disease (vide supra), it is apparent that a major therapeutic challenge is now to find a way to control this toxic process. CYP2E1 inhibitors oppose alcohol-induced liver damage, but heretofore available compounds are too toxic for clinical use. Recently, however, polyenylphosphatidylcholine (PPC), an innocuous mixture of polyunsaturated phosphatidylcholines extracted from soybeans (and its active component dilinoleoylphosphatidylcholine), were discovered to decrease CYP2E1 activity. PPC also opposes hepatic oxidative stress and fibrosis. It is now being tested clinically. C1 Bronx Vet Affairs Med Ctr, Mt Sinai Sch Med, Sect Liver Dis & Nutr, Bronx, NY 10468 USA. Bronx Vet Affairs Med Ctr, Mt Sinai Sch Med, Alcohol Res Ctr, Bronx, NY 10468 USA. RP Lieber, CS (reprint author), Bronx Vet Affairs Med Ctr, Mt Sinai Sch Med, Sect Liver Dis & Nutr, Bronx, NY 10468 USA. NR 117 TC 115 Z9 125 U1 4 U2 24 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 USA SN 0360-2532 J9 DRUG METAB REV JI Drug Metab. Rev. PD OCT PY 2004 VL 36 IS 3-4 BP 511 EP 529 DI 10.1081/DMR-200033441 PG 19 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 869CW UT WOS:000224962000011 PM 15554233 ER PT J AU Gelling, RW Overduin, J Morrison, CD Morton, GJ Frayo, RS Cummings, DE Schwartz, MW AF Gelling, RW Overduin, J Morrison, CD Morton, GJ Frayo, RS Cummings, DE Schwartz, MW TI Effect of uncontrolled diabetes on plasma ghrelin concentrations and ghrelin-induced feeding SO ENDOCRINOLOGY LA English DT Article ID GROWTH-HORMONE SECRETAGOGUE; NEUROPEPTIDE-Y; CIRCULATING GHRELIN; FOOD-INTAKE; ACYLATED PEPTIDE; GENE-EXPRESSION; INSULIN-TREATMENT; ENERGY-BALANCE; MESSENGER-RNA; RATS AB Plasma levels of the orexigenic hormone, ghrelin, decrease rapidly on nutrient ingestion and yet are paradoxically elevated in rats with hyperphagia induced by streptozotocin-induced diabetes (STZ-DM). In the current work, we investigated the mechanisms underlying the relationships among uncontrolled diabetes, food intake, and plasma ghrelin concentrations in an effort to clarify whether increased ghrelin signaling contributes to diabetic hyperphagia. Whereas food intake did not increase until d 3 after STZ administration, plasma ghrelin levels were increased by more than 2-fold ( P < 0.05) on d 1. As hyperphagia developed, however, plasma ghrelin levels declined steadily. Because this reduction of plasma ghrelin levels was reversed by matching food intake of STZ-DM rats to that of nondiabetic controls, our results demonstrated that the effect of uncontrolled diabetes to increase plasma ghrelin levels is partially offset by hyperphagic feeding. In addition, we found that although intragastric nutrient infusion rapidly and comparably decreased plasma ghrelin levels in both groups ( by 46 - 49%; P < 0.05), this effect was short lived in STZ-DM rats relative to nondiabetic controls ( 60 min vs. 120 min; P< 0.05). We further demonstrated that in rats with STZ-DM, food intake increased by 357% ( P < 0.05) in response to intracerebroventricular administration of ghrelin at a dose that was subthreshold for feeding effects in nondiabetic controls. Collectively, these findings demonstrate that uncontrolled diabetes increases both circulating ghrelin levels and behavioral sensitivity to ghrelin. Although plasma ghrelin levels fall in response to hyperphagic feeding, these findings support the hypothesis that increased ghrelin signaling contributes to the pathogenesis of diabetic hyperphagia. C1 Univ Washington, Harborview Med Ctr, Div Endocrinol, Dept Med, Seattle, WA 98104 USA. Vet Affairs Puget Sound Healthcare Syst, Dept Med, Seattle, WA 98108 USA. RP Schwartz, MW (reprint author), Univ Washington, Harborview Med Ctr, Div Endocrinol, Dept Med, 325 9th Ave,Box 359657, Seattle, WA 98104 USA. EM mschwart@u.washington.edu RI Morrison, Christopher/A-6093-2010; Schwartz, Michael/H-9950-2012 FU NIDDK NIH HHS [DK12829, DK52989, DK61516]; NINDS NIH HHS [NS 32273] NR 54 TC 49 Z9 54 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD OCT PY 2004 VL 145 IS 10 BP 4575 EP 4582 DI 10.1210/en.2004-0605 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 854FB UT WOS:000223885600020 PM 15256489 ER PT J AU Hu, J Mata, M Hao, SL Zhang, G Fink, DJ AF Hu, J Mata, M Hao, SL Zhang, G Fink, DJ TI Central sprouting of uninjured small fiber afferents in the adult rat spinal cord following spinal nerve ligation SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE neural plasticity; neuropathic; pain; spinal nerve ligation; sprouting ID DORSAL-ROOT GANGLION; CHOLERAGENOID-HORSERADISH-PEROXIDASE; PRIMARY SENSORY NEURONS; GENE-RELATED PEPTIDE; SCIATIC-NERVE; NEUROPATHIC PAIN; PERIPHERAL-NERVE; TRANSGANGLIONIC TRANSPORT; SOMATOTOPIC ORGANIZATION; SUBSTANTIA-GELATINOSA AB Partial nerve injury results in chronic pain that is difficult to treat effectively. To investigate the anatomic basis of this phenomenon we used wheat germ agglutinin-horseradish peroxidase (WGA-HRP) to label the central projections of uninjured small fibers (Adelta and C) in a well-established model of neuropathic pain created by selective spinal nerve ligation in the adult. We found extensive sprouting of uninjured WGA-HRP-labeled afferents into the central termination field in lamina II of dorsal horn normally occupied by L5 afferents whose peripheral axons had been ligated distal to the dorsal root ganglion. The formation of new projections by uninjured fibers into a functionally but not anatomically deafferented field in the adult may play a role in the development of chronic pain. C1 Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI 48109 USA. Ann Arbor VA Healthcare Syst, Ann Arbor, MI 48109 USA. RP Fink, DJ (reprint author), 1914 Taubman Ctr,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA. EM djfink@umich.edu NR 53 TC 16 Z9 17 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0953-816X J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD OCT PY 2004 VL 20 IS 7 BP 1705 EP 1712 DI 10.1111/j.1460-9568.2004.03652.x PG 8 WC Neurosciences SC Neurosciences & Neurology GA 855TJ UT WOS:000223996900002 PM 15379991 ER PT J AU Sala, M Perez, J Soloff, P di Nemi, SU Caverzasi, E Soares, JC Brambilla, P AF Sala, M Perez, J Soloff, P di Nemi, SU Caverzasi, E Soares, JC Brambilla, P TI Stress and hippocampal abnormalities in psychiatric disorders SO EUROPEAN NEUROPSYCHOPHARMACOLOGY LA English DT Review DE posttraumatic stress disorder; borderline personality disorder; depression; MRI; MRS; PET ID BORDERLINE PERSONALITY-DISORDER; CHILDHOOD SEXUAL-ABUSE; CA3 PYRAMIDAL NEURONS; PROTEIN-KINASE-A; ELEMENT-BINDING PROTEIN; LONG-TERM-MEMORY; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; PROLONGED GLUCOCORTICOID EXPOSURE; MAGNETIC-RESONANCE SPECTROSCOPY; PITUITARY-ADRENOCORTICAL AXIS AB The hippocampus plays a main role in regulating stress response in humans, but is itself highly sensitive to neurotoxic effects of repeated stressful episodes. Hippocampal atrophy related to experimental stress has been reported in laboratory studies in animals. Several controlled brain imaging studies have also shown hippocampal abnormalities in psychiatric disorders, including posttraumatic stress disorder (PTSD), major depressive disorder (MDD), and borderline personality disorder (BPD). This paper reviews the physiological role of the hippocampus in stress circuitry and the effects of stress on cognitive functions mediated by the hippocampus. We also review brain imaging studies investigating hippocampus in PTSD, MDD, and BPD. This literature suggests that individuals with PTSD, MDD, and BPD may suffer hippocampal atrophy as a result of stressors associated with these disorders. Prospective, longitudinal studies will be needed in high-risk offspring and first-episode subjects to explore the relationship between stress and hippocampal atrophy in these neuropsychiatric illnesses. (C) 2004 Elsevier B.V. and ECNP. All rights reserved. C1 Univ Pavia, Policlin San Matteo, IRCCS, Dept Psychiat,Sch Med, I-27100 Pavia, Italy. IRCCS S Giovanni Dio, Biol Psychiat Unit, I-25125 Brescia, Italy. Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Brambilla, P (reprint author), Univ Udine, Dept Pathol & Expt & Clin Med, Sect Psychiat, I-33100 Udine, Italy. EM brambillapf@tiscali.it RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 FU NIMH NIH HHS [MH048463] NR 160 TC 88 Z9 98 U1 6 U2 18 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-977X J9 EUR NEUROPSYCHOPHARM JI Eur. Neuropsychopharmacol. PD OCT PY 2004 VL 14 IS 5 BP 393 EP 405 DI 10.1016/j.euroneuro.2003.12.005 PG 13 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 856BJ UT WOS:000224018300008 PM 15336301 ER PT J AU Huang, WB Carlsen, B Wulur, I Rudkin, G Ishida, K Wu, B Yamaguchi, DT Miller, TA AF Huang, WB Carlsen, B Wulur, I Rudkin, G Ishida, K Wu, B Yamaguchi, DT Miller, TA TI BMP-2 exerts differential effects on differentiation of rabbit bone marrow stromal cells grown in two-dimensional and three-dimensional systems and is required for in vitro bone formation in a PLGA scaffold SO EXPERIMENTAL CELL RESEARCH LA English DT Article DE bone marrow stromal cell; BMP; PLGA; two-dimensional; three-dimensional; bone formation; osteogenic differentiation ID MORPHOGENETIC PROTEIN-2 INCREASES; MESENCHYMAL STEM-CELLS; OSTEOBLASTIC CELLS; REGENERATION; VIVO; ANGIOGENESIS; BIOMATERIALS; EXPRESSION; COLLAGEN; CARRIER AB Osteogenic differentiation of bone marrow stromal cells (BMSC) in a three-dimensional (3-D) scaffold has not been well studied. In this work, we studied expression of bone-related genes during differentiation of rabbit BMSCs in response to bone morphogenetic protein (BMP)-2 in both 2-D and 3-D culture systems. When BMSCs were cultured on films (2-D) of biodegradable poly(lactide-co-glycolide) (PLGA), increases in mRNA expression of type I collagen (Col 1) and vascular endothelial growth factor (VEGF) became evident after I week. However, expression of both genes was only mildly stimulated by BMP-2. Expression of the osteopontin gene was highly stimulated by BMP-2 treatment. Expression of chordin, a BMP antagonist, increased significantly after 7 days. The increase was abrogated by BMP-2 treatment. BMP-2 was also able to stimulate mineralization of cultured BMSCs. After cells were switched to 3-D PLGA scaffolds for 24 h, expression of osteopontin and VEGF were markedly increased while expression of type I collagen and chordin remained unchanged. Expression of Col I did not increase with time in a 3-D culture as it did when cells were cultured on a 2-D film. We further explored the possibility of engineering bone tissue in vitro by seeding BMSCs into PLGA scaffolds. Cellular differentiation and bone formation in the scaffolds were analyzed histologically at 2 weeks and 2 months. Secretion of ECM by cells was evident at both 2-week and 2-month scaffolds, and was enhanced by rhBMP-2. Striking differences in 2-month scaffolds were observed between BMP-treated and untreated cells. A woven bone-like structure appeared in the scaffolds treated with BMP-2. The structure was verified to be bone-related by: (1) the presence of organized collagen fibrils; (2) the presence of mineral; and (3) morphological features of trabecular bone. Although collagen was abundant in the untreated 2-month scaffolds, it was disorganized. The untreated scaffolds also lacked mineral deposits, which were present in 2-D cultured cells even in the absence of BMP-2. Our results indicate that the requirement of osteo-inductive agents, such as BMP-2, is essential for bone tissue engineering. (C) 2004 Published by Elsevier Inc. C1 VA Greater LA Healthcare Syst, Plast Surg Lab, Plast Surg Sect, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Surg, Div Plast Surg, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Biomed Engn, Los Angeles, CA 90095 USA. RP Miller, TA (reprint author), VA Greater LA Healthcare Syst, Plast Surg Lab, Plast Surg Sect, Room 221,Bldg 114,11301 Wilts Blvd, Los Angeles, CA 90073 USA. EM millerlab@hotmail.com NR 39 TC 78 Z9 94 U1 2 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4827 J9 EXP CELL RES JI Exp. Cell Res. PD OCT 1 PY 2004 VL 299 IS 2 BP 325 EP 334 DI 10.1016/j.yexcr.2004.04.051 PG 10 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 855AW UT WOS:000223946300007 PM 15350532 ER PT J AU Lieberman, D Fennerty, MB Morris, CD Holub, J Eisen, G Sonnenberg, A AF Lieberman, D Fennerty, MB Morris, CD Holub, J Eisen, G Sonnenberg, A TI Endoscopic evaluation of patients with dyspepsia: Results from the national endoscopic data repository SO GASTROENTEROLOGY LA English DT Article ID BARRETTS-ESOPHAGUS; GASTROESOPHAGEAL REFLUX; UNCOMPLICATED DYSPEPSIA; WORKING PARTY; MANAGEMENT; MALIGNANCY; DIAGNOSIS; THERAPY AB Background & Aims: Endoscopy is commonly performed to evaluate symptoms of dyspepsia. The aim of this study was to characterize patients who receive endoscopy for dyspepsia and measure predictors of primary endoscopic outcomes, utilizing a large national endoscopic database. Methods: The Clinical Outcomes Research Initiative (CORI) receives endoscopy reports from a network of 74 sites in the United States. Sixty-one percent of reports come from private practice settings. Patients with reflux dyspepsia and nonreflux dyspepsia were identified from January 2000 to June 2002. Patients with dysphagia and known Barrett's esophagus were excluded. Primary endoscopic outcomes included esophageal inflammation and stricture, gastric ulcer, duodenal ulcer, suspected Barrett's esophagus (greater than or equal to2cm), and suspected esophageal and gastric malignancy. The presence or absence of alarm symptoms (vomiting, weight loss, and evidence of GI blood loss) was determined. Adjusted relative risk (RR) for predicting serious outcomes was calculated in a multivariate model. Results: We received 117,497 endoscopic reports, representing 99,558 unique patients. Dyspepsia, with and without reflux symptoms, accounted for 43% of upper endoscopies. Among dyspeptic patients, 36.5% were younger than 50 years of age without alarm symptoms. Esophageal or gastric malignancy in patients with dyspepsia was associated with increasing age, male sex, Asian race, Native American race, and symptoms of weight loss and vomiting. Suspected Barrett's esophagus (greater than or equal to2cm) was associated with reflux symptoms, male sex, age, and white race. Ulcers were associated with evidence of bleeding, vomiting, male sex, black race, and Hispanic ethnicity. Conclusions: These practice-based data reveal important practice behaviors and outcomes. C1 Oregon Hlth & Sci Univ, Div Gastroenterol, Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA. RP Oregon Hlth & Sci Univ, Div Gastroenterol, Portland VA Med Ctr, P3-GI,1037 SW Vet Hosp Rd, Portland, OR 97239 USA. EM lieberma@ohsu.edu FU NCI NIH HHS [U01 CA 89389-01]; NIDDK NIH HHS [R33-DK61778-01] NR 20 TC 65 Z9 67 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD OCT PY 2004 VL 127 IS 4 BP 1067 EP 1075 DI 10.1053/j.gastro.2004.07.060 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 864AG UT WOS:000224604400012 PM 15480985 ER PT J AU Hirokawa, M Takeuchi, T Chu, S Akiba, Y Wu, V Guth, PH Engel, E Montrose, MH Kaunitz, JD AF Hirokawa, M Takeuchi, T Chu, S Akiba, Y Wu, V Guth, PH Engel, E Montrose, MH Kaunitz, JD TI Cystic fibrosis gene mutation reduces epithelial cell acidification and injury in acid-perfused mouse duodenum SO GASTROENTEROLOGY LA English DT Article ID TRANSMEMBRANE CONDUCTANCE REGULATOR; APICAL CL-/HCO3-EXCHANGER; PEPTIC-ULCER DISEASE; BICARBONATE SECRETION; INTRACELLULAR PH; ALKALINE SECRETION; GASTROINTESTINAL-TRACT; MUCOSAL PERMEABILITY; HYDROCHLORIC-ACID; INDUCED INCREASE AB Background & Aims: Dysfunction of the cystic fibrosis transmembrane regulator (CFTR) is associated with diminished duodenal HCO3- secretion, despite a reported lack of clinical duodenal ulceration in affected subjects. We hypothesized that duodenal epithelial cells expressing a mutant CFTR have enhanced resistance to acid-induced injury. To test this hypothesis, we measured duodenal epithelial cell intracellular pH (pH(i)), injury, and acid back-diffusion in response to a luminal acid challenge in transgenic mice. Methods: A murine colony was established for the CFTR DeltaF508 (DeltaF) mutation. Epithelial cell pH(i) was measured by microscopy with a trapped, fluorescent pH-sensitive dye in living C57BL/6 and DeltaF/ DeltaF, +/DeltaF, and +/+ mice. In vivo confocal microscopy confirmed the localization of the dye in the cytoplasm of the epithelial cells. Epithelial injury was measured fluorometrically using propidium iodide. Duodenal epithelial bicarbonate secretion and proton permeability were measured by back-titration. Bicarbonate secretion and acid back-diffusion were measured in a perfused duodenal loop. Results: Basal and post-acid exposure bicarbonate secretion were reduced in DeltaF/DeltaF mice, although acid back-diffusion was similar to controls. Epithelial pHi of CFTR DeltaF/DeltaF mice during luminal acid exposure was significantly higher than pH(i) in +/DeltaF, +/+, or C57BL/6 mice. Acid-related epithelial injury was markedly less in DeltaF/DeltaF mice in comparison with the other groups. Conclusions: Increased cellular buffering power of the epithelial cells of DeltaF/DeltaF mice likely protects against acidification and injury during acid exposure. We speculate that this protective mechanism partially underlies the perceived relative lack of peptic ulceration in patients affected by cystic fibrosis. C1 Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Digest Dis Res Ctr, Dept Digest Dis, Sch Med,CURE, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA 90024 USA. Indiana Univ, Sch Med, Dept Cellular & Intergrat Physiol, Indianapolis, IN 46204 USA. RP Kaunitz, JD (reprint author), W Los Angeles Vet Affairs Med Ctr, Bldg 114,Room 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU NIDDK NIH HHS [DK54221, R01 DK054940, DK54940] NR 74 TC 23 Z9 25 U1 0 U2 3 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD OCT PY 2004 VL 127 IS 4 BP 1162 EP 1173 DI 10.1053/j.gastro.2004.06.057 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 864AG UT WOS:000224604400021 PM 15480994 ER PT J AU MacIntosh, DG Love, J Abraham, NS AF MacIntosh, DG Love, J Abraham, NS TI Endoscopic sphincterotomy by using pure-cut electrosurgical current and the risk of post-ERCP pancreatitis: a prospective randomized trial SO GASTROINTESTINAL ENDOSCOPY LA English DT Article; Proceedings Paper CT Digestive Disease Week Meeting/104th Annual Meeting of the American-Gastroenterological-Association CY MAY 17-22, 2003 CL ORLANDO, FL SP Amer Gastroenterol Assoc ID COMPLICATIONS; MULTICENTER AB Background: It has been suggested that the use of pure-cut electrosurgical current for endoscopic sphincterotomy may reduce the risk of post-ERCP pancreatitis. The aim of this study was to determine whether pure-cut current reduces the risk of pancreatitis compared with blend current. Methods: Patients were randomly assigned to undergo sphincterotomy over a non-conductive guidewire with 30 W/sec pure-cut current or 30 W/sec blend-2 current by a blinded endoscopist. Serum amylase and lipase levels were determined 1 day before and within 24 hours after ERCP. Post-ERCP pancreatitis was the primary outcome of interest. Secondary outcomes were as follows: severity of immediate bleeding, as graded by a 3-point scale from 1 (no bleeding) to 3 (injection or balloon tamponade therapy required to stop bleeding) and evidence of delayed bleeding 24 hours after ERCP. Analyses were performed in intention-to-treat fashion. Results: A total of 246 patients were randomized (116 pure-cut current, 130 blend current). There were no differences in baseline characteristics between the groups. The overall frequency of post-ERCP pancreatitis was 6.9%, with no significant difference in frequency between treatment arms (pure cut, 7.8% vs. blend, 6.1%; p = 0.62). The difference in rates of pancreatitis between the two groups was 1.7%: 95% CI[-4.8%, 8.2%]. Six patients (2.4%) had delayed bleeding after ERCP, of which two required transfusion. There was a significant increase in minor bleeding episodes (grade 2) in the pure-cut group (p < 0.0001). Delayed episodes of bleeding were equal (n = 3) in each arm. Conclusions: The type of current used when performing endoscopic sphincterotomy does not appear to alter the risk of post-ERCP pancreatitis. The selection of electrosurgical current for biliary endoscopic sphincterotomy should be based on endoscopist preference. C1 Dalhousie Univ, Div Gastroenterol, Halifax, NS, Canada. Vet Affairs Med Ctr, Hlth Serv Res, Houston, TX 77030 USA. Vet Affairs Med Ctr, Dept Hlth Gastroenterol, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Abraham, NS (reprint author), Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. NR 12 TC 23 Z9 24 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD OCT PY 2004 VL 60 IS 4 BP 551 EP 556 AR PII S0016-5107(04)01917-0 DI 10.1016/S0016-5107(04)01917-0 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 864LO UT WOS:000224635200009 PM 15472677 ER PT J AU Mader, S Reed, J Schutzer, W AF Mader, S Reed, J Schutzer, W TI Interaction between G protein receptor kinase-2 and caveolin decline with age in Fischer 344 vascular smooth muscle SO GERONTOLOGIST LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2004 VL 44 SI 1 BP 9 EP 9 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 875YJ UT WOS:000225458800027 ER PT J AU Rafi, A Makinodan, T Uyemura, K Castle, S AF Rafi, A Makinodan, T Uyemura, K Castle, S TI Modulation of the immune response by histamine in adults versus elders SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, David Geffen Sch Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2004 VL 44 SI 1 BP 10 EP 11 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 875YJ UT WOS:000225458800032 ER PT J AU Shores, M Platas, A Legner, V Kivlahan, D Li, E Matsumoto, A Sadak, T AF Shores, M Platas, A Legner, V Kivlahan, D Li, E Matsumoto, A Sadak, T TI The effect of testosterone on depressive symptoms and function in hypogonadal men with subsyndromal depression SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2004 VL 44 SI 1 BP 33 EP 33 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 875YJ UT WOS:000225458800106 ER PT J AU Webber, A Martin, J Alessi, C Josephson, K Harker, J AF Webber, A Martin, J Alessi, C Josephson, K Harker, J TI Nighttime noise in the post-acute rehabilitation nursing home setting SO GERONTOLOGIST LA English DT Meeting Abstract C1 Sepulveda GRECC, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2004 VL 44 SI 1 BP 38 EP 38 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 875YJ UT WOS:000225458800118 ER PT J AU Boyd, C Fortinsky, R Landefeld, C Palmer, R Counsell, S Burant, C Covinsky, K AF Boyd, C Fortinsky, R Landefeld, C Palmer, R Counsell, S Burant, C Covinsky, K TI Functional recovery in activities of daily living (ADLS) among older adults whose ADL function declined during hospitalization for acute illness SO GERONTOLOGIST LA English DT Meeting Abstract C1 Johns Hopkins Univ, Ctr Aging & Hlth, Div Geriatr Med & Gerontol, Baltimore, MD USA. Ctr Aging, Farmington, CT USA. San Francisco VAMC, Div Geriatr, San Francisco, CA USA. Cleveland Clin Fdn, Dept Gen Internal Med, Cleveland, OH USA. Univ Connecticut, Ctr Hlth, Div Geriatr, Ctr Aging, Storrs, CT 06269 USA. Case Western Reserve Univ, Dept Sociol & Bioeth, Cleveland, OH USA. Case Western Reserve Univ, Sch Nursing, Cleveland, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2004 VL 44 SI 1 BP 40 EP 41 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 875YJ UT WOS:000225458800124 ER PT J AU Webber, A Harker, J Martin, J Alessi, C Josephson, K AF Webber, A Harker, J Martin, J Alessi, C Josephson, K TI Social isolation and rehabilitation outcomes in older people receiving postacute rehabilitation in the nursing home setting SO GERONTOLOGIST LA English DT Meeting Abstract C1 Sepulveda GRECC, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2004 VL 44 SI 1 BP 41 EP 41 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 875YJ UT WOS:000225458800126 ER PT J AU Ostwald, S Robinson-Whelen, S Swank, P AF Ostwald, S Robinson-Whelen, S Swank, P TI Minority stroke survivors and spousal caregivers: Are poorer outcomes due to ethnicity, SES or age? SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, Houston, TX USA. VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2004 VL 44 SI 1 BP 81 EP 81 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 875YJ UT WOS:000225458800236 ER PT J AU Burant, C Graham, G Ibrahim, S Kwoh, C Siminoff, L AF Burant, C Graham, G Ibrahim, S Kwoh, C Siminoff, L TI Predictors of depression and subjective health in a male VA population treated for osteoarthritis: A structural equation model SO GERONTOLOGIST LA English DT Meeting Abstract C1 Case Western Reserve Univ, Cleveland, OH 44106 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. RI Siminoff, Laura /H-6277-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2004 VL 44 SI 1 BP 99 EP 99 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 875YJ UT WOS:000225458800289 ER PT J AU Kimbell, A AF Kimbell, A TI A psychometric study of items predicting decisions on allegations of elder abuse, neglect, and exploitation SO GERONTOLOGIST LA English DT Meeting Abstract C1 S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2004 VL 44 SI 1 BP 158 EP 158 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 875YJ UT WOS:000225458800452 ER PT J AU Radcliff, T Duncan, R Dobalian, A AF Radcliff, T Duncan, R Dobalian, A TI Seasonal migration of elders and its impact on hospital financial performance SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Colorado, Denver, CO USA. Denver VAMC, Denver, CO USA. Univ Florida, Gainesville, FL USA. VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2004 VL 44 SI 1 BP 249 EP 249 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 875YJ UT WOS:000225458801032 ER PT J AU Jarvik, L Matsuyama, S Rasgon, N Jimenez, E La Rue, A Holt, L Larson, S Steh, B Schaeffer, J Harrison, T Yaralian, P AF Jarvik, L Matsuyama, S Rasgon, N Jimenez, E La Rue, A Holt, L Larson, S Steh, B Schaeffer, J Harrison, T Yaralian, P TI Alzheimer offspring 20-years later - No significant cognitive decline? SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Stanford Sch Med, Palo Alto, CA USA. Huebner & Associates, Richland Ctr, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2004 VL 44 SI 1 BP 259 EP 260 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 875YJ UT WOS:000225458801061 ER PT J AU Hightower, A Larson, E Borson, S Asthana, S Boyko, E AF Hightower, A Larson, E Borson, S Asthana, S Boyko, E TI Medication management test performance in cognitively intact community-dwelling elders SO GERONTOLOGIST LA English DT Meeting Abstract C1 VA Puget Sound Hlth Care Syst, HSR&D, Ctr Excellence, Seattle, WA USA. Ctr Hlth Studies Grp Hlth Cooperat, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. Univ Wisconsin, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2004 VL 44 SI 1 BP 308 EP 309 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 875YJ UT WOS:000225458801208 ER PT J AU Kramer, B Harker, J Wang, M Finke, B AF Kramer, B Harker, J Wang, M Finke, B TI Dual use of VA and Indian Health Service: A pilot study SO GERONTOLOGIST LA English DT Meeting Abstract C1 VA Geriatr Res Educ Clin Ctr, Sepulveda, CA USA. Va Greater Los Angeles Healthcare Syst GRECC, Sepulveda, CA USA. Va Greater Los Angeles Healthcare Syst HSR&D, Sepulveda, CA USA. Indian Hlth Serv, Northampton, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2004 VL 44 SI 1 BP 449 EP 449 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 875YJ UT WOS:000225458802031 ER PT J AU Sherman, A Howe, J Villanti, A Sheehan, C Toner, J Fulmer, T AF Sherman, A Howe, J Villanti, A Sheehan, C Toner, J Fulmer, T TI Emergency preparedness: Geriatric mental health concerns SO GERONTOLOGIST LA English DT Meeting Abstract C1 Consortium New York Geriatr Educ Ctr, New York, NY USA. Mt Sinai Sch Med, Brookdale Dept Geriatr, New York, NY USA. Columbia Univ, Relig & Earth Inst, Ctr Study Sci, New York, NY USA. Bronx Vet Adm Med Ctr, New York, NY USA. Columbia Univ, Stroud Ctr, New York, NY USA. NYU, Div Nursing, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2004 VL 44 SI 1 BP 501 EP 501 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 875YJ UT WOS:000225458802191 ER PT J AU Chau, C Zeleznik, J Martino-Starvaggi, F AF Chau, C Zeleznik, J Martino-Starvaggi, F TI Are preprinted hospice orders appropriate for geriatric patients? SO GERONTOLOGIST LA English DT Meeting Abstract C1 Bronx Vet Adm Med Ctr, Bronx, NY USA. Montefiore Med Ctr, Bronx, NY 10467 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2004 VL 44 SI 1 BP 503 EP 503 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 875YJ UT WOS:000225458802196 ER PT J AU Rodrigez, K Young, A Appelt, C AF Rodrigez, K Young, A Appelt, C TI Elderly veterans' decision-making processes regarding life-sustaining treatment SO GERONTOLOGIST LA English DT Meeting Abstract C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. GRECC, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2004 VL 44 SI 1 BP 524 EP 524 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 875YJ UT WOS:000225458802256 ER PT J AU Vilaichone, RK Mahachai, V Tumwasorn, S Wu, JY Graham, DY Yamaoka, Y AF Vilaichone, RK Mahachai, V Tumwasorn, S Wu, JY Graham, DY Yamaoka, Y TI Molecular epidemiology and outcome of Helicobacter pylori infection in Thailand: A cultural cross roads SO HELICOBACTER LA English DT Article DE cagA; genotype; Helicobacter pylori; Thailand; vacA ID CAGA; GENOTYPES; VACA; ASSOCIATION; POPULATIONS; DISEASES; REGION; CANCER AB Background. Thailand is at the cultural cross roads between East and South Asia. It has been suggested that this is also the region where the predominant Helicobacter pylori (H. pylori) genotype changes from East Asian to South Asian. Methods. We compared the molecular epidemiology and outcome of H. pylori infections among different ethnic groups in Thailand (Thai, Thai-Chinese and Chinese). H. pylori isolates were genotyped by polymerase chain reaction based on cagA, cag right end junction and vacA genotypes. Results. Ninety-eight isolates from 38 ethnic Thai, 20 ethnic Chinese and 40 Thai-Chinese were categorized into East Asian (45%), South/Central Asian (26%), Western (1%) or mixed type (29%). The East Asian genotype was the most common among Chinese (85%) and Thai-Chinese (55%) (p < .01 compared to ethnic Thai). The ethnicity of the mother among mixed Thai-Chinese marriages predicted the genotype of the child's H. pylori (e.g. when the mother was Chinese, 84% had East Asian type vs. 29% when the mother was Thai) (p < .001). Gastric cancer was common among ethnic Chinese with East Asian genotype (e.g. all Chinese with gastric cancer or peptic ulcer disease had East Asian genotype, whereas only 40% of Chinese with gastritis had this genotype). Conclusions. Immigration, intermarriage and the variety of H. pylori genotypes in Thailand suggest that Thailand is an ideal site for epidemiological studies attempting to relate H. pylori genotypes and host factors to outcome. Our data also support the hypothesis that the primary caretaker of the children is most likely the source of the infection. C1 Michael E Debakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. Thammasat Univ Hosp, Dept Med, Gastroenterol Unit, Pathum Thani, Thailand. Baylor Coll Med, Houston, TX 77030 USA. Chulalongkorn Univ Hosp, Dept Med, Gastroenterol Unit, Bangkok, Thailand. Chulalongkorn Univ Hosp, Dept Microbiol, Bangkok, Thailand. RP Yamaoka, Y (reprint author), Michael E Debakey Vet Affairs Med Ctr, Dept Med, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM yyamaoka@bcm.tmc.edu FU NIDDK NIH HHS [DK56,338] NR 17 TC 56 Z9 58 U1 0 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD OCT PY 2004 VL 9 IS 5 BP 453 EP 459 DI 10.1111/j.1083-4389.2004.00260.x PG 7 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 852UE UT WOS:000223781200011 PM 15361085 ER PT J AU Golden-Mason, L Rosen, H O'Farrelly, C AF Golden-Mason, L Rosen, H O'Farrelly, C TI Early changes in CD56+lymphoid populations predict outcome post liver transplantation (LT) for hepatitis C viral infection SO HEPATOLOGY LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY OCT 29-NOV 02, 2004 CL Boston, MA SP Amer Assoc Study Liver Dis C1 St Vincents Univ Hosp, Dublin, Ireland. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2004 VL 40 IS 4 SU 1 BP 163A EP 163A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 857FR UT WOS:000224102100006 ER PT J AU Rosen, H Hinrichs, DJ Leistikow, R Callender, G Nishimura, M Lewinsohn, D AF Rosen, H Hinrichs, DJ Leistikow, R Callender, G Nishimura, M Lewinsohn, D TI Selection of HCV-specific CD8+T cells by donor HLA alleles following liver transplantation SO HEPATOLOGY LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY OCT 29-NOV 02, 2004 CL Boston, MA SP Amer Assoc Study Liver Dis C1 Portland VA Med Ctr, Portland, OR USA. Univ Chicago, Chicago, IL 60637 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2004 VL 40 IS 4 SU 1 BP 164A EP 164A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 857FR UT WOS:000224102100007 ER PT J AU Kramer, JR Julapalli, V El-Serag, HB DeBakey, ME AF Kramer, JR Julapalli, V El-Serag, HB DeBakey, ME TI Adherence to guidelines for referral to liver transplantation SO HEPATOLOGY LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY OCT 29-NOV 02, 2004 CL Boston, MA SP Amer Assoc Study Liver Dis C1 Michael E deBakey Vet Affairs Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2004 VL 40 IS 4 SU 1 BP 165A EP 165A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 857FR UT WOS:000224102100010 ER PT J AU Rosen, HR Weston, SJ Im, K Belle, SH AF Rosen, HR Weston, SJ Im, K Belle, SH CA Virahep-C Grp TI Ethnicity and the cellular immune response in patients with chronic hepatitis C genotype 1 infection. SO HEPATOLOGY LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY OCT 29-NOV 02, 2004 CL Boston, MA SP Amer Assoc Study Liver Dis C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2004 VL 40 IS 4 SU 1 BP 178A EP 178A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 857FR UT WOS:000224102100038 ER PT J AU Wang, CC McBride, L Weston, SJ Steele, M Scott, E Krantz, E Wald, A Thiede, H Rosen, HR AF Wang, CC McBride, L Weston, SJ Steele, M Scott, E Krantz, E Wald, A Thiede, H Rosen, HR TI Frequent iatrogenic and sexual acquisition of acute hepatitis C in a multi-center study. SO HEPATOLOGY LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY OCT 29-NOV 02, 2004 CL Boston, MA SP Amer Assoc Study Liver Dis C1 Univ Washington, Seattle, WA 98195 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. Univ Tennessee, Memphis, TN USA. Publ Hlth Seattle & King Cty, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2004 VL 40 IS 4 SU 1 BP 270A EP 270A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 857FR UT WOS:000224102100243 ER PT J AU Brau, N Xiao, PY Trikha, A Sulkowski, MS Rigsby, MO Wright, TL Dieterich, DT Aytaman, A Denenburg, I Paronetto, F Brown, ST Bini, EJ AF Brau, N Xiao, PY Trikha, A Sulkowski, MS Rigsby, MO Wright, TL Dieterich, DT Aytaman, A Denenburg, I Paronetto, F Brown, ST Bini, EJ TI Hepatocellular carcinoma in HIV-infected patients and influence of HIV viral load on survival. A multicenter study. SO HEPATOLOGY LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY OCT 29-NOV 02, 2004 CL Boston, MA SP Amer Assoc Study Liver Dis C1 Bronx Vet Adm Med Ctr, New York, NY USA. CUNY Mt Sinai Sch Med, New York, NY 10029 USA. NYU, Downtown Hosp, New York, NY USA. Johns Hopkins Univ, Baltimore, MD USA. VA Connecticut HCS, New Haven, CT USA. Yale Univ, New Haven, CT USA. San Francisco VA Med Ctr, San Francisco, CA USA. UCSF, San Francisco, CA USA. VA New York Harbor HCS, Brooklyn, NY USA. SUNY Downstate Hlth Sci Ctr, Brooklyn, NY USA. NR 0 TC 2 Z9 3 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2004 VL 40 IS 4 SU 1 BP 308A EP 309A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 857FR UT WOS:000224102100337 ER PT J AU Anand, BS Currie, SL Bini, EJ Ho, SB Dieperink, E Shen, H Wright, TL AF Anand, BS Currie, SL Bini, EJ Ho, SB Dieperink, E Shen, H Wright, TL CA VA-HCV-001 Study Grp TI Recent alcohol use but not prior alcohol use influences hepatitis C antiviral treatment adherence and outcomes: Results of a national multicenter study. SO HEPATOLOGY LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY OCT 29-NOV 02, 2004 CL Boston, MA SP Amer Assoc Study Liver Dis C1 Houston VAMC, Houston, TX USA. San Francisco VAMC, San Francisco, CA USA. VA NY Harbor Healthcare Syst, New York, NY USA. Minneapolis VAMC, Minneapolis, MN USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2004 VL 40 IS 4 SU 1 BP 316A EP 317A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 857FR UT WOS:000224102100357 ER PT J AU Rousseau, CM Ioannou, GN Todd-Stenberg, JA Sloan, KL Dominitz, JA AF Rousseau, CM Ioannou, GN Todd-Stenberg, JA Sloan, KL Dominitz, JA TI The association of race and treatment for hepatitis C SO HEPATOLOGY LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY OCT 29-NOV 02, 2004 CL Boston, MA SP Amer Assoc Study Liver Dis C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2004 VL 40 IS 4 SU 1 BP 339A EP 339A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 857FR UT WOS:000224102100405 ER PT J AU Huckans, MS Blackwell, AD Harms, TA Indest, DW Hauser, P AF Huckans, MS Blackwell, AD Harms, TA Indest, DW Hauser, P TI Hepatitis C and human immunodeficiency virus: Co-infection rates and co-testing patterns among veterans. SO HEPATOLOGY LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY OCT 29-NOV 02, 2004 CL Boston, MA SP Amer Assoc Study Liver Dis C1 Portland VA Med Ctr, Portland, OR USA. RI Blackwell, Aaron/B-5258-2008 OI Blackwell, Aaron/0000-0002-5871-9865 NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2004 VL 40 IS 4 SU 1 BP 412A EP 413A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 857FR UT WOS:000224102100573 ER PT J AU Ahmad, J Cacciarelli, T AF Ahmad, J Cacciarelli, T TI Disparity in the MELD scores of liver transplant recipients in the US according to the size of transplant center. SO HEPATOLOGY LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY OCT 29-NOV 02, 2004 CL Boston, MA SP Amer Assoc Study Liver Dis C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2004 VL 40 IS 4 SU 1 BP 718A EP 718A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 857FR UT WOS:000224102101275 ER PT J AU Piasecki, BA Lewis, JD Reddy, KR Bellamy, SL Porter, SB Weinrieb, RM Stieritz, DD Chang, KM AF Piasecki, BA Lewis, JD Reddy, KR Bellamy, SL Porter, SB Weinrieb, RM Stieritz, DD Chang, KM TI Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population SO HEPATOLOGY LA English DT Article ID HEPATITIS-C VIRUS; CELLULAR IMMUNE-RESPONSE; LIVER-DISEASE; NATURAL-HISTORY; INTERFERON THERAPY; AFRICAN-AMERICANS; UNITED-STATES; B-VIRUS; INFECTION; PREVALENCE AB Hepatitis C virus (HCV) is spontaneously cleared in 15% to 45% of individuals during primary infection. To define the role of alcohol, race, and HBV or HIV coinfections in natural HCV clearance, we examined these parameters in 203 spontaneously HCV-recovered subjects (HCV Ab(+)/RNA(-) subjects without prior antiviral therapy) and 293 chronically HCV-infected patients (HCV Ab(+)/RNA(+)). Subjects were identified from 1,454 HCV antibody-seropositive US veterans tested for HCV RNA between January 2000 and July 2002 at the Philadelphia Veterans Affairs Medical Center. In univariate analysis, alcohol use disorder (odds ratio [OR] 0.52; 95% CI, 0.31-0.85; P=.006) and black race (OR 0.65; 95% CI, 0.44-0.96; P=.024) were both associated with decreased likelihood of spontaneous HCV clearance. In multivariate analyses adjusting for race, HIV infection, age, and alcohol use disorder, alcohol remained strongly associated with reduced HCV clearance (OR 0.49; 95% CI, 0.30-0.8 1; P=.005). In contrast, the association between black race and viral clearance was no longer statistically significant (adjusted OR 0.72; 95% CI, 0.48-1.09; P=.125). HIV coinfection was negatively associated with HCV clearance (OR 0.37; 95% CI, 0.16-0.83; P=.016), while HBV coinfection was positively associated with HCV clearance (unadjusted OR 5.0; 95% CI, 1.26-28.6; P=.008). In conclusion, the likelihood of spontaneous clearance of HCV may be influenced by alcohol and viral coinfections. C1 Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Piasecki, BA (reprint author), Radnor Gastroenterol Clin, Penn Med, 250 King Prussia Rd, Radnor, PA 19087 USA. EM Barbara_piasecki@yahoo.com FU NIAAA NIH HHS [AA12849]; NIAID NIH HHS [AI47519]; NIDDK NIH HHS [T32 DK007740] NR 45 TC 50 Z9 53 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2004 VL 40 IS 4 BP 892 EP 899 DI 10.1002/hep.20384 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 857AX UT WOS:000224088800016 PM 15382122 ER PT J AU Royall, DR Espino, DV Polk, MJ Palmer, RF Markides, KS AF Royall, DR Espino, DV Polk, MJ Palmer, RF Markides, KS TI Prevalence and patterns of executive impairment in community dwelling Mexican Americans: results from the Hispanic EPESE Study SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE aging; assessment; cognition; disability; dementia; executive functions; Hispanics ID MINI-MENTAL-STATE; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; DEMENTING ILLNESSES; FUNCTIONAL STATUS; FREEDOM HOUSE; POPULATION; FEATURES; RETIREES; RATES AB Introduction Little is known about the prevalence of impaired executive control function (ECF) in community dwelling elderly or minority populations. We have determined the prevalence of cognitive impairment and impaired ECF in a community dwelling Mexican American elderly population, and their associations with functional status. Subjects Subjects were 1165 Mexican Americans age 65 and over who were administered CLOX as part of the third wave of the Hispanic Established Population for Epidemiological Study (HEPESE) conducted from 1998 to 1999. Methods ECF was measured by an executive clock-drawing task (CDT) (i.e. CLOX1). Non-executive cognitive function was assessed by the Mini-Mental State Examination (MMSE) and a non-executive CDT (CLOX2). CLOX scores were combined to estimate the prevalence of global CLOX failure (i.e. 'Type 1' cognitive impairment) vs isolated CLOX1 failure (i.e. Type 2 cognitive impairment). Results 59.3% of subjects failed CLOX1. 31.1% failed both CLOX1 and CLOX2 (Type 1 cognitive impairment). 33.3% failed CLOX1 only (Type 2 cognitive impairment). 35.6% passed both measures [no cognitive impairment (NCI)]. Many subjects with CLOX1 impairment at Wave 3 had normal MMSE scores. This was more likely to occur in the context of Type 2 cognitive impairment. Both CLOX defined cognitive impairment groups were associated with functional impairment. Conclusions A large percentage of community dwelling Mexican American elderly suffer cognitive impairment that can be demonstrated through a CDT. Isolated executive impairments appear to be most common. The ability of a CDT to demonstrate ECF impairments potentially offers a rapid, culturally unbiased and cost-effective means of assessing this domain. In contrast, the MMSE is relatively insensitive to ECF assessed by CLOX1. Copyright (C) 2004 John Wiley Sons, Ltd. C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. S Texas Vet Hlth Syst, Audie L Murphy Div, GRECC, DRR, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Family Practice, San Antonio, TX 78284 USA. Univ Texas, Med Branch, Dept Prevent Med, Galveston, TX 77550 USA. RP Royall, DR (reprint author), Univ Texas, Hlth Sci Ctr, Dept Psychiat, Floyd Curl Dr, San Antonio, TX 78284 USA. EM royall@uthscsa.edu FU NIA NIH HHS [AG10939] NR 47 TC 20 Z9 20 U1 0 U2 1 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD OCT PY 2004 VL 19 IS 10 BP 926 EP 934 DI 10.1002/gps.1185 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 863EQ UT WOS:000224544100002 PM 15449370 ER PT J AU Weisbart, RH Wakelin, R Chan, G Miller, CW Koeffler, PH AF Weisbart, RH Wakelin, R Chan, G Miller, CW Koeffler, PH TI Construction and expression of a bispecific single-chain antibody that penetrates mutant p53 colon cancer cells and binds p53 SO INTERNATIONAL JOURNAL OF ONCOLOGY LA English DT Article DE antibodies; cell trafficking; cytotoxicity ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; MONOCLONAL-ANTIBODY; DNA ANTIBODIES; LIVING CELLS; RESTORATION; PROTEIN; TRANSFECTION; FRAGMENTS; PEPTIDES; DELIVERY AB A bispecific, single-chain antibody Fv fragment (BsscFv) was constructed from a single-chain Fv fragment of mAb 3E10 that penetrates living cells and localizes in the nucleus, and a single-chain Fv fragment of a non-penetrating antibody, mAb PAb421 that binds the C-terminal of p53. PAb421 binding restores wild-type functions of some p53 mutants, including those of SW480 human colon cancer cells. The BsscFv penetrated SW480 cells and was cytotoxic, suggesting an ability to restore activity to mutant p53. COS-7 cells (monkey kidney cells with wild-type p53) served as a control since they are unresponsive to PAb421 due to the presence of SV40 large T antigen that inhibits binding of PAb421 to p53. Bs-scFv penetrated COS-7 cells but was not cytotoxic, thereby eliminating non-specific toxicity of Bs-scFv unrelated to binding p53. A single mutation in CDR1 of PAb421 VH eliminated binding of the Bs-scFv to p53 and abrogated cytotoxicity for SW480 cells without altering cellular penetration, further supporting the requirement of PAb421 binding to p53 for cytotoxicity. Our study demonstrates the use of an antibody that penetrates living cells in the design of a bispecific single chain antibody to target and restore the function of an intracellular protein. C1 Vet Affairs Greater Los Angeles Hlth Care Syst 11, Dept Med, Div Rheumatol, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Cedars Sinai Res Inst Ctr, Los Angeles, CA 90048 USA. RP Weisbart, RH (reprint author), Vet Affairs Greater Los Angeles Hlth Care Syst 11, Dept Med, Div Rheumatol, 1611 Plummer St, Sepulveda, CA 91343 USA. EM rweisbar@ucla.edu NR 22 TC 15 Z9 15 U1 1 U2 4 PU PROFESSOR D A SPANDIDOS PI ATHENS PA 1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE SN 1019-6439 J9 INT J ONCOL JI Int. J. Oncol. PD OCT PY 2004 VL 25 IS 4 BP 1113 EP 1118 PG 6 WC Oncology SC Oncology GA 856VP UT WOS:000224073700037 PM 15375563 ER PT J AU Clark, RA Epperson, TK Valente, AJ AF Clark, RA Epperson, TK Valente, AJ TI Mechanisms of activation of NADPH oxidases SO JAPANESE JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 4th International Peroxidase Meeting CY OCT 27-30, 2004 CL Kyoto, JAPAN AB The members of the NOX family of enzymes are expressed in a variety of tissues and serve a number of functions. There is a high level of conservation of primary protein sequence, as well as functional features, although specialized responses are beginning to emerge. In this context, our data demonstrate that the NOX1 cytoplasmic domains interact efficiently with the cytoplasmic subunits of the phagocyte NADPH oxidase and identify the second cytoplasmic loop of NOX electron transporters as a crucial domain for enzyme function. Studies of cytosolic co-factors showed that the C-terminal cytoplasmic domain of NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain with NOXA1. Finally, we have provided the first example of how alternative splicing of a NOX co-factor may be involved in the regulation of NADPH oxidase function. C1 Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX 78284 USA. RP Clark, RA (reprint author), Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX 78284 USA. EM clarkra@uthscsa.edu NR 4 TC 11 Z9 11 U1 0 U2 0 PU NATL INST INFECTIOUS DISEASES PI TOKYO PA JPN J INFECT DIS ED OFF NATL INST INFECTIOUS DISEASES TOYAMA 1-23-1, SHINJUKU-KU, TOKYO, 162-8640, JAPAN SN 1344-6304 EI 1884-2836 J9 JPN J INFECT DIS JI Jpn. J. Infect. Dis. PD OCT PY 2004 VL 57 IS 5 BP S22 EP S23 PG 2 WC Infectious Diseases SC Infectious Diseases GA 867WE UT WOS:000224872600027 PM 15507761 ER PT J AU Parameswaran, V Schumacher, HR AF Parameswaran, V Schumacher, HR TI An Ayurvedic-Derived Osteoarthritis treatment - What can this teach us? SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Editorial Material ID ANTIINFLAMMATORY AGENT; RHEUMATOID-ARTHRITIS; DIFERULOYL METHANE; BOSWELLIA SERRATA; CURCUMIN; ACIDS; MEDICINE; EXTRACT; SYSTEM C1 Univ Penn, Sch Med, Div Rheumatol, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Parameswaran, V (reprint author), Univ Penn, Sch Med, Div Rheumatol, 533 Maloney Bldg, Philadelphia, PA 19104 USA. EM pvid@yahoo.com NR 25 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-1608 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD OCT PY 2004 VL 10 IS 5 BP 231 EP 233 DI 10.1097/01.rhu.0000136090.53441.0b PG 3 WC Rheumatology SC Rheumatology GA 860TY UT WOS:000224367400001 PM 17043518 ER PT J AU Cohen, AN Hammen, C Henry, RM Daley, SE AF Cohen, AN Hammen, C Henry, RM Daley, SE TI Effects of stress and social support on recurrence in bipolar disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE bipolar disorder; social support; life events; recurrence ID LIFE EVENTS AB Background: Limited research has examined the impact of social support on the course of bipolar disorder, although results suggest a probable link. This study examines prospectively the effects of stressful events and social support on episode recurrence in bipolar I disorder. Methods: Fifty-two outpatients with bipolar I disorder recruited from an urban community were followed every 3 months for up to 1 year. At the initial interview, individuals reported separately on perceived social support from a best friend, parent, and romantic partner, combined to form a total network support score. Ongoing prospective assessments of stressful life events, symptomatology, and medication compliance were completed over I year. Logistic regressions were utilized to predict episode recurrence. Results: As predicted, both higher levels of stress and lower levels of social support from the total network independently predicted depressive recurrence over a 1-year follow-up, after controlling for clinical history and compliance. Social support did not moderate the impact of stress. Limitations: Only a 1-year follow-up was obtained, and sample sizes may have been insufficient to detect prediction of manic episodes. Direction of causality between support and recurrence is hypothesized but cannot be definitively determined. Conclusions: Higher levels of stress and perceptions of less available and poorer quality close relationships are associated with recurrence. Interventions that target these psychosocial vulnerabilities may help alter the course of bipolar 1 disorder. Research with larger samples should further examine the possible polarity-specific effects of social risk factors. (C) 2003 Elsevier B.V. All rights reserved. C1 Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA. W Los Angeles Va Healthcare Ctr, Los Angeles, CA USA. Mental Illness Educ & Clin Ctr, Los Angeles, CA USA. RP Hammen, C (reprint author), Univ Calif Los Angeles, Dept Psychol, 405 Hilgard Ave, Los Angeles, CA 90095 USA. EM hammen@psych.ucla.edu FU NIMH NIH HHS [MH-14584] NR 12 TC 64 Z9 65 U1 3 U2 15 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD OCT 1 PY 2004 VL 82 IS 1 BP 143 EP 147 DI 10.1016/j.jad.2003.10.008 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 864YY UT WOS:000224670500019 PM 15465589 ER PT J AU Bischoff, DS Makhijani, N Zhu, J Tachiki, K Yamaguchi, DT AF Bischoff, DS Makhijani, N Zhu, J Tachiki, K Yamaguchi, DT TI ELR+ CXC chemokine production by and action in human mesenchymal stem cells. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY OCT 01-05, 2004 CL Seattle, WA SP Amer Soc Bone & Mineral Res C1 VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD OCT PY 2004 VL 19 SU 1 BP S132 EP S132 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 860FB UT WOS:000224326800516 ER PT J AU Chen, T Rodriguez, L Chang, W Shoback, D AF Chen, T Rodriguez, L Chang, W Shoback, D TI Ca2+-sensing by cell populations in murine bone marrow: Effects on osteoclast formation and gene expression. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY OCT 01-05, 2004 CL Seattle, WA SP Amer Soc Bone & Mineral Res C1 Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD OCT PY 2004 VL 19 SU 1 BP S155 EP S155 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 860FB UT WOS:000224326800611 ER PT J AU Christian, RC Elliott, ME Vallarta-Ast, N Hansen, K AF Christian, RC Elliott, ME Vallarta-Ast, N Hansen, K TI Efficacy and safety of long-term alendronate in male solid organ transplant recipients. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY OCT 01-05, 2004 CL Seattle, WA SP Amer Soc Bone & Mineral Res C1 Univ Wisconsin, Madison, WI 53706 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD OCT PY 2004 VL 19 SU 1 BP S172 EP S172 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 860FB UT WOS:000224326801037 ER PT J AU Franco, GEL Stone, DS Blank, RD AF Franco, GEL Stone, DS Blank, RD TI Young's modulus of C57BL/6J cortical bone is less than that of Outbred Col1aI(oim) heterozygotes or their wild-type littermates. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY OCT 01-05, 2004 CL Seattle, WA SP Amer Soc Bone & Mineral Res C1 Univ Wisconsin, Madison, WI 53706 USA. William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. RI Stone, Donald/A-7496-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD OCT PY 2004 VL 19 SU 1 BP S223 EP S223 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 860FB UT WOS:000224326801243 ER PT J AU Ghosh-Choudhury, N AF Ghosh-Choudhury, N TI Statins stimulate phosphatidylinositol 3 kinase (PI 3 K) signaling during osteoblast differentiation: A mechanism of new bone formation in osteoporosis SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY OCT 01-05, 2004 CL Seattle, WA SP Amer Soc Bone & Mineral Res C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD OCT PY 2004 VL 19 SU 1 BP S274 EP S274 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 860FB UT WOS:000224326801456 ER PT J AU Goel, N Orces, CH Lee, S AF Goel, N Orces, CH Lee, S TI Hip fracture trends from 1990-2001: Indirect evidence of improved diagnosis and treatment SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY OCT 01-05, 2004 CL Seattle, WA SP Amer Soc Bone & Mineral Res C1 Univ Texas, Med Branch, Galveston, TX 77550 USA. S Texas Vet Hlth Syst, Laredo, TX USA. S Texas Vet Hlth Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD OCT PY 2004 VL 19 SU 1 MA M353 BP S428 EP S428 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 860FB UT WOS:000224326802425 ER PT J AU Huang, W Rudkin, G Ishida, K Yamaguchi, DT Miller, TA AF Huang, W Rudkin, G Ishida, K Yamaguchi, DT Miller, TA TI Knockdown of chordin using siRNA induces osteoblastic differentiation in MC3T3-E1 preosteoblastic cells SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY OCT 01-05, 2004 CL Seattle, WA SP Amer Soc Bone & Mineral Res C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD OCT PY 2004 VL 19 SU 1 BP S404 EP S404 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 860FB UT WOS:000224326802321 ER PT J AU Rao, H Kajiya, H Safran, K Choi, SJ Kurihara, N Anderson, J Roodman, GD AF Rao, H Kajiya, H Safran, K Choi, SJ Kurihara, N Anderson, J Roodman, GD TI alpha(9)beta(1) integrin is expressed on osteoclast precursors and mediates osteoclast formation though its interaction with ADAM8. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY OCT 01-05, 2004 CL Seattle, WA SP Amer Soc Bone & Mineral Res C1 Univ Pittsburgh, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD OCT PY 2004 VL 19 SU 1 BP S153 EP S153 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 860FB UT WOS:000224326800604 ER PT J AU Shoback, DM Pollina, C Chang, W Pratt, S Hyodo, S Takei, Y Loretz, CA AF Shoback, DM Pollina, C Chang, W Pratt, S Hyodo, S Takei, Y Loretz, CA TI Ca2+-sensing receptor of Mozambique tilapia (tCaR): cDNA expression, signal transduction, and salinity-dependent mRNA expression in vivo. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY OCT 01-05, 2004 CL Seattle, WA SP Amer Soc Bone & Mineral Res C1 Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. Natl Sci Fdn, Tokyo Reg Off, Tokyo, Japan. Univ Tokyo, Ocean Res Inst, Tokyo 164, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD OCT PY 2004 VL 19 SU 1 BP S196 EP S196 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 860FB UT WOS:000224326801129 ER PT J AU Shoback, DM Arends, RH Roskos, L Shetty, S Wyres, M Huang, S Raie, N Bell, GM AF Shoback, DM Arends, RH Roskos, L Shetty, S Wyres, M Huang, S Raie, N Bell, GM TI Treatment of parathyroid carcinoma with ABX10241, a monoclonal antibody to parathyroid hormone. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 26th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY OCT 01-05, 2004 CL Seattle, WA SP Amer Soc Bone & Mineral Res C1 Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. Abgenix Inc, Fremont, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD OCT PY 2004 VL 19 SU 1 BP S187 EP S187 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 860FB UT WOS:000224326801095 ER PT J AU Massie, BM AF Massie, BM TI Should the management of heart failure become a new subspecialty? SO JOURNAL OF CARDIAC FAILURE LA English DT Editorial Material ID CARDIOLOGISTS; PROGRAM C1 San Francisco VAMC, Cardiol Div 111C, San Francisco, CA 94121 USA. RP Massie, BM (reprint author), San Francisco VAMC, Cardiol Div 111C, 4150 Clement St, San Francisco, CA 94121 USA. NR 5 TC 0 Z9 0 U1 1 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD OCT PY 2004 VL 10 IS 5 BP 363 EP 365 DI 10.1016/j.cardfail.2004.08.164 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 863VJ UT WOS:000224591200001 PM 15470643 ER PT J AU Masoudi, FA Rumsfeld, JS Havranek, EP House, JA Peterson, ED Krumholz, HM Spertus, JA Spertus, J Tsuyuki, RT Clark, CB Hott, B Havranek, EP Masoudi, FA Rumsfeld, JS Kale, P Williams, RE Heidenreich, PA Peterson, ED McCullough, P Krumholz, H Dunlap, M Goff, D AF Masoudi, FA Rumsfeld, JS Havranek, EP House, JA Peterson, ED Krumholz, HM Spertus, JA Spertus, J Tsuyuki, RT Clark, CB Hott, B Havranek, EP Masoudi, FA Rumsfeld, JS Kale, P Williams, RE Heidenreich, PA Peterson, ED McCullough, P Krumholz, H Dunlap, M Goff, D CA Cardiovascular Outcomes Res TI Age, functional capacity, and health-related quality of life in patients with heart failure SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE heart failure; elderly; quality of life; functional status ID CITY CARDIOMYOPATHY QUESTIONNAIRE; CONTROLLED-TRIAL; EXERCISE CAPACITY; CLINICAL-TRIALS; OLDER; DIGOXIN; WITHDRAWAL; OUTCOMES; WALK AB Background: Although heart failure disproportionately affects older persons and is associated with significant physical disability, existing data on physical limitations and health-related quality of life (HRQL) derive largely from studies of younger subjects. We compared the relationship between functional limitation and HRQL between older and younger patients with heart failure. Methods and Results: We evaluated 546 outpatients with heart failure enrolled in a multicenter prospective cohort study. At baseline and 6 2 weeks later, functional status was assessed by New York Heart Association (NYHA) classification and 6-minute walk testing. HRQL was measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ). Comparing older (age >65 years, n = 218) and younger patients (n = 328), we assessed baseline HRQL across strata of functional status. In the 484 patients who completed follow-up (194 older and 290 younger patients), we also assessed the changes in HRQL associated with changes in functional status over time. At baseline, older patients had better HRQL than younger patients (mean KCCQ score 60 +/- 25 versus 54 +/- 28, P = .005) in spite of worse NYHA class (mean 2.54 versus 2.35, P < .001) and lower 6-minute walk distances (824 +/- 378 versus 1064 +/- 371 feet, P < .001). After multivariable adjustment including baseline NYHA class, older age was independently correlated with better HRQL (beta = +7.9 points, P < .001). At follow-up, older patients with a deterioration in NYHA class experienced marked declines in HRQL compared with younger patients (mean HRQL change of - 14.4 points versus +03 points, respectively, P < .001). Analyses using 6-minute walk distance as the functional measure yielded similar results. Conclusions: Although older patients with heart failure have relatively good HRQL in spite of significant functional limitations, they are at risk for worsening HRQL with further decline in functional status. These results underscore the importance of treatments aimed at maintaining functional status in older persons with heart failure, including those with significant baseline functional limitations. C1 Denver Hlth Med Ctr, Div Cardiol MC 0960, Dept Med, Denver, CO 80204 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Denver VA Med Ctr, Dept Med, Denver, CO USA. UMKC, Mid Amer Heart Inst, Kansas City, MO USA. Duke Univ, Duke Clin Res Inst, Durham, NC USA. Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA. Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA. RP Masoudi, FA (reprint author), Denver Hlth Med Ctr, Div Cardiol MC 0960, Dept Med, 777 Bannock St, Denver, CO 80204 USA. RI Tsuyuki, Ross/E-2462-2016 OI Tsuyuki, Ross/0000-0002-3724-598X FU NIA NIH HHS [K08-AG01011] NR 32 TC 84 Z9 86 U1 1 U2 2 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD OCT PY 2004 VL 10 IS 5 BP 368 EP 373 DI 10.1016/j.cardfail.2004.01.009 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 863VJ UT WOS:000224591200003 PM 15470645 ER PT J AU Castellon, SA Ganz, PA Bower, JE Petersen, L Abraham, L Greendale, GA AF Castellon, SA Ganz, PA Bower, JE Petersen, L Abraham, L Greendale, GA TI Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article ID CEREBRAL-BLOOD-FLOW; QUALITY-OF-LIFE; COGNITIVE FUNCTION; LONG-TERM; ESTROGEN; WOMEN; BRAIN; THERAPY; DYSFUNCTION; REPLACEMENT AB The primary aim of the current study was to examine whether neurocognitive functioning among breast cancer survivors (BCS) exposed to systemic adjuvant chemotherapy differs from that seen among BCS who did not receive chemotherapy. The performance of each of these BCS groups was compared to a demographically matched comparison group without history of breast cancer, a group not included in the majority of previous cognitive functioning studies. We also sought to explore whether usage of the anti-estrogen drug tamoxifen, a common component of breast cancer treatment, was related to neurocognitive functioning. Finally, we wished to examine the relationship between subjective report of cognitive functioning and objective performance on neurocognitive measures among BCS. Fifty-three survivors of breast cancer (all between 2-5 years after diagnosis and initial surgical removal of cancerous tissue) and 19 healthy non-BCS comparison subjects were administered a comprehensive neurocognitive battery, and measures of mood, energy level, and self-reported cognitive functioning. Those BCS who received adjuvant chemotherapy performed significantly worse in the domains of verbal learning, vistiospatial functioning, and visual memory than BCS treated with surgery only. Those who received both chemotherapy and tamoxifen showed the greatest compromise. Although patients who received chemotherapy (with and without tamoxifen) performed worse than those treated with surgery only on several domains, neither group was significantly different from demographically matched comparison subjects without a history of breast cancer. Finally, we found no relationship between subjective cognitive complaints and objective performance, although cognitive complaints were associated with measures of psychological distress and fatigue. We highlight ways in which these data converge with other recent studies to suggest that systemic chemotherapy, especially in combination with tamoxifen, can have adverse yet subtle effects on cognitive functioning. C1 Univ Calif Los Angeles, Inst Neuropsychiat, Dept Psychiat & Biobehav Sci, Sch Med, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Mental Hlth Serv, Los Angeles, CA USA. Univ Calif Los Angeles, Div Canc Prevent & Control Res, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Geriatr Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90024 USA. RP Castellon, SA (reprint author), Univ Calif Los Angeles, Inst Neuropsychiat, Dept Psychiat & Biobehav Sci, Sch Med, 760 Westwood Plaza,C8-747, Los Angeles, CA 90024 USA. EM scastell@ucla.edu NR 53 TC 221 Z9 225 U1 1 U2 10 PU SWETS ZEITLINGER PUBLISHERS PI LISSE PA P O BOX 825, 2160 SZ LISSE, NETHERLANDS SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD OCT PY 2004 VL 26 IS 7 BP 955 EP 969 DI 10.1080/13803390490510905 PG 15 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 876ZF UT WOS:000225536900008 PM 15742545 ER PT J AU Doyle, PJ McNeil, MR Mikolic, JM Prieto, L Hula, WD Lustig, AP Ross, K Wambaugh, JL Gonzalez-Rothi, LJ Elman, RJ AF Doyle, PJ McNeil, MR Mikolic, JM Prieto, L Hula, WD Lustig, AP Ross, K Wambaugh, JL Gonzalez-Rothi, LJ Elman, RJ TI The Burden of Stroke Scale (BOSS) provides valid and reliable score estimates of functioning and well-being in stroke survivors with and without communication disorders SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE Burden of Stroke Scale (BOSS); stroke; communication disorders; psychometrics; health status ID QUALITY-OF-LIFE; HEALTH SURVEY SF-36; REHABILITATION OUTCOMES; NEGATIVE AFFECT; DISABILITY; INDEPENDENCE; TRIALS AB Background and Objective: This study describes the conceptual foundation and psychometric properties of the Burden of Stroke Scale (BOSS), a patient-reported health status assessment designed to quantify the physical, cognitive, and psychological burden of stroke. Methods: Qualitative research methods were used to develop a 112-item pilot version of the instrument. The pilot version was administered to healthy controls (n = 251) and stroke survivors with (n = 135) and without (n = 146) communication disorders on a single occasion for the purposes of reducing the global item pool, describing the resulting scale properties, examining the dimensionality of the burden of stroke construct, and examining the known-groups validity of the instrument. Results: Sixty-four items were retained, comprising 12 internally consistent and unidimensional scales. Principal components analysis revealed three second-order factors (Physical Activity Limitations, Cognitive Activity Limitations, and Psychological Distress) comprising the Burden of Stroke construct. Comparisons between groups revealed that stroke survivors reported greater activity limitations and psychological distress on all scales relative to controls, and that stroke survivors with communication disorders reported greater activity limitations on swallowing, communication, cognition, and social relations scales relative to non-communicatively disordered stroke survivors. Conclusion: These findings support the internal consistency of the BOSS scales, the hypothesized dimensionality of the burden of stroke construct, and the known-groups validity of the instrument. (C) 2004 Elsevier Inc. All rights reserved. C1 VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA. Eli Lilly & Co, Hlth Outcomes Res Unit, Madrid, Spain. Univ Pittsburgh, Ctr Social & Urban Res, Pittsburgh, PA USA. Carl T Hayden VA Med Ctr, Phoenix, AZ USA. VA Med Ctr, Salt Lake City, UT USA. VA RR&D Brain Rehabil Res Ctr, Gainesville, FL USA. Aphasia Ctr Calif, Oakland, CA USA. RP Doyle, PJ (reprint author), VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM patrick.doyle@med.va.gov NR 55 TC 40 Z9 43 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD OCT PY 2004 VL 57 IS 10 BP 997 EP 1007 DI 10.1016/j.jclinepi.2003.11.016 PG 11 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 873JP UT WOS:000225276100001 PM 15528050 ER PT J AU Grossberg, R Zhang, YW Gross, R AF Grossberg, R Zhang, YW Gross, R TI A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE adherence; HIV-1; antiretroviral therapy; measurement; validity; viral load ID PROTEASE INHIBITORS; DRUG-RESISTANCE; THERAPY; INFECTION AB Objective: The goal of this study was to determine the validity and utility of a pharmacy-based time-to-refill measure of antiretroviral therapy adherence. Methods: We performed an observational cohort study of 110 HIV-infected subjects on a stable, highly active antiretroviral regimen for at least 3 months at a Veterans' Affairs Medical Center in Philadelphia, Pennsylvania. Results: The viral load decreased by 0.12 log c/mL (95% confidence interval [CI] 0.01-0.23 log c/mL) for each 10% increase in pharmacy-based time-to-refill defined adherence as compared with 0.05 log c/mL (95% CI -0.14-0.25 log c/mL) for the self-reported adherence measure. Thus, only the refill-defined measure was statistically significantly associated with viral load change. When adherence was classified as good (greater than or equal to85%) versus poor (<85%), both measures demonstrated a significant difference in outcome between groups. Yet, in individuals self-reporting 100% adherence, those classified as good adherers using the pharmacy-based measure had greater viral load reductions than poor adherers (2.4 log c/mL [interquartile range 1.4-3.4] vs. 1.5 log c/mL [interquartile range 0.8-2.4, P = .03). Conclusions: The pharmacy-based technique is a valid measure of antiretroviral therapy adherence. Because it provides clinically relevant information in subjects who self-report 100% adherence, it should be incorporated into clinical practice and adherence research. (C) 2004 Elsevier Inc. All rights reserved. C1 Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Gross, R (reprint author), Univ Penn, Sch Med, Dept Med, Div Infect Dis, 804 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rgross@cceb.med.upenn.edu FU AHRQ HHS [HS10399]; NIAID NIH HHS [U01-AI32783, P30-AI45008]; NIMH NIH HHS [K08 MH01584] NR 14 TC 103 Z9 106 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD OCT PY 2004 VL 57 IS 10 BP 1107 EP 1110 DI 10.1016/j.jclinepi.2004.04.002 PG 4 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 873JP UT WOS:000225276100014 PM 15528063 ER PT J AU Gralnek, IM Hays, RD Kilbourne, AM Chang, L Mayer, EA AF Gralnek, IM Hays, RD Kilbourne, AM Chang, L Mayer, EA TI Racial differences in the impact of irritable bowel syndrome on health-related quality of life SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article; Proceedings Paper CT Digestive Disease Week/102nd Annual Meeting of the American-Gastroenterological-Association CY MAY 20-23, 2001 CL ATLANTA, GA SP Amer Gastroenterol Assoc DE health-related quality of life; functional status; irritable bowel syndrome; functional bowel disease ID NON-HISPANIC WHITES; CLINICAL-TRIALS; UNITED-STATES; GASTROINTESTINAL SYMPTOMS; MEDICAL OUTCOMES; PATIENT OUTCOMES; SURVEY SF-36; DISEASE; CARE; PREVALENCE AB Goals: To compare the impact of irritable bowel syndrome (IBS) on health related quality of life (HRQOI) for non-white and white IBS patients. Background: There are no reported data evaluating the HRQOL of non-white persons with IBS. Study: SF-36 scores are compared between non-white IBS patients (n = 166), white IBS patients (n = 707), the general US population, and patients with selected chronic diseases. Results: Of the n = 166 non-white IBS patients included for analysis, 66 (40%) described themselves as African-American, 56 (34%) as Hispanic, 25 (15%) as Asian-American, 2 (1%) as Native American and the remaining 17 (10%) as "other." Compared with white IBS patients, non-white IBS patients reported similar decrements in their HRQOL after controlling for age, gender, income and education level. On all 8 SF-36 scales, non-white IBS patients had significantly worse HRQOL compared with the general US population, (P < 0.001). Compared with GERD patients, non-white IBS patients scored significantly lower on all SF-36 scales (P < 0.001) except physical functioning. Similarly, non-white IBS patients had significantly worse HRQOL on selected SF-36 scales compared with diabetes mellitus and ESRD patients. Non-white IBS patients had significantly better emotional well-being than depressed patients, (P < 0.001). Conclusions: Non-white IBS patients experience impairment in vitality, role limitations-physical, and bodily pain. Yet overall, non-white IBS patients report similar HRQOL to white IBS patients. These data provide the first detailed evaluation of the impact of IBS on HRQOL in non-white IBS patients. C1 CURE, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Hlth Sci Ctr, Dept Med,Div Digest Dis, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Ctr Study Digest Hlth Care Qual & Outcomes, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Hlth Sci Ctr, Dept Med,Div Gen Internal Med Hlth Serv Res, Los Angeles, CA 90024 USA. RAND Corp, Santa Monica, CA USA. VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA USA. RP Gralnek, IM (reprint author), CURE, Digest Dis Res Ctr, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM igralnek@mednet.ucla.edu RI Hays, Ronald/D-5629-2013 FU NIA NIH HHS [AG-02-004]; NIMHD NIH HHS [P20-MD00148-01] NR 51 TC 15 Z9 16 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD OCT PY 2004 VL 38 IS 9 BP 782 EP 789 DI 10.1097/01.mcg.0000140190.65405.fb PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 856KZ UT WOS:000224045400012 PM 15365405 ER PT J AU Chinman, M Young, AS Schell, T Hassell, J Mintz, J AF Chinman, M Young, AS Schell, T Hassell, J Mintz, J TI Computer-assisted self-assessment in persons with severe mental illness SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID WORLD-WIDE-WEB; RISK BEHAVIORS; HIV-INFECTION; INFORMATION-SYSTEMS; QUALITY ASSURANCE; RANDOMIZED TRIAL; PATIENT OUTCOMES; SEXUAL-BEHAVIOR; DRUG-USE; SCHIZOPHRENIA AB Background: It has been difficult to improve care for severe mental illness (SMI) in usual care settings because clinical information is not reliably and efficiently managed. Methods are needed for efficiently collecting this information to evaluate and improve health care quality. Audio computer-assisted self-interviewing (ACASI) can facilitate this data collection and has improved outcomes for a number of disorders, suggesting the need to test its accuracy and reliability in people with SMI. Method: Ninety patients with DSM-IV schizophrenia or schizoaffective disorder (N = 45) or bipolar disorder (N = 45) recruited between Oct. 15, 2002, and July 1, 2003, were randomly assigned to 1 of 2 study groups and completed 2 standardized symptom surveys (Revised Behavior and Symptom Identification Scale and the symptom severity scale of the Schizophrenia Outcomes Module 2) 20 minutes apart in a crossover study design. Half of the patients first completed the scales via an in-person interview, and the other half first completed the scales via an ACASI survey self-administered through an Internet browser using a touchscreen developed to meet the cognitive needs of people with SMI. We evaluated attitudes toward ACASI, understanding of the ACASI survey, internal consistency, correlations between the ACASI and interview modes, concurrent validity, and a possible administration mode bias. Results: All ACASI and in-person interview scales had similar internal reliability, high correlations (r = 0.78-1.00), and mean scores similar enough as not to be different at p < .05. A large majority rated the ACASI survey as easier, more enjoyable, more preferable if monthly completion of a survey were required, and more private, and 97% to 99% perfectly answered questions about how to use it. Conclusion: ACASI data collection is reliable among people with bipolar disorder and schizophrenia and could be a valuable tool to improve their care. C1 W Los Angeles VA MIRECC, Los Angeles, CA 90073 USA. RAND Corp, Santa Monica, CA USA. RP Chinman, M (reprint author), W Los Angeles VA MIRECC, 11301 Wilshire Blvd,210A, Los Angeles, CA 90073 USA. EM chinman@rand.org RI Young, Alexander/A-1523-2009 OI Young, Alexander/0000-0002-9367-9213 FU NIMH NIH HHS [MH 068639] NR 89 TC 51 Z9 52 U1 3 U2 9 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD OCT PY 2004 VL 65 IS 10 BP 1343 EP 1351 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 864SR UT WOS:000224653700007 PM 15491237 ER PT J AU Dresselhaus, TR Peabody, JW Luck, J Bertenthal, D AF Dresselhaus, TR Peabody, JW Luck, J Bertenthal, D TI An evaluation of vignettes for predicting variation in the quality of preventive care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE compliance; preventive care guidelines; physician practice; clinical vignettes; quality of care ID STANDARDIZED PATIENTS; INFLUENZA VACCINATION; CLINICAL-PERFORMANCE; SIMULATED PATIENTS; CONTROLLED-TRIAL; HEALTH-CARE; PHYSICIANS; GUIDELINES; REMINDERS; MORTALITY AB OBJECTIVE: Clinical vignettes offer an inexpensive and convenient alternative to the benchmark method of chart audits for assessing quality of care. We examined whether vignettes accurately measure and predict variation in the quality of preventive care. DESIGN: We developed scoring criteria based on national guidelines for 11 prevention items, categorized as vaccine, vascular-related, cancer screening, and personal behaviors. Three measurement methods were used to ascertain the quality of care provided by clinicians seeing trained actors (standardized patients; SPs) presenting with common outpatient conditions: 1) the abstracted medical record from an SP visit; 2) SP reports of physician practice during those visits; and 3) physician responses to matching computerized case scenarios (clinical vignettes). SETTING: Three university-affiliated (including 2 VA) and one community general internal medicine clinics. PATIENTS/PARTICIPANTS: Seventy-one randomly selected physicians from among eligible general internal medicine residents and attending physicians. MEASUREMENTS AND MAIN RESULTS: Physicians saw 480 SPs (120 at each site) and completed 480 vignettes. We calculated the proportion of prevention items for each visit reported or recorded by the 3 measurement methods. We developed a multiple regression model to determine whether site, training level, or clinical condition predicted prevention performance for each measurement method. We found that overall prevention scores ranged from 57% (SP) to 54% (vignettes) to 46% (chart abstraction). Vignettes matched or exceeded SP scores for 3 prevention categories (vaccine, vascular-related, and personal behavior). Prevention quality varied by site (from 40% to 67%) and was predicted similarly by vignettes and SPs. CONCLUSIONS: Vignettes can measure and predict prevention performance. Vignettes may be a less costly way to assess prevention performance that also controls for patient case-mix. C1 Univ Calif San Francisco, Inst Global Hlth, San Francisco, CA 94105 USA. Univ Calif San Diego, VA San Diego Healthcare Syst, San Diego, CA USA. Univ Calif San Diego, Sch Med, San Diego, CA USA. Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, Inst Global Hlth, San Francisco, CA USA. Calif State Univ Los Angeles, RAND, Sch Publ Hlth, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. VA Ctr Study Hlth Care Provider Behav, Los Angeles, CA USA. RP Peabody, JW (reprint author), Univ Calif San Francisco, Inst Global Hlth, 74 New Montgomery St,Suite 508, San Francisco, CA 94105 USA. EM peabody@psg.ucsf.edu NR 28 TC 61 Z9 61 U1 0 U2 5 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2004 VL 19 IS 10 BP 1013 EP 1018 DI 10.1007/s11606-004-0003-2 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 860MG UT WOS:000224347100004 PM 15482553 ER PT J AU Li, W Henry, G Fan, JH Bandyopadhyay, B Pang, K Garner, W Chen, M Woodley, DT AF Li, W Henry, G Fan, JH Bandyopadhyay, B Pang, K Garner, W Chen, M Woodley, DT TI Signals that initiate, augment, and provide directionality for human keratinocyte motility SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article DE ECM; growth factor; human keratinocyte; motility; signal transduction; wound healing ID EPIDERMAL-GROWTH-FACTOR; FIBROBLAST MIGRATION; CELL-MIGRATION; ALPHA(V)BETA(3) INTEGRIN; EXTRACELLULAR-MATRIX; PHAGOKINETIC TRACKS; EPITHELIAL-CELLS; DERMAL COLLAGEN; EGF RECEPTOR; FACTOR-BB AB Human keratinocytes (HK) migration plays a critical role in the re-epithelialization of acute skin wounds. Although extracellular matrices (ECM) and growth factors (GF) are the two major pro-motility signals, their functional relationship remains unclear. We investigated how ECM and GF regulate HK motility under defined conditions: (1) in the absence of GF and ECM and (2) with or without GF with cells apposed to a known pro-motility ECM. Our results show that HK migrate on selected ECM even in the total absence of GF. This suggests that certain ECM alone are able to "initiate" HK migration. Unlike ECM, however, GF alone cannot initiate HK migration. HK cannot properly migrate when plated in the presence of GF, regardless of the concentration, without an ECM substratum. The role of GF, instead, is to augment ECM-initiated motility and provide directionality. To gain insights into the mechanism of action by ECM and GF, we compared, side-by-side, the roles of three major mitogen-activated protein kinase cascades, extracellular-signal-regulated kinase (ERK)1/2, p38, and c-Jun N-terminal kinase (JNK). Our data show that ERK1/2 is involved in mediating collagen's initiation signal and GF's augmentation signal. p38 is specific for GF's augmentation signal. JNK is uninvolved in HK motility. Constitutively activated p38 and ERK1/2 alone could not initiate HK migration. Co-expression of both constitutively activated p38 and ERK1/2, however, could partially mimic the pro-motility effects of collagen and GF. This study reveals for the first time the specific functions of ECM and GF in cell motility. C1 Univ So Calif, Dept Med, Div Dermatol, Keck Sch Med, Los Angeles, CA 90033 USA. VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Univ So Calif, Dept Surg, Div Plast Surg, Keck Sch Med, Los Angeles, CA USA. RP Li, W (reprint author), Univ So Calif, Dept Med, Div Dermatol, Keck Sch Med, 1303 N Mission Rd, Los Angeles, CA 90033 USA. EM wli@usc.edu NR 58 TC 49 Z9 50 U1 0 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD OCT PY 2004 VL 123 IS 4 BP 622 EP 633 DI 10.1111/j.0022-202X.2004.23416.x PG 12 WC Dermatology SC Dermatology GA 855OF UT WOS:000223982900010 PM 15373765 ER PT J AU Virella, G Thorpe, SR Alderson, NL Derrick, MB Chassereau, C Rhett, JM Lopes-Virella, ME AF Virella, G Thorpe, SR Alderson, NL Derrick, MB Chassereau, C Rhett, JM Lopes-Virella, ME TI Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies SO JOURNAL OF LIPID RESEARCH LA English DT Article DE low density lipoprotein modifications; low density lipoprotein autoantibodies; modified low density lipoprotein antibodies; immunology of atherosclerosis; autoimmunity; atherosclerosis ID LOW-DENSITY-LIPOPROTEIN; ADVANCED GLYCATION ENDPRODUCTS; ATHEROSCLEROTIC LESIONS; OXIDIZED LDL; OXIDATIVE MODIFICATION; DIABETES-MELLITUS; IMMUNE-COMPLEXES; LYSINE RESIDUES; END-PRODUCT; EPITOPES AB Humans and laboratory animals recognize human modified LDL as immunogenic. Immune complexes (ICs) isolated from human sera contain malondialdehyde-modified LDL (MDA-LDL) and N-epsilon(carboxymethyl)lysine-modified LDL (CML-LDL) as well as antibodies reacting with MDA-LDL, copper-oxidized LDL (OxLDL), CML-LDL, and advanced glycosylation end product (AGE)-modified LDL. OxLDL and AGE-LDL antibodies isolated from human sera recognize the same LDL modifications and do not react with modified non-LDL proteins. Rabbit antibodies have different reactivity patterns: MDA-LDL antibodies react strongly with MDA-LDL and MDA-BSA but weakly with OxLDL; OxLDL antibodies react strongly with OxLDL and weakly with MDA-LDL; CML-LDL antibodies react with CML-LDL > CML-BSA > AGE-LDL > OxLDL; AGE-LDL antibodies react strongly with AGE-LDL, react weakly with OxLDL, and do not react with CML-LDL. Thus, human and rabbit antibodies seem to recognize different epitopes. Capture assays carried out with all rabbit antibodies showed binding of apolipoprotein B-rich lipoproteins isolated from ICs, suggesting that laboratory-generated epitopes are expressed by in vivo-modified LDL, although they are not necessarily recognized by the human immune system. jlr Thus, the definition of immunogenic forms of modified LDL eliciting human autoimmune responses requires the isolation and characterization of autoantibodies and modified LDL from human samples, whereas rabbit antibodies can be used to detect in vivo-modified human LDL. -Virella, G., S. R. Thorpe, N. L. Alderson, M. B. Derrick, C. Chassereau, J. M. Rhett, and M. E Lopes-Virella. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. C1 Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA. Med Univ S Carolina, Dept Med, Div Endocrinol Metab & Nutr, Charleston, SC 29425 USA. Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. RP Virella, G (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. EM virellag@musc.edu FU NHLBI NIH HHS [P01 HL 55782]; NIDDK NIH HHS [DK 19971] NR 28 TC 42 Z9 42 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD OCT PY 2004 VL 45 IS 10 BP 1859 EP 1867 DI 10.1194/jlr.M400095-JLR200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 859ZR UT WOS:000224307400008 PM 15258197 ER PT J AU Wilson, EM Diwan, A Spinale, FG Mann, DL AF Wilson, EM Diwan, A Spinale, FG Mann, DL TI Duality of innate stress responses in cardiac injury, repair, and remodeling SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Article DE myocardium; cardiac injury; innate stress response ID TUMOR-NECROSIS-FACTOR; ISCHEMIA-REPERFUSION INJURY; LEUKEMIA-INHIBITORY FACTOR; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; ADULT FELINE MYOCARDIUM; FACTOR-ALPHA GENE; TRANSGENIC MICE; ANGIOTENSIN-II; INDUCED EXPRESSION AB The ability of the myocardium to successfully adapt to cardiac injury ultimately determines whether the heart will decompensate and fail, or whether instead it will maintain preserved function. Despite the importance of the myocardial response to cardiac injury, very little is known with respect to the biochemical mechanisms that are responsible for mediating and integrating the stress response in the heart. In the present review we will summarize recent experimental material which suggests that the heart possess a germ-line encoded "innate" stress response that is activated in response to diverse forms of tissue injury. The extant literature suggests that this innate stress response plays an important role in initiating and integrating homeostatic responses within the heart. Nonetheless, as will be discussed further herein, these inflammatory mediators all have the potential to produce cardiac decompensation when expressed at sufficiently high concentrations. (C) 2004 Elsevier Ltd. All rights reserved. C1 Baylor Coll Med, Michael E DeBakey Vet Adm Med Ctr, Winters Ctr Heart fAILURE rES, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Methodist Hosp, Houston, TX 77030 USA. Med Univ S Carolina, Dept Surg Cardiothorac Res, Charleston, SC 29425 USA. RP Mann, DL (reprint author), Baylor Coll Med, Michael E DeBakey Vet Adm Med Ctr, Winters Ctr Heart fAILURE rES, Dept Med, 6565 Fannin,MS 524, Houston, TX 77030 USA. EM dmann@bcm.tmc.edu OI Mann, Douglas /0000-0002-2516-0145 FU NHLBI NIH HHS [HL 42250-10/10, R01 HL 58081-01, R01 HL 61543-01] NR 74 TC 31 Z9 35 U1 1 U2 4 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD OCT PY 2004 VL 37 IS 4 BP 801 EP 811 DI 10.1016/j.yjmcc.2004.05.028 PG 11 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA 859TR UT WOS:000224291300001 PM 15380670 ER PT J AU Mularski, R Curtis, JR Osborne, M Engelberg, RA Ganzini, L AF Mularski, R Curtis, JR Osborne, M Engelberg, RA Ganzini, L TI Agreement among family members in their assessment of the quality of dying and death SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE death; quality of dying; outcome assessment; quality of health care; quality indicators; health care; end-of-life care; family; proxy; terminal care; attitude to death ID END-OF-LIFE; ILL HOSPITALIZED-PATIENTS; INTENSIVE-CARE UNITS; PROXY RESPONDENTS; CANCER-PATIENTS; CRITICALLY ILL; SYMPTOM BURDEN; DECISIONS; ILLNESS; OLDER AB Improving end-of-life care requires accurate indicators of the quality of dying. The purpose of this study was to measure the agreement among family members who rate a loved one's dying experience. We administered the Quality of Dying and Death instrument to 94 family members of 38 patients who died in the intensive care unit. We measured a quality of dying score of 60 out of 100 points and found moderate agreement among family members as measured by an intraclass correlation coefficient (ICC) of 0.44. Variability on individual items ranged from an ICC of 0.15 to 1.0. Families demonstrated more agreement on frequencies of events (ICC 0.54) than, on determinations of quality (ICC 0.32). These findings reveal important variability among family raters and suggest that until the variability is understood, multiple raters may generate more comprehensive end-of-life data and may more accurately reflect the quality of dying and death. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Div Pulm & Crit Care Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. Oregon Hlth Sci Univ, Dept Psychiat, Div Mental Hlth, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Mularski, R (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, 11301 Wilshire Blvd,Mailcode 111G, Los Angeles, CA 90073 USA. FU NCRR NIH HHS [5 M01 RR00334] NR 49 TC 44 Z9 44 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD OCT PY 2004 VL 28 IS 4 BP 306 EP 315 DI 10.1016/j.jpainsymman.2004.01.008 PG 10 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 864SU UT WOS:000224654000003 PM 15471648 ER PT J AU Staretz, LR Otomo-Corgel, J Lin, JI AF Staretz, LR Otomo-Corgel, J Lin, JI TI Effects of intravenous midazolam and diazepan on patient response, percentage of oxygen saturation, and hemodynamic factors during periodontal surgery SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE anesthesia; intravenous; conscious sedation; diazepam/therapeutic use; double-blind method; hemodynamics; midazolam/therapeutic use; periodontal diseases/surgery ID WATER-SOLUBLE BENZODIAZEPINE; LOCAL-ANESTHESIA; CONSCIOUS SEDATION; IV SEDATION; INDUCTION; RECOVERY; GASTROSCOPY; FENTANYL; MALEATE; AGENTS AB Background: The purpose of this double-masked study was to evaluate effects of intravenous sedation (IVS) using midazolam or diazepam during periodontal procedures on patient recall, psychomotor response, oxygen saturation, and hemodynamic factors. Methods: Seventeen patients received either two or three scheduled periodontal surgeries under IVS with midazolam, diazepam, or placebo control. Patients were monitored throughout the procedure for hemodynamic variables, percent oxygen saturation, level of recall of common objects presented at baseline, and psychomotor function via the perceptual speed test (PST). Results: Fifteen patients completed the study with average titrated dosages of 3.3 and 12.1 mg for midazolam and diazepam, respectively. Within the limitations of the study, there were few differences observed between the drugs with regard to hemodynamic variables, oxygen saturation, and overall percentage of objects recalled by patients sedated with either drug. However, midazolam was found to cause a greater incidence of amnesia lasting up to 30 minutes when compared to placebo. Patients on diazepam required an average of 15 minutes longer to recover accuracy as measured by the PST. Conclusions: The results suggest that diazepam and midazolam each may have advantages for IVS. In procedures lasting over 45 minutes, diazepam appears to be more clinically advantageous including a wider margin of safety during titration and gradual recovery. IAidazolam may be used for shorter procedures for faster onset of action, predictable amnesic effects, and relatively rapid recovery. C1 Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Wadsworth VA Med Ctr, Sect Periodont, Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Lin, JI (reprint author), W Los Angeles Vet Affairs Wadsworth VA Med Ctr, Sect Periodont, Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jilin@ucla.edu NR 44 TC 3 Z9 3 U1 0 U2 1 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 J9 J PERIODONTOL JI J. Periodont. PD OCT PY 2004 VL 75 IS 10 BP 1319 EP 1326 DI 10.1902/jop.2004.75.10.1319 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 866KJ UT WOS:000224772100004 PM 15562908 ER PT J AU Cooper, GS Parks, CG Treadwell, EL Clair, EWS Gilkeson, GS Dooley, MA AF Cooper, GS Parks, CG Treadwell, EL Clair, EWS Gilkeson, GS Dooley, MA TI Occupational risk factors for the development of systemic lupus erythematosus SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE systemic lupus erythematosus; autoimmune disease; occupation; mercury; solvents; pesticides ID DENTAL LABORATORY TECHNICIANS; SOUTHEASTERN UNITED-STATES; MRL-+/+ MICE; AUTOIMMUNE-RESPONSE; SOLVENT EXPOSURE; MERCURY; DISEASE; MELATONIN; CONCORDANCE; SCLERODERMA AB Objective. There have been few studies of occupational exposures and systemic lupus erythematosus (SLE). We examined the association between the risk of SLE and occupational exposures (mercury, solvents, and pesticides), specific jobs (ever worked in teaching, healthcare, and cosmetology), and working night or rotating shifts. Methods. Patients with recently diagnosed SLE (n = 265) were recruited through 4 university based and 30 community based rheumatology practices in North Carolina and South Carolina, USA. Controls (n = 355) were identified through driver's license records and were frequency matched to patients by age, sex, and state. Data collection included ail in-person interview with detailed farming and work histories. Results. Associations were seen with self-reported occupational exposure to mercury (OR 3.6, 95% CI 1.3, 10.0), mixing pesticides for agricultural work (OR 7.4, 95% CI 1.4, 40.0), and among dental workers (OR 7.1, 95% CI 2.2, 23.4). Although these associations were fairly strong and statistically significant, the prevalence of these exposures was very low and thus these estimates are based on a small number of exposed cases and controls. Weaker associations were seen between SLE and shift work (OR 1.6, 95% CI 0.99, 2.7) and among healthcare workers with patient contact (OR 1.7, 95% CI 0.99, 2.9). There was no association of SLE with use of solvents or among teachers or cosmetologists. Conclusion. This study reveals the potential contribution of occupational exposures to the development of SLE, and highlights some exposures and experiences that should be examined in other studies using more extensive exposure assessment techniques and in experimental studies of autoimmunity. C1 NIEHS, Epidemiol Branch, Durham, NC 27709 USA. E Carolina Univ, Sch Med, Div Rheumatol, Greenville, NC USA. Duke Univ, Med Ctr, Div Rheumatol, Durham, NC USA. Ralph H Johnson Vet Adm Med Ctr, Med Res Serv, Charleston, SC USA. Med Univ S Carolina, Charleston, SC 29425 USA. Univ N Carolina, Div Rheumatol, Chapel Hill, NC USA. RP Cooper, GS (reprint author), NIEHS, Epidemiol Branch, A3-05,POB 12233, Durham, NC 27709 USA. EM cooper1@niehs.nih.gov OI Parks, Christine/0000-0002-5734-3456 NR 32 TC 82 Z9 84 U1 0 U2 3 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD OCT PY 2004 VL 31 IS 10 BP 1928 EP 1933 PG 6 WC Rheumatology SC Rheumatology GA 860FC UT WOS:000224326900011 PM 15468355 ER PT J AU O'Connell, JB Maggard, MA Liu, JH Etzioni, DA Ko, CY AF O'Connell, JB Maggard, MA Liu, JH Etzioni, DA Ko, CY TI A report card on outcomes for surgically treated gastrointestinal cancers: Are we improving? SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE gastrointestinal cancer; esophageal; gastric; small bowel; colorectal; hepatobiliary; population-based; survival; report card; inpatient mortality ID SPECIAL SECTION; NATION; MORTALITY; TRENDS; US AB Introduction. Longitudinal analyses of cancer registries provide an opportunity for population-based explanations of epidemiology and survival-related outcomes. This study used two population-based data sets to report on nine surgery-related cancers over the past three decades. Materials and methods. Using the SEER cancer database (1973-1999), all patients (>18 years old) with adenocarcinoma of esophagus, gastric, biliary system, pancreas, small bowel, colon, rectum; esophageal squamous cell carcinoma (ESC), or hepatocellular (HCC) carcinoma (n = 379,640) were analyzed. Changes in incidence rates, stage at diagnosis, and 5-year cancer and stage-specific survivals were determined. A separate database, the California inpatient database (1990-2000), was concurrently used to evaluate inpatient mortality after surgical resection (n = 34,057). Results. Incidence rates increased for three cancers (esophageal, HCC, small bowel); decreased for three (rectal, gastric, ESC); and stayed constant for three (biliary, pancreatic, colon). More patients presented with local/regional disease in the 1990s versus 1970s for eight tumors (except small bowel, P < 0.05). Five-year overall survival improved for all but small bowel (P < 0.05); and local stage survival was improved for all except small bowel and biliary (P < 0.05). Finally, inpatient mortality rates improved significantly for liver, esophageal, pancreatic, and gastric resections (P < 0.05) over the past decade. Conclusions. For these nine surgically treated cancers, we are detecting disease at earlier and therefore more treatable stages, and surgical care and outcomes also appear to have improved. Continued reexamination of longitudinal trends of surgically relevant outcomes is important for future improvement of surgical care. (C) 2004 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. RP O'Connell, JB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave,Room 72-215 CHS, Los Angeles, CA 90095 USA. EM jbocjboc@hotmail.com NR 16 TC 13 Z9 15 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD OCT PY 2004 VL 121 IS 2 BP 214 EP 221 DI 10.1016/j.jss.2004.04.002 PG 8 WC Surgery SC Surgery GA 866EU UT WOS:000224757400008 PM 15501461 ER PT J AU Bryson, CL Smith, NL Kuller, LH Chaves, PHM Manolio, TA Lewis, W Boyko, EJ Furberg, CD Psaty, BM AF Bryson, CL Smith, NL Kuller, LH Chaves, PHM Manolio, TA Lewis, W Boyko, EJ Furberg, CD Psaty, BM TI Risk of congestive heart failure in an elderly population treated with peripheral alpha-1 antagonists SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE hypertension treatment; heart failure; alpha-1 antagonist; thiazide ID LIPID-LOWERING TREATMENT; ATTACK TRIAL ALLHAT; SYSTEMIC HYPERTENSION; CARDIOVASCULAR EVENTS; BLOOD-PRESSURE; OLDER PERSONS; DOXAZOSIN; HEALTH; CHLORTHALIDONE; ATENOLOL AB Objectives: To compare the risk of congestive heart failure (CHF) in elderly individuals treated with any peripheral alpha-1 antagonist for hypertension with any thiazide, test whether the risk persists in subjects without cardiovascular disease (CVD) at baseline, and examine CHF risk in normotensive men with prostatism treated with alpha antagonists. Design: Prospective cohort study. Setting: Four U.S. sites: Washington County, Maryland; Allegheny County, Pennsylvania; Sacramento County, California; and Forsyth County, North Carolina. Participants: A total of 5,888 community-dwelling subjects aged 65 and older. Measurements: Adjudicated incident CHF. Results: The 3,105 participants with treated hypertension were at risk for CHF; 22% of men and 8% of women took alpha antagonists during follow-up. The age-adjusted risk of CHF in those receiving monotherapy treated with alpha antagonists was 1.90 (95% confidence interval=1.03-3.50) compared with thiazides. In subjects without CVD at baseline receiving monotherapy, women taking an alpha antagonist had a 3.6 times greater age-adjusted risk of CHF, whereas men had no difference in risk. Adjustment for systolic blood pressure attenuated statistical differences in risk. There were 930 men without hypertension at risk for CHF; 5% used alpha antagonists during follow-up, with no observed increase in CHF risk. Conclusion: Subjects receiving alpha antagonist monotherapy for hypertension had a two to three times greater risk of incident CHF, also seen in lower-risk subjects, but differences in blood pressure control partly explained this. C1 VA Puget Sound HSR&D, Seattle VAMC, Seattle, WA 98108 USA. VA Puget Sound Healthcare Syst, Epidemiol Res & Informat Ctr, VAMC, Seattle, WA USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol & Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. Johns Hopkins Univ, Dept Med, Baltimore, MD USA. Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA. NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA. Univ Calif Davis, Dept Internal Med, Sacramento, CA 95817 USA. Wake Forest Univ, Winston Salem, NC 27109 USA. RP Bryson, CL (reprint author), VA Puget Sound HSR&D, Seattle VAMC, MS 152,1660 S Columbian Way, Seattle, WA 98108 USA. EM cbryson@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X FU NHLBI NIH HHS [N01-HC-15103, N01-HC-35129, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086] NR 21 TC 10 Z9 10 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2004 VL 52 IS 10 BP 1648 EP 1654 DI 10.1111/j.1532-5415.2004.52456.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 855TU UT WOS:000223998300007 PM 15450040 ER PT J AU Ruckdeschel, K Katz, IR AF Ruckdeschel, K Katz, IR TI Care of dementia and other mental disorders in assisted living facilities: New research and borrowed knowledge SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Editorial Material ID NURSING-HOMES C1 Univ Penn, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. RP Ruckdeschel, K (reprint author), Univ Penn, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA. FU PHS HHS [P3066270] NR 6 TC 3 Z9 3 U1 1 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2004 VL 52 IS 10 BP 1771 EP 1773 DI 10.1111/j.1532-5415.2004.52476.x PG 3 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 855TU UT WOS:000223998300028 PM 15450061 ER PT J AU O'Keeffe, T Goldman, RK Mayberry, JC Rehm, CG Hart, RA AF O'Keeffe, T Goldman, RK Mayberry, JC Rehm, CG Hart, RA TI Tracheostomy after anterior cervical spine fixation SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article DE tracheostomy; anterior; cervical spine; fixation; spinal cord injury; American Spinal Injury Association; (ASIA) ID PERCUTANEOUS DILATIONAL TRACHEOSTOMY; RESPIRATORY COMPLICATIONS; CORD INJURY; INTENSIVE-CARE; DILATATIONAL TRACHEOSTOMY; TRAUMA PATIENTS; FOLLOW-UP; SURGERY; MANAGEMENT; FUSION AB Background: Patients with cervical spine injury may require both anterior cervical spine fusion and tracheostomy, particularly in the setting of associated cervical spinal cord injury (SCI). Despite the close proximity of the two surgical incisions, we postulated that tracheostomy could be safely performed after anterior spine fixation. In addition, we postulated that the severity of motor deficits in patients with cervical spine injury would correlate with the need for tracheostomy. Methods: A retrospective review was undertaken of all adult trauma patients diagnosed with cervical spine fractures or cervical SCI admitted between June 1996 and June 2001 at our university Level I trauma center. Demographic data, severity of neurologic injury based on the classification of the American Spinal Injury Association (ASIA), complications, and use and type of tracheostomy were collected. In the subgroup of patients with unstable cervical spine injury that under-went anterior stabilization and tracheostomy, data regarding timing and technique of these procedures and wound outcomes were also collected. Categorical data were analyzed using X-2 analysis using Yates correction when appropriate, with p < 0.05 considered significant. Results: During this time period, 275 adult survivors were diagnosed with cervical spinal cord or bony injury. Fortyfive percent of patients with SCI (27 of 60) and 14% of patients without SCI (30 of 215) underwent tracheostomy (p < 0.001). Moreover, on the basis of the ASIA classification system, 76% of ASIA A and B patients, 38% of ASIA C patients, 23% of ASIA D patients, and 14% of ASIA E patients were treated with tracheostomy (p < 0.001). In the subgroup that underwent both anterior spine fixation and tracheostomy (n = 17), the median time interval from spine fixation to airway placement was 7 days (interquartile range, 6-10 days), with 71% of these tracheostomies performed percutaneously. No patient developed a wound infection or nonunion as a consequence of tracheostomy placement, and there were no deaths because of complications of either procedure. Conclusions: These data support the safety of tracheostomy insertion 6 to 10 days after anterior cervical spine fixation, particularly in the presence of cervical SCL The presence of severe motor neurologic deficits was strongly associated with the use of tracheostomy in patients with cervical spine injury. Percutaneous tracheostomy, which is our technique of choice, may be advantageous in this setting by virtue of creating only a small wound. The optimal timing and use of tracheostomy in patients with cervical spine injury requires further study. C1 Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Trauma Crit Care Sect, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Orthopaed Surg, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR USA. RP Goldman, RK (reprint author), Oregon Hlth & Sci Univ, Div Gen Surg, 3181 SW Sam Jackson Pk Rd,L223A, Portland, OR 97239 USA. EM goldmanr@ohsu.edu NR 40 TC 25 Z9 26 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD OCT PY 2004 VL 57 IS 4 BP 855 EP 860 DI 10.1097/01.TA.000083006.48501.B2 PG 6 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 871EN UT WOS:000225112300032 PM 15514542 ER PT J AU Andriole, G Bruchovsky, N Chung, LWK Matsumoto, AM Rittmaster, R Roehrborn, C Russell, D Tindall, D AF Andriole, G Bruchovsky, N Chung, LWK Matsumoto, AM Rittmaster, R Roehrborn, C Russell, D Tindall, D TI Dihydrotestosterone and the prostate: the scientific rationale for 5 alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia SO JOURNAL OF UROLOGY LA English DT Article DE prostate; dihydrotestosterone; prostatic hyperplasia; finasteride; GG 745 ID BONE-MINERAL DENSITY; FINASTERIDE; EXPRESSION; MEN; EPITHELIUM; TESTOSTERONE; DUTASTERIDE; STROMA; TYPE-1; CANCER AB Purpose: We reviewed the physiological and pathogenic role of dihydrotestosterone (DHT), evidence for the beneficial effects of decreasing DHT through 5alpha-reductase inhibition and the effects of altering the androgen balance with these agents. Materials and Methods: A review of the relevant literature was done using published studies identified from the MEDLINE database. Results: The androgens DHT and testosterone have complementary roles in male physiology. Each is mediated through the intracellular androgen receptor. It has been hypothesized that DHT may provide an amplification mechanism for testosterone, which could be a beneficial adaptation in men with low circulating testosterone. The recognition of the central role of DHT in benign prostatic hyperplasia (BPH) has changed the way the disease is viewed and has led to the introduction of 5alpha-reductase inhibitors, which can prevent and retard the progression of BPH by suppressing DHT synthesis. The 5alpha-reductase inhibitors decrease prostate volume. In doing so they improve symptoms and urinary flow, and decrease the risks of acute urinary retention and the need for BPH related surgery. The predominant drug related adverse events with 5a-reductase inhibitors are reproductive events, that is typically decreased libido, impotence and ejaculatory dysfunction. These events occur in a minority of men and tend to decrease with a longer treatment duration. Conclusions: DHT appears to have an obligatory role in the development of BPH. The role of 5alpha-reductase inhibitors in the treatment of BPH has been firmly established with an adverse events profile that is suitable for long-term use. C1 Washington Univ, Sch Med, Div Urol Surg, St Louis, MO 63110 USA. British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. Univ Washington, Sch Med & Geriatr Res Educ, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Ctr Clin, Seattle, WA 98195 USA. GlaxoSmithKline, Res Triangle Pk, NC USA. Univ Texas, SW Med Ctr, Dallas, TX 75230 USA. Mayo Clin, Coll Med, Rochester, MN USA. RP Andriole, G (reprint author), Washington Univ, Sch Med, Div Urol Surg, 4960 Childrens Pl,Campus Box 8242, St Louis, MO 63110 USA. OI Russell, David/0000-0002-0277-403X NR 20 TC 121 Z9 128 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD OCT PY 2004 VL 172 IS 4 BP 1399 EP 1403 DI 10.1097/01.ju.0000139539.94828.29 PN 1 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 854JN UT WOS:000223899000044 PM 15371854 ER PT J AU Morgan, RO Virnig, BA Duque, M Abdel-Moty, E DeVito, CA AF Morgan, RO Virnig, BA Duque, M Abdel-Moty, E DeVito, CA TI Low-intensity exercise and reduction of the risk for falls among at-risk elders SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; OLDER PERSONS; MOBILITY; STRENGTH; WOMEN; PROGRAM; PEOPLE; KNEE; GAIT; MEN AB Background. Among elderly persons, falls account for 87% of all fractures and are contributing factors in many nursing home admissions. This study evaluated the effect of an easily implemented, low-intensity exercise program on the incidence of falls and the time to first fall among a clinically defined population of elderly men and women. Methods. This community-based, randomized trial compared the exercise intervention with a no-intervention control. The participants were 294 men and women, aged 60 years or older, who had either a hospital admission or bed rest for 2 days or more within the previous month. Exercise participants were scheduled to attend exercise sessions lasting 45 minutes, including warm-up and cool-down, 3 times a week for 8 weeks (24 sessions). Assessments included gait and balance measures, self-reported physical function, the number of medications being taking at baseline, participant age, sex, and history of falling. Falls were tracked for 1 year after each participant's baseline assessment. Results. 29% of the study participants reported a fall during the study period. The effect of exercise in preventing falls varied significantly by baseline physical function level (p < .002). The risk for falls decreased for exercise participants with low baseline physical functioning (hazard ratio .5 1) but increased for exercise participants with high baseline physical functioning (hazard ratio, 3.51). Conclusions. This easily implemented, low-intensity exercise program appears to reduce the risk for falls among elderly men and women recovering from recent hospitalizations, bed rest, or both who have low levels of physical functioning. C1 Houston VA Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Univ Minnesota, Sch Publ Hlth, Div Hlth Serv Res & Policy, Minneapolis, MN 55455 USA. Univ Miami, Sch Educ, Dept Exercise & Sport Sci, Coral Gables, FL 33124 USA. Miami VA Med Ctr, Hlth Serv Res & Dev Ctr, Miami, FL USA. Univ Miami, Coll Engn, Dept Ind Engn, Coral Gables, FL 33124 USA. Univ Miami, Sch Med, Dept Neurol Surg, Coral Gables, FL 33124 USA. Univ Miami, S Shore Hosp & Med Ctr, Comprehens Pain & Rehabil Ctr, Miami Beach, FL 33124 USA. Univ Miami, Sch Med, Dept Psychiat & Behav Sci, Coral Gables, FL 33124 USA. RP Morgan, RO (reprint author), Houston VA Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM nnorgan@bcm.tmc.edu RI Morgan, Robert/A-8577-2009 NR 27 TC 41 Z9 43 U1 1 U2 5 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD OCT PY 2004 VL 59 IS 10 BP 1062 EP 1067 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 868IQ UT WOS:000224907700012 PM 15528779 ER PT J AU Jarvik, LF Harrison, TR Holt, L Jimenez, E Larson, SW LaRue, A Matsuyama, SS Rasgon, N Schaeffer, J Steh, B Yaralian, P AF Jarvik, LF Harrison, TR Holt, L Jimenez, E Larson, SW LaRue, A Matsuyama, SS Rasgon, N Schaeffer, J Steh, B Yaralian, P TI Children of Alzheimer patients: More data needed SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Letter ID PERFORMANCE; DISEASE C1 Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Wisconsin, Wisconsin Alzheimers Inst, Madison, WI 53706 USA. Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. RP Jarvik, LF (reprint author), 760 Westwood Plaza, Los Angeles, CA 90095 USA. EM ljarvik@ucla.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD OCT PY 2004 VL 59 IS 10 BP 1076 EP 1077 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 868IQ UT WOS:000224907700014 PM 15528781 ER PT J AU An, J Sun, Y Fisher, M Rettig, MB AF An, J Sun, Y Fisher, M Rettig, MB TI Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas SO LEUKEMIA LA English DT Article DE proteasome inhibition; PS-341; primary effusion lymphoma; chemotherapy; TRAIL; NF-kappa B ID NF-KAPPA-B; PROTEASOME INHIBITOR PS-341; TRAIL-INDUCED APOPTOSIS; PROSTATE-CANCER CELLS; INTERFERON-ALPHA; ACTIVATION; RESISTANCE; AZIDOTHYMIDINE; MYELOMA; LIGAND AB Primary effusion lymphomas (PELs) are a rare type of non-Hodgkin's lymphoma that are resistant to cytotoxic chemotherapy. PELs manifest constitutive activation of nuclear factor kappa B (NF-kappaB), and inhibition of NF-kappaB induces apoptosis of PELs and sensitizes to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced death. Bortezomib (PS-341), a peptidyl boronic acid inhibitor of the proteasome, is a potent agent against a wide range of hematologic malignancies and has been shown to inhibit NF-kappaB. Thus, we examined the cytotoxic effects of bortezomib alone and in combination with various drugs. Bortezomib potently inhibited NF-kappaB in PEL cells in a dose-dependent manner. In addition, bortezomib inhibited growth and induced apoptosis of PEL cell lines (IC50 values of 3.4 - 5.0 nM). Results of drug interactions between bortezomib and chemotherapy ( doxorubicin and Taxol) were schedule-dependent: synergistic interactions were generally observed when PEL cells were pretreated with bortezomib prior to chemotherapy, whereas additive or even antagonistic interactions occurred with chemotherapy pretreatment or simultaneous treatment with bortezomib and chemotherapy. Most schedules of bortezomib and dexamethasone were synergistic, although pretreatment with dexamethasone resulted in additive interactions. Effects of combinations of bortezomib and TRAIL were generally additive. Thus, bortezomib represents a promising potential therapy for the treatment of PEL. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Rettig, MB (reprint author), VAGLAHS W LA, 11301 Wilshire Blvd,Bldg 304,Room E1-113, Los Angeles, CA 90073 USA. EM matthew.rettig@med.va.gov FU NCI NIH HHS [5R01CA80004] NR 27 TC 61 Z9 64 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD OCT PY 2004 VL 18 IS 10 BP 1699 EP 1704 DI 10.1038/sj.leu.2403460 PG 6 WC Oncology; Hematology SC Oncology; Hematology GA 857NP UT WOS:000224124500023 PM 15343345 ER PT J AU Echchgadda, I Song, CS Oh, TS Cho, SH Rivera, OJ Chatterjee, B AF Echchgadda, I Song, CS Oh, TS Cho, SH Rivera, OJ Chatterjee, B TI Gene regulation for the senescence marker protein DHEA-sulfotransferase by the xenobiotic-activated nuclear pregnane X receptor (PXR) SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Article DE aging; Sult2A1; xenobiotic metabolism; nuclear receptors; PXR; sulfonation ID CONSTITUTIVE ANDROSTANE RECEPTOR; HUMAN CYTOSOLIC SULFOTRANSFERASES; RAT-LIVER; DEHYDROEPIANDROSTERONE-SULFOTRANSFERASE; MOLECULAR-CLONING; HYDROXYSTEROID SULFOTRANSFERASE; ANDROGEN RECEPTOR; LITHOCHOLIC ACID; MESSENGER-RNA; BILE-ACIDS AB Dehydroepiandrosterone (DHEA)-sulfotransferase (SULT2A1) is a phase 11 metabolizing/detoxifying enzyme with substrate preference for physiological hydroxysteroids, diverse drugs and other xenobiotics. The first-pass,tissues (liver and intestine) express SULT2A1 at high levels. In senescent male rodents, Sult2A1 gene transcription in the liver is markedly enhanced and calorie restriction retards this increase. Age-associated loss of the liver expression of androgen receptor in part explains the up-regulation of Sult2A1 expression at late life, since androgen receptor is a negative regulator of this gene. In line with its role in xenobiotic metabolism, the Sidt2A1 gene is induced by the pregnane X receptor (PXR). PXR is a xenosensing nuclear receptor that is activated by endobiotic (natural steroids) and xenobiotic (therapeutic drugs and environmental chemicals) molecules. An inverted-repeat arrangement (IR0) of the consensus half site binding sequence for nuclear receptors mediates the xenobiotic induction of the Sult2A1 promoter. The IR0 element is a specific binding site for PXR and its heterodimer partner retinoid X receptor (RXR-alpha) and it directs PXR-mediated induction of a heterologous promoter. In contrast to the loss of androgen receptor expression, PXR and RXR-alpha mRNA expression is invariant during aging. Repression by the androgen receptor and induction by PXR may act coordinately to cause the senescence associated and xenobiotic mediated stimulation of Sult2A1 transcription. Increased Sult2A1 expression appears to be an adaptive response to ensure optimal metabolism of Sult2A1 substrates at old age. (C) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Chatterjee, B (reprint author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM chatterjee@uthscsa.edu FU NIA NIH HHS [T32 AG 00165, R01 AG 10486] NR 81 TC 32 Z9 33 U1 0 U2 2 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing Dev. PD OCT-NOV PY 2004 VL 125 IS 10-11 BP 733 EP 745 DI 10.1016/j.mad.2004.08.008 PG 13 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 877ZM UT WOS:000225614800009 PM 15541768 ER PT J AU Vijg, J AF Vijg, J TI Impact of genome instability on transcription regulation of aging and senescence SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Article DE genome instability; somatic mutations; gene regulation; aging ID TRANSGENIC MOUSE MODEL; IN-VIVO MUTATIONS; SOMATIC MUTATION; GENE-EXPRESSION; AGE; MICE; ACCUMULATION; CHROMOSOME; REARRANGEMENTS; RESTRICTION AB Genomic instability has been implicated as a major stochastic mechanism of aging. Using a transgenic mouse model with chromosomally integrated lacZ mutational target genes, mutations were found to accumulate with age at an organ- and tissue-specific rate. Also, the spectrum of age-accumulated mutations was found to differ greatly from organ-to-organ; while initially similar, mutation spectra of different tissues diverged significantly over the lifetime. To explain how genomic instability, which is inherently stochastic, can be a causal factor in aging, it is proposed that randomly induced mutations may adversely affect normal patterns of gene regulation, resulting in a mosaic of cells at various stages on a trajectory of functional decline, eventually resulting in cell death or neoplastic transformation. To directly address this question, we demonstrate that it is now possible to analyze single cells, isolated from old and young tissues, for specific alterations in gene expression. (C) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78245 USA. S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. RP Vijg, J (reprint author), Univ Texas, Hlth Sci Ctr, STCBM Bldg,Suite 2-200,15355 Lambda, San Antonio, TX 78245 USA. EM vijg@uthsesa.edu FU NIA NIH HHS [AG 17242] NR 39 TC 27 Z9 29 U1 1 U2 2 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing Dev. PD OCT-NOV PY 2004 VL 125 IS 10-11 BP 747 EP 753 DI 10.1016/j.mad.2004.07.004 PG 7 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 877ZM UT WOS:000225614800010 PM 15541769 ER PT J AU Clark, RA Valente, AJ AF Clark, RA Valente, AJ TI Nuclear factor kappa B activation by NADPH oxidases SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Article DE ageing; NADPH oxidase; NF-kappa B; NOX; superoxide ID CHRONIC GRANULOMATOUS-DISEASE; TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE-CELLS; HEMATOLOGICALLY IMPORTANT MUTATIONS; SIGNAL-TRANSDUCTION PATHWAYS; PEROXIDE-HALIDE SYSTEM; HUMAN-NEUTROPHILS; TRANSCRIPTION FACTOR; REACTIVE OXYGEN; HYDROGEN-PEROXIDE AB Reactive oxygen species (ROS) initiate activation of the transcription factor NF-kappaB in a variety of cell systems. Perhaps the most potent biological source of ROS is the NADPH oxidase of phagocytic cells, a multi-component system that catalyzes the formation of superoxide anion. Although phagocytes use this oxidase to kill ingested microorganisms, the products also mediate a broad range of biological oxidation reactions and some evidence exists for activation of NF-kappaB through this mechanism. Moreover, the components of the phagocyte NADPH oxidase are present in certain non-phagocytic cells and recently discovered homologues of the catalytic component gp91(phox) are expressed in a number of tissues. We explored the hypothesis that the products of NADPH oxidases cause the activation of NF-kappaB. K562 human erythrokeukemia cells transfected with constructs for expression of gp91(phox), plus other essential NADPH oxidase components generated substantial amounts of superoxide when activated with phorbol ester, lesser amounts with arachidonic acid exposure, and none with TNFalpha. Gel shift assays demonstrated induction of NF-KB in K562 cells exposed to TNFa and specificity was shown by oligonucleotide competition. Supershift assays demonstrated the presence in nuclear complexes of the NF-kappaB components p65/RelA and p50. Nuclear complexes of identical electrophoretic mobility were induced in phorbol ester-stimulated K562 cells that expressed the complete NADPH oxidase system, but not in cells lacking one of the essential oxidase components. K562 cells were relatively resistant to NF-KB induction by exogenous peroxide, but certain other cell types (HEK293 and HeLaS3) demonstrated such induction upon exposure to reagent hydrogen peroxide or glucose oxidase plus glucose and this was blocked by catalase. Finally, we found a biphasic pattern of gp91(phox) expression in rat liver during aging. High levels observed in young animals decreased in middle age, but increased again in old age. Collectively, these studies demonstrate the potential for NADPH-dependent induction of NF-KB and raise the possibility of a role for this pathway in the biology of aging. (C) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Clark, RA (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM clarkra@uthscsa.edu FU NIA NIH HHS [R01 AG019519, R01 AG 19519] NR 82 TC 40 Z9 41 U1 1 U2 7 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing Dev. PD OCT-NOV PY 2004 VL 125 IS 10-11 BP 799 EP 810 DI 10.1016/j.mad.2004.08.009 PG 12 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 877ZM UT WOS:000225614800015 PM 15541774 ER PT J AU Bokov, A Chaudhuri, A Richardson, A AF Bokov, A Chaudhuri, A Richardson, A TI The role of oxidative damage and stress in aging SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Review DE antioxidants; oxidative damage; oxidative stress; free radicals ID SUPEROXIDE DISMUTASE/CATALASE MIMETICS; METHIONINE SULFOXIDE REDUCTASE; EXTENDED LIFE-SPAN; ADULT DROSOPHILA-MELANOGASTER; METAL-CATALYZED OXIDATION; TERM CALORIC RESTRICTION; FREE-RADICAL THEORY; LONG-LIVED STRAIN; CAENORHABDITIS-ELEGANS; DIETARY RESTRICTION AB The Free Radical/Oxidative Stress Theory of Aging, which was first proposed in 1956, is currently one of the most popular explanations for how aging occurs at the biochemical/molecular level. However, most of the evidence in support of this theory is correlative, e.g., oxidative damage to various biomolecules increases with age, and caloric restriction, which increases life span and retards aging, reduces the age-related increase in oxidative damage to biomolecules. The most direct test of the Free Radical/Oxidative Stress Theory of Aging is to specifically alter the age-related increase in oxidative damage and determine how this alteration affects life span. For the first time, investigators can use genetically altered animals to test directly the role of oxidative damage in aging. In this manuscript, we critically review the past research in this area and discuss potential future research directions in testing the Free Radical/Oxidative Theory of Aging. (C) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX 78284 USA. RP Richardson, A (reprint author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr,MSC 7762, San Antonio, TX 78229 USA. EM richardsona@uthscsa.edu NR 194 TC 318 Z9 334 U1 3 U2 30 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing Dev. PD OCT-NOV PY 2004 VL 125 IS 10-11 BP 811 EP 826 DI 10.1016/j.mad.2004.07.009 PG 16 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 877ZM UT WOS:000225614800016 PM 15541775 ER PT J AU Chren, MM Sahay, AP Sands, LP Maddock, L Lindquist, K Bertenthal, D Bacchetti, P AF Chren, MM Sahay, AP Sands, LP Maddock, L Lindquist, K Bertenthal, D Bacchetti, P TI Variation in care for nonmelanoma skin cancer in a private practice and a veterans affairs clinic SO MEDICAL CARE LA English DT Article; Proceedings Paper CT 63rd Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 15-18, 2002 CL LOS ANGELES, CA SP Soc Investigat Dermatol DE practice variation; ambulatory care; skin cancer ID BASAL-CELL CARCINOMA; PATIENT; SURGERY AB Background: Nonmelanoma skin cancer is the most common malignancy. Multiple therapies prevent recurrence but vary widely in cost. The most common therapies are local destruction, excision, and Mohs surgery (histologically guided tumor removal). Clinical variables that may affect treatment choices can be identified, but little is known about how clinicians choose among therapies. Objective: The objective of this study was to learn if variations exist in the treatment of nonmelanoma skin cancer in different practice settings. Research Design: Prospective cohort study. Subjects: Subjects consisted of consecutive patients with nonmelanoma skin cancer at a university-affiliated private dermatology practice and the dermatology clinic at the nearby affiliated Veterans Affairs (VA) medical center. Data: We studied data from medical records and patient surveys. Results: Overall, 1777 nonrecurrent nonmelanoma skin cancers were diagnosed in 1375 patients. Compared with the VA site, patients at the private site were younger, more likely to be female, and less likely to be poor, and their tumors were smaller and less likely to be on visible areas of the body. Treatments varied between the 2 sites (P < 0.001). The proportions of tumors treated at the private and VA sites, respectively, were 23% and 19% for destruction, 25% and 48% for excision, and 37% and 25% for Mohs surgery. In multiple clinical subgroups, Mohs surgery was more likely to be performed at the private site than at the VA. Moreover, in multivariable models controlling for clinical features that may have affected treatment choice, tumors at the private site were more likely than tumors at the VA to be treated with Mohs surgery (odds ratio, 2.39; 95% confidence interval, 1.54-3.70). Conclusions: Care for nonmelanoma skin cancer varied at 2 academic practice sites that are near each other and that share some clinician staff. These findings raise questions not only about overuse or underuse of procedures at the 2 sites, but also about systematic differences in patient preferences and/or physician incentives in prepaid and fee-for-service settings. C1 San Francisco VAMC, Dermatol Serv, San Francisco, CA 94121 USA. San Francisco VAMC, Dept Vet Affairs, Interdisciplinary Res Program Improve Care Older, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Chren, MM (reprint author), San Francisco VAMC, Dermatol Serv, 151R,4150 Clement St, San Francisco, CA 94121 USA. EM mmchren@itsa.ucsf.edu RI Sands, Laura/E-8919-2015 OI Sands, Laura/0000-0003-2446-4486 FU NIAMS NIH HHS [K02 AR 02203-01] NR 16 TC 21 Z9 21 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD OCT PY 2004 VL 42 IS 10 BP 1019 EP 1026 DI 10.1097/00005650-200410000-00011 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 858MW UT WOS:000224196900011 PM 15377935 ER PT J AU Pietz, K Ashton, CM McDonell, M Wray, NP AF Pietz, K Ashton, CM McDonell, M Wray, NP TI Predicting healthcare costs in a population of veterans affairs beneficiaries using diagnosis-based risk adjustment and self-reported health status SO MEDICAL CARE LA English DT Article DE risk adjustment; case-mix; health status ID CASE-MIX MEASURES; CAPITATION RATES; CHRONIC DISEASE; INFORMATION; HOSPITALS; OUTCOMES; MODEL AB Background: Many healthcare organizations use diagnosis-based risk adjustment systems for predicting costs. Health self-report may add information not contained in a diagnosis-based system but is subject to incomplete response. Objective: The objective of this study was to evaluate the added predictive power of health self-report in combination with a diagnosis-based risk adjustment system in concurrent and prospective models of healthcare cost. Research Design: This was a cohort study using Department of Veterans Affairs (VA) administrative databases. We tested the predictive ability of the Adjusted Clinical Group (ACG) methodology and the added value of SF-36V (short form functional status for veterans) results. Linear regression models were compared using R-2, mean absolute prediction error (MAPE), and predictive ratio. Subjects: Subjects were 35,337 VA beneficiaries at 8 VA medical centers during fiscal year (FY) 1998 who voluntarily completed an SF-36V survey. Measures: Outcomes were total FY 1998 and FY 1999 cost. Demographics and ACG-based Adjusted Diagnostic Groups (ADGs) with and without 8 SF-36V multiitem scales and the Physical Component Score and Mental Component Score were compared. Results: The survey response rate was 45%. Adding the 8 scales to ADGs and demographics increased the crossvalidated R-2 by 0.007 in the prospective model. The 8 scales reduced the MAPE by $236 among patients in the upper 10% of FY 1999 cost. Conclusions: The limited added predictive power of health self-report to a diagnosis-based risk adjustment system should be weighed against the cost of collecting these data. Adding health self-report data may increase predictive accuracy in high-cost patients. C1 Michael E DeBakey Vet Affairs Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. NW Healthcare Serv Res & Dev Ctr Excellence, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Dept Vet Affairs, Washington, DC USA. RP Pietz, K (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM kpietz@bcm.tmc.edu NR 27 TC 29 Z9 29 U1 4 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD OCT PY 2004 VL 42 IS 10 BP 1027 EP 1035 DI 10.1097/00005650-200410000-00012 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 858MW UT WOS:000224196900012 PM 15377936 ER PT J AU Klein, RL McHenry, MB Lok, KH Hunter, SJ Le, NA Jenkins, AJ Zheng, D Semler, AJ Brown, WV Lyons, TJ Garvey, WT AF Klein, RL McHenry, MB Lok, KH Hunter, SJ Le, NA Jenkins, AJ Zheng, D Semler, AJ Brown, WV Lyons, TJ Garvey, WT CA DCCTEDIC Res Grp TI Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: Associations with lipoprotein subclasses SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Article ID CORONARY-ARTERY-DISEASE; MAGNETIC-RESONANCE-SPECTROSCOPY; FAMILIAL COMBINED HYPERLIPIDEMIA; TRIGLYCERIDE-RICH LIPOPROTEINS; FRAGMENT-LENGTH-POLYMORPHISMS; INSULIN-RESPONSE ELEMENT; HEART-DISEASE; APOC-III; A-I; PLASMA-LIPOPROTEINS AB Serum apolipoprotein C-III (apoCIII) concentration and apoCIII gene polymorphisms have been shown to be a risk factor for cardiovascular disease; however, the underlying mechanisms remain unclear. In addition, no studies have been performed that address these issues in type 1 diabetes. The current study investigated apoCIII protein and apoCIII gene variation in a normotriglyceridemic (82 +/- 57 mg/dL) population of patients with type 1 diabetes, the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications (DCCT/EDIC) cohort. Blood samples were obtained in 409 patients after an overnight fast. Serum apoCIII concentration was highly correlated with multiple changes in lipids and lipoproteins that resulted in an adverse cardiovascular disease risk profile. Higher apoCIII concentrations were associated (P < .0001) with increased triglycerides (r = 0.78), total (r = 0.61) and low-density lipoprotein (LDL) (r = 0.40) cholesterol, apoA-I (r = 0.26), and apoB (r = 0.50), and these relationships persisted after controlling for age, gender, body mass index (BMI), and hemoglobin A(1c) (HbA(1c)). Nuclear magnetic resonance (NMR) lipoprotein subclass analyses demonstrated that apoCIII was correlated with an increase in very-low-density lipoprotein (VLDL) subclasses (P = .0001). There also was a highly significant positive relationship between serum apoCIII concentration and the LDL particle concentration in both men (r = 0.49, P = .001) and women (r = 0.40, P = .001), and a highly significant negative relationship between serum apoCIII levels and average LDL particle size in both men (r = -0.37, P = .001) and women (r = -0.22, P = .001) due primarily to an augmentation in the small L1 subclass (r = 0.42, P = .0001). Neither the T-455-->C polymorphism affecting an insulin response element in the apoCIII gene promoter nor a Sad polymorphism in the 3'UTR were associated with any alterations in circulating apoCIII concentrations, serum lipids, apolipoprotein concentrations, lipoprotein composition, or parameters measured by NMR lipoprotein subclass analyses. In summary, elevated apoCIII concentration was associated with risk factors for cardiovascular disease in normolipidemic type 1 diabetic patients through associated changes in lipoprotein subfraction distributions, which were independent of apoCIII genotype. (C) 2004 Elsevier Inc. All rights reserved. C1 Med Univ S Carolina, Dept Med, Div Endocrinol Metab & Med Genet, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA. Vet Affairs Med Ctr, Res Serv, Ralph H Johnson Dept, Charleston, SC 29403 USA. Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. Emory Univ, Div Atherosclerosis & Lipid Metab, Atlanta, GA 30322 USA. Univ Melbourne, St Vincent Hosp, Dept Med, Fitzroy, Vic 3052, Australia. Univ Oklahoma, Hlth Sci Fdn, Sect Endocrinol Diabet & Hypertens, Oklahoma City, OK USA. Vet Affairs Med Ctr, Birmingham, AL USA. DCCT, NDIC, Bethesda, MD USA. RP Klein, RL (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Metab & Med Genet, 114 Doughty St,POB 250770, Charleston, SC 29425 USA. RI Jenkins, Alicia/N-2482-2015; Hegele, Robert/G-3301-2011 OI Le, Ngoc-Anh/0000-0002-2634-4798 FU NHLBI NIH HHS [P01-HL55782] NR 57 TC 21 Z9 21 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0026-0495 J9 METABOLISM JI Metab.-Clin. Exp. PD OCT PY 2004 VL 53 IS 10 BP 1296 EP 1304 DI 10.1016/j.metabol.2004.05.004 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 861MT UT WOS:000224421500008 PM 15375785 ER PT J AU Handforth, A Martin, FC AF Handforth, A Martin, FC TI Pilot efficacy and tolerability: A randomized, placebo-controlled trial of levetiracetam for essential tremor SO MOVEMENT DISORDERS LA English DT Article DE essential tremor; levetiracetam; clinical trial ID ANTIEPILEPTIC DRUG LEVETIRACETAM; DOUBLE-BLIND; PROPRANOLOL; GABAPENTIN; MYOCLONUS; DESIGNS; BRAIN AB The purpose of this pilot single-site study was to assess efficacy and safety of levetiracetam for essential tremor, using a placebo-controlled, double-blind, randomized crossover design with an interim analysis planned after completion of the first 10 to 15 subjects. The study was designed to detect a mean 30% reduction in composite tremor score, comparable to that of primidone or propranolol, which can be demonstrated with 30 or fewer subjects. Each treatment arm included baseline tremor assessments, a 4-week medication titration, 2 weeks of stable dose, and treatment tremor assessments. Levetiracetam was titrated to 3,000 mg/day or to a lower maximal tolerated dose. The median age was 72 years, with 28 years median tremor duration. There was no statistically significant difference in response between placebo and levetiracetam on any tremor rating scale or accelerometry measure. The 95 % confidence interval for the true mean difference between placebo and levetiracetarn treatments was +18.5 to -22.5%, which excludes the minimum 30% drop required to consider levetiracetam clinically effective to a degree comparable to primidone or propranolol. Whether levetiracetam has lesser-degree antitremor efficacy was not addressed in this pilot study. (C) 2004 Movement Disorder Society. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Neurol Serv W127, Los Angeles, CA 90073 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. RP Handforth, A (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Neurol Serv W127, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM charles.handforth@med.va.gov NR 29 TC 33 Z9 33 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD OCT PY 2004 VL 19 IS 10 BP 1215 EP 1221 DI 10.1002/mds.20147 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 861MY UT WOS:000224422000013 PM 15390011 ER PT J AU Sternini, C Patierno, S Selmer, IS Kirchgessner, A AF Sternini, C Patierno, S Selmer, IS Kirchgessner, A TI The opioid system in the gastrointestinal tract SO NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Article DE ascending excitatory neurones; descending inhibitory neurones; G-protein-coupled receptors; interneurones; receptor endocytosis ID GUINEA-PIG ILEUM; MYENTERIC PLEXUS PREPARATION; ENTERIC NERVOUS-SYSTEM; MU-OPIATE RECEPTOR; POSTOPERATIVE ILEUS; CIRCULAR MUSCLE; SMALL-INTESTINE; ENDOGENOUS OPIOIDS; PORCINE ILEUM; CHOLINERGIC TRANSMISSION AB mu-, delta- and kappa-opioid receptors (ORs) mediate the effects of endogenous opioids and opiate drugs. Here we report (1) the distribution of muOR in the guinea-pig and human gastrointestinal tract in relation to endogenous ligands, to functionally distinct structures in the gut and to deltaOR and kappaOR; and (2) the ligand-induced muOR endocytosis in enteric neurones using in vitro and in vivo models. In the guinea pig, muOR immunoreactivity is confined mainly to the myenteric plexus. muOR myenteric neurones are most numerous in the small intestine, followed by the stomach and the proximal colon. muOR immunoreactive fibres are dense in the muscle layer and the deep muscular plexus, where they are in close association with interstitial cells of Cajal. This distribution closely matches the pattern of enkephalin. muOR enteric neurones comprise functionally distinct populations of neurones of the ascending and descending pathways of the peristaltic reflex. In human gut, muOR immunoreactivity is localized to myenteric and submucosal neurones and to immune cells of the lamina propria. deltaOR immunoreactivity is located in both plexuses where it is predominantly in varicose fibres in the plexuses, muscle and mucosa, whereas kappaOR immunoreactivity appears to be confined to the myenteric plexus and to bundles of fibres in the muscle. muOR undergoes endocytosis in a concentration-dependent manner, in vitro and in vivo. Pronounced muOR endocytosis is observed in neurones from animals that underwent abdominal surgery that has been shown to induce delay in gastrointestinal transit. We can conclude that all three ORs are localized to the enteric nervous system with differences among species, and that muOR endocytosis can be utilized as a means to visualize enteric neurones activated by opioids and sites of opioid release. C1 Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med,Div Digest Dis, CURE Digest Dis Res Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol,Div Digest Dis, CURE Digest Dis Res Ctr, Los Angeles, CA USA. GlaxoSmithKline, Neurol & GI Ctr Excellence Drug Discovery, Harlow, Essex, England. RP Sternini, C (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Bldg 115,Room 224,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM csternin@ucla.edu FU NIDDK NIH HHS [DK 41301, DK 54155] NR 89 TC 97 Z9 101 U1 0 U2 13 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 1350-1925 J9 NEUROGASTROENT MOTIL JI Neurogastroenterol. Motil. PD OCT PY 2004 VL 16 SU 2 BP 3 EP 16 DI 10.1111/j.1743-3150.2004.00553.x PG 14 WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences SC Gastroenterology & Hepatology; Neurosciences & Neurology GA 852MT UT WOS:000223760100002 PM 15357847 ER PT J AU Brambilla, P Stanley, JA Sassi, RB Nicoletti, MA Mallinger, AG Keshavan, MS Soares, JC AF Brambilla, P Stanley, JA Sassi, RB Nicoletti, MA Mallinger, AG Keshavan, MS Soares, JC TI H-1 MRS study of dorsolateral prefrontal cortex in healthy individuals before and after lithium administration SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE proton magnetic resonance spectroscopy; lithium; healthy individuals; glutamate; N-acetyl aspartate; prefrontal cortex ID MAGNETIC-RESONANCE-SPECTROSCOPY; N-ACETYL-ASPARTATE; HUMAN BRAIN; BIPOLAR DISORDER; IN-VIVO; TEMPORAL-LOBE; PROTEIN BCL-2; P-31 MRS; CREATINE; SCHIZOPHRENIA AB The mechanism of action of lithium is still largely unknown. However, recent animal and human studies suggested the possible neuroprotective effects of this medication. In particular, a recent magnetic resonance spectroscopy (MRS) study showed the increase of cortical brain levels of N-acetyl-aspartate (NAA), a putative marker of neuronal integrity/functioning, in both bipolar patients and normal controls after 4 weeks of lithium administration. We investigated the effects of lithium on NAA levels in a sample of healthy individuals using in vivo H-1 MRS in dorsolateral prefrontal cortex (DLPFC), a region likely implicated in the pathophysiology of bipolar disorder. In vivo short echo-time H-1-MRS measurements of 8 cm(3) single voxels placed bilaterally in the DLPFC were conducted at baseline and after 4 weeks of lithium administration on 12 healthy individuals ( mean age +/- SD = 25.0 +/- 9.8 years; six males). After lithium administration, no significant differences in NAA, phosphocreatine plus creatine, glycerophosphocholine plus phosphocholine ( or choline-containing molecules), and myo-inositol absolute levels or ratios were found in DLPFC ( paired t-tests, p>0.05). Contrary to prior MRS reports in bipolar patients, we found that lithium administration did not significantly increase NAA levels in the DLPFC of healthy individuals. Future longitudinal studies will be needed to further investigate whether chronic lithium treatment increases NAA levels in other brain regions in healthy individuals, and whether it promotes changes in these levels in specific brain regions in bipolar patients. C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX 78229 USA. Univ Udine, Sch Med, Dept Pathol & Expt & Clin Med, Sect Psychiat, I-33100 Udine, Italy. Univ Genoa, Adv Biotechnol Ctr, Genoa, Italy. Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA USA. Univ Sao Paulo, Sch Med, Dept Psychiat, BR-05508 Sao Paulo, Brazil. Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Soares, JC (reprint author), Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, MC 7792,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM soares@uthscsa.edu RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 FU NIMH NIH HHS [MH 01736, MH 30915] NR 42 TC 46 Z9 46 U1 2 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD OCT PY 2004 VL 29 IS 10 BP 1918 EP 1924 DI 10.1038/sj.npp.1300520 PG 7 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 855TY UT WOS:000223998700016 PM 15257303 ER PT J AU Skarda, S Eidem, M Schenker, S Lee, S Finch, J AF Skarda, S Eidem, M Schenker, S Lee, S Finch, J TI Hyperamylasemia and acidemia: Is there an association? SO PANCREAS LA English DT Letter ID DIABETIC-KETOACIDOSIS; HYPERLIPASEMIA; AMYLASE C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Skarda, S (reprint author), Univ Texas, Hlth Sci Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 9 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD OCT PY 2004 VL 29 IS 3 BP 243 EP 245 DI 10.1097/00006676-200410000-00012 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 861ZP UT WOS:000224458100012 PM 15367893 ER PT J AU Martinez, V Wang, LX Million, M Rivier, J Tache, Y AF Martinez, V Wang, LX Million, M Rivier, J Tache, Y TI Urocortins and the regulation of gastrointestinal motor function and visceral pain SO PEPTIDES LA English DT Review DE urocortin 1; urocortin 2; urocortin 3; CRF; stresscopin; stresscopin-related peptide; urotensin-I; CRF receptors; CRF receptor antagonists ID CORTICOTROPIN-RELEASING-FACTOR; CENTRAL-NERVOUS-SYSTEM; STRESS-RELATED ALTERATIONS; MESSENGER-RNA EXPRESSION; STIMULATED GASTRIC CONTRACTILITY; FACTOR-RECEPTOR EXPRESSION; EDINGER-WESTPHAL NUCLEUS; IRRITABLE-BOWEL-SYNDROME; ANXIETY-LIKE BEHAVIOR; TYPE-2 CRF RECEPTORS AB Urocortin (Ucn) 1, 2 and 3 are corticotropin-releasing factor (CRF)-related peptides recently characterized in mammals. Urocortin I binds with high affinity to CRF type 1 (CRF1) and type 2 (CRF2) receptors while Ucn 2 and Ucn 3 are selective CRF2 ligands. They also have a distinct pattern of distribution, both in the brain and the gastrointestinal tract, compatible with a role mediating, with CRF, the response to stress. In rats and mice, Ucn 1 injected centrally or peripherally inhibited gastric emptying and stimulated colonic propulsive motor function, mimicking the effects of stress or exogenous CRF. Centrally administered Ucn 2 inhibited gastric emptying with similar potency as CRF, while Ucn 1 and Ucn 3 were less potent. However, after peripheral administration, Ucn I and Ucn 2 were more potent than CRF. In mice, centrally administered Ucn 1 and 2 stimulated colonic motility with lower potency than CRF, and Ucn 3 was inactive. Studies with selective CRF1 and CRF2 antagonists demonstrated that the gastric-inhibitory and colonic-stimulatory effects of exogenously administered Ucns are mediated through CRF2 and CRF1 receptors, respectively. In addition, Ucn 2 showed visceral anti-nociceptive activity associated with the selective activation of CRF2 receptors. These observations suggest that, acting centrally and peripherally, Ucns might play a significant role in the modulation of gastrointestinal motor and pain responses during stress and stress-related pathophysiological conditions. (C) 2004 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Dept Med,CURE,Digest Dis Res Ctr, Ctr Neurovisceral Sci & Womens Hlth,Div Digest Di, Los Angeles, CA 90073 USA. AstraZeneca R&D Molndal, Integrat Pharmacol, Gastrointestinal Biol, SE-43183 Molndal, Sweden. Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA. RP Tache, Y (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Dept Med,CURE,Digest Dis Res Ctr, Ctr Neurovisceral Sci & Womens Hlth,Div Digest Di, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@ucla.edu RI Martinez, Vicente/N-1189-2014 FU NIAMS NIH HHS [P50 AR049550]; NIDDK NIH HHS [DK-57238-01A1S1, R01 DK-26741, P01 DK-57328, DK-41301, R01-DK-30110] NR 113 TC 67 Z9 67 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD OCT PY 2004 VL 25 IS 10 BP 1733 EP 1744 DI 10.1016/j.peptides.2004.05.025 PG 12 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 865TX UT WOS:000224727200018 PM 15476940 ER PT J AU Marceille, JR Goins, JA Soni, R Biery, JC Lee, TA AF Marceille, JR Goins, JA Soni, R Biery, JC Lee, TA TI Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin SO PHARMACOTHERAPY LA English DT Article; Proceedings Paper CT 32nd Annual Meeeting of the American-College-of-Clinical-Pharmacy CY NOV 02-05, 2003 CL Atlanta, GA SP Amer Coll Clin Pharmacy DE rosiglitazone; insulin; chronic heart failure ID FLUID RETENTION; THERAPY AB Study Objective. To determine whether rosiglitazone is associated with the onset or worsening of chronic heart failure (CHF) when administered to patients with type 2 diabetes mellitus who receive insulin. Design. Retrospective cohort analysis. Setting. Veterans Affairs medical center. Subjects. One hundred thirty-nine patients who received insulin for treatment of type 2 diabetes mellitus and had rosiglitazone added to their drug regimens. Intervention. Medical records were reviewed for 6 months before and 6 months after each patient's first rosiglitazone prescription. Records were assessed for the diagnosis of CHF and documented patient complaints of CHF symptoms requiring a medical intervention (unscheduled primary care or emergency room visit, start or dosage adjustment of CHF pharmaco therapy, or hospitalization). Measurements and Main Results. A diagnosis of CHF was documented in Thirty-five (25%) patients in the preindex period (before receiving rosiglitazone) versus 42 (30%) in the postindex period (after receiving rosiglitazone). Fifty (36%) patients received a medical intervention for CHF signs or symptoms in the postindex period compared with only 20 (14%) in the preindex period (p<0.0001). Of the 50 patients requiring a medical intervention in the postindex period, 33 (66%) had not required an intervention in the preindex period. The most common symptom was lower extremity edema; this occurred in 25 (18%) patients in the preindex period and 50 (36%) patients in the postindex period (p<0.0001). Conclusion. More patients were diagnosed with CHF during the 6 months after rosiglitazone was added to their drug regimens than in the previous 6 months, when these patients received insulin but not rosiglitazone. In addition, more medical interventions related to CHF occurred after administration of rosightazone. Data from this study appear to support the Food and Drug Administration's warning of an increased risk of cardiac failure in patients receiving concurrent treatment with rosiglitazone and insulin. C1 US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. RP Marceille, JR (reprint author), Edward Hines Vet Adm Med Ctr, Serv Pharm, M-C 119K,5th Ave & Roosevelt Rd, Hines, IL 60141 USA. NR 12 TC 17 Z9 18 U1 0 U2 0 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD OCT PY 2004 VL 24 IS 10 BP 1317 EP 1322 DI 10.1592/phco.24.14.1317.43155 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 858HG UT WOS:000224182300004 PM 15628829 ER PT J AU Dergalust, S Licht, E Ferrer, C Baumhefner, AR Lee, WT Sayers, JF AF Dergalust, S Licht, E Ferrer, C Baumhefner, AR Lee, WT Sayers, JF TI Is occurrence of an antiepileptic drug related adverse drug reaction related to an active or prior history of neoplasm? SO PHARMACOTHERAPY LA English DT Meeting Abstract CT Annual Meeting of the American-College-of-Clinical-Pharmacy CY OCT 24-27, 2004 CL Dallas, TX SP Amer Coll Clin Pharm C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD OCT PY 2004 VL 24 IS 10 MA 11 BP 1421 EP 1422 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 858HG UT WOS:000224182300024 ER PT J AU Miller, CD Echevarria, K Summers, KK AF Miller, CD Echevarria, K Summers, KK TI Inaccurate susceptibility results with VITEK 1 may impair proper empiric antimicrobial selection for Pseudomonas aeruginosa infection SO PHARMACOTHERAPY LA English DT Meeting Abstract CT Annual Meeting of the American-College-of-Clinical-Pharmacy CY OCT 24-27, 2004 CL Dallas, TX SP Amer Coll Clin Pharm C1 S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD OCT PY 2004 VL 24 IS 10 MA 124 BP 1440 EP 1440 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 858HG UT WOS:000224182300118 ER PT J AU Lambert, MJ Hawkins, EJ AF Lambert, MJ Hawkins, EJ TI Measuring outcome in professional practice: Considerations in selecting and using brief outcome instruments SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article ID PSYCHOTHERAPY; QUESTIONNAIRE; METAANALYSIS; VALIDITY; PROGRESS; TIME AB Despite external pressures (e.g., quality assurance, therapist accountability) to measure outcome in psychotherapy, less than a third of clinicians choose to monitor outcome. A growing body of evidence suggests that monitoring patient progress can enhance patient outcome, particularly for patients who are at risk of not responding to treatment. To facilitate the adoption of routine assessment of patient outcome, recommendations for selecting an appropriate outcome instrument are suggested. In addition, procedures for implementing routine assessment of outcome and the use of outcome results are discussed. C1 Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Lambert, MJ (reprint author), Brigham Young Univ, Dept Psychol, 272 TLRB, Provo, UT 84602 USA. EM michael_lambert@byu.edu NR 33 TC 32 Z9 37 U1 1 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD OCT PY 2004 VL 35 IS 5 BP 492 EP 499 DI 10.1037/0735-7028.35.5.492 PG 8 WC Psychology, Multidisciplinary SC Psychology GA 858SD UT WOS:000224211100008 ER PT J AU Morales, M Mendez-Alvarez, S Martin-Lopez, JV Marrero, C Freytes, C AF Morales, M Mendez-Alvarez, S Martin-Lopez, JV Marrero, C Freytes, C TI Biofilm: the microbial "bunker" for intravascular catheter-related infection SO SUPPORTIVE CARE IN CANCER LA English DT Review DE catheter-related infection; biofilm; polysaccharide intercellular adhesin (PIA); ica-gene cluster ID STAPHYLOCOCCUS-EPIDERMIDIS; CANDIDA-PARAPSILOSIS; INHIBITING PEPTIDE; IN-VIVO; AUREUS; PATHOGENESIS; ADHESION; EXPRESSION; MECHANISM; ALBICANS AB Catheter-related infection in cancer patients remains an important health-care problem with major financial implications. During the last few years a better understanding of the pathogenesis of catheter-related infections and the interaction between microorganisms and catheter surfaces has emerged. Recently the influence of biofilm formation in catheter-related infections has been established. The development of biofilm by the colonizing microbes permits attachment of the organisms to the vascular access device and confers resistance to antibiotics and host defense mechanisms. Strategies to overcome the development of biofilm are being developed to prevent catheter- and other medical device-related infections. C1 Univ Hosp Nuestra Senora de Candelaria, Med Oncol Serv, Santa Cruz de Tenerife 38010, Canary Islands, Spain. Univ La Laguna, Dept Cellular Biol & Microbiol, Santa Cruz de Tenerife, Canary Islands, Spain. Univ Hosp Nuestra Senora de Candelaria, Res Unit, Mol Biol Lab, Santa Cruz de Tenerife 38010, Canary Islands, Spain. Univ Hosp Nuestra Senora de Candelaria, Hematol Serv, Santa Cruz de Tenerife 38010, Canary Islands, Spain. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Morales, M (reprint author), Univ Hosp Nuestra Senora de Candelaria, Med Oncol Serv, Santa Cruz de Tenerife 38010, Canary Islands, Spain. EM mmoralesg@comtf.es NR 48 TC 13 Z9 15 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0941-4355 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD OCT PY 2004 VL 12 IS 10 BP 701 EP 707 DI 10.1007/s00520-004-0630-5 PG 7 WC Oncology; Health Care Sciences & Services; Rehabilitation SC Oncology; Health Care Sciences & Services; Rehabilitation GA 863SV UT WOS:000224583600003 PM 15095074 ER PT J AU Niswender, KD Baskin, DG Schwartz, MW AF Niswender, KD Baskin, DG Schwartz, MW TI Insulin and its evolving partnership with leptin in the hypothalamic control of energy homeostasis SO TRENDS IN ENDOCRINOLOGY AND METABOLISM LA English DT Review ID CENTRAL-NERVOUS-SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; BLOOD-BRAIN-BARRIER; ELEGANS LIFE-SPAN; FOOD-INTAKE; ARCUATE NUCLEUS; BODY-WEIGHT; DIABETIC HYPERPHAGIA; RECEPTOR SUBSTRATE-2; GLUT4 TRANSLOCATION AB Despite an alarming increase in the burden of obesity worldwide, body adiposity seems to be a regulated physiological variable. Regulation of adiposity occurs through a classical endocrine feedback loop, in which the pancreatic beta-cell-derived hormone insulin and the adipocyte-derived hormone leptin signal the status of body energy stores to the hypothalamus. Recent advances in our understanding of the signal transduction mechanisms used by insulin and leptin in the hypothalamus to modulate neuronal firing suggest that intracellular cross-talk occurs at several levels and is a potentially important determinant of regulated body weight. These pathways are thus an attractive target for pharmacological intervention in the treatment of obesity. C1 Vanderbilt Univ, Ctr Med, Nashville, TN 37232 USA. VA Puget Sound Hlth Care Syst, Div Endocrinol Metabol, Seattle, WA 98108 USA. Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. RP Niswender, KD (reprint author), Vanderbilt Univ, Ctr Med, 722 Preston Res Bldg,2220 Pierce Ave, Nashville, TN 37232 USA. EM kevin.niswender@vanderbilt.edu RI Schwartz, Michael/H-9950-2012 FU NIDDK NIH HHS [DK 12829, DK 17047, DK 52989, DK 64857-01]; NINDS NIH HHS [NS 32273] NR 70 TC 164 Z9 168 U1 0 U2 7 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1043-2760 J9 TRENDS ENDOCRIN MET JI Trends Endocrinol. Metab. PD OCT PY 2004 VL 15 IS 8 BP 362 EP 369 DI 10.1016/j.tem.2004.07.009 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 865IN UT WOS:000224696000004 PM 15380807 ER PT J AU Peng, ZC Huang, CS Stell, BM Mody, I Houser, CR AF Peng, ZC Huang, CS Stell, BM Mody, I Houser, CR TI Altered expression of the delta subunit of the GABA(A) receptor in a mouse model of temporal lobe epilepsy SO JOURNAL OF NEUROSCIENCE LA English DT Article DE tonic inhibition; neurosteroids; dentate gyrus; hippocampus; pilocarpine; immunohistochemistry ID CEREBELLAR GRANULE CELLS; RAT HIPPOCAMPUS; DENTATE GYRUS; A RECEPTORS; TONIC INHIBITION; NEURONAL EXCITABILITY; GAMMA-2 SUBUNITS; ALPHA-5 SUBUNIT; MESSENGER-RNA; UP-REGULATION AB delta Subunit-containing GABA(A) receptors are located predominantly at nonsynaptic sites in the dentate gyrus where they may play important roles in controlling neuronal excitability through tonic inhibition and responses to GABA spillover. Immunohistochemical methods were used to determine whether delta subunit expression was altered after pilocarpine-induced status epilepticus in C57BL/6 mice in ways that could increase excitability of the dentate gyrus. In pilocarpine-treated animals, the normal diffuse labeling of the delta subunit in the dentate molecular layer was decreased by 4 d after status epilepticus ( latent period) and remained low throughout the period of chronic seizures. In contrast, diffuse labeling of alpha4 and gamma2 subunits, potentially interrelated GABA(A) receptor subunits, was increased during the chronic period. Interestingly, delta subunit labeling of many interneurons progressively increased after pilocarpine treatment. Consistent with the observed changes in delta subunit labeling, physiological studies revealed increased excitability in the dentate gyrus of slices obtained from the pilocarpine-treated mice and demonstrated that physiological concentrations of the neurosteroid tetrahydrodeoxycorticosterone were less effective in reducing excitability in the pilocarpine-treated animals than in controls. The findings support the idea that alterations in nonsynaptic delta subunit-containing GABA(A) receptors in both principal cells and interneurons could contribute to increased seizure susceptibility in the hippocampal formation in a temporal lobe epilepsy model. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol & Physiol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. Vet Adm Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. RP Houser, CR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, CHS 73-235,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM houser@mednet.ucla.edu FU BLRD VA [I01 BX000404]; NINDS NIH HHS [NS35985] NR 61 TC 189 Z9 191 U1 0 U2 2 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD SEP 29 PY 2004 VL 24 IS 39 BP 8629 EP 8639 DI 10.1523/JNEUROSCI.2877-04.2004 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 858FB UT WOS:000224175000028 PM 15456836 ER PT J AU Siegel, RE AF Siegel, RE TI Prevention of contrast-induced nephropathy with sodium bicarbonate SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 Bronx Vet Adm Med Ctr, Crit Care Ctr, Bronx, NY 10468 USA. RP Siegel, RE (reprint author), Bronx Vet Adm Med Ctr, Crit Care Ctr, Bronx, NY 10468 USA. EM robert.siegel@med.va.gov NR 1 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 22 PY 2004 VL 292 IS 12 BP 1428 EP 1428 DI 10.1001/jama.292.12.1428-b PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 856FT UT WOS:000224031800015 PM 15383508 ER PT J AU O'Brien, JM Welsh, CH AF O'Brien, JM Welsh, CH TI Excess body weight in critically ill patients - In response SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 Ohio State Univ, Columbus, OH 43210 USA. Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP O'Brien, JM (reprint author), Ohio State Univ, Columbus, OH 43210 USA. RI O'Brien, James/A-2624-2009 NR 1 TC 1 Z9 1 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 21 PY 2004 VL 141 IS 6 BP 485 EP 486 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 856TM UT WOS:000224067900021 ER PT J AU Shlipak, MG Massie, BM AF Shlipak, MG Massie, BM TI The clinical challenge of cardiorenal syndrome SO CIRCULATION LA English DT Editorial Material DE heart failure; kidney; natriuretic peptides; vasodilation ID CONGESTIVE-HEART-FAILURE; WORSENING RENAL-FUNCTION; VENTRICULAR SYSTOLIC DYSFUNCTION; RANDOMIZED CONTROLLED-TRIAL; NATRIURETIC PEPTIDE; INTRAVENOUS NESIRITIDE; INSUFFICIENCY; THERAPY; CREATININE; ANTAGONIST C1 Vet Affairs Med Ctr, Cardiol Div 111C, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA. San Francisco VAMC, Gen Internal Med Sect, San Francisco, CA USA. RP Massie, BM (reprint author), Vet Affairs Med Ctr, Cardiol Div 111C, 4150 Clement St, San Francisco, CA 94121 USA. EM barry.massie@med.va.gov FU NHLBI NIH HHS [R01 HL073208-01] NR 26 TC 90 Z9 111 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD SEP 21 PY 2004 VL 110 IS 12 BP 1514 EP 1517 DI 10.1161/01.CIR.0000143547.55093.17 PG 4 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 855MP UT WOS:000223977700001 PM 15381655 ER PT J AU Chen, K Holschneider, DP Wu, WH Rebrin, I Shih, JC AF Chen, K Holschneider, DP Wu, WH Rebrin, I Shih, JC TI A spontaneous point mutation produces monoamine oxidase A/B knock-out mice with greatly elevated monoamines and anxiety-like behavior SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID AGGRESSIVE-BEHAVIOR; DEFICIENT MICE; PLUS-MAZE; B GENES; MOLECULAR-BASIS; NORRIE DISEASE; A-DEFICIENT; MAO-B; RECEPTOR; SEROTONIN AB A spontaneous monoamine oxidase A (MAO A) mutation (A863T) in exon 8 introduced a premature stop codon, which produced MAO A/B double knock-out ( KO) mice in a MAO B KO mouse colony. This mutation caused a nonsense-mediated mRNA decay and resulted in the absence of MAO A transcript, protein, and catalytic activity and abrogates a DraI restriction site. The MAO A/B KO mice showed reduced body weight compared with wild type mice. Brain levels of serotonin, norepinephrine, dopamine, and phenylethylamine increased, and serotonin metabolite 5-hydroxyindoleacetic acid levels decreased, to a much greater degree than in either MAO A or B single KO mice. Observed chase/ escape and anxiety-like behavior in the MAO A/B KO mice, different from MAO A or B single KO mice, suggest that varying monoamine levels result in both a unique biochemical and behavioral phenotype. These mice will be useful models for studying the molecular basis of disorders associated with abnormal monoamine neurotransmitters. C1 Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA. Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA. Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90089 USA. Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90089 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Shih, JC (reprint author), Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, 1985 Zonal Ave,Rm 528, Los Angeles, CA 90089 USA. EM jcshih@usc.edu FU NIMH NIH HHS [R37 MH039085-23, R01 MH NS62148, R37 MH039085, R37 MH38635]; NINDS NIH HHS [K23 NS062148] NR 58 TC 68 Z9 69 U1 2 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD SEP 17 PY 2004 VL 279 IS 38 BP 39645 EP 39652 DI 10.1074/jbc.M405550200 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 852YA UT WOS:000223791500055 PM 15272015 ER PT J AU Solomons, JTG Zimmerly, EM Burns, S Krishnamurthy, N Swan, MK Krings, S Muirhead, H Chirgwin, J Davies, C AF Solomons, JTG Zimmerly, EM Burns, S Krishnamurthy, N Swan, MK Krings, S Muirhead, H Chirgwin, J Davies, C TI The crystal structure of mouse phosphoglucose isomerase at 1.6 angstrom resolution and its complex with glucose 6-phosphate reveals the catalytic mechanism of sugar ring opening SO JOURNAL OF MOLECULAR BIOLOGY LA English DT Article DE phosphoglucoseisomerase; aldose-ketose isomerase; enzyme mechanism; cytokine; X-ray crystallography ID AUTOCRINE MOTILITY FACTOR; CONFORMATIONAL-CHANGES; RABBIT; NEUROLEUKIN; PHOSPHATE; ENZYME; DIFFERENTIATION; 6-PHOSPHATE; HISTIDINE; LOCATION AB Phosphoglucose isomerase (PGI) is an enzyme of glycolysis that interconverts, glucose 6-phosphate (G6P) and fructose 6-phosphate (F6P) but, outside the cell, is a multifunctional cytokine. High-resolution crystal structures of the enzyme from mouse have been determined in native form and in complex with the inhibitor erythrose 4-phosphate, and with the substrate glucose 6-phosphate. In the substrate-bound structure, the glucose sugar is observed in both straight-chain and ring forms. This structure supports a specific role for Lys518 in enzyme-catalyzed ring opening and we present a "push-pull" mechanism in which His388 breaks the O5-C1 bond by donating a proton to the ring oxygen atom and, simultaneously, Lys518 abstracts a proton from the Cl hydroxyl group. The reverse occurs in ring closure. The transition from ring form to straight-chain substrate is achieved through rotation of the C3-C4 bond, which brings the C1-C2 region into close proximity to Glu357, the base catalyst for the isomerization step. The structure with G6P also explains the specificity of PGI for glucose 6-phosphate over mannose 6-isomerase (M6P). To isomerize M6P to F6P requires a rotation of its C2-C3 bond but in PGI this is sterically blocked by Gln511. (C) 2004 Elsevier Ltd. All rights reserved. C1 Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Vet Adm Med Ctr, Res Serv, San Antonio, TX 78230 USA. Univ Bristol, Sch Med Sci, Bristol BS8 1TD, Avon, England. Univ Virginia, Dept Med, Charlottesville, VA 22908 USA. RP Davies, C (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. EM davies@musc.edu FU NIGMS NIH HHS [R25GM067084] NR 36 TC 26 Z9 27 U1 1 U2 9 PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2836 J9 J MOL BIOL JI J. Mol. Biol. PD SEP 17 PY 2004 VL 342 IS 3 BP 847 EP 860 DI 10.1016/j.jmb.2004.07.085 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 853OX UT WOS:000223838000012 PM 15342241 ER PT J AU Joo, YH Sanders, RD Almasy, L Gur, RE Wood, J Dayal, M Keshavan, M Nimgaonkar, VL AF Joo, YH Sanders, RD Almasy, L Gur, RE Wood, J Dayal, M Keshavan, M Nimgaonkar, VL TI Neurological soft signs in large extended multiplex schizophrenia families: Heritability estimation and their relationship with neuropsychological tests SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Meeting Abstract CT 12th World Congress of Psychiatric Genetics CY OCT 09-13, 2004 CL Dublin, IRELAND SP Int Soc Psychiat Genet C1 Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. SW Fdn Biomed Res, San Antonio, TX 78284 USA. Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0148-7299 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD SEP 15 PY 2004 VL 130B IS 1 BP 57 EP 57 PG 1 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 852GE UT WOS:000223742600213 ER PT J AU Medina, RA Escamilla, MA Walss-Bass, C Raventos, H Montero, AP Dassori, A Armas, R Contreras, S AF Medina, RA Escamilla, MA Walss-Bass, C Raventos, H Montero, AP Dassori, A Armas, R Contreras, S TI Increased frequency of AD18S70 allele in a factor-derived cluster of patients with non-affective psychosis SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Meeting Abstract CT 12th World Congress of Psychiatric Genetics CY OCT 09-13, 2004 CL Dublin, IRELAND SP Int Soc Psychiat Genet C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Costa Rica, San Jose, Costa Rica. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0148-7299 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD SEP 15 PY 2004 VL 130B IS 1 BP 139 EP 139 PG 1 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 852GE UT WOS:000223742600533 ER PT J AU Seshadri, P Iqbal, N Stern, L Williams, M Chicano, KL Daily, DA McGrory, J Gracely, EJ Rader, DJ Samaha, FF AF Seshadri, P Iqbal, N Stern, L Williams, M Chicano, KL Daily, DA McGrory, J Gracely, EJ Rader, DJ Samaha, FF TI A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity SO AMERICAN JOURNAL OF MEDICINE LA English DT Article ID MAGNETIC-RESONANCE-SPECTROSCOPY; INSULIN-RESISTANCE ATHEROSCLEROSIS; ISCHEMIC-HEART-DISEASE; WEIGHT-LOSS; CORONARY ATHEROSCLEROSIS; CARDIOVASCULAR-DISEASE; PARTICLE-SIZE; RISK; SUBCLASSES; PLASMA AB PURPOSE: To compare the effects of a low- carbohydrate diet and a conventional (fat- and calorie- restricted) diet on lipoprotein subfractions and inflammation in severely obese subjects. METHODS: We compared changes in lipoprotein subfractions and C-reactive protein levels in 78 severely obese subjects, including 86% with either diabetes or metabolic syndrome, who were randomly assigned to either a low- carbohydrate or conventional diet for 6 months. RESULTS: Subjects on a low-carbohydrate diet experienced a greater decrease in large very low-density lipoprotein (VLDL) levels (difference = -0.26 mg/dL, P = 0.03) but more frequently developed detectable chytomicrons (44% vs. 22%,.P = 0.04). Both diet groups experienced similar decreases in the number of low-density lipoprotein (LDL) particles (difference = -30 nmol/L, P = 0.74) and increases in large high-density lipoprotein (HDL) concentrations (difference = 0.70 mg/dL, P = 0.63). Overall, C-reactive protein levels decreased modestly in both diet groups. However, patients with a high-risk baseline level ( > 3 mg/dL, n 48) experienced a greater decrease in C-reactive protein levels on a low- carbohydrate diet (adjusted difference = -2.0 mg/dL, P = 0.005), independent of weight loss. CONCLUSION: In this 6-month study involving severely obese subjects, we found an overall favorable effect of a lowcarbohydrate diet on lipoprotein subfractions, and on inflammation in high-risk subjects. Both diets had similar effects on LDL and HDL subfractions. 9)2004 by Elsevier Inc. C1 Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Hlth Syst, Dept Internal Med, Div Endocrinol & Cardiol, Philadelphia, PA 19104 USA. Drexel Univ, Dept Family Community & Prevent Med, Coll Med, Philadelphia, PA 19104 USA. RP Samaha, FF (reprint author), Philadelphia VA Med Ctr, 8th Floor,MC 111C,Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM rick.samaha@med.va.gov NR 32 TC 89 Z9 91 U1 0 U2 9 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD SEP 15 PY 2004 VL 117 IS 6 BP 398 EP 405 DI 10.1016/j.amjmed.2004.04.009 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 855VT UT WOS:000224003700004 PM 15380496 ER PT J AU Cummings, DE AF Cummings, DE TI Helicobacter pylori and ghrelin: Interrelated players in body-weight regulation? SO AMERICAN JOURNAL OF MEDICINE LA English DT Editorial Material ID NONULCER DYSPEPSIA; GASTRIC-CARCINOMA; FOOD-INTAKE; INFECTION; APPETITE; GROWTH; ERADICATION; PEPTIDE; HUMANS; RISK C1 Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. RP Cummings, DE (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 1660 S Columbian Way,S-111-Endo, Seattle, WA 98108 USA. EM davidec@u.washington.edu NR 29 TC 21 Z9 21 U1 0 U2 1 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD SEP 15 PY 2004 VL 117 IS 6 BP 436 EP 439 DI 10.1016/j.amjmed.2004.07.034 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 855VT UT WOS:000224003700010 PM 15380502 ER PT J AU Chen, BK Sassi, R Axelson, D Hatch, JP Sanches, M Nicoletti, M Brambilla, P Keshavan, MS Ryan, ND Birmaher, B Soares, JC AF Chen, BK Sassi, R Axelson, D Hatch, JP Sanches, M Nicoletti, M Brambilla, P Keshavan, MS Ryan, ND Birmaher, B Soares, JC TI Cross-sectional study of abnormal amygdala development in adolescents and young adults with bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Article DE adolescence; affective disorders; development; mood disorders; MRI; neuroimaging ID TEMPORAL-LOBE STRUCTURES; DEVELOPING HUMAN BRAIN; MAGNETIC-RESONANCE; HIPPOCAMPAL VOLUME; MAJOR DEPRESSION; MOOD DISORDERS; FACIAL EXPRESSIONS; HEALTHY CONTROLS; MRI; SCHIZOPHRENIA AB Background: In vivo imaging studies in adult bipolarpatients have suggested enlargement of the amygdala. It is not known whether this abnormality is already present early in the illness course or whether it develops later in life. We conducted a morphometric MRI study to examine the size of specific temporal lobe structures in adolescents and young adults with bipolar disorder and healthy control subjects, as well as their relationship with age, to examine possible neurodevelopmental abnormalities. Methods: Subjects included 16 DSM-IV bipolarpatients (16 +/- 3 years) and 21 healthy controls (mean age SD = 17 +/- 4 years). Measures of amygdala, bippocampus, temporal gray matter, temporal lobe, and intracranial volumes (ICV) were obtained. Results: There was a trend to smaller left amygdala volumes inpatients (mean volumes +/- SD = 1.58 +/- .42 mL) versus control subjects (1.83 +/- .4 mL; F = 3.87, df = 1,32, p =.06). Bipolar patients did not show significant differences in right or left bippocampus, temporal lobe gray matter, temporal lobe, or right amygdala volumes (analysis of covariance, age, gender, and JCV as covariates, p >.05) compared with healthy control subjects. Furthermore, there was a direct correlation between left amygdala volumes and age (r =.50, p =.047) in patients, whereas in healthy controls there was an inverse correlation (r = -. 48, p =.03). Conclusions: The direct correlation between left amygdala volumes and age in bipolar patients, not present in healthy control subjects, may reflect abnormal developmental mechanisms in bipolar disorder, C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78229 USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. Univ Sao Paulo, Sch Med, Inst Psychiat, Sao Paulo, Brazil. Univ Fed Sao Paulo, Dept Psychiat, Sao Paulo, Brazil. IRCCS, Brescia, Italy. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Soares, JC (reprint author), Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM soares@uthscsa.edu RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 FU NIMH NIH HHS [MH 01736, MH 30915, MH 55123, MH 59929] NR 46 TC 110 Z9 113 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD SEP 15 PY 2004 VL 56 IS 6 BP 399 EP 405 DI 10.1016/j.biopsych.2004.06.024 PG 7 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 853UU UT WOS:000223855200004 PM 15364037 ER PT J AU Bai, J He, F Novikova, SI Undie, AS Dracheva, S Haroutunian, V Lidow, MS AF Bai, J He, F Novikova, SI Undie, AS Dracheva, S Haroutunian, V Lidow, MS TI Abnormalities in the dopamine system in schizophrenia may lie in altered levels of dopamine receptor-interacting proteins SO BIOLOGICAL PSYCHIATRY LA English DT Article DE calcyon; cerebral cortex; humans; monkeys; neuronal calcium sensor-1; postmortem tissue; protein and mRNA levels ID DORSOLATERAL PREFRONTAL CORTEX; PRIMATE CEREBRAL-CORTEX; CALCIUM SENSOR NCS-1; WORKING-MEMORY; D1 RECEPTORS; CYTOARCHITECTONIC DEFINITION; ANTIPSYCHOTIC-DRUGS; ELDERLY-PATIENTS; NAIVE PATIENTS; UP-REGULATION AB Background: Dopamine receptor-interacting proteins constitute a pan of the dopamine system that is involved in regulation Of dopamine receptor-associated intracellular signaling. Previously, we demonstrated that two such proteins, the D1 receptor-interacting protein calcyon and the D2 receptor-interacting protein neuronal calcium sensor-1 (NCS-1), were elevated in the prefrontal cortex of schizophrenia cases from the Stanley Foundation Neuropathology Consortium. Methods: The aim of this study was to confirm and expand these findings. We employed Western blot and real-time reverse transcriptase polymerase chain reaction analyses to compare prefrontal (area 46) and occipital (area 17) conical levels of calcyon and NCS-1 proteins and mRNAs between schizophrenia (n = 3 7) and control (h = 30) cohorts from the Brain Collection of the Mount Sinai Medical School/Bronx Veterans Administration Medical Center. Results: The schizophrenia cohort showed significant up-regulation of calcyon protein and message levels in both prefrontal and occipital cortical regions, both of which also displayed schizophrenia-associated up-regulation of NCS-1 message. Protein levels of NCS-1 were elevated only in the prefrontal conex. All increases in protein levels were correlated with those of corresponding messages. Furthermore, scbizopbrenia-associated alterations in the levels of calcyon and NCS-1 messages were correlated. Conclusions. Up-regulation of calcyon and NCS-1 in the second schizophrenia cohort strengthens the proposition that abnormalities of the dopamine system in this disease may lie in altered levels of dopamine receptor-interacting proteins. Also, up-regulation of both calcyon and NCS-1 in the cortex of schizophrenia patients can be attributed largely to an enhanced transcription or reduced degradation of their messages, Finally, our findings suggest that elevations in the expressions of calcyon and NCS-1 in schizophrenia may have the same underlying cause. C1 Univ Maryland, Dept Biomed Sci, Baltimore, MD 21201 USA. Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21201 USA. CUNY Mt Sinai Sch Med, Bronx Vet Affairs Med Ctr, Dept Psychiat, New York, NY 10029 USA. RP Lidow, MS (reprint author), Univ Maryland, Dept Biomed Sci, 5-A-12,HHH,666 W Baltimore St, Baltimore, MD 21201 USA. EM mlidow@umaryland.edu OI Undieh, Ashiwel/0000-0003-1823-5230 FU NIMH NIH HHS [P50 MH066392, P50 MH44866, R01-MH064673] NR 63 TC 59 Z9 60 U1 4 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD SEP 15 PY 2004 VL 56 IS 6 BP 427 EP 440 DI 10.1016/j.biopsych.2004.06.022 PG 14 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 853UU UT WOS:000223855200008 PM 15364041 ER PT J AU Krysan, K Dalwadi, H Sharma, S Pold, M Dubinett, S AF Krysan, K Dalwadi, H Sharma, S Pold, M Dubinett, S TI Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer SO CANCER RESEARCH LA English DT Article ID DOWN-REGULATION; POOR-PROGNOSIS; MELANOMA-CELLS; IN-VIVO; PROLIFERATION; INHIBITION; CARCINOMA; INDUCTION; INVASION; MARKER AB Elevated tumor cyclooxygenase 2 (COX-2) expression is associated with increased angiogenesis, tumor invasion, and promotion of tumor cell resistance to apoptosis. In our previous studies using non-small cell lung cancer (NSCLC) cell lines constitutively expressing COX-2 cDNA in sense and antisense orientations, we demonstrated that constitutive overexpression of COX-2 leads to stabilization of the inhibitor of apoptosis protein survivin resulting in the elevated apoptosis resistance of COX-2-overexpressing cells. Genetic or pharmacologic suppression of COX-2 activity increased proteasomal degradation of survivin and cellular response to apoptosis induction. Our data show that expression of survivin in non-small cell lung cancer cells can be significantly down-regulated by RNA interference. Whereas COX-2-overexpressing NSCLC cells have significantly higher apoptosis resistance than the parental cells, inhibition of survivin expression by small interfering RNA decreases apoptosis resistance to the level of the parental non-small cell lung cancer. We conclude that COX-2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. C1 Univ Calif Los Angeles, Lung Canc Res Program, David Geffen Sch Med, Jonsson Comprehens Canc Ctr,Div Pulm & Crit Care, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Dubinett, S (reprint author), Univ Calif Los Angeles, Lung Canc Res Program, David Geffen Sch Med, Jonsson Comprehens Canc Ctr,Div Pulm & Crit Care, 37-131 CHS 10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM sdubinett@mednet.ucla.edu FU NCI NIH HHS [P50 CA90388] NR 20 TC 82 Z9 96 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD SEP 15 PY 2004 VL 64 IS 18 BP 6359 EP 6362 DI 10.1158/0008-5472.CAN-04-1681 PG 4 WC Oncology SC Oncology GA 857BG UT WOS:000224089700001 PM 15374938 ER PT J AU Qin, M Escuadro, B Dohadwala, M Sharma, S Batra, RK AF Qin, M Escuadro, B Dohadwala, M Sharma, S Batra, RK TI A novel role for the coxsackie adenovirus receptor in mediating tumor formation by lung cancer cells SO CANCER RESEARCH LA English DT Article ID HUMAN BLADDER-CANCER; CELLULAR RECEPTOR; GENE-THERAPY; MECHANISM; CAR; ENDOCYTOSIS; EXPRESSION; ADHESION; VIRUSES; BINDING AB The Coxsackie Adenovirus Receptor (CAR) has primarily been studied in its role as the initial cell surface attachment receptor for Coxsackie and group C adenoviruses. Recent reports suggest that CAR mediates homotypic intercellular adhesion as part of the tight and/or adherens junction. Thus, CAR is well positioned to participate in intercellular interactions and signaling. Using an antisense (AS)-CAR plasmid vector, we silenced surface CAR expression in lung cancer cells that possessed a high basal expression of this molecule and monitored the resultant tumorigenesis. AS-CAR transfectants exhibit a profound loss in the ability to generate xenografts in scid/scid mice. The emergence of delayed-onset tumors in animals that received injection with AS-CAR transfectants correlates with the resurfacing of CAR expression, suggesting that such expression and tumor emergence are temporally related. To study the mechanism underlying the differences in tumorigenicity, control and AS-CAR cells were compared in terms of their in vitro growth potential. Whereas only subtle differences in the proliferative capacity of the two populations were evident when assayed with growth on plastic, significant differences became apparent when one compared the relative ability of these populations to form colonies in soft agar. These data indicate that silencing surface CAR expression abrogates xenograft tumorigenesis ill vivo and colony formation in vitro and invoke the novel possibility that CAR expression is needed for the efficient formation of tumors by a subset of lung cancer cells. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA. Vet Adm Greater Los Angeles Hlth Care Syst, Div Pulm & Crit Care Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Lung Canc Res Program, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90073 USA. RP Batra, RK (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, 111Q,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM rbatra@ucla.edu FU NCI NIH HHS [R01 CA078654-03, R01-CA78654]; PHS HHS [P50-90388] NR 21 TC 20 Z9 27 U1 1 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD SEP 15 PY 2004 VL 64 IS 18 BP 6377 EP 6380 DI 10.1158/0008-5472.CAN-04-1490 PG 4 WC Oncology SC Oncology GA 857BG UT WOS:000224089700005 PM 15374942 ER PT J AU Pold, M Krysan, K Pold, A Dohadwala, M Heuze-Vourc'h, N Mao, JT Riedl, KL Sharma, S Dubinett, SM AF Pold, M Krysan, K Pold, A Dohadwala, M Heuze-Vourc'h, N Mao, JT Riedl, KL Sharma, S Dubinett, SM TI Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer SO CANCER RESEARCH LA English DT Article ID IGF-BINDING PROTEIN-3; I RECEPTOR PATHWAY; BREAST-CANCER; PROSTAGLANDIN BIOSYNTHESIS; CARCINOMA CELLS; FACTOR (IGF)-I; PLASMA-LEVELS; UP-REGULATION; EXPRESSION; APOPTOSIS AB Constitutive overexpression of cyclooxygenase-2 (COX-2) occurs frequently in several different malignancies, including lung, colon, breast, and prostate cancer. Clinical studies have established elevated serum insulin-like growth factor (IGF-I) content and IGF-I:IGF-binding protein 3 (IGFBP-3) ratio as risk factors for these same malignancies. Therefore, we sought to determine the link between COX-2 expression and the IGF axis in COX-2 gene-modified human non-small-cell lung cancer (NSCLC) cells. Overexpression of COX-2 in NSCLC cells enhanced the antiapoptotic and mitogenic effects of IGF-I and IGF-II, facilitated the autophosphorylation of the type 1 IGF receptor, increased class IA phosphatidylinositol 3'-kinase activity, and decreased expression of IGFBP-3. Thus, these findings show that COX-2 augments the stimulatory arm of the IGF axis. C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Lung Canc Res Program, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. RP Dubinett, SM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, 37-131 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM sdubinett@mednet.ucla.edu RI HEUZE-VOURC'H, Nathalie/P-8081-2016 FU NCI NIH HHS [P50 CA90388] NR 50 TC 26 Z9 28 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD SEP 15 PY 2004 VL 64 IS 18 BP 6549 EP 6555 DI 10.1158/0008-5472.CAN-04-1225 PG 7 WC Oncology SC Oncology GA 857BG UT WOS:000224089700030 PM 15374967 ER PT J AU Darouiche, RO AF Darouiche, RO TI Echinocandins: Ask not what they can do for esophageal candidiasis - Ask what studies of esophageal candidiasis can do for them SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID AMPHOTERICIN-B; DOUBLE-BLIND; INVASIVE CANDIDIASIS; MULTICENTER TRIAL; FLUCONAZOLE; CASPOFUNGIN; CANDIDEMIA; EFFICACY; OROPHARYNGEAL; ANIDULAFUNGIN C1 Baylor Coll Med, Ctr Protheses Infect, Houston, TX 77030 USA. Michael E Debakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX USA. Michael E Debakey Vet Affairs Med Ctr, Ctr Protheses Infect, Houston, TX USA. RP Darouiche, RO (reprint author), Baylor Coll Med, Ctr Protheses Infect, 1333 Moursund Ave,Ste A221, Houston, TX 77030 USA. EM rdarouiche@aol.com NR 17 TC 4 Z9 4 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 15 PY 2004 VL 39 IS 6 BP 850 EP 852 DI 10.1086/423391 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 904JD UT WOS:000227491500016 PM 15472818 ER PT J AU Fagerlie, SR Koretsky, T Torok-Storb, B Bagby, GC AF Fagerlie, SR Koretsky, T Torok-Storb, B Bagby, GC TI Impaired type IIFN-induced Jak/STAT signaling in FA-C cells and abnormal CD4(+) Th cell subsets in Fancc(-/-) mice SO JOURNAL OF IMMUNOLOGY LA English DT Article ID FANCONI-ANEMIA PROTEIN; HUMAN-PAPILLOMAVIRUS HPV; INTERFERON-GAMMA; TH1/TH2 BALANCE; IFN-GAMMA; HEMATOPOIETIC-CELLS; PERIPHERAL-BLOOD; FAMILY-MEMBERS; I INTERFERONS; CANCER AB The Fanconi anemia (FA) group C protein, FANCC, interacts with STAT1 following stimulation with IFN-gamma and is required for proper docking of STAT1 at the IFN-gamma receptor a-chain (IFN-gammaRa, IFN-gammaR1). Consequently, loss of a functional FANCC results in decreased activation of STATI following IFN-gamma stimulation. Because type I IFN receptors influence the function of type II receptors, and vice versa, we conducted experiments designed to determine whether type I IFN-induced activation of other STAT proteins is compromised in FA-C cells and found that activation of STAT 1, 3, and 5 is diminished in type I IFN-stimulated cells bearing Fance -inactivating mutations. We also determined that the reduced activation of STATs was accompanied by significant reduction of type I IFN-induced tyrosine kinase 2 and Jak1 phosphorylation. Because tyrosine kinase 2 plays a role in differentiation of Th cells, we quantified cytokine secretion from CD4(+) cells and in vitro generated CD4(+) Th cell subsets from splenocytes of Fancc null mice to that of heterozygous mice and discovered reduced CD4(+) IFN-gamma secretion in the Fancc(-/-) mouse, indicating impaired Th1 differentiation. We suggest that Fancc mutations result in a subtle immunological defect owing to the failure of FANCC to normally support Jak/STAT signaling. C1 Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. Oregon Hlth Sci Univ, Inst Canc, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. RP Fagerlie, SR (reprint author), Fred Hutchinson Canc Res Ctr, D1-100,1100 Fairview Ave N, Seattle, WA 98109 USA. EM sfagerli@fhcrc.org FU NHLBI NIH HHS [HL72321, HL62923, HL48546] NR 74 TC 15 Z9 15 U1 1 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD SEP 15 PY 2004 VL 173 IS 6 BP 3863 EP 3870 PG 8 WC Immunology SC Immunology GA 854CN UT WOS:000223878000035 PM 15356134 ER PT J AU Reilly, CM Mishra, N Miller, JM Joshi, D Ruiz, P Richon, VM Marks, PA Gilkeson, GS AF Reilly, CM Mishra, N Miller, JM Joshi, D Ruiz, P Richon, VM Marks, PA Gilkeson, GS TI Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid SO JOURNAL OF IMMUNOLOGY LA English DT Article ID HISTONE DEACETYLASE INHIBITORS; NITRIC-OXIDE SYNTHASE; CLASS-II EXPRESSION; MRL-LPR MICE; MHC CLASS-I; IFN-GAMMA; INTERFERON-GAMMA; LUPUS NEPHRITIS; GENE-EXPRESSION; MURINE LUPUS AB Epigenetic regulation of gene expression is involved in the development of many diseases. Histone acetylation is a posttranslational modification of the nucleosomal histone tails that is regulated by the balance of histone deacetylases and histone acetyltransferases. Alterations in the balance of histone acetylation have been shown to cause aberrant expression of genes that are a hallmark of many diseases, including systemic lupus erythematosus. In this study, we determined whether suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor: 1) inhibits inflammatory mediator production in vitro and 2) modulates lupus progression in vivo. Mesangial cells isolated from 10-wk-old MRL/lpr mice were stimulated with LPS/IFN-gamma and incubated with SAHA. TNF-alpha, IL-6, NO, and inducible NO synthase expression were inhibited by SAHA. We then treated MRL/lpr mice with daily injections of SAHA from age 10 to 20 wk. The animals treated with SAHA had decreased spleen size and a concomitant decrease in CD4(-)CD8(-) (double-negative) T cells compared with controls. Serum autoantibody levels and glomerular IgG and C3 deposition in SAHA-treated mice were similar to controls. In contrast, proteinuria and pathologic renal disease were significantly inhibited in the mice receiving SAHA. These data indicate that SAHA blocks mesangial cell inflammatory mediator production in vitro and disease progression in vivo in MRL/lpr mice. C1 Virginia Polytech Inst & State Univ, Virginia Maryland Reg Coll Vet Med, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24060 USA. Edward Via Coll Osteopath Med, Blacksburg, VA 24060 USA. Ralph H Johnson Vet Adm Med Ctr, Med Res Serv, Charleston, SC 29405 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Univ Miami, Med Ctr, Dept Immunopathol, Coral Gables, FL 33124 USA. Aton Pharmaceut, Tarrytown, NY 10580 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Wake Forest Univ, Sch Med, Dept Internal Med, Rheumatol Sect, Winston Salem, NC 27109 USA. Wake Forest Univ, Sch Med, Dept Internal Med, Clin Immunol Sect, Winston Salem, NC 27109 USA. RP Reilly, CM (reprint author), Virginia Polytech Inst & State Univ, Virginia Maryland Reg Coll Vet Med, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24060 USA. EM chreilly@vconi.vt.edu; nmishra@wfubine.edu FU NIAMS NIH HHS [R01 AR 47451] NR 51 TC 101 Z9 104 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD SEP 15 PY 2004 VL 173 IS 6 BP 4171 EP 4178 PG 8 WC Immunology SC Immunology GA 854CN UT WOS:000223878000069 PM 15356168 ER PT J AU Villarreal, G Hamilton, DA Graham, DP Driscoll, I Qualls, C Petropoulos, H Brooks, WM AF Villarreal, G Hamilton, DA Graham, DP Driscoll, I Qualls, C Petropoulos, H Brooks, WM TI Reduced area of the corpus callosurn in posttraumatic stress disorder SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE magnetic resonance imaging; white matter; automated tissue segmentation; genu; stress ID INTERHEMISPHERIC-TRANSFER DEFICIT; CHILDHOOD SEXUAL-ABUSE; HIPPOCAMPAL VOLUME; MAGNETIC-RESONANCE; HYPERACTIVITY DISORDER; BRAIN-DEVELOPMENT; MATTER VOLUME; ALEXITHYMIA; MORPHOLOGY; MRI AB Magnetic resonance imaging (MR-1) studies have revealed decreases in the mid-sagittal area of the corpus callosum (CC) in pediatric posttraumatic stress disorder (PTSD), but at present no data are available in adult PTSD patients. We have previously reported decreased whole-brain white matter (WM) volume in adults with PTSD and now report corpus callosum area from the same sample. MRI was used to obtain whole-brain images in 12 adult patients with PTSD and 10 matched controls. Total parenchyma (white matter plus gray matter [GM]) volume, mid-sagittal area of the CC and seven sub-regions of this structure were calculated. In PTSD patients, the total CC area, absolute and normalized to total brain parenchyma, was smaller compared with control values. Several absolute and normalized CC sub-regions were also smaller in PTSD patients: genu (region 2), mid-body (region 5) and isthmus (region 6). There was also a trend for the anterior mid-body (area 4) to be smaller in PTSD patients. No differences were found in the rostrum (region 1), rostral body (region 3) or splenium (region 7). Adult patients with PTSD had decreased CC area after correcting for total brain tissue, indicating that these differences are not attributable to generalized white matter atrophy. These findings are similar to previous results in children with PTSD and suggest specific changes in the CC. (C) 2004 Elsevier Ireland Ltd. All rights reserved. C1 New Mexico VA Healthcare Syst, PTSD Program 116A, Albuquerque, NM 87108 USA. Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB T1K 3M4, Canada. Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Univ New Mexico, Biomed Res Inst New Mexico, VAMC, Albuquerque, NM 87108 USA. Univ Washington, Neuroimaging Res Grp, Seattle, WA 98115 USA. Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Kansas City, KS 66160 USA. RP Villarreal, G (reprint author), New Mexico VA Healthcare Syst, PTSD Program 116A, 1501 San Pedro Dr SE, Albuquerque, NM 87108 USA. EM Gerardo.Villarreal@med.va.gov RI Hamilton, Derek/H-4447-2013; Graham, David /J-1158-2014 OI Hamilton, Derek/0000-0001-7021-3288; brooks, william/0000-0001-6227-7636 FU NCRR NIH HHS [RR15636]; NICHD NIH HHS [HD41237]; NINDS NIH HHS [NS35708, NS39123] NR 49 TC 48 Z9 55 U1 3 U2 5 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD SEP 15 PY 2004 VL 131 IS 3 BP 227 EP 235 DI 10.1016/j.pscychresns.2004.05.002 PG 9 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 864BV UT WOS:000224608800005 PM 15465292 ER PT J AU Bibbins-Domingo, K Lin, F Vittinghoff, E Barrett-Connor, E Hulley, SB Grady, D Shlipak, MG AF Bibbins-Domingo, K Lin, F Vittinghoff, E Barrett-Connor, E Hulley, SB Grady, D Shlipak, MG TI Predictors of heart failure among women with coronary disease SO CIRCULATION LA English DT Article DE coronary disease; diabetes millitus; heart failure; prevention; women ID LEFT-VENTRICULAR DYSFUNCTION; DIABETES-MELLITUS; MYOCARDIAL-INFARCTION; ESTROGEN/PROGESTIN REPLACEMENT; MICROVASCULAR COMPLICATIONS; BLOOD-PRESSURE; OUTCOMES; SURVIVAL; RISK; CARDIOMYOPATHY AB Background-Although heart failure is common among women with coronary disease, the risk factors for developing heart failure have not been well studied. We determined the risk factors for developing heart failure among postmenopausal women with established coronary disease. Methods and Results-This is a prospective cohort study using data from the Heart and Estrogen/progestin Replacement Study (HERS), a randomized, blinded, placebo-controlled trial of 4.1 years' duration, and subsequent open-label observational follow-up for 2.7 years (HERS II), performed at 20 US clinical centers between 1993 and 2000. Of the 2763 postmenopausal women with established coronary disease in the HERS trial, we studied the 2391 women with no heart failure at baseline by self-report and physical examination. The primary outcome of this analysis was incident heart failure defined by hospital admission or death from heart failure. During the 6.3+/-1.4-year follow-up, 237 women (10%) developed heart failure. Nine predictors were identified: diabetes (defined as a self-reported history of diabetes on treatment), atrial fibrillation, myocardial infarction, creatinine clearance <40 mL/min, systolic blood pressure >120 mm Hg, current smoking, body mass index >35 kg/m(2), left bundle-branch block, and left ventricular hypertrophy. Randomization to estrogen/progestin was not associated with heart failure (hazard ratio=1.0; 95% CI, 0.7 to 1.3). Diabetes was the strongest risk factor (adjusted hazard ratio=3.1; 95% CI, 2.3 to 4.2). Diabetic women with elevated body mass index or depressed creatinine clearance were at highest risk, with annual incidence rates of 7% and 13%, respectively. Among diabetic women, hyperglycemia was associated with heart failure risk (adjusted hazard ratio=3.0; 95% CI, 1.2 to 7.5 for fasting glucose>300 mg/dL compared with fasting glucose 80 to 150 mg/dL). Conclusions-We identified 9 predictors of heart failure in postmenopausal women with coronary disease. Diabetes was the strongest risk factor, particularly when poorly controlled or with concomitant renal insufficiency or obesity. C1 Univ Calif San Francisco, San Francisco Gen Hosp, Div Gen Internal Med, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Univ San Francisco, San Francisco VA Med Ctr, Sect Gen Med, San Francisco, CA 94117 USA. Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA. RP Bibbins-Domingo, K (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Div Gen Internal Med, Dept Epidemiol & Biostat, Box 1364, San Francisco, CA 94143 USA. EM bibbinsk@medicine.ucsf.edu NR 42 TC 87 Z9 93 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD SEP 14 PY 2004 VL 110 IS 11 BP 1424 EP 1430 DI 10.1161/01.CIR.0000141726.01302.83 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 853MC UT WOS:000223830700015 PM 15353499 ER PT J AU Ikonomidis, JS Gibson, WC Butler, JE McClister, DM Sweterlitsch, SE Thompson, RP Mukherjee, R Spinale, FG AF Ikonomidis, JS Gibson, WC Butler, JE McClister, DM Sweterlitsch, SE Thompson, RP Mukherjee, R Spinale, FG TI Effects of deletion of the tissue inhibitor of matrix metalloproteinases-1 gene on the progression of murine thoracic aortic aneurysms SO CIRCULATION LA English DT Article DE mouse; aneurysm; aorta; thorax; TIMP-1 ID NATURAL-HISTORY; PERIARTERIAL APPLICATION; THORACOABDOMINAL AORTA; CARDIOPULMONARY BYPASS; CIRCULATORY ARREST; SURGICAL-TREATMENT; CALCIUM-CHLORIDE; MATRIX-METALLOPROTEINASE-9; MODEL; INFLAMMATION AB Objective-The cause of thoracic aortic aneurysms (TAAs) is poorly understood. Previous work has suggested an association between development of aortic aneurysms and matrix metalloproteinase (MMP) activity. We hypothesized that removal of the primary endogenous aortic MMP inhibitor (TIMP) through TIMP-1 gene deletion will increase TAA progression. Methods and Results-The descending thoracic aortas of wild-type 129 SvE and TIMP-1 gene knockout (TIMP-1(-/-)) mice were exposed to 0.5 mol/L CaCl2 for 15 minutes, with terminal studies performed at 4 or 8 weeks. TAA lumen diameter was measured using confocal microscopy and normalized to the ascending aorta. In addition, sections were studied with in situ zymography and immunohistochemistry staining for MMP-9. Both wild-type [TAA/ascending ratio (mean+/-SEM): control, 0.85+/-0.02 (n=14); 4 weeks, 1.00+/-0.03 (n=13); 8 weeks, 1.05+/-0.10 (n=9)] and TfMP-1(-/-) [control, 0.98+/-0.04 (n= 11); 4 weeks, 1.10+/-0.03 (n =21); 8 weeks, 1.22+/-0.09 (n=10)] groups developed aneurysms at 4 and 8 weeks compared with their respective controls (P<0.05). TIMP-1(-/-) animals developed larger aneurysms than the corresponding wild-type group (P<0.05). Aneurysms in the TIMP-1(-/-) group were larger at 8 weeks than at 4 weeks (P<0.05), which was not seen in the wild-type aneurysm groups. Both groups showed presence of MMP-9 in 4 and 8 weeks, most prominently in the adventitia and outer media. In situ zymographic activity was increased in the 8-week TIMP-1(-/-) group compared with wild-type. Conclusions-Deletion of the TIMP-1 gene results in increased and continued progression of aneurysm formation compared with wild-type mice in a unique TAA model caused at least in part by an alteration in the balance between gelatinase activity and its endogenous inhibition. Therapeutic strategies aimed at modifying MMP activity may reduce or prevent the progression of TAAs. C1 Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Anat & Cell Biol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Ikonomidis, JS (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Suite 409 CSB,96 Jonathan Lucas St, Charleston, SC 29425 USA. EM ikonomij@musc.edu FU NCRR NIH HHS [P20 RR 16434]; NHLBI NIH HHS [R01 HL 059165-07] NR 43 TC 2 Z9 3 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD SEP 14 PY 2004 VL 110 IS 11 SU S BP II268 EP II273 DI 10.1161/01.CIR.0000138384.68947.20 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 856DI UT WOS:000224023600046 PM 15364874 ER PT J AU Spiegel, BMR Gralnek, IM Bolus, R Lin, C Dulai, GS Mayer, EA Naliboff, B AF Spiegel, BMR Gralnek, IM Bolus, R Lin, C Dulai, GS Mayer, EA Naliboff, B TI Clinical determinants of health-related quality of life in patients with irritable bowel syndrome SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID GASTROINTESTINAL DISORDERS; MODEL; DEPRESSION; SYMPTOMS; ANXIETY; SYSTEM; STRESS; COSTS; PAIN; FEAR AB Background: Current guidelines recommend routine assessment of health-related quality of life (HRQOL) in patients with irritable bowel syndrome (IBS). However, physicians rarely have the time to measure HRQOL with the appropriate methodological rigor, and data suggest that HRQOL in patients with IBS is often estimated using inaccurate clinical gestalt. The identification of predictive factors could allow physicians to better assess HRQOL without using misleading clinical clues. We, therefore, sought to identify determinants of HRQOL in patients with IBS. Methods: We examined 770 patients, 18 years or older, with IBS at a university-based referral center. Subjects completed a symptom questionnaire, the Symptoms Checklist-90 items psychometric checklist, and the 36-Item Short-Form Health Survey. The main outcome was HRQOL as measured by the mental and physical component scores of the 36-Item Short-Form Health Survey. We first developed a list of hypothesis-driven HRQOL predictors, and then performed multivariate regression analysis to measure the independent association of each predictor with HRQOL. Results: Seven factors (r(2)=0.39) independently predicted physical HRQOL: (1) more than 5 physician visits per year, (2) tiring easily, (3) low in energy, (4) severe symptoms, (5) predominantly painful symptoms, (6) the feeling that there is "something seriously wrong with body," and (7) symptom flares for longer than 24 hours. Eight factors (r(2)=0.36) independently predicted mental HRQOL: (1) feeling tense, (2) feeling nervous, (3) feeling hopeless, (4) difficulty sleeping, (5) tiring easily, (6) low sexual interest, (7) IBS symptom interference with sexual function, and (8) low energy. Conclusions: Health-related quality of life in patients with IBS is primarily related to extraintestinal symptoms rather than traditionally elicited gastrointestinal symptoms. These findings suggest that rather than focusing on physiological epiphenomena (stool characteristics and subtype of IBS) and potentially misleading clinical factors (age and disease duration), physicians might be better served to gauge global symptom severity, address anxiety, and eliminate factors contributing to chronic stress in patients with IBS. C1 Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Ctr Digest Healthcare Qual & Outcomes,VA Greater, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Gastroenterol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA 90073 USA. RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Ctr Digest Healthcare Qual & Outcomes,VA Greater, 11301 Wilshire Blvd,Bldg 115,Room 215B, Los Angeles, CA 90073 USA. EM bspiegel@ucla.edu FU NCRR NIH HHS [K23RR-16188]; NIDDK NIH HHS [DK-07180, P50 DK-64539, R01 DK-07768, R01 DK-48351] NR 37 TC 94 Z9 94 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD SEP 13 PY 2004 VL 164 IS 16 BP 1773 EP 1780 DI 10.1001/archinte.164.16.1773 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 853MO UT WOS:000223831900009 PM 15364671 ER PT J AU Vagin, O Turdikulova, S Sachs, G AF Vagin, O Turdikulova, S Sachs, G TI The H,K-ATPase beta subunit as a model to study the role of N-glycosylation in membrane trafficking and apical sorting SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID POLYCYSTIC KIDNEY-DISEASE; TRANS-GOLGI NETWORK; DARBY CANINE KIDNEY; EPITHELIAL-CELLS; PLASMA-MEMBRANE; GASTRIC H+,K+-ATPASE; ENDOPLASMIC-RETICULUM; TRANSPORTING ATPASE; EXPRESSION; SIGNALS AB The role of N-glycosylation in trafficking of an apical membrane protein, the gastric H, K-ATPase beta subunit linked to yellow fluorescent protein, was analyzed in polarized LLC-PK1 cells by confocal microscopy and surface-specific biotinylation. Deletion of the N-glycosylation sites at N1, N3, N5, and N7 but not at N2, N4, and N6 significantly slowed endoplasmic reticulum-to-Golgi trafficking, impaired apical sorting, and enhanced endocytosis from the apical membrane, resulting in decreased apical expression. Golgi mannosidase inhibition to prevent carbohydrate chain branching and elongation resulted in faster internalization and degradation of the beta subunit, indicating that terminal glycosylation is important for stabilization of the protein in the apical membrane and protection of internalized protein from targeting to the degradation pathway. The decrease in the apical content of the beta subunit was less with mannosidase inhibition compared with that found in the N1, N3, N5, and N7 site mutants, suggesting that the core region sugars are more important than the terminal sugars for apical sorting. C1 Vet Affairs Greater Los Angeles Hlth Care Syst W, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. RP Vagin, O (reprint author), Vet Affairs Greater Los Angeles Hlth Care Syst W, Bldg 113,Rm 324,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM olgav@uvla.edu FU NIDDK NIH HHS [DK53462, DK41301, DK46917, DK17294] NR 32 TC 47 Z9 48 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD SEP 10 PY 2004 VL 279 IS 37 BP 39026 EP 39034 DI 10.1074/jbc.M405453200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 851KN UT WOS:000223684100117 PM 15247221 ER PT J AU Kampman, KM Pettinati, H Lynch, KG Dackis, C Sparkman, T Weigley, C O'Brien, CP AF Kampman, KM Pettinati, H Lynch, KG Dackis, C Sparkman, T Weigley, C O'Brien, CP TI A pilot trial of topiramate for the treatment of cocaine dependence SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE cocaine; topiramate; clinical trial; GABA; glutamate ID NUCLEUS-ACCUMBENS; INDUCED REINSTATEMENT; WITHDRAWAL SYMPTOMS; TREATMENT ATTRITION; PREFRONTAL CORTEX; SEEKING BEHAVIOR; DOPAMINE NEURONS; GABA; INCREASES; SEVERITY AB Background: Both GABAergic and glutamatergic neurons appear to be important modulators of the brain reward system and medications that affect GABA and glutamatergic neurotransmission may reduce the rewarding properties of cocaine and reduce cocaine craving. Topiramate, an anticonvulsant, raises cerebral GABA levels, facilitates GABAergic neurotransmission and inhibits glutametergic activity at AMPA/kainite receptors. Thus, it may be useful for treating cocaine dependence. Methods: The efficacy of topiramate for cocaine dependence was tested in a 13-week, double-blind, placebo-controlled pilot trial (n = 40). Topiramate was titrated gradually over 8 weeks to a dose of 200 mg daily. The primary outcome measure was cocaine abstinence verified by twice weekly urine benzoylecgonine tests (UBT). Results: Eighty-two percent of subjects completed the trial. Analysis of the UBT using a GEE model showed that after week 8, when the dose titration was completed, topiramate-treated subjects were more likely to be abstinent from cocaine compared to placebo-treated subjects (Z = 2.67, P = 0.01). Topiramate-treated subjects were also more likely to attain 3 weeks of continuous abstinence from cocaine (chi(2) = 3.9, d.f. = 1, P = 0.05). Conclusion: Topiramate may be effective for the treatment of cocaine dependence. (C) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. RP Kampman, KM (reprint author), Univ Penn, Sch Med, Dept Psychiat, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM kampman_k@mail.trc.upenn.edu FU NIDA NIH HHS [DA12756] NR 46 TC 174 Z9 180 U1 1 U2 5 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD SEP 6 PY 2004 VL 75 IS 3 BP 233 EP 240 DI 10.1016/j.drugalcdep.2004.03.008 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 846JY UT WOS:000223313000002 PM 15283944 ER PT J AU Johnson, SW Wu, YN AF Johnson, SW Wu, YN TI Multiple mechanisms underlie burst firing in rat midbrain doparnine neurons in vitro SO BRAIN RESEARCH LA English DT Article DE apamin; nifedipine; N-methyl-D-aspartate; substantia nigra; ventral tegmental area ID DOPAMINE-CONTAINING NEURONS; APAMIN; INVITRO; CONDUCTANCE; CHANNELS; NUCLEUS AB Both apamin and NMDA evoke burst firing in dopamine neurons recorded intracellularly in slices of rat midbrain. However, apamin-induced bursting required injection of depolarizing currents, and was mimicked by Bay K8644 and blocked by nifedipine. In contrast, NMDA-induced bursting required hyperpolarizing currents and was not blocked by nifedipine. Our results show that burst firing can be evoked in dopamine neurons via two different mechanisms. (C) 2004 Elsevier B.V. All rights reserved. C1 Portland VA Med Ctr, Portland, OR 97207 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97239 USA. RP Johnson, SW (reprint author), Portland VA Med Ctr, RD-61,3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. EM johnsost@ohsu.edu FU NIMH NIH HHS [MH40416] NR 17 TC 47 Z9 47 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD SEP 3 PY 2004 VL 1019 IS 1-2 BP 293 EP 296 DI 10.1016/j.brainres.2004.06.022 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 851UI UT WOS:000223710800036 PM 15306267 ER PT J AU Calon, F Lim, GP Yang, FS Morihara, T Teter, B Ubeda, O Rostaing, P Triller, A Salem, N Ashe, KH Frautschy, SA Cole, GM AF Calon, F Lim, GP Yang, FS Morihara, T Teter, B Ubeda, O Rostaing, P Triller, A Salem, N Ashe, KH Frautschy, SA Cole, GM TI Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model SO NEURON LA English DT Article ID AMYLOID-PRECURSOR-PROTEIN; POLYUNSATURATED FATTY-ACIDS; NICOTINIC ACETYLCHOLINE-RECEPTOR; LONG-TERM POTENTIATION; TRANSGENIC MICE; A-BETA; COGNITIVE IMPAIRMENT; LIPID-PEROXIDATION; PHOSPHATIDYLINOSITOL 3-KINASE; POSTSYNAPTIC DENSITY-95 AB Learning and memory depend on dendritic spine actin assembly and docosahexaenoic acid (DHA), an essential n-3 (omega-3) polyunsaturated fatty acid (PFA). High DHA consumption is associated with reduced Alzheimer's disease (AD) risk, yet mechanisms and therapeutic potential remain elusive. Here, we report that reduction of dietary n-3 PFA in an AD mouse model resulted in 80%-90% losses of the p85alpha subunit of phosphatidylinositol 3-kinase and the postsynaptic actin-regulating protein drebrin, as in AD brain. The loss of postsynaptic proteins was associated with increased oxidation, without concomitant neuron or presynaptic protein loss. N-3 PFA depletion increased caspase-cleaved actin, which was localized in dendrites ultrastructurally. Treatment of n-3 PFA-restricted mice with DHA protected against these effects and behavioral deficits and increased antiapoptotic BAD phosphorylation. Since n-3 PFAs are essential for p85-mediated CNS insulin signaling and selective protection of postsynaptic proteins, these findings have implications for neurodegenerative diseases where synaptic loss is critical, especially AD. C1 Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Geriatr Res Educ & Clin Ctr, Sepulveda, CA 91343 USA. INSERM, Lab Biol Cellulaire Synapse Normale & Pathol, U497, Ecole Normale Super, F-75005 Paris, France. NIAAA, Sect Nutr Neurosci, Lab Membrane Biochem & Biophys, Div Intramural Clin & Biol Res, Rockville, MD 20852 USA. Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA. Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA. RP Cole, GM (reprint author), Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. EM gmcole@ucla.edu FU NIA NIH HHS [AG10685, AG16793, P01 AG16570, P50 AG 16570, P50 AG005142, P50 AG016570, P50 AG05142, R01 AG010685, R01 AG013741, R01 AG016793, R01 AG13741]; NINDS NIH HHS [R01 NS043946, NS43946] NR 81 TC 435 Z9 460 U1 7 U2 49 PU CELL PRESS PI CAMBRIDGE PA 1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA SN 0896-6273 J9 NEURON JI Neuron PD SEP 2 PY 2004 VL 43 IS 5 BP 633 EP 645 DI 10.1016/j.neuron.2004.08.013 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 851NN UT WOS:000223691900010 PM 15339646 ER PT J AU Kampov-Polevoy, AB Eick, C Boland, G Khalitov, E Crews, FT AF Kampov-Polevoy, AB Eick, C Boland, G Khalitov, E Crews, FT TI Sweet liking, novelty seeking, and gender predict alcoholic status SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE sweet liking; novelty seeking; alcoholism; genetic risk ID TRIDIMENSIONAL PERSONALITY QUESTIONNAIRE; PITUITARY BETA-ENDORPHIN; SUBSTANCE USE DISORDERS; FAMILY-HISTORY; DISINHIBITORY PSYCHOPATHOLOGY; OPIOID INVOLVEMENT; SENSATION SEEKING; HEDONIC RESPONSE; SACCHARIN INTAKE; TASTE RESPONSES AB Background: The relationship between a hedonic response to sweet taste and a propensity to excessive alcohol drinking is supported by both animal and human studies. There is evidence indicating that the tendency to rate more concentrated sweet solutions as the most pleasurable (i.e., sweet liking) is associated with the genetic vulnerability to alcoholism. However, sweet liking by itself is insufficient to predict the alcoholic status of the individual. Our previous study indicated that alcoholic status can be predicted by a combination of hedonic response to sweet taste and personality profile as measured by the Tridimensional Personality Questionnaire (TPQ). This study was designed to further test this hypothesis. Methods: Participants were 165 patients admitted to a residential treatment program for the treatment of alcoholism, drug dependence and/or interpersonal problems secondary to substance-abusing family members. In addition to a routine medical examination, on the 24th day after admission, patients completed the TPQ, the standard sweet taste test was conducted, and paternal family history of alcoholism was evaluated. Results: Sweet liking was strongly associated with a paternal history of alcoholism. The odds of receiving an alcohol dependence diagnosis were shown to increase, on the average, by 11% for every one-point increase in the TPQ novelty-seeking score in sweet-liking but not in sweet-disliking subjects. Gender contributed independently to the probability of alcohol dependence, with males exhibiting higher rates of alcoholism than females. Conclusions: These findings support the hypothesis that a hedonic response to sweet taste is associated with a genetic risk for alcoholism. Alcoholic status may be predicted by a combination of sweet liking, the TPQ novelty-seeking score, and gender in a mixed group of alcoholic, polysubstance-dependent, and psychiatric patients. C1 Bronx Vet Affairs Med Ctr, Div Addict Psychiat, Mt Sinai Sch Med, Bronx, NY 10468 USA. Pavillon Int, Mill Spring, NC USA. Univ Minnesota, Sch Stat, Minneapolis, MN 55455 USA. Univ N Carolina, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27515 USA. RP Kampov-Polevoy, AB (reprint author), Bronx Vet Affairs Med Ctr, Div Addict Psychiat, Mt Sinai Sch Med, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM kampov@earthlink.net NR 85 TC 54 Z9 55 U1 3 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD SEP PY 2004 VL 28 IS 9 BP 1291 EP 1298 DI 10.1097/01.ALC.0000137808.69482.75 PG 8 WC Substance Abuse SC Substance Abuse GA 856VV UT WOS:000224074300003 PM 15365298 ER PT J AU Ramirez, FC Holland, JF Harker, J Leung, FW AF Ramirez, FC Holland, JF Harker, J Leung, FW TI Effect of acid on duodenal blood flow and mucus secretion measured by reflectance spectrophotometry: a prospective, randomized-controlled study SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RAT DUODENUM; MUCOSAL HEMODYNAMICS; ADAPTIVE CYTOPROTECTION; GASTRODUODENAL MUCOSA; ENDOSCOPIC ASSESSMENT; GEL THICKNESS; GASTRIC-ULCER; INJURY; ACIDIFICATION AB Background: In animals, hydrochloric acid increases blood flow and mucus secretion in the duodenal mucosa. A significant correlation between index of haemoglobin oxygen saturation and mucosal blood flow, and between change in index of haemoglobin concentration and mucus thickness, respectively, has been demonstrated by reflectance spectrophotometry. Aim: To examine the effect of topical hydrochloric acid upon mucosal blood flow and mucus secretion in the human duodenum. Methods: This prospective study of 120 patients undergoing routine upper endoscopy, examined the effect of topical 0.1 N hydrochloric acid or 0.9% saline on the duodenal bulb in a randomized, double-blind fashion. Duodenal mucosal index of haemoglobin oxygen saturation and index of haemoglobin concentration were measured by endoscopic reflectance spectrophotometry before and after hydrochloric acid or saline. Results: Baseline index of haemoglobin oxygen saturation, calculated blood flow and index of haemoglobin concentration measurements were comparable between hydrochloric acid (n = 60) and saline (n =60) treated groups. A history of current use of non-steroidal anti-inflammatory drug was associated with a significantly lower baseline index of haemoglobin oxygen saturation and calculated blood flow. Hydrochloric acid resulted in a significant increase in index of haemoglobin oxygen saturation and calculated blood flow, but a decrease in index of haemoglobin concentration, reflecting an increase in mucus thickness compared with saline. Conclusions: Our observations in humans confirm data in animal studies that topical exposure to hydrochloric acid induces an increase in duodenal mucosal blood flow and mucus secretion. Post hoc analysis of the data also revealed that attenuation of basal duodenal mucosal blood flow is associated with a history of current non-steroidal anti-inflammatory drug use. Endoscopic reflectance spectrophotometry appears to be adequate to assess factors that influence duodenal defence mechanisms of blood flow and mucus secretion in humans. C1 Carl T Hayden VA Med Ctr, Res & Med Serv, Phoenix, AZ 85012 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr & Nursing Home, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Ctr Ulcer Res & Educ, Los Angeles, CA USA. RP Ramirez, FC (reprint author), Carl T Hayden VA Med Ctr, Res & Med Serv, 650 E Indian Sch Rd, Phoenix, AZ 85012 USA. EM francisco.ramirez2@med.va.gov NR 41 TC 2 Z9 2 U1 0 U2 1 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD SEP 1 PY 2004 VL 20 IS 5 BP 517 EP 525 DI 10.1111/j.1365-2036.2004.02122.x PG 9 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 850VR UT WOS:000223643000004 PM 15339323 ER PT J AU Jewell, KD Black, DA Bankson, DD AF Jewell, KD Black, DA Bankson, DD TI Comparison of chemiluminescent and enzyme immunoassays for the detection of hepatitis B core antibody. SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Meeting Abstract CT 83nd ASCP Annual Meeting CY OCT, 2004 CL San Antonio, TX SP ASCP C1 Vet Affairs Puget Sound Hlth Care Syst, Dept Pathol, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Lab Med, Seattle, WA USA. Univ Washington, Med Ctr, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0002-9173 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD SEP PY 2004 VL 122 IS 3 MA 9 BP 456 EP 456 PG 1 WC Pathology SC Pathology GA 849RO UT WOS:000223558500023 ER PT J AU Wigren, C Clarridge, JE AF Wigren, C Clarridge, JE TI Translating 16S rDNA sequencing identification into cost effective phenotypic testing. SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Meeting Abstract CT 83nd ASCP Annual Meeting CY OCT, 2004 CL San Antonio, TX SP ASCP C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0002-9173 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD SEP PY 2004 VL 122 IS 3 MA 12 BP 456 EP 457 PG 2 WC Pathology SC Pathology GA 849RO UT WOS:000223558500025 ER PT J AU Allison, KH Black, DA Garbin, J Bankson, DD AF Allison, KH Black, DA Garbin, J Bankson, DD TI Evaluation of a specific oxycodone assay for urine drug of abuse screening. SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Meeting Abstract CT 83nd ASCP Annual Meeting CY OCT, 2004 CL San Antonio, TX SP ASCP C1 Vet Affairs Puget Sound Hlth Care Syst, Dept Pathol, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Lab Med, Seattle, WA USA. Univ Washington, Med Ctr, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0002-9173 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD SEP PY 2004 VL 122 IS 3 MA 14 BP 457 EP 458 PG 2 WC Pathology SC Pathology GA 849RO UT WOS:000223558500027 ER PT J AU Abraham, NS Fallone, CA Mayrand, S Huang, J Wieczorek, P Barkun, AN AF Abraham, NS Fallone, CA Mayrand, S Huang, J Wieczorek, P Barkun, AN TI Sedation versus no sedation in the performance of diagnostic upper gastrointestinal endoscopy: A Canadian randomized controlled cost-outcome study SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article; Proceedings Paper CT Digestive Diseases Week 2003 CY 2003 CL Orlando, FL ID CONSCIOUS SEDATION; PATIENT TOLERANCE; NATIONWIDE SURVEY; THROAT SPRAY; ESOPHAGOGASTRODUODENOSCOPY; GASTROSCOPY AB BACKGROUND: Sedation is not required to perform a technically adequate gastroscopy (EGDE), but does improve patient satisfaction, comfort, and willingness to repeat particularly in the elderly and those with decreased pharyngeal sensitivity. The comparative cost-efficacy of sedation versus no sedation remains poorly characterized. AIM: To compare the cost-efficacy of diagnostic EGDE with and without sedation in an adult ambulatory Canadian population. METHODS: A double-blind randomized controlled trial assigned patients to sedation versus placebo. "Successful endoscopy" was considered an EGDE rated 4/4 in technical adequacy (1 = inadequate to 4 = totally adequate), and 1-2/5 in patient self-reported comfort (1 = acceptable to 5 = unacceptable). Secondary outcomes included recovery room time, patient satisfaction alone, and willingness to repeat the procedure. Cost data were obtained using a published, institutional activity-based costing methodology. Analysis was intention to treat using standard univariate and multivariate methods. RESULTS: 419 patients (mean age 54.5, 48% male) were randomized (N = 210 active vs N = 209 placebo). Among patients randomized to active medication 76% of procedures were "successful" (placebo 46%), 79% were satisfied with their level of comfort (placebo 47%), and willingness to repeat was 81% (placebo 65%). We observed a 10% crossover rate from placebo to active medications. The use of sedation was the major determinant of successful endoscopy (OR = 3.8; 95% Cl: 2.5-5.7), but contributed to an increased recovery room time (29 vs 15 min; p < 0.0001). The expected cost of an additional successful endoscopy using sedation was $90.06 (CDN). In a planned subgroup analysis, among the elderly (>75; N = 53) unsedated endoscopy became the dominant approach. Indeed, in this population, a trend was observed favoring the effectiveness of placebo (63%) versus active medication (57%) (OR = 0.75; 95% Cl: 0.25-2.3) and was less costly resulting in $450 savings/unsedated EGDE. CONCLUSIONS: In the average Canadian ambulatory adult population, sedated diagnostic EGDE is more costly but remains an efficacious strategy by increasing the rate of successful endoscopies, patient satisfaction, and willingness to repeat. However, among the elderly (>75 yr), an unsedated strategy may be more cost-efficacious. C1 Baylor Coll Med, Houston VAMC, Houston, TX 77030 USA. McGill Univ, Ctr Hlth, Div Gastroenterol, Montreal, PQ, Canada. McGill Univ, Ctr Hlth, Div Clin Epidemiol, Montreal, PQ, Canada. RP Abraham, NS (reprint author), Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Div Gastroenterol, 152,2002 Holcombe Blvd, Houston, TX 77030 USA. NR 27 TC 63 Z9 66 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2004 VL 99 IS 9 BP 1692 EP 1699 DI 10.1111/j.1572-0241.2004.40157.x PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 850XY UT WOS:000223648900014 PM 15330904 ER PT J AU Kanwal, F Hays, RD Kilbourne, AM Dulai, GS Gralnek, IM AF Kanwal, F Hays, RD Kilbourne, AM Dulai, GS Gralnek, IM TI Are physician-derived disease severity indices associated with health-related quality of life in patients with end-stage liver disease? SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID CHRONIC HEPATITIS-C; CLINICAL-PRACTICE; MEDICAL OUTCOMES; VIRUS-INFECTION; INSTRUMENT; ALLOCATION; CIRRHOSIS; IMPACT; SYSTEM; MODEL AB OBJECTIVES: Model for end-stage liver disease (MELD) score is now often used as an overall indicator of health status for patients with end-stage liver disease. However, there are no data evaluating the associations between MELD scores and patient reports of health-related quality of life (HRQOL). METHODS: Two hundred-three patients with end-stage liver disease completed a disease-targeted HRQOL instrument (the LDQOL 1.0). Patients also rated the severity of their liver disease and reported number of disability days attributed to their liver disease in the preceding month. MELD and Child Turcott Pugh (CTP) scores were calculated for all patients. Associations of MELD and CTP scores with patient-derived outcomes were estimated. RESULTS: The mean MELD and CTP scores were 12 and 7, respectively, indicating mild severity of liver disease. HRQOL of patients was generally poor, with the mean SF-36 physical and mental component summary scores of 35 and 40. Seventy percent of patients rated their liver disease symptoms as moderate to severe. Similarly, 70% reported being disabled from their liver disease. MELD was associated with physical functioning scale and the physical component summary (PCS) score in patients with end-stage liver disease. In contrast, CTP score was significantly associated with physical functioning, role limitations due to physical health problems, PCS score, effects of liver disease, sexual functioning, and sexual problems. Both MELD and CTP scores correlated with self-rated severity of liver disease symptoms but not with self-reported disability days. CONCLUSIONS: Despite objectively mild liver disease, the subjective HRQOL of this cohort was severely impaired. CTP score was more closely associated with patient-reported estimates of HRQOL than the MELD score. CTP or disease-specific HRQOL instruments may compliment MELD by providing insights into outcomes of importance to patients with low risk of mortality. C1 Univ Calif Los Angeles, Ctr Study Digest Healthcare Qual & Outcomes, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Pittsburgh, CURE Digest Dis Res Ctr, Pittsburgh, PA USA. Univ Pittsburgh, Ctr Study Digest Healthcare Qual & Outcomes, Pittsburgh, PA USA. Univ Pittsburgh, Ctr Neurovisceral Sci & Womens Hlth, Pittsburgh, PA USA. Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Ctr Hlth Equit Res & Promot, Pittsburgh, PA USA. Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. UCLA Ctr Hlth Sci, Div Digest Dis, Los Angeles, CA USA. UCLA Div Internal Med Hlth Serv Res, Los Angeles, CA USA. RAND Corp, Hlth Sci Program, Santa Monica, CA USA. RP Gralnek, IM (reprint author), Univ Calif Los Angeles, Ctr Study Digest Healthcare Qual & Outcomes, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd CURE Bldg 115,Room 215, Los Angeles, CA 90073 USA. RI Hays, Ronald/D-5629-2013 NR 37 TC 49 Z9 50 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2004 VL 99 IS 9 BP 1726 EP 1732 DI 10.1111/j.1572-0241.2004.30300.x PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 850XY UT WOS:000223648900020 PM 15330910 ER PT J AU Wijsman, EM Daw, EW Yu, CE Payami, H Steinbart, EJ Nochlin, D Conlon, EM Bird, TD Schellenberg, GD AF Wijsman, EM Daw, EW Yu, CE Payami, H Steinbart, EJ Nochlin, D Conlon, EM Bird, TD Schellenberg, GD TI Evidence for a novel late-onset Alzheimer disease locus on chromosome 19p13.2 SO AMERICAN JOURNAL OF HUMAN GENETICS LA English DT Article ID 2-LOCUS LINKAGE ANALYSIS; RECEPTOR-RELATED PROTEIN; RNA-BINDING PROTEINS; AGE-OF-ONSET; APOLIPOPROTEIN-E; GENETIC-LINKAGE; MISSENSE MUTATIONS; EXTENDED PEDIGREES; MARKOV-CHAINS; TYPE-4 ALLELE AB Late-onset familial Alzheimer disease (LOFAD) is a genetically heterogeneous and complex disease for which only one locus, APOE, has been definitively identified. Difficulties in identifying additional loci are likely to stem from inadequate linkage analysis methods. Nonparametric methods suffer from low power because of limited use of the data, and traditional parametric methods suffer from limitations in the complexity of the genetic model that can be feasibly used in analysis. Alternative methods that have recently been developed include Bayesian Markov chain Monte Carlo methods. These methods allow multipoint linkage analysis under oligogenic trait models in pedigrees of arbitrary size; at the same time, they allow for inclusion of covariates in the analysis. We applied this approach to an analysis of LOFAD on five chromosomes with previous reports of linkage. We identified strong evidence of a second LOFAD gene on chromosome 19p13.2, which is distinct from APOE on 19q. We also obtained weak evidence of linkage to chromosome 10 at the same location as a previous report of linkage but found no evidence for linkage of LOFAD age-at-onset loci to chromosomes 9, 12, or 21. C1 Univ Washington, Div Med Genet, Seattle, WA 98195 USA. Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. Univ Washington, Dept Stat, Seattle, WA 98195 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. Univ Washington, Harborview Med Ctr, Neuropathol Lab, Seattle, WA 98104 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. RP Wijsman, EM (reprint author), Univ Washington, Div Med Genet, Box 357720, Seattle, WA 98195 USA. EM wijsman@u.washington.edu FU NIA NIH HHS [U24 AG021886, AG 05136, P30 AG008017, AG 21544, R37 AG011762, P50 AG005136, AG 11762, R01 AG011762, R01 AG021544, AG 08017]; NIGMS NIH HHS [GM 46255, R37 GM046255, R01 GM046255] NR 75 TC 74 Z9 77 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0002-9297 J9 AM J HUM GENET JI Am. J. Hum. Genet. PD SEP PY 2004 VL 75 IS 3 BP 398 EP 409 DI 10.1086/423393 PG 12 WC Genetics & Heredity SC Genetics & Heredity GA 845VA UT WOS:000223272200005 PM 15248153 ER PT J AU Kashyap, SR Belfort, R Berria, R Suraamornkul, S Pratipranawatr, T Finlayson, J Barrentine, A Bajaj, M Mandarino, L DeFronzo, R Cusi, K AF Kashyap, SR Belfort, R Berria, R Suraamornkul, S Pratipranawatr, T Finlayson, J Barrentine, A Bajaj, M Mandarino, L DeFronzo, R Cusi, K TI Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE insulin resistance; free fatty acids; insulin signal transduction ID FREE FATTY-ACIDS; INTRAMYOCELLULAR LIPID-CONTENT; PROTEIN-KINASE-C; GLYCOGEN-SYNTHASE ACTIVITY; SKELETAL-MUSCLE; GLUCOSE-UPTAKE; CARBOHYDRATE-METABOLISM; NONDIABETIC SUBJECTS; NIDDM PARENTS; RISK-FACTORS AB Muscle insulin resistance develops when plasma free fatty acids (FFAs) are acutely increased to supraphysiological levels (similar to1,500 - 4,000 mumol/l). However, plasma FFA levels >1,000 mumol/l are rarely observed in humans under usual living conditions, and it is unknown whether insulin action may be impaired during a sustained but physiological FFA increase to levels seen in obesity and type 2 diabetes mellitus (T2DM) (similar to600 - 800 mumol/l). It is also unclear whether normal glucose-tolerant subjects with a strong family history of T2DM (FH+) would respond to a low-dose lipid infusion as individuals without any family history of T2DM ( CON). To examine these questions, we studied 7 FH+ and 10 CON subjects in whom we infused saline ( SAL) or low- dose Liposyn ( LIP) for 4 days. On day 4, a euglycemic insulin clamp with [3-H-3] glucose and indirect calorimetry was performed to assess glucose turnover, combined with vastus lateralis muscle biopsies to examine insulin signaling. LIP increased plasma FFA similar to 1.5-fold, to levels seen in T2DM. Compared with CON, FH+ were markedly insulin resistant and had severely impaired insulin signaling in response to insulin stimulation. LIP in CON reduced insulin-stimulated glucose disposal (R-d) by 25%, insulin-stimulated insulin receptor tyrosine phosphorylation by 17%, phosphatidylinositol 3-kinase activity associated with insulin receptor substrate-1 by 20%, and insulin-stimulated glycogen synthase fractional velocity over baseline (44 vs. 15%; all P < 0.05). In contrast to CON, a physiological elevation in plasma FFA in FH+ led to no further deterioration in Rd or to any additional impairment of insulin signaling. In conclusion, a 4-day physiological increase in plasma FFA to levels seen in obesity and T2DM impairs insulin action/insulin signaling in CON but does not worsen insulin resistance in FH+. Whether this lack of additional deterioration in insulin signaling in FH+ is due to already well-established lipotoxicity, or to other molecular mechanisms related to insulin resistance that are nearly maximally expressed early in life, remains to be determined. C1 Univ Texas, Hlth Sci Ctr, Diabet Div, Dept Med, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Diabet Div, Dept Biochem, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Diabet Div, Dept Physiol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Diabet Div, Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78229 USA. RP Cusi, K (reprint author), Univ Texas, Hlth Sci Ctr, Diabet Div, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM cusi@uthscsa.edu RI Bajaj, Mandeep/B-6060-2009; Belfort Jr, Rubens/E-2252-2012 OI Belfort Jr, Rubens/0000-0002-8422-3898 FU NCRR NIH HHS [M01-RR-01346]; NIDDK NIH HHS [R01-DK-24092] NR 67 TC 52 Z9 55 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD SEP PY 2004 VL 287 IS 3 BP E537 EP E546 DI 10.1152/ajpendo.00541.2003 PG 10 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 848CL UT WOS:000223444700020 PM 15126243 ER PT J AU Satoh, A Gukovskaya, AS Nieto, JM Cheng, JH Gukovsky, I Reeve, JR Shimosegawa, T Pandol, SJ AF Satoh, A Gukovskaya, AS Nieto, JM Cheng, JH Gukovsky, I Reeve, JR Shimosegawa, T Pandol, SJ TI PKC-delta and -epsilon regulate NF-kappa B activation induced by cholecystokinin and TNF-alpha in pancreatic acinar cells SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE phosphatidylcholine-specific phospholipase C; phosphatidylinositol-specific phospholipase C; Src kinases; translocation; tyrosine phosphorylation ID PROTEIN-KINASE-C; TUMOR-NECROSIS-FACTOR; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-C; B/REL ACTIVATION; INFLAMMATORY RESPONSE; INTRACELLULAR CA2+; ENZYME SECRETION; PHOSPHATIDYLCHOLINE; RAT AB Although NF-kappaB plays an important role in pancreatitis, mechanisms underlying its activation remain unclear. We investigated the signaling pathways mediating NF-kappaB activation in pancreatic acinar cells induced by high-dose cholecystokinin-8 (CCK-8), which causes pancreatitis in rodent models, and TNF-alpha, which contributes to inflammatory responses of pancreatitis, especially the role of PKC isoforms. We determined subcellular distribution and kinase activities of PKC isoforms and NF-kappaB activation in dispersed rat pancreatic acini. We applied isoform-specific, cell-permeable peptide inhibitors to assess the role of individual PKC isoforms in NF-kappaB activation. Both CCK-8 and TNF-alpha activated the novel isoforms PKC-delta and -epsilon and the atypical isoform PKC-zeta but not the conventional isoform PKC-alpha. Inhibition of the novel PKC isoforms but not the conventional or the atypical isoform resulted in the prevention of NF-kappaB activation induced by CCK-8 and TNF-alpha. NF-kappaB activation by CCK-8 and TNF-alpha required translocation but not tyrosine phosphorylation of PKC-delta. Activation of PKC-delta, PKC-epsilon, and NF-kappaB with CCK-8 involved both phosphatidylinositol-specific PLC and phosphatidylcholine (PC)-specific PLC, whereas with TNF-alpha they only required PC-specific PLC for activation. Results indicate that CCK-8 and TNF-alpha initiate NF-kappaB activation by different PLC pathways that converge at the novel PKCs (delta and epsilon) to mediate NF-kappaB activation in pancreatic acinar cells. These findings suggest a key role for the novel PKCs in pancreatitis. C1 W Los Angeles Healthcare Ctr, Vet Affairs Greater Los Angeles Healthcare Syst, Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA 90073 USA. Tohoku Univ, Grad Sch Med, Div Gastroenterol, Miyagi 9808574, Japan. RP Gukovskaya, AS (reprint author), W Los Angeles Healthcare Ctr, Vet Affairs Greater Los Angeles Healthcare Syst, Res Ctr Alcohol Liver & Pancreat Dis, Bldg 258,Rm 340,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM agukovsk@ucla.edu FU NIAAA NIH HHS [P50-AA-11999]; NIDDK NIH HHS [DK-59508] NR 58 TC 104 Z9 110 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD SEP PY 2004 VL 287 IS 3 BP G582 EP G591 DI 10.1152/ajpgi.00087.2004 PG 10 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 848DB UT WOS:000223446400012 PM 15117677 ER PT J AU Engel, D Peshock, R Armstong, RC Sivasubramanian, N Mann, DL AF Engel, D Peshock, R Armstong, RC Sivasubramanian, N Mann, DL TI Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE tumor necrosis factor; cell death; caspase; congestive heart failure; magnetic resonance imaging ID NECROSIS-FACTOR-ALPHA; FAILING HUMAN HEART; CELL-DEATH; CARDIOMYOCYTE APOPTOSIS; MYOCARDIAL EXPRESSION; CASPASE INHIBITOR; FAILURE; BCL-2; INJURY; RATS AB Although cardiac myocyte apoptosis has been detected in explanted hearts from patients with end-stage dilated and ischemic cardiomyopathy, the relative contribution of apoptotic cell death to left ventricular (LV) remodeling and cardiac decompensation is not known. To determine whether progressive cardiac myocyte apoptosis contributes to the transition from a hypertrophic to a dilated cardiac phenotype that is observed in transgenic myosin heavy chain secreted TNF (MHCsTNF) mice with cardiac restricted overexpression of tumor necrosis factor ( TNF), we assessed cardiac myocyte apoptosis ( using a DNA ligase technique) in MHCsTNF mice and littermate control mice in relation to serial changes in LV structure, which was assessed using MRI. The prevalence of cardiac myocyte apoptosis increased progressively from 4 to 12 wk as the hearts of the MHCsTNF mice underwent the transition from a concentric hypertrophic to a dilated cardiac phenotype. Treatment of the MHCsTNF mice with the broad-based caspase inhibitor N-[(1,3-dimethylindole-2-carbonyl)-valinyl]-3-amino-4- oxo-5-fluoropentanoic acid significantly decreased cardiac myocyte apoptosis and significantly attenuated LV wall thinning and adverse cardiac remodeling. Additional studies suggested that the TNF-induced decrease in Bcl-2 expression and activation of the intrinsic mitochondrial death pathway were responsible for the cardiac myocyte apoptosis observed in the MHCsTNF mice. These studies show that progressive cardiac myocyte apoptosis is sufficient to contribute to adverse cardiac remodeling in the adult mammalian heart through progressive LV wall thinning. C1 Baylor Coll Med, Winters Ctr Heart Failure Res, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Univ Texas, SW Med Ctr, Dept Radiol, Dallas, TX 75235 USA. Idun Pharmaceut, San Diego, CA 92121 USA. RP Mann, DL (reprint author), Baylor Coll Med, Winters Ctr Heart Failure Res, 6565 Fannin St,MS 524, Houston, TX 77030 USA. EM dmann@bcm.tmc.edu OI Mann, Douglas /0000-0002-2516-0145 FU NHLBI NIH HHS [HL-42250-10/10, P50 HL-O6H, R01 HL-58081-01, R01 HL-61543-01] NR 38 TC 66 Z9 67 U1 2 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD SEP PY 2004 VL 287 IS 3 BP H1303 EP H1311 DI 10.1152/ajpheart.00053.2004 PG 9 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 847MZ UT WOS:000223398600040 PM 15317679 ER PT J AU Altemeier, WA Matute-Bello, G Frevert, CW Kawata, Y Kajikawa, O Martin, TR Glenny, RW AF Altemeier, WA Matute-Bello, G Frevert, CW Kawata, Y Kajikawa, O Martin, TR Glenny, RW TI Mechanical ventilation with moderate tidal volumes synergistically increases lung cytokine response to systemic endotoxin SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE acute lung injury; innate immunity; transcription factor-1; nuclear factor-kappa B ID RESPIRATORY-DISTRESS-SYNDROME; FACTOR-KAPPA-B; INTERLEUKIN-8 GENE-EXPRESSION; HEMORRHAGIC-SHOCK; INJURY; ACTIVATION; INFLAMMATION; RABBITS; MODEL; STRETCH AB Previous animal studies have identified a role for activation of innate immunity in the pathogenesis of ventilator-associated lung injury. These studies have used large tidal volume ventilation to study the effect of alveolar overdistension on induction of inflammatory pathways. We hypothesized an alternative mechanism for the pathogenesis of lung injury in which moderate tidal volume ventilation does not independently cause clinical inflammation but rather interacts with innate immune activation by bacterial products, resulting in an enhanced inflammatory response. We measured cytokine expression and lung injury in normal and lipopolysaccharide (LPS)-treated anesthetized rabbits randomized to either spontaneous respiration or mechanical ventilation. Outcome parameters were analyzed by two-way factorial analysis of variance to identify synergism between ventilation and systemic LPS. Mechanical ventilation alone resulted in minimal cytokine expression in the lung but did enhance LPS-induced expression of tumor necrosis factor-alpha, the CXC chemokines interleukin-8 and growth-related protein-alpha, and the CC chemokine monocyte chemoattractant protein-1. Increased mRNA expression and activation of the transcription factors nuclear factor-kappaB and activator protein-1 accompanied the cytokine responses. We conclude that moderate volume ventilation strategies augment the innate immune response to bacterial products in the lung and may play a role in the development of acute lung injury in patients with sepsis. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Healthcare Syst, Med Res Serv, Seattle, WA 98108 USA. RP Altemeier, WA (reprint author), Box 356500,1959 NE Pacific St, Seattle, WA 98195 USA. EM billa@u.washington.edu FU NHLBI NIH HHS [HL-30542, HL-71020, HL-24163, K08 HL071020] NR 39 TC 98 Z9 102 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD SEP PY 2004 VL 287 IS 3 BP L533 EP L542 DI 10.1152/ajplung.00004.2004 PG 10 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 845NG UT WOS:000223251000014 PM 15145786 ER PT J AU Lee, DBN Jamgotchian, N Allen, SG Kan, FWK Hale, IL AF Lee, DBN Jamgotchian, N Allen, SG Kan, FWK Hale, IL TI Annexin A2 heterotetramer: role in tight junction assembly SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE annexin II; zonula occludens-1; occludin; claudin-1; hemifusion ID CELL-CELL CONTACTS; EPITHELIAL-CELLS; MEMBRANE-FUSION; II TETRAMER; MDCK CELLS; E-CADHERIN; MESENCHYMAL TRANSITION; MOLECULAR PHYSIOLOGY; POSSIBLE INVOLVEMENT; ZONULA OCCLUDENS-1 AB The tight junction has been characterized as a domain of focal fusions of the exoplasmic leaflets of the lipid bilayers from adjacent epithelial cells. Approximating membranes to within fusion distance is a thermodynamically unfavorable process and requires the participation of membrane-bridging or -fusion proteins. No known tight junction protein exhibits such activities. Annexin A2 (A2), in particular its heterotetramer (A2t), is known to form junctions between lipid bilayer structures through molecular bridging of their external leaflets. We demonstrate abundant A2 expression in Madin-Darby canine kidney II monolayers by two-dimensional gel electrophoresis. Confocal immunofluorescence microscopic analysis suggests the bulk of A2 is located along the apical and lateral plasma membrane in its tetrameric configuration, consisting of two A2 and two p11 (an 11-kDa calmodulin-related protein, S100A10) subunits. Immunocytochemistry and ultrastructural immunogold labeling demonstrate colocalization of the A2 subunit with bona fide tight junction proteins, zonula occludens-1, occludin, and claudin-1, at cell-cell contacts. The extracellular addition of a synthetic peptide, targeted to disrupt the binding between A2 and p11, completely aborts tight junction assembly in calcium chelation studies. We propose A2t as a member of a new class of tight junction proteins responsible for the long-observed convergence of adjacent exoplasmic lipid leaflets in tight junction assembly. C1 Vet Affairs Greater Los Angeles Healthcare Syst, VISN 22, Epithelial Transport Lab, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada. RP Lee, DBN (reprint author), Vet Adm Med Ctr, Dept Med 111, 16111 Plummer St, Sepulveda, CA 91343 USA. EM dbnlee@ucla.edu FU NHLBI NIH HHS [T32HL-07656]; NIDDK NIH HHS [1R01DK/HD-51948] NR 90 TC 28 Z9 29 U1 0 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD SEP PY 2004 VL 287 IS 3 BP F481 EP F491 DI 10.1152/ajprenal.00175.2003 PG 11 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 844RT UT WOS:000223178000017 PM 15113748 ER PT J AU Chew, LD Bradley, KA Flum, DR Cornia, PB Koepsell, TD AF Chew, LD Bradley, KA Flum, DR Cornia, PB Koepsell, TD TI The impact of low health literacy on surgical practice SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE health literacy; VA clinic; preoperative instructions; adherence to medication ID AFFAIRS AB Background: We sought to determine the prevalence of low health literacy (LHL) among patients in a preoperative clinic, the characteristics associated with LHL, and the association between LHL and adherence to preoperative instructions. Methods: We conducted a cohort study and interviewed patients at a VA preoperative clinic. We administered a health literacy test and collected sociodemographic information. When patients returned for their scheduled surgical procedures, adherence to preoperative instructions was, assessed. Results: Of 332 participants, 12% (n = 40) had LHL. Low health literacy was more prevalent among older adults (more than 65 years) compared with those under age 65. Patients with LHL were more likely to be nonadherent to preoperative medication instructions (odds ratio = 1.9; 95% confidence interval: 0.8 to 4.8), but this was of borderline statistical significance. Conclusions: Low health literacy was common among older patients and appeared to be associated with lower adherence to preoperative medication instructions. Published by Excerpta Medica, Inc. C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98108 USA. Univ Washington, Div Gen Internal Med, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Surg, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Chew, LD (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way, Seattle, WA 98108 USA. EM lchew@u.washington.edu NR 10 TC 47 Z9 47 U1 2 U2 5 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD SEP PY 2004 VL 188 IS 3 BP 250 EP 253 DI 10.1016/j.amjsurg.2004.04.005 PG 4 WC Surgery SC Surgery GA 854RQ UT WOS:000223921400009 PM 15450829 ER PT J AU Barchiesi, F Spreghini, E Maracci, M Fothergill, AW Baldassarri, I Rinaldi, MG Scalise, G AF Barchiesi, F Spreghini, E Maracci, M Fothergill, AW Baldassarri, I Rinaldi, MG Scalise, G TI In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID AMPHOTERICIN-B; SCEDOSPORIUM-PROLIFICANS; CRYPTOCOCCUS-NEOFORMANS; INVASIVE CANDIDIASIS; FLUCONAZOLE; TERBINAFINE; ITRACONAZOLE; ALBICANS; THERAPY; INFECTION AB Candida glabrata has recently emerged as a significant pathogen involved in both superficial and deep-seated infections. In the present study, a checkerboard broth microdilution method was performed to investigate the in vitro activities of voriconazole (VOR) in combination with terbinafine (TRB), amphotericin B (AMB), and flucytosine (5FC against 20 clinical isolates of C. glabrata. Synergy, defined as a fractional inhibitory concentration (FIC index of less than or equal to0.50, was observed in 75% of VOR-TRB, 10% of VOR-AMB, and 5% of VOR-5FC interactions. None of these combinations yielded antagonistic interactions (FIC index > 4). When synergy was not achieved, there was still a decrease in the MIC of one or both drugs used in the combination. In particular, the MICs were reduced to less than or equal to1.0 mug/ml as a result of the combination for all isolates for which the AMB MIC at the baseline was greater than or equal to2.0 mug/ml. By a disk diffusion assay, the halo diameters produced by antifungal agents in combination were greater that those produced by each drug alone. Finally, killing curves showed that VOR-AMB exhibited synergistic interactions, while VOR-5FC sustained fungicidal activities against C. glabrata. These studies demonstrate that the in vitro activity of VOR against this important yeast pathogen can be enhanced upon combination with other drugs that have different modes of action or that target a different step in the ergosterol pathway. Further studies are warranted to elucidate the potential beneficial effects of such combination regimens in vivo. C1 Univ Politecn Marche, Ist Malattie Infett & Med Publ, I-60020 Ancona, Italy. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX USA. RP Barchiesi, F (reprint author), Univ Politecn Marche, Ist Malattie Infett & Med Publ, Azienda Osped Umberto 1,Via Conca, I-60020 Ancona, Italy. EM l.infettive@ao-umbertoprimo.marche.it RI Spreghini, Elisabetta/G-9378-2012 NR 39 TC 17 Z9 23 U1 1 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD SEP PY 2004 VL 48 IS 9 BP 3317 EP 3322 DI 10.1128/AAC.48.9.3317-3322.2004 PG 6 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 850PV UT WOS:000223625800016 PM 15328091 ER PT J AU Maslow, JN Lautenbach, E Glaze, T Bilker, W Johnson, JR AF Maslow, JN Lautenbach, E Glaze, T Bilker, W Johnson, JR TI Colonization with extraintestinal pathogenic Escherichia coli among nursing home residents and its relationship to fluoroquinolone resistance SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID INFECTIONS; KLEBSIELLA; STRAINS; URINARY AB In a cross-sectional fecal prevalence survey involving 49 residents of a Veterans Affairs nursing home, 59% of subjects were colonized with extraintestinal pathogenic Escherichia coli (ExPEC), 22% were colonized with adhesin-positive E. coli, and 51% were colonized with fluoroquinolone-resistant E. coli. Among 80 unique isolates, adhesins correlated negatively and aerobactin correlated positively with fluoroquinolone resistance. C1 Vet Affairs Med Ctr, Infect Dis Sect, Philadelphia, PA 19104 USA. Univ Penn, Div Infect Dis, Philadelphia, PA 19104 USA. Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. Univ Penn, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. Vet Affairs Med Ctr, Mucosal & Vaccine Res Ctr, Minneapolis, MN 55455 USA. RP Maslow, JN (reprint author), Vet Affairs Med Ctr, Infect Dis Sect, 151,Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM joel.maslow@med.va.gov FU AHRQ HHS [U18-HS10399, U18 HS010399]; NIAID NIH HHS [U01 AI032783, AI32783]; NIDDK NIH HHS [DK-02987-01] NR 15 TC 16 Z9 17 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD SEP PY 2004 VL 48 IS 9 BP 3618 EP 3620 DI 10.1128/AAC.48.9.3618-3620.2004 PG 3 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 850PV UT WOS:000223625800067 PM 15328142 ER PT J AU McNeil, MR Hula, WD Matthews, CT Doyle, PJ AF McNeil, MR Hula, WD Matthews, CT Doyle, PJ TI Resource theory and aphasia: A fugacious theoretical dismissal SO APHASIOLOGY LA English DT Editorial Material ID PERFORMANCE; BOTTLENECK C1 Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP McNeil, MR (reprint author), Univ Pittsburgh, Dept Commun Sci & Disorders, 4033 Forbes Tower, Pittsburgh, PA 15260 USA. NR 11 TC 1 Z9 2 U1 0 U2 0 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0268-7038 J9 APHASIOLOGY JI Aphasiology PD SEP PY 2004 VL 18 IS 9 BP 836 EP 839 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 845WK UT WOS:000223275800005 ER PT J AU Brey, RL Fox, PT Narayana, S Martinez, MJ Naqibuddin, M Holliday, SL Wallace, DJ Weisman, MH Petri, M AF Brey, RL Fox, PT Narayana, S Martinez, MJ Naqibuddin, M Holliday, SL Wallace, DJ Weisman, MH Petri, M TI Brain imaging findings in an SLE inception cohort: Brain CONECTIONS. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 16-21, 2004 CL San Antonio, TX SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 UTHSCSA, San Antonio, TX USA. Johns Hopkins Univ, Baltimore, MD USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2004 VL 50 IS 9 SU S BP S194 EP S194 PG 1 WC Rheumatology SC Rheumatology GA 853AS UT WOS:000223799000456 ER PT J AU Herrera, M Gonzalez, E Kulkarni, H Correa, P Holliday, SL Brey, RL Rovin, BH Anaya, JM Ahuja, SK AF Herrera, M Gonzalez, E Kulkarni, H Correa, P Holliday, SL Brey, RL Rovin, BH Anaya, JM Ahuja, SK TI Genetic evidence for the common variants/multiple disease hypothesis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 16-21, 2004 CL San Antonio, TX SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 UTHSCSA, San Antonio, TX USA. CIB, Medellin, Colombia. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Ohio State Univ, Columbus, OH 43210 USA. RI Anaya, Juan-Manuel/J-1960-2016 OI Anaya, Juan-Manuel/0000-0002-6444-1249 NR 0 TC 1 Z9 1 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2004 VL 50 IS 9 SU S BP S120 EP S120 PG 1 WC Rheumatology SC Rheumatology GA 853AS UT WOS:000223799000239 ER PT J AU Holliday, SL Saklad, AR Fischbach, M Garcia-Cavasos, R Padilla, PA Brey, RL AF Holliday, SL Saklad, AR Fischbach, M Garcia-Cavasos, R Padilla, PA Brey, RL TI Risk factors for cognitive dysfunction in SLE: San Antonio lupus study of neuropsychiatric disease (SALUD). SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 16-21, 2004 CL San Antonio, TX SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 S Texas Vet Hlth Care Syst, San Antonio, TX USA. UTHSCSA, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2004 VL 50 IS 9 SU S BP S256 EP S257 PG 2 WC Rheumatology SC Rheumatology GA 853AS UT WOS:000223799000639 ER PT J AU Hsu, HC Zhou, T Yang, PA Wu, Q Zhou, JL Wang, Z Liu, D Mountz, JD AF Hsu, HC Zhou, T Yang, PA Wu, Q Zhou, JL Wang, Z Liu, D Mountz, JD TI Generation of kidney- or joint-specific pathogenic hybridomas derived from the spleen of a mouse of the BXD2 strain, which exhibit both lupus and an erosive arthritis. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 16-21, 2004 CL San Antonio, TX SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Univ Alabama, Birmingham, AL USA. Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2004 VL 50 IS 9 SU S BP S220 EP S221 PG 2 WC Rheumatology SC Rheumatology GA 853AS UT WOS:000223799000536 ER PT J AU Kahn, KL Liu, HH MacLean, C Fitzpatrick, D Chen, WP Wong, A Bulpitt, K Bradley, M Harker, J Traina, S Mittman, B Rubenstein, L Hahn, B Paulus, H AF Kahn, KL Liu, HH MacLean, C Fitzpatrick, D Chen, WP Wong, A Bulpitt, K Bradley, M Harker, J Traina, S Mittman, B Rubenstein, L Hahn, B Paulus, H TI Depression in patients with rheumatoid arthritis (RA) SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 16-21, 2004 CL San Antonio, TX SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Univ Calif Los Angeles, Los Angeles, CA USA. W Los Angeles VA Med Ctr, Los Angeles, CA USA. RAND, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2004 VL 50 IS 9 SU S BP S322 EP S322 PG 1 WC Rheumatology SC Rheumatology GA 853AS UT WOS:000223799000829 ER PT J AU Kahn, KL MacLean, CH Liu, HH Fitzpatrick, D Wong, A Bulpitt, K Bradley, M Harker, J Mittman, B Rubenstein, LZ Hahn, BH Paulus, HE AF Kahn, KL MacLean, CH Liu, HH Fitzpatrick, D Wong, A Bulpitt, K Bradley, M Harker, J Mittman, B Rubenstein, LZ Hahn, BH Paulus, HE TI Variations in adherence to recommended process for rheumatoid arthritis (RA) patients SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 16-21, 2004 CL San Antonio, TX SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Univ Calif Los Angeles, Los Angeles, CA USA. W Los Angeles VA Med Ctr, Los Angeles, CA USA. RAND, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2004 VL 50 IS 9 SU S BP S322 EP S322 PG 1 WC Rheumatology SC Rheumatology GA 853AS UT WOS:000223799000828 ER PT J AU Lee, YH Kaufman, KM Harley, JB Sestak, AL AF Lee, YH Kaufman, KM Harley, JB Sestak, AL TI The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: A meta-analysis. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 16-21, 2004 CL San Antonio, TX SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Univ Oklahoma, Oklahoma City, OK USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2004 VL 50 IS 9 SU S BP S204 EP S205 PG 2 WC Rheumatology SC Rheumatology GA 853AS UT WOS:000223799000488 ER PT J AU McLaurin, EY Holliday, SL Wing, NF Russell, IJ Brey, RL AF McLaurin, EY Holliday, SL Wing, NF Russell, IJ Brey, RL TI Cognitive functioning in patients with fibromyalgia compared to patients with lupus and normal controls. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 16-21, 2004 CL San Antonio, TX SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 UTHSCSA, San Antonio, TX USA. Vet Affairs Med Ctr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2004 VL 50 IS 9 SU S BP S494 EP S494 PG 1 WC Rheumatology SC Rheumatology GA 853AS UT WOS:000223799001335 ER PT J AU Naqibuddin, M Wallace, DJ Weisman, MH Holliday, SL Wing, NF Brey, RL Petri, M AF Naqibuddin, M Wallace, DJ Weisman, MH Holliday, SL Wing, NF Brey, RL Petri, M TI Cognitive functioning in recently-diagnosed systemic lupus erythematosus. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 16-21, 2004 CL San Antonio, TX SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas, Ctr Hlth Sci, San Antonio, TX 78285 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2004 VL 50 IS 9 SU S BP S195 EP S195 PG 1 WC Rheumatology SC Rheumatology GA 853AS UT WOS:000223799000459 ER PT J AU Quinones, MP Ahuja, SK Reddick, RL Jimenez, F Melby, PM Kuziel, WA Ahuja, SS AF Quinones, MP Ahuja, SK Reddick, RL Jimenez, F Melby, PM Kuziel, WA Ahuja, SS TI Role of chemokine receptor-2 in autoimmune arthritis. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 16-21, 2004 CL San Antonio, TX SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Texas, Austin, TX 78712 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2004 VL 50 IS 9 SU S BP S442 EP S442 PG 1 WC Rheumatology SC Rheumatology GA 853AS UT WOS:000223799001180 ER PT J AU Saklad, AR Holliday, SL Fischbach, M Brey, RL AF Saklad, AR Holliday, SL Fischbach, M Brey, RL TI Psychiatric diagnoses in adults SLE patients. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 16-21, 2004 CL San Antonio, TX SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 UTHSCSA, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2004 VL 50 IS 9 SU S BP S195 EP S196 PG 2 WC Rheumatology SC Rheumatology GA 853AS UT WOS:000223799000461 ER PT J AU Traina, SB MacLean, CH Park, GS Paulus, HE Harker, JO Wong, AL Rubenstein, LZ Fitzpatrick, D Louie, R Liu, HH Chen, WP Hahn, BH Kahn, KL AF Traina, SB MacLean, CH Park, GS Paulus, HE Harker, JO Wong, AL Rubenstein, LZ Fitzpatrick, D Louie, R Liu, HH Chen, WP Hahn, BH Kahn, KL TI Mental health scores and social support are not associated with disease duration in rheumatoid arthritis patients SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 16-21, 2004 CL San Antonio, TX SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 VA Greater LA Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. RAND, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2004 VL 50 IS 9 SU S BP S321 EP S321 PG 1 WC Rheumatology SC Rheumatology GA 853AS UT WOS:000223799000826 ER PT J AU Wong, AL Harker, JO Park, GS Paulus, HE AF Wong, AL Harker, JO Park, GS Paulus, HE TI Longitudinal measurement of RA disease activity in a clinical practice setting: Usefulness of the SDAL SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 16-21, 2004 CL San Antonio, TX SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Olive View UCLA Med Ctr, Sylmar, CA 91342 USA. Greater Los Angeles VA Healthcare Syst, Sepulveda, CA USA. Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. NR 0 TC 5 Z9 5 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2004 VL 50 IS 9 SU S BP S386 EP S387 PG 2 WC Rheumatology SC Rheumatology GA 853AS UT WOS:000223799001021 ER PT J AU Richardson, A Liu, F Adamo, ML Van Remmen, H Nelson, JF AF Richardson, A Liu, F Adamo, ML Van Remmen, H Nelson, JF TI The role of insulin and insulin-like growth factor-1 in mammalian ageing SO BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article DE insulin; insulin-like growth factor-1; caloric restriction; dwarf mice ID AGE-1 PI3 KINASE; LIFE-SPAN; CALORIE RESTRICTION; CAENORHABDITIS-ELEGANS; DIETARY RESTRICTION; DWARF MICE; SKELETAL-MUSCLE; GLUCOSE-METABOLISM; STRESS RESISTANCE; PROTEIN-SYNTHESIS AB Research with invertebrates over the past 10 years has suggested that alterations in insulin and/or insulin-like growth factor I (IGF-I) signalling result in increased lifespan and retard ageing. In this chapter, we describe the current research in mammalian systems with respect to the role of insulin or IGF-I in ageing. Using rodent models of caloric restriction and genetic mouse models, e.g. the Ames and Snell dwarf mice, fat-specific insulin receptor knockout mice (FIRKO) and mice that are heterozygous for the IGF-I receptor (IgfIr(+/-)), investigators have shown that a reduction in plasma levels of insulin and/or IGF-I or reductions in insulin/IGF-I signalling appear to be correlated with increased longevity and retarded ageing. C1 Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Barshop Ctr Longev & Aging Studies, San Antonio, TX 78229 USA. Geriatr Res Educ & Clin Ctr & Res Serv, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. Univ Texas, Ctr Hlth Sci, Dept Pharmacol, San Antonio, TX 78229 USA. Univ Texas, Ctr Hlth Sci, Dept Biochem, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA. RP Richardson, A (reprint author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. EM richardsona@uthscsa.edu NR 76 TC 43 Z9 46 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1521-690X EI 1532-1908 J9 BEST PRACT RES CL EN JI Best Pract. Res. Clin. Endoc. Metab. PD SEP PY 2004 VL 18 IS 3 BP 393 EP 406 DI 10.1016/j.beem.2004.02.002 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 847KQ UT WOS:000223391700007 PM 15261845 ER PT J AU Waldman, KL AF Waldman, KL TI The psychologist's companion: A guide to scientific writing for students and researchers SO BULLETIN OF THE MENNINGER CLINIC LA English DT Book Review C1 Michael E Debakey Vet Affairs Med Ctr, Houston, TX USA. RP Waldman, KL (reprint author), Michael E Debakey Vet Affairs Med Ctr, Houston, TX USA. NR 1 TC 0 Z9 0 U1 1 U2 1 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0025-9284 J9 B MENNINGER CLIN JI Bull. Menninger Clin. PD FAL PY 2004 VL 68 IS 4 BP 364 EP 365 PG 2 WC Psychiatry; Psychology, Psychoanalysis SC Psychiatry; Psychology GA 892TZ UT WOS:000226674200020 ER PT J AU Waldman, KL AF Waldman, KL TI Psychological approaches to PAIN management: A practitioner's handbook. SO BULLETIN OF THE MENNINGER CLINIC LA English DT Book Review C1 Michael E Debakey Vet Affairs Med Ctr, Houston, TX USA. RP Waldman, KL (reprint author), Michael E Debakey Vet Affairs Med Ctr, Houston, TX USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0025-9284 J9 B MENNINGER CLIN JI Bull. Menninger Clin. PD FAL PY 2004 VL 68 IS 4 BP 365 EP 366 PG 2 WC Psychiatry; Psychology, Psychoanalysis SC Psychiatry; Psychology GA 892TZ UT WOS:000226674200021 ER PT J AU Mendez, MR AF Mendez, MR TI Aphemia-like syndrome from a right supplementary motor area lesion SO CLINICAL NEUROLOGY AND NEUROSURGERY LA English DT Article DE aphemia; aphasia; SMA ID APHASIA; DISORDER; SPEECH AB Lesions in the left supplementary motor area (SMA) can result in a transcortical motor aphasia with nonfluent spontaneous verbal output and relatively preserved repetition. Reading and writing are proportionally affected. We report a patient with an ischemic lesion in the right SMA. He had impaired articulation and normal repetition plus preserved reading and writing, consistent with an aphemia. This patient supports the dissociation of articulatory fluency and linguistic fluency and suggests that both SMAs affect the initiating of articulatory movements required to produce words whereas the left SMA also affects linguistic aspects of speech. (C) 2004 Elsevier B.V. All rights reserved. C1 Univ Calif Los Angeles, Reed Neurol Res Ctr, Dept Neurol, Neurobehav Unit,VA Greater Los Angeles Healthcare, Los Angeles, CA 90073 USA. RP Mendez, MR (reprint author), Univ Calif Los Angeles, Reed Neurol Res Ctr, Dept Neurol, Neurobehav Unit,VA Greater Los Angeles Healthcare, 116AF,11301 Wiltshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@ucla.edu NR 17 TC 6 Z9 7 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0303-8467 J9 CLIN NEUROL NEUROSUR JI Clin. Neurol. Neurosurg. PD SEP PY 2004 VL 106 IS 4 BP 337 EP 339 DI 10.1016/j.clineuro.2003.12.008 PG 3 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 849EW UT WOS:000223522500013 PM 15297011 ER PT J AU Baddley, JW Moser, SA AF Baddley, JW Moser, SA TI Emerging fungal resistance SO CLINICS IN LABORATORY MEDICINE LA English DT Article ID ANTIFUNGAL DRUG-RESISTANCE; AMPHOTERICIN-B RESISTANCE; BLOOD-STREAM INFECTIONS; HUMAN-IMMUNODEFICIENCY-VIRUS; CANDIDA-KRUSEI INFECTION; IN-VITRO SUSCEPTIBILITY; ASPERGILLUS-FUMIGATUS; CRYPTOCOCCUS-NEOFORMANS; 1,3-BETA-D-GLUCAN SYNTHASE; ITRACONAZOLE RESISTANCE AB There has been an increase in systemic fungal infections over the past several decades, partially because of an increasing number of critically ill patients, surgical procedures, and immunosuppressive therapies, as well as the use of more invasive diagnostic and therapeutic medical procedures. Concomitant with this increase in infections has been the increase in azole-resistant Candida species and opportunistic molds with intrinsic resistance to many of the currently available antifungal agents. This review focuses on antifungal resistance, with emphasis on emerging resistance patterns and emerging fungi that are intrinsically resistant to antifungal agents. C1 Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. Univ Alabama, Div Infect Dis, Dept Med, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Moser, SA (reprint author), Univ Alabama, Dept Pathol, 619 19th St S, Birmingham, AL 35294 USA. EM moser@uab.edu RI Moser, Stephen/A-1168-2008 NR 94 TC 24 Z9 24 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0272-2712 J9 CLIN LAB MED JI Clin. Lab. Med. PD SEP PY 2004 VL 24 IS 3 BP 721 EP + DI 10.1016/j.cll.2004.05.003 PG 16 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 852JQ UT WOS:000223752000008 PM 15325062 ER PT J AU Bracha, HS AF Bracha, HS TI Freeze, flight, fight, fright, faint: Adaptationist perspectives on the acute stress response spectrum SO CNS SPECTRUMS LA English DT Review ID BLOOD-INJURY PHOBIA; AUTONOMIC SPACE; VASOVAGAL SYNCOPE; VAGAL TONE; DISORDER; EVOLUTIONARY; ANXIETY; TRAUMA; FEARS; PROPRANOLOL AB This article reviews the existing evolutionary perspectives on the acute stress response habitual faintness and blood-injection-injury type-specific Phobia (BIITS phobia). In this article, an alternative evolutionary perspective, based on recent advances in evolutionary psychology, is proposed. Specifically, that fear-induced faintness (eg, fainting following the sight of a syringe, blood, or following a trivial skin injury) is a distinct Homo sapiens-specific extreme-stress survival response to an inescapable threat. The article suggests that faintness evolved in response to middle paleolithic intra-group and inter-group violence (of con-specifics) rather than as a pan-mammalian defense response, as is presently assumed. Based on recent literature, freeze, flight, fight, fright, faint Provides a more complete description of the human acute stress response sequence than current descriptions. Faintness, one of three primary physiological reactions involved in WITS phobia, is extremely rare in other phobias. Since heritability estimates are higher for faintness than for fears or phobias I the author suggests that trait-faintness may be a useful complement to trait-anxiety as an endophenotype in research on the human fear circuitry. Some implications for the forthcoming Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition as well as for clinical, health services, and transcriptomic research are briefly discussed. C1 US Dept Vet Affairs, Spark M Matsunaga Med Ctr, Natl Ctr PTSD, Pacific Isl Hlth Care Syst, Honolulu, HI 96813 USA. RP Bracha, HS (reprint author), US Dept Vet Affairs, Spark M Matsunaga Med Ctr, Natl Ctr PTSD, Pacific Isl Hlth Care Syst, 1132 Bishop St,307, Honolulu, HI 96813 USA. NR 71 TC 78 Z9 80 U1 4 U2 50 PU M B L COMMUNICATIONS, INC PI NEW YORK PA 333 HUDSON ST, 7TH FLOOR, NEW YORK, NY 10013 USA SN 1092-8529 J9 CNS SPECTRUMS JI CNS Spectr. PD SEP PY 2004 VL 9 IS 9 BP 679 EP 685 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 895VK UT WOS:000226891700015 PM 15337864 ER PT J AU Moates, JM Magnuson, MA AF Moates, JM Magnuson, MA TI The Pal elements in the upstream glucokinase promoter exhibit dyad symmetry and display cell-specific enhancer activity when multimerised SO DIABETOLOGIA LA English DT Article DE dimer; dyad symmetry; enhancer; glucokinase; inverted repeat; methylation interference; promoter ID INSULIN GENE-TRANSCRIPTION; ISLET BETA-CELLS; RETINOIC ACID; THYROID-HORMONE; HOMEOBOX FACTOR; EXPRESSION; ACTIVATION; BINDING; RECEPTORS; DIFFERENTIATION AB Aims/hypothesis. The upstream glucokinase (betaGK) promoter has previously been shown to contain two 9-bp sequences, termed the Pal motifs, that are conserved in humans, rats and mice. These motifs are necessary for expression of the betaGK promoter in pancreatic beta cell lines and pituitary corticotrope cell lines. DNA probes containing the Pal motifs bind cell-type-specific protein complexes, but these motifs have not been completely characterised. Methods. Methylation interference and ultraviolet-crosslinking analysis were utilised to characterise, at the single nucleotide level, sites of protein binding within the elements themselves. To determine the function of these elements, mutational analysis of the betaGK promoter and of multimerised GK promoter sequences was performed. Results. Both Pal elements are 14 bp in length and have dyad symmetry. However, while the Pal-1 element is a perfect inverted repeat (GTCACCA-TGGTGAC), the Pal-2 element (GTCACCA-TAGAAAC) is an imperfect repeat. Ultraviolet-crosslinking analysis using nuclear extracts prepared from hamster insulinoma tumour (HIT) cells revealed that the three resolvable complexes that bind to the Pal-1 and Pal-2 elements contain different ratios of three proteins of different size (similar to90, 110 and 150 M-r). Mutation of a single nucleotide binding site abrogates betaGK promoter activity. Multimerised repeats of the Pal-1 element augment transcription in HIT cells, but not in baby hamster kidney (BHK) cells. Conclusions/interpretation. These results suggest that different combinations of three proteins of different size bind to the Pal elements, probably as homodimers and heterodimers. Together, these results indicate that the beta(2)GK promoter contains two novel 14-bp elements that, when multimerised, exhibit enhancer activity specific to neuroendocrine cells. C1 Univ Alabama, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA. Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA. Nashville Vet Affairs Med Ctr, Nashville, TN 37212 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37212 USA. RP Moates, JM (reprint author), Univ Alabama, Dept Med, Div Endocrinol Diabet & Metab, Rm 706 BDB,1808 7th Ave S, Birmingham, AL 35294 USA. EM mmoates@uab.edu RI Magnuson, Mark/B-1335-2009 OI Magnuson, Mark/0000-0002-8824-6499 FU NIDDK NIH HHS [DK42502, DK42612] NR 33 TC 4 Z9 4 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD SEP PY 2004 VL 47 IS 9 BP 1632 EP 1640 DI 10.1007/s00125-004-1497-1 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 863TE UT WOS:000224584700021 PM 15365616 ER PT J AU Nelson, KM Geiger, AM Mangione, CM AF Nelson, KM Geiger, AM Mangione, CM TI Racial and ethnic variation in response to mailed and telephone surveys among women in a managed care population SO ETHNICITY & DISEASE LA English DT Article DE data collection/methods; ethnic groups; health surveys ID CERVICAL-CANCER; HEALTH SURVEY; ANGLO WOMEN; RESPONDENTS; NONRESPONSE; HISPANICS; BEHAVIOR; LATINAS; BELIEFS; BREAST AB Purpose: To describe the characteristics of participants who completed a mailed survey, compared to those initial non-responders who completed the same survey over the telephone. Study Design and Patient Populations: We conducted a mailed survey, in both Spanish and English, among women with abnormal Pap smears, who were members of a large managed care organization. Telephone follow up for non-responders was performed by a bilingual interviewer. A 20-minute long distance telephone card was offered as an incentive to individuals who completed the telephone survey. We used bivariate and multivariate analyses to describe the population characteristics of respondents who replied by mail, as compared to those who completed the survey by telephone. Results: Of the 1049 potentially eligible participants, 733 women completed the survey, for an overall response rate of 70%. Fifty-six percent (N=411) of the surveys were received by mail, and 44% (N=322) were completed by telephone. Thirty-four percent of the telephone surveys were completed in Spanish, compared to 13% of the mailed surveys (P<.001). Telephone respondents were less satisfied with their health care than were those who responded by mail. Conclusions: Among this insured cohort of women, Latinas who completed the survey in Spanish were more likely to participate in a telephone survey that offered an incentive, than in a mailed survey. These findings should be considered when planning health surveys in this population. C1 VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. So Calif Permanente Med Grp, Dept Res & Evaluat, Pasadena, CA USA. Univ Calif Los Angeles, Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA. RP Nelson, KM (reprint author), VA Puget Sound Med Ctr, S-111 GIMC,1660 S Columbian Way, Seattle, WA 98108 USA. EM karin.nelson@med.va.gov FU NCI NIH HHS [1F32 CA 88495-01] NR 23 TC 3 Z9 3 U1 1 U2 1 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X J9 ETHNIC DIS JI Ethn. Dis. PD FAL PY 2004 VL 14 IS 4 BP 580 EP 583 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 866GK UT WOS:000224761800017 PM 15724779 ER PT J AU Rumsfeld, JS Masoudi, FA AF Rumsfeld, JS Masoudi, FA TI Heart failure disease management works, but will it succeed? SO EUROPEAN HEART JOURNAL LA English DT Editorial Material ID QUALITY-OF-CARE; TASK-FORCE; GUIDELINES; PROGRAM AB This editorial refers to "The effectiveness of disease management programmes in reducing hospital readmission in older patients with heart failure: a systematic review and meta-analysis of published reports" by J. Gonseth et al. on page 1570 and "Heart failure clinics and outpatient management: review of the evidence and call for quality assurance" by F. Gustafssofi and J.M.O. Arnold on page 1596(dagger). C1 Univ Colorado, Denver Hlth Med Ctr, Denver VA Med Ctr, Hlth Sci Ctr, Denver, CO 80220 USA. RP Rumsfeld, JS (reprint author), Univ Colorado, Denver Hlth Med Ctr, Denver VA Med Ctr, Hlth Sci Ctr, Cardiol CV Outcomes Res 111B,1055 Clermont St, Denver, CO 80220 USA. EM john.rumsfetd@med.va.gov NR 15 TC 11 Z9 13 U1 1 U2 2 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0195-668X J9 EUR HEART J JI Eur. Heart J. PD SEP PY 2004 VL 25 IS 18 BP 1565 EP 1567 DI 10.1016/j.ehj.2004.08.004 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 856PC UT WOS:000224056100003 PM 15351155 ER PT J AU Shea, JA Beers, BB McDonald, VJ Quistberg, A Ravenell, KL Asch, DA AF Shea, JA Beers, BB McDonald, VJ Quistberg, A Ravenell, KL Asch, DA TI Assessing health literacy in African American and Caucasian adults: Disparities in rapid estimate of adult literacy in medicine (REALM) scores SO FAMILY MEDICINE LA English DT Article ID KNOWLEDGE; ASSOCIATION; CARE AB Background and Objectives: The influence of literacy on health and health care is an important area of investigation. Studies with a literacy focus are most valuable when literacy is assessed with psychometrically sound instruments. Methods: This study used a prospective cohort sample of 1,610 primary care patients. Patients provided sociodemographics and took the Rapid Estimate of Adult Literacy in Medicine (REALM), a 66-item word pronunciation literacy test. Results: The sample was 65% African American; 66% were men; 51% had a high school education or less. REALM scores were significantly related to education, age, and race but not gender When stratified by education, differences between African Americans and Caucasians remained significant. Using 19 different strategies to shorten the 66-item instrument, reliability coefficients above .80 were maintained. Conclusions: The REALM is a robust assessment of health literacy. However, the discordance in scores between African Americans and Caucasians with similar educational attainment needs to be further addressed. A much shorter instrument would still have internally consistent scores and potentially be more useful in clinical settings. C1 Univ Penn, CHERP, Philadelphia, PA 19104 USA. Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Shea, JA (reprint author), Univ Penn, CHERP, 1223 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM sheaja@mail.med.upenn.edu RI Quistberg, D Alex/C-7953-2009 OI Quistberg, D Alex/0000-0001-9730-2686 NR 24 TC 46 Z9 48 U1 2 U2 3 PU SOC TEACHERS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, STE 540, LEAWOOD, KS 66207 USA SN 0742-3225 J9 FAM MED JI Fam. Med. PD SEP PY 2004 VL 36 IS 8 BP 575 EP 581 PG 7 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 852BQ UT WOS:000223730600011 PM 15343419 ER PT J AU Chew, LD Bradley, KA Boyko, EJ AF Chew, LD Bradley, KA Boyko, EJ TI Brief questions to identify patients with inadequate health literacy SO FAMILY MEDICINE LA English DT Article ID MANAGED CARE ORGANIZATION; MEDICARE ENROLLEES; HOSPITAL ADMISSION; DIAGNOSTIC-TEST; KNOWLEDGE; SKILLS; INSTRUMENT; EDUCATION; ABILITY; ADULTS AB Background and Objectives: No practical method for identifying patients with low heath literacy exists. We sought to develop screening questions for identifying patients with inadequate or marginal health literacy. Methods: Patients (n=332) at a VA preoperative clinic completed in-person interviews that included 16 health literacy screening questions on a 5-point Likert scale, followed by a validated health literacy measure, the Short Test of Functional Health Literacy in Adults (STOHFLA). Based on the STOFHLA, patients were classified as having either inadequate, marginal, or adequate health literacy. Each of the 16 screening questions was evaluated and compared to two comparison standards: (1) inadequate health literacy and (2) inadequate or marginal health literacy on the STOHFLA. Results: Fifteen participants (4.5%) had inadequate health literacy and 25 (7.5%) had marginal health literacy on the STOHFLA. Three of the screening questions, "How often do you have someone help you read hospital materials?" "How confident are you filling out medical forms by yourself?" and "How often do you have problems learning about your medical condition because of difficulty understanding written information?" were effective in detecting inadequate health literacy (area under the receiver operating characteristic curve of 0.87, 0.80, and 0.76, respectively). These questions were weaker for identifying patients with marginal health literacy. Conclusions: Three questions were each effective screening tests for inadequate health literacy in this population. C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Ctr Excellence, Seattle, WA 98101 USA. VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98101 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Chew, LD (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Ctr Excellence, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM lchew@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X FU NIAAA NIH HHS [K23AA00313] NR 29 TC 461 Z9 464 U1 4 U2 54 PU SOC TEACHERS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, STE 540, LEAWOOD, KS 66207 USA SN 0742-3225 J9 FAM MED JI Fam. Med. PD SEP PY 2004 VL 36 IS 8 BP 588 EP 594 PG 7 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 852BQ UT WOS:000223730600013 PM 15343421 ER PT J AU Lau, DTY Membreno, FE AF Lau, DTY Membreno, FE TI Antiviral therapy for treatment-naive hepatitis B virus patients SO GASTROENTEROLOGY CLINICS OF NORTH AMERICA LA English DT Article ID TERM-FOLLOW-UP; E-ANTIGEN SEROCONVERSION; ADEFOVIR DIPIVOXIL THERAPY; INTERFERON-ALPHA TREATMENT; LAMIVUDINE THERAPY; UNITED-STATES; ACUTE EXACERBATION; HBEAG SEROCONVERSION; COMBINATION THERAPY; POSITIVE PATIENTS AB Hepatitis B virus infection is a major public health problem worldwide, responsible for considerable morbidity and mortality from chronic liver disease. It is estimated that there are 350 million hepatitis B virus carriers globally. The prevalence of chronic hepatitis B infection varies greatly in different regions of the world. In the United States, approximately 1.5 million people are infected and 50,000 to 100,000 new cases are reported annually despite the availability of effective vaccines. This article reviews various antiviral therapies for treatment-naive hepatitis B virus patients. C1 Univ Texas, Med Branch, Dept Internal Med, Div Gastroenterol & Hepatol, Galveston, TX 77555 USA. Denver Vet Affairs Med Ctr, Eastern Colorado Hlth Care Syst, Gastroenterol & Hepatol Sect, Denver, CO 80220 USA. RP Lau, DTY (reprint author), Univ Texas, Med Branch, Dept Internal Med, Div Gastroenterol & Hepatol, 4106 McCullough Bldg,301 Univ Blvd, Galveston, TX 77555 USA. EM dalau@utmb.edu NR 68 TC 4 Z9 7 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0889-8553 J9 GASTROENTEROL CLIN N JI Gastroenterol. Clin. North Am. PD SEP PY 2004 VL 33 IS 3 BP 581 EP + DI 10.1016/j.gtc.2004.04.008 PG 21 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 852JU UT WOS:000223752400009 PM 15324945 ER PT J AU Yu, CE Devlin, B Galloway, N Loomis, E Schellenberg, GD AF Yu, CE Devlin, B Galloway, N Loomis, E Schellenberg, GD TI ADLAPH: A molecular haplotyping method based on allele-discriminating long-range PCR SO GENOMICS LA English DT Article DE molecular haplotyping; long-range PCR; apolipoprotein E; APOE ID HUMAN APOLIPOPROTEIN-E; SINGLE-NUCLEOTIDE POLYMORPHISMS; EXPECTATION-MAXIMIZATION ALGORITHM; LINKAGE DISEQUILIBRIUM; ALZHEIMERS-DISEASE; E GENE; DNA-POLYMERASE; GENOTYPE DATA; HUMAN GENOME; APOE GENE AB We present a method, called Allele-Discriminating Long and Accurate PCR Haplotyping (ADLAPH), for directly determining haplotypes from an extended genomic region. This method uses allele-discriminating primers in long-range PCR to amplify only one of the two chromosome homologues for the region of interest. Haplotypes are then determined from these phase-separated PCR fragments by conventional single nucleotide polymorphism (SNP) genotyping methods. This simple robust procedure makes it practical for high-throughput haplotyping of unrelated individuals, and potentially allows direct observation of haplotype information for up to 40 kb or more. We demonstrate the feasibility of this molecular haplotyping procedure by generating apolipoprotein E (APOE) haplotypes from 100 unrelated subjects. Published by Elsevier Inc. C1 Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. Univ Washington, Sch Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. Univ Washington, Sch Med, Div Neurogenet, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA. RP Yu, CE (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, 1660 S Columbian Way, Seattle, WA 98108 USA. EM changeyu@u.washington.edu FU NIA NIH HHS [AG21544, P50 AG05136]; NIMH NIH HHS [R01 MH057881, MH057881] NR 53 TC 15 Z9 16 U1 1 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0888-7543 J9 GENOMICS JI Genomics PD SEP PY 2004 VL 84 IS 3 BP 600 EP 612 DI 10.1016/j.ygeno.2004.06.003 PG 13 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 847QD UT WOS:000223409100017 PM 15498468 ER PT J AU Woods, SP Rippeth, JD Frol, AB Levy, JK Ryan, E Soukup, VM Hinkin, CH Lazzaretto, D Cherner, M Marcotte, TD Gelman, BB Morgello, S Singer, EJ Grant, I Heaton, RK AF Woods, SP Rippeth, JD Frol, AB Levy, JK Ryan, E Soukup, VM Hinkin, CH Lazzaretto, D Cherner, M Marcotte, TD Gelman, BB Morgello, S Singer, EJ Grant, I Heaton, RK TI Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article ID NEUROPSYCHOLOGICAL IMPAIRMENT; INFECTED INDIVIDUALS; PERFORMANCE STATUS; WORKING-MEMORY; DISEASE; DISORDERS; CLASSIFICATION; SCHIZOPHRENIA; COEFFICIENTS; DYSFUNCTION AB We examined the interrater reliability (IRR) of clinical ratings of neuropsychological (NP) impairment and neurocognitive diagnoses in HIV. Thirty participants with advanced HIV-infection who were enrolled in a multicenter HIV brain banking research project underwent comprehensive NP and neuromedical evaluations. Using a standardized system of guidelines, neuropsychologists from six participating sites independently assigned clinical ratings of NP impairment, as well as multilevel diagnoses reflecting the inferred etiology of the impairments and their effects on everyday functioning. Findings indicated excellent IRR in rating the presence and severity of NP impairment, but overall modest IRR for neurocognitive diagnoses. Not surprisingly, most diagnostic disagreements concerned the etiology of impairments in persons with medical and neuropsychiatric risk factors in addition to HIV. C1 Univ Calif San Diego, HIV Neurobehav Res Ctr, Dept Psychiat 0603H, San Diego, CA 92103 USA. Univ Texas, SW Med Ctr, Dallas, TX USA. Baylor Coll Med, Houston, TX 77030 USA. CUNY Mt Sinai Sch Med, New York, NY 10029 USA. Univ Texas, Med Branch, Galveston, TX 77550 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif San Diego, VA San Diego Healthcare Syst, San Diego, CA 92103 USA. RP Woods, SP (reprint author), Univ Calif San Diego, HIV Neurobehav Res Ctr, Dept Psychiat 0603H, 150 W Washington St,2nd Floor, San Diego, CA 92103 USA. EM spwoods@ucsd.edu FU NIMH NIH HHS [R24MH59745, P30 MH62512-01, R24MH59656, R24MH59724]; NINDS NIH HHS [R24NS38841, R24NS45491] NR 68 TC 154 Z9 155 U1 1 U2 4 PU SWETS ZEITLINGER PUBLISHERS PI LISSE PA P O BOX 825, 2160 SZ LISSE, NETHERLANDS SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD SEP PY 2004 VL 26 IS 6 BP 759 EP 778 DI 10.1080/13803390490509565 PG 20 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 865LX UT WOS:000224705700004 PM 15370374 ER PT J AU Franco, GEL O'Neil, TK Litscher, SJ Urban-Piette, M Blank, RD AF Franco, GEL O'Neil, TK Litscher, SJ Urban-Piette, M Blank, RD TI Accuracy and precision of PIXImus densitometry for ex vivo mouse long bones SO JOURNAL OF CLINICAL DENSITOMETRY LA English DT Article DE bone mineral density (BMD); bone mineral content (BMC); dual energy X-ray absorptiometry (DXA) mouse; accuracy; precision ID QUANTITATIVE TRAIT LOCI; X-RAY ABSORPTIOMETRY; MINERAL DENSITY; INBRED STRAINS; FAN-BEAM; MICE; C57BL/6J; STRENGTH; C3H/HEJ; FEMUR AB Many densitometric studies in mice assess bone mineral density (BMD) at specified regions of interest, often using ex vivo specimens. In the present study, we sought to determine the precision and accuracy of ex vivo densitometry of mouse bones, comparing two software versions and two data acquisition techniques. The newer software allows manual adjustment of the threshold value for bone, improving the ability to analyze bone edges correctly. Root mean square standard deviations were 2-3 mg/cm(2), with coefficients of variation ranging between 3% and 5% for femora and humeri and between 6% and 7% for radii. The regression coefficients for bone mineral content as a function of ash mass were near 1 for femora and humeri, but considerably lower for radii. Coefficients of determination were inversely related to bone size, with R-2 values exceeding 0.9 at the femur, 0.8 at the humerus, and ranging between 0.3 and 0.6 at the radius. We found that our instrument has a position artifact, with BMD and bone mineral content dependent on the specimen's coordinates in the scanned field. Our findings establish the limitations of ex vivo densitometry with the PIXImus and support our recommendation that investigators seek position artifacts in their instruments. C1 Univ Wisconsin, Sch Med, Dept Med, Endocrinol Sect, Madison, WI 53792 USA. William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. RP Blank, RD (reprint author), Univ Wisconsin, Sch Med, Dept Med, Endocrinol Sect, H4-556 CSC 5148,600 Highland Ave, Madison, WI 53792 USA. EM rdb@medicine.wisc.edu NR 14 TC 18 Z9 18 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1094-6950 J9 J CLIN DENSITOM JI J. Clin. Densitom. PD FAL PY 2004 VL 7 IS 3 BP 326 EP 333 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 850QP UT WOS:000223627800012 ER PT J AU Lara-Castro, C Garvey, WT AF Lara-Castro, C Garvey, WT TI Diet, insulin resistance, and obesity: Zoning in on data for Atkins dieters living in South Beach SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID HIGH-CARBOHYDRATE DIET; LOW-FAT DIET; CARDIOVASCULAR RISK-FACTORS; CONJUGATED LINOLEIC-ACID; CORONARY-ARTERY DISEASE; TREATMENT PANEL-III; WEIGHT-LOSS; METABOLIC SYNDROME; SATURATED FAT; GLUCOSE-METABOLISM AB Insulin resistance is a central pathogenic factor for the metabolic syndrome and is associated with both generalized obesity and the accumulation of fat in the omental and intramyocellular compartments. In the context of the current obesity epidemic, it is imperative to consider diets in terms of their ability to both promote weight loss and ameliorate insulin resistance. Weight loss under any dietary formulation depends on hypocaloric intake, and only moderate weight loss (5 - 10%) is sufficient to augment insulin sensitivity. However, increments in insulin sensitivity may be more directly related to loss of intramyocellular or omental fat rather than loss of total body weight per se. The widespread acceptance of popular low-carbohydrate high-fat diets (e.g. Atkins Diet, Zone Diet, South Beach diet) further underscores the need to evaluate dietary interventions regarding their safety and metabolic effects. These high-fat diets have been shown to be safe in the short term; however, their long-term safety has not been established. With respect to insulin sensitivity, diets enriched in saturated fats can induce insulin resistance, whereas fat substitution with monounsaturated fats can enhance insulin sensitivity. On the other hand, high-fiber, high-carbohydrate diets comprised of foods with low caloric density can similarly be used for effective weight reduction and to ameliorate insulin resistance. Although some data suggest that low-glycemic index diets are most advantageous in this regard, these effects may have more to do with increments in dietary fiber than differences in available carbohydrates. Popular low-carbohydrate, high-fat diets are being fervently embraced as an alternative to challenging modifications in lifestyle and intentional calorie reduction. Current data do not support such unbridled enthusiasm for these diets, particularly in relationship to high-fiber, high-carbohydrate diets emphasizing intake of fresh vegetables and fruits. Long-term studies to determine the efficacy and safety of both popular and experimental diets are warranted. C1 Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Garvey, WT (reprint author), Univ Alabama, Dept Nutr Sci, Webb 232,1675 Univ Blvd, Birmingham, AL 35294 USA. EM garveyt@uab.edu FU NCRR NIH HHS [M01-RR-1070, M01-RR-00032]; NHLBI NIH HHS [P01 HL-55782]; NIDDK NIH HHS [DK-38764] NR 95 TC 55 Z9 56 U1 1 U2 12 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD SEP PY 2004 VL 89 IS 9 BP 4197 EP 4205 DI 10.1210/jc.2004-0683 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 852GM UT WOS:000223743600001 PM 15356006 ER PT J AU Natarajan, S Nietert, PJ AF Natarajan, S Nietert, PJ TI Hypertension, diabetes, hypercholesterolemia, and their combinations increased health care utilization and decreased health status SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE diabetes mellitus; hypertension; hypercholesterolemia; emergency treatment; hospitalization; office visits; health status ID CORONARY HEART-DISEASE; RESOURCE UTILIZATION; CIGARETTE-SMOKING; ILLNESS BEHAVIOR; RISK-FACTORS; CHOLESTEROL; OUTCOMES; BENEFITS; ACCESS; RATES AB Background and objective: For individuals with hypertension, diabetes, or hypercholesterolemia, the relative magnitude of cardiovascular risk factors and the effect of multiple risk factors remains controversial and both treatment practices and health care usage vary. We sought to determine the effect of hypertension, diabetes, hypercholesterolemia, and their combinations on health care utilization and health status through analysis of data from a large national survey. Methods: We applied the Anderson model to a cross-sectional representative sample (n = 15,107) of the U.S. civilian, noninstitutionalized population (the 1996 Medical Expenditure Panel Survey). Results: For diabetes, additional risk factors did not increase the likelihood of emergency room (ER) visits or hospitalizations but were associated with increased outpatient visits and poorer health status. For hypertension, additional risk factors increased the likelihood of hospitalization (but not ER visits), the number of outpatient visits, and poorer health status. For hypercholesterolemia, additional risk factors were associated with increased likelihood of ER visits, hospitalizations, and poorer health status but not more outpatient visits. Diabetes had the largest effect on health care utilization and health status. Conclusion: These findings re-emphasize the magnitude of diabetes as a major risk factor associated with increased ER visits, hospitalizations, outpatients visits, and lower health status. (C) 2004 Elsevier Inc. All rights reserved. C1 Med Univ S Carolina, Div Gen Internal Med, Ctr Hlth Care Res, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Natarajan, S (reprint author), Med Univ S Carolina, Div Gen Internal Med, Ctr Hlth Care Res, 135 Cannon St,Suite 403,POB 250837, Charleston, SC 29425 USA. EM nataraja@musc.edu OI Nietert, Paul/0000-0002-3933-4986 NR 36 TC 17 Z9 18 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD SEP PY 2004 VL 57 IS 9 BP 954 EP 961 DI 10.1016/j.jclinepi.2004.01.011 PG 8 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 870YB UT WOS:000225093700009 PM 15504638 ER PT J AU Shapiro, M Chren, MM Levy, RM Elder, DE LeBoit, PE Mihm, MC Margolis, DJ Gimotty, PA Ming, ME AF Shapiro, M Chren, MM Levy, RM Elder, DE LeBoit, PE Mihm, MC Margolis, DJ Gimotty, PA Ming, ME TI Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Article; Proceedings Paper CT 39th Annual Meeting of the American-Society-of-Dermatopathology CY OCT 10-13, 2002 CL PHOENIX, ARIZONA SP Amer Soc Dermatopathol ID CONSENSUS DEVELOPMENT PROGRAM; ACQUIRED MELANOCYTIC NEVI; EARLY MELANOMA; CUTANEOUS MELANOMA; RISK FACTOR; DNA-REPAIR; CONFERENCES; BENIGN; DISSEMINATION; TERMINOLOGY AB Background: Although a nevus with the microscopic features of a 'dysplastic nevus' is commonly seen, the nomenclature used to describe such a lesion has been thought to be inconsistent. A 1992 National Institutes of Health (NIH) Consensus Conference sought to unify nomenclature and suggested that the term 'nevus with architectural disorder' be used along with a comment on melanocytic atypia. Methods: We performed a cross-sectional mail survey to determine preferred terminology as well as the level of adherence to the NIH-recommended nomenclature. All 856 active members of the American Society of Dermatopathology (ASDP) and 1100 (13.0%) of the 8471 active members of the American Academy of Dermatology (AAD) were surveyed. Results: Five hundred and thirty-three ASDP members and 483 AAD members who fulfilled eligibility criteria completed the questionnaire. The term 'dysplastic nevus' was favored by the largest number of responders (favored by 39.1% of ASDP members and 62.3% of AAD members), while the 1992 NIH Consensus Conference-recommended terminology was the second most popular term (25.3% of ASDP and 15.1% of AAD members). Dermatopathologists (OR=1.9, p=0.0001) and those who had dual training in dermatology and dermatopathology (OR=1.6, p=0.02 for ASDP members; OR=2.3, p=0.02 for AAD members) were more likely to adhere to the 1992 NIH Consensus Conference nomenclature. Conclusions: Despite attempts to unify nomenclature for microscopically dysplastic nevi through the NIH Consensus Conference, wide variation in terminology persists. C1 Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. Univ Penn, Sch Med, Dept Biostat, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Epidemiol, Philadelphia, PA 19104 USA. RP Ming, ME (reprint author), Hosp Univ Penn, Dept Dermatol, 2 Maloney Bldg,3600 Spruce St, Philadelphia, PA 19104 USA. EM mmingmd@yahoo.com NR 58 TC 31 Z9 31 U1 0 U2 0 PU BLACKWELL MUNKSGAARD PI COPENHAGEN PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD SEP PY 2004 VL 31 IS 8 BP 523 EP 530 DI 10.1111/j.0303-6987.2004.00216.x PG 8 WC Dermatology; Pathology SC Dermatology; Pathology GA 840EJ UT WOS:000222839600002 PM 15268706 ER PT J AU Mishory, A Molnar, C Koola, J Li, XB Kozel, FA Myrick, H Stroud, Z Nahas, Z George, MS AF Mishory, A Molnar, C Koola, J Li, XB Kozel, FA Myrick, H Stroud, Z Nahas, Z George, MS TI The maximum-likelihood strategy for determining transcranial magnetic stimulation motor threshold, using parameter estimation by sequential testing is faster than conventional methods with similar precision SO JOURNAL OF ECT LA English DT Article DE transcranial magnetic stimulation; motor threshold; excitability; parameter estimation by sequential testing; algorithm; maximum-likelihood strategy; method ID CORTICOMOTOR THRESHOLD; DEPRESSION AB The resting motor threshold (rMT) is the basic unit of transcranial magnetic stimulation (TMS) dosing. Traditional methods of determining rMT involve finding a threshold of either visible movement or electromyography (EMG) motor-evoked potentials, commonly approached from above and below and then averaged. This time-consuming method typically uses many TMS pulses. Mathematical programs can efficiently determine a threshold by calculating the next intensity needed based on the prior results. Within our group of experienced TMS researchers, we sought to perform an illustrative study to compare one of these programs, the Maximum-Likelihood Strategy using Parameter Estimation by Sequential Testing (MLS-PEST) approach, to a modification of the traditional International Federation of Clinical Neurophysiology (IFCN) method for determining rMT in terms of the time and pulses required and the rMT value. C1 Med Univ S Carolina, Brain Stimulat Lab, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA. RP Mishory, A (reprint author), Med Univ S Carolina, Brain Stimulat Lab, 502 N,67 President St, Charleston, SC 29425 USA. EM mishory@musc.edu RI Kozel, Frank/I-5366-2012 FU NCRR NIH HHS [R01 RR 14080-02, R01 RR14080-01]; NIAAA NIH HHS [2 P50 AA10761-03]; NINDS NIH HHS [R01 NS40956-1] NR 16 TC 48 Z9 48 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1095-0680 J9 J ECT JI J. ECT PD SEP PY 2004 VL 20 IS 3 BP 160 EP 165 DI 10.1097/00124509-200409000-00007 PG 6 WC Behavioral Sciences; Psychiatry SC Behavioral Sciences; Psychiatry GA 856TN UT WOS:000224068000008 PM 15343000 ER PT J AU Gordon, HS Paterniti, DA Wray, NP AF Gordon, HS Paterniti, DA Wray, NP TI Race and patient refusal of invasive cardiac procedures SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 25th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 02-04, 2002 CL ATLANTA, GA SP Soc Gen Internal Med DE patient acceptance of health care; treatment refusal; ethnic groups; racial variation; coronary artery disease ID CORONARY-REVASCULARIZATION PROCEDURES; UNDERSTANDING RACIAL VARIATION; ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR PROCEDURES; SEX-DIFFERENCES; ETHNIC DISPARITIES; CLINICAL METHOD; MEDICAL-CENTER; HEALTH-CARE; VETERANS AB OBJECTIVE: To determine whether patients' decisions are an important determinant of nonuse of invasive cardiac procedures and whether decisions vary by race. DESIGN: Observational prospective cohort. PARTICIPANTS: Patients (N= 681) enrolled at the exercise treadmill or the cardiac catheterization laboratories at a large Veterans Affairs hospital. MEASURES: Doctors' recommendations and patients' decisions were determined by both direct observation of doctor and patient verbal behavior and by review of medical charts. Performance of coronary angiography, angioplasty, and bypass surgery were determined by chart review for a minimum of 3 months follow-up. RESULTS: Coronary angiography was recommended after treadmill testing for 83 of 375 patients and 72 patients underwent angiography. Among 306 patients undergoing angiography, recommendations for coronary angioplasty or bypass surgery were given to 113 and 45 patients and were completed for 98 and 33 patients, respectively. Recommendations were not significantly different by race. However, 4 of 83 (4.8%) patients declined or did not return for recommended angiograms and this was somewhat more likely among black and Hispanic patients, compared with white patients (13% and 33% vs 2%; P= .05). No patients declined angioplasty and 2 of 45 (4.4%) patients declined or did not return for recommended bypass surgery. Other recommended procedures were not completed after further medical evaluation (n= 32). There was no difference (P > .05) by race/ethnicity in doctor-level reasons for nonreceipt of recommended invasive cardiac procedures. CONCLUSIONS: Patient decisions to decline recommended invasive cardiac procedures were infrequent and may explain only a small fraction of racial disparities in the use of invasive cardiac procedures. C1 Baylor Coll Med, Dept Internal Med, Houston Ctr Qual Care & Utilizat Studies, Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Dept Internal Med, Sect Hlth Serv Res, Houston, TX 77030 USA. Univ Calif Davis, Dept Internal Med & Sociol, Ctr Hlth Serv Res Primary Care, Sacramento, CA 95817 USA. RP Gordon, HS (reprint author), Houston VAMC, 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM hgordon@bcm.tmc.edu RI Gordon, Howard/E-4420-2010 OI Gordon, Howard/0000-0002-6712-5954 NR 31 TC 23 Z9 23 U1 1 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2004 VL 19 IS 9 BP 962 EP 966 DI 10.1111/j.1525-1497.2004.30131.x PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 847OL UT WOS:000223404700009 PM 15333061 ER PT J AU Matute-Bello, G Lee, JS Frevert, CW Liles, WC Sutlief, S Ballman, K Wong, V Selk, A Martin, TR AF Matute-Bello, G Lee, JS Frevert, CW Liles, WC Sutlief, S Ballman, K Wong, V Selk, A Martin, TR TI Optimal timing to repopulation of resident alveolar macrophages with donor cells following total body irradiation and bone marrow transplantation in mice SO JOURNAL OF IMMUNOLOGICAL METHODS LA English DT Article DE adoptive transfer; alveolar macrophages; total body irradiation; bone marrow transplantation ID EMIGRATION; MONOCYTES; INJURY AB To determine the time required to repopulate mouse lungs with donor alveolar macrophages following total body irradiation (TBI) and bone marrow transplantation (BMT), C57BI/6 mice were subjected to TBI with 900 cGy, followed by transplantation of bone marrow cells from mice expressing green fluorescent protein (GFP) in their somatic cells. The mice were euthanized at either 30 (n=5), 60 (n=5) or 90 (n=5) days following BMT. Thirty days following transplantation, 87.8+/-3.9% (mean+/-S.E.M.) circulating leukocytes in recipient mice were derived from the donor, as determined by fluorescence activated cell sorting (FACS) analysis for GFP. However, only 46.9+/-7.4% of the resident alveolar cells expressed GFP, indicating incomplete repopulation. By day 60 post-transplantation, the percentage of bronchoalveolar lavage fluid (BALF) cells expressing GFP reached 74.5+/-2.4%, remaining stable 90 days after transplantation (80.4+/-1.9%). We conclude that 60 days after TBI with 900 cGy and bone marrow transplantation, the majority of the lung resident alveolar macrophages is of donor origin. This study provides useful information regarding the time of reconstitution with donor alveolar macrophages in the pulmonary airspaces of recipient mice following marrow transplantation. (C) 2004 Elsevier B.V. All rights reserved. C1 Univ Washington, Dept Med, Div Pulm & Crit Care, Seattle, WA 98108 USA. VA Puget Sound Healthcare Syst, Med Res Serv, Seattle, WA USA. Univ Washington, Dept Med, Div Allergy & Infect Dis, St Louis, MO 63130 USA. VA Puget Sound Healthcare Syst, Sect Radiat Oncol, Seattle, WA USA. RP Martin, TR (reprint author), Univ Washington, Dept Med, Div Pulm & Crit Care, 1660 S Columbian Way,GMR 151-L, Seattle, WA 98108 USA. EM trmartin@u.washington.edu FU NHLBI NIH HHS [HL62995, HL70178, HL70840]; PHS HHS [65892] NR 11 TC 48 Z9 48 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-1759 J9 J IMMUNOL METHODS JI J. Immunol. Methods PD SEP PY 2004 VL 292 IS 1-2 BP 25 EP 34 DI 10.1016/j.jim.2004.05.010 PG 10 WC Biochemical Research Methods; Immunology SC Biochemistry & Molecular Biology; Immunology GA 854WT UT WOS:000223935200003 PM 15350509 ER PT J AU Graville, DJ Cohen, JI Rau, MT AF Graville, DJ Cohen, JI Rau, MT TI Acoustic parameters that identify listeners' perceptions of good near-total laryngectomy voice SO JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY LA English DT Article ID TRACHEOESOPHAGEAL SPEECH; FREQUENCY; SPEAKERS; SHUNT AB Ten near-total laryngectomy (NTL) speakers performed a number of voicing tasks that were recorded for acoustic, temporal, and aerodynamic feature analysis. A paired comparison within groups design was used to objectify the perceptual parameters that constitute good near-total laryngectomized voice. The pairs were judged by three speech-language pathologist who chose which subject sounded "most like normal." The judgments were used to assign the NTL speakers into three groups (Most Like Normal, Middle, Least Like Normal). The analysis revealed that listeners could reliably rate NTL speakers as Most Like Normal (MLN). A correlation was found between listener ratings and the acoustic parameter shimmer (r = .684, p = .021). No other significant correlations were noted. A step-wise regression revealed that speaker rating could be predicted by shimmer, H/N ratio, jitter, weight, and flow. These parameters accounted for 93% of the variance. C1 Oregon Hlth Sci Univ, Dept Otolaryngol, NW Clin Voice & Swallowing, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR USA. RP Graville, DJ (reprint author), Oregon Hlth Sci Univ, Dept Otolaryngol, NW Clin Voice & Swallowing, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM graville@ohsu.edu NR 23 TC 1 Z9 1 U1 0 U2 0 PU DELMAR LEARNING PI CLIFTON PARK PA EXECUTIVE WOODS, 5 MAXWELL DR, CLIFTON PARK, NY 12065 USA SN 1065-1438 J9 J MED SPEECH-LANG PA JI J. Med. Speech-Lang. Pathol. PD SEP PY 2004 VL 12 IS 3 BP 107 EP 116 PG 10 WC Audiology & Speech-Language Pathology; Clinical Neurology SC Audiology & Speech-Language Pathology; Neurosciences & Neurology GA 853RZ UT WOS:000223846600007 ER PT J AU Brickman, AM Buchsbaum, MS Bloom, R Bokhoven, P Paul-Odouard, R Haznedar, MM Dahlman, KL Hazlett, EA Aronowitz, J Heath, D Shihabuddin, L AF Brickman, AM Buchsbaum, MS Bloom, R Bokhoven, P Paul-Odouard, R Haznedar, MM Dahlman, KL Hazlett, EA Aronowitz, J Heath, D Shihabuddin, L TI Neuropsychological functioning in first-break, never-medicated adolescents with psychosis SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article; Proceedings Paper CT 9th International Congress on Schizophrenia Research CY MAR 29-APR 02, 2003 CL Colorado Springs, CO DE cognition; neuropsychological functioning; adolescent; psychosis; schizophrenia ID CHILDHOOD-ONSET SCHIZOPHRENIA; FIRST-EPISODE SCHIZOPHRENIA; GLUCOSE METABOLIC-RATE; 1ST-EPISODE SCHIZOPHRENIA; COGNITIVE IMPAIRMENT; GENDER DIFFERENCES; SEX-DIFFERENCES; STRIATAL SIZE; DEFICITS; DISORDER AB The purpose of the current study was to examine neuropsychological functioning in a group of never-medicated first-break adolescents with psychosis. It is the first report of cognition in a sample of adolescents with psychosis in which all patients were drug-naive. Twenty-nine adolescent patients (mean age = 16.07; SD = 2.00; 15 male and 14 female patients) experiencing their first psychotic episode and 17 age-matched and sex-matched normal volunteers (mean age = 16.88; SD = 2.39; 9 male and 8 female subjects) were recruited and assessed with a neuropsychological battery. Measures of attention, memory, language, executive functioning, perceptual motor processing, and motor speed were obtained. Psychiatric symptomatology, estimated verbal IQ, and parental socioeconomic status were also determined. Patients with psychosis were significantly more impaired than normal volunteers; effect sizes were greatest in the areas of executive functioning, attention, and memory, and significantly smaller in areas of language, perceptual motor processing, and motor speed. The pattern was not altered when differences in verbal IQ and parental socioeconomic status were controlled. Sex and age interactions indicated that younger male patients were particularly impaired. The findings demonstrate neuropsychological deficits in adolescents with psychosis and suggest that cognitive deficits are core symptoms in psychotic disorders. C1 CUNY Mt Sinai Sch Med, Dept Psychiat, Neurosci PET Lab, New York, NY 10029 USA. Columbia Univ, Coll Phys & Surg, Taub Inst Res Alzheimer Dis & Aging Brain, New York, NY USA. Brown Med Sch, Dept Psychait & Behav Med, Providence, RI USA. Bronx Vet Adm Med Ctr, Dept Vet Affairs, Bronx, NY USA. RP Brickman, AM (reprint author), CUNY Mt Sinai Sch Med, Dept Psychiat, Neurosci PET Lab, Box 1505,1 Gustave L Levy Pl, New York, NY 10029 USA. FU NCRR NIH HHS [M01-RR-00071]; NIMH NIH HHS [MH56489, MH60023, MH60384S] NR 55 TC 55 Z9 56 U1 5 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD SEP PY 2004 VL 192 IS 9 BP 615 EP 622 DI 10.1097/01.nmd.0000138229.29157.3e PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 856GS UT WOS:000224034300006 PM 15348978 ER PT J AU Jiang, JF Borisenko, GG Osipov, A Martin, I Chen, RW Shvedova, AA Sorokin, A Tyurina, YY Potapovich, A Tyurin, VA Graham, SH Kagan, VE AF Jiang, JF Borisenko, GG Osipov, A Martin, I Chen, RW Shvedova, AA Sorokin, A Tyurina, YY Potapovich, A Tyurin, VA Graham, SH Kagan, VE TI Arachidonic acid-induced carbon-centered radicals and phospholipid peroxidation in cyclo-oxygenase-2-transfected PC12 cells SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE carbon-centered radical formation; cyclo-oxygenase-2 inhibitor; cyclo-oxygenase-2 transfection; PC12 cells; phosphatidylserine oxidation; radical spin-trapping ID PROSTAGLANDIN-H SYNTHASE-2; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD NEURONS; OXIDATIVE STRESS; OXYGEN RADICALS; ISCHEMIC BRAIN; CYTOCHROME-C; INDUCIBLE CYCLOOXYGENASE AB Cyclo-oxygenase-2 (COX-2) is believed to induce neuronal oxidative stress via production of radicals. While oxygen radicals are not directly involved in COX-2-catalytic cycle, superoxide anion radicals have been repeatedly reported to play a critical role in COX-2-associated oxidative stress. To resolve the controversy, we characterized production of free radicals in PC12 cells in which COX-2 expression was manipulated either genetically or by direct protein transfection and compared them with those generated by a recombinant COX-2 in a cell-free system. Using spin-traps alpha-(4-pyridyl-1-oxide)-N-t-butylnitrone, 5,5-dimethyl-1-pyrroline-N-oxide and 4-((9-acridinecarbonyl) amino)-2,2,6,6- tetramethylpiperidine-1-oxyl (Ac-Tempo), we observed arachidonic acid (AA)-dependent production of carbon-centered radicals by heme-reconstituted recombinant COX-2. No oxygen radicals or thiyl radicals have been detected. COX-2 also catalyzed AA-dependent one-electron co-oxidation of ascorbate to ascorbate radicals. Next, we used two different approaches of COX-2 expression in cells, PCXII cells which express isopropyl-1-thio-beta-D-galactopyranoside inducible COX-2, and PC12 cells transfected with COX-2 using a protein delivery reagent, Chariot. In both models, COX-2-dependent AA-induced generation of carbon-centered radicals was documented using spin-traps and Ac-Tempo. No oxygen radical formation was detected in COX-2-transfected cells by either spin-traps or fluorogenic probe, dihydroethidium. In the presence of ascorbate, AA-induced COX-2-dependent ascorbate radicals were detected. AA caused a significant and selective oxidation of one of the major phospholipids, phosphatidylserine (PS). PS was not a direct substrate for COX-2 but was co-oxidized in the presence of AA. The radical generation and PS oxidation were inhibited by COX-2 inhibitors, niflumic acid, nimesulide, or NS-398. Thus, COX-2 generated carbon-centered radicals but not oxygen radicals or thiyl radicals are responsible for oxidative stress in AA-challenged PC12 cells overexpressing COX-2. C1 Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. NIOSH, Hlth Effects Lab Div, Morgantown, WV USA. Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA. VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Kagan, VE (reprint author), Univ Pittsburgh, Dept Environm & Occupat Hlth, 3343 Forbes Ave, Pittsburgh, PA 15260 USA. EM kagan+@pitt.edu OI Tyurin, Vladimir/0000-0002-3474-1697; Sorokin, Andrey/0000-0002-5660-0190 FU NINDS NIH HHS [R01 NS037459, R01 NS037459-07, F05 NS 43922, NS 30318, NS 37459] NR 73 TC 44 Z9 47 U1 0 U2 4 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD SEP PY 2004 VL 90 IS 5 BP 1036 EP 1049 DI 10.1111/j.1471-4159.2004.02577.x PG 14 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 847CN UT WOS:000223366500002 PM 15312159 ER PT J AU Jones, RE Kitzerow, N Estrada, M Moes, N Vandenbark, A Offner, H Whitham, R Bourdette, D AF Jones, RE Kitzerow, N Estrada, M Moes, N Vandenbark, A Offner, H Whitham, R Bourdette, D TI Central nervous system antigen presenting cells develop from distinct subset of bone marrow cells SO JOURNAL OF NEUROIMMUNOLOGY LA English DT Meeting Abstract CT 7th International Congress of the International-Society-of-Neuroimmunology CY SEP 28-OCT 02, 2004 CL Venice, ITALY SP Int Soc Neuroimmunol C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Nancy Davis Ctr Walls, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-5728 J9 J NEUROIMMUNOL JI J. Neuroimmunol. PD SEP PY 2004 VL 154 IS 1-2 SI SI MA 211 BP 66 EP 66 PG 1 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 855VO UT WOS:000224003200216 ER PT J AU Liang, QH Liou, AKF Ding, YM Cao, GD Xiao, X Perez, RG Chen, J AF Liang, QH Liou, AKF Ding, YM Cao, GD Xiao, X Perez, RG Chen, J TI 6-hydroxydopamine induces dopaminergic cell degeneration via a caspase-9-mediated apoptotic pathway that is attenuated by caspase-9dn expression SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE MN9D; 6-OHDA; caspase; apoptosis; caspase-9dn ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; FOCAL CEREBRAL-ISCHEMIA; CYTOCHROME-C RELEASE; PARKINSONS-DISEASE; OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; MITOCHONDRIAL RELEASE; PRIMARY CULTURES; DEATH PROGRAM AB This study showed that primary dopaminergic neurons or the dopaminergic cell line MN9D, when exposed to 15 min of the parkinsonian toxin 6-hydroxydopamine (6-OHDA) in the range of 30-100 muM, underwent delayed degeneration and exhibited hallmarks of apoptosis. These results, along with the absence of any increase in lactate dehydrogenase (LDH) release from the degenerated cells, imply that apoptosis was the dominant mode of cell death. Moreover, a distinct elevation in the measured cellular activities of caspase-9 and -3 but not of caspase-8 points to the caspase-9/caspase-3 cascade as the predominant apoptotic pathway in the degeneration of dopaminergic neurons and MN9D cells. In addition, the presence of caspase-9 or -3 peptide inhibitors but not of caspase-8 inhibitor attenuated cell death significantly, supporting the notion that only the intrinsic apoptotic pathway is utilized to achieve cell death. Finally, overexpression of a mutant caspase-9 with dominant negative phenotype (caspase-9dn) in MN9D cells and primary dopaminergic neurons via the adenovirus and adenoassociated virus gene delivery system, respectively, conferred marked increases in tolerance to the toxicity of 6-OHDA. These results point to the intrinsic caspase-9/caspase-3 cascade as the predominant signaling pathway underlying dopaminergic cell death induced by 6-OHDA and suggest that gene delivery of caspase-9dn can attenuate this pathway and its degenerative consequences. (C) 2004 Wiley-Liss, Inc. C1 Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. Pittsburgh Inst Neurodegenerat Disorders, Pittsburgh, PA USA. Univ Chicago, Dept Neurol, Chicago, IL 60637 USA. Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA. Vet Affairs Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S507 Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15261 USA. EM chenj2@upmc.edu FU NINDS NIH HHS [P01 NS059806, NS44178, NS45048, NS43802, R01 NS044178] NR 60 TC 29 Z9 31 U1 1 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD SEP 1 PY 2004 VL 77 IS 5 BP 747 EP 761 DI 10.1002/jnr.20198 PG 15 WC Neurosciences SC Neurosciences & Neurology GA 852DL UT WOS:000223735300015 PM 15352222 ER PT J AU Wallis, RA Panizzon, KL AF Wallis, RA Panizzon, KL TI Simvastatin provides protection against CA1 traumatic neuronal injury SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 22nd Annual National-Neurotrauma-Society Symposium CY OCT 20-22, 2004 CL San Diego, CA SP Natl Neurotrauma Soc DE statin; CA1; trauma; LTR; neuron C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD SEP PY 2004 VL 21 IS 9 MA P268 BP 1330 EP 1330 PG 1 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 855HC UT WOS:000223962900271 ER PT J AU Panizzon, KL Wallis, RA AF Panizzon, KL Wallis, RA TI Modulation of the mitochondrial ATP-sensitive potassium channel by diazoxide provides protection against CA1 traumatic neuronal injury SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 22nd Annual National-Neurotrauma-Society Symposium CY OCT 20-22, 2004 CL San Diego, CA SP Natl Neurotrauma Soc DE trauma; CA1; mitochondria; potassium channels; ATP C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD SEP PY 2004 VL 21 IS 9 MA P271 BP 1331 EP 1331 PG 1 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 855HC UT WOS:000223962900273 ER PT J AU Chou, R Helfand, M AF Chou, R Helfand, M TI Re: Systematic review of long-acting oral opioids - Authors' response SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Letter C1 Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR USA. RP Chou, R (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD SEP PY 2004 VL 28 IS 3 BP 195 EP 195 DI 10.1016/j.jpainsymman.2004.06.009 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 856UY UT WOS:000224071900003 ER PT J AU Koenigsberg, HW Teicher, MH Mitropoulou, V Navalta, C New, AS Trestman, R Siever, LJ AF Koenigsberg, HW Teicher, MH Mitropoulou, V Navalta, C New, AS Trestman, R Siever, LJ TI 24-h monitoring of plasma norepinephrine, MHPG, cortisol, growth hormone and prolactin in depression SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE depression; circadian rhythm; norepinephrine; cortisol; MHPG; Dysregulation ID POSTTRAUMATIC-STRESS-DISORDER; MAJOR DEPRESSION; ENDOGENOUS-DEPRESSION; CIRCADIAN-RHYTHMS; DIURNAL RHYTHM; PHASE-ADVANCE; SECRETION; METABOLITES; ILLNESS; PSYCHONEUROENDOCRINOLOGY AB Depression is associated with alterations in hormone and catecholamine circadian rhythms. Analysis of these alterations has the potential to distinguish between three neurobiological models of depression, the catecholamine model, the phase advance model and the dysregulation model. Although a number of studies of 24-h rhythms have been reported, inconsistencies among the findings have complicated efforts to model the chronobiology of depression. The present study takes advantage of frequent plasma sampling over the 24-h period and a multioscillator cosinor model to fit the 24-h rhythms. Method: Plasma levels of norepinephrine, cortisol, prolacatin and growth hormone were sampled at 30-min intervals, and MHPG at 60-min intervals, over a 24-h period in 22 patients with major depressive disorder and 20 healthy control volunteers. Results: The depressed patients had phase advanced circadian rhythms for cortisol, norepinephrine and MHPG, phase advanced hemicircadian rhythms for cortisol and prolactin, and a phase advanced ultradian rhythm for prolactin compared to healthy control subjects. In addition, the rhythm-corrected 24-h mean value (mesor) of norepinephrine was lower in the depressed patients compared to the healthy controls. There also was a poorer goodness-of-fit for norepinephrine to the circadian oscillator in the depressed patients relative to the healthy controls. Conclusions: These findings provide partial support for the dysregulation model of depression and are consistent with those studies that have found phase advances in cortisol, norepinephrine and MHPG rhythms in depression. Published by Elsevier Ltd. C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. Bronx Vet Affairs Med Ctr, Mental Hlth Patient Care Ctr 116A, Bronx, NY 10468 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Univ Connecticut, Ctr Hlth, Farmington, CT USA. Vet Hlth Adm, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. RP Koenigsberg, HW (reprint author), Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. EM harold.koenigsberg@med.va.gov OI Trestman, Robert/0000-0002-3306-4380 FU NCRR NIH HHS [5M01 RR00071] NR 51 TC 46 Z9 51 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIAT RES JI J. Psychiatr. Res. PD SEP-OCT PY 2004 VL 38 IS 5 BP 503 EP 511 DI 10.1016/j.jpsychires.2004.03.006 PG 9 WC Psychiatry SC Psychiatry GA 861VH UT WOS:000224446200007 PM 15380401 ER PT J AU Douglas, G Reilly, C Dooley, MA Page, G Cooper, G Gilkeson, G AF Douglas, G Reilly, C Dooley, MA Page, G Cooper, G Gilkeson, G TI Angiotensin-converting enzyme (insertion/deletion) and endothelial nitric oxide synthase polymorphisms in patients with systemic lupus erythematosus SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE systemic lupus erythematosus; nitric oxide; genetics; predisposition; angiotensin-converting enzyme; African American; polymorphism ID CORONARY-ARTERY-DISEASE; GENE POLYMORPHISM; DELETION POLYMORPHISM; DIABETIC-NEPHROPATHY; ESSENTIAL-HYPERTENSION; MYOCARDIAL-INFARCTION; 5'-FLANKING REGION; HEART-DISEASE; ACE GENE; ASSOCIATION AB Objective. Genetic polymorphisms in the angiotensin-converting enzyme (ACE) and endothelial nitric oxide synthase (eNOS) are linked with expression and/or progression of renal disease. We hypothesized that polymorphisms in the genes coding for ACE and eNOS may influence the development and/or progression of systemic lupus erythematosus (SLE) and lupus nephritis given their linkage with other renal diseases. Methods. DNA from patients with SLE (n = 227) and their age and sex matched controls (n = 275) from the Carolina Lupus (CLU) Study cohort was assessed for ACE and eNOS polymorphisms. Seventy patients had biopsy-proven lupus nephritis. Two different eNOS polymorphisms (eNOS promoter T-786-->C nucleotide substitution and eNOS 27 base pair tandem repeat in intron 4) and the ACE insertion/deletion (I/D) polymorphism in intron 16 were examined by restriction fragment length polymorphism-polymerase chain reaction. Results. Allele frequency of the eNOS polymorphisms varied significantly between SLE patients and controls. There was no association of these polymorphisms with lupus within ethnic groups. We found no association of the polymorphism with the development of renal disease. No association was observed for the ACE I/D polymorphism with SLE or nephritis, or with ethnicity or sex. Conclusion. eNOS genetic polymorphisms differed significantly across ethnic groups. There was no significant increased risk of SLE and/or lupus nephritis associated with eNOS or ACE polymorphisms in either the African American or Caucasian groups compared to ethnically matched controls. These studies emphasize the need to control for ethnicity when investigating genetic polymorphisms and disease. C1 Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Med Res Serv, Charleston, SC USA. Edward Via Virginia Coll Osteopath Med, Dept Physiol, Blacksburg, VA USA. Univ N Carolina, Affiliated Hosp, Dept Med, Chapel Hill, NC USA. Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA. Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA. RP Gilkeson, G (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol, 96 Jonathan Lucas St,Suite 912,POB 250623, Charleston, SC 29425 USA. EM gilkeson@musc.edu FU NIAID NIH HHS [AI41764]; NIAMS NIH HHS [AR39162, AR45476] NR 43 TC 22 Z9 22 U1 0 U2 0 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD SEP PY 2004 VL 31 IS 9 BP 1756 EP 1762 PG 7 WC Rheumatology SC Rheumatology GA 852ZS UT WOS:000223796200016 PM 15338496 ER PT J AU Burman, ML Kivlahan, D Buchbinder, M Broglio, K Zhou, XH Merrill, JO McDonell, MB Fihn, SD Bradley, KA AF Burman, ML Kivlahan, D Buchbinder, M Broglio, K Zhou, XH Merrill, JO McDonell, MB Fihn, SD Bradley, KA CA Ambulatory Care Quality Improveme TI Alcohol-related advice for veterans affairs primary care patients: Who gets it? Who gives it? SO JOURNAL OF STUDIES ON ALCOHOL LA English DT Article ID BEHAVIORAL-COUNSELING INTERVENTIONS; RANDOMIZED CONTROLLED TRIAL; AT-RISK DRINKING; BRIEF PHYSICIAN; DRINKERS; MEDICINE; VA; CONSUMPTION; DISCUSSIONS; PREVENTION AB Objective: Most patients who misuse alcohol do not receive alcohol counseling from their providers. This study evaluated primary care patient and provider characteristics associated with receipt of alcohol-related advice and whether patients were advised to drink less or to abstain. Method: Outpatients from seven Veterans Affairs (VA) general medicine clinics were eligible if they screened positive for alcohol misuse, completed the Alcohol Use Disorders Identification Test (AUDIT) and answered questions about alcohol-related treatment and advice. Hierarchical logistic regression wag used to evaluate patient and provider characteristics associated with patient reports of alcohol-related advice from a primary care provider in the past year. Results: Among 5,191 patients with alcohol misuse in the past year, 1,554 (30%) reported receiving alcohol-related advice from their primary care provider during that time. Of patients advised, 73% reported advice to abstain. The likelihood of reporting advice increased as AUDIT scores increased: from 13% of patients with AUDIT scores <8 to 71% of those with scores greater than or equal to20. After adjustment for important confounders, measures reflecting the severity of alcohol misuse were most strongly associated with receipt of alcohol-related advice. Adjusted analyses also revealed increased odds of receiving advice among patients who reported liver disease, hypertension, current smoking or continuity of care. No measured provider characteristic was associated with giving advice in the fully adjusted model. Conclusions: This multisite VA study found that most patients with alcohol misuse did not receive alcohol counseling from a primary care provider. Moreover, providers predominantly offered advice to abstain, and they appeared to focus on patients with the most severe problems due to drinking or medical contraindications to drinking. C1 Vet Affairs Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Substance Abuse Treatment & Educ, Seattle, WA USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Case Western Reserve Univ, Dept Anthropol, Cleveland, OH 44106 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Washington, Harborview Med Ctr, Div Gen Internal Med, Seattle, WA 98104 USA. RP Bradley, KA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. EM willi@u.washington.edu OI Buchbinder, Mara/0000-0002-2319-662X FU NIAAA NIH HHS [K23 AA 00313] NR 38 TC 52 Z9 52 U1 3 U2 5 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 0096-882X J9 J STUD ALCOHOL JI J. Stud. Alcohol PD SEP PY 2004 VL 65 IS 5 BP 621 EP 630 PG 10 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA 863VE UT WOS:000224590700009 PM 15536772 ER PT J AU Martin, B Alfers, J Kulig, C Clapp, L Bialkowski, D Bridgeford, D Beresford, TP AF Martin, B Alfers, J Kulig, C Clapp, L Bialkowski, D Bridgeford, D Beresford, TP TI Disulfiram therapy in patients with hepatitis C: A 12-month, controlled, follow-up study SO JOURNAL OF STUDIES ON ALCOHOL LA English DT Article ID ALCOHOLIC LIVER-DISEASE; AMINOTRANSFERASE LEVELS; VIRUS-RNA; ANTIBODIES; INTERFERON; CIRRHOSIS; RISK AB Objective: Although abstinence slows liver injury in alcoholic Hepatitis C (HCV) infected patients, few clinicians prescribe disulfiram because of concern over its hepatotoxic effect. Finding no controlled studies on this effect, we investigated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) patterns in seropositive (HCV[-]) and seronegative (HCV[-]) patients who received supervised disulfiram over 12 months. Method: We recorded retrospective aminotransferase measurements from medical records of 26 HCV(+) and 20 HCV(-) cases receiving 1,500 mg disulfiram weekly in divided doses. within groups, paired mean AST and ALT levels at 3, 6, 9 and 12 months were compared with baseline; between groups, nonpaired mean comparisons were used. Results: There were no statistically or clinically significant elevations for the HCV(+) group at any time point. Between-group means were identical at all time points. Conclusions: Although sample size and retrospective design invite replication, the data suggest that disulfiram may be useful for HCV(+) alcohol-dependent patients in slowing hepatic injury by eliminating alcohol use and thereby removing the purported alcohol-HCV hepatotoxic synergy. It may also help to establish the abstinence criteria necessary to qualify for antiviral treatment. If disulfiram is used in HCV treatment, AST and ALT must be monitored closely. C1 Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Martin, B (reprint author), Denver Vet Affairs Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. EM thomas.beresford@uchsc.edu FU NIAAA NIH HHS [R21 AA014010] NR 23 TC 10 Z9 10 U1 0 U2 0 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 0096-882X J9 J STUD ALCOHOL JI J. Stud. Alcohol PD SEP PY 2004 VL 65 IS 5 BP 651 EP 657 PG 7 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA 863VE UT WOS:000224590700013 PM 15536776 ER PT J AU Patten, LC Belaguli, NS Baek, MJ Fagan, SP Awad, SS Berger, DH AF Patten, LC Belaguli, NS Baek, MJ Fagan, SP Awad, SS Berger, DH TI Serum response factor is alternatively spliced in human colon cancer SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE serum response factor; colon cancer; epithelial cells; alternative splicing ID INTESTINAL EPITHELIAL-CELLS; C-FOS GENE; MESSENGER-RNA; T-CELLS; TRANSCRIPTION; EXPRESSION; RAS; APOPTOSIS; ELEMENT; BINDING AB Background. Serum response factor (SRF) is a transcription factor that plays an important role in cellular differentiation and cell cycle regulation. SRF function is regulated in part by alternative splicing. Little is known about the expression or role of these alternatively spliced isoforms during tumorigenesis. We hypothesized that there is a change in the splice variants during intestinal tumorigenesis and that this change promotes the tumor phenotype. Materials and methods. SRF expression was determined by Western blotting of benign intestinal cells and human colon cancer cell lines. To determine the effect of alternative splicing of SRF on intestinal growth and proliferation, the predominant alternatively spliced isoform of SRF that we identified in colon cancer cells, SRFDelta5, was transfected into IEC-6 cells. IEC-6 and IEC-6SRFDelta5 cells were plated and cell numbers were determined at four time points. Results. Western blotting demonstrates that full-length SRF is the predominant form of SRF in rat IEC-6 cells, normal human colonic mucosa, and HT-29 cells, derived from a well-differentiated human colonic adenocarcinoma. In the colon cancer cell lines derived from poorly differentiated tumors (WiDr, HCT 116, LoVo, and SW480), SRFA5 is the predominant isoform expressed. There was a significant increase in cell survival in IEC-6 cells transfected with SRFA5 compared to parental cells. Conclusion. Our data demonstrate that an alternatively spliced isoform. of SRF, SRFA5, is expressed in human colon cancer cell lines. Additionally, these data demonstrate that expression of SRFA5 may contribute to the tumor phenotype by affecting cell survival. This is the first study to document a change in expression of the alternatively spliced isoform of SRF in human malignancy. (C) 2004 Elsevier Inc. All rights reserved. C1 Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. Houston Vet Aff Hosp, Houston, TX 77030 USA. RP Berger, DH (reprint author), Houston VAMC, Surg Serv, OCL 112,2002 Holocombe Blvd, Houston, TX 77030 USA. EM dhb@bcm.tmc.edu NR 32 TC 12 Z9 15 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD SEP PY 2004 VL 121 IS 1 BP 92 EP 100 DI 10.1016/j.jss.2004.02.031 PG 9 WC Surgery SC Surgery GA 847ZU UT WOS:000223437500015 PM 15313381 ER PT J AU Riekse, RG Leverenz, JB McCormick, W Bowen, JD Teri, L Nochlin, D Simpson, K Eugenio, C Larson, EB Tsuang, D AF Riekse, RG Leverenz, JB McCormick, W Bowen, JD Teri, L Nochlin, D Simpson, K Eugenio, C Larson, EB Tsuang, D TI Effect of vascular lesions on cognition in Alzheimer's disease: A community-based study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT 8th International Meeting on Alzheimers Disease and Related Disorders CY JUL 20-25, 2002 CL STOCKHOLM, SWEDEN SP Alzheimers Assoc DE Alzheimer's disease; vascular lesions; clinical-neuropathological; autopsy; dementia ID MINI-MENTAL-STATE; CLINICAL-DIAGNOSIS; AMYLOID ANGIOPATHY; APOLIPOPROTEIN-E; ELDERLY PEOPLE; BLOOD-PRESSURE; UNITED-STATES; CASE SERIES; DEMENTIA; CERAD AB Objectives: To investigate whether clinical and neuropathological differences exist between Alzheimer's disease (AD) cases with and without vascular lesions neuropathologically diagnosed using Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria. Design: Descriptive observational study. Setting: A community-based registry that identified incident dementia cases. Participants: Of the 124 subjects with available clinical and neuropathological assessments, 30 had AD lesions alone, and 18 had AD with vascular lesions. Patients with other neuropathological findings were excluded. Measurements: Dependent measures included demographic, clinical, and neuropathological characteristics. Neuropathological diagnoses were made using the CERAD criteria and Braak and Braak staging. Results: Of the 124 autopsied cases, 85 cases were diagnosed with neuropathological AD. Of these, 30 had pathology consistent with "pure" AD, whereas 18 had AD pathology with significant vascular lesions (AD/V). There were no differences in age, sex, or education between groups. AD/V cases had higher baseline and final Mini-Mental State Examination (MMSE) scores than pure AD cases, but after adjusting for education, differences in MMSE scores were not statistically significant. The AD/V group had significantly lower Braak staging than the pure AD group, after adjusting for education and final MMSE scores. Conclusion: In this comparison study of AD cases with and without vascular lesions, AD/V cases had less severe AD pathology than those with AD alone, indicating that cerebrovascular disease likely contributes to the severity of cognitive impairment in those with AD. Controlling for vascular risk factors in patients with AD may have a significant effect on severity of dementia. C1 Univ Washington, Dept Med, Seattle, WA USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Pathol, Div Neuropathol, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Sch Nursing, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Ctr Clin, Seattle, WA USA. RP Riekse, RG (reprint author), VAPSHCS, MIRECC 116, 1660 S Columbian Way, Seattle, WA 98108 USA. EM riekse@u.washington.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 FU NIA NIH HHS [U01 AG006781, U01AG06781]; NINDS NIH HHS [R01 NS048595] NR 55 TC 75 Z9 79 U1 0 U2 3 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2004 VL 52 IS 9 BP 1442 EP 1448 DI 10.1111/j.1532-5415.2004.52405.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 847CQ UT WOS:000223366900005 PM 15341544 ER PT J AU Chodosh, J Seeman, TE Keeler, E Sewall, A Hirsch, SH Guralnik, JM Reuben, DB AF Chodosh, J Seeman, TE Keeler, E Sewall, A Hirsch, SH Guralnik, JM Reuben, DB TI Cognitive decline in high-functioning older persons is associated with an increased risk of hospitalization SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE cognitive impairment; dementia; health service utilization ID MENTAL STATUS QUESTIONNAIRE; ALZHEIMERS-DISEASE; DEPRESSIVE SYMPTOMATOLOGY; ELDERLY POPULATION; UNITED-STATES; DEMENTIA; COMMUNITY; IMPAIRMENT; HEALTH; COSTS AB Objectives: To examine hospital use for patients with evidence of cognitive decline indicative of early cognitive impairment. Design: Medicare Part A hospital utilization data were linked to data from the MacArthur Research Network on Successful Aging Community Study to examine the association between baseline cognition and decline in cognitive function over a 3-year period and any hospitalization over that same period. Setting: New Haven, Connecticut, and East Boston, Massachusetts. Participants: Subjects (N=598) were from two sites of the MacArthur Research Network on Successful Aging Community Study, a 7-year cohort study of community-dwelling older persons with high physical and cognitive functioning. Measurements: Multivariate logistic regression was used to determine the association between any hospitalization over 3 years (1988-91) as the outcome variable and baseline cognitive function and decline in cognition over 3 years as primary predictor variables. Decline was based upon repeated (1988 and 1991) measures of delayed verbal recall and the Short Portable Mental Status Questionnaire (SPMSQ). Results: Of 598 subjects, 48 died between 1988 and 1991. No baseline (1988) delayed recall scores or change in recall scores (1988-91) were associated with hospitalization. Although 48.2% declined on verbal memory scores, decline was not associated with risk of hospitalization. Of 494 subjects with complete 3-year data, 31.2% declined at least one point on the SPMSQ, and 4.7% declined more than two points. Among individuals aged 75 and older at baseline, the adjusted odds ratio for hospitalization for those who declined more than 2 points compared with those who declined less was 7.8 (95% confidence interval=2.0-30.8). Conclusion: Although specific memory tests were not associated with hospitalization, high-functioning older persons who experienced decline in overall cognitive function were more likely to be hospitalized. Variation in baseline cognitive function in this high-functioning cohort did not affect hospitalization, but additional research is needed to evaluate associations with other healthcare costs. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA USA. RAND Corp, Santa Monica, CA USA. Sewall Inc, Bethesda, MD USA. NIA, Bethesda, MD 20892 USA. RP Chodosh, J (reprint author), 10945 Le Conte Ave,Suite 2339, Los Angeles, CA 90095 USA. EM jchodosh@mednet.ucla.edu OI Chodosh, Joshua/0000-0001-7784-4306 FU NIA NIH HHS [AG16677] NR 40 TC 40 Z9 40 U1 3 U2 4 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2004 VL 52 IS 9 BP 1456 EP 1462 DI 10.1111/j.1532-5415.2004.52407.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 847CQ UT WOS:000223366900007 PM 15341546 ER PT J AU Bridevaux, IP Bradley, KA Bryson, CL McDonell, MB Fihn, SD AF Bridevaux, IP Bradley, KA Bryson, CL McDonell, MB Fihn, SD TI Alcohol screening results in elderly male veterans: Association with health status and mortality SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE elderly; alcohol; problem drinking; health status; mortality ID PRIMARY-CARE PATIENTS; QUALITY-OF-LIFE; OLDER-ADULTS; CONSUMPTION; QUESTIONNAIRE; POPULATION; DRINKERS; SF-36; CONSEQUENCES; RELIABILITY AB Objectives: To evaluate the association between alcohol screening results and health status or mortality in elderly patients. Design: Cross-sectional and longitudinal cohort studies. Setting: Primary care clinics at seven Veterans Affairs medical centers. Participants: A total of 16,958 male patients aged 65 and older. Measurements: Alcohol screening questionnaires were used to divide patients into four mutually exclusive groups: drinkers who screened negative or positive for problem drinking and nondrinkers (in the previous year) who screened negative or positive for problem drinking. A subset of patients (n=12,491) completed a measure of health status, the Medical Outcomes Study Short Form (SF-36). All-cause mortality was ascertained using Veterans Affairs data over a mean follow-up of 2.8 years. Results: Forty-eight percent of participants reported drinking in the previous year. Half of the drinkers and nondrinkers screened positive for problem drinking. The SF-36 item scores were consistently higher for drinkers than for nondrinkers and for patients who screened negative for problems than for those who screened positive. Similarly, survival was consistently better in drinkers than nondrinkers (mortality hazard ratio (HR)=0.74, 95% confidence interval (CI)=0.68-0.82) and in patients who screened negative for problem drinking than in those who screened positive (mortality HR=0.87, 95% CI=0.80-0.95). Nondrinkers who screened positive for problem drinking had the poorest health status and survival, whereas drinkers who screened negative for problem drinking had the best health status and survival. Conclusion: Elderly patients who reported drinking alcohol and those who screened negative for problem drinking had consistently better health status and survival than those who did not drink and those who screened positive. C1 VA Puget Sound Hlth Care Syst, HSR&D, NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA USA. RP Bridevaux, IP (reprint author), VA Puget Sound Hlth Care Syst, HSR&D, NW Hlth Serv Res & Dev Ctr Excellence, MS 152,1660 S Columbian Way, Seattle, WA 98108 USA. EM Isabelle.Peytremann-Bridevaux@hospd.ch FU NIAAA NIH HHS [K23 AA00313] NR 44 TC 39 Z9 39 U1 3 U2 4 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2004 VL 52 IS 9 BP 1510 EP 1517 DI 10.1111/j.1532-5415.2004.52414.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 847CQ UT WOS:000223366900014 PM 15341553 ER PT J AU Rubenstein, LZ Solomon, DH Roth, CP Young, RT Shekelle, PG Chang, JT MacLean, CH Kamberg, CJ Saliba, D Wenger, NS AF Rubenstein, LZ Solomon, DH Roth, CP Young, RT Shekelle, PG Chang, JT MacLean, CH Kamberg, CJ Saliba, D Wenger, NS TI Detection and management of falls and instability in vulnerable elders by community physicians SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE falls; geriatrics; instability; gait; vulnerable elders; quality of care ID ASSESSING CARE; OLDER-ADULTS; QUALITY; PREVENTION; PEOPLE AB Objectives: To investigate quality of care for falls and instability provided to vulnerable elders. Design: Six process of care quality indicators (QIs) for falls and instability were developed and applied to community-living persons aged 65 and older who were at increased risk of death or decline. QIs were implemented using medical records and patient interviews. Setting: Northeastern and southwestern United States. Participants: Three hundred seventy-two vulnerable elders enrolled in two senior managed care plans. Measurements: Percentage of QIs satisfied concerning falls or mobility disorders. Results: Of the 372 consenting vulnerable elders with complete medical records, 57 had documentation of 69 episodes of two or more falls or fall with injury during the 13-month study period (14% of patients fell per year, 18% incidence). Double this frequency was reported at interview. An additional 22 patients had documented mobility problems. Clinical history of fall circumstances, comorbidity, medications, and mobility was documented from 47% of fallers and two or more of these four elements from 85%. Documented physical examination was less complete, with only 6% of fallers examined for orthostatic blood pressure, 7% for gait or balance, 25% for vision, and 28% for neurological findings. The evaluation led to specific recommendations in only 26% of cases, but when present they usually led to appropriate treatment modalities. Mobility problems without falls were evaluated with gait or balance examination in 23% of cases and neurological examination in 55%. Conclusion: Community physicians appear to underdetect falls and gait disorders. Detected falls often receive inadequate evaluation, leading to a paucity of recommendations and treatments. Adhering to guidelines may improve outcomes in community-dwelling older adults. C1 Greater Los Angeles VA Med Ctr, Ctr Geriatr Res Educ & Clin, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RAND Corp, Santa Monica, CA USA. RP Rubenstein, LZ (reprint author), Greater Los Angeles VA Med Ctr, Ctr Geriatr Res Educ & Clin, 11E,16111 Plummer St, Sepulveda, CA 91343 USA. EM Lzrubens@ucla.edu NR 13 TC 41 Z9 41 U1 3 U2 10 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2004 VL 52 IS 9 BP 1527 EP 1531 DI 10.1111/j.1532-5415.2004.52417.x PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 847CQ UT WOS:000223366900017 PM 15341556 ER PT J AU Lorenz, KA Lynn, J AF Lorenz, KA Lynn, J TI Oregon's lessons for improving advance care planning SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Editorial Material ID LIFE-SUSTAINING TREATMENT C1 Univ Calif Los Angeles, Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. RAND Hlth, Santa Monica, CA USA. Washington Home Ctr Palliat Care Studies, Washington, DC USA. RP Lorenz, KA (reprint author), Univ Calif Los Angeles, Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. NR 7 TC 2 Z9 2 U1 1 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2004 VL 52 IS 9 BP 1574 EP 1575 DI 10.1111/j.1532-5415.2004.52426.x PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 847CQ UT WOS:000223366900026 PM 15341565 ER PT J AU McQueen, L Mittman, BS Demakis, JG AF McQueen, L Mittman, BS Demakis, JG TI Overview of the veterans health administration (VHA) quality enhancement research initiative (QUERI) SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID CARE-SYSTEM; REORGANIZATION AB The U.S. Veterans Health Administration (VHA)'s Quality Enhancement Research Initiative (QUERI) is an innovative integration of health services research, policy, and clinical care delivery designed to improve the quality, outcomes, and efficiency of VHA health care through the identification and implementation of evidence-based practices in routine care settings. A total of eight condition-specific QUERI centers are currently in operation, each pursuing an integrated portfolio of activities designed to identify and correct gaps in clinical quality and performance and to derive generalizable scientific knowledge regarding quality improvement processes and methods and their effectiveness. This overview article describes QUERI's mission, history, structure, and activities and provides a brief summary of key findings and impacts. C1 US Dept Vet Affairs 10Q, Off Qual & Performance, Washington, DC 20420 USA. US Dept Vet Affairs, Qual Enhancement Res Initiat, Washington, DC 20420 USA. US Dept Vet Affairs, Hlth Serv Res & Dev Serv, Washington, DC 20420 USA. RP McQueen, L (reprint author), US Dept Vet Affairs 10Q, Off Qual & Performance, 810 Vermont Ave NW, Washington, DC 20420 USA. EM lynn.mcqueen@hq.med.va.gov NR 22 TC 68 Z9 68 U1 0 U2 4 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD SEP-OCT PY 2004 VL 11 IS 5 BP 339 EP 343 DI 10.1197/jamia.M1499 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 854JD UT WOS:000223898000001 PM 15187071 ER PT J AU Hynes, DM Perrin, RA Rappaport, S Stevens, JM Demakis, JG AF Hynes, DM Perrin, RA Rappaport, S Stevens, JM Demakis, JG TI Informatics resources to support health care quality improvement in the veterans health administration SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Review ID DATABASES AB Information systems are increasingly important for measuring and improving health care quality. A number of integrated health care delivery systems use advanced information systems and integrated decision support to carry out quality assurance. activities, but none as large as the Veterans Health Administration (VHA). The VHA!s Quality Enhancement Research Initiative (QUERI) is a large-scale, multidisciplinary quality improvement initiative designed to ensure excellence in all areas where VHA provides health care services, including inpatient, outpatient, and long-term care settings. In this paper, we describe the role of information systems in the VHA QUERI process, highlight the major information systems critical to this quality improvement process, and discuss issues associated with the use of these systems. C1 Vet Affairs Edward Hines Jr Hosp, VA Informat Resource Ctr, Hines, IL 60141 USA. Vet Affairs Edward Hines Jr Hosp, Midwest Ctr Hlth Serv & Policy Res, Hines, IL 60141 USA. Loyola Univ, Maywood, IL 60153 USA. VA Off Informat, Washington, DC USA. US Dept Vet Affairs, Hlth Serv Res & Dev Serv, Washington, DC USA. RP Hynes, DM (reprint author), Vet Affairs Edward Hines Jr Hosp, VA Informat Resource Ctr, POB 5000,151V, Hines, IL 60141 USA. EM hynes@research.hines.med.va.gov NR 20 TC 47 Z9 47 U1 0 U2 1 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD SEP-OCT PY 2004 VL 11 IS 5 BP 344 EP 350 DI 10.1197/jamia.M1548 PG 7 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 854JD UT WOS:000223898000002 PM 15187063 ER PT J AU Owen, RR Thrush, CR Cannon, D Sloan, KL Curran, G Hudson, TR Austen, M Ritchie, M AF Owen, RR Thrush, CR Cannon, D Sloan, KL Curran, G Hudson, TR Austen, M Ritchie, M TI Use of electronic medical record data for quality improvement in schizophrenia treatment SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID PRESCRIBING PRACTICES; CARE; OUTCOMES; PERFORMANCE; GUIDELINE; COMPUTER; SYSTEM AB An understanding of the strengths and limitations of automated data is valuable when using administrative or clinical databases to monitor and improve the quality of health care. This study discusses the feasibility and validity of using data electronically extracted from the Veterans Health Administration (VHA) computer database (VistA) to monitor guideline performance for inpatient and outpatient treatment of schizophrenia. The authors also discuss preliminary results and their experience in applying these methods to monitor antipsychotic prescribing using the South Central VA Healthcare Network (SCVAHCN) Data Warehouse as a tool for quality improvement. C1 Vet Adm Med Ctr, Ctr Mental Healthcare & Outcomes Res, Cent Arkansas Vet Healthcare Syst, Hlth Serv Res & Dev Serv, N Little Rock, AR 72114 USA. Univ Arkansas Med Sci, Coll Med, Dept Psychiat & Behav Sci, Div Hlth Serv Res, Little Rock, AR USA. Univ Utah, Dept Psychiat, Salt Lake City, UT USA. Univ Utah, VA Salt Lake Hlth Care Syst, Salt Lake City, UT USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Owen, RR (reprint author), Vet Adm Med Ctr, Ctr Mental Healthcare & Outcomes Res, Cent Arkansas Vet Healthcare Syst, Hlth Serv Res & Dev Serv, 152 NLR,2200 Ft Roots Dr, N Little Rock, AR 72114 USA. EM owenrichardr@uams.edu NR 38 TC 17 Z9 17 U1 2 U2 2 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD SEP-OCT PY 2004 VL 11 IS 5 BP 351 EP 357 DI 10.1197/jamia.M1498 PG 7 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 854JD UT WOS:000223898000003 PM 15187073 ER PT J AU Palevsky, PM AF Palevsky, PM TI Acute renal failure SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Review ID RADIOCONTRAST-INDUCED NEPHROPATHY; CRITICALLY-ILL PATIENTS; ACUTE TUBULAR-NECROSIS; RECOMBINANT-HUMAN-ERYTHROPOIETIN; INHIBITING LEUKOCYTE ACTIVATION; ACUTE INTERSTITIAL NEPHRITIS; CONTRAST-INDUCED NEPHROPATHY; RANDOMIZED CONTROLLED TRIAL; VASODILATORY SEPTIC SHOCK; AGENT-INDUCED NEPHROPATHY C1 VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. NR 125 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2004 SU S BP 245 EP 277 PG 33 WC Urology & Nephrology SC Urology & Nephrology GA 888UB UT WOS:000226398600002 ER PT J AU Simmons, SF Schnelle, JF AF Simmons, SF Schnelle, JF TI Individualized feeding assistance care for nursing home residents: Staffing requirements to implement two interventions SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID LONG-TERM-CARE; FLUID INTAKE; PREDICTORS AB feeding assistance during meals and to individualize care for residents. However, there are few data reflecting the number of residents responsive to feeding assistance during meals and what alternative interventions might be appropriate for other residents. The purpose of this study was to evaluate the effects and staffing requirements of two individualized feeding assistance interventions to improve oral food and fluid intake in NH residents. Methods. Skilled nursing participants (n = 134) in 3 NHs received a 2-day trial of one-on-one feeding assistance during 6 meals. 68 participants who did not increase their oral intake in response to feeding assistance during meals received a 2-day intervention trial during which snacks were offered between meals 3 times daily. As part of both interventions, research staff provided adequate feeding assistance that enhanced the resident's self-feeding ability, social stimulation throughout the meal or snack period, and availability of choices for foods and fluids. Results. 46% significantly increased their oral intake in response to one-on-one mealtime feeding assistance, and the staff time required to implement this intervention was 35 ( +/- 8) minutes/meal per resident compared with usual NH care, which averaged 6 ( +/- 9) minutes. 44% of the participants significantly increased their oral intake in response to the between-meal snack intervention, which required 12 ( +/- 6) minutes of staff time per snack/resident compared with usual NH care (1 +/- 4 minutes). Conclusions. Most participants (90%) significantly increased their daily oral food and fluid intake in response to one of two individualized interventions. The staff time necessary to implement each intervention was significantly greater than the staff time currently being spent on feeding assistance care delivery. Suggestions are made to increase the efficiency of staff time when delivering feeding assistance. C1 Univ Calif Los Angeles, Sch Med, Borun Ctr Gerontol Res, Dept Geriatr,Jewish Home Aging, Reseda, CA 91335 USA. Vet Adm Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Sepulveda Geriatr Res Educ & Clin Ctr, Sepulveda, CA USA. RP Simmons, SF (reprint author), Univ Calif Los Angeles, Sch Med, Borun Ctr Gerontol Res, Dept Geriatr,Jewish Home Aging, 7150 Tampa Ave, Reseda, CA 91335 USA. EM ssimmons@ucla.edu NR 29 TC 51 Z9 54 U1 1 U2 2 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD SEP PY 2004 VL 59 IS 9 BP 966 EP 973 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 862VY UT WOS:000224520500016 ER PT J AU Lorenz, KA Ettner, SL Rosenfeld, KE Carlisle, D Liu, H Asch, SM AF Lorenz, KA Ettner, SL Rosenfeld, KE Carlisle, D Liu, H Asch, SM TI Accommodating ethnic diversity - A study of California hospice programs SO MEDICAL CARE LA English DT Article DE hospice; palliative care; economics; minority groups ID HEALTH-CARE; SERVICES; BARRIERS; WOMEN AB Background: Studies have confirmed ethnic disparities in the use of hospice services and identified barriers that minorities face in accessing care. Objectives: We sought to determine whether hospices provide services that might affect minority participation. Research Design: We surveyed California hospices to determine whether programs use diverse health care providers and volunteers, offer translation, diverse spiritual care, or outreach materials and whether they plan to expand such services. Linking the data to the California Office of Statewide Health Planning and Development annual home care and hospice survey and 2000 US Census, we used multivariate linear regression to evaluate the relationship of program characteristics (profit status, size, chain/freestanding status, urban/rural location, and proportion of nonwhite residents) to services that might affect minority participation. Subjects: One hundred of 149 programs that we surveyed responded. Results: Many programs offer translation (81%),diverse providers (63%) and volunteers (64%), and culturally diverse spiritual services (52%). Few (21%) were conducting outreach, but 23/25 programs expanding services reported plans to improve outreach. In multivariate models adjusted for program size, chain status, profit status, urban/rural location, proportion of nonwhite residents, we found that larger hospices and those in ethnically diverse zip codes were more likely to offer such services. Larger hospices are more likely to report expanding such services. Conclusions: Many hospices are making efforts to accommodate ethnically diverse patients, but a substantial number are not. Culturally appropriate care and outreach should be addressed in efforts to improve the acceptability and experience of hospice care among minorities. C1 VA Greater Los Angeles Healthcare Syst, Vet Integrated Palliat Program, Div Gen Internal Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA 90024 USA. RAND Corp, Santa Monica, CA USA. Calif Off Statewide Hlth Planning & Dev, Sacramento, CA USA. RP Lorenz, KA (reprint author), VA Greater Los Angeles Healthcare Syst, Vet Integrated Palliat Program, Div Gen Internal Med, 11303 Wilshire Blvd,Code 111-G, Los Angeles, CA 90073 USA. EM karl.lorenz@med.va.gov NR 21 TC 16 Z9 16 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD SEP PY 2004 VL 42 IS 9 BP 871 EP 874 DI 10.1097/01.mlr.0000135830.13777.9c PG 4 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 851IC UT WOS:000223677800006 PM 15319612 ER PT J AU Harada, ND Pourat, N AF Harada, ND Pourat, N TI Does membership in veterans' service organizations influence use of the Department of Veterans Affairs as the usual source of care? SO MILITARY MEDICINE LA English DT Article ID HEALTH-CARE; REGULAR SOURCE; MEDICAL-CARE; DIFFERENCE; PHYSICIAN AB Veterans' service organizations (VSOs) provide outreach regarding veterans' benefits. Medical care provided by the Department of Veterans Affairs (VA) is one such benefit that has improved health and quality of life. This study evaluates the characteristics of veterans who report VSO membership and who use the VA as their usual source of care, and it determines whether VSO membership influences the choice of a VA or non-VA facility as the usual source of care. The findings reveal that VSO members, compared with nonmembers, are Caucasian, older, retired, of lower income, and more functionally impaired. Veterans who use the VA, compared with non-VA users, are African American, of lower income, unemployed, and more functionally impaired. VSO members are more likely to use the VA as the usual source of care than are VSO nonmembers, with the effects varying according to race/ethnicity. Policy recommendations include increasing the diversity of VSO membership, because VSOs play an important outreach and informational role for veterans. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Ctr Hlth Policy Res, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA. RP Harada, ND (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 18 TC 2 Z9 2 U1 0 U2 1 PU ASSN MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD SEP PY 2004 VL 169 IS 9 BP 735 EP 740 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 019JB UT WOS:000235830300019 PM 15495731 ER PT J AU Huamani, J McMahan, CA Herbert, DC Reddick, R McCarrey, JR MacInnes, MI Chen, DJ Walter, CA AF Huamani, J McMahan, CA Herbert, DC Reddick, R McCarrey, JR MacInnes, MI Chen, DJ Walter, CA TI Spontaneous mutagenesis is enhanced in Apex heterozygous mice SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID BASE EXCISION-REPAIR; DNA-POLYMERASE-BETA; GERM-CELL APOPTOSIS; APURINIC APYRIMIDINIC SITES; SPONTANEOUS MUTATION; TRANSGENIC MICE; MEIOTIC RECOMBINATION; SPERMATOGENIC CELLS; SECTORED PLAQUES; BINDING ACTIVITY AB Germ line DNA directs the development of the next generation and, as such, is profoundly different from somatic cell DNA. Spermatogenic cells obtained from young adult lacI transgenic mice display a lower spontaneous mutant frequency and greater in vitro base excision repair activity than somatic cells and tissues obtained from the same mice. However, spermatogenic cells from old lacI mice display a 10-fold higher mutant frequency. This increased spontaneous mutant frequency occurs coincidentally with decreased in vitro base excision repair activity for germ cell and testicular extracts that in turn corresponds to a decreased abundance of AP endonuclease. To directly test whether a genetic diminution of AP endonuclease results in increased spontaneous mutant frequencies in spermatogenic cell types, AP endonuclease heterozygous (Apex(+/-)) knockout mice were crossed with lacI transgenic mice. Spontaneous mutant frequencies were significantly elevated (approximately twofold) for liver and spleen obtained from 3-month-old Apex(+/-) lacI(+) mice compared to frequencies from Apex(+/+) lacI(+) littermates and were additionally elevated for somatic tissues from 9-month-old mice. Spermatogenic cells from 9-month-old Apex(+/+) lacI(+) mice were significantly elevated twofold compared to levels for 9-month-old Apex(+/+) lacI(+) control mice. These data indicate that diminution of AP endonuclease has a significant effect on spontaneous mutagenesis in somatic and germ line cells. C1 Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA. Univ Texas, Dept Biol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Div Res, San Antonio, TX USA. Los Alamos Natl Lab, Biosci Div, Los Alamos, NM USA. Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA. RP Walter, CA (reprint author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, Mail Code 7762,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM walter@uthscsa.edu FU NCI NIH HHS [CA86936, R01 CA086936]; NIA NIH HHS [P01 AG019316, AG19316, R01 AG021163, AG21163]; NIEHS NIH HHS [R01 ES009136, ES09136] NR 67 TC 40 Z9 43 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD SEP PY 2004 VL 24 IS 18 BP 8145 EP 8153 DI 10.1128/MCB.24.18.8145-8153 PG 9 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 852MY UT WOS:000223760600030 PM 15340075 ER PT J AU Nguyen, PT Holschneider, DP Maarek, JMI Yang, J Mandelkern, MA AF Nguyen, PT Holschneider, DP Maarek, JMI Yang, J Mandelkern, MA TI Statistical parametric mapping applied to an autoradiographic study of cerebral activation during treadmill walking in rats SO NEUROIMAGE LA English DT Article DE statistical parametric mapping; autoradiography; cerebral blood flow; rats ID BLOOD-FLOW; INDICATOR FRACTIONATION; BRAIN; SECTIONS; RECONSTRUCTION; INFORMATION; ALIGNMENT; IMAGES AB Autoradiographs are conventionally analyzed by a region-of-interest (ROI) analysis. However, definition of ROIs on an image set is labor intensive, is subject to potential inter-rater bias, and is not well suited for anatomically variable structures that may not consistently correspond to specific ROIs. Most importantly, the ROI method is poorly suited for whole-brain analysis, where one wishes to detect all activations resulting from an experimental paradigm. A system developed for analysis of imaging data in humans, Statistical Parametric Mapping (SPM), avoids some of these limitations but has not previously been adapted as a toot for the analysis of autoradiographs. Here, we describe the application of SPM to an autoradiographic data set mapping cerebral activation in rats during treadmill walking. We studied freely moving, non-tethered rats that received injections of the cerebral blood flow tracer [C-14]-iodoantipyrine, while they were performing a treadmill task (n=7) or during a quiescent control condition (n=6). Results obtained with SPM were compared to those previously reported using a standard ROI-based method of analysis [J. Cereb. Blood Flow Metab. 23(2003) 925]. The SPM method confirmed most areas detected as significant using the ROI approach. However, in the subcortex, SPM detected additional significant regions that, because of their irregular structures, fell short of statistical significance when analyzed by ROI. The SPM approach offers the ability to perform a semi-automated whole-brain analysis, and coupled with autoradiography, provides an effective means to globally localize functional activity in small animals. (C) 2004 Elsevier Inc. All rights reserved. C1 Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA. Univ Calif Irvine, Dept Phys & Astron, Irvine, CA USA. Univ So Calif, Dept Psychiat & Behav Sci, Los Angeles, CA USA. Univ So Calif, Dept Neurol, Los Angeles, CA USA. Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Holschneider, DP (reprint author), Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, 1333 San Pablo St,BMT 401,MC 9112, Los Angeles, CA 90089 USA. EM holschne@usc.edu FU NIBIB NIH HHS [R01 EB-00300-03, R01 EB000300] NR 25 TC 42 Z9 42 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD SEP PY 2004 VL 23 IS 1 BP 252 EP 259 DI 10.1016/j.neuroimage.2004.05.014 PG 8 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 850WL UT WOS:000223645000027 PM 15325372 ER PT J AU Holschneider, DP Maarek, JMI AF Holschneider, DP Maarek, JMI TI Mapping brain function in freely moving subjects SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS LA English DT Review DE brain mapping; nontethered; freely moving; positron emission tomography; single photon emission computed tomography; behavior; Tc-99m-HMPAO; Tc-99m-bicisate; Cu-64-PTSM ID CEREBRAL BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; CYTOCHROME-OXIDASE ACTIVITY; POSTTRAUMATIC-STRESS-DISORDER; PREFRONTAL ACTIVATION PROBE; SURFACE-AREA PRODUCT; GLUCOSE-UTILIZATION; PARKINSONS-DISEASE; NEURONAL-ACTIVITY; DYNAMIC EXERCISE AB Expression of many fundamental mammalian behaviors such as, for example, aggression, mating, foraging or social behaviors, depend on locomotor activity. A central dilemma in the functional neuroimaging of these behaviors has been the fact that conventional neuroimaging techniques generally rely on immobilization of the subject, which extinguishes all but the simplest activity. Ideally, imaging could occur in freely moving subjects, while presenting minimal interference with the subject's natural behavior. Here we provide an overview of several approaches that have been undertaken in the past to achieve this aim in both tethered and freely moving animals, as well as in nonrestrained human subjects. Applications of specific radiotracers to single photon emission computed tomography and positron emission tomography are discussed in which brain activation is imaged after completion of the behavioral task and capture of the tracer. Potential applications to clinical neuropsychiatry are discussed, as well as challenges inherent to constraint-free functional neuroimaging. Future applications of these methods promise to increase our understanding of the neural circuits underlying mammalian behavior in health and disease. (C) 2004 Elsevier Ltd. All rights reserved. C1 Univ So Calif, Dept Psychiat & Behav Sci, Los Angeles, CA 90089 USA. Univ So Calif, Dept Neurol, Los Angeles, CA 90089 USA. Univ So Calif, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA. RP Holschneider, DP (reprint author), Univ So Calif, Dept Psychiat & Behav Sci, 1333 San Pablo St,BMT 401,MC 9112, Los Angeles, CA 90089 USA. EM holschne@usc.edu FU NIBIB NIH HHS [R01 EB-00300-03, R01 EB000300] NR 136 TC 14 Z9 14 U1 3 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0149-7634 J9 NEUROSCI BIOBEHAV R JI Neurosci. Biobehav. Rev. PD SEP PY 2004 VL 28 IS 5 BP 449 EP 461 DI 10.1016/j.neubiorev.2004.06.007 PG 13 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 864LM UT WOS:000224635000001 PM 15465134 ER PT J AU Fishman, SM Gallagher, RM Carr, DB Sullivan, LW AF Fishman, SM Gallagher, RM Carr, DB Sullivan, LW TI The case for pain medicine SO PAIN MEDICINE LA English DT Editorial Material DE pain medicine; specialty; primary specialty; classification ID PRIMARY-CARE; RHEUMATOID-ARTHRITIS; PALLIATIVE CARE; PUBLIC-HEALTH; RHEUMATOLOGISTS; DISABILITY; EDUCATION; OUTCOMES; DISEASE; BURDEN AB Pain Medicine has its roots in multiple primary specialties and has developed into a discrete specialty with disparate practice styles. Its identity is in flux and is threatened by forces that may fragment this new field before it can set firm roots. The public health crisis of under treated pain parallels medicine's struggle to adequately classify Pain Medicine as a specialty. We review the case for Pain Medicine as a discrete discipline, with specialized knowledge, treatments, training and education. Without recognition of the specialty of Pain Medicine, and resolution of the fragmentation of the field throughout healthcare, medicine's approach to the current problem of under treated pain is likely to continue to be inadequate. C1 Univ Calif Davis, Sch Med, Dept Anesthesiol & Pain Med, Div Pain Med, Sacramento, CA 95817 USA. Philadelphia VA Med Ctr, Dept Anesthesia, Pain Med Serv, Philadelphia, PA USA. Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Univ Penn, Dept Anesthesiol, Philadelphia, PA 19104 USA. Tufts Univ, Sch Med, Dept Anesthesiol, Boston, MA 02111 USA. Tufts Univ, Sch Med, Dept Internal Med, Boston, MA 02111 USA. Morehouse Coll Sch Med, Off President Emeritus, Atlanta, GA USA. RP Fishman, SM (reprint author), Univ Calif Davis, Sch Med, Dept Anesthesiol & Pain Med, Div Pain Med, 4860 Y St,Suite 3200, Sacramento, CA 95817 USA. EM smfishman@ucdavis.edu NR 52 TC 16 Z9 16 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD SEP PY 2004 VL 5 IS 3 BP 281 EP 286 DI 10.1111/j.1526-4637.2004.04050.x PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 852UJ UT WOS:000223781700009 PM 15367306 ER PT J AU Chamlin, SL Frieden, IJ Williams, ML Chren, MM AF Chamlin, SL Frieden, IJ Williams, ML Chren, MM TI Effects of atopic dermatitis on young American children and their families SO PEDIATRICS LA English DT Article DE atopic dermatitis; quality of life; child-family relationships ID SLEEP; ECZEMA; DERMATOLOGY; IMPACT; INFANT; INDEX AB Objective. The psychologic, physical, and social impact of atopic dermatitis is complex and varies among children of different ages, and the effects of atopic dermatitis on the quality of life of very young American children and their families are not well understood. This study was conducted to document these effects of atopic dermatitis on young children and their families. Methods. Directed focus sessions were performed with parents of 26 young children with atopic dermatitis and 6 expert clinicians. Specific mentions of the ways in which atopic dermatitis affected the children and parents were reviewed, rank ordered, and categorized according to similarity in content. The categories were examined to determine the domains represented, and the domains were used to compose a conceptual framework of all of the ways that atopic dermatitis affects children and their families. Results. Parents and experts mentioned a total of 181 specific quality-of-life effects. A conceptual framework, developed from the 181 effects, contains the domains of physical health, emotional health, physical functioning, and social functioning; each domain includes effects on both the child and the parents. Conclusions. Atopic dermatitis greatly affects the quality of life of afflicted children and their families. The comprehensive conceptual framework summarizes the ways in which atopic dermatitis affects the quality of life in young American children. This conceptual framework forms the basis from which quality-of-life instruments can be developed. C1 Childrens Mem Hosp, Div Pediat Dermatol, Chicago, IL 60614 USA. Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, Dermatol Serv, San Francisco, CA USA. San Francisco Vet Affairs Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA. RP Chamlin, SL (reprint author), 2300 Childrens Plaza,Box 107, Chicago, IL 60614 USA. EM schamlin@childrensmemorial.org OI Frieden, Ilona/0000-0001-7305-5940 NR 16 TC 126 Z9 133 U1 1 U2 3 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD SEP PY 2004 VL 114 IS 3 BP 607 EP 611 DI 10.1542/peds.2004-0374 PG 5 WC Pediatrics SC Pediatrics GA 851AU UT WOS:000223657600005 PM 15342828 ER PT J AU Mital, S Fried, LF Piraino, B AF Mital, S Fried, LF Piraino, B TI Bleeding complications associated with peritoneal dialysis catheter insertion SO PERITONEAL DIALYSIS INTERNATIONAL LA English DT Article DE Tenckhoff catheter; bleeding; insertion; placement; complications; anticoagulation ID PLACEMENT; ACCESS AB Objective: To identify the incidence of bleeding complications associated with peritoneal dialysis catheter insertion. Design: Retrospective review at a tertiary-care center of all double-cuffed Tenckhoff catheters placed surgically from 1 January 1992 to 1 October 2003 to identify the incidence of major bleeding complications occurring with catheter insertion. Major bleeding episodes were defined as greater than or equal to3% decline in hematocrit, or the need for surgical intervention or blood transfusion within 2 weeks of insertion. Results: 292 catheters had been inserted in 263 patients. Six patients satisfied the criteria for a major bleeding event, for a major bleeding complication rate of 2%. Bleeding was associated with perioperative anticoagulation in 3 patients, uremia and thrombocytopenia in 1 patient, aspirin use and thrombocytopenia in 1 patient, and I patient experienced intraoperative bleeding. Coagulation parameters were not obtained prior to the procedure in 2 of the 6 patients. Conclusion:The rate of serious bleeding complications related to catheter insertion is low and usually associated with anticoagulation. Holding anticoagulation therapy for a minimum of 24 hours during the postoperative period should eliminate much of the risk. Coagulation parameters should also be obtained and corrected preoperatively. C1 Univ Pittsburgh, Sch Med, Div Renal & Electrolyte, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Mital, S (reprint author), A915 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM mitals@upmc.edu OI Piraino, Beth/0000-0001-5061-0841 NR 12 TC 10 Z9 11 U1 0 U2 0 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 0896-8608 J9 PERITON DIALYSIS INT JI Perit. Dial. Int. PD SEP-OCT PY 2004 VL 24 IS 5 BP 478 EP 480 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 861KP UT WOS:000224415700014 PM 15490989 ER PT J AU Bhidayasiri, R Truong, DD AF Bhidayasiri, R Truong, DD TI Chorea and related disorders SO POSTGRADUATE MEDICAL JOURNAL LA English DT Review ID DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; SYSTEMIC LUPUS-ERYTHEMATOSUS; BENIGN HEREDITARY CHOREA; HUNTINGTONS-DISEASE; SYDENHAMS CHOREA; TRINUCLEOTIDE REPEAT; MOVEMENT-DISORDERS; GENE CARRIERS; ACANTHOCYTOSIS; TETRABENAZINE AB Chorea refers to irregular, flowing, non-stereotyped, random, involuntary movements that often possess a writhing quality referred to as choreoathetosis. When mild, chorea can be difficult to differentiate from restlessness. When chorea is proximal and of large amplitude, it is called ballism. Chorea is usually worsened by anxiety and stress and subsides during sleep. Most patients attempt to disguise chorea by incorporating it into a purposeful activity. Whereas ballism is most often encountered as hemiballism due to contralateral structural lesions of the subthalamic nucleus and/or its afferent or efferent projections, chorea may be the expression of a wide range of disorders, including metabolic, infectious, inflammatory, vascular, and neurodegenerative, as well as drug induced syndromes. In clinical practice, Sydenham's chorea is the most common form of childhood chorea, whereas Huntington's disease and drug induced chorea account for the majority of adult onset cases. The aim of this review is to provide an up to date discussion of this disorder, as well as a practical approach to its management. C1 Parkinsons & Movement Disorders Inst, Fountain Valley, CA 92708 USA. Univ Calif Los Angeles, Med Ctr, Dept Neurol, David Geffen UCLA Sch Med, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Los Angeles, CA 90073 USA. RP Truong, DD (reprint author), Parkinsons & Movement Disorders Inst, 9940 Talbert Ave,204, Fountain Valley, CA 92708 USA. EM dtruong@pmdi.org OI Bhidayasiri, Roongroj/0000-0002-6901-2064 NR 64 TC 37 Z9 42 U1 3 U2 9 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0032-5473 J9 POSTGRAD MED J JI Postgrad. Med. J. PD SEP PY 2004 VL 80 IS 947 BP 527 EP 534 DI 10.1136/pgmj.2004.019356 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 852KF UT WOS:000223753500005 PM 15356354 ER PT J AU Yao, JK Magan, S Sonel, AF Gurklis, JA Sanders, R Reddy, RD AF Yao, JK Magan, S Sonel, AF Gurklis, JA Sanders, R Reddy, RD TI Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS LA English DT Article; Proceedings Paper CT 1st Brain Phospholipids Conference CY AUG-SEP -, 2003 CL Aviemore, SCOTLAND ID MAGNETIC-RESONANCE SPECTROSCOPY; CELL MEMBRANE DYNAMICS; FATTY-ACIDS; EICOSAPENTAENOIC ACID; DIETARY SUPPLEMENTATION; HUMAN ERYTHROCYTES; SYMPTOM REMISSION; RECEPTOR-BINDING; FRONTAL-CORTEX; POSTMORTEM AB Studies suggest that the omega-3 fatty acid supplementation may be beneficial in reducing symptom severity in schizophrenia. The mechanism(s) underlying the clinical effect is not known. Serotonin (5-HT) has been implicated in the pathophysiology of schizophrenia and in the mechanism of some antipsychotic agents. 5-HT receptors are known to be modified by omega-3 fatty acids. We examined whether supplementation with the omega-3 fatty acid eicosapentaenoic acid (EPA)-modified 5-HT amplified ADP-induced platelet aggregation in patients with schizophrenia. Two grams of ethyl-EPA was administered daily for 6 months supplementally to ongoing antipsychotic treatment in 12 patients with chronic schizophrenia, using an open-label design. Red blood cell membrane fatty acids and platelet functions (platelet aggregation and dense granule secretion) were monitored at baseline, 1-, 3- and 6-months. The EPA levels were elevated more than five-fold in RBC membranes of all patients after 3 months supplementation, indicating a high degree of compliance. Consistent with previous reports, there was inhibition of ADP-induced platelet aggregation by EPA supplementation. Moreover, EPA markedly enhanced the 5-HT responsivity as measured by the magnitude of 5-HT amplification on ADP-induced platelet aggregation. Previously, we have demonstrated a significant inverse correlation between 5-HT responsivity and psychosis severity in unmedicated patients with schizophrenia. Taken together, the present data support the notion that EPA may be mediating its therapeutic effects in schizophrenia via modulation of the 5-HT2 receptor complex. Published by Elsevier Ltd. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. VA Med Ctr, Dayton, OH USA. RP Yao, JK (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. EM jkyao@pitt.edu NR 42 TC 37 Z9 39 U1 2 U2 5 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0952-3278 J9 PROSTAG LEUKOTR ESS JI Prostaglandins Leukot. Essent. Fatty Acids PD SEP PY 2004 VL 71 IS 3 BP 171 EP 176 DI 10.1016/j.plefa.2004.03.011 PG 6 WC Biochemistry & Molecular Biology; Cell Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Cell Biology; Endocrinology & Metabolism GA 842JZ UT WOS:000223001600006 PM 15253886 ER PT J AU Ziada, A Barqawi, A Glode, LM Varella-Garcia, M Crighton, F Majeski, S Rosenblum, M Kane, M Chen, L Crawford, ED AF Ziada, A Barqawi, A Glode, LM Varella-Garcia, M Crighton, F Majeski, S Rosenblum, M Kane, M Chen, L Crawford, ED TI The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial SO PROSTATE LA English DT Article DE prostate; cancer; trastuzumab; HER-2 receptor ID METASTATIC BREAST-CANCER; IN-SITU HYBRIDIZATION; HER-2/NEU ONCOGENE AMPLIFICATION; MONOCLONAL-ANTIBODIES; PLUS TRASTUZUMAB; NEU ONCOGENE; RECEPTOR; CHEMOTHERAPY; DOCETAXEL; PROGRESSION AB PURPOSE. To investigate the efficacy and toxicity of the antibody to the HER-2/neu receptor (trastuzumab, Herceptin(R)) in the treatment of advanced hormone-refractory prostate cancer (HRPC). MATERIALS AND METHODS. Eighteen patients with HRPC were recruited for this phase 11 trial in which they received trastuzumab for 12 weeks or until disease progression or unacceptable toxicity was documented. HER-2 receptor overexpression was evaluated using immunohistochemistry (IHC) and dual-color fluorescence in-situ hybridization (FISH) assays. RESULTS. Trastuzumab as a single agent demonstrated little efficacy in treating HRPC. Two patients demonstrated stable disease based on a decrease in PSA level to less than 50% of baseline. No patient demonstrated a regression of radiographic bony or soft tissue metastatic disease. The medication was well tolerated in 16 patients (89%), and 2 patients (11%) had to be hospitalized for cardiac complications. CONCLUSIONS. Trastuzumab (Herceptin(R)) as a single agent demonstrated poor efficacy in treating HRPC. Based on promising results in treating breast cancer with regimens using Herceptin(R) and cytotoxic agents, a similar combination approach might demonstrate better efficacy in treating HRPC. (C) 2004 Wiley-Liss, Inc. C1 Univ Colorado, Hlth Sci Ctr, Dept Med, Div Med Oncol, Denver, CO 80262 USA. Anschutz Canc Pavil, Aurora, CO USA. Denver VA Med Ctr, Denver, CO USA. RP Barqawi, A (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Med Oncol, 4200 E 9th Ave C-319, Denver, CO 80262 USA. EM al.barqawi@uchsc.edu RI Barqawi, Al/A-3002-2008 NR 25 TC 105 Z9 112 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-4137 J9 PROSTATE JI Prostate PD SEP 1 PY 2004 VL 60 IS 4 BP 332 EP 337 DI 10.1002/pros.20065 PG 6 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 845DJ UT WOS:000223215700009 PM 15264245 ER PT J AU Cook, JM Orvaschel, H Simco, E Hersen, M Joiner, T AF Cook, JM Orvaschel, H Simco, E Hersen, M Joiner, T TI A test of the tripartite model of depression and anxiety in older adult psychiatric outpatients SO PSYCHOLOGY AND AGING LA English DT Article ID COGNITIVE CONTENT-SPECIFICITY; LATE-LIFE ANXIETY; NEGATIVE AFFECTIVITY; PSYCHOMETRIC PROPERTIES; MOOD DISORDERS; INVENTORY; SYMPTOMS; HYPERAROUSAL; RELIABILITY; ADOLESCENTS AB This study examined the tripartite model of depression and anxiety in 131 psychiatric outpatients, ages 55-87. Confirmatory factor analyses revealed that a 3-factor model provided an adequate fit to the observed data, that the 3-factor model was empirically superior to 1- or 2-factor models, and that the 3-factor structure obtained in the current sample of older adult outpatients converged with that obtained on a separate, younger sample. Negative affect was significantly related to depression and anxiety symptoms and syndromes, and positive affect was more highly related to depression than anxiety symptoms and syndromes. Ways for taking into account possible age-associated differences in emotion in older adults and thus improving the conceptual model of anxiety and depression are briefly noted. C1 Univ Penn, Treatment Res Ctr, Dept Psychiat, Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Nova SE Univ, Ctr Psychol Studies, Ft Lauderdale, FL 33314 USA. Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA. RP Cook, JM (reprint author), Univ Penn, Treatment Res Ctr, Dept Psychiat, Sch Med, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM cook_j@mail.trc.upenn.edu NR 55 TC 21 Z9 22 U1 1 U2 3 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0882-7974 J9 PSYCHOL AGING JI Psychol. Aging PD SEP PY 2004 VL 19 IS 3 BP 444 EP 451 DI 10.1037/0882-7974.19.3.444 PG 8 WC Gerontology; Psychology, Developmental SC Geriatrics & Gerontology; Psychology GA 850QH UT WOS:000223627000007 PM 15382995 ER PT J AU Hawkins, EJ Lambert, MJ Vermeersch, DA Slade, KL Tuttle, KC AF Hawkins, EJ Lambert, MJ Vermeersch, DA Slade, KL Tuttle, KC TI The therapeutic effects of providing patient progress information to therapists and patients SO PSYCHOTHERAPY RESEARCH LA English DT Article ID CLINICAL-SIGNIFICANCE; GROUP-PSYCHOTHERAPY; TREATMENT FAILURE; FEEDBACK; OUTCOMES; METAANALYSIS; INVENTORY AB Patient-focused research systems have been developed to monitor and inform therapists of patients' treatment progress in psychotherapy as a method of enhancing outcome. The current study examined the effects of providing treatment progress information to only therapists and to both patients and therapists during the course of psychotherapy. Outpatients (N = 201) at a hospital-based psychotherapy clinic were randomly assigned to 1 of 3 treatment groups: treatment as usual, therapist feedback, and patient-therapist feedback. Patients in the 2 feedback conditions demonstrated significantly greater improvement at termination than those in the treatment-as-usual condition, with no average increase in sessions attended. These findings suggest that providing feedback to patients and therapists may be a viable approach to enhancing patient outcomes. C1 Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Loma Linda Univ, Loma Linda, CA 92350 USA. RP Lambert, MJ (reprint author), Brigham Young Univ, Dept Psychol, 272 TLRB, Provo, UT 84602 USA. EM michael_lambert@byu.edu NR 38 TC 93 Z9 93 U1 1 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1050-3307 J9 PSYCHOTHER RES JI Psychother. Res. PD FAL PY 2004 VL 14 IS 3 BP 308 EP 327 DI 10.1093/ptr/kph027 PG 20 WC Psychology, Clinical SC Psychology GA 844GA UT WOS:000223144700003 ER PT J AU Binkert, CA Baker, PD Petersen, BD Szumowski, J Kaufman, JA AF Binkert, CA Baker, PD Petersen, BD Szumowski, J Kaufman, JA TI Peripheral vascular disease: Blinded study of dedicated calf MR angiography versus standard bolus-chase MR angiography and film hard-copy angiography SO RADIOLOGY LA English DT Article DE angiography, comparative studies; arteries, extremities; arteries, MR; arteries, stenosis or obstruction; magnetic resonance (MR), vascular studies ID DIGITAL-SUBTRACTION-ANGIOGRAPHY; LOWER-EXTREMITY; ARTERIES; AORTA; VESSELS AB PURPOSE: To compare the accuracy of contrast material-enhanced three-dimensional (3D) dedicated calf magnetic resonance (MR) angiography with that of bolus-chase MR angiography, with conventional angiography as the reference standard, in patients with symptomatic peripheral vascular disease (PVD). MATERIALS AND METHODS: Thirty men with symptomatic PVD were examined. MR angiography was performed at 1.5 T before conventional angiography. MR angiographic examination included 3D contrast-enhanced dedicated calf MR angiography and three-station bolus-chase MR angiography. Two radiologists blinded to conventional angiographic results evaluated the MR angiograms independently. Two angiographers evaluated the conventional angiograms in consensus. Calf artery segments were graded as having 50% or less stenosis, greater than 50% stenosis, or occlusion or as being nondiagnostic. Statistical analyses were performed with paired permutation testing. RESULTS: Analyses of 472 calf segments and 420 pelvic and thigh segments were performed. Of the 472 calf segments, three and 75 segments (reader 1) and seven and 91 segments (reader 2) were graded as nondiagnostic at dedicated calf MR angiography and bolus-chase MR angiography, respectively. Differences in diagnostic grade between the two examinations were significant (P < .001), accounting for within-subject correlations, with a mean estimated difference of -17.1% (95% confidence interval [CI]: -25.8%, -8.4%). In the calf arteries, the dedicated and bolus-chase MR angiographic sequences had diagnostic accuracies, respectively, of 81.5% (reader 1) and 79.1% (reader 2) and of 67.8% (reader 1) and 63.4% (reader 2). The dedicated calf sequence was significantly more accurate than the bolus-chase sequence (P = .001). The point estimate of the difference was 14.7%, with estimated correct diagnosis rates of 80.3% and 65.6% for the dedicated calf and bolus-chase examinations, respectively (95% CI for difference: 4.0%, 25.4%). The diagnostic accuracy of bolus-chase MR angiography at the pelvis-thigh level was slightly higher when it was performed first: 81.9% (reader 1) and 83.8% (reader 2) versus 74.3% (reader 1) and 80.0% (reader 2) when it was performed last. The difference was not significant (P = .21). CONCLUSION: Use of dedicated calf MR angiography led to significantly increased diagnostic accuracy in the calf arteries compared with standard bolus-chase MR angiography. Use of the dual-bolus technique did not jeopardize the diagnostic accuracy in the pelvic and thigh arteries. (C) RSNA, 2004. C1 Oregon Hlth Sci Univ, Dotter Intervent Inst, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Diagnost Radiol, Portland, OR 97201 USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA. Portland VA Med Ctr, Imaging Serv, Portland, OR USA. RP Binkert, CA (reprint author), Oregon Hlth Sci Univ, Dotter Intervent Inst, Portland, OR 97201 USA. EM cbinkert@partners.org NR 14 TC 25 Z9 27 U1 1 U2 1 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD SEP PY 2004 VL 232 IS 3 BP 860 EP 866 DI 10.1148/radiol.2323030244 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 848GG UT WOS:000223455000030 PM 15333800 ER PT J AU Schneider, A Barmada, MM Slivka, A Martin, JA Whitcomb, DC AF Schneider, A Barmada, MM Slivka, A Martin, JA Whitcomb, DC TI Clinical characterization of patients with idiopathic chronic pancreatitis and SPINK1 mutations SO SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID SERINE-PROTEASE INHIBITOR; KAZAL TYPE-1; DISEASE C1 Univ Pittsburgh, VA Pittsburgh Hlth Care Syst, Dept Med, Pittsburgh, PA 15101 USA. Univ Pittsburgh, VA Pittsburgh Hlth Care Syst, Dept Human Genet, Pittsburgh, PA 15101 USA. Univ Pittsburgh, VA Pittsburgh Hlth Care Syst, Dept Cell Biol & Physiol, Pittsburgh, PA 15101 USA. Univ Pittsburgh, Ctr Genome Sci, Pittsburgh, PA 15101 USA. RP Whitcomb, DC (reprint author), Univ Pittsburgh, VA Pittsburgh Hlth Care Syst, Dept Med, 571 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15101 USA. EM whitcomb@pitt.edu OI Barmada, M Michael/0000-0002-3604-6460 NR 5 TC 17 Z9 17 U1 0 U2 1 PU TAYLOR & FRANCIS AS PI OSLO PA CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY SN 0036-5521 J9 SCAND J GASTROENTERO JI Scand. J. Gastroenterol. PD SEP PY 2004 VL 39 IS 9 BP 903 EP 904 DI 10.1080/00365520410006710 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 854NL UT WOS:000223910500016 PM 15513391 ER PT J AU Shaner, A Miller, G Mintz, J AF Shaner, A Miller, G Mintz, J TI Schizophrenia as one extreme of a sexually selected fitness indicator SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; genetics; evolution; sexual selection; mate choice; fitness indicator ID MATE CHOICE; LEK PARADOX; GENETIC EPIDEMIOLOGY; REPRODUCTIVE RATES; ELABORATE TRAINS; MENSTRUAL-CYCLE; EVOLUTION; PSYCHOSIS; RESOLUTION; DISORDER AB Schizophrenia remains an evolutionary paradox. Its delusions, hallucinations and other symptoms begin in adolescence or early adulthood and so devastate sexual relationships and reproductive success that selection should have eliminated the disorder long ago. Yet it persists as a moderately heritable disorder at a global 1% prevalence-too high for new mutations at a few genetic loci. We suggest that schizophrenia persists and involves many loci because it is the unattractive, low-fitness extreme of a highly variable mental trait that evolved as a fitness ("good genes") indicator through mutual mate choice. Here we show that this hypothesis explains many key features of schizophrenia and predicts that some families carry modifier alleles that increase the indicator's neurodevelopmental sensitivity to heritable fitness and condition. Such alleles increase the extent to which high-fitness family members develop impressive courtship abilities and achieve high reproductive success, but also increase the extent to which low-fitness family members develop schizophrenia. Here we introduce this fitness indicator model of schizophrenia, discuss its explanatory power, explain how it resolves the evolutionary paradox, discuss its implications for gene hunting, and identify some empirically testable predictions as directions for further research. (C) 2003 Elsevier B.V. All rights reserved. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA. RP Shaner, A (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Andrew.Shaner@med.va.gov; gfmiller@unm.edu RI Miller, Geoffrey/C-4145-2008 NR 68 TC 24 Z9 26 U1 1 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD SEP 1 PY 2004 VL 70 IS 1 BP 101 EP 109 DI 10.1016/j.schres.2003.09.014 PG 9 WC Psychiatry SC Psychiatry GA 841VD UT WOS:000222958800012 PM 15246469 ER PT J AU Kraut, JA Madias, NE AF Kraut, JA Madias, NE TI What unique acid-base considerations exist in dialysis patients? SO SEMINARS IN DIALYSIS LA English DT Editorial Material ID HEMODIALYSIS-PATIENTS; METABOLIC-ACIDOSIS; POTASSIUM BICARBONATE; POSTMENOPAUSAL WOMEN; RENAL-DISEASE; BALANCE; INCREASES; ALBUMIN; RISK C1 Univ Calif Los Angeles, Sch Med, VA Greater Los Angeles Hlth Care Syst, Nephrol Sect 691 111L, Los Angeles, CA 90073 USA. Tufts Univ, Sch Med, Caritas St Elizabeths Med Ctr, Dept Med, Boston, MA 02111 USA. RP Kraut, JA (reprint author), Univ Calif Los Angeles, Sch Med, VA Greater Los Angeles Hlth Care Syst, Nephrol Sect 691 111L, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jkraut@ucla.edu NR 20 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0894-0959 J9 SEMIN DIALYSIS JI Semin. Dial. PD SEP-OCT PY 2004 VL 17 IS 5 BP 358 EP 360 DI 10.1111/j.0894-0959.2004.17344.x PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 856TK UT WOS:000224067700009 ER PT J AU Long, JA Gomez, A Asch, DA Shea, JA AF Long, JA Gomez, A Asch, DA Shea, JA TI Effect of race on ratings of hypothetical candidates for a research scholarship/research assistant position SO TEACHING AND LEARNING IN MEDICINE LA English DT Article; Proceedings Paper CT 26th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 30-MAY 03, 2003 CL VANCOUVER, CANADA SP Soc Gen Internal Med ID MEDICAL-STUDENTS; CULTURAL COMPETENCE; CARE; AWARENESS; SCHOOL; SEX AB Background: Study of the racial-ethnic biases of medical students is necessary to further understand health disparities. The objectives of this study were to (a) determine if medical students exhibit racial biases, (b) assess whether there are differences in racial biases among medical students who have and have not received a curriculum in cultural sensitivity, and (c) determine if these findings vary by student race-ethnicity. Description: We evaluated medical students' preferences in hiring hypothetical candidates for a research scholarship and a research assistant position. Each student received a packet containing four curricula vitae (CVs) with attached photographs. Three CVs and photographs were identical. The fourth CV was identical, but in half the packets the photograph was of an African American man and in the other half of a White man. Students were asked to provide ratings of suitability. Evaluation: The African American candidate received better ratings than the White candidate. There were no differences in the ratings by student curriculum receipt or race-ethnicity. Conclusion: We found no evidence that an African American candidate was discriminated against by medical students. Teaching and Learning in Medicine, 16(4), 355-360 Copyright (C) 2004 by Lawrence Erlbaum Associates, Inc. C1 Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. Univ Penn, Sch Arts & Sci, Philadelphia, PA 19104 USA. RP Long, JA (reprint author), 1201 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19146 USA. EM jalon@mail.med.upenn.edu NR 31 TC 1 Z9 1 U1 4 U2 7 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA SN 1040-1334 J9 TEACH LEARN MED JI Teach. Learn. Med. PD FAL PY 2004 VL 16 IS 4 BP 355 EP 360 DI 10.1207/s15328015tlm1604_8 PG 6 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 868GG UT WOS:000224901500008 PM 15582872 ER PT J AU Chaiswing, L Cole, MP St Clair, DK Ittarat, W Szweda, LI Oberley, TD AF Chaiswing, L Cole, MP St Clair, DK Ittarat, W Szweda, LI Oberley, TD TI Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury SO TOXICOLOGIC PATHOLOGY LA English DT Article DE adriamycin; 4-hydroxy-2-nonenal protein adducts; nitrotyrosine; reactive oxygen species; reactive nitrogen species; cardiac injury ID MANGANESE SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION PRODUCTS; NITRIC-OXIDE; SKELETAL-MUSCLE; TRANSGENIC MICE; 4-HYDROXY-2-NONENAL-MODIFIED PROTEINS; ANTHRACYCLINE ANTIBIOTICS; IMMUNOCHEMICAL DETECTION; PEROXYNITRITE FORMATION; ELECTRON-TRANSPORT AB The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach. B6C3 mice were treated with a single dose of 20 mg/kg ADR. Ultrastructural damage and levels of 4-hydroxy-2-nonenal (4HNE)-protein adducts and 3-nitrotyrosine (3NT) were analyzed. Quantitative ultrastructural damage using computerized image techniques showed cardiomyocyte injury as early as 3 hours, with mitochondria being the most extensively and progressively injured subcellular organelle. Analysis of 4HNE protein adducts by immunogold electron microscopy showed appearance of 4HNE protein adducts in mitochondria as early as 3 hours, with a peak at 6 hours and subsequent decline at 24 hours. 3NT levels were significantly increased in all subcellular compartments at 6 hours and subsequently declined at 24 hours. Our data showed ADR induced 4HNE-protein adducts in mitochondria at the same time point as when mitochondrial injury initially appeared. These results document for the first time in vivo that mitochondrial oxidative damage precedes nitrative damage. The progressive nature of mitochondrial injury suggests that mitochondria, not other subcellular organelles, are the major site of intracellular injury. C1 William S Middleton Mem Vet Adm Med Ctr, Dept Pathol & Lab Med, Madison, WI 53705 USA. Univ Wisconsin, Sch Med, Madison, WI 53705 USA. Mahidol Univ, Fac Med Technol, Bangkok 10700, Thailand. Univ Kentucky, Dept Toxicol, Lexington, KY 40506 USA. Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA. RP Oberley, TD (reprint author), William S Middleton Mem Vet Adm Med Ctr, Dept Pathol & Lab Med, Rm A-35,2500 Overlook Terrace, Madison, WI 53705 USA. EM dstc100@pop.uky.edu FU NCI NIH HHS [CA 49797, CA 59835]; NIDDK NIH HHS [T32DK07778] NR 64 TC 51 Z9 58 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0192-6233 J9 TOXICOL PATHOL JI Toxicol. Pathol. PD SEP-OCT PY 2004 VL 32 IS 5 BP 536 EP 547 DI 10.1080/01926230490502601 PG 12 WC Pathology; Toxicology SC Pathology; Toxicology GA 887GF UT WOS:000226293000006 PM 15605432 ER PT J AU Brennan, FX Beck, KD Servatius, RJ AF Brennan, FX Beck, KD Servatius, RJ TI Proinflammatory cytokines differentially affect leverpress avoidance acquisition in rats SO BEHAVIOURAL BRAIN RESEARCH LA English DT Article DE IL-1 beta; IL-6; TNF alpha; escape/avoidance conditioning ID NECROSIS-FACTOR-ALPHA; BEHAVIORAL VARIATIONS; CENTRAL MONOAMINE; IMMUNE-SYSTEM; INTERLEUKIN-1-BETA; MEMORY; PERFORMANCE; BRAIN; CORTICOSTERONE; HIPPOCAMPUS AB Recent evidence indicates that the pro-inflammatory cytokines (PICs) can affect learning and memory processes. To examine the effect of the PICs on leverpress escape/avoidance conditioning, we injected male Sprague-Dawley rats with IL-1beta, IL-6 (both 3.0 mug/kg, i.p.), TNFalpha (6.0 mug/kg, i.p.) or vehicle, 24 h before a single 4-h session of leverpress escape/avoidance conditioning. The TNFalpha-treated animals made more avoidance responses and fewer escape responses than controls during the last hour of the session. Further, both TNFalpha- and IL-1beta-treated animals had a higher percent avoidance than controls during the 4th hour of the session. None of the cytokines had an effect on the number of leverpresses during safety, a putative measure of anxiety. Results are discussed in terms of the differential central effects of the pro-inflammatory cytokines and the possible relationship to avoidance conditioning. (C) 2004 Elsevier B.V. All rights reserved. C1 Philadelphia VA Med Ctr, Med Res Serv 151, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. VA Med Ctr, Neurobehav Res Lab, E Orange, NJ 07018 USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosci, Newark, NJ 07103 USA. RP Brennan, FX (reprint author), Philadelphia VA Med Ctr, Med Res Serv 151, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM francis.brennan@med.va.gov NR 25 TC 21 Z9 22 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-4328 J9 BEHAV BRAIN RES JI Behav. Brain Res. PD AUG 31 PY 2004 VL 153 IS 2 BP 351 EP 355 DI 10.1016/j.bbr.2003.12.025 PG 5 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 845JX UT WOS:000223239800005 PM 15265629 ER PT J AU Bermejo, J Rojo-Alvarez, JL Antoranz, JC Abel, M Burwash, IG Yotti, R Moreno, M Garcia-Fernandez, MA Lehmann, KG Otto, CM AF Bermejo, J Rojo-Alvarez, JL Antoranz, JC Abel, M Burwash, IG Yotti, R Moreno, M Garcia-Fernandez, MA Lehmann, KG Otto, CM TI Estimation of the end of ejection in aortic stenosis - An unreported source of error in the invasive assessment of severity SO CIRCULATION LA English DT Article; Proceedings Paper CT Scientific Sessions of the American-Heart-Association CY NOV 11-14, 2001 CL Anaheim, CA SP Amer Heart Assoc DE valves; stenosis; catheterization; hemodynamics; animal experimentation ID LEFT-VENTRICULAR EJECTION; PRESSURE DIFFERENCE; VALVE; FLOW; GRADIENTS; DYNAMICS; CATHETER; RECOVERY; DISEASE; VOLUME AB Background-All indices of aortic stenosis (AS) rely on measurements of mean transvalvular pressure gradient ((&UDelta;P) over bar) and flow rate. Because the gradient is reversed during late ejection, the late systolic left ventricular (LV)-aortic pressure crossover may be an erroneous landmark of end-ejection. The aortic incisura should be a better reference to calculate indices of AS invasively. Methods and Results-The accuracy of the pressure crossover and the incisura to define end-ejection was assessed in a chronic AS experimental model (9 dogs) with the use of an implantable flowmeter and Doppler echocardiography as reference. In 288 hemodynamic recordings analyzed (aortic valve area [AVA]: 0.74+/-0.46 cm(2)), ejection ended 37+/-29 ms after the pressure crossover but almost simultaneously with the incisura (2+/-17 ms). Pressure crossover error accounted for significant errors in the measurement of (&UDelta;P) over bar (95% limits of agreement, +0 to +7 mm Hg) and AVA (-0.1 to +0.2 cm(2)). These errors were reduced to less than half with the use of the incisura to define end-ejection. Additionally, the agreement with Doppler-derived AS indices was best with use of the incisura. Pressure crossover error was maximal in situations of higher output, moderate orifice narrowing, higher arterial compliance, and lower vascular resistance. In 32 consecutive patients undergoing cardiac catheterization for AS, the pressure crossover induced a clinically important overestimation of the (&UDelta;P) over bar from +22 to +50%. Errors in AVA estimation were considerably smaller (-2% to +6%) because of simultaneous and offsetting errors in the measurements of (&UDelta;P) over bar and flow. Conclusions-The aortic incisura and not the second pressure crossover should be used to obtain invasive indices of AS. C1 Hosp Gen Gregorio Maranon, Lab Echocardiog, Dept Cardiol, Madrid 28007, Spain. Univ Carlos III Madrid, Dept Signal Theory & Commun, Madrid, Spain. Univ Nacl Educ Distancia, Dept Math Phys & Fluids, Fac Ciencias, E-28040 Madrid, Spain. Univ Washington, Div Cardiol, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Providence Hlth Grp, Seattle, WA USA. Univ Ottawa, Inst Heart, Ottawa, ON, Canada. Univ Washington, Div Cardiol, Seattle, WA 98195 USA. RP Bermejo, J (reprint author), Hosp Gen Gregorio Maranon, Lab Echocardiog, Dept Cardiol, Dr Esquerdo 46, Madrid 28007, Spain. EM javbermejo@jet.es RI Antoranz, Carlos/A-5414-2009 OI Antoranz, Carlos/0000-0003-2925-3629; Garcia Fernandez, Miguel Angel/0000-0001-7010-0830; Otto, Catherine/0000-0002-0527-9392 NR 28 TC 15 Z9 15 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD AUG 31 PY 2004 VL 110 IS 9 BP 1114 EP 1120 DI 10.1161/01.CIR.0000139846.66047.62 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 850FD UT WOS:000223595700015 PM 15326077 ER PT J AU Yaffe, K Blackwell, T Kanaya, AM Davidowitz, N Barrett-Connor, E Krueger, K AF Yaffe, K Blackwell, T Kanaya, AM Davidowitz, N Barrett-Connor, E Krueger, K TI Diabetes, impaired fasting glucose, and development of cognitive impairment in older women SO NEUROLOGY LA English DT Article ID INSULIN-DEGRADING ENZYME; ALZHEIMERS-DISEASE; RISK-FACTORS; POSTMENOPAUSAL WOMEN; DEMENTIA; POPULATION; MELLITUS; DECLINE; HEALTH; PERFORMANCE AB Objective: To investigate the association between diabetes and impaired fasting glucose (IFG) and cognition and risk of developing both dementia and mild cognitive impairment (MCI) in older women. Methods: The authors analyzed data from a 4-year randomized trial of raloxifene among 7,027 osteoporotic postmenopausal women (mean age, 66.3 years) at 178 sites. Diabetes was defined by history, fasting blood glucose greater than or equal to7.0 mmol/L (greater than or equal to126 mg/dL), or use of hypoglycemic agents; IFG was defined as fasting glucose <7.0 mmol/L but >6.11 mmol/ L (110 mg/dL); all others were considered to have normal glucose (NG). The main outcome was baseline and 4-year change on five standardized cognitive tests (z scores with lower scores indicating worse performance) and risk of developing clinically significant impairment (dementia, mild cognitive impairment, or very low cognitive score). Results: A total of 267 (3.8%) women had diabetes and 297 (4.2%) had IFG. Women with IFG had worse baseline cognitive scores compared to women with NG but better scores than diabetics (age-adjusted composite z score based on five tests: NG 0.40, 95% CI 0.30 to 0.49; IFG 0.14, 95% CI -0.36 to 0.64; diabetics -0.78, 95% CI -1.23 to -0.33; p<0.001). There was greater 4-year decline among diabetics (age and treatment-adjusted composite z score: NG -0.05, 95% CI -0.16 to 0.05; IFG 0.11, 95% CI -0.53 to 0.75; diabetics -1.00, 95% CI -1.50 to -0.50; p=0.001). Further adjustment for education, race, and depression led to similar results. Risk of developing cognitive impairment among women with IFG or diabetes was increased by almost twofold (age and treatment-adjusted OR=1.64; 95% CI 1.03 to 2.61 for IFG; OR=1.79; 95% CI 1.14 to 2.81 for diabetics). Conclusions: Diabetic as well as pre-diabetic women have impaired cognitive performance and greater risk of developing cognitive impairment. C1 Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Diego, Dept Community & Family Med, La Jolla, CA 92093 USA. Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat, Box 181 4150 Clement St, San Francisco, CA 94121 USA. EM kyaffe@itsa.ucsf.edu FU NIA NIH HHS [R01 AG021918-01] NR 34 TC 258 Z9 268 U1 1 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD AUG 24 PY 2004 VL 63 IS 4 BP 658 EP 663 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 848UP UT WOS:000223493800012 PM 15326238 ER PT J AU Sonnenberg, A AF Sonnenberg, A TI Personal view: 'Don't ask, don't tell' - the undesirable consequences of incidental test results in gastroenterology SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID HELICOBACTER-PYLORI; GUIDELINES; THERAPY; ARTICLE AB A gastroenterologist is frequently approached to perform an endoscopic procedure after an incidental test has resulted in an unexpected positive finding. Should the incidental test result be ignored or automatically followed by an endoscopic procedure? The present analysis strives to characterize the common pattern of such scenarios and resolve their underlying dilemma. A model of game theory is used as a mathematical tool to develop general management strategies. Three clinical scenarios are used as examples to demonstrate this approach. The model is based on how doctors rank the various outcomes with which they are confronted by the incidental test results. The ranks of different outcomes are listed in a decision matrix that is converted into a two-by-two, non-zero, ordinal game. All scenarios of incidental test results emerge as a similar type of game that is best played by both parties adhering to the same set of strategies: 'Don't do the test' and 'don't respond to whatever test result it yields'. These two strategies lead to a Nash equilibrium for a non-zero game, where neither party can improve its payoff any further by choosing a different strategy. Although the equilibrium does not provide the individual players with their best possible payoff, it yields the best overall outcome available to both parties given the economic and medical constraints of the situation. C1 Portland VA Med Ctr, Gastroenterol Sect, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Portland, OR USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Gastroenterol Sect, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 16 TC 5 Z9 5 U1 0 U2 1 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD AUG 15 PY 2004 VL 20 IS 4 BP 381 EP 387 DI 10.1111/j.1365-2036.2004.02087.x PG 7 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 844JK UT WOS:000223154000002 PM 15298631 ER PT J AU Poorkaj, P Nutt, JG James, D Gancher, S Bird, TD Steinbart, E Schellenberg, GD Payami, H AF Poorkaj, P Nutt, JG James, D Gancher, S Bird, TD Steinbart, E Schellenberg, GD Payami, H TI parkin mutation analysis in clinic patients with early-onset Parkinson's disease SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE Parkinson's disease; parkin; clinical testing; gene dosage ID RECESSIVE JUVENILE PARKINSONISM; PSEUDO-DOMINANT INHERITANCE; GENE-MUTATIONS; LEWY BODIES; 2 FAMILIES; PHENOTYPE; PATHWAY; ALLELES; EUROPE AB parkin mutations are the most common identified cause of Parkinson's disease (PD). It has been suggested that patients with young-onset PD be screened for parkin mutations as a part of their clinical work-up. The aim of this study was to assess parkin mutation frequency in a clinical setting, correlate genotype with phenotype, and evaluate the current justification for clinical parkin testing. Patients were selected from a movement disorder clinic based on diagnosis of PD and onset age less than or equal to 40 years.parkin was genotyped by sequence and dosage analysis for all 12 exons. Key relatives and controls were screened for identified mutations. Mutations were found in 7/ 39 patients. Two patients were compound heterozygous; five were heterozygous. Mutations included deletions in exons 2, 3, and 8, duplications in exons 2-4, and 9, and P437L substitution. Seventy-eight percent of mutations were deletions/multiplications. A novel substitution (R402W) was found in one patient and in one control. None of the point mutations found in patients were detected in 96 controls. parkin phenotypes were consistent with idiopathic PD. In conclusion, parkin mutations are common in the clinic setting: 10% of PD patients had early-onset and 18% of them had parkin mutations. However, if parkin is recessive, only 5% of early-onset cases who had compound mutations could be attributed to this locus. Mutation frequency was 0.12 (95% Cl 0.04-0.19). parkin cases can present as typical idiopathic PD, distinguishable only by molecular testing. Seventy percent of parkin cases were heterozygous. It is unclear whether heterozygous mutations are pathogenic. parkin-based diagnosis and counseling require a better understanding of the mode of inheritance, penetrance, and carrier frequencies. (C) 2004 Wiley-Liss, Inc. C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR USA. New York State Dept Hlth, Wadsworth Ctr, Genom Inst, Div Genet Disorders, Albany, NY 12208 USA. Kaiser Permanente Ctr Hlth Res, Portland, OR USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA. Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. RP Payami, H (reprint author), New York State Dept Hlth, Wadsworth Ctr, Genom Inst, Div Genet Disorders, 120 New Scotland Ave, Albany, NY 12208 USA. EM hpayami@wadsworth.org FU NINDS NIH HHS [R01 NS36960] NR 32 TC 31 Z9 32 U1 2 U2 8 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0148-7299 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD AUG 15 PY 2004 VL 129A IS 1 BP 44 EP 50 DI 10.1002/ajmg.a.30157 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA 842AP UT WOS:000222975000010 PM 15266615 ER PT J AU Kolevzon, A Smith, CJ Schmeidler, J Buxbaum, JD Silverman, JM AF Kolevzon, A Smith, CJ Schmeidler, J Buxbaum, JD Silverman, JM TI Familial symptom domains in monozygotic siblings with autism SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE autism; monozygotic twins; concordance; genetics; heterogeneity; symptom domains ID PERVASIVE DEVELOPMENTAL DISORDERS; MULTIPLEX FAMILIES; CHROMOSOME 7Q; CHILDREN; LANGUAGE; HISTORY; TWINS; INDIVIDUALS; LINKAGE; PHENOTYPES AB Autism is characterized by a triad of symptom domains (impaired social interaction, communication deficits, and repetitive behaviors) that vary significantly in their clinical presentation across the population. Within families with more than one affected member, however, discrepant findings exist with regard to symptom variability. Reduced intrafamily variance is of particular importance because it supports an underlying model of genetic heterogeneity in the transmission of autism, and the identification of familial clinical subtypes can be used to select more homogeneous samples for linkage analysis in the future. This study examines whether there are specific features of autism that show decreased variance within 16 families with monozygotic siblings concordant for autism. Evidence for familiality was defined as significantly decreased variance of symptom levels within monozygotic siblingships as compared to between siblingships. Using regression analysis, we demonstrated Significant aggregation of symptoms within monozygotic siblingships for two of the three main symptom domains in autism: impairments in communication and social interaction showed significant familiality. Within the repetitive behavior domain, only the categories of circumscribed interests and preoccupation with part-objects showed reduced variance within siblingships. In addition, with the exception of a negative association between the social and behavior domains, partial correlation coefficients did not reveal significant associations between the levels of different symptom domains within families, suggesting that the levels of clinical features seen in autism may be a result of mainly independent genetic traits. Because of presumed genetic heterogeneity and the wide clinical variation seen in autism and other pervasive developmental disorders, selecting probands according to specific features known to show reduced variance within families may provide more homogeneous samples for genetic analysis and strengthen the power to detect the specific genes involved in autism. (C) 2004 Wiley-Liss, Inc. C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. Bronx Vet Adm Med Ctr, Psychiat Serv, Bronx, NY USA. Mt Sinai Sch Med, Seaver Autism Res Ctr, New York, NY USA. RP Kolevzon, A (reprint author), Mt Sinai Sch Med, Dept Psychiat, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA. EM alexander.kolevzon@mssm.edu OI Buxbaum, Joseph/0000-0001-8898-8313 FU NIMH NIH HHS [U54 MH 066673] NR 34 TC 35 Z9 35 U1 3 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0148-7299 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD AUG 15 PY 2004 VL 129B IS 1 BP 76 EP 81 DI 10.1002/ajmg.b.30011 PG 6 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 842AW UT WOS:000222975700018 PM 15274045 ER PT J AU Wiest, FC Bryson, CL Burman, M McDonell, MB Henikoff, JG Fihn, SD AF Wiest, FC Bryson, CL Burman, M McDonell, MB Henikoff, JG Fihn, SD TI Suboptimal pharmacotherapeutic management of chronic stable angina in the primary care setting SO AMERICAN JOURNAL OF MEDICINE LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY-DISEASE; CONGESTIVE-HEART-FAILURE; PRACTICE GUIDELINES; FUNCTIONAL STATUS; ELDERLY-PATIENTS; HEALTH-STATUS; PHYSICIAN SPECIALTY; MEDICAL-TREATMENT; BETA-BLOCKERS AB PURPOSE: To assess the adequacy of symptomatic treatment for chronic stable angina among primary care patients who receive care from the Department of Veterans Affairs (VA). METHODS: We conducted a cross-sectional analysis involving 7038 veterans with self-reported coronary heart disease who completed the Seattle Angina Questionnaire and who had made a primary care visit to one of seven VA general internal medicine clinics between May 1997 and January 2000. The main outcome measures included the anginal frequency scale of the questionnaire and receipt of prescriptions for antianginal medication in three classes (beta-blockers, calcium antagonists, and long-acting nitrates). RESULTS: Seventy percent of the patients experienced angina or took sublingual nitroglycerin preparations two or fewer times per week. Of the 30% of patients with more frequent symptoms, 22% were receiving no antianginal medications and 33% were receiving only one class of antianginal medication. Of the patients with frequent angina who were prescribed medications, 18% were taking no medications at the recommended therapeutic dose and 50% were receiving only one class of antianginal medication at the recommended therapeutic dose. CONCLUSION: A substantial proportion of patients with frequent episodes of chronic stable angina appeared to be receiving an inadequate antianginal regimen in terms of number of agents and dosages. While numerous studies have described inadequate treatment of asymptomatic conditions and risk factors, our results suggest similar deficiencies in addressing a serious and eminently treatable symptomatic problem. (C) 2004 by Elsevier Inc. C1 Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98108 USA. RP Bryson, CL (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, 1660 S Columbian Way,Mail Stop 152, Seattle, WA 98108 USA. EM cbryson@u.washington.edu NR 44 TC 32 Z9 33 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD AUG 15 PY 2004 VL 117 IS 4 BP 234 EP 241 DI 10.1016/j.amjmed.2004.02.044 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 846NW UT WOS:000223323500003 PM 15308432 ER PT J AU Burton, EC Phillips, RS Covinsky, KE Sands, LP Goldman, L Dawson, NV Connors, AF Landefeld, CS AF Burton, EC Phillips, RS Covinsky, KE Sands, LP Goldman, L Dawson, NV Connors, AF Landefeld, CS TI The relation of autopsy rate to physicians' beliefs and recommendations regarding autopsy SO AMERICAN JOURNAL OF MEDICINE LA English DT Article ID ILL HOSPITALIZED ADULTS; QUALITY-ASSURANCE; CLINICIAN; ATTITUDES; SUPPORT; PATHOLOGIST; DIAGNOSES; MORTALITY; CONSENT; TRENDS AB PURPOSE: Multiple factors have affected the decline in autopsy rates. Our goal was to determine the relation of physicians' recommendations regarding autopsy, as well as patient and surrogate decision-maker characteristics, to autopsy performance. METHODS: We assessed measures related to autopsy performance using data from two teaching institutions in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. We included patients who had died within 6 months of their index hospitalization and for whom information was available on autopsy performance,. physicians' response to questions about autopsy, and interviews with surrogate decision makers about autopsy performance. We assessed the association between autopsy performance and the strength of a physician's recommendation for autopsy, adjusting for patient, surrogate, and physician characteristics. RESULTS: Of the 680 patients who died, 59% (n = 402) met our inclusion criteria. Based on physician and surrogate responses, the expected autopsy rate was 42% while the actual autopsy rate was 23%. The autopsy rate was higher when the physician's recommendation for autopsy was strong or very strong at the time of death compared with when autopsy was not recommended strongly or not at all (P <0.001). The strength of the physician's postmortem recommendation was independently associated with autopsy performance after adjusting for patient, surrogate, and physician characteristics (P <0.001). CONCLUSION: Autopsies are less likely to be performed when not recommended strongly or not at all. Training physicians (or others) how to recommend autopsies may increase autopsy rates. (C) 2004 by Elsevier Inc. C1 Baylor Univ, Med Ctr, Dept Pathol, Dallas, TX 75246 USA. Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA. San Francisco VA Med Ctr, Dept Vet Affairs, Natl Qual Scholars Fellowship Program, San Francisco, CA USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. Univ Calif San Francisco, Ctr Aging, San Francisco, CA 94143 USA. Purdue Univ, Dept Nursing, W Lafayette, IN 47907 USA. Case Western Reserve Univ, Ctr Hlth Care Res & Policy, Cleveland, OH 44106 USA. Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA. Metro Hlth Med Ctr, Cleveland, OH USA. RP Burton, EC (reprint author), Baylor Univ, Med Ctr, Dept Pathol, 5th Floor,Y Wing,3500 Gaston Ave, Dallas, TX 75246 USA. EM LizBu@baylorhealth.edu RI Sands, Laura/E-8919-2015 OI Sands, Laura/0000-0003-2446-4486 NR 39 TC 28 Z9 28 U1 2 U2 3 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD AUG 15 PY 2004 VL 117 IS 4 BP 255 EP 261 DI 10.1016/j.amjmed.2004.01.028 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 846NW UT WOS:000223323500006 PM 15308435 ER PT J AU Gurubhagavatula, I Maislin, G Nkwuo, JE Pack, AI AF Gurubhagavatula, I Maislin, G Nkwuo, JE Pack, AI TI Occupational screening for obstructive sleep apnea in commercial drivers SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE nocturnal pulse oximetry; polysomnography; questionnaire ID POSITIVE AIRWAY PRESSURE; PROSPECTIVE PARALLEL TRIAL; DAYTIME SLEEPINESS; POPULATION; PERFORMANCE; ADULTS; RISK; CPAP; PREDICTION; DISORDERS AB Excluding the presence of obstructive sleep apnea in commercial drivers is valuable, as the syndrome may increase their risk of sleepiness-related accidents. Using polysomnography as the criterion standard, we prospectively compared accuracies of five strategies in excluding the presence of severe sleep apnea and, secondarily, any sleep apnea among 406 commercial drivers. These strategies were as follows: (1) symptoms; (2) body mass index; (3) symptoms plus body mass index; (4) a two-stage approach with symptoms plus body mass index for everyone, followed by oximetry for a subset; and (5) oximetry for all. For excluding severe apnea, the two-stage strategy was highly successful, with 91% sensitivity and specificity, and a negative likelihood ratio of 0.10. This strategy was comparable in accuracy to oximetry, which had a negative likelihood ratio of 0.12, and was 88% sensitive and 95% specific. If we avoided oximetry altogether, then symptoms together with body mass index were 81% sensitive and 73% specific, with a negative likelihood ratio of 0.26. On the other hand, excluding any apnea could not be done with reasonable accuracy unless oximetry was used. We conclude that two-stage screening is likely to be a viable means of excluding severe sleep apnea among commercial drivers. C1 Univ Penn, Neurobiol Hosp, Ctr Sleep & Resp, Philadelphia, PA 19104 USA. Univ Penn, Med Ctr, Ctr Sleep & Resp Neurobiol, Philadelphia, PA 19104 USA. Univ Penn, Med Ctr, Dept Med, Div Sleep Med, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Pulm & Crit Care & Sleep Sect, Philadelphia, PA USA. RP Gurubhagavatula, I (reprint author), Univ Penn, Neurobiol Hosp, Ctr Sleep & Resp, 9th Floor,Maloney Bldg,3600 Spruce St, Philadelphia, PA 19104 USA. EM gurubhag@mail.med.upenn.edu FU NCRR NIH HHS [K23-RR16068-03, 3-M01-RR00040, K23 RR016068]; NHLBI NIH HHS [P01-HL60287] NR 42 TC 64 Z9 65 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD AUG 15 PY 2004 VL 170 IS 4 BP 371 EP 376 DI 10.1164/rccm.200307-968OC PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 845DY UT WOS:000223217300008 PM 15142866 ER PT J AU Freedland, SJ Aronson, WJ Kane, CJ Terris, MK Presti, JC Trock, B Amling, CL AF Freedland, SJ Aronson, WJ Kane, CJ Terris, MK Presti, JC Trock, B Amling, CL TI Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels SO CANCER LA English DT Article DE prostate carcinoma; radical prostatectomy; prostate-specific antigen; prostate-specific antigen recurrence ID DISEASE RECURRENCE; RADIATION-THERAPY; CANCER; CUTOFF; SPECIMENS; NOMOGRAM; SURVIVAL; NG./ML.; NG/ML; STAGE AB BACKGROUND. Recent studies have shown that a significant number of men with normal prostate-specific antigen (PSA) levels have prostate carcinoma, Whether malignancies in such men are associated with better outcomes is unclear. The authors compared the risk of biochemical failure after radical prostatectomy (RP) between men with normal PSA levels and men with elevated PSA levels. METHODS. Data were examined from 1582 men who underwent RP between 1988 and 2002 at I of 5 equal-access medical centers. Patients were segregated into groups based on serum PSA levels (with stratification according to age-specific reference ranges). Clinical and pathologic characteristics and biochemical outcome data were compared across groups using analyses of variance, log-rank tests, and Cox proportional hazards analysis. RESULTS. Men who had normal PSA levels had significantly fewer high-grade tumors compared with men who had higher PSA levels (P < 0.001). The former group had a significantly decreased incidence of positive surgical margins, extracapsular disease, seminal vesicle invasion, and lymph node involvement (P < 0.001). On multivariate analysis, only serum PSA level (P < 0.001) and biopsy Gleason score (P < 0.001) predicted the time to disease recurrence. When only men with serum PSA levels < 10 ng/mL were examined, PSA level treated as a continuous variable remained a significant predictor of time to biochemical failure (P = 0.02). CONCLUSIONS. Men who had normal PSA levels had significantly fewer high-grade tumors and significantly better biochemical outcomes after undergoing RP compared with men who had elevated PSA levels. Overall, men with normal PSA levels who undergo RP represent a favorable risk group. Cancer 2004;101:748-53. (C) 2004 American Cancer Society. C1 Johns Hopkins Sch Med, Dept Urol, Baltimore, MD 21287 USA. Vet Adm Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. Vet Adm Med Ctr, Urol Sect, Dept Surg, San Francisco, CA 94121 USA. Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA. Med Coll Georgia, Dept Surg, Urol Sect, Augusta, GA 30912 USA. Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA. San Diego Naval Hosp, Dept Urol, San Diego, CA USA. RP Freedland, SJ (reprint author), Johns Hopkins Sch Med, Dept Urol, 600 N Wolfe St, Baltimore, MD 21287 USA. EM sfreedl1@jhmi.edu OI Terris, Martha/0000-0002-3843-7270 NR 24 TC 14 Z9 14 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER JI Cancer PD AUG 15 PY 2004 VL 101 IS 4 BP 748 EP 753 DI 10.1002/cncr.20390 PG 6 WC Oncology SC Oncology GA 843UD UT WOS:000223111200011 PM 15305405 ER PT J AU Keith, RL Miller, YE Hudish, TM Girod, CE Sotto-Santiago, S Franklin, WA Nemenoff, RA March, TH Nana-Sinkam, SP Geraci, MW AF Keith, RL Miller, YE Hudish, TM Girod, CE Sotto-Santiago, S Franklin, WA Nemenoff, RA March, TH Nana-Sinkam, SP Geraci, MW TI Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice SO CANCER RESEARCH LA English DT Article ID ACTIVATED RECEPTOR-GAMMA; CIGARETTE-SMOKE; GENE-EXPRESSION; BETA-CAROTENE; RESPIRATORY BRONCHIOLITIS; CARDIOVASCULAR-DISEASE; INTERSTITIAL PNEUMONIA; INDUCED EMPHYSEMA; TRANSGENIC MICE; ASPIRIN USE AB Increased pulmonary production of prostaglandin 12 (prostacyclin) by lung-specific overexpression of prostacyclin synthase decreases lung tumor incidence and multiplicity in chemically induced murine lung cancer models. We hypothesized that pulmonary prostacyclin synthase overexpression would prevent lung carcinogenesis in tobacco-smoke exposed mice. Murine exposure to tobacco smoke is an established model of inducing pulmonary adenocarcinomas and allows for the testing of potential chemopreventive strategies. Transgenic FVB/N mice with lung-specific prostacyclin synthase overexpression were exposed to mainstream cigarette smoke for 22 weeks and then held unexposed for an additional 20 weeks. All of the exposed animals developed bronchiolitis analogous to the respiratory bronchiolitis seen in human smokers. The transgenic mice, when compared with smoke-exposed transgene negative littermates, had significant decreases in tumor incidence and multiplicity. Significantly fewer transgenics (6 of 15; 40%) developed tumors compared with the tumor incidence in wild-type littermates (16 of 19; 84%; Fisher's exact test, P = 0.012). Tumor multiplicity was also significantly decreased in the transgenic animals (tg(+) = 0.4 +/- 0.5 versus wild-type = 1.2 +/- 0.86 tumors/mouse; P < 0.001). Targeted prostaglandin levels at the time of sacrifice revealed significantly elevated prostaglandin 12 levels in the transgenic animals, coupled with significantly decreased prostaglandin E-2 levels. Gene expression analysis of isolated type II pneumocytes suggests potential explanations for the observed chemoprevention, with Western blot analysis confirming decreased expression of cytochrome p450 2e1. These studies extend our previous studies and demonstrate that manipulation of prostaglandin production distal to cyclooxygenase significantly reduces lung carcinogenesis in a tobacco smoke exposure model, and gene expression studies show critical alterations in antioxidation, immune response, and cytokine pathways. C1 Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80220 USA. Denver VA Med Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO USA. Univ Texas, SW Med Ctr, Dept Med, Div Pulm & Crit Care Med, Dallas, TX 75230 USA. Lovelace Resp Res Inst, Inhalat Toxicol Lab, Albuquerque, NM USA. RP Keith, RL (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, 1055 Clermont, Denver, CO 80220 USA. EM robert.keith@uchsc.edu NR 50 TC 69 Z9 72 U1 1 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD AUG 15 PY 2004 VL 64 IS 16 BP 5897 EP 5904 DI 10.1158/0008-5472.CAN-04-1070 PG 8 WC Oncology SC Oncology GA 846NH UT WOS:000223321900051 PM 15313935 ER PT J AU Sekiguchi, K Li, X Coker, M Flesch, M Barger, PM Sivasubramanian, N Mann, DL AF Sekiguchi, K Li, X Coker, M Flesch, M Barger, PM Sivasubramanian, N Mann, DL TI Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure SO CARDIOVASCULAR RESEARCH LA English DT Review DE angiotensin II; renin-angiotensin system; heart failure; tumor necrosis factor; inflammation ID TUMOR-NECROSIS-FACTOR; ACTIVATED PROTEIN-KINASE; LEFT-VENTRICULAR DYSFUNCTION; CONVERTING ENZYME-INHIBITION; CONGESTIVE-HEART-FAILURE; KAPPA-B ACTIVATION; FACTOR-ALPHA; C-JUN; CARDIOMYOCYTE HYPERTROPHY; TRANSCRIPTION FACTOR AB One of the major conceptual advances ill Our understanding of the pathogenesis of heart failure has been the insight that heart failure may progress as the result of the sustained overexpression of biologically active "neurohormones", such as norepinephrine and angiotensin II, which by virtue of their deleterious effects are sufficient to contribute to disease progression by provoking worsening left ventricular (LV) remodeling and progressive LV dysfunction. Recently, a second class of biologically active molecules, termed cytokines, has also been identified in the setting of heart failure. Analogous to the situation with neurohormones, the overexpression of cytokines is sufficient to contribute to disease progression in heart failure phenotype. Although important interactions between proinflammatory cytokines and the adrenergic system have been recognized in the heart for over a decade, the nature of the important interactions between proinflammatory cytokines and the renin-angiotensin system has become apparent only recently. Accordingly, in the present review, we will discuss the evidence which suggests that there is a functionally significant cross-talk between neurohormonal and inflammatory cytokine signaling in cardiac hypertrophy and failure. (C) 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved. C1 Houston VAMC, Winters Ctr Heart Failure Res, Dept Med, Cardiol Sect, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Univ Cologne, Innere Med Klin 3, Cologne, Germany. RP Mann, DL (reprint author), Houston VAMC, Winters Ctr Heart Failure Res, Dept Med, Cardiol Sect, 6565 Fannin,MS 524, Houston, TX 77030 USA. EM dmann@bcm.tmc.edu OI Mann, Douglas /0000-0002-2516-0145 NR 56 TC 44 Z9 51 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0008-6363 J9 CARDIOVASC RES JI Cardiovasc. Res. PD AUG 15 PY 2004 VL 63 IS 3 BP 433 EP 442 DI 10.1016/j.cardiores.2004.02.005 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 845KP UT WOS:000223241600008 PM 15276468 ER PT J AU Birdsall, HH Porter, WJ Green, DM Rubio, J Trial, JA Rossen, RD AF Birdsall, HH Porter, WJ Green, DM Rubio, J Trial, JA Rossen, RD TI Impact of fibronectin fragments on the transendothelial migration of HIV-infected leukocytes and the development of subendothelial foci of infectious leukocytes SO JOURNAL OF IMMUNOLOGY LA English DT Article ID CELL-ADHESION MOLECULE-1; NECROSIS-FACTOR-ALPHA; TNF-ALPHA; DENDRITIC CELLS; HUMAN MONOCYTES; T-LYMPHOCYTES; HIV-1-INFECTED PATIENTS; FLOW CONDITIONS; NERVOUS-SYSTEM; P-SELECTIN AB Leukocyte infiltrates that can serve as viral reservoirs, and sites for viral replication are found in many organs of HIV-1-infected patients. Patients whose blood leukocytes migrate across confluent endothelial monolayers ex vivo and transmit infectious virus to mononuclear leukocytes (MNLs) lodged beneath this endothelial barrier have a worse prognosis. We evaluated the ability of 110- to 120-kDa fibronectin fragments (FNf), which are found in the blood of >60% of HIV-1-infected patients, to stimulate transendothelial migration and drive productively infected MNLs into a potential perivascular space. FNf induced MNLs to release TNF-alpha in a dose-dependent fashion; the resulting increase in lymphocyte and monocyte transendothelial migration could be blocked with soluble TNF receptor I. Rather than penetrate deeply into the subendothelial matrix, as is seen with untreated controls, FNf-treated MNLs clustered just below the endothelial monolayer. Treatment with FNf during migration increased subsequent recovery of HIV-infected cells from the subendothelial compartment. FNf treatment also significantly increased the numbers of HLA-DRbright, dendritic-type cells that reverse-migrated from the subendothelial depot to the apical endothelial surface 48 h after migration. Fibronectin fragments can be produced by viral and host proteases in the course of inflammatory conditions. The ability of FNf to stimulate transendothelial migration of HIV-1-infected MNLs may help to explain the dissemination of this infection into cardiac, renal, and CNS tissues. C1 Michael E DeBakey Vet Affairs Med Ctr, Res Ctr AIDS & HIV Infect, Immunol Res Lab, Houston, TX 77030 USA. Baylor Coll Med, Dept Otorhinolaryngol, Houston, TX 77030 USA. Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA. Baylor Coll Med, Dept Orthoped, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Birdsall, HH (reprint author), Houston Vet Affairs Med Ctr, Bldg 110,Room 328,2002 Holcombe Blvd, Houston, TX 77030 USA. EM birdsall@bcm.tmc.edu FU NIAID NIH HHS [R01AI46285, AI36211]; NIMH NIH HHS [R01MH63035]; NINDS NIH HHS [R01NS32583] NR 49 TC 14 Z9 14 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD AUG 15 PY 2004 VL 173 IS 4 BP 2746 EP 2754 PG 9 WC Immunology SC Immunology GA 845AV UT WOS:000223208900065 PM 15294993 ER PT J AU Anand, BS Velez, M AF Anand, Bhupinder S. Velez, Maria TI Assessment of correlation between serum titers of hepatitis c virus and severity of liver disease SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article AB AIM: The significance of hepatitis C virus (HCV) serum titers has been examined in several clinical situations. There is much evidence that patients with a lower viral load have better response rates to anti-viral therapy compared to those with higher levels. Moreover, a direct association has been observed between serum titers of HCV and transmission rates of the virus. The aim of the present study was to determine if there was any correlation between HCV viral load and the severity of liver disease. METHODS: Fifty patients with HCV infection were included in the study. These comprised of 34 subjects with a history of alcohol use and 16 non-alcoholics. Quantitative serum HCV RNA assay was carried out using the branched DNA (bDNA) technique. Linear regression analysis was performed between serum viral titers and liver tests. In addition, for the purpose of comparison, the subjects were divided into two groups: those with low viral titers (50 mEq/mL). RESULTS: All subjects were men, with a mean +/- SD age of 47 +/- 7.8 years. The mean HCV RNA level in the blood was 76.3x10(5) +/- 109.1 genome equivalents/mL. There was no correlation between HCV RNA levels and age of the patients (r = 0.181), and the history or amount (g/d) of alcohol consumption (r = 0.07). Furthermore, no correlation was observed between serum HCV RNA levels and the severity of liver disease as judged by the values of serum albumin (r = 0.175), bilirubin (r = 0.217), ALT (r = 0.06) and AST (r = 0.004) levels. Similarly, no significant difference was observed between patients with low viral titers and high titers with respect to any of the parameters. CONCLUSION: Our results indicate that the severity of liver disease is independent of serum levels of hepatitis C virus. These findings are important since they have a direct impact on the current debate regarding the role of direct cytopathic effect of hepatitis C virus versus immune-mediated injury in the pathogenesis of HCV-related liver damage. C1 [Anand, Bhupinder S.] VA Med Ctr, Digest Dis Sect 111D, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Anand, BS (reprint author), VA Med Ctr, Digest Dis Sect 111D, Dept Med, 2002 Holcombe Blvd Houston, Houston, TX 77030 USA. EM ana0@flash.net NR 26 TC 20 Z9 23 U1 0 U2 0 PU BAISHIDENG PUBL GRP CO LTD PI BEIJING PA RM 903, BLDG D, OCEAN INTERNATIONAL CTR, NO 62 DONGSIHUAN ZHONGLU, BEIJING, CHAOYANG DISTRICT 100025, PEOPLES R CHINA SN 1007-9327 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD AUG 15 PY 2004 VL 10 IS 16 BP 2409 EP 2411 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA V23BF UT WOS:000208317600021 PM 15285030 ER PT J AU Nadeau, KJ Leitner, JW Gurerich, I Draznin, B AF Nadeau, KJ Leitner, JW Gurerich, I Draznin, B TI Insulin regulation of sterol regulatory element-binding protein-1 expression in L-6 muscle cells and 3T3 L1 adipocytes SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; GENE-EXPRESSION; SKELETAL-MUSCLE; PHOSPHOINOSITIDE 3-KINASE; DIABETES-MELLITUS; GLUCOSE-TRANSPORT; RECEPTOR SUBSTRATE-1; ADIPOSE-TISSUE; FATTY RATS; KINASE AB Sterol regulatory element-binding proteins (SREBPs) are transcription factors that regulate enzymes required for cholesterol and fatty acid synthesis. Expression of SREBP-1 is enhanced by insulin; however, the actual insulin-signaling cascades employed are yet unclear. We determined the roles of the phosphatidylinositol (PI) 3-kinase and mitogen-activated protein (MAP) kinase-dependent pathways in the effect of mediating insulin on SREBP-1 in L-6 skeletal muscle cells and 3T3 L1 adipocytes, using wortmannin or LY294002 to inhibit the PI 3-kinase pathway, and PD98059 to inhibit the MAP kinase-dependent pathway. In myocytes, insulin increased SREBP-1 protein in a dose-dependent manner. 1 and 10 nM insulin significantly increased expression of total cellular SREBP-1 protein at 24 and 48 h, nuclear SREBP-1 protein at 24 h, and SREBP-1a mRNA at 24 h. Although wortmannin and LY294002 had no effect on this aspect of insulin action, PD98059 completely blocked each of these responses. Transfection of a dominant negative mutant of Ras similarly blocked the insulin effect on SREBP-1. In contrast, in adipocytes, the insulin effect on SREBP-1 was mediated via the PI 3-kinase and not the MAP kinase pathway. In conclusion, although insulin increases skeletal muscle SREBP-1 expression in a dose-dependent fashion via the MAP kinase-dependent signaling pathway, insulin action on adipocyte SREBP-1 is mediated via the PI 3-kinase signaling pathway. In the state of insulin resistance, characterized by selective inhibition of the PI 3-kinase pathway, the usual stimulation of lipogenesis by insulin in adipocytes may be inhibited, whereas intramyocellular lipogenesis via the MAP kinase pathway of insulin may continue unabated. C1 Univ Colorado, Hlth Sci Ctr, Dept Pediat, Div Pediat Endocrinol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Div Endocrinol Metab & Diabet, Denver, CO 80262 USA. Denver VA Med Ctr, Vet Affairs Res Serv, Denver, CO 80220 USA. RP Nadeau, KJ (reprint author), Pediat Endocrinol Box 256,1056 E 19th Ave, Denver, CO 80218 USA. EM kristen.nadeau@UCHSC.edu NR 40 TC 27 Z9 29 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD AUG 13 PY 2004 VL 279 IS 33 BP 34380 EP 34387 DI 10.1074/jbc.M403596200 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 844CL UT WOS:000223134800038 PM 15187085 ER PT J AU Vaquero, EC Edderkaoui, M Pandol, SJ Gukovsky, I Gukovskaya, AS AF Vaquero, EC Edderkaoui, M Pandol, SJ Gukovsky, I Gukovskaya, AS TI Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID CULTURED ENDOTHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; NF-KAPPA-B; NADPH OXIDASE; HYDROGEN-PEROXIDE; SUPEROXIDE ANION; REGULATES GROWTH; MITOCHONDRIAL; ACTIVATION; DEATH AB One reason why pancreatic cancer is so aggressive and unresponsive to treatments is its resistance to apoptosis. We report here that reactive oxygen species (ROS) are a prosurvival, antiapoptotic factor in pancreatic cancer cells. Human pancreatic adenocarcinoma MIA PaCa-2 and PANC-1 cells generated ROS, which was stimulated by growth factors ( serum, insulin-like growth factor I, or fibroblast growth factor-2). Growth factors also stimulated membrane NAD(P) H oxidase activity in these cells. Both intracellular ROS and NAD( P) H oxidase activity were inhibited by antioxidants tiron and N-acetylcysteine and the inhibitor of flavoprotein-dependent oxidases, diphenylene iodonium, but not by inhibitors of various other ROS-generating enzymes. Using Rho(0) cells deficient in mitochondrial DNA, we showed that a nonmitochondrial NAD( P) H oxidase is a major source of growth factor-induced ROS in pancreatic cancer cells. Among proteins that have been implicated in NAD( P) H oxidase activity, MIA PaCa-2 and PANC-1 cells do not express the phagocytic gp91(phox) subunit but express several nonphagocytic oxidase (NOX) isoforms. Transfection with Nox4 antisense oligonucleotide inhibited NAD( P) H oxidase activity and ROS production in MIA PaCa-2 and PANC-1 cells. Inhibiting ROS with the antioxidants, Nox4 antisense, or MnSOD overexpression all stimulated apoptosis in pancreatic cancer cells as measured by internucleosomal DNA fragmentation, phosphatidylserine externalization, cytochrome c release, and effector caspase activation. The results show that growth factor-induced ROS produced by NAD( P) H oxidase ( probably Nox4) protect pancreatic cancer cells from apoptosis. This mechanism may play an important role in pancreatic cancer resistance to treatment and thus represent a novel therapeutic target. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, W Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA 90073 USA. RP Gukovskaya, AS (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, W Los Angeles Healthcare Ctr, Bldg 258,Rm 340,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM agukovsk@ucla.edu RI Bell, Tiffany/F-4403-2010 FU NIDDK NIH HHS [DK 59936] NR 57 TC 214 Z9 224 U1 1 U2 14 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD AUG 13 PY 2004 VL 279 IS 33 BP 34643 EP 34654 DI 10.1074/jbc.M400078200 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 844CL UT WOS:000223134800069 PM 15155719 ER PT J AU Lincoff, AM Kleiman, NS Kereiakes, DJ Feit, F Bittl, JA Jackman, JD Sarembock, IJ Cohen, DJ Spriggs, D Ebrahimi, R Keren, G Carr, J Cohen, EA Betriu, A Desmet, W Rutsch, W Wilcox, RG de Feyter, PJ Vahanian, A Topol, EJ AF Lincoff, AM Kleiman, NS Kereiakes, DJ Feit, F Bittl, JA Jackman, JD Sarembock, IJ Cohen, DJ Spriggs, D Ebrahimi, R Keren, G Carr, J Cohen, EA Betriu, A Desmet, W Rutsch, W Wilcox, RG de Feyter, PJ Vahanian, A Topol, EJ CA REPLACE-2 Investigators TI Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization - REPLACE-2 randomized trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID MYOCARDIAL-INFARCTION; ISCHEMIC EVENTS; RECEPTOR BLOCKADE; UNSTABLE ANGINA; ABCIXIMAB; INTERVENTION; ANGIOPLASTY; PREVENTION; COMPLICATIONS; EPTIFIBATIDE AB Context In the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial, bivalirudin with provisional glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibition was found to be noninferior to heparin plus planned Gp IIb/IIIa blockade in the prevention of acute ischemic end points and was associated with significantly less bleeding by 30 days after percutaneous coronary intervention (PCI). Objective To determine whether the efficacy of bivalirudin remains comparable with that of heparin plus Gp IIb/IIIa blockade over 6 months and 1 year. Design, Setting, and Participants Follow-up study to 1 year of a randomized, double-blind trial conducted among 6010 patients undergoing urgent or elective PCI at 233 community or referral hospitals in 9 countries from October 2001 through August 2002. Interventions Patients were randomly assigned to receive intravenously bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg per hour for the duration of PCI), with provisional Gp IIb/IIIa inhibition, or to receive heparin (65 U/kg bolus), with planned Gp IIb/IIIa inhibition (abciximab or eptifibatide). Both groups received daily aspirin and a thienopyridine for at least 30 days after PCI. Main Outcome Measures incidence of death, myocardial infarction, or repeat revascularization by 6 months and death by 12 months after enrollment. Results At 6 months, death occurred in 1.4% of patients in the heparin plus Gp IIb/IIIa group and in 1.0% of patients in the bivalirudin group (hazard ratio [HR], 0.70; 95% confidence interval [CI], 0.43-1.14; P=.15). Myocardial infarction occurred in 7.4% and 8.2% of patients, respectively (HR, 1.12; 95% CI, 0.93-1.34; P=.24), and repeat revascularization was required in 11.4% and 12.1% of patients, respectively (HR, 1.06; 95% CI, 0.91-1.23; P=.45). By 1 year, death occurred in 2.46% of patients treated with heparin plus Gp IIb/IIIa blockade and in 1.89% of patients treated with bivalirudin (HR, 0.78; 95% CI, 0.55-1.11; P=.16). Nonsignificant trends toward lower 1-year mortality with bivalirudin were present in all patient subgroups analyzed and were of greatest magnitude among high-risk patients. Conclusion Long-term clinical outcome with bivalirudin and provisional Gp IIb/IIIa blockade is comparable with that of heparin plus planned Gp IIb/IIIa inhibition during contemporary PCI. C1 Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA. Baylor Coll Med, Houston, TX 77030 USA. Methodist Hosp, Houston, TX 77030 USA. Ohio Heart Hlth Ctr, Lindner Ctr, Cincinnati, OH USA. NYU, Sch Med, New York, NY USA. Ocala Heart Inst, Munroe Reg Med Ctr, Ocala, FL USA. Trinity Mother Frances Hosp, Tyler, TX USA. Univ Virginia Hlth Syst, Charlottesville, VA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Clearwater Cardiovasc Consultants, Clearwater, FL USA. W Los Angeles VA, Los Angeles, CA USA. Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel. E Texas Med Ctr, Tyler, TX USA. Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON, Canada. Univ Barcelona, Hosp Clin, Barcelona, Spain. Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium. Univ Clin Charite Berlin, Berlin, Germany. Univ Nottingham Hosp, Nottingham NG7 2UH, England. Univ Hosp Dijkzigt, NL-3015 GD Rotterdam, Netherlands. Hop Bichat, F-75877 Paris, France. RP Lincoff, AM (reprint author), Cleveland Clin Fdn, Dept Cardiovasc Med, Desk F25,9500 Euclid Ave, Cleveland, OH 44195 USA. EM lincofa@ccf.org OI Topol, Eric/0000-0002-1478-4729 NR 23 TC 274 Z9 285 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 11 PY 2004 VL 292 IS 6 BP 696 EP 703 DI 10.1001/jama.292.6.696 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 844RM UT WOS:000223177300023 PM 15304466 ER PT J AU Mortensen, EM Cornell, J Whittle, J AF Mortensen, EM Cornell, J Whittle, J TI Racial variations in processes of care for patients with community-acquired pneumonia SO BMC HEALTH SERVICES RESEARCH LA English DT Article ID ELDERLY PATIENTS; PULSE OXIMETRY; HEALTH-CARE; QUALITY; SYSTEM; ACCURACY; OUTCOMES; RACE AB Background: Patients hospitalized with community acquired pneumonia (CAP) have a substantial risk of death, but there is evidence that adherence to certain processes of care, including antibiotic administration within 8 hours, can decrease this risk. Although national mortality data shows blacks have a substantially increased odds of death due to pneumonia as compared to whites previous studies of short-term mortality have found decreased mortality for blacks. Therefore we examined pneumonia-related processes of care and short-term mortality in a population of patients hospitalized with CAP. Methods: We reviewed the records of all identified Medicare beneficiaries hospitalized for pneumonia between 10/1/1998 and 9/30/1999 at one of 101 Pennsylvania hospitals, and randomly selected 60 patients at each hospital for inclusion. We reviewed the medical records to gather process measures of quality, pneumonia severity and demographics. We used Medicare administrative data to identify 30-day mortality. Because only a small proportion of the study population was black, we included all 240 black patients and randomly selected 720 white patients matched on age and gender. We performed a resampling of the white patients 10 times. Results: Males were 43% of the cohort, and the median age was 76 years. After controlling for potential confounders, blacks were less likely to receive antibiotics within 8 hours (odds ratio with 95% confidence interval 0.6, 0.4-0.97), but were as likely as whites to have blood cultures obtained prior to receiving antibiotics (0.7, 0.3-1.5), to have oxygenation assessed within 24 hours of presentation (1.6, 0.9-3.0), and to receive guideline concordant antibiotics (OR 0.9, 0.6-1.7). Black patients had a trend towards decreased 30-day mortality (0.4, 0.2 to 1.0). Conclusion: Although blacks were less likely to receive optimal care, our findings are consistent with other studies that suggest better risk-adjusted survival among blacks than among whites. Further study is needed to determine why this is the case. C1 Audie L Murphy Mem Vet Adm Med Ctr, VERDICT, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Adm Med Ctr, Div Gen Internal Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Kansas City VA Med Ctr, Kansas City, MO USA. Univ Kansas, Sch Med, Div Gen Med & Geriatr, Lawrence, KS 66045 USA. RP Mortensen, EM (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, VERDICT, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. EM mortensen@verdict.uthscsa.edu; jcornell@verdict.uthscsa.edu; JWHITTLE@kumc.edu OI Mortensen, Eric/0000-0002-3880-5563 FU AHRQ HHS [F32 HS000135] NR 19 TC 12 Z9 12 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD AUG 10 PY 2004 VL 4 AR 20 DI 10.1186/1472-6963-4-20 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 850HF UT WOS:000223601100001 PM 15304197 ER PT J AU Craig, WA AF Craig, WA TI Overview of newer antimicrobial formulations for overcoming pneumococcal resistance SO AMERICAN JOURNAL OF MEDICINE LA English DT Article; Proceedings Paper CT Roundtable Meeting on Streptococcus Pneumoniae - Resistance Patterns, Disease Trends and Cllinical Implications CY AUG 28, 2003 CL Rosemont, IL ID COMMUNITY-ACQUIRED PNEUMONIA; RESPIRATORY-TRACT INFECTIONS; STREPTOCOCCUS-PNEUMONIAE; AMOXICILLIN-CLAVULANATE; PHARMACODYNAMICS; PHARMACOKINETICS; MANAGEMENT; GUIDELINES; THERAPY; AMOXICILLIN/CLAVULANATE AB The pharmacokinetic (PK) and pharmacodynamic (PD) profile of an antimicrobial agent provides important information that can be used to maximize bacteriologic and clinical efficacy, minimize selective pressure for the development of antimicrobial resistance, and determine an optimal dosing regimen. Judicious selection of an antimicrobial based on local susceptibility data and PK and PD parameters is imperative in this era of increasing resistance among Streptococcus pneumoniae, a leading cause of community-acquired respiratory tract infections. The beta-lactam antimicrobials display time-dependent bacterial killing with minimal to no persistent effects. Ketolides and fluoroquinolones display concentration-dependent bacterial killing, and tetracyclines and macrolides display time-dependent killing. All have prolonged persistent effects (e.g., postantibiotic effect) that retard or prevent bacterial regrowth when free drug levels fall below the minimum inhibitory concentration (MIC). New high-dose and/or ex tended-release formulations of traditional antimicrobials have been added to the current armamentarium for treatment of community-acquired respiratory tract infections. These formulations include amoxicillin-clavulanate potassium powder for oral suspension 90/6.4 mg/kg per day divided every 12 hours (Augmentin ES-600; GlaxoSmithKline, Research Triangle Park, NC), amoxicillin-clavulanate potassium extended-release tablets 2 x 1,000 mg/62.5 mg every 12 hours (Augmentin XR; GlaxoSmithKline), clarithromycin extended-release tablets 2 x 500 mg once daily (Biaxin XL; Abbott Laboratories, North Chicago, IL), and cefaclor extended-release tablets 375 mg or 500 mg every 12 hours (Ceclor CD; Eli Lilly Pharmaceuticals, Indianapolis, IN). Of these agents, only amoxicillin-clavulanate potassium powder for oral suspension and amoxicillin-clavulanate potassium extended-release tablets were designed to treat infections caused by penicillin-resistant pneumococci (penicillin MIC less than or equal to 2 mug/mL). Extended-release clarithromycin does not provide higher daily doses than its immediate-release counterpart; rather, it allows for once-daily dosing of this agent because of its slower absorption following oral administration. Extended-release cefaclor is considered clinically equivalent to 250 mg of immediate-release cefaclor pulvules administered 3 times daily; it cannot be used interchangeably with 500 mg 3-times-daily dosages of other cefaclor formulations. Thus, despite providing a similar or higher total daily dose than its immediate-release counterpart, extended-release cefaclor is indicated only for the treatment of patients with mild to moderate infections caused by susceptible strains of certain organisms. (C) 2004 by Elsevier Inc. C1 Univ Wisconsin, William S Middleton Mem Vet Adm Hosp, Dept Med, Madison, WI 53705 USA. RP Craig, WA (reprint author), Univ Wisconsin, William S Middleton Mem Vet Adm Hosp, Dept Med, 2500 Overlook Terrace, Madison, WI 53705 USA. NR 39 TC 5 Z9 5 U1 0 U2 3 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD AUG 2 PY 2004 VL 117 SU 3A BP 16 EP 22 DI 10.1016/j.amjmed.2004.07.004 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 843RC UT WOS:000223101200003 ER PT J AU Lieber, CS AF Lieber, CS TI Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis SO ALCOHOL LA English DT Article; Proceedings Paper CT Symposium on Role of Fatty Liver Dietary Fatty Acid Supplements and Obesity in the Progression of Alcoholic Liver Disease CY OCT 03, 2003 CL Bethesda, MD DE alcoholic steatosis; alcoholic steatchepatitis; cytochrome P450 2E1; obesity; dilinoleoylphosphatidylcholine; S-adenosylmethionine; oxidative stress; TNF-alpha; acetaldehyde ID ETHANOL-OXIDIZING SYSTEM; ADENOSYL-L-METHIONINE; HEPATIC STELLATE CELLS; ACID-BINDING-PROTEIN; RAT-LIVER; CYTOCHROME P-4502E1; DOUBLE-BLIND; NONALCOHOLIC STEATOHEPATITIS; COLLAGEN-SYNTHESIS; MITOCHONDRIAL ABNORMALITIES AB Liver disease in the alcoholic is due not only to malnutrition but also to ethanol's hepatotoxicity linked to its metabolism by means of the alcohol dehydrogenase and cytochrome P450 2E1 (CYP2E1) pathways and the resulting production of toxic acetaldehyde. In addition, alcohol dehydrogenase-mediated ethanol metabolism generates the reduced form of nicotinamide adenine dinuclectide (NADH), which promotes steatosis by stimulating the synthesis of fatty acids and opposing their oxidation. Steatosis is also promoted by excess dietary lipids and can be attenuated by their replacement with medium-chain triglycerides. Through reduction of pyruvate, elevated NADH also increases lactate, which stimulates collagen synthesis in myofibroblasts. Furthermore, CYP2E1 activity is inducible by its substrates, not only ethanol but also fatty acids. Their excess and metabolism by means of this pathway generate release of free radicals, which cause oxidative stress, with peroxidation of lipids and membrane damage, including altered enzyme activities. Products of lipid peroxidation such as 4-hydroxynonenal stimulate collagen generation and fibrosis, which are further increased through diminished feedback inhibition of collagen synthesis because acetaldehyde forms adducts with the carboxyl-tertninal propeptide of procollagen in hepatic stellate cells. Acetaldehyde is also toxic to the mitochondria, and it aggravates their oxidative stress by binding to reduced glutathione and promoting its leak-age. Oxidative stress and associated cellular injury promote inflammation, which is aggravated by increased production of the proinflammatory cytokine tumor necrosis factor-alpha in the Kupffer cells. These are activated by induction of their CYP2E1 as well as by endotoxin. The endotoxin-stimulated tumor necrosis factor-alpha release is decreased by dilinoleoylphosphatidylcholine, the active phosphatidylcholine (PC) species of polyenylphosphatidlcholine (PPC). Moreover, defense mechanisms provided by peroxisome proliferator-activated receptor alpha and omega fatty acid oxidation are readily overwhelmed, particularly in female rats and also in women who have low hepatic induction of fatty acid-binding protein (L-FABPc). Accordingly, the intracellular concentration of free fatty acids may become high enough to injure membranes, thereby contributing to necrosis, inflammation, and progression to fibrosis and cirrhosis. Eventually, hepatic S-adenosylmethionine and PCs become depleted in the alcoholic, with impairment of their multiple cellular functions, which can be restored by PC replenishment. Thus, prevention and therapy opposing the development of steatosis and its progression to more severe injury can be achieved by a multifactorial approach: control of alcohol consumption, avoidance of obesity and of excess dietary long-chain fatty acids, or their replacement with medium-chain fatty acids, and replenishment of S-adenosylmethionine and PCs by using PPC. Progress in the understanding of the pathogenesis of alcoholic fatty liver and its progression to inflammation and fibrosis has resulted in prospects for their better prevention and treatment. (C) 2005 Elsevier Inc. All rights reserved. C1 Bronx Vet Affairs Med Ctr, Bronx, NY 10468 USA. Mt Sinai Sch Med, New York, NY 10029 USA. RP Lieber, CS (reprint author), Bronx Vet Affairs Med Ctr, 130 W Kingsbridge Rd 151-2, Bronx, NY 10468 USA. EM liebercs@aol.com FU NCCIH NIH HHS [AT001583]; NIAAA NIH HHS [AA11115] NR 115 TC 267 Z9 292 U1 2 U2 39 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0741-8329 J9 ALCOHOL JI Alcohol PD AUG PY 2004 VL 34 IS 1 BP 9 EP 19 DI 10.1016/j.alcohol.2004.07.008 PG 11 WC Substance Abuse; Pharmacology & Pharmacy; Toxicology SC Substance Abuse; Pharmacology & Pharmacy; Toxicology GA 898KB UT WOS:000227074600003 PM 15670660 ER PT J AU Myrick, H Anton, RF Li, X Henderson, S George, M AF Myrick, H Anton, RF Li, X Henderson, S George, M TI Neuroimaging in alcoholism: Relationship to craving. SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 12th International Congress of the International-Society-for-Biomedical-Research-on-Alcoholism CY SEP 29-OCT 02, 2004 CL Heidelberg, GERMANY SP Int Soc Biomed Res Alcoholism C1 Med Univ S Carolina, Alcohol Res Ctr, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD AUG PY 2004 VL 28 IS 8 SU S BP 72A EP 72A DI 10.1097/00000374-200408002-00393 PG 1 WC Substance Abuse SC Substance Abuse GA 850LS UT WOS:000223613600392 ER PT J AU Johansen, KL Young, B Kaysen, GA Chertow, GM AF Johansen, KL Young, B Kaysen, GA Chertow, GM TI Association of body size with outcomes among patients beginning dialysis SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article DE end-stage renal disease; dialysis; body mass index; adiposity; survival; outcomes ID RENAL-TRANSPLANT OUTCOMES; HEMODIALYSIS-PATIENTS; RISK FACTOR; MASS INDEX; OBESITY; MORTALITY; WEIGHT; SURVIVAL; IMPACT; DEATH AB Background: Although obesity confers an increased risk of mortality in the general population, observational reports on the dialysis population have suggested that obesity is associated with improved survival. These reports have generally not examined extremely high values of body mass index (BMI; in kg/m(2)), survival >1 y, or alternative measures of adiposity. Objective: We sought to clarify the relation between body size and outcomes among a large cohort of patients beginning dialysis. Design: Data on 418 055 patients beginning dialysis between I April 1995 and 1 November 2000 were analyzed by using US Renal Data System data. BMI was divided into 8 categories in increments of 3 units, ranging from <19 to greater than or equal to37, and the relation between survival and BMI was examined by using proportional hazards regression with adjustment for demographic, laboratory, and comorbidity data. Results: High BMI was associated with increased survival in this cohort, even at extremely high BMI, after adjustment, and over a 2-y average follow-up time. This was true for whites, African Americans, and Hispanics but not for Asians. High BMI was also associated with a reduced risk of hospitalization and a lower rate of mortality in all mortality categories. Alternative estimates of adiposity, including the Berm index and estimated fat mass, yielded similar results, and adjustments for lean body mass did not substantially alter the findings. Conclusions: High BMI is not associated with increased mortality among patients beginning dialysis. This finding does not appear to be a function of lean body mass and, although modified by certain patient characteristics, it is a robust finding. C1 Univ Calif San Francisco, Dept Med Res, Div Nephrol, San Francisco, CA 94118 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif Davis, Div Nephrol, Davis, CA USA. RP Chertow, GM (reprint author), Univ Calif San Francisco, Dept Med Res, Div Nephrol, UCSF Laurel Heights Suite 430,3333 Calif St, San Francisco, CA 94118 USA. EM chertowg@medicine.ucsf.edu FU NIDDK NIH HHS [N01 DK 12450] NR 28 TC 163 Z9 166 U1 0 U2 2 PU AMER SOC CLINICAL NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD AUG PY 2004 VL 80 IS 2 BP 324 EP 332 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 841ET UT WOS:000222912800013 PM 15277152 ER PT J AU Quintero-del-Rio, AI Kelly, JA Garriott, CP Hutchings, DC Frank, SG Aston, CE Harley, JB AF Quintero-del-Rio, AI Kelly, JA Garriott, CP Hutchings, DC Frank, SG Aston, CE Harley, JB TI SLEN2 (2q34-35) and SLEN1 (10q22.3) replication in systemic lupus erythematosus stratified by nephritis SO AMERICAN JOURNAL OF HUMAN GENETICS LA English DT Letter C1 Oklahoma Med Res Fdn, Arthrit & Immunol Program, Oklahoma City, OK 73104 USA. Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Quintero-del-Rio, AI (reprint author), Oklahoma Med Res Fdn, Arthrit & Immunol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM ana-quintero@omrf.ouhsc.edu RI Frank, Summer/E-6861-2016 OI Frank, Summer/0000-0003-0779-4926 FU NCRR NIH HHS [P41 RR003655, RR03655]; NIAID NIH HHS [AI31584, R01 AI031584]; NIAMS NIH HHS [AR-1-2253, AR24717, AR42460, AR45231, AR52221, R43 AR052221] NR 5 TC 19 Z9 19 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0002-9297 J9 AM J HUM GENET JI Am. J. Hum. Genet. PD AUG PY 2004 VL 75 IS 2 BP 346 EP 348 DI 10.1086/422460 PG 3 WC Genetics & Heredity SC Genetics & Heredity GA 838GR UT WOS:000222702000020 PM 15307049 ER PT J AU Li, SX Gerrard, ER Balkovetz, DF AF Li, SX Gerrard, ER Balkovetz, DF TI Evidence for ERK1/2 phosphorylation controlling contact inhibition of proliferation in Madin-Darby canine kidney epithelial cells SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE cell density; cyclin D1; hepatocyte growth factor; cell cycle; extracellular signal-regulated kinases ID ACTIVATED PROTEIN-KINASE; HEPATOCYTE GROWTH-FACTOR; CYCLIN D1 EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; MAP KINASES; MDCK CELLS; E-CADHERIN; PATHWAY; PROGRESSION; TRANSLOCATION AB Increasing cell density arrests epithelial cell proliferation by a process termed contact inhibition. We investigated mechanisms of contact inhibition using a model of contact-inhibited epithelial cells. Hepatocyte growth factor (HGF) treatment of contact-inhibited Madin-Darby canine kidney (MDCK) cells stimulated cell proliferation and increased levels of phosphorylated ERK1/2 (phospho-ERK1/2) and cyclin D1. MEK inhibitors PD-98059 and U0126 inhibited these HGF-dependent changes, indicating the dependence on phosphorylation of ERK1/2 during HGF-induced loss of contact inhibition. In relation to contact-inhibited high-density cells, low-density MDCK cells proliferated and had higher levels of phospho-ERK1/2 and cyclin D1. PD-98059 and U0126 inhibited low-density MDCK cell proliferation. Trypsinization of high-density MDCK cells immediately increased phospho-ERK1/2 and was followed by a transient increase in cyclin D1 levels. Reformation of cell junctions after trypsinization led to decreases in phospho-ERK1/2 and cyclin D1 levels. High-density MDCK cells express low levels of both cyclin D1 and phospho-ERK1/2, and treatment of these cells with fresh medium containing HGF but not fresh medium alone for 6 h increased phospho-ERK1/2 and cyclin D1 levels compared with cells without medium change. These data provide evidence that HGF abrogates MDCK cell contact inhibition by increasing ERK1/2 phosphorylation and levels of cyclin D1. These results suggest that in MDCK cells, contact inhibition of cell proliferation in the presence of serum occurs by cell density-dependent regulation of ERK1/2 phosphorylation. C1 Univ Alabama, Dept Med, Birmingham, AL 35294 USA. Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA. Univ Alabama, Dept Surg, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Balkovetz, DF (reprint author), Univ Alabama, Dept Med, 1530 3rd Ave S,LHRB 642, Birmingham, AL 35294 USA. EM balkovet@uab.edu NR 35 TC 15 Z9 15 U1 1 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD AUG PY 2004 VL 287 IS 2 BP C432 EP C439 DI 10.1152/ajpcell.00020.2004 PG 8 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 835ED UT WOS:000222462400023 PM 15070810 ER PT J AU Cummings, DE Frayo, RS Marmonier, C Aubert, R Chapelot, D AF Cummings, DE Frayo, RS Marmonier, C Aubert, R Chapelot, D TI Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE appetite; insulin ID AGOUTI-RELATED PROTEIN; CIRCULATING GHRELIN; BODY-WEIGHT; INTERMEAL INTERVAL; ACYLATED PEPTIDE; GLUCOSE; SECRETION; APPETITE; INSULIN; RATS AB Ghrelin is an orexigenic hormone that is implicated in meal initiation, in part because circulating levels rise before meals. Because previous human studies have examined subjects fed on known schedules, the observed preprandial ghrelin increases could have been a secondary consequence of meal anticipation. A causal role for ghrelin in meal initiation would be better supported if preprandial increases occurred before spontaneously initiated meals not prompted by external cues. We measured plasma ghrelin levels among human subjects initiating meals voluntarily without cues related to time or food. Samples were drawn every 5 min between a scheduled lunch and a freely requested dinner, and hunger scores were obtained using visual analog scales. Insulin, glucose, fatty acids, leptin, and triglycerides were also measured. Ghrelin levels decreased shortly after the first meal in all subjects. A subsequent preprandial increase occurred over a wide range of intermeal intervals (IMI; 320-425 min) in all but one subject. Hunger scores and ghrelin levels showed similar temporal profiles and similar relative differences in magnitude between lunch and dinner. One subject displayed no preprandial ghrelin increase and was also the only individual whose insulin levels did not return to baseline between meals. This finding, along with a correlation between area-under-the-curve values of ghrelin and insulin, suggests a role for insulin in ghrelin regulation. The preprandial increase of ghrelin levels that we observed among humans initiating meals voluntarily, without time- or food-related cues, and the overlap between these levels and hunger scores are consistent with a role for ghrelin in meal initiation. C1 Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. Univ Paris 13, Lab Physiol Comportement Alimentaire, Unite Format & Rech Sante Med & Biol Humaine, F-93014 Bobigny, France. Univ Paris 07, Fac Xavier Bichat, Lab Nutr Humaine, F-75018 Paris, France. RP Cummings, DE (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 1660 S Columbian Way,S-111 Endo, Seattle, WA 98108 USA. EM davidec@u.washington.edu FU NIDDK NIH HHS [R01 DK-61516] NR 53 TC 233 Z9 235 U1 0 U2 15 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD AUG PY 2004 VL 287 IS 2 BP E297 EP E304 DI 10.1152/ajpendo.00582.2003 PG 8 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 839KQ UT WOS:000222784400016 PM 15039149 ER PT J AU Reeve, JR Liddle, RA McVey, DC Vigna, SR Solomon, TE Keire, DA Rosenquist, G Shively, JE Lee, TD Chew, P Green, GM Coskun, T AF Reeve, JR Liddle, RA McVey, DC Vigna, SR Solomon, TE Keire, DA Rosenquist, G Shively, JE Lee, TD Chew, P Green, GM Coskun, T TI Identification of nonsulfated cholecystokinin-58 in canine intestinal extracts and its biological properties SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE gallbladder; pancreas; gastric acid; receptor binding; CCKA; CCKB ID GASTRIC-ACID-SECRETION; SULFATION; TYROSINE; CCK-58; METABOLISM; RECEPTORS; FORMS; DEGRADATION; OCTAPEPTIDE; INHIBITION AB Nonsulfated CCK58 [CCK58(ns)] has not been considered to be of biological importance because CCK58(ns) binds poorly to the CCKA receptor and has only been identified once in intestinal extracts. In this work, a radioimmunoassay specific for the COOH-terminal region of gastrin and CCK (antibody 5135) was used to monitor the purification of CCK molecular forms from canine intestinal extracts. A minor immunoreactive peak was associated with a major absorbance peak during an ion-exchange, HPLC step. Characterization of this minor immunoreactive peak demonstrated that it was CCK58(ns). CCK58(ns) is 14% as immunoreactive as sulfated CCK8 [CCK8(s)]. Amino acid analysis demonstrated that CCK58(ns) was present at 50% the amount of CCK58(s). In addition, we found that CCK58(ns) does not potently displace an I-125-labeled CCK10 analog from the CCKA receptor in mouse pancreatic membranes and does not stimulate amylase release from isolated pancreatic acini, or stimulate pancreatic secretion in an anesthetized rat model. By contrast, CCK58(ns) does bind to CCKB receptors and stimulates gastric acid secretion via this receptor. The presence of CCK58(ns) and its ability to selectively stimulate the CCKB receptor without stimulation of the CCKA receptor suggest that CCK58(ns) may have unique physiological properties, especially tissues where the nonsulfated peptide can act as a paracrine or neurocrine agent. C1 Vet Affairs Greater Los Angeles Healthcare Syst, CURE, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Div Digest Dis, Los Angeles, CA 90024 USA. Univ Calif Davis, Sect Neurobiol Physiol & Behav, Davis, CA 95616 USA. City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA. Duke Univ, Med Ctr, Div Gastroenterol, Durham, NC USA. Durham Vet Affairs Med Ctr, Durham, NC USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA. RP Reeve, JR (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, CURE, Digest Dis Res Ctr, Bldg 115,Rm 115, Los Angeles, CA 90073 USA. EM jreeve@ucla.edu FU NCI NIH HHS [CA-3572]; NCRR NIH HHS [R01-RR-06217]; NIDDK NIH HHS [DK-41301, R01-DK-33580, R01-DK-37482, R01-DK-38626] NR 44 TC 16 Z9 17 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD AUG PY 2004 VL 287 IS 2 BP G326 EP G333 DI 10.1152/ajpgi.00520.2003 PG 8 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 836JT UT WOS:000222552500005 PM 15064233 ER PT J AU Veal, N Hsieh, CL Xiong, SG Mato, JM Lu, S Tsukamoto, H AF Veal, N Hsieh, CL Xiong, SG Mato, JM Lu, S Tsukamoto, H TI Inhibition of lipopolysaccharide-stimulated TNF-alpha promoter activity by S-adenosylmethionine and 5 '-methylthioadenosine SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE Kupffer cells; macrophages; gene regulation; nuclear factor-kappa B ID NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; ADENOSYL-L-METHIONINE; INDUCED HEPATIC-INJURY; INDUCED LIVER-INJURY; RAT-LIVER; TRANSCRIPTIONAL ACTIVATION; PRIMARY MACROPHAGES; PROTEIN-KINASE; METHYLATION AB S-adenosylmethionine (SAM) is the principal biological methyl donor and precursor for polyamines. SAM is known to be hepatoprotective in many liver disease models in which TNF-alpha is implicated. The present study investigated whether and how SAM inhibited LPS-stimulated TNF-alpha expression in Kupffer cells (hepatic macrophages). SAM downregulated TNF-alpha expression in LPS-stimulated Kupffer cells at the transcriptional level as suggested by a transfection experiment with a TNF-alpha promoter-reporter gene. This inhibition was not mediated through decreased NF-kappaB binding to four putative kappaB binding elements located within the promoter. The inhibited promoter activity was neither prevented by overexpression of p65 and/or its coactivator p300 nor enhanced by overexpression of coactivator-associated arginine methyltransferase-1, an enzyme that methylates p300 and inhibits a p65-p300 interaction. SAM did not lead to DNA methylation at the most common CpG target sites in the TNF-alpha promoter. Moreover, 5'-methylthioadenosine (MTA), which is derived from SAM but does not serve as a methyl donor, recapitulated SAM's effect with more potency. These data demonstrate that SAM inhibits TNF-alpha expression at the level downstream of NF-kappaB binding and at the level of the promoter activity via mechanisms that do not appear to involve the limited availability of p65 or p300. Furthermore, our study is the first to demonstrate a potent inhibitory effect on NF-kappaB promoter activity and TNF-alpha expression by a SAM's metabolite, MTA. C1 Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA. Univ So Calif, Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA 90033 USA. Univ So Calif, Res Ctr Liver Dis, Los Angeles, CA 90033 USA. Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA. Univ So Calif, Keck Sch Med, Dept Urol, Div Gastrointestinal & Liver Dis, Los Angeles, CA 90033 USA. Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA. CIC Biogune, Parque Tecnol, Bizkaia, Spain. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Tsukamoto, H (reprint author), Univ So Calif, Keck Sch Med, Dept Pathol, 1333 San Pablo St,MMR-402, Los Angeles, CA 90033 USA. EM htsukamo@usc.edu RI MATO, JOSE/A-5187-2011 FU NIAAA NIH HHS [R24-AA12885, R37-AA-006603, R01-AA-013847, P50-AA-11999, R01-AA-12677]; NIDDK NIH HHS [P30-DK-48522] NR 48 TC 42 Z9 45 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD AUG PY 2004 VL 287 IS 2 BP G352 EP G362 DI 10.1152/ajpgi.00316.2003 PG 11 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 836JT UT WOS:000222552500008 PM 15064230 ER PT J AU Sharafkhaneh, A Officer, TM Goodnight-White, S Rodarte, JR Boriek, AM AF Sharafkhaneh, A Officer, TM Goodnight-White, S Rodarte, JR Boriek, AM TI Innovative methodology - Novel method for measuring effects of gas compression on expiratory flow SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE flow-volume loop; chronic obstructive pulmonary disease; asthma; lung mechanics ID BODY PLETHYSMOGRAPH; VOLUME CURVE; LIMITATION; MECHANICS; PRESSURE AB During forced vital capacity maneuvers in subjects with expiratory flow limitation, lung volume decreases during expiration both by air flowing out of the lung (i.e., exhaled volume) and by compression of gas within the thorax. As a result, a flow-volume loop generated by using exhaled volume is not representative of the actual flow-volume relationship. We present a novel method to take into account the effects of gas compression on flow and volume in the first second of a forced expiratory maneuver (FEV1). In addition to oral and esophageal pressures, we measured flow and volume simultaneously using a volume-displacement plethysmograph and a pneumotachograph in normal subjects and patients with expiratory flow limitation. Expiratory flow vs. plethysmograph volume signals was used to generate a flow-volume loop. Specialized software was developed to estimate FEV1 corrected for gas compression (NFEV1). We measured reproducibility of NFEV1 in repeated maneuvers within the same session and over a 6-mo interval in patients with chronic obstructive pulmonary disease. Our results demonstrate that NFEV1 significantly correlated with FEV1, peak expiratory flow, lung expiratory resistance, and total lung capacity. During intrasession, maneuvers with the highest and lowest FEV1 showed significant statistical difference in mean FEV1 (P < 0.005), whereas NFEV1 from the same maneuvers were not significantly different from each other (P > 0.05). Furthermore, variability of NFEV1 measurements over 6 mo was <5%. We concluded that our method reliably measures the effect of gas compression on expiratory flow. C1 Baylor Coll Med, MEDVAMC, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Sharafkhaneh, A (reprint author), Baylor Coll Med, MEDVAMC, Bldg 100 111I,2002 Holcombe Blvd, Houston, TX 77030 USA. EM amirs@bcm.tmc.edu FU NHLBI NIH HHS [HL-072839] NR 23 TC 5 Z9 5 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD AUG PY 2004 VL 287 IS 2 BP R479 EP R484 DI 10.1152/ajpregu.00573.2003 PG 6 WC Physiology SC Physiology GA 840CT UT WOS:000222835300034 PM 15117729 ER PT J AU Yehuda, R Golier, JA Halligan, SL Meaney, M Bierer, LM AF Yehuda, R Golier, JA Halligan, SL Meaney, M Bierer, LM TI The ACTH response to dexamethasone in PTSD SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; PITUITARY-ADRENAL AXIS; COMBAT VETERANS; PLASMA-CORTISOL; SUPPRESSION; CHILDHOOD; WOMEN; ABUSE; DEPRESSION; SURVIVORS AB Objective: Enhanced negative feedback and reduced adrenal output are two different models that have been put forth to explain the paradoxical observations of increased release of corticotropin-releasing factor in the face of low cortisol levels in posttraumatic stress disorder (PTSID). To discriminate between these models, the authors measured levels of adrenocorticopic hormone (ACTH) and cortisol at baseline and in response to dexamethasone in medically healthy subjects with and without PTSID. Under conditions of enhanced negative feedback inhibition, ACTH levels would not be altered relative to cortisol levels, but the ACTH response to dexamethasone would be augmented, in concert with the enhanced cortisol response to dexamethasone. In contrast, under conditions of reduced adrenal output, ACTH levels would be expected to be higher at baseline relative to cortisol levels, but the ACTH response to dexamethasone would be unchanged in PTSID relative to healthy comparison subjects. Method: The ACTH and cortisol responses to 0.50 mg of dexamethasone were assessed in 19 subjects (15 men and four women) with PTSID and 19 subjects (14 men and five women) without psychiatric disorder. Results: The ACTH-to-cortisol ratio did not differ between groups before or after dexamethasone, but the subjects with PTSD showed greater suppression of ACTH (as well as cortisol) in response to dexamethasone. Conclusions: The data support the hypothesis of enhanced cortisol negative feedback inhibition of ACTH secretion at the level of the pituitary in PTSD. Pituitary glucocorticoid receptor binding, rather than low adrenal output, is implicated as a likely mechanism for this effect. C1 Mt Sinai Sch Med, Dept Psychiat, Traumat Stress Studies Program, New York, NY USA. Bronx Vet Affairs Med Ctr, New York, NY USA. Univ Reading, Sch Psychol, Reading, Berks, England. Douglas Hosp, Res Ctr, Dept Neurosci, Montreal, PQ, Canada. RP Yehuda, R (reprint author), Bronx VA OOMH, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM rachel.yehuda@med.va.gov OI Halligan, Sarah/0000-0002-3436-3358 FU NIMH NIH HHS [R01 MH-49555] NR 30 TC 93 Z9 94 U1 2 U2 3 PU AMER PSYCHIATRIC PRESS, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD AUG PY 2004 VL 161 IS 8 BP 1397 EP 1403 DI 10.1176/appi.ajp.161.8.1397 PG 7 WC Psychiatry SC Psychiatry GA 842BC UT WOS:000222976400012 PM 15285965 ER PT J AU Bartels, SJ Coakley, EH Zubritsky, C Ware, JH Miles, KM Arean, PA Chen, HT Oslin, DW Llorente, MD Costantino, G Quijano, L McIntyre, JS Linkins, KW Oxman, TE Maxwell, J Levkoff, SE AF Bartels, SJ Coakley, EH Zubritsky, C Ware, JH Miles, KM Arean, PA Chen, HT Oslin, DW Llorente, MD Costantino, G Quijano, L McIntyre, JS Linkins, KW Oxman, TE Maxwell, J Levkoff, SE CA PRISM-E investigators TI Improving access to geriatric mental health services: A randomized trial comparing treatment engagement with integrated versus enhanced referral care for depression, anxiety, and at-risk alcohol use SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article; Proceedings Paper CT 16th Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 01-04, 2003 CL HONOLULU, HI SP Amer Assoc Geriatr Psychiat ID OLDER; MANAGEMENT; VALIDATION; SYMPTOMS; ILLNESS AB Objective: The authors sought to determine whether integrated mental health services or enhanced referral to specialty mental health clinics results in greater engagement in mental health/substance abuse services by older primary care patients. Method: This multisite randomized trial included 10 sites consisting of primary care and specialty mental health/substance abuse clinics. Primary care patients 65 years old or older (N=24,930) were screened. The final study group consisted of 2,022 patients (mean age=73.5 years; 26% female; 48% ethnic minority) with depression (N=1,390), anxiety (N= 70), at-risk alcohol use (N=414), or dual diagnosis (N=1 48) who were randomly assigned to integrated care (mental health and substance abuse providers co-located in primary care; N=999) or enhanced referral to specialty mental health/substance abuse clinics (i.e., facilitated scheduling, transportation, payment; N=1,023). Results: Seventy-one percent of patients engaged in treatment in the integrated model compared with 49% in the enhanced referral model. Integrated care was associated with more mental health and substance abuse visits per patient (mean=3.04) relative to enhanced referral (mean=1.91). Overall, greater engagement was predicted by integrated care and higher mental distress. For depression, greater engagement was predicted by integrated care and more severe depression. For at-risk alcohol users, greater engagement was predicted by integrated care and more severe problem drinking. For all conditions, greater engagement was associated with closer proximity of mental health/substance abuse services to primary care. Conclusions: Older primary care patients are more likely to accept collaborative mental health treatment within primary care than in mental health/substance abuse clinics. These results suggest that integrated service arrangements improve access to mental health and substance abuse services for older adults who underuse these services. C1 Dartmouth Coll Sch Med, Dept Psychiat, Lebanon, NH USA. John Snow Inc, Boston, MA USA. Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. Miami VA Med Ctr, Ctr Geriatr Res Educ & Clin, Miami, FL USA. Univ Miami, Sch Med, Miami, FL USA. Lutheran Med Ctr, Sunset Pk Family Hlth Ctr Network, Brooklyn, NY USA. Baylor Coll Med, Baylor, TX USA. Unity Hlth Syst, Dept Psychiat & Hlth Behav, Rochester, NY USA. Lewin Grp, Falls Church, VA USA. RP Bartels, SJ (reprint author), New Hampshire Dartmouth Psychiat Res Ctr, 2 Whippleplace,Suite 202, Lebanon, NH 03766 USA. EM stephen.j.bartels@dartmouth.edu NR 26 TC 197 Z9 200 U1 5 U2 10 PU AMER PSYCHIATRIC PRESS, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD AUG PY 2004 VL 161 IS 8 BP 1455 EP 1462 DI 10.1176/appi.ajp.161.8.1455 PG 8 WC Psychiatry SC Psychiatry GA 842BC UT WOS:000222976400020 PM 15285973 ER PT J AU Saliba, D Buchanan, J Kington, RS AF Saliba, D Buchanan, J Kington, RS TI Function and response of nursing facilities during community disaster SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID LOMA-PRIETA EARTHQUAKE; NORTHRIDGE EARTHQUAKE; NATURAL DISASTERS; HEALTH-CARE; HOME; LESSONS; NEEDS; RESIDENTS; SYSTEM; RECOMMENDATIONS AB Objectives. We sought to describe the role and function of nursing facilities after disaster. Methods. We surveyed administrators at 144 widely dispersed nursing facilities after the Los Angeles Northridge earthquake. Results. Of the 113 (78%) nursing facilities that responded (11365 beds), 23 sustained severe damage, 5 closed (625 beds), and 72 lost vital services. Of 87 nursing facilities implementing disaster plans, 56 cited problems that plans did not adequately address, including absent staff, communication problems, and insufficient water and generator fuel. Fifty-nine (52%) reported disaster-related admissions from hospitals, nursing facilities, and community residences. Nursing facilities received limited postdisaster assistance. Five months after the earthquake, only half of inadequate nursing facility disaster plans had been revised. Conclusions. Despite considerable disaster-related stresses, nursing facilities met important community needs. To optimize disaster response, community-wide disaster plans should incorporate nursing facilities. C1 RAND Corp, Santa Monica, CA 90407 USA. NIH, Bethesda, MD 20892 USA. Harvard Univ, Sch Med, Dept Hlth Care Policy, Cambridge, MA 02138 USA. Univ Calif Los Angeles, Vet Adm Med Ctr, Multicampus Program Geriatr, Los Angeles, CA USA. Vet Adm Greater Los Angeles Hlth Care Syst, Los Angeles, CA 91343 USA. RP Saliba, D (reprint author), RAND Corp, 1700 Main St M-28, Santa Monica, CA 90407 USA. EM saliba@rand.org NR 44 TC 21 Z9 22 U1 0 U2 7 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 1015 FIFTEENTH ST NW, WASHINGTON, DC 20005 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD AUG PY 2004 VL 94 IS 8 BP 1436 EP 1441 DI 10.2105/AJPH.94.8.1436 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 843AT UT WOS:000223047600039 PM 15284056 ER PT J AU Nahar, A Akom, M Hanes, D Briglia, A Drachenberg, CB Weinman, EJ AF Nahar, A Akom, M Hanes, D Briglia, A Drachenberg, CB Weinman, EJ TI Pyelonephritis and acute renal failure SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE pyelonephritis; acute renal failure ID SECONDARY AB Bacterial invasion of the renal parenchyma, pyelonephritis, is rarely considered as a primary cause of acute renal failure, particularly in adults. We report two cases of acute renal failure occurring in absence of hypotension, urinary tract obstruction, or nephrotoxic medications that are likely the direct consequence of pyelonephritis. The first case involved a 48-year-old HIV-positive woman who presented with 3 days of nonspecific symptoms and was noted to have acute renal failure. Due to unremitting renal dysfunction, a renal biopsy was performed confirming the diagnosis of bacterial pyelonephritis. The second case, a 33-year-old man with HIV disease, presented with fever and was found to have pyelonephritis by urine culture and ultrasonography. These cases represented initial diagnostic dilemmas for the admitting physicians and demonstrate the varied clinical presentations of acute renal failure as a direct consequence of bacterial infiltration of the renal parenchyma. C1 Univ Maryland, Sch Med, Div Nephrol, Baltimore, MD 21201 USA. Univ Maryland, Ctr Med, Dept Pathol, Baltimore, MD 21201 USA. US Dept Vet Affairs, Med Ctr, Baltimore, MD USA. RP Weinman, EJ (reprint author), Univ Maryland, Sch Med, Div Nephrol, N3W143,UHM,22 S Greene St, Baltimore, MD 21201 USA. EM eweinman@medicine.umaryland.edu NR 10 TC 9 Z9 9 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-9629 J9 AM J MED SCI JI Am. J. Med. Sci. PD AUG PY 2004 VL 328 IS 2 BP 121 EP 123 DI 10.1097/00000441-200408000-00009 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 845QF UT WOS:000223258700009 PM 15311172 ER PT J AU Finegold, SM St John, S Vu, AW Li, CM Molitoris, D Song, YL Liu, CX Wexler, HM AF Finegold, SM St John, S Vu, AW Li, CM Molitoris, D Song, YL Liu, CX Wexler, HM TI In vitro activity of ramoplanin and comparator drugs against anaerobic intestinal bacteria from the perspective of potential utility of pathology involving bowel flora SO ANAEROBE LA English DT Article ID RESISTANT ENTEROCOCCI; VANCOMYCIN; GLYCOLIPODEPSIPEPTIDE; GLYCOPEPTIDE; ANTIBIOTICS; MECHANISMS; INVITRO; COCCI AB Susceptibility of intestinal bacteria to various antimicrobial agents in vitro, together with levels of those agents achieved in the gut, provides information on the likely impact of the agents on the intestinal flora. Orally administered drugs that are poorly absorbed may be useful for treatment of intestinal infections and for certain other situations in which intestinal bacteria may play a role. The antimicrobial activity of ramoplanin (MDL 62,198) against 928 strains of intestinal anaerobic bacteria was determined using the NCCLS-approved Wadsworth brucella laked-blood agar dilution method. The activity of ramoplanin was compared with that of ampicillin, bacitracin, metronidazole, trimethoprim/sulfamethoxazole (TMP/SMX), and vancomycin. The organisms tested included Bacteroides fragilis group (n = 89), other Bacteroides species (n = 16), other anaerobic Gram-negative rods (n = 56) anaerobic cocci (n = 114), Clostridium species (n = 426), and non-sporeforming anaerobic Gram-positive rods (n = 227). The overall MIC(90)s of ramoplanin, ampicillin, bacitracin, metronidazole, and vancomycin were 256, 32, 128, 16, and 128 mcg/ml, respectively. Ramoplanin was almost always highly active vs. Gram-positive organisms and relatively poor in activity against Gram-negative organisms, particularly Bacteroides, Bilophila, Prevotella, and Veillonella. Vancomycin was quite similar to ramoplanin in its activity. Ampicillin was relatively poor in activity vs. organisms that often produce beta-lactamase, including most of the Gram-negative rods as well as Clostridium bolteae and C clostridioforme. Bacitracin was relatively poor in activity against most anaerobic Gram-negative rods, but better vs. most Gram-positive organisms. Metronidazole was very active against all groups other than bifidobacteria and some strains of other types of non-sporeforming Gram-positive bacilli. TMP/SMX was very poorly active, with an MIC90 of > 2048 mcg/ml. (C) 2004 Elsevier Ltd. All rights reserved. C1 VA Greater Los Angeles Healthcare Syst, Med Serv, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90024 USA. RP Finegold, SM (reprint author), VA Med Ctr W Los Angeles, Infect Dis Sect, 111 F,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM sidfinegol@aol.com NR 25 TC 18 Z9 19 U1 1 U2 4 PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1075-9964 J9 ANAEROBE JI Anaerobe PD AUG PY 2004 VL 10 IS 4 BP 205 EP 211 DI 10.1016/j.anaerobe.2004.04.003 PG 7 WC Microbiology SC Microbiology GA 848OU UT WOS:000223477800001 PM 16701520 ER PT J AU Markovitz, JH Matthews, KA Whooley, M Lewis, CE Greenlund, KJ AF Markovitz, JH Matthews, KA Whooley, M Lewis, CE Greenlund, KJ TI Increases in job strain are associated with incident hypertension in the CARDIA study SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Article ID AMBULATORY BLOOD-PRESSURE; CORONARY HEART-DISEASE; RISK-FACTORS; YOUNG-ADULTS; FOLLOW-UP; DEPRESSION; UNEMPLOYMENT; SYMPTOMS; HEALTH; WOMEN AB Background: Job strain, defined as high job demands and low decision latitude, has been associated with increased blood pressure levels in some studies, but most of these studies have been cross-sectional. Purpose: We sought to determine whether changes in job strain during young adulthood were associated with the development of hypertension, using the Coronary Artery Risk Development in Young Adults cohort. Methods: A total of 3,200 employed, initially normotensive participants, aged 20 to 32 in 1987-1988, were followed for 8 years; the Job Content Questionnaire was completed twice: initially and 8 years later. Hypertension at follow-up was defined as systolic blood pressure (SBP) of 160 or higher and diastolic blood pressure of 95 mmHg or higher or reporting being on antihypertensive medication. Results: Job strain (based on job demands above the median and decision latitude below the median of the sample) was associated with hypertension incidence (ps <.05) for the entire cohort and among White women and men. Adjustment for baseline SBP education, body mass index (BMI), change in BMI, and age did not alter these relations. The ratio of increasing demands relative to decreasing decision latitude was also associated with greater incidence of hypertension in the entire cohort in the multivariate model (odds ratio = 2.06, 95% confidence interval = 1.01-4.26). Conclusions: An increase in job strain is associated with incident hypertension, particularly among Whites. C1 Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. Univ Alabama, Div Prevent Med, Birmingham, AL 35487 USA. San Francisco Vet Affairs Med Ctr, Div Gen Internal Med, San Francisco, CA USA. Univ Alabama, Div Prevent Med, Birmingham, AL 35487 USA. Ctr Dis Control & Prevent, Atlanta, GA USA. RP Matthews, KA (reprint author), Univ Pittsburgh, Dept Psychiat, 3811 O Hara St, Pittsburgh, PA 15213 USA. EM matthewska@upmc.edu FU NHLBI NIH HHS [N01-HC-48047, N01-HC-48048, N01-HC-48049, N01-HC-48050, N01-HC-95100] NR 35 TC 52 Z9 56 U1 1 U2 12 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD AUG PY 2004 VL 28 IS 1 BP 4 EP 9 DI 10.1207/s15324796abm2801_2 PG 6 WC Psychology, Multidisciplinary SC Psychology GA 840DF UT WOS:000222836500002 PM 15249254 ER PT J AU Spacey, SD Hildebrand, ME Materek, LA Bird, TD Snutch, TP AF Spacey, SD Hildebrand, ME Materek, LA Bird, TD Snutch, TP TI Functional implications of a novel EA2 mutation in the P/Q-type calcium channel SO ANNALS OF NEUROLOGY LA English DT Article ID EPISODIC ATAXIA TYPE-2; FAMILIAL HEMIPLEGIC MIGRAINE; NEURONS AB Episodic ataxia type 2 (EA2) is an autosomal dominant condition characterized by paroxysmal attacks of ataxia, vertigo, and nausea, typically lasting minutes to days in duration. These symptoms can be prevented or significantly attenuated by the oral administration of acetazolamide; however, the mechanism by which acetazolamide ameliorates EA2 symptoms is unknown. EA2 typically results from nonsense mutations in the CACNA1A gene that encodes the alpha(1A) (Ca(v)2.1) subunit of the P/Q-type calcium (Ca2+) channel. We have identified a novel H1736L missense mutation in the CACNA1A gene associated with the EA2 phenotype. This mutation is localized near the pore-forming region of the P/Q-type Ca2+ channel. Functional analysis of P/Q-type channels containing the mutation show that the H1736L alteration affects several channel properties, including reduced current density, increased rate of inactivation, and a shift in the voltage dependence of activation to more positive values. Although these findings are consistent with an overall loss of P/Q-type channel function, the mutation also caused some biophysical changes consistent with a gain of function. We also tested the direct effect of acetazolamide on both wild-type and H1736L mutated P/Q-type channels and did not observe any direct action on channel properties of this pharmacological agent used to treat EA2 patients. C1 Univ British Columbia, Div Neurol, Vancouver, BC V5Z 1M9, Canada. Univ British Columbia, Biotechnol Lab, Vancouver, BC V5Z 1M9, Canada. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Spacey, SD (reprint author), UBC Hosp, Room S-127,2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada. EM spacey@interchange.ubc.ca RI Hildebrand, Michael/J-9102-2012 NR 14 TC 42 Z9 45 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD AUG PY 2004 VL 56 IS 2 BP 213 EP 220 DI 10.1002/ana.20169 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 847YT UT WOS:000223434700007 PM 15293273 ER PT J AU Tyler, KL AF Tyler, KL TI West Nile virus infection in the United States SO ARCHIVES OF NEUROLOGY LA English DT Review ID ACUTE FLACCID PARALYSIS; NEW-YORK; INTRAVENOUS IMMUNOGLOBULIN; ENCEPHALITIS; POLIOMYELITIS; PATHOLOGY; RIBAVIRIN; OUTBREAK; EFFICACY; WEAKNESS AB West Nile virus (WNV), an arthropod-borne flavivirus belonging to the Japanese encephalitis virus antigenic complex, first appeared as a cause of naturally acquired meningitis and encephalitis in the United States in the New York City area in the summer of 1999.(1) During succeeding years, the virus has spread rapidly throughout North America, becoming enzootic in bird and mosquito populations throughout much of the continental United States. In 2003, WNV was responsible for one of the largest arboviral encephalitis epidemics in US history (9858 cases; 2863 with meningoencephalitis and 262 deaths) and one of the largest WNV meningoencephalitis epidemics yet recorded.(2) C1 Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Denver VA Med Ctr, Denver, CO 80262 USA. RP Tyler, KL (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, 4200 E 9th Ave,Campus Box B-182, Denver, CO 80262 USA. EM ken.tyler@uchsc.edu OI Tyler, Kenneth/0000-0003-3294-5888 NR 55 TC 26 Z9 29 U1 1 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD AUG PY 2004 VL 61 IS 8 BP 1190 EP 1195 DI 10.1001/archneur.61.8.1190 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 844SM UT WOS:000223180100006 PM 15313835 ER PT J AU Kozel, FA Padgett, TM George, MS AF Kozel, FA Padgett, TM George, MS TI A replication study of the neural correlates of deception SO BEHAVIORAL NEUROSCIENCE LA English DT Article ID FUNCTIONAL MAGNETIC-RESONANCE; ORBITOFRONTAL CORTEX; INTERFERENCE TASK; STROOP; POLYGRAPH; FMRI AB The authors attempted to replicate prior group brain correlates of deception (F. Kozel et al., in press) and improve on the consistency of individual results. Healthy, right-handed adults were instructed to tell the truth or to lie while being imaged in a 3T magnetic resonance imaging (MRI) scanner. Blood oxygen level-dependent functional MRI significance maps were generated for subjects giving a deceptive answer minus a truthful answer (lie minus true) and the reverse (true minus lie). The lie minus true group analysis (n = 10) revealed significant activation in 5 regions, consistent with a previous study (right orbitofrontal, inferior frontal, middle frontal cortex, cingulate gyrus, and left middle frontal), with no significant activation for true minus lie. Individual results of the lie minus true condition were variable. Results show that functional MRI is a reasonable tool with which to study deception. C1 Med Univ S Carolina, Dept Psychiat, Ctr Adv Imaging Res, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA. RP Kozel, FA (reprint author), Med Univ S Carolina, Dept Psychiat, Ctr Adv Imaging Res, 67 President St,POB 250861, Charleston, SC 29425 USA. EM kozelfa@musc.edu RI Kozel, Frank/I-5366-2012 NR 22 TC 93 Z9 97 U1 0 U2 10 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7044 J9 BEHAV NEUROSCI JI Behav. Neurosci. PD AUG PY 2004 VL 118 IS 4 BP 852 EP 856 DI 10.1037/0735-7044.118.4.852 PG 5 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 841IM UT WOS:000222923500018 PM 15301611 ER PT J AU Kontush, A Atwood, CS AF Kontush, A Atwood, CS TI Amyloid-beta: phylogenesis of a chameleon SO BRAIN RESEARCH REVIEWS LA English DT Letter DE amyloid-beta; Alzheimer's disease; antioxidant; prooxidant; oxidative stress; toxicity; trophic activity ID ALZHEIMER A-BETA; CEREBROSPINAL-FLUID; OXIDATIVE STRESS; DISEASE; ANTIOXIDANT; PEPTIDE; CU(II) C1 Hop Pitie, Natl Inst Hlth & Med Res, INSERM, Res Unit 551, F-75651 Paris 13, France. Univ Wisconsin, Dept Med, Madison, WI 53705 USA. William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. RP Kontush, A (reprint author), Hop Pitie, Natl Inst Hlth & Med Res, INSERM, Res Unit 551, Pavillon Benjamin Delessert,83 Blvd Hop, F-75651 Paris 13, France. EM kontush@chupsjussieu.fr; csa@medicine.wisc.edu RI Kontush, Anatol/J-2198-2016 NR 25 TC 9 Z9 9 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0173 J9 BRAIN RES REV JI Brain Res. Rev. PD AUG PY 2004 VL 46 IS 1 BP 118 EP 120 DI 10.1016/j.brainresrev.2004.05.001 PG 3 WC Neurosciences SC Neurosciences & Neurology GA 851UG UT WOS:000223710600005 PM 15297156 ER PT J AU Kessler, DA Kademani, D Feldman, RS Howlett, P AF Kessler, DA Kademani, D Feldman, RS Howlett, P TI Mesenchymoma: an unusual tumour of the lip SO BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY LA English DT Article DE benign neoplasm; mouth neoplasm; head and neck neoplasm; mesenchymoma; mesenchymal hamartoma; oral pathology ID BENIGN MESENCHYMOMAS AB The purpose of this paper is to present a case report of a benign mesenchymoma involving the lip. A brief review of relevant literature is presented. (C) 2004 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved. C1 Univ Penn, Hlth Syst, Dept Oral & Maxillofacial Surg, Philadelphia, PA USA. Univ Penn, Sch Dent Med, Dent Serv, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. Philadelphia Vet Affairs Med Ctr, Dept Pathol, Philadelphia, PA USA. Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Kessler, DA (reprint author), Univ Penn, Hlth Syst, Dept Oral & Maxillofacial Surg, 3400 Spruce St,White Bldg,5th Floor, Philadelphia, PA USA. EM kesslerd@uphs.upenn.edu; kademani@yahoo.com; roy.feldman@med.va.gov; paut.howlett@med.va.gov NR 7 TC 5 Z9 5 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0266-4356 J9 BRIT J ORAL MAX SURG JI Br. J. Oral Maxillofac. Surg. PD AUG PY 2004 VL 42 IS 4 BP 348 EP 350 DI 10.1016/j.bjoms.2004.03.002 PG 3 WC Dentistry, Oral Surgery & Medicine; Surgery SC Dentistry, Oral Surgery & Medicine; Surgery GA 839CE UT WOS:000222760100015 PM 15225956 ER PT J AU Chauncey, TR AF Chauncey, TR TI Autologous bone marrow transplantation improves disease free survival but not overall survival in people with acute myeloid leukaemia SO CANCER TREATMENT REVIEWS LA English DT Editorial Material ID STEM-CELL TRANSPLANTATION; AML 10 TRIAL; INTENSIVE CHEMOTHERAPY; 1ST REMISSION; POSTREMISSION THERAPY; CURRENT CONTROVERSIES; RECEIVE; VIEW C1 Univ Washington, Sch Med, Fred Hutchinson Canc Res Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Chauncey, TR (reprint author), Univ Washington, Sch Med, Fred Hutchinson Canc Res Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. EM tchaunce@u.washington.edu NR 13 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0305-7372 J9 CANCER TREAT REV JI Cancer Treat. Rev. PD AUG PY 2004 VL 30 IS 5 BP 483 EP 487 DI 10.1061/j.ctrv.2004.05.005 PG 5 WC Oncology SC Oncology GA 850NT UT WOS:000223619800009 PM 15245781 ER PT J AU Meyer, AM Dwyer-Nield, LD Hurteau, GJ Keith, RL O'Leary, E You, M Bonventre, JV Nemenoff, RA Malkinson, AM AF Meyer, AM Dwyer-Nield, LD Hurteau, GJ Keith, RL O'Leary, E You, M Bonventre, JV Nemenoff, RA Malkinson, AM TI Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A(2) SO CARCINOGENESIS LA English DT Article ID PLATELET-ACTIVATING-FACTOR; A/J MICE; CANCER; TUMORS; CELLS; EXPRESSION; GENE; LIPOXYGENASE; INHIBITORS; ACID AB Epidemiological investigations suggest that chronic lung inflammation increases lung cancer risk. Pharmacologic and genetic evidence in mouse models indicates that lipid mediators released during pulmonary inflammation enhance lung tumor formation. Cytosolic phospholipase A(2) (cPLA(2)) catalyzes arachidonic acid (AA) release from membrane phospholipids. AA can then lead to the synthesis of several classes of lipid mediators, including prostaglandin (PG) biosynthesis through the cyclooxygenase (COX) pathway. We investigated a role for cPLA(2) in mouse lung tumorigenesis by using mice genetically deficient in cPLA(2). After multiple urethane injections into cPLA(2) null mice and wild-type littermates, the number of lung tumors was determined. cPLA(2) null mice developed 43% fewer tumors (from 16 +/- 2 to 9 +/- 2 tumors/mouse; P < 0.05) than wild-type littermates. cPLA(2), COX-1, COX-2 and microsomal prostaglandin E-2 synthase (mPGES), examined by immunohistochemistry, are present in alveolar and bronchiolar epithelia and in alveolar macrophages in lungs from naive mice and tumor-bearing mice. Tumors express higher levels of each of these four enzymes than control lungs, as determined by immunoblotting. No differences were detected in the contents of COX-1, COX-2 and mPGES between wild-type and cPLA(2) null mice. Although the steady-state levels of prostaglandin E-2 and prostaglandin I-2 in lung tissue extracts prepared from wild-type or cPLA(2) (-/-) mice were not significantly different, both prostaglandins markedly increased in tumors from wild-type mice, an increase that was significantly blunted in tumors from cPLA(2) (-/-) mice. These results demonstrate a role for cPLA(2) in mouse lung tumorigenesis that may be mediated by decreased prostaglandin synthesis. C1 Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Denver VA Med Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO 80220 USA. Harvard Univ, Sch Med, Dept Med, Charlestown, MA 02129 USA. Harvard MIT Div Hlth Sci & Technol, Charlestown, MA 02129 USA. Washington Univ, Dept Surg, St Louis, MO 63110 USA. RP Malkinson, AM (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, 4200 E 9th Ave, Denver, CO 80262 USA. EM al.malkinson@uchsc.edu FU NCI NIH HHS [CA33497, CA58187, CA103618] NR 52 TC 57 Z9 58 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD AUG PY 2004 VL 25 IS 8 BP 1517 EP 1524 DI 10.1093/carcin/bgh150 PG 8 WC Oncology SC Oncology GA 844FJ UT WOS:000223142700024 PM 15033900 ER PT J AU Dhillon, SS Roberto, A AF Dhillon, SS Roberto, A TI A 62-year-old man with shoulder pain SO CHEST LA English DT Editorial Material ID CHEST-WALL; PYOMYOSITIS C1 Baylor Coll Med, Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Dhillon, SS (reprint author), 85 Spring St,3rd Floor, Laconia, NH 03246 USA. EM samjot@yahoo.com OI Dhillon, Samjot/0000-0003-2955-2266 NR 9 TC 1 Z9 1 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD AUG PY 2004 VL 126 IS 2 BP 614 EP 616 DI 10.1378/chest.126.2.614 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 846CZ UT WOS:000223293900045 PM 15302751 ER PT J AU Perencevich, EN Kaye, KS Strausbaugh, LJ Fisman, DN Harris, AD AF Perencevich, EN Kaye, KS Strausbaugh, LJ Fisman, DN Harris, AD TI Clear clinical definitions of failure are needed in studies of diabetic foot infections - Reply SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID OSTEOMYELITIS C1 Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA. Vet Affairs Maryland Hlth Care Syst, Baltimore, MD USA. Duke Univ, Med Ctr, Durham, NC USA. Portland Vet Affairs Med Ctr, Portland, OR USA. Drexel Univ, Philadelphia, PA 19104 USA. RP Perencevich, EN (reprint author), Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, 100 N Greene St,Lower Level, Baltimore, MD 21201 USA. EM eperence@epi.umaryland.edu NR 6 TC 1 Z9 1 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 1 PY 2004 VL 39 IS 3 BP 437 EP 438 DI 10.1086/422153 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 839VR UT WOS:000222813500023 ER PT J AU Jeffcoate, WJ Lipsky, BA AF Jeffcoate, WJ Lipsky, BA TI Controversies in diagnosing and managing osteomyelitis of the foot in diabetes SO CLINICAL INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 5th Annual Almelo Diabetic Foot Symposium CY 2001 CL Almelo, NETHERLANDS ID PERIPHERAL VASCULAR-DISEASE; UNDERLYING OSTEOMYELITIS; CONSERVATIVE MANAGEMENT; COST-EFFECTIVENESS; SOFT-TISSUE; INFECTIONS; ULCERS; FEET; MELLITUS; THERAPY AB The optimal approach to diagnosing and managing osteomyelitis of the foot in diabetes is unclear. Diagnosis is based on clinical signs, supplemented by a variety of imaging tests. Bone biopsy is the accepted criterion standard for diagnosis but is not used by many. Management traditionally involves surgical removal of infected bone, combined with antibiotic therapy. However, recent studies have shown that antibiotics alone may apparently eliminate bone infection in many cases. There is also evidence that early amputation of infected digits is frequently noncurative. Agreement on criteria for diagnosing osteomyelitis is required, and randomized trials are urgently needed, to determine the relative benefits of various surgical interventions and the optimal deployment of antibiotics. We review the microbiology of osteomyelitis of the foot in diabetes, the benefits and limitations of various diagnostic procedures, and the evidence for the effectiveness of both surgical and nonsurgical approaches to management. C1 City Hosp, Dept Endocrinol & Diabet, Nottingham NG5 1PB, England. Univ Washington, Sch Med, Dept Med, Gen Internal Med Clin, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Antibiot Res Clin, Seattle, WA USA. RP Jeffcoate, WJ (reprint author), City Hosp, Dept Endocrinol & Diabet, Nottingham NG5 1PB, England. EM jeffcoate@bigfoot.com NR 64 TC 82 Z9 84 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 1 PY 2004 VL 39 SU 2 BP S115 EP S122 DI 10.1086/383272 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 839VU UT WOS:000222813800008 PM 15306989 ER PT J AU Lipsky, BA AF Lipsky, BA TI Medical treatment of diabetic foot infections SO CLINICAL INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 5th Annual Almelo Diabetic Foot Symposium CY 2001 CL Almelo, NETHERLANDS ID LOWER-EXTREMITY INFECTIONS; COLONY-STIMULATING FACTOR; HYPERBARIC-OXYGEN THERAPY; OPEN-LABEL TRIAL; STAPHYLOCOCCUS-AUREUS; CHRONIC OSTEOMYELITIS; ANTIBIOTIC-THERAPY; MELLITUS; CIPROFLOXACIN; MANAGEMENT AB Diabetic foot infections frequently cause morbidity, hospitalization, and amputations. Gram-positive cocci, especially staphylococci and also streptococci, are the predominant pathogens. Chronic or previously treated wounds often yield several microbes on culture, including gram-negative bacilli and anaerobes. Optimal culture specimens are wound tissue taken after debridement. Infection of a wound is defined clinically by the presence of purulent discharge or inflammation; systemic signs and symptoms are often lacking. Only infected wounds require antibiotic therapy, and the agents, route, and duration are predicated on the severity of infection. Mild to moderate infections can usually be treated in the outpatient setting with oral agents; severe infections require hospitalization and parenteral therapy. Empirical therapy must cover gram-positive cocci and should be broad spectrum for severe infections. Definitive therapy depends on culture results and the clinical response. Bone infection is particularly difficult to treat and often requires surgery. Several adjuvant agents may be beneficial in some cases. C1 VA Puget Sound Hlth Care Syst, Gen Internal Med Clin, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Lipsky, BA (reprint author), VA Puget Sound Hlth Care Syst, Gen Internal Med Clin, S-111-GIMC,1660 S Columbian Way, Seattle, WA 98108 USA. EM Benjamin.Lipsky@med.va.gov OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 86 TC 62 Z9 65 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 1 PY 2004 VL 39 SU 2 BP S104 EP S114 DI 10.1086/383271 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 839VU UT WOS:000222813800007 PM 15306988 ER PT J AU van Baal, JG Harding, KG Lipsky, BA AF van Baal, JG Harding, KG Lipsky, BA TI Foot infections in diabetic patients: An overview of the problem SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material C1 Twenteborg Hosp, Dept Surg, Diabet Foot Unit, Almelo, Netherlands. Cardiff Medictr, Wound Healing Res Unit, Cardiff, S Glam, Wales. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Gen Internal Med Clin, Seattle, WA USA. RP van Baal, JG (reprint author), Twenteborg Hosp, Dept Surg, Diabet Foot Unit, Almelo, Netherlands. EM Baal0020@wxs.nl RI Lipsky, Benjamin/B-4645-2013 NR 4 TC 1 Z9 1 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 1 PY 2004 VL 39 SU 2 BP S71 EP S72 DI 10.1086/383265 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 839VU UT WOS:000222813800001 ER PT J AU Bellomo, R Ronco, C Kellum, JA Mehta, RL Palevsky, P AF Bellomo, R Ronco, C Kellum, JA Mehta, RL Palevsky, P CA ADQI Workgroup TI Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group SO CRITICAL CARE LA English DT Article DE acute renal failure; animal models; creatinine; glomerular filtration rate; information technology; intravenous fluids; kidney; outcome research; randomized controlled trials; urea ID CRITICALLY ILL PATIENTS; OCCULT HYPOPERFUSION; SEPTIC SHOCK; MAJOR TRAUMA; SOFA SCORE; MULTICENTER; PRESSURE; SEPSIS; TRIAL; CARE AB Introduction There is no consensus definition of acute renal failure (ARF) in critically ill patients. More than 30 different definitions have been used in the literature, creating much confusion and making comparisons difficult. Similarly, strong debate exists on the validity and clinical relevance of animal models of ARF; on choices of fluid management and of end-points for trials of new interventions in this field; and on how information technology can be used to assist this process. Accordingly, we sought to review the available evidence, make recommendations and delineate key questions for future studies. Methods We undertook a systematic review of the literature using Medline and PubMed searches. We determined a list of key questions and convened a 2-day consensus conference to develop summary statements via a series of alternating breakout and plenary sessions. In these sessions, we identified supporting evidence and generated recommendations and/or directions for future research. Results We found sufficient consensus on 47 questions to allow the development of recommendations. Importantly, we were able to develop a consensus definition for ARF. In some cases it was also possible to issue useful consensus recommendations for future investigations. We present a summary of the findings. (Full versions of the six workgroups' findings are available on the internet at http://www.ADQI.net) Conclusion Despite limited data, broad areas of consensus exist for the physiological and clinical principles needed to guide the development of consensus recommendations for defining ARF, selection of animal models, methods of monitoring fluid therapy, choice of physiological and clinical end-points for trials, and the possible role of information technology. C1 Austin Hlth, Dept Intens Care & Med, Melbourne, Vic, Australia. San Bortolo Hosp, Dept Nephrol, Vicenza, Italy. Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. RP Bellomo, R (reprint author), Austin Hlth, Dept Intens Care & Med, Melbourne, Vic, Australia. EM rinaldo.bellomo@austin.org.au NR 45 TC 2618 Z9 2798 U1 22 U2 123 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1466-609X J9 CRIT CARE JI Crit. Care PD AUG PY 2004 VL 8 IS 4 BP R204 EP R212 DI 10.1186/cc2872 PG 9 WC Critical Care Medicine SC General & Internal Medicine GA 846GU UT WOS:000223304600007 PM 15312219 ER PT J AU Sambamurti, K Granholm, AC Kindy, MS Bhat, NR Greig, NH Lahiri, DK Mintzer, JE AF Sambamurti, K Granholm, AC Kindy, MS Bhat, NR Greig, NH Lahiri, DK Mintzer, JE TI Cholesterol and Alzheimer's disease: Clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors SO CURRENT DRUG TARGETS LA English DT Review DE aging; cognition; diets; dementia; high fats; apolipoprotein E; secretase; myelin; memory ID AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN-E GENOTYPE; LOW-DENSITY-LIPOPROTEIN; ALPHA-SECRETASE CLEAVAGE; INSOLUBLE MEMBRANE COMPARTMENT; BETA-PEPTIDE PRODUCTION; TRANSGENIC MOUSE MODEL; NECROSIS-FACTOR-ALPHA; NERVE GROWTH-FACTOR; HIGH-FAT DIETS AB Alzheimer's disease (AD) is a progressive senile dementia characterized by deposition of a 4 kDa peptide of 39-42 residues known as amyloid beta-peptide (AD) in the form of senile plaques and the microtubule associated protein tau as paired helical filaments. Genetic studies have identified mutations in the Abeta precursor protein (APP) as the key triggers for the pathogenesis of AD. Other genes such as presenilins 1 and 2 (PS1/2) and apolipoprotein E (APOE) also play a critical role in increased Abeta deposition. Severial biochemical and molecular studies using transfected cultured cells and transgenic animals point to mechanisms by which AD is generated and aggregated to trigger the neurodegeneration that may cause AD. Three important enzymes collectively known as 'secretases' participate in APP processing leading to the generation of either Abeta or non-amyloid proteins. However, the mechanisms of neurotoxicity of Abeta and the role of APP function in AD remain important unanswered questions. Although early studies recognized the loss of cholesterol and other lipids in the brain, these findings have been poorly connected with AD pathogenesis, despite the identification of the epsilon4 allele of APOE as a major risk factor in AD. The recent finding that cholesterol can modulate the yield of potentially toxic Abeta has boosted research on its role in AD. Consequently, several cholesterol-reducing drugs are currently being evaluated for the treatment of AD. The present review summarizes our current understanding of the relationship of AD pathogenesis with cholesterol, lipids and other genetic and environmental risk factors. C1 Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA. Med Univ S Carolina, Ctr Aging, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA. NIA, Drug Design & Dev Sect, Neurosci Lab, Intramural Res Program,NIH, Baltimore, MD 21224 USA. Indiana Univ, Sch Med, Dept Psychiat, Inst Psychiat Res, Indianapolis, IN 46202 USA. Dept Psychiat, N Charleston, SC USA. Ctr Aging, N Charleston, SC USA. RP Sambamurti, K (reprint author), Med Univ S Carolina, Dept Physiol & Neurosci, 173 Ashley Ave,BSB 403, Charleston, SC 29425 USA. EM sambak@musc.edu NR 165 TC 41 Z9 42 U1 1 U2 2 PU BENTHAM SCIENCE PUBL LTD PI HILVERSUM PA PO BOX 1673, 1200 BR HILVERSUM, NETHERLANDS SN 1389-4501 J9 CURR DRUG TARGETS JI Curr. Drug Targets PD AUG PY 2004 VL 5 IS 6 BP 517 EP 528 DI 10.2174/1389450043345335 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 836GG UT WOS:000222543200004 PM 15270198 ER PT J AU Carr, DB Utzschneider, KM Hull, RL Kodama, K Retzlaff, BM Brunzell, JD Shofer, JB Fish, BE Knopp, RH Kahn, SE AF Carr, DB Utzschneider, KM Hull, RL Kodama, K Retzlaff, BM Brunzell, JD Shofer, JB Fish, BE Knopp, RH Kahn, SE TI Intra-abdominal fat is a major determinant of the national cholesterol education program adult treatment panel III criteria for the metabolic syndrome SO DIABETES LA English DT Article ID CORONARY-HEART-DISEASE; IMPAIRED GLUCOSE-TOLERANCE; NECROSIS-FACTOR-ALPHA; INSULIN-RESISTANCE; VISCERAL FAT; RISK-FACTORS; ABDOMINAL FAT; DIABETES-MELLITUS; JAPANESE-AMERICANS; ADIPOSE-TISSUE AB The underlying pathophysiology of the metabolic syndrome is the subject of debate, with both insulin resistance and obesity considered as important factors. We evaluated the differential effects of insulin resistance and central body fat distribution in determining the metabolic syndrome as defined by the National Cholesterol Education Program (NCEP) Adult Treatment Panel III. In addition, we determined which NCEP criteria were associated with insulin resistance and central adiposity. The subjects, 218 healthy men (n = 89) and women (n = 129) with a broad range of age (26-75 years) and BMI (18.4-46.8 kg/m(2)), underwent quantification of the insulin sensitivity index (S-i) and intraabdominal fat (IAF) and subcutaneous fat (SCF) areas. The metabolic syndrome was present in 34 (15.6%) of subjects who had a lower S-i [median:3.13 vs. 6.09 x 10(-5) min(-1)/(pmol/l)] and higher IAF (166.3 vs. 79.1 cm(2)) and SCF (285.1 vs. 179.8 cm(2)) areas compared with subjects without the syndrome (P < 0.001). Multivariate models including S-i, IAF, and SCF demonstrated that each parameter was associated with the syndrome. However, LAX was independently associated with all five of the metabolic syndrome criteria. In multivariable models containing the criteria as covariates, waist circumference and triglyceride levels were independently associated with S-i and IAF and SCF areas (P < 0.001). Although insulin resistance and central body fat are both associated with the metabolic syndrome, IAF is independently associated with all of the criteria, suggesting that it may have a pathophysiological role. Of the NCEP criteria, waist circumference and triglycerides may best identify insulin resistance and visceral adiposity in individuals with a fasting plasma glucose < 6.4 mmol/l. C1 Univ Washington, Dept Obstet & Gynecol, Div Maternal Fetal Med, Seattle, WA 98195 USA. Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. Univ Washington, Harborview Med Ctr, Seattle, WA 98195 USA. Univ Washington, Dept Rehabil Res & Dev, Seattle, WA 98195 USA. RP Carr, DB (reprint author), Univ Washington, Dept OB GYN, Box 356460, Seattle, WA 98195 USA. EM darcarr@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002; Hull, Rebecca/0000-0001-9690-4087 FU NCRR NIH HHS [RR-16066, RR-37]; NHLBI NIH HHS [HL-30086]; NIDDK NIH HHS [DK-02456, DK-02654, DK-17047, DK-35747, DK-35816, DK-50129] NR 53 TC 473 Z9 520 U1 1 U2 20 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD AUG PY 2004 VL 53 IS 8 BP 2087 EP 2094 DI 10.2337/diabetes.53.8.2087 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 842TL UT WOS:000223027000022 PM 15277390 ER PT J AU Yuan, BZ Xing, Y Horst, RL Drezner, MK AF Yuan, BZ Xing, Y Horst, RL Drezner, MK TI Evidence for abnormal translational regulation of renal 25-hydroxyvitamin D-1 alpha-hydroxylase activity in the Hyp-mouse SO ENDOCRINOLOGY LA English DT Article ID LINKED HYPOPHOSPHATEMIC RICKETS; 25-HYDROXYVITAMIN D-1-ALPHA-HYDROXYLASE ACTIVITY; VITAMIN-D METABOLISM; SERUM 1,25-DIHYDROXYVITAMIN-D LEVELS; 1-ALPHA-HYDROXYLASE GENE-EXPRESSION; PARATHYROID-HORMONE; MESSENGER-RNA; D-3-1-ALPHA-HYDROXYLASE GENE; CALCITONIN STIMULATION; CALCITRIOL PRODUCTION AB Hyp-mice exhibit abnormal regulation of 25-hydroxyvitamin D [25(OH)D]-1alpha-hydroxylase activity. Previous observations suggest such aberrant modulation is posttranscriptional. To investigate this possibility further, we examined whether hypmice manifest abnormal translation of 25(OH) D-1alpha-hydroxylase mRNA. We compared phosphate, parathyroid, and calcitonin effects on renal 25(OH) D-1alpha-hydroxylase protein as well as mRNA and enzyme activity in normal and hyp-mice. We assayed protein by Western blots, mRNA by real-time RT-PCR, and enzyme activity by measuring 1,25-dihydroxyvitamin D production. Although phosphate-depleted mice exhibited enhanced enzyme function, with significantly increased mRNA and protein expression, hyp-mice comparably increased mRNA but failed to augment enzyme activity, concordant with an inability to increase protein expression. PTH stimulation increased mRNA and protein expression as well as enzyme activity in normal mice but in hyp-mice, despite effecting mRNA enhancement, did not increment enzyme function or protein. The inability of hypophosphatemia and PTH to increase 25(OH)D-1alpha-hydroxylase activity and protein expression in hyp-mice was not universal because calcitonin stimulation was normal, suggesting proximal convoluted tubule localization of the defect. These data, in accord with absent undue enhancement of protein expression in hyp-mice treated with protease inhibitors, establish that abberrant regulation of vitamin D metabolism results from abnormal translational activity. C1 Univ Wisconsin, Sch Med, Dept Med, Clin Sci Ctr H4 554, Madison, WI 53792 USA. Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Ctr Geriatr Res Educ & Clin, Madison, WI 53792 USA. ARS, Natl Anim Dis Ctr, USDA, Ames, IA 50010 USA. RP Drezner, MK (reprint author), Univ Wisconsin, Sch Med, Dept Med, Clin Sci Ctr H4 554, 600 Highland Ave, Madison, WI 53792 USA. EM mkd@medicine.wisc.edu NR 56 TC 18 Z9 19 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD AUG PY 2004 VL 145 IS 8 BP 3804 EP 3812 DI 10.1210/en.2004-0192 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 837XB UT WOS:000222673500036 PM 15265826 ER PT J AU Wong, M Latini, R Staszewsky, L Masson, S Carretta, E Barlera, S Tognoni, G Cohn, JN AF Wong, M Latini, R Staszewsky, L Masson, S Carretta, E Barlera, S Tognoni, G Cohn, JN CA Val-HeFT Investigators TI Brain natriuretic peptide and symptoms as markers of severity in patients with chronic heart failure: Val-HeFT data SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT ESC Congress 2004 CY AUG 28-SEP 01, 2004 CL Munich, GERMANY SP ESC C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Ist Ric Farmacol Mario Negri, Milan, Italy. Univ Minnesota, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0195-668X J9 EUR HEART J JI Eur. Heart J. PD AUG-SEP PY 2004 VL 25 SU S BP 136 EP 137 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 856PG UT WOS:000224056500541 ER PT J AU Kevork, HA Ramsey, JJ Weindruch, R AF Kevork, HA Ramsey, JJ Weindruch, R TI Krebs cycle enzymes from livers of old mice are differentially regulated by caloric restriction SO EXPERIMENTAL GERONTOLOGY LA English DT Article DE caloric restriction; Krebs cycle enzymes; liver; aging ID ALPHA-KETOGLUTARATE DEHYDROGENASE; ACETYL-COA CARBOXYLASE; FATTY-ACID SYNTHESIS; GENE-EXPRESSION; PYRUVATE-CARBOXYLASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; MITOCHONDRIAL ACONITASE; MULTIPLE TRANSCRIPTS; ALTERNATE PROMOTERS; OXIDATIVE DAMAGE AB Krebs cycle enzyme activities and levels of five metabolites were determined from livers of old mice (30 months) maintained either on control or on long-term caloric restriction (CR) diets (28 months). In CR mice, the cycle was divided into two major blocks, the first containing citrate synthase, aconitase and NAD-dependent isocitrate dehydrogenase which showed decreased activities, while the second block, containing the remaining enzymes, displayed increased activity (except for fumarase, which was unchanged). CR also resulted in decreased levels of citrate, glutamate and alpha-ketoglutarate, increased levels of malate, and unchanged levels of aspartate. The alpha-ketoglutarate/glutamate and malate/alpha-ketoglutarate ratios were higher in CR, in parallel with previously reported increases with CR in pyruvate carboxylase activity and glucagon levels, respectively. The results indicate that long-term CR induces a differential regulation of Krebs cycle in old mice and this regulation may be the result of changes in gene expression levels, as well as a complex interplay between enzymes. hormones and other effectors. Truncation of Krebs cycle by CR may be an important adaptation to utilize available substrates for the gluconeogenesis necessary to sustain glycolytic tissues, such as brain. (C) 2004 Elsevier Inc. All rights reserved. C1 Univ Calif Davis, Dept Mol Biosci, Sch Vet Med, Davis, CA 95616 USA. Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53706 USA. William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53715 USA. RP Kevork, HA (reprint author), Univ Calif Davis, Dept Mol Biosci, Sch Vet Med, 1 Shields Ave, Davis, CA 95616 USA. EM khagopian@ucdavis.edu NR 58 TC 0 Z9 0 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0531-5565 J9 EXP GERONTOL JI Exp. Gerontol. PD AUG PY 2004 VL 39 IS 8 BP 1145 EP 1154 DI 10.1016/j.exger.2004.04.009 PG 10 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 848VZ UT WOS:000223497500004 ER PT J AU Wen, PH Hof, PR Chen, XP Gluck, K Austin, G Younkin, SG Younkin, LH DeGasperi, R Sosa, MAG Robakis, NK Haroutunian, V Elder, GA AF Wen, PH Hof, PR Chen, XP Gluck, K Austin, G Younkin, SG Younkin, LH DeGasperi, R Sosa, MAG Robakis, NK Haroutunian, V Elder, GA TI The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult mice SO EXPERIMENTAL NEUROLOGY LA English DT Article DE presenilin 1; familial Alzheimer disease; bromodeoxyuridine ID AMYLOID-BETA-PROTEIN; GENERATED GRANULE CELLS; DENTATE GYRUS; TRANSGENIC MICE; SUBVENTRICULAR ZONE; GENETIC INFLUENCE; PROGENITOR CELLS; RAT HIPPOCAMPUS; SENILE PLAQUES; SPINAL-CORD AB The functions of presenilin 1 (PS1) and how PS1 mutations cause familial Alzheimer's disease (FAD) are incompletely understood. PS1 expression is essential for neurogenesis during embryonic development and may also influence neurogenesis in adult brain. We examined how increasing PS1 expression or expressing an FAD mutant would affect neurogenesis in the adult hippocampus. A neuron-specific enolase (NSE) promoter was used to drive neuronal overexpression of either wild-type human PS1 or the FAD mutant P117L in transgenic mice, and the animals were studied under standard-housing conditions or after environmental enrichment. As judged by bromodeoxyuridine (BrdU) labeling, neural progenitor proliferation rate was mostly unaffected by increasing expression of either wild-type or FAD mutant PS1. However, in both housing conditions, the FAD mutant impaired the survival of BrdU-Iabeled neural progenitor cells leading to fewer new beta-III-tubulin-immunoreactive neurons being generated in FAD mutant animals during the 4-week postlabeling period. The effect was FAD mutant specific in that neural progenitor survival and differentiation in mice overexpressing wild-type human PS1 were similar to nontransgenic controls. Two additional lines of PS1 wild-type and FAD mutant transgenic mice showed similar changes indicating that the effects were not integration site-dependent. These studies demonstrate that a PS1 FAD mutant impairs new neuron production in adult hippocampus by decreasing neural progenitor survival. They also identify a new mechanism whereby PS1 FAD mutants may impair normal neuronal function and may have implications for the physiological functioning of the hippocampus in FAD. (C) 2004 Elsevier Inc. All rights reserved. C1 Bronx Vet Adm Med Ctr, Psychiat Res Serv, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. Mt Sinai Sch Med, Kastor Neurobiol Aging Labs, New York, NY 10029 USA. Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA. Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA. Mayo Clin Jacksonville, Jacksonville, FL 32224 USA. RP Elder, GA (reprint author), Bronx Vet Adm Med Ctr, Psychiat Res Serv, 3F22,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM gregory.elder@mssm.edu FU NIA NIH HHS [P50 AG05138, R01 AG17926, R01 AG20139] NR 79 TC 115 Z9 120 U1 1 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD AUG PY 2004 VL 188 IS 2 BP 224 EP 237 DI 10.1016/j.expneurol.2004.04.002 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 838PX UT WOS:000222726500005 PM 15246822 ER PT J AU Ayasolla, K Khan, M Singh, AK Singh, I AF Ayasolla, K Khan, M Singh, AK Singh, I TI Inflammatory mediator and beta-amyloid (25-35)-induced ceramide generation and iNOS expression are inhibited by vitamin E SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE Alzheimer disease; inducible nitric oxide synthase; vitamin E; amyloid peptide; ceramide; reactive oxygen species; CCAAT enhancer binding proteins; free radicals ID NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; NEUTRAL SPHINGOMYELINASE; SPHINGOLIPID METABOLISM; GENE-TRANSCRIPTION; GLIAL-CELLS; ASTROCYTES AB To investigate the putative role of beta-amyloid peptide (Abeta) in inducing oxidative stress damage in Alzheimer disease (AD), we studied the effects of proinflammatory cytokines and Abeta peptide on the induction of inducible nitric oxide synthase (iNOS). Abeta(25-35) upregulated the cytokine (TNF-alpha/IL-1beta)-induced expression of iNOS and the production of nitric oxide (NO) in astrocytes, which were inhibited by vitamin E. Abeta treatment of C6 glial cells (together with LPS and IFN-gamma), in addition to inducing iNOS, enhanced the oxidative stress as measured by increased expression of manganese superoxide dismutase and an increase in 2,7'-dichlorofluorescein diacetate fluorescence. We also observed that LPS, IFN-gamma, and Abeta(25-35) treatment led to the activation of the sphingomyelin-ceramide (SM-Cer) cascade with an increase in cellular ceramide. Inhibition of the SM-Cer cascade either by vitamin E treatment or by the neutral sphingomyelinase inhibitor 3-O-methyl sphingomyelin also resulted in alteration of the transcriptional binding activities of C/EBP, NFkappaB, AP-1, and CREB in C6 glial cells. Hence, these findings suggest a role for ceramide in iNOS induction and NO production in Abeta-induced AD pathobiology and provide a possible explanation for the beneficial effects of vitamin E therapy. (C) 2004 Elsevier Inc. All rights reserved. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Singh, I (reprint author), Med Univ S Carolina, Childrens Hosp, 316 CSB,96 Jonathan Lucas St, Charleston, SC 29425 USA. EM singhi@muse.edu OI Ayasolla, kameshwar/0000-0002-4265-2168 FU NINDS NIH HHS [NS-22576, NS-34741, NS-37766, NS-40144] NR 50 TC 73 Z9 81 U1 0 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD AUG 1 PY 2004 VL 37 IS 3 BP 325 EP 338 DI 10.1016/j.freeadbiomed.2004.04.007 PG 14 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 838VG UT WOS:000222740800004 PM 15223066 ER PT J AU Spiegel, BMR Targownik, LE Kanwal, F Derosa, V Dulai, GS Gralnek, IM Chiou, CF AF Spiegel, BMR Targownik, LE Kanwal, F Derosa, V Dulai, GS Gralnek, IM Chiou, CF TI The quality of published health economic analyses in digestive diseases: A systematic review and quantitative appraisal SO GASTROENTEROLOGY LA English DT Review ID COST-EFFECTIVENESS; GASTROENTEROLOGY LITERATURE; STRATEGIES; IMPACT AB Background & Aims: Health economic analyses are increasingly common in the digestive diseases literature and often are cited to frame practice guidelines. Although clinical trials are subjected routinely to critical appraisal, there has been no attempt to appraise the quality of health economic analyses with a validated instrument. We sought to appraise the quality of health economic analyses in digestive diseases, and to identify predictors of study quality. Methods: We performed a systematic review to identify digestive disease health economic analyses published since 1980. We assessed these studies using the Quality of Health Economic Studies (QHES), a validated quality-scoring instrument (score range = 0-100; > 75 = high quality). We conducted regression analysis to identify predictors of high quality. Results: Of :186 identified analyses, 29% were high quality, 71% failed to address potential model biases, 52% failed to disclose conflicts of interest, and 74% failed to describe methods for deriving the model assumptions. Four factors predicted high quality in logistic regression: (1) one or more authors had an advanced degree in health services or a related field (odds ratio for high quality, 5.0; 95% confidence interval, 2.6-9.3); (2) the study used decision-analysis software package (odds ratio, 2.4; 95% confidence interval, :1.2-4.7); (3) the study was federally funded (odds ratio, 2.2; 95% confidence interval, 1.2-4.1); and (4) the study cited the National Panel on Cost Effectiveness guidelines (odds ratio, 2.1; 95% confidence interval, 1.1-4.2). Conclusions: Less than one third of health economic analyses in digestive diseases meet criteria for high quality. Study quality is limited by factors that potentially can be remedied. These data may be used to focus the attention of journal editors and peer reviewers to ensure the future high quality of health economic analyses in digestive diseases. C1 Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr,Ctr Study Digest Healthca, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA USA. Univ Manitoba, Winnipeg, MB, Canada. CURE Digest Dis Res Ctr, Los Angeles, CA USA. Ctr Study Digest Healthcare Qual & Outcomes, Los Angeles, CA USA. Zync Hlth, Cerner Co, Beverly Hills, CA USA. RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr,Ctr Study Digest Healthca, 11301 Wilshire Blvd,Bldg 115,Room 215C, Los Angeles, CA 90073 USA. EM bspiegel@ucla.edu FU NCRR NIH HHS [K23 RR-16188]; NIDDK NIH HHS [DK-07180] NR 15 TC 33 Z9 35 U1 0 U2 2 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD AUG PY 2004 VL 127 IS 2 BP 403 EP 411 DI 10.1053/j.gastro.2004.04.020 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 847XK UT WOS:000223431200010 PM 15300571 ER PT J AU Simmons, SF Cadogan, MP Cabrera, GR Al-Samarrai, NR Jorge, JS Levy-Storms, L Osterweil, D Schnelle, JF AF Simmons, SF Cadogan, MP Cabrera, GR Al-Samarrai, NR Jorge, JS Levy-Storms, L Osterweil, D Schnelle, JF TI The minimum data set depression quality indicator: Does it reflect differences in care processes? SO GERONTOLOGIST LA English DT Editorial Material DE nursing homes; quality of care; mental health ID NURSING-HOME; VULNERABLE ELDERS; RESIDENTS; SCORES AB Purpose. The objective of this work was to determine if nursing homes that score differently on prevalence of depression, according to the Minimum Data Set (MDS) quality indicator, also provide different processes of care related to depression. Design and Methods. A cross-sectional study with 396 long-term residents in 14 skilled nursing facilities was conducted: 10 homes in the lower (25th percentile: low prevalence 0-2%) quartile and 4 homes in the upper (75th percentile: high prevalence 12-14%) quartile on the MDS depression quality indicator. Ten care processes related to depression were defined and operationalized into clinical indicators. Measurement of nursing home staff implementation of each care process and the assessment of depressive symptoms were conducted by trained research staff during 3 consecutive 12-hr days (7 a.m. to 7 p.m.), which included resident interviews (Geriatric Depression Scale), direct observations, and medical record review using standardized protocols. Results. The prevalence of depressive symptoms according to independent assessments was significantly higher than prevalence based on the MDS quality indicator and comparable between homes reporting low versus high rates of depression (46% and 41%, respectively). Documentation of depressive symptoms was significantly more common in homes reporting a high prevalence rate; however, documentation of symptoms on the MDS did not result in better treatment or management of depression according to any care-process measure. Psychosocial prevention and intervention efforts, such as resident participation in organized social group activities, were not widely used within either group of homes. Implications. The MDS depression quality indicator underestimates the prevalence of depressive symptoms in all homes but, in particular, among those reporting low or nonexistent rates. The indicator may be more reflective of measurement processes related to detection of symptoms than of prevention, intervention, or management of depression outcomes. A depression quality indicator should not be eliminated from MDS reports because of the importance and prevalence of the condition. However, efforts to improve nursing home staff detection of depressive symptoms should be initiated prior to the use of any MDS-based depression indicator for improvement purposes. Homes that report a low prevalence of depression according to the nationally publicized MDS quality indicator should not be regarded as providing better care. C1 Univ Calif Los Angeles, Jewish Home Aging, Borun Ctr Gerontolog Res, Dept Geriatr,Sch Med, Reseda, CA 91335 USA. Vet Adm Greater Los Angeles Healthcare Syst, Sepulveda Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. RP Simmons, SF (reprint author), Univ Calif Los Angeles, Jewish Home Aging, Borun Ctr Gerontolog Res, Dept Geriatr,Sch Med, 7150 Tampa Ave, Reseda, CA 91335 USA. EM ssimmons@ucla.edu FU NIA NIH HHS [AG10415] NR 21 TC 26 Z9 26 U1 4 U2 5 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD AUG PY 2004 VL 44 IS 4 BP 554 EP 564 PG 11 WC Gerontology SC Geriatrics & Gerontology GA 850EZ UT WOS:000223595300012 PM 15331813 ER PT J AU Huang, PY Yano, EM Lee, ML Chang, BL Rubenstein, LV AF Huang, PY Yano, EM Lee, ML Chang, BL Rubenstein, LV TI Variations in nurse practitioner use in Veterans Affairs primary care practices SO HEALTH SERVICES RESEARCH LA English DT Article DE nurse practitioner; primary care staffing; practice characteristics; environmental characteristics ID IMPROVING PRIMARY-CARE; PHYSICIAN ASSISTANTS; MANAGED CARE; SETTINGS; ORGANIZATIONS; SATISFACTION; MIDWIVES; SYSTEM; IMPACT; MODEL AB Background. Increasingly, primary care practices include nurse practitioners (NPs) in their staffing mix to contain costs and expand primary care. To achieve these aims in U.S. Department of Veterans Affairs medical centers (VAMCs), national policy endorsed involvement of NPs as primary care (PC) providers. Objectives. To evaluate the degree to which VAMCs incorporated NPs into PC practices between 1996 and 1999, and to identify the internal and external practice environment features associated with NP use. Study Design. We surveyed 131 PC directors of all VAMCs in 1996 and 1999 to ascertain the staffing and characteristics of the PC practice and parent organization (e.g., academic affiliation, level of physician staffing, use of managed care arrangements), and drew on previously published studies and HRSA State Health Workforce Profiles to characterize each practice's regional health care environment (e.g., geographic region, state NP practice laws, state managed care penetration). Using multivariate linear regression, we evaluate the contribution of these environmental and organizational factors on the number of NPs/10,000 PC patients in 1999, controlling for the rate of NP use in 1996. Principal Findings. From 1996-1999, NP use increased from 75 percent to 90 percent in VA PC practices. The mean number of NPs per practice increased by about 60 percent (2.0 versus 3.2; p<.001), while the rate of NPs/10,000 PC patients trended upward (2.2 versus 2.7; p=.09). Staffing of other primary care clinicians (e.g., physicians and physician assistants per practice) remained stable, while the NP-per-physician rate increased (0.2 versus 0.4; p<.001). After multivariate adjustment, greater reliance on managed-care-oriented provider education programs (p=.02), the presence of NP training programs (p=.05), and more specialty-trained physicians/10,000 PC patients (p=.09) were associated with greater NP involvement in primary care. Conclusions. Staffing models in VA PC practices have, in fact, changed, with NPs having a greater presence. However, we found substantial practice-based variations in their use, suggesting that more research is needed to better understand how they have been integrated into practice and what impact their involvement has had on the VA's ability to achieve its restructuring goals. C1 VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda Ambulatory Care Ctr, Sepulveda, CA 91343 USA. So Calif Permanente Med Grp, Harbor City, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RAND Hlth Program, Santa Monica, CA USA. RP Yano, EM (reprint author), VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda Ambulatory Care Ctr, 16111 Plummer St 152, Sepulveda, CA 91343 USA. NR 60 TC 19 Z9 19 U1 1 U2 4 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD AUG PY 2004 VL 39 IS 4 BP 887 EP 904 DI 10.1111/j.1475-6773.2004.00263.x PN 1 PG 18 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 893HT UT WOS:000226710600011 PM 15230933 ER PT J AU Franceschi, F Satta, MA Mentella, MC Penland, R Candelli, M Grillo, RL Leo, D Fini, L Nista, EC Cazzato, IA Lupascu, A Pola, P Pontecorvi, A Gasbarrini, G Genta, RM Gasbarrini, A AF Franceschi, F Satta, MA Mentella, MC Penland, R Candelli, M Grillo, RL Leo, D Fini, L Nista, EC Cazzato, IA Lupascu, A Pola, P Pontecorvi, A Gasbarrini, G Genta, RM Gasbarrini, A TI Helicobacter pylori infection in patients with Hashimoto's thyroiditis SO HELICOBACTER LA English DT Letter ID DISEASE C1 Catholic Univ Rome, Rome, Italy. VA Med Ctr, Dept Pathol, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Univ Hosp Geneva, Div Clin Pathol, Geneva, Switzerland. RP Franceschi, F (reprint author), Univ Sacred Heart, Policlin Gemelli, Dept Internal Med, Largo A Gemelli 8, I-00168 Rome, Italy. EM francesco.franceschi@rm.unicatt.it NR 6 TC 21 Z9 23 U1 0 U2 2 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD AUG PY 2004 VL 9 IS 4 BP 369 EP 369 DI 10.1111/j.1083-4389.2004.00241.x PG 1 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 838MX UT WOS:000222718600011 PM 15270751 ER PT J AU Toivola, DA Ku, NO Resurreccion, EZ Nelson, DR Wright, TL Omary, MB AF Toivola, DA Ku, NO Resurreccion, EZ Nelson, DR Wright, TL Omary, MB TI Keratin 8 and 18 hyperphosphorylation is a marker of progression of human liver disease SO HEPATOLOGY LA English DT Article ID HUMAN ALCOHOLIC HEPATITIS; INTERMEDIATE-FILAMENTS; EPITHELIAL-CELLS; TRANSGENIC MICE; CULTURED-CELLS; DESMIN PHOSPHORYLATION; NEUROFILAMENT PROTEINS; I KERATINS; APOPTOSIS; MUTATION AB Keratin 8 and 18 (K8/18) phosphorylation plays a significant and site-specific role in regulating keratin filament organization, association with binding proteins, and modulation of cell cycle progression. Keratin hyperphosphorylation correlates with exposure to a variety of stresses in cultured cells and in mouse models of liver, pancreatic, and gallbladder injury, and it is found in association with mouse and human Mallory bodies. We asked whether K8/18 phosphorylation correlates with human liver disease progression by analyzing liver explants and biopsies of patients with chronic noncirrhotic hepatitis C virus (HCV) or cirrhosis. We also examined the effect of HCV therapy with interleukin-10 on keratin phosphorylation. Using site-specific antiphosphokeratin antibodies we found keratin hyperphosphorylation on most K8/18 sites in all cirrhotic liver explants tested and in most liver biopsies from patients with chronic HCV infection. Immunofluorescence staining of precirrhotic HCV livers showed focal keratin hyperphosphorylation and limited reorganization of keratin filament networks. In cirrhotic livers, keratin hyperphosphorylation occurred preferentially in hepatic nodule cells adjacent to bridging fibrosis and associated with increased stress kinase activation and apoptosis. Histological and serological improvement after interleukin-10 therapy was accompanied by normalization of keratin hyperphosphorylation on some sites in 7 of 10 patients. In conclusion, site-specific keratin phosphorylation in liver disease is a progression marker when increased and a likely regression marker when decreased. C1 Palo Alto VA Med Ctr, Dept Med, Palo Alto, CA 94304 USA. Stanford Univ, Sch Med, Ctr Digest Dis, Palo Alto, CA 94304 USA. Univ Florida, Coll Med, Gainesville, FL USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Toivola, DA (reprint author), Palo Alto VA Med Ctr, Dept Med, 3801 Miranda Ave,Mail Code 1541, Palo Alto, CA 94304 USA. EM dtoivola@stanford.edu FU NIDDK NIH HHS [DK52951, DK56339] NR 49 TC 57 Z9 67 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD AUG PY 2004 VL 40 IS 2 BP 459 EP 466 DI 10.1002/hep.20277 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 848AN UT WOS:000223439400022 PM 15368451 ER PT J AU Swarup, A Sachdeva, N Schumacher, HR AF Swarup, A Sachdeva, N Schumacher, HR TI Dosing of antirheumatic drugs in renal disease and dialysis SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Review DE rheumatoid arthritis; gout; renal insufficiency; drug dosing; hemodialysis ID ANTITUMOR NECROSIS FACTOR; URINARY PROSTAGLANDIN EXCRETION; LOW-DOSE METHOTREXATE; RHEUMATOID-ARTHRITIS; CLINICAL PHARMACOKINETICS; MYCOPHENOLATE-MOFETIL; PERITONEAL-DIALYSIS; TRANSPLANT RECIPIENTS; CYCLOOXYGENASE-2 INHIBITION; KETOROLAC TROMETHAMINE AB Many patients with rheumatic diseases have their management complicated by renal problems. Renal failure modifies the metabolism of many drugs, especially by retention. Questions often arise about the effects of renal failure on the handling of drugs commonly used in rheumatology. For which drugs must we be especially concerned about increased toxicity? Patients on chronic dialysis may also need a variety of drugs for rheumatic disease. How are our drugs dialyzed, and which of these can be safety used and how best to use them? Decisions about dosing of rheumatic drugs are often required for the patients with chronic renal insufficiency or on long-term dialysis, although many drugs have not been formally studied in these settings. Patients with renal insufficiency are excluded from most drug trials. Data for some of these drugs have to be extrapolated based on the information available about the pharmacokinetics of the drug. This review addresses dosing of commonly used drugs in rheumatology in patients with chronic renal insufficiency or failure. It is compiled from a MEDLINE search of papers dealing with renal handling of antirheumatic drugs and suggestions for dose adjustments for these drugs. Drugs reviewed include commonly used disease-modifying antirheumatic drugs (DMARDS), drugs used for treatment of gout, commonly used nonsteroidal antnflammatory drugs (NSAIDS) and the newer COX-2 inhibitors. C1 Arizona Arthritis Rheumatol Associates, Paradise Valley, AZ USA. Wall St Internal Med, Louisville, KY USA. Univ Penn, Sch Med, Div Rheumatol, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Swarup, A (reprint author), 10599 N Tatum Blvd S,F 150, Paradise Valley, AZ 85253 USA. EM areena1@hotmail.com NR 131 TC 8 Z9 8 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-1608 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD AUG PY 2004 VL 10 IS 4 BP 190 EP 204 DI 10.1097/01.rhu.0000135555.83088.a2 PG 15 WC Rheumatology SC Rheumatology GA 846DZ UT WOS:000223296600006 PM 17043508 ER PT J AU Ahmed, SH Pennington, WR Clark, LL Hardin, AE McClure, C Webb, CS Finklea, L Spinale, FG Zile, MR AF Ahmed, SH Pennington, WR Clark, LL Hardin, AE McClure, C Webb, CS Finklea, L Spinale, FG Zile, MR TI Hypertensive hypertrophy: Relation between left ventricular (LV) structure/function and matrix metalloproteinases (MMP) tissue inhibitors of metalloproteinases (TIMP) SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 8th Annual Scientific Meeting of the Heart-Failure-Society-of-American CY SEP 12-15, 2004 CL Toronto, CANADA SP Heart Failure Soc Amer C1 Med Univ S Carolina, Div Cardiol, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD AUG PY 2004 VL 10 IS 4 SU S MA 094 BP S44 EP S44 DI 10.1016/j.cardfail.2004.06.091 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 853VV UT WOS:000223857900094 ER PT J AU Ahmed, SH Baicu, CF Webb, CS Hapke, E Van Laer, AO Zile, MR AF Ahmed, SH Baicu, CF Webb, CS Hapke, E Van Laer, AO Zile, MR TI Pressure overload hypertrophy and aging: Effects on myocardial vs cellular viscoelastic properties SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 8th Annual Scientific Meeting of the Heart-Failure-Society-of-American CY SEP 12-15, 2004 CL Toronto, CANADA SP Heart Failure Soc Amer C1 Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA. Med Univ S Carolina, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD AUG PY 2004 VL 10 IS 4 SU S MA 027 BP S25 EP S25 DI 10.1016/j.cardfail.2004.06.024 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 853VV UT WOS:000223857900028 ER PT J AU Bhella, PS Doshi, HM Reuben, A O'Brien, TX AF Bhella, PS Doshi, HM Reuben, A O'Brien, TX TI Diastolic dysfunction in end-stage liver disease post-liver transplant SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 8th Annual Scientific Meeting of the Heart-Failure-Society-of-American CY SEP 12-15, 2004 CL Toronto, CANADA SP Heart Failure Soc Amer C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VAMC, Off Res & Dev, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD AUG PY 2004 VL 10 IS 4 SU S MA 051 BP S32 EP S32 DI 10.1016/j.cardfail.2004.06.050 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 853VV UT WOS:000223857900051 ER PT J AU Huehnergarth, KV Mozaffarian, D Sullivan, MD Wilkinson, C Lawler, RL McDonald, GB Fishbein, DP Levy, WC AF Huehnergarth, KV Mozaffarian, D Sullivan, MD Wilkinson, C Lawler, RL McDonald, GB Fishbein, DP Levy, WC TI Relative lymphocyte count is an independent predictor of death/urgent transplant in heart failure SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 8th Annual Scientific Meeting of the Heart-Failure-Society-of-American CY SEP 12-15, 2004 CL Toronto, CANADA SP Heart Failure Soc Amer C1 Univ Washington, Seattle, WA 98195 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Vet Affairs Puget Sound Hlth Care Syst, Psychiat, Seattle, WA USA. Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. RI Mozaffarian, Dariush/B-2276-2008 NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD AUG PY 2004 VL 10 IS 4 SU S MA 119 BP S50 EP S50 DI 10.1016/j.cardfail.2004.06.116 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 853VV UT WOS:000223857900118 ER PT J AU Teerlink, JR Massie, BM Cleland, JGF Tzivoni, D Rainisio, M Frey, A AF Teerlink, JR Massie, BM Cleland, JGF Tzivoni, D Rainisio, M Frey, A CA RITZ-1 Investigators TI The relationship between hypotension and renal dysfunction during Tezosentan treatment for acute decompensated heart failure: An analysis of the Randomized Interventions with Tezosentan (RITZ-1) trial SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 8th Annual Scientific Meeting of the Heart-Failure-Society-of-American CY SEP 12-15, 2004 CL Toronto, CANADA SP Heart Failure Soc Amer C1 UCSF, San Francisco VAMC, San Francisco, CA USA. Castle Hill Hosp, Kingston Upon Hull, Yorks, England. Shaare Zedek Med Ctr, Jerusalem, Israel. Actel Pharmaceut LTD, Allshwil, Switzerland. RI Teerlink, John/D-2986-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD AUG PY 2004 VL 10 IS 4 SU S MA 260 BP S89 EP S89 DI 10.1016/j.cardfail.2004.06.259 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 853VV UT WOS:000223857900259 ER PT J AU Hull, RL Westermark, GT Westermark, P Kahn, SE AF Hull, RL Westermark, GT Westermark, P Kahn, SE TI Islet amyloid: A critical entity in the pathogenesis of type 2 diabetes SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Review ID GENE-RELATED PEPTIDE; IMPAIRED GLUCOSE-TOLERANCE; INSULIN-DEGRADING ENZYME; BETA-CELL FUNCTION; TRANSGENIC MOUSE MODEL; AMYLIN BINDING-SITES; POLYPEPTIDE FIBRIL FORMATION; HUMAN PANCREATIC-ISLETS; JAPANESE-AMERICAN MEN; PERFUSED RAT PANCREAS AB Islet amyloid deposition is a pathogenic feature of type 2 diabetes, and these deposits contain the unique amyloidogenic peptide islet amyloid polypeptide. Autopsy studies in humans have demonstrated that islet amyloid is associated with loss of beta-cell mass, but a direct role for amyloid in the pathogenesis of type 2 diabetes cannot be inferred from such studies. Animal studies in both spontaneous and transgenic models of islet amyloid formation have shown that amyloid forms in islets before fasting hyperglycemia and therefore does not arise merely as a result of the diabetic state. Furthermore, the extent of amyloid deposition is associated with both loss of beta-cell mass and impairment in insulin secretion and glucose metabolism, suggesting a causative role for islet amyloid in the islet lesion of type 2 diabetes. These animal studies have also shown that beta-cell dysfunction seems to be an important prerequisite for islet amyloid formation, with increased secretory demand from obesity and/or insulin resistance acting to further increase islet amyloid deposition. Recent in vitro studies suggest that the cytotoxic species responsible for islet amyloid-induced beta-cell death are formed during the very early stages of islet amyloid formation, when islet amyloid polypeptide aggregation commences. Interventions to prevent islet amyloid formation are emerging, with peptide and small molecule inhibitors being developed. These agents could thus lead to a preservation of beta-cell mass and amelioration of the islet lesion in type 2 diabetes. C1 Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. Linkoping Univ, Div Cell Biol, Linkoping, Sweden. Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, Uppsala, Sweden. Univ Washington, Seattle, WA 98108 USA. RP Kahn, SE (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM skahn@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002; Hull, Rebecca/0000-0001-9690-4087 FU NIDDK NIH HHS [DK-02654, DK-17047, DK-50703] NR 225 TC 267 Z9 277 U1 1 U2 22 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD AUG PY 2004 VL 89 IS 8 BP 3629 EP 3643 DI 10.1210/jc.2004-0405 PG 15 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 843IQ UT WOS:000223072400001 PM 15292279 ER PT J AU Gaglio, PJ Rodriguez-Torres, M Herring, R Anand, B Box, T Rabinovitz, M Brown, RS AF Gaglio, PJ Rodriguez-Torres, M Herring, R Anand, B Box, T Rabinovitz, M Brown, RS CA Infergen Study Grp TI Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE hepatitis C; Hispanic; African American; consensus interferon ID CHRONIC HEPATITIS-C; PEGINTERFERON ALPHA-2A; INITIAL TREATMENT; VIRAL-HEPATITIS; PLUS RIBAVIRIN; TRIAL AB Background: Despite a rapid evolution in the treatment of Hepatitis C (HCV), response to therapy among different racial and ethnic groups is poorly characterized. Study: Three hundred and thirty HCV infected patients naive to previous therapy received induction therapy followed by every other day dosing with consensus interferon. Greater than 30% of treated patients were not white, allowing comparison of response among different races/ethnicities and genotypes. Results: An overall sustained virologic response (SVR) was achieved in 24% of white, 12% of Hispanic, and 4% of AA patients (P = 0.003 white vs. non-white). 15% of white and 13% of Hispanic Genotype I patients achieved an SVR; 2% of AA patients achieved an SVR (P = 0.001 AA vs. non AA). Surprisingly, an SVR of 50% and 40% was achieved by AA and White Genotype 2 patients, compared with 10% in Hispanic patients (P = 0.001). Conclusion: Significant differences in response rates to induction therapy followed by every other day dosing with consensus Interferon was observed when comparing white to non-white patients, particularly when comparing response rates by genotype. These observations reinforce the requirement that prospective studies that enroll a significant percentage of non-whites are needed to adequately characterize response rates to anti-HCV directed therapy. C1 Ponce Med Sch, Ponce, PR USA. Univ Tennessee, Sch Med, Nashville, TN USA. Baylor Univ, Coll Med, VA Med Ctr, Houston, TX 77030 USA. Mt W Gastroenterol, Salt Lake City, UT USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Gaglio, PJ (reprint author), Columbia Univ Coll Phys & Surg, Ctr Liver Dis & Transplantat, 622 W 168th St PH-14, New York, NY 10032 USA. EM pg2011@columbia.edu NR 13 TC 16 Z9 16 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD AUG PY 2004 VL 38 IS 7 BP 599 EP 604 DI 10.1097/00004836-200408000-00012 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 840RA UT WOS:000222875800012 PM 15232365 ER PT J AU Wu, JD Higgins, LM Steinle, A Cosman, D Haugk, K Plymate, SR AF Wu, JD Higgins, LM Steinle, A Cosman, D Haugk, K Plymate, SR TI Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID DELTA T-CELLS; TUMOR-ASSOCIATED IMMUNITY; HUMAN SEMINAL PLASMA; NKG2D RECEPTOR; RETINOIC-ACID; CUTTING EDGE; NK CELLS; RECOGNITION; LIGANDS; MICA AB The MHC class I chain-related molecules (MICs) have previously been shown to be induced on most epithelial tumor cells. Engagement of MIC by the activating immune receptor NKG2D triggers NK cells and augments antigen-specific CTL anti-tumor immunity. The MIC-NKG2D system was proposed to participate in epithelial tumor immune surveillance. Paradoxically, studies suggest that tumors may evade MIC-NKG2D-mediated immunity by MIC shedding-induced impairment of effector cell function. Here we demonstrate the first evidence to our knowledge of a significant correlation of MIC shedding and deficiency in NK cell function with the grade of disease in prostate cancer. MIC is widely expressed in prostate carcinoma. The presence of surface target MIC, however, is counteracted by shedding. A significant increase in serum levels of soluble MIC (sMIC) and deficiency in NK cell function was shown in patients with advanced cancer. Finally, the deficiency in NK cell function can be overcome by treatment with IL-2 or IL-15 in vitro. Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Tubingen, Dept Immunol, Tubingen, Germany. Amgen Inc, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Tacoma, WA USA. RP Wu, JD (reprint author), Box 359755,325 9th Ave, Seattle, WA 98104 USA. EM wuj@u.washington.edu RI Steinle, Alexander/E-6131-2012 FU NCI NIH HHS [P01 CA085859, P01 CA 85859]; NIDDK NIH HHS [R01 DK 52683, R01 DK052683] NR 48 TC 188 Z9 207 U1 0 U2 7 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD AUG PY 2004 VL 114 IS 4 BP 560 EP 568 DI 10.1172/JCI200422206 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 846AR UT WOS:000223287500016 PM 15314693 ER PT J AU State, RC Frye, MA Altshuler, LL Strober, M DeAntonio, M Hwang, S Mintz, J AF State, RC Frye, MA Altshuler, LL Strober, M DeAntonio, M Hwang, S Mintz, J TI Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT 153rd Annual Meeting of the American-Psychiatric-Association CY MAY 13-18, 2000 CL CHICAGO, ILLINOIS SP Amer Psychiat Assoc ID DEFICIT HYPERACTIVITY DISORDER; BIPOLAR DISORDER; VALPROIC ACID; DOUBLE-BLIND; CHILDREN; CHILDHOOD; ONSET; SYMPTOMS; EXPERIENCE; EFFICACY AB Purpose: Although adolescent onset of bipolar disorder is common, the optimal treatment approach for mania in this age group remains understudied. Comorbid attention-deficit/hyperactivity disorder (ADHD) has been reported to predict lithium resistance in adolescents with bipolar disorder. Little is known about response to divalproex sodium in adolescents with bipolar disorder comorbid with ADHD. This study was conducted to evaluate comparative response rates to lithium and divalproex sodium in adolescent mania with and without this comorbidity. Method: Medical records were reviewed for 42 patients (ages 12-19 years) who were hospitalized for acute mania and discharged with a diagnosis of DSM-III-R or DSM-IV bipolar disorder on either lithium (N = 29) or divalproex sodium (N = 13) treatment. A clinician blinded to treatment status rated improvement on the basis of abstracted notes in each case utilizing the Clinical Global Impressions Scale modified for use in bipolar illness (CGI-BP). Response was defined as a discharge CGI-BP overall change score of I or 2 (much or very much improved). Data were collected from January 1992 through May 1999. Results: 36/42 (85.7%) patients presented with mixed mania, and 14/41 (34.1%)patients had a history of ADHD. The overall response rate was 80.9% (34/42). 92.6% (25/27) of patients without ADHD were responders versus 57.1% (8/14) of subjects with comorbid ADHD (p =.007). There were no significant differences in response rates for lithium versus divalproex sodium in subjects with and without ADHD. Conclusion: These retrospective data suggest overall equivalent response rates for lithium and divalproex sodium in predominantly mixed adolescent mania. However, a history of ADHD was associated with a significantly diminished acute response to both divalproex sodium and lithium as a primary treatment for the manic phase of bipolar disorder. C1 Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, Biostat Unit, Los Angeles, CA 90073 USA. Harbor UCLA Med Ctr, Dept Psychiat, Torrance, CA 90509 USA. Neuropsychiat Inst & Hosp, Dept Psychiat & Behav Sci, Los Angeles, CA USA. RP Altshuler, LL (reprint author), Univ Calif Los Angeles, Sch Med, 300 Med Plaza,1544,Box 957057, Los Angeles, CA 90095 USA. EM laltshuler@mednet.ucla.edu NR 34 TC 38 Z9 40 U1 3 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD AUG PY 2004 VL 65 IS 8 BP 1057 EP 1063 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 851FU UT WOS:000223671800005 PM 15323589 ER PT J AU Schneider, A Togel, S Barmada, MM Whitcomb, DC AF Schneider, A Togel, S Barmada, MM Whitcomb, DC TI Genetic analysis of the glutathione s-transferase genes MGST1, GSTM3, GSTT1, and GSTM1 in patients with hereditary pancreatitis SO JOURNAL OF GASTROENTEROLOGY LA English DT Article DE hereditary pancreatitis; chronic pancreatitis; oxidative stress ID IDIOPATHIC CHRONIC-PANCREATITIS; SERINE-PROTEASE INHIBITOR; SUPERGENE FAMILY; KAZAL TYPE-1; MUTATIONS; POLYMORPHISMS; RESISTANCE; DISEASE; CANCER; PSTI AB Background. Specific mutations in the cationic trypsinogen gene (PRSS1) are disease-causing in patients with hereditary pancreatitis, but the genetic background still remains mysterious in about 40% of patients with the disease. It has been suggested that oxidative stress contributes to pancreatic damage. The glutathione s-transferases (GSTs) represent major detoxification enzymes that protect cells from oxidative stress. Methods. In the present study we tested whether mutations in the MGST1 and GSTM3 genes or common deletions in the GSTT1 and GSTM1 genes are associated with hereditary pancreatitis. We analyzed the entire coding region of MGST1 and GSTM3 in 30 patients that were tested negative for PRSS1 mutations, and we studied 55 controls. For GSTT1 and GSTM1, we investigated 75 hereditary pancreatitis patients who had been tested negative for PRSS1 mutations, 135 hereditary pancreatitis patients with a PRSS1 mutation, and 183 controls. Patients were further subclassified with regard to age of onset of disease as a marker of severity. Results. No mutation was found in the MGST1 gene. In the GSTM3 gene, we detected a homozygous 670G > A polymorphism (V224I) with similar frequencies in patients and controls. We found no difference in the frequencies of the GSTT1 and GSTM1 null genotypes between patients and controls, and we detected no differences in age of onset in patients with or without GSTT1 and GSTM1 deletions. Conclusions. We conclude that genetic alterations in the MGST1, GSTM3, GSTT1, and GSTM1 genes do not play a dominant role in hereditary pancreatitis. C1 Univ Pittsburgh, Dept Med, Div Gastroenterol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA USA. Univ Pittsburgh, VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. Univ Pittsburgh, Ctr Genom Sci, Pittsburgh, PA USA. RP Whitcomb, DC (reprint author), Univ Pittsburgh, Dept Med, Div Gastroenterol, 571 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15213 USA. OI Barmada, M Michael/0000-0002-3604-6460 FU NIDDK NIH HHS [DK54709] NR 23 TC 11 Z9 12 U1 0 U2 0 PU SPRINGER TOKYO PI TOKYO PA 3-3-13, HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN SN 0944-1174 J9 J GASTROENTEROL JI J. Gastroenterol. PD AUG PY 2004 VL 39 IS 8 BP 783 EP 787 DI 10.1007/s00535-004-1389-7 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 849RV UT WOS:000223559300011 PM 15338373 ER PT J AU Shrank, WH Reed, VA Jernstedt, GC AF Shrank, WH Reed, VA Jernstedt, GC TI Fostering professionalism in medical education - A call for improved assessment and meaningful incentives SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE professionalism; incentives; medical education; evaluation ID STRUCTURED CLINICAL EXAMINATION; STANDARDIZED PATIENTS; HIDDEN CURRICULUM; STUDENTS; SKILLS; FEEDBACK; GENERALIZABILITY; PERSPECTIVES; RELIABILITY; ENVIRONMENT AB Increasing attention has been focused on developing professionalism in medical school graduates. Unfortunately, the culture of academic medical centers and the behaviors that faculty model are often incongruent with our image of professionalism. The need for improved role modeling, better assessment of student behavior, and focused faculty development is reviewed. We propose that the incentive structure be adjusted to reward professional behavior in both students and faculty. The third-year medicine clerkship provides an ideal opportunity for clinician-educators to play a leading role in evaluating, rewarding, and ultimately fostering professionalism in medical school graduates. C1 VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA. Ctr Educ Outcomes Dartmouth, Hanover, NH USA. RP Shrank, WH (reprint author), VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med, 111G,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM shrankw@aol.com NR 67 TC 37 Z9 38 U1 10 U2 16 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD AUG PY 2004 VL 19 IS 8 BP 887 EP 892 DI 10.1111/j.1525-1497.2004.30635.x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 834OW UT WOS:000222421400012 PM 15242476 ER PT J AU Haug, T Sigg, D Ciani, S Toro, L Stefani, E Olcese, R AF Haug, T Sigg, D Ciani, S Toro, L Stefani, E Olcese, R TI Regulation of K+ flow by a ring of negative charges in the outer pore of BKCa channels. Part I: Aspartate 292 modulates K+ conduction by external surface charge effect SO JOURNAL OF GENERAL PHYSIOLOGY LA English DT Article DE MaxiK channel; conduction; permeation; surface charge; Markov model ID ACTIVATED POTASSIUM CHANNELS; ION CONDUCTION; SIGNATURE SEQUENCE; PERMEABILITY; SELECTIVITY; PERMEATION; MUTATIONS; SURVIVAL; KINETICS; RECEPTOR AB The pore region of the majority of K+ channels contains the highly conserved GYGD sequence, known as the K+ channel signature sequence, where the GYG is critical for K+ selectivity (Heginbotham, L., T. Abramson, and R. MacKinnon. 1992. Science. 258:1152-1155). Exchanging the aspartate residue with asparagine in this sequence abolishes ionic conductance of the Shaker K+ channel (D447N) (Hurst, R.S., L. Toro, and E. Stefani. 1996. FEBS Lett. 388:59-65). In contrast, we found that the corresponding mutation (D292N) in the pore forming a Subunit (hSlo) of the voltage- and Ca2+-activated K+ channel (BKCa, MaxiK) did not prevent conduction but reduced single channel conductance. We have investigated the role of outer pore negative charges in ion conduction (this paper) and channel gating (Haug, T, R. Olcese, T Ligia, and E. Stefani. 2004. J. Gen Physiol. 124: 185-197). In symmetrical 120 mM [K+], the D292N mutation reduced the outward single channel conductance by similar to40% and nearly abolished inward K+ flow (outward rectification). This rectification was partially relieved by increasing the external K+ concentration to 700 mM. Small inward currents were resolved by introducing an additional initiation (R207Q) that greatly increases the open probability of the channel. A four-state multi-ion pore model that incorporates the effects of surface charge was used to simulate the essential properties of channel conduction. The conduction properties of the mutant channel (D292N) could be predicted by a simple similar to8.5-fold reduction of the surface charge density without altering any other parameter. These results indicate that the, pore plays a key role in conduction and suggest that the pore structure is not affected aspartate residue in the BKCa by the mutation. We speculate that the negative charge strongly accumulates K+ in the outer vestibule close to the selectivity filter, thus increasing the rate of ion entry into the pore. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol, Div Mol Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Dept Nucl Med, Los Angeles, CA 90073 USA. RP Olcese, R (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol, Div Mol Med, BH-570 CHS,Box 95711, Los Angeles, CA 90095 USA. EM rolcese@ucla.edu FU NHLBI NIH HHS [HL54970, R01 HL054970]; NIGMS NIH HHS [GM52203]; NINDS NIH HHS [NS43240, R01 NS043240] NR 42 TC 33 Z9 33 U1 0 U2 2 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA SN 0022-1295 J9 J GEN PHYSIOL JI J. Gen. Physiol. PD AUG PY 2004 VL 124 IS 2 BP 173 EP 184 DI 10.1085/jgp.200308949 PG 12 WC Physiology SC Physiology GA 844HT UT WOS:000223149600008 PM 15277578 ER PT J AU Berg, JT Ramanathan, S Gabrielli, MG Swenson, ER AF Berg, JT Ramanathan, S Gabrielli, MG Swenson, ER TI Carbonic anhydrase in mammalian vascular smooth muscle SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY LA English DT Article DE carbonic anhydrase; smooth muscle; vasculature; acetazolamide; dorzolamide; immunocytochemistry; bovine ID HYPOXIC PULMONARY VASOCONSTRICTION; SKELETAL-MUSCLE; IMMUNOHISTOCHEMICAL LOCALIZATION; ACETAZOLAMIDE; INHIBITION; RABBIT; SULFONAMIDES; ISOENZYMES; CELLS; CA2+ AB Carbonic anhydrase (CA) is ubiquitously expressed and plays a pivotal role in acid-base balance, ion transport, and gas exchange. Limited observations by others, derived from functional, pharmacological, and histochemical studies, suggest that CA is present in vascular smooth muscle and is involved in vasoregulation. The present study, using measurements of bioactivity, inhibition characteristics, and immunohistochemical analysis, was undertaken to more fully evaluate CA in vascular smooth muscle. In isolated bovine aortic smooth muscle, which is devoid of erythrocytes, CA is present in low concentrations with a CO2 hydration activity (at 0C) of 3.5 +/- 2.7 U/g. The I-50 for acetazolamide inhibition is 0.07 +/- 0.01 muM. Results with dorzolamide and bromopyruvate, selective inhibitors of the CA II and I isozymes, respectively, show that roughly 75% of the CA activity is accounted for by CA I, with 20% due to CA II. These results accord qualitatively with immunocytochemical staining with specific CA I and II antibodies, showing that both isozymes are present and that their staining co-localizes with cells positive for smooth muscle alpha-actin. These data establish the activity, inhibition, and isozyme pattern of carbonic anhydrase expression in mammalian vascular smooth muscle. C1 Univ Washington, VA Puget Sound Hlth Care Syst, Pulm Sect, Dept Med, Seattle, WA 98108 USA. Univ Hawaii, John A Burns Sch Med, Dept Pharmacol, Honolulu, HI 96822 USA. Univ Camerino, Dept Comparat Morphol & Biochem, I-62032 Camerino, Italy. RP Swenson, ER (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Pulm Sect, Dept Med, S-111 Pulm,1660 S Columbian Way, Seattle, WA 98108 USA. EM eswenson@u.washington.edu FU NHLBI NIH HHS [HL-24163] NR 36 TC 17 Z9 17 U1 0 U2 0 PU HISTOCHEMICAL SOC INC PI SEATTLE PA UNIV WASHINGTON, DEPT BIOSTRUCTURE, BOX 357420, SEATTLE, WA 98195 USA SN 0022-1554 J9 J HISTOCHEM CYTOCHEM JI J. Histochem. Cytochem. PD AUG PY 2004 VL 52 IS 8 BP 1101 EP 1106 DI 10.1369/jhc.4a6266.2004 PG 6 WC Cell Biology SC Cell Biology GA 841JZ UT WOS:000222927400013 PM 15258186 ER PT J AU Shams, H Klucar, P Ewer, SE Lalvani, A Moonan, PK Safi, H Wizel, B Ewer, K Nepom, GT Lewinsohn, DM Andersen, P Barnes, PF AF Shams, H Klucar, P Ewer, SE Lalvani, A Moonan, PK Safi, H Wizel, B Ewer, K Nepom, GT Lewinsohn, DM Andersen, P Barnes, PF TI Characterization of a Mycobacterium tuberculosis peptide that is recognized by human CD4(+) and CD8(+) T cells in the context of multiple HLA alleles SO JOURNAL OF IMMUNOLOGY LA English DT Article ID GAMMA-INTERFERON PRODUCTION; SYNTHETIC PEPTIDES; ESAT-6 ANTIGEN; BEIJING GENOTYPE; RAPID DETECTION; INFECTED-CELLS; EPITOPES; RESPONSES; ENUMERATION; PROTEIN AB The secreted Mycobacterium tuberculosis 10-kDa culture filtrate protein (CFP)10 is a potent T cell Ag that is recognized by a high percentage of persons infected with M. tuberculosis. We determined the molecular basis for this widespread recognition by identifying and characterizing a 15-mer peptide, CFP10(71-85), that elicited IFN-gamma production and CTL activity by both CD4(+) and CD8(+) T cells from persons expressing multiple MHC class 11 and class I molecules, respectively. CFP1071-85 contained at least two epitopes, one of 10 aa (peptide T1) and another of 9 aa (peptide T6). T1 was recognized by CD4(+) cells in the context of DRB1*04, DR5*0101, and DQB1*03, and by CD8(+) cells of A2(+) donors. T6 elicited responses by CD4(+) cells in the context of DRB1*04 and DQB1*03, and by CD8(+) cells of B35(+) donors. Deleting a single amino acid from the amino or carboxy terminus of either peptide markedly reduced IFN-gamma production, suggesting that they are minimal epitopes for both CD4(+) and CD8(+) cells. As far as we are aware, these are the shortest microbial peptides that have been found to elicit responses by both T cell subpopulations. The capacity of CFP10(71-85) to Stimulate IFN-gamma production and CTL activity by CD4(+) and CD8(+) cells from persons expressing a spectrum of MHC molecules suggests that this peptide is an excellent candidate for inclusion in a subunit antituberculosis vaccine. C1 Univ Texas Hlth Ctr, Ctr Pulm & Infect Dis Control, Tyler, TX 75708 USA. Univ Texas Hlth Ctr, Dept Microbiol, Tyler, TX 75708 USA. Univ Texas Hlth Ctr, Dept Immunol, Tyler, TX 75708 USA. Univ Texas Hlth Ctr, Dept Med, Tyler, TX 75708 USA. Univ N Texas, Hlth Sci Ctr, Dept Internal Med, Ft Worth, TX 76107 USA. Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England. Benaroya Res Inst, Seattle, WA 98101 USA. Oregon Hlth Sci Univ, Div Pulm & Crit Care Med, Portland Vet Affairs Med Ctr, Portland, OR 97207 USA. Statens Scruminst, Copenhagen, Denmark. RP Shams, H (reprint author), Univ Texas Hlth Ctr, Ctr Pulm & Infect Dis Control, 11937 US Highway 271, Tyler, TX 75708 USA. EM amir.shams@uthct.edu RI Moonan, Patrick/F-4307-2014; Ewer, Katie/B-4328-2011; Lewinsohn, David/I-4936-2013 OI Ewer, Katie/0000-0001-9827-9836; Moonan, Patrick/0000-0002-3550-2065; Lewinsohn, David/0000-0001-9906-9494 FU NIAID NIH HHS [AI44935] NR 49 TC 62 Z9 63 U1 0 U2 5 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD AUG 1 PY 2004 VL 173 IS 3 BP 1966 EP 1977 PG 12 WC Immunology SC Immunology GA 839TF UT WOS:000222807100058 PM 15265931 ER PT J AU Trial, J Rubio, JA Birdsall, HH Rodriguez-Barradas, M Rossen, RD AF Trial, J Rubio, JA Birdsall, HH Rodriguez-Barradas, M Rossen, RD TI Monocyte activation by circulating fibronectin fragments in HIV-1-infected patients SO JOURNAL OF IMMUNOLOGY LA English DT Article ID IMMUNODEFICIENCY-VIRUS-INFECTION; CELL-BINDING DOMAIN; PERIPHERAL-BLOOD MONOCYTES; GELATIN-BOUND FIBRONECTIN; PLASMA FIBRONECTIN; TRANSENDOTHELIAL MIGRATION; ANTIRETROVIRAL THERAPY; STAPHYLOCOCCUS-AUREUS; SIGNAL-TRANSDUCTION; LEUKOCYTE ELASTASE AB To identify signals that can alter leukocyte function in patients receiving highly active antiretroviral therapy (HAART), we analyzed single blood samples from 74 HIV-1-infected patients and additional blood was collected at 90-day intervals from 51 HIV-1-infected patients over a 516 +/- 172 (mean +/- Sb) day interval. Despite the absence of circulating immune complexes and normalization of phagocytic function, compared with controls, the fraction of patients' monocytes expressing CD49e and CD62L was decreased and expression of CD11b and CD86 increased. Plasma from 63% of patients but none from normal controls contained 110-120 kDa fibronectin fragments (FNf). Presence of FNf did not reflect poor adherence to therapy. Addition of FNf to normal donor blood in vitro replicated changes in monocyte CD49e, CD62L, CD11b, and CD86 seen in vivo. FNf also induced monocytes to release a serine proteinase, nominally identified as proteinase-3, that hydrolyzed cell surface CD49e. alpha(1)-Antitrypsin blocked FNf-induced shedding of CD49e in a dose-dependent manner. Plasma with a normal frequency of CD49e(+) monocytes contained antiproteases that partially blocked FNf-induced monocyte CD49e shedding, whereas plasma from patients with a low frequency of CD49e(+) monocytes did not block this effect of FNf. Electrophoretic analyses of plasma from the latter group of patients suggested that a significant fraction of their alpha(1)-antitrypsin was tied up in high molecular mass complexes. These results suggest that monocyte behavior in HIV-1-infected patients may be influenced by FNf and the ratio of protease and antiproteases in the cells' microenvironment. C1 Michael E DeBakey Vet Affairs Med Ctr, Res Ctr AIDS & HIV Infect, Immunol Res Lab, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Otorhinolaryngol, Houston, TX 77030 USA. Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA. RP Rossen, RD (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Res Ctr AIDS & HIV Infect, Immunol Res Lab, Bldg 109,Room 288,2002 Holcombe Blvd, Houston, TX 77030 USA. EM rrossen@bcm.tmc.edu FU NIAID NIH HHS [R01 AI046285]; NIMH NIH HHS [MH63035] NR 52 TC 14 Z9 14 U1 0 U2 4 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD AUG 1 PY 2004 VL 173 IS 3 BP 2190 EP 2198 PG 9 WC Immunology SC Immunology GA 839TF UT WOS:000222807100084 PM 15265957 ER PT J AU Tyler, KL AF Tyler, KL TI Oral transmission of kuru, Creutzfeldt- Jakob disease, and scrapie to nonhuman primates. Commentary SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material ID FOLLICULAR DENDRITIC CELLS; BOVINE SPONGIFORM ENCEPHALOPATHY; ENTERIC NERVOUS-SYSTEM; HUMAN PRION DISEASES; PROTEIN EXPRESSION; LAMININ RECEPTOR; B-CELLS; INFECTION; NEUROINVASION; HAMSTERS C1 Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Neurol Serv, Denver, CO USA. RP Tyler, KL (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, 4200 E 9th Ave, Denver, CO 80262 USA. EM ken.tyler@uchsc.edu NR 42 TC 2 Z9 2 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD AUG 1 PY 2004 VL 190 IS 3 BP 653 EP 656 DI 10.1086/422260 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 836IQ UT WOS:000222549500035 PM 15243947 ER PT J AU Shen, X Li, QL Brent, GA Friedman, TC AF Shen, X Li, QL Brent, GA Friedman, TC TI Thyroid hormone regulation of prohormone convertase 1 (PC1): regional expression in rat brain and in vitro characterization of negative thyroid hormone response elements SO JOURNAL OF MOLECULAR ENDOCRINOLOGY LA English DT Article ID GENE-EXPRESSION; ANTERIOR-PITUITARY; MESSENGER-RNA; PROPROTEIN CONVERTASES; HALF-SITES; MICE; RECEPTOR; PROOPIOMELANOCORTIN; DISRUPTION; MECHANISM AB Most pro-neuropeptides are processed by the prohormone convertases, PC1 and PC2. We previously reported that changes in thyroid status altered anterior pituitary PC1 mRNA and this regulation was due to triiodothyronine (T-3)-dependent interaction of thyroid hormone receptor (TR) with negative thyroid hormone response elements (nTREs) contained in a large region of the human PC1 promoter. In this study, we demonstrated that hypothyroidism stimulated, while hyperthyroidism suppressed, PC1 mRNA levels in rat hypothalamus and cerebral cortex, but not in hippocampus. In situ hybridization was used to confirm real-time PCR changes and localize the regulation within the hypothalamus and cortex. Using a human PC1 (hPC1) promoter construct (with and without deletions in two regions that each contain a negative TRE) transiently transfected into GH3 cells, we found that T-3 negatively regulated hPC1 promoter activity, and this regulation required both of these two regions. Electrophoretic mobility shift assays (EMSAs) using purified thyroid hormone receptor alpha1 (TRalpha1) and retinoid X receptor beta (RXRbeta) proteins demonstrated that RXR and TRalpha both bound the PC1 promoter. Addition of TRalpha1/RXRbeta to the wild-type PC1 probe demonstrated binding as both homodimers and a heterodimer. EMSAs with oligonucleotides containing deletion mutations of the putative nTREs demonstrated that the proximal nTRE binds more strongly to TR and RXR than the distal nTRE, but that both regions exhibit specific binding. We conclude that there are multiple novel TRE-like sequences in the hPC1 promoter and that these regions act in a unique manner to facilitate the negative effect of thyroid hormone on PC1. C1 Univ Calif Los Angeles, Div Endocrinol, Charles R Drew Univ Med & Sci, Sch Med, Los Angeles, CA 90059 USA. W Los Angeles Vet Affairs Med Ctr, Dept Med, Div Endocrinol, Los Angeles, CA 90073 USA. Cedars Sinai Med Ctr, Dept Med, Div Endocrinol, Los Angeles, CA 90048 USA. RP Univ Calif Los Angeles, Div Endocrinol, Charles R Drew Univ Med & Sci, Sch Med, 1731 E 120th St, Los Angeles, CA 90059 USA. EM tefriedm@cdrewu.edu FU NCI NIH HHS [CA8936401]; NCRR NIH HHS [U54 RR14616-01, G21 RR03026-13] NR 44 TC 21 Z9 21 U1 0 U2 3 PU BIOSCIENTIFICA LTD PI BRISTOL PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND SN 0952-5041 J9 J MOL ENDOCRINOL JI J. Mol. Endocrinol. PD AUG PY 2004 VL 33 IS 1 BP 21 EP 33 DI 10.1677/jme.0.0330021 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 849PN UT WOS:000223552100003 PM 15291740 ER PT J AU Paintlia, MK Paintlia, AS Barbosa, E Singh, I Singh, AK AF Paintlia, MK Paintlia, AS Barbosa, E Singh, I Singh, AK TI NAC prevents endotoxin induced loss of OPC in fetus and hypomyelination in postnatal rat brain SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 35th Annual Meeting of the Transactions-of-the-American-Society-for-Neurochemistry CY AUG 14-18, 2004 CL New York, NY SP Transact Amer Soc Neurochem C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2004 VL 90 SU 1 BP 5 EP 5 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 852NB UT WOS:000223760900016 ER PT J AU Khan, M Jatana, M Giri, S Gilg, AG Singh, I Singh, AK AF Khan, M Jatana, M Giri, S Gilg, AG Singh, I Singh, AK TI Administration of N-acetylcysteine after focal cerebral ischemia protects brain in a rat model of experimental stroke SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 35th Annual Meeting of the Transactions-of-the-American-Society-for-Neurochemistry CY AUG 14-18, 2004 CL New York, NY SP Transact Amer Soc Neurochem C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2004 VL 90 SU 1 BP 14 EP 14 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 852NB UT WOS:000223760900047 ER PT J AU Lee, JK Won, JS Singh, AK Singh, I AF Lee, JK Won, JS Singh, AK Singh, I TI Adenosine kinase inhibitor attenuates the expression of iNOS in glial cells SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 35th Annual Meeting of the Transactions-of-the-American-Society-for-Neurochemistry CY AUG 14-18, 2004 CL New York, NY SP Transact Amer Soc Neurochem C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Lab Med, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2004 VL 90 SU 1 BP 20 EP 20 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 852NB UT WOS:000223760900073 ER PT J AU Won, JS Im, YB Singh, AK Singh, I AF Won, JS Im, YB Singh, AK Singh, I TI Dual role of cAMP in iNOS expression in glial cells and macrophages: differential regulation of P38 activation and iNOS stability SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 35th Annual Meeting of the Transactions-of-the-American-Society-for-Neurochemistry CY AUG 14-18, 2004 CL New York, NY SP Transact Amer Soc Neurochem C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2004 VL 90 SU 1 BP 20 EP 20 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 852NB UT WOS:000223760900072 ER PT J AU Yao, JK Carroll, JJ Runyan, C Wengenack, TM Poduslo, JF AF Yao, JK Carroll, JJ Runyan, C Wengenack, TM Poduslo, JF TI Reduced membrane lipids in the cortex of AD transgenic model SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 35th Annual Meeting of the Transactions-of-the-American-Society-for-Neurochemistry CY AUG 14-18, 2004 CL New York, NY SP Transact Amer Soc Neurochem C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. Mayo Clin, Coll Med, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2004 VL 90 SU 1 BP 42 EP 42 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 852NB UT WOS:000223760900146 ER PT J AU Nath, N Giri, S Singh, AK Singh, I AF Nath, N Giri, S Singh, AK Singh, I TI Lovastatin induces bone marrow-derived dendritic cell maturation and production of pro-inflammatory cytokines SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 35th Annual Meeting of the Transactions-of-the-American-Society-for-Neurochemistry CY AUG 14-18, 2004 CL New York, NY SP Transact Amer Soc Neurochem C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2004 VL 90 SU 1 BP 46 EP 46 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 852NB UT WOS:000223760900159 ER PT J AU Singh, I Stanislaus, RC Gilg, AG Singh, AK AF Singh, I Stanislaus, RC Gilg, AG Singh, AK TI N-acetyl-L-cysteine protects against the inflammatory disease process in experimental autoimmune encephalomyelitis SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 35th Annual Meeting of the Transactions-of-the-American-Society-for-Neurochemistry CY AUG 14-18, 2004 CL New York, NY SP Transact Amer Soc Neurochem C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2004 VL 90 SU 1 BP 48 EP 48 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 852NB UT WOS:000223760900168 ER PT J AU Paintlia, AS Paintlia, MK Singh, AK Gilg, AG Barbosa, E Singh, I AF Paintlia, AS Paintlia, MK Singh, AK Gilg, AG Barbosa, E Singh, I TI Regulation of immune response genes associated with acute experimental autoimmune encephalomyelitis by lovastatin SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 35th Annual Meeting of the Transactions-of-the-American-Society-for-Neurochemistry CY AUG 14-18, 2004 CL New York, NY SP Transact Amer Soc Neurochem C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2004 VL 90 SU 1 BP 59 EP 59 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 852NB UT WOS:000223760900210 ER PT J AU Giri, S Rattan, R Singh, AK Singh, I AF Giri, S Rattan, R Singh, AK Singh, I TI 15d PGJ2 inhibits inflammatory response in primary astrocytes via down regulating multiple steps in PI3K-Akt-NF-kappa B-P300 pathway SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 35th Annual Meeting of the Transactions-of-the-American-Society-for-Neurochemistry CY AUG 14-18, 2004 CL New York, NY SP Transact Amer Soc Neurochem C1 MUSC, Dept Pathol & Lab Med, Charleston, SC USA. MUSC, Dept Pediat, Charleston, SC USA. Ralph Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2004 VL 90 SU 1 BP 61 EP 61 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 852NB UT WOS:000223760900216 ER PT J AU Pannu, R Barbosa, E Singh, AK Singh, I AF Pannu, R Barbosa, E Singh, AK Singh, I TI Attenuation of acute inflammatory response by atorvastatin following spinal cord injury in rats SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 35th Annual Meeting of the Transactions-of-the-American-Society-for-Neurochemistry CY AUG 14-18, 2004 CL New York, NY SP Transact Amer Soc Neurochem C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2004 VL 90 SU 1 BP 69 EP 69 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 852NB UT WOS:000223760900244 ER PT J AU Haq, E Khan, A Giri, S Singh, I Singh, AK AF Haq, E Khan, A Giri, S Singh, I Singh, AK TI Peroxisomal participation in psychosine-mediated lipotoxicity: implications for Krabbe disease SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 35th Annual Meeting of the Transactions-of-the-American-Society-for-Neurochemistry CY AUG 14-18, 2004 CL New York, NY SP Transact Amer Soc Neurochem C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. OI Haq, Ehtishamul/0000-0002-4195-0606 NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2004 VL 90 SU 1 BP 72 EP 72 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 852NB UT WOS:000223760900254 ER PT J AU Hunt, SC Richardson, RD Engel, CC Atkins, DC McFall, M AF Hunt, SC Richardson, RD Engel, CC Atkins, DC McFall, M TI Gulf war veterans' illnesses: A pilot study of the relationship of illness beliefs to symptom severity and functional health status SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; CHRONIC FATIGUE SYNDROME; SELF-REPORTED SYMPTOMS; CAUSAL ATTRIBUTIONS; PHYSICAL SYMPTOMS; PRIMARY-CARE; UNEXPLAINED ILLNESS; PREVALENCE; THERAPY; SELECTION AB This investigation describes the illness beliefs of veterans regarding their Gulf War-related health concerns and investigates the relationship of these illness beliefs to physical and mental health functioning. Gulf War veterans (N = 583) presenting for evaluation at a Veteran's Affairs and Department of Defense facility completed se self-report measures of symptom-related beliefs, psychosocial distress, and functional status. Hierarchical multiple regression analyses were performed to determine the extent that symptom-related beliefs impacted symptom-reporting and functional status independent of demographic factors and psychiatric illness. Several beliefs predicted physical symptom reporting and functional impairment in physical health and mental health domains after controlling for demographic variables and psychiatric illness. Gulf War veterans' illness beliefs may impact clinical outcomes. Discussing illness beliefs and providing accurate information is an important component Of medical care for Gulf War veterans. C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Dept Occupat & Environm Med, Seattle, WA 98195 USA. NW Network Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA. Walter Reed Army Med Ctr, Deployment Hlth Clin Ctr, Washington, DC 20307 USA. Univ Washington, Dept Psychol, Seattle, WA 98195 USA. RP Hunt, SC (reprint author), VA Puget Sound Hlth Care Syst, 111PC,1660 S Columbian Way, Seattle, WA 98108 USA. EM stephen.hunt@med.va.gov OI Atkins, David/0000-0002-5781-9880 NR 66 TC 4 Z9 4 U1 3 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD AUG PY 2004 VL 46 IS 8 BP 818 EP 827 DI 10.1097/01.jom.0000135529.88069.04 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 845WU UT WOS:000223276800010 PM 15300134 ER PT J AU Lento, J Glynn, S Shetty, V Asarnow, J Wang, JM Belin, T AF Lento, J Glynn, S Shetty, V Asarnow, J Wang, JM Belin, T TI Psychologic functioning and needs of indigent patients with facial injury: A prospective controlled study SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID OROFACIAL INJURY; TRAUMA PATIENTS; PSYCHOPATHOLOGY; DEPRESSION; DISORDER; SEQUELAE; ANXIETY; URBAN; LIFE; CAGE AB Purpose: This study sought to examine 1) temporal changes in psychologic functioning over 12 months and 2) baseline differences in mental health and social service needs between orofacial injury patients and sociodemographically comparable controls undergoing elective oral surgery. Materials and Methods: Prospective, case-control study of patients treated at a public hospital in Los Angeles, CA. A total of 336 subjects with mandible fractures and 119 subjects undergoing elective removal of their third molars participated in structured, repeated follow-up assessments (10 days, 6 months, and 12 months after their surgical procedures). Multiple imputation was used to manage incomplete data, and propensity score analysis was used to correct for covariate imbalances between the injury and the control cohort. A series of ANOVAs, chi(2) analyses, and odds ratios was conducted. Results: The injury patients continue to experience significant psychologic distress for tip to 12 months following the traumatic event. Orofacial injury patients also tend to report more lifetime and current mental health and social service needs than the sociodemographically similar elective-surgery cohort. Conclusion: The management of facial injuries in disadvantaged individuals should integrate case management that addresses psychosocial sequelae and service needs of patients. (C) 2004 American Association of Oral and Maxillofacial Surgeons. C1 Univ San Diego, Dept Psychol, San Diego, CA 92110 USA. VA Greater LA Hlth Care Syst, Los Angeles, CA USA. UCSD, SDSU, Joint Doctoral Program Clin Psychol, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Dent, Sect Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90024 USA. RP Lento, J (reprint author), Univ San Diego, Dept Psychol, 5998 Alcala Pk, San Diego, CA 92110 USA. EM jlento@sandiego.edu FU NIDCR NIH HHS [P05 DE-10598] NR 31 TC 22 Z9 22 U1 2 U2 3 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0278-2391 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD AUG PY 2004 VL 62 IS 8 BP 925 EP 932 DI 10.1016/j.joms.2004.02.009 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 842RS UT WOS:000223022300004 PM 15278855 ER PT J AU Lin, AL Johnson, DA Stephan, KT Yeh, CK AF Lin, AL Johnson, DA Stephan, KT Yeh, CK TI Salivary secretory leukocyte protease inhibitor increases in HIV infection SO JOURNAL OF ORAL PATHOLOGY & MEDICINE LA English DT Article DE HAART; HIV; saliva; SLP1 ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; PROTEINASE-INHIBITOR; ANTILEUKOPROTEASE; TRANSMISSION; LOCALIZATION; DEFENSE; TYPE-1; AIDS; LEUKOPROTEASE AB BACKGROUND: Secretory leukocyte protease inhibitor (SLPI) is an antimicrobial protein found in saliva and having anti-HIV activity. The concentrations of SLPI in parotid and submandibular/sublingual (SMSL) saliva were determined in an HIV(+) population and compared with uninfected controls. The effect of highly active antiretroviral therapy (HAART) on the concentrations in saliva was determined. METHODS: Stimulated parotid and SMSL saliva was collected from 65 HIV(+) patients and 19 healthy controls. Flow rates, total protein and SLPI concentrations were determined as well as the effect of HAART on these measurements. RESULTS: Mean flow rates were reduced for parotid (64%) and SMSL (44%) saliva of HIV(+) patients. Flow rate reductions were unaffected by HAART. Total protein concentration in HIV(+) parotid saliva was increased 56%; patients on HAART had higher concentrations than control. For both groups, SLPI concentrations of SMSL saliva were twice that of parotid saliva. For HIV(+) patients SLPI concentrations of both saliva types were 70% greater than control; the increase in parotid saliva was greater for those taking HAART. For each saliva type, the secretory rate and specific SLPI protein concentration were not different between the groups. Patients with low CD4(+) counts had greater SLPI concentrations in parotid saliva than control. There was a negative correlation between CD4(+) counts and the SLPI concentration of parotid saliva. CONCLUSIONS: Salivary flow rate is decreased and the concentration of SLPI is increased in the presence of HIV infection. SLPI concentration in parotid and SMSL saliva is greater with HAART. C1 S Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr 182, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Dent Diagnost Sci, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Community Dent, San Antonio, TX USA. Wilford Hall USAF Med Ctr, Dept Infect Dis, HIV Unit, San Antonio, TX 78236 USA. RP Yeh, CK (reprint author), S Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr 182, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM yeh@uthscsa.edu FU NCRR NIH HHS [M01-RR-01346]; NIDCR NIH HHS [DE12188] NR 43 TC 22 Z9 23 U1 0 U2 1 PU BLACKWELL MUNKSGAARD PI COPENHAGEN PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK SN 0904-2512 J9 J ORAL PATHOL MED JI J. Oral Pathol. Med. PD AUG PY 2004 VL 33 IS 7 BP 410 EP 416 DI 10.1111/j.1600-0714.2004.00218.x PG 7 WC Dentistry, Oral Surgery & Medicine; Pathology SC Dentistry, Oral Surgery & Medicine; Pathology GA 837ET UT WOS:000222611900006 PM 15250833 ER PT J AU Chou, R Peterson, K Helfand, M AF Chou, R Peterson, K Helfand, M TI Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Review DE muscle relaxants; central; muscle spasticity; meta-analysis; musculoskeletal diseases ID LOW-BACK-PAIN; DOUBLE-BLIND CROSSOVER; CONTROLLED MULTICENTER TRIAL; MULTIPLE-SCLEROSIS PATIENTS; CHRONIC DAILY HEADACHE; TIZANIDINE DS 103-282; TENSION-TYPE HEADACHE; DANTROLENE SODIUM; PARAFON-FORTE; BACLOFEN WITHDRAWAL AB Skeletal muscle relaxants are a heterogeneous group of medications used to treat two different types of underlying conditions: spasticity from upper motor neuron syndromes and muscular pain or spasms from peripheral musculoskeletal conditions. Although widely used for these indications, there appear to be gaps in our understanding of the comparative efficacy and safety of different skeletal muscle relaxants. This systematic review summarizes and assesses the evidence for the comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions. Randomized trials (for comparative efficacy and adverse events) and observational studies (for adverse events only) that included oral medications classified as skeletal muscle relaxants by the FDA were sought using electronic databases, reference lists, and pharmaceutical company submissions. Searches were performed through January 2003. The validity of each included study was assessed using a data abstraction form and predefined criteria. An overall grade was allocated fir the body of evidence for each key question. A total of 101 randomized trials were included in this review. No randomized trial was rated good quality, and there was little evidence of rigorous adverse event assessment in included trials or observational studies. There is fair evidence that baclofen, tizanidine, and dantrolene are effective compared to placebo in patients with spasticity (primarily multiple sclerosis). There is fair evidence that baclofen and tizanidine are roughly equivalent for efficacy in patients with spasticity, but insufficient evidence to determine the efficacy of dantrolene compared to baclofen or tizanidine. There is fair evidence that although the overall rate of adverse effects between tizanidine and baclofen is similar, tizanidine is associated with more dry mouth and baclofen with more weakness. There is fair evidence that cyclobenzaprine, carisoprodol, orphenadrine, and tizanidine are effective compared to placebo in patients with muscaloskeletal conditions (primarily acute back or neck pain). Cyclobenzaprine has been evaluated in the most clinical trials and has consistently been found to be effective. There is very limited or inconsistent data regarding the effectiveness of metaxalonem methocarbamol, chlorzoxazone, baclofen, or dantrolene compared to placebo in patients with musculoskeletal conditions. There is insufficient evidence to determine the relative efficacy or safety of cyclobenzaprine, carisoprodol, orphenadrine, tizanidine, metaxalone, methocarbamol, and chlorzoxazone. Dantrolene, and to a lesser degree chlorzoxazone, have been associated. with rare serious hepatotoxicity. (C) 2004 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. C1 Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA. Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, Portland, OR USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Chou, R (reprint author), 3181 SW Sam Jackson Pk Rd,Mail Code BICC, Portland, OR 97239 USA. NR 159 TC 99 Z9 104 U1 2 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD AUG PY 2004 VL 28 IS 2 BP 140 EP 175 DI 10.1016/j.jpainsymman.2004.05.002 PG 36 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 844US UT WOS:000223186700008 PM 15276195 ER PT J AU Brothers, TE Cox, MH Robison, JG Elliott, BM Nietert, P AF Brothers, TE Cox, MH Robison, JG Elliott, BM Nietert, P TI Prospective decision analysis modeling indicates that clinical decisions in vascular surgery often fail to maximize patient expected utility SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE peripheral vascular disease; revascularization; angioplasty; amputation; quality of life; decision analysis ID QUALITY-OF-LIFE; LIMB SALVAGE; BYPASS; PREFERENCES; MANAGEMENT; OUTCOMES; ISCHEMIA AB Background. Applied prospectively to patients with peripheral arterial disease, individualized decision analysis has the potential to improve the surgeon's ability to optimize patient outcome. Methods. A prospective, randomized trial comparing Markov surgical decision analysis to standard decision-making was performed in 206 patients with symptomatic lower extremity arterial disease. Utility assessment and quality of life were determined from individual patients prior to treatment. Vascular surgeons provided estimates of probability of treatment outcome, intended and actual treatment plans, and assessment of comfort with the decision (PDPI). Treatment plans and PDPI evaluations were repeated after each surgeon was made aware of model predictions for half of the patients in a randomized manner. Results. Optimal treatments predicted by decision analysis differed significantly from the surgeon's initial plan and consisted of bypass for 30 versus 29%, respectively, angioplasty for 28 versus 11%, amputation for 31 versus 6%, and medical management for 34 versus 54% (agreement 50%, kappa 0.28). Surgeon awareness of the decision model results did not alter the verbalized final plan, but did trend toward less frequent use of bypass. Patients for whom the model agreed with the surgeon's initial plan were less likely to undergo bypass (13 versus 30%, P < 0.01). Greater surgeon comfort was present when the initial plan and model agreed (PDPI score 47.5 versus 45.6, P < 0.005). Conclusions. Individualized application of a decision model to patients with peripheral arterial disease suggests that arterial bypass is frequently recommended even when it may not maximize patient expected utility. (C) 2004 Elsevier Inc. All rights reserved. C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Brothers, TE (reprint author), 96 Jonathan Lucas St,POB 250614,Suite 424, Charleston, SC 29425 USA. EM brothete@musc.edu OI Nietert, Paul/0000-0002-3933-4986 NR 38 TC 21 Z9 21 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD AUG PY 2004 VL 120 IS 2 BP 278 EP 287 DI 10.1016/j.jss.2004.01.004 PG 10 WC Surgery SC Surgery GA 835RX UT WOS:000222504300016 PM 15234224 ER PT J AU Friedlander, AH AF Friedlander, AH TI Codeine use - Response SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Letter C1 VA Greater Los Angles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Hosp Dent Serv, Ctr Med, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), VA Greater Los Angles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER DENTAL ASSN PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD AUG PY 2004 VL 135 IS 8 BP 1086 EP 1086 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 846NC UT WOS:000223321400011 ER PT J AU Sink, KM Covinsky, KE Newcomer, R Yaffe, K AF Sink, KM Covinsky, KE Newcomer, R Yaffe, K TI Ethnic differences in the prevalence and pattern of dementia-related behaviors SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Geriatrics-Society CY MAY 14-18, 2003 CL BALTIMORE, MD SP American Geriatr Soc DE dementia; behavior; Alzheimer disease; ethnicity ID NURSING-HOME PLACEMENT; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; NEUROPSYCHIATRIC SYMPTOMS; CAREGIVER BURDEN; OLDER-PEOPLE; DEPRESSION; PATIENT; ELDERS; FRAIL AB OBJECTIVES: To determine the prevalence of dementia-related behaviors in a large, multiethnic sample of community-dwelling patients with moderate to severe dementia and to determine whether differences in patient or caregiver characteristics could explain any differences in prevalence of these behaviors between white and nonwhite patients. DESIGN: Cross-sectional study. SETTING: Community-based. PARTICIPANTS: A total of 5,776 Medicare patients (5,090 white, 469 black, 217 Latino; mean age 78.9) enrolled in the Medicare Alzheimer's Disease Demonstration and Evaluation study at eight sites across the United States between 1989 and 1991. MEASUREMENTS: Trained interviewers collected information on patient demographic characteristics, cognitive and functional status, and caregiver characteristics such as relationship to patient, functional status, depression, and burden. Ethnicity was obtained by self-report. Caregivers were asked if the patient typically demonstrated any of eight dementia-related behaviors. To determine the independent association between ethnicity and dementia-related behaviors, logistic regression models were developed for each of the behaviors, adjusting for patient and caregiver characteristics. RESULTS: Overall, 92% of patients had one or more dementia-related behaviors. Sixty-one percent of black and 57% of Latino patients were reported to have four or more behaviors, compared with 46% of white patients (P < .001). The prevalence of specific behaviors ranged from 24% for combativeness to 67% for wandering. After multivariate adjustment, black patients were significantly more likely than whites to be constantly talkative (odds ratio (OR) = 1.41, 95% confidence interval (CI) = 1.11-1.80), to have hallucinations (OR = 1.89, 95% CI = 1.49-2.40) and episodes of unreasonable anger (OR = 1.70, 95% CI = 1.34-2.15), to wander (OR = 1.40, 95% CI = 1.08-1.81), and to wake their caregiver (OR= 1.33, 95% CI = 1.04-1.69). Latinos had a significantly higher likelihood than whites of having hallucinations (OR = 1.49, 95% CI = 1.10-2.01), episodes of unreasonable anger (OR 1.59, 95% CI = 1.18-2.16), combativeness (OR = 1.59, 95% CI = 1.17-2.17), and wandering (OR 1.59, 95% CI = 1.21-2.26). For most behaviors, these adjusted ORs are similar in magnitude of effect and statistical significance to the unadjusted estimates. CONCLUSION: Black and Latino community-dwelling patients with moderate to severe dementia have a higher prevalence of dementia-related behaviors than whites. Therefore, as the aging minority population grows, it will be especially important to target caregiver education, in-home support, and resources to minority communities. C1 Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Social & Behav Sci, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Sink, KM (reprint author), Univ Calif San Francisco, Div Geriatr, 4150 Clement St,Bldg 1,Rm 306, San Francisco, CA 94121 USA. EM ksink@itsa.ucsf.edu FU NIA NIH HHS [K23-AG00888, AG00888, R01AG19827, T32 AG000212-10] NR 33 TC 44 Z9 45 U1 0 U2 2 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD AUG PY 2004 VL 52 IS 8 BP 1277 EP 1283 DI 10.1111/j.1532-5415.2004.52356.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 843ZQ UT WOS:000223127000007 PM 15271114 ER PT J AU Schnelle, JE Bates-Jensen, BM Chu, L Simmons, SE AF Schnelle, JE Bates-Jensen, BM Chu, L Simmons, SE TI Accuracy of nursing home medical record information about care-process delivery: Implications for staff management and improvement SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE quality improvement; staff management ID REFLECT DIFFERENCES; QUALITY INDICATORS; RESIDENTS; DOCUMENTATION; INCONTINENCE AB Arguments have been made that the culture of nursing homes (NHs) must change to improve the quality of care, and two initiatives have been designed to accomplish this goal. One initiative is to provide resident outcome information (quality indicators) to NH management and consumers via public reporting systems. This initiative is based on the assumptions that resident outcomes are related to care processes implemented by NH staff, the NH industry will respond to market forces, and there are management systems in place within NHs to change the behavior of direct care staff if outcomes are poor. A separate staffing initiative argues that NH care will not improve until there are resources available to increase the number of direct care staff and improve staff training. This initiative also assumes that systems are in place to manage staff resources. Unfortunately, these initiatives may have limited efficacy because information useful for managing the behavior of direct care providers is unavailable within NHs. Medical record documentation about daily care-process implementation may be so erroneous that even the best-intentioned efforts to improve the care received by residents will not be successful. A culture of inaccurate documentation is largely created by a discrepancy between care expectations placed on NHs by regulatory guidelines and inadequate reimbursement to fulfill these expectations. Nursing home staff have little incentive to implement the technologies necessary to audit and assure data quality if accurate documentation reveals that care consistent with regulatory guidelines is not or cannot be provided. A survey process that largely focuses on chart documentation to assess quality provides further incentive for care-process documentation as opposed to care-process delivery. This article reviews methods to improve the accuracy of NH medical record documentation and to create data systems useful for staff training and management. C1 Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA. Jewish Home Aging, Borun Ctr Gerontol Res, Reseda, CA USA. Vet Adm Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. RP Schnelle, JE (reprint author), 7150 Tampa Ave, Reseda, CA 91335 USA. EM jschnell@ucla.edu FU NIA NIH HHS [AG10415] NR 35 TC 47 Z9 47 U1 3 U2 11 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD AUG PY 2004 VL 52 IS 8 BP 1378 EP 1383 DI 10.1111/j.1532-5415.2004.52372.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 843ZQ UT WOS:000223127000023 PM 15271130 ER PT J AU Freedland, SJ Terris, MK Presti, JC Amling, CL Kane, CJ Trock, B Aronson, WJ AF Freedland, SJ Terris, MK Presti, JC Amling, CL Kane, CJ Trock, B Aronson, WJ CA Search Database Study Grp TI Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins SO JOURNAL OF UROLOGY LA English DT Article DE prostatic neoplasms; prostatectomy; obesity; African Americans ID BODY-MASS INDEX; PATHOLOGICAL VARIABLES; SERUM TESTOSTERONE; US ADULTS; CANCER; MEN; FINASTERIDE; RACE; MORTALITY; DATABASE AB Purpose: We have previously shown that men with a body mass index (BMI) greater than 35 kg/m(2) had higher rates of positive surgical margins and significantly higher biochemical recurrence rates following radical prostatectomy (RP). To determine whether the higher prostate specific antigen (PSA) recurrence rates were due solely to the higher positive margin rate, we examined whether obesity was an independent predictor of biochemical failure among men with negative surgical margins. Materials and Methods: We examined data from 1,250 men treated with RP between 1988 and 2003 at 5 equal access medical centers, of whom 731 had pathologically organ confined disease and negative surgical margins. Multivariate Cox proportional hazards analysis was used to determine if BMI was a significant independent predictor of biochemical recurrence. Results: Mean BMI significantly increased over time (p = 0.010). Black men were significantly more likely to be obese than white or nonwhite-nonblack men. After controlling for all preoperative characteristics, body mass index was a significant predictor of biochemical failure with moderately and severely obese men (BMI 35 kg/m(2) or greater) having greater than a 4-fold increased risk of PSA failure (p = 0.035). After controlling for the higher pathological Gleason grades among obese men, body mass index remained a significant predictor of biochemical failure with moderately and severely obese men (BMI 35 kg/m(2) or greater) having nearly a 4-fold increased risk for PSA failure (p = 0.036). Conclusions: BMI 35 kg/m(2) or greater was associated with higher grade tumors and worse outcome following RP in a cohort of men with favorable pathological findings. Thus, surgical technique (margin status) cannot fully explain the worse outcomes among obese men, suggesting that obesity may be associated with a biologically more aggressive form of prostate cancer. C1 Johns Hopkins Sch Med, Dept Urol, Baltimore, MD 21287 USA. Med Coll Georgia, Urol Sect, Augusta, GA USA. Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA USA. San Diego Naval Hosp, Dept Urol, San Diego, CA USA. Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA USA. Vet Adm Med Ctr, Dept Surg, Urol Sect, San Francisco, CA USA. Univ Calif Los Angeles, Sch Med, Dept Surg, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. RP Freedland, SJ (reprint author), Johns Hopkins Sch Med, Dept Urol, 600 N Wolfe St, Baltimore, MD 21287 USA. EM sfreedl1@jhmi.edu OI Terris, Martha/0000-0002-3843-7270 FU NCI NIH HHS [P50 CA92131-01A1] NR 20 TC 62 Z9 68 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD AUG PY 2004 VL 172 IS 2 BP 520 EP 524 DI 10.1097/01.ju.0000135302.58378.ae PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 837MJ UT WOS:000222639300026 PM 15247719 ER PT J AU Zhou, W Lin, PH Bush, RL Nguyen, L Lumsden, AB AF Zhou, W Lin, PH Bush, RL Nguyen, L Lumsden, AB TI Acute arterial thrombosis associated with cocaine abuse SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID ACTIVATION; AUTOPSY; DISEASE AB Purpose: Cocaine-induced arterial thrombosis is uncommon, and most reported cases involved small-diameter vessels such as the cerebral and coronary arteries. This study was undertaken to review our experience with peripheral arterial thrombosis presumed caused by cocaine abuse. Methods: Hospital records were reviewed for all patients admitted over 10 years with acute arterial occlusion involving the peripheral arterial system. Patients with confirmation of cocaine use or of its derivative, crack cocaine, within 24 hours of hospital admission formed the basis of this study. Symptoms at presentation, management, and outcome in these patients were reviewed. Results: Three hundred eighty-two patients with acute peripheral arterial occlusion were identified during the study period. The presumptive diagnosis of cocaine-induced arterial occlusion was made in 5 patients (4 men, mean age 38 years). Cocaine use was achieved via intranasal inhalation in 2 patients (40%), whereas the 3 remaining patients smoked crack cocaine (60%). The mean time between cocaine use and onset of arterial thrombosis was 9.2 hours (range, 2-20 hours). Symptoms at presentation included acute limb ischemia without pedal Doppler signals (3 patients, 60%) and abdominal pain without femoral pulses (2 patients, 40%). Arterial occlusion was confirmed on angiograms in all patients, which revealed aortic thrombosis in 1 patient (20%), iliac thrombosis in 2 patients (40%), superficial femoral artery thrombosis in 1 patient (20%), and popliteal artery occlusion in 1 patient (20%). Surgical thrombectomy was successfully performed in 4 patients (80%), and 1 patient (20%) underwent successful thrombolytic therapy for femoropopliteal artery occlusion. There was no perioperative mortality. All 5 patients who were discharged were available for follow-up (mean, 36 months; range, 6-75 months). There was 1 late death from myocardial infarction. In 1 patient recurrent lower extremity arterial thrombosis developed after 28 months, which was successfully treated with thrombolytic therapy. Conclusions: Our study underscores cocaine abuse as a potential cause of acute arterial thrombosis. Cocaine-induced arterial thrombosis should be suspected in patients with recent history of cocaine abuse with acute limb ischemia without an identifiable source or overt cardiovascular risk factors. Prompt angiography with operative or endovascular intervention should be performed to avert arterial ischemic sequelae. C1 Baylor Coll Med, Dept Surg, Houston VAMC, Div Vasc Surg & Endovasc Therapy, Houston, TX 77030 USA. Methodist Hosp, Houston, TX 77030 USA. RP Lin, PH (reprint author), Baylor Coll Med, Dept Surg, Houston VAMC, Div Vasc Surg & Endovasc Therapy, 2002 Holcomb Blvd 112, Houston, TX 77030 USA. EM plin@bcm.tmc.edu NR 22 TC 19 Z9 20 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD AUG PY 2004 VL 40 IS 2 BP 291 EP 295 DI 10.1016/j.jvs.2004.04.026 PG 5 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 902WT UT WOS:000227388100017 PM 15297823 ER PT J AU Jenkins, AJ Thorpe, SR Alderson, NL Hermayer, KL Lyons, TJ King, LP Chassereau, CN Klein, RL AF Jenkins, AJ Thorpe, SR Alderson, NL Hermayer, KL Lyons, TJ King, LP Chassereau, CN Klein, RL TI In vivo glycated low-density lipoprotein is not more susceptible to oxidation than nonglycated low-density lipoprotein in type 1 diabetes SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Article ID LIPID-PEROXIDATION; DCCT/EDIC COHORT; CONTROLLED IDDM; LDL; PLASMA; COMPLICATIONS; GLYCOXIDATION; ASSOCIATIONS; CHOLESTEROL; CELLS AB It has been suggested that low-density lipoprotein (LDL) modified by glycation may be more susceptible to oxidation and thus, enhance its atherogenicity. Using affinity chromatography, LDL glycated in vivo (G-LDL) and relatively nonglycated. (N-LDL) subfractions can be isolated from the same individual. The extent of and susceptibility to oxidation of N-LDL compared with G-LDL was determined in 15 type 1 diabetic patients. Total LDL was isolated and separated by boronate affinity chromatography into relatively glycated (G-) and nonglycated (N-) subfractions. The extent of glycation, glycoxidation, and lipoxidation, lipid soluble antioxidant content, susceptibility to in vitro oxidation, and nuclear magnetic resonance (NMR)-determined particle size and subclass distribution were determined for each subfraction. Glycation, (fructose-lysine) was higher in G-LDL versus N-LDL, (0.28 +/- 0.08 v 0.13 +/- 0.04 mmol/mol lysine, P < .0001). However, levels of glycoxidation/ lipoxidation products and of antioxidants were similar or lower in G-LDL compared with N-LDL and were inversely correlated with fructose-lysine (FL) concentrations in G-LDL, but positively correlated in N-LDL. In vitro LDL (CuCl2) oxidation demonstrated a longer lag time for oxidation of G-LDL than N-LDL (50 +/- 0.16 v 37 +/- 0.15 min, P < .01), but there was no difference in the rate or extent of lipid oxidation, nor in any aspect of protein oxidation. Mean LDL particle size and subclass distribution did not differ between G-LDL and N-LDL. Thus, G-LDL from well-controlled type 1 diabetic patients is not more modified by oxidation, more susceptible to oxidation, or smaller than relatively N-LDL, suggesting alternative factors may contribute to the atherogenicity of LDL from type 1 diabetic patients. (C) 2004 Elsevier Inc. All rights reserved. C1 Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Charleston, SC 29403 USA. Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia. Univ Oklahoma, Hlth Sci Fdn, Sect Endocrinol Diabet & Hypertens, Oklahoma City, OK USA. Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA. Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. RP Klein, RL (reprint author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Room 501,Strom Thurmond Gazes Biomed Res Bldg,114, Charleston, SC 29403 USA. RI Jenkins, Alicia/N-2482-2015 FU NIDDK NIH HHS [DK 19971] NR 37 TC 9 Z9 10 U1 0 U2 2 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0026-0495 J9 METABOLISM JI Metab.-Clin. Exp. PD AUG PY 2004 VL 53 IS 8 BP 969 EP 976 DI 10.1016/j.metabol.2004.01.002 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 846KL UT WOS:000223314300004 PM 15281003 ER PT J AU Klopper, JP Hays, WR Sharma, V Baumbusch, MA Hershman, JM Haugen, BR AF Klopper, JP Hays, WR Sharma, V Baumbusch, MA Hershman, JM Haugen, BR TI Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID HUMAN PROSTATE-CANCER; REDIFFERENTIATION THERAPY; INDUCE APOPTOSIS; PPAR-GAMMA; ACID; LIGAND; GROWTH; LINES; DIFFERENTIATION; INFLAMMATION AB Poorly differentiated, metastatic thyroid cancer is difficult to treat. These tumors often do not concentrate radioactive iodine and may require chemotherapy, which is suboptimal and toxic. Nuclear hormone receptors peroxisome proliferator-activated receptor gamma (PPARgamma) and retinoid X receptor (RXR) are variably expressed in thyroid carcinoma cell lines. Expression of these receptors may predict thyroid cancer cell response to treatment with rexinoids and thiazolidinediones. We studied three thyroid carcinoma cell lines: BHP 5-16 (PPARgamma-/RXRgamma+), BHP 2-7 (PPARgamma+/-/RXRgamma-), and DRO-90 (RXRgamma+/PPARgamma+). BHP 5-16 (RXRgamma+) cells treated with rexinoid had decreased proliferation to 69 +/- 6% growth compared with vehicle. BHP 2-7 (PPARgamma+) cells treated with thiazolidinedione had no decrease in cellular proliferation. DRO-90 (RXRgamma+ and PPARgamma+) cells had 36 +/- 10%, 15 +/- 3%, and 13 +/- 4% growth when treated with rexinoid, thiazolidinedione, or a combination, respectively. We next investigated the role of apoptosis in the ligand-responsive BHP 5-16 and DRO-90 cells. BHP 5-16 cells underwent no significant apoptosis with rexinoid (1 mumol/L). DRO-90 cells, however, had 3.6 +/- 1.3% apoptotic cells with vehicle, 13 +/- 3.5% with rexinoid (1 mumol/L), 18 +/- 4% with thiazolidinedione (1 mumol/L), and 28 +/- 6% with combination treatment (1 mumol/L), suggesting that apoptosis plays a major role in this anaplastic cell line and that the effects of the two ligands are additive. We conclude that receptor expression is necessary for inhibition of thyroid carcinoma growth with ligand treatment but may not be sufficient for response. Additionally, expression of both RXRgamma and PPARgamma may be necessary for maximal growth inhibition by ligands and may be required for the increased apoptosis. C1 Univ Colorado, Ctr Hlth Sci, Ctr Canc, Dept Med,Div Endocrinol Metab & Diabet, Denver, CO 80262 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. W Los Angeles VAMC, Dept Med, Los Angeles, CA USA. RP Klopper, JP (reprint author), Univ Colorado, Ctr Hlth Sci, Ctr Canc, Dept Med,Div Endocrinol Metab & Diabet, Box B151,4200 E 9th Ave, Denver, CO 80262 USA. EM joshua.klopper@uchsc.edu FU NCI NIH HHS [R25CA49981]; NIDDK NIH HHS [DK54383] NR 33 TC 38 Z9 45 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD AUG PY 2004 VL 3 IS 8 BP 1011 EP 1020 PG 10 WC Oncology SC Oncology GA 845LR UT WOS:000223244700013 PM 15299084 ER PT J AU Regenold, WT Phatak, P Kling, MA Hauser, P AF Regenold, WT Phatak, P Kling, MA Hauser, P TI Post-mortem evidence from human brain tissue of disturbed glucose metabolism in mood and psychotic disorders SO MOLECULAR PSYCHIATRY LA English DT Letter ID SORBITOL PATHWAY; RAT C1 Univ Maryland, Med Ctr, Dept Psychiat, Div Geriatr Psychiat, Baltimore, MD 21201 USA. Univ Maryland, Baltimore VA Med Ctr, Mood Disorders Program, Baltimore, MD 21201 USA. Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR USA. Oregon Hlth & Sci Univ, Hepatitis C Resource Ctr, Portland, OR USA. RP Regenold, WT (reprint author), Univ Maryland, Med Ctr, Dept Psychiat, Div Geriatr Psychiat, Box 351,Room S12A09,22 S Greene St, Baltimore, MD 21201 USA. EM wregenol@psych.umaryland.edu RI Kling, Mitchel/F-4152-2010 OI Kling, Mitchel/0000-0002-2232-1409 NR 9 TC 12 Z9 14 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD AUG PY 2004 VL 9 IS 8 BP 731 EP 733 DI 10.1038/sj.mp.4001517 PG 4 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA 840IP UT WOS:000222851700002 PM 15098005 ER PT J AU Suzuki, T Delgado-Escueta, AV Aguan, K Alonso, ME Shi, J Hara, Y Nishida, M Numata, T Medina, MT Takeuchi, T Morita, R Bai, DS Ganesh, S Sugimoto, Y Inazawa, J Bailey, JN Ochoa, A Jara-Prado, A Rasmussen, A Ramos-Peek, J Cordova, S Rubio-Donnadieu, F Inoue, Y Osawa, M Kaneko, S Oguni, H Mori, Y Yamakawa, K AF Suzuki, T Delgado-Escueta, AV Aguan, K Alonso, ME Shi, J Hara, Y Nishida, M Numata, T Medina, MT Takeuchi, T Morita, R Bai, DS Ganesh, S Sugimoto, Y Inazawa, J Bailey, JN Ochoa, A Jara-Prado, A Rasmussen, A Ramos-Peek, J Cordova, S Rubio-Donnadieu, F Inoue, Y Osawa, M Kaneko, S Oguni, H Mori, Y Yamakawa, K TI Mutations in EFHC1 cause juvenile myoclonic epilepsy SO NATURE GENETICS LA English DT Article ID IDIOPATHIC GENERALIZED EPILEPSY; CHILDHOOD ABSENCE EPILEPSY; E CALCIUM-CHANNEL; CA2+ CHANNEL; GENE; LINKAGE; CANDIDATE; SUBUNIT; LOCUS; HETEROGENEITY AB Juvenile myoclonic epilepsy (JME) is the most frequent cause of hereditary grand mal seizures(1,2). We previously mapped and narrowed a region associated with JME on chromosome 6p12-p11 (EJM1)(3-5). Here, we describe a new gene in this region, EFHC1, which encodes a protein with an EF-hand motif. Mutation analyses identified five missense mutations in EFHC1 that cosegregated with epilepsy or EEG polyspike wave in affected members of six unrelated families with JME and did not occur in 382 control individuals. Overexpression of EFHC1 in mouse hippocampal primary culture neurons induced apoptosis that was significantly lowered by the mutations. Apoptosis was specifically suppressed by SNX-482, an antagonist of R-type voltage-dependent Ca2+ channel (Ca(v)2.3). EFHC1 and Ca(v)2.3 immunomaterials overlapped in mouse brain, and EFHC1 coimmunoprecipitated with the Cav2.3 C terminus. In patch-clamp analysis, EFHC1 specifically increased R-type Ca2+ currents that were reversed by the mutations associated with JME. C1 RIKEN, Brain Sci Inst, Neurogenet Lab, Wako, Saitama 3510198, Japan. Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan. Univ Calif Los Angeles, David Geffen Sch Med, Comprehens Epilepsy Program, Epilepsy Genet Gen Labs, Los Angeles, CA 90024 USA. VA GLAHS W Los Angeles, W Los Angeles DVA Med Ctr, Los Angeles, CA 90073 USA. Natl Inst Neurol & Neurosurg, Mexico City, DF, Mexico. Grad Univ Adv Studies, Ctr Integrat Biosci, Okazaki, Aichi, Japan. Kyoto Univ, Grad Sch Engn, Kyoto, Japan. Natl Autonomous Univ, Tegucigalpa, Honduras. Univ Calif Los Angeles, David Geffen Sch Med, Inst Neuropsychiat, Los Angeles, CA USA. Shizuoka Med Inst Neurol Disorders, Natl Epilepsy Ctr, Shizuoka, Japan. Tokyo Womens Med Univ, Dept Pediat, Tokyo, Japan. Hirosaki Univ, Sch Med, Dept Neuropsychiat, Aomori, Japan. RP Delgado-Escueta, AV (reprint author), RIKEN, Brain Sci Inst, Neurogenet Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan. EM escueta@ucla.edu; yamakawa@brain.riken.go.jp RI Ganesh, Subramniam/B-4131-2009; shi, jun/C-2389-2011; Yamakawa, Kazuhiro/N-5050-2015 OI Delgado-Escueta, Antonio V./0000-0002-1581-6999 NR 29 TC 207 Z9 219 U1 1 U2 13 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD AUG PY 2004 VL 36 IS 8 BP 842 EP 849 DI 10.1038/ng1393 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 842AG UT WOS:000222974000016 PM 15258581 ER PT J AU Jara, A Chacon, C Ibaceta, M Valdivieso, A Felsenfeld, AJ AF Jara, A Chacon, C Ibaceta, M Valdivieso, A Felsenfeld, AJ TI Effect of ammonium chloride and dietary phosphorus in the azotaemic rat. I. Renal function and biochemical changes SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE ammonium chloride; calcium; dietary phosphorus; phosphorus; renal failure ID CHRONIC METABOLIC-ACIDOSIS; SEVELAMER HYDROCHLORIDE; PHOSPHATE-DEPLETION; FAILURE; CALCIUM; PROGRESSION; DISEASE; CALCIFICATION; SERUM AB Background. Both dietary phosphorus restriction and the ingestion of ammonium chloride (NH4Cl) given to rats on a high-phosphorus diet have been shown to preserve renal function in the azotaemic rat. Parathyroidectomy also has been reported to preserve renal function and, in addition, to prevent kidney hypertrophy in the remnant kidney model. Our goals were (i) to evaluate in azotaemic rats the effect of dietary phosphorus on renal function in a shorter time frame than previously studied and (ii) to determine whether NH4Cl administration (a) enhances the renoprotective effect of dietary phosphorus restriction and (b) improves renal function in the absence of parathyroid hormone (PTH). Methods. High (H; 1.2%), normal (N; 0.6%) and low (L; <0.05%) phosphorus diets (PD) were given for 30 days to 5/6 nephrectomized rats. In each dietary group, one-half of the rats were given NH4Cl in the drinking water. The six groups were HPD+NH4Cl, HPD, NPD + NH4Cl, NPD, LPD + NH4Cl and LPD. The effect of NH4Cl administration was also evaluated in 5/6 nephrectomized, parathyroidectomized (PTX) rats on NPD. Results. In each of the three dietary phosphorus groups, creatinine and urea clearances were greater (P<0.01) in rats receiving NH4Cl. Neither creatinine nor urea clearance was reduced by high dietary phosphorus. Urine calcium excretion was greatest in the LPD group and was increased (Pless than or equal to0.001) in all three groups by NH4Cl ingestion. An inverse correlation was present between plasma calcium and phosphorus in the parathyroid intact (r = -0.79, P<0.001) and PTX groups (r = -0.46, P = 0.02). In PTX rats, NH4Cl ingestion increased (P<0.01) creatinine and urea clearances and both an increasing plasma calcium concentration (r = 0.67, P<0.001) and urine calcium excretion (r = 0.73, P<0.001) increased urine phosphorus excretion. Conclusions. At 30 days of renal failure (i) NH4Cl ingestion increased creatinine and urea clearances, irrespective of dietary phosphorus; (ii) high urine calcium excretion, induced by dietary phosphorus restriction and NH4Cl ingestion, did not adversely affect renal function; (iii) high dietary phosphorus did not decrease renal function; (iv) the absence of PTH did not preserve renal function or prevent NH4Cl from improving renal function; and (v) both an increasing plasma calcium concentration and urine calcium excretion resulted in an increase in urine phosphorus excretion in PTX rats. C1 Pontificia Univ Catolica Chile, Dept Nephrol, Santiago, Chile. W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. RP Jara, A (reprint author), Pontificia Univ Catolica Chile, Dept Nephrol, Lira 85, Santiago, Chile. EM ajara@med.puc.cl NR 20 TC 9 Z9 9 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD AUG PY 2004 VL 19 IS 8 BP 1986 EP 1992 DI 10.1093/ndt/gfh311 PG 7 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 843VF UT WOS:000223114000007 PM 15173378 ER PT J AU Jara, A Chacon, C Ibaceta, M Valdivieso, A Felsenfeld, AJ AF Jara, A Chacon, C Ibaceta, M Valdivieso, A Felsenfeld, AJ TI Effect of ammonium chloride and dietary phosphorus in the azotaemic rat. Part II - kidney hypertrophy and calcium deposition SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE ammonium chloride; dietary phosphorus; kidney hypertrophy; nephrocalcinosis ID SEVELAMER HYDROCHLORIDE; RENAL HYPERTROPHY; HEMODIALYSIS-PATIENTS; PHOSPHATE; PROGRESSION; RESTRICTION; PREVENTION; FAILURE; PARATHYROIDECTOMY; NEPHROCALCINOSIS AB Background. Kidney hypertrophy is stimulated by both partial nephrectomy and NH4Cl administration. Also, parathyroidectomy (PTX) has been reported to prevent kidney hypertrophy induced by a high protein diet. Our goal was to determine in the azotaemic rat: (i) the combined effects of NH4Cl administration and dietary phosphorus on the development of kidney hypertrophy and calcium deposition in the kidney and (11) whether the absence of parathyroid hormone (PTH) affected the development of kidney hypertrophy and calcium deposition. Methods. High (HPD., 1.2%), normal (NPD, 0.6%) or low (LPD, <0.05%) phosphorus diets were given to 5/6 nephrectomized rats for 30 days. In each dietary group, one-half of the rats were given NH4Cl in the drinking water. The six groups of rats were: (i) HPD+NH4Cl; (ii) HPD; (iii) NPD+NH4Cl; (iv) NPD; (v) LPD + NH4Cl and (vi) LPD. In a separate study, PTX was performed to determine whether PTH affected renal hypertrophy in 5/6 nephrectomized rats given NH4Cl. Results. Both with and without NH4Cl (+/-NH4Cl), kidney weight was greatest (P<0.05) in the HPD groups. In each dietary phosphorus group, kidney weight was greater (P<0.05) in the NH4Cl group. In both the +/-NH4Cl groups, kidney calcium content was greatest (P<0.05) in the HPD group, but was less (P<0.05) in the NPD and HPD groups given NH4Cl. An inverse correlation was present between creatinine clearance and kidney, calcium content (r=-0.51, P<0.001). When factored for kidney weight, creatinine clearance was less (P<0.05) in the HPD group in both the +/-NH4Cl groups, but was greater in the HPD+NH4Cl than in the HPD group. In PTX rats, kidney weight was greater (P<0.05) and kidney calcium deposition was less (P<0.05) in rats given NH4Cl. Conclusions. In azotaemic rats studied for 30 days, NH4Cl administration induced kidney hypertrophy. A HPD also induced kidney hypertrophy. The effects on kidney calcium deposition were divergent for which NH4Cl administration decreased and a HPD increased calcium deposition. The inverse correlation between kidney calcium content and creatinine clearance suggests that kidney calcium deposition is harmful to renal function. When factored for kidney weight, the lower creatinine clearance in the high phosphorus group suggests that kidney hypertrophy does not completely compensate for the harmful effects of a HPD. This result also suggests that a longer study would probably result in more rapid deterioration in the high phosphorus group. In PTX rats, the absence of PTH did not prevent NH4Cl from inducing kidney hypertrophy and reducing kidney calcium deposition. In conclusion, NH4Cl and dietary phosphorus each independently affect kidney growth and calcium deposition in the growing rat with renal failure. C1 Pontificia Univ Catolica Chile, Dept Nephrol, Santiago, Chile. W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. RP Jara, A (reprint author), Pontificia Univ Catolica Chile, Dept Nephrol, Lira 85, Santiago, Chile. EM ajara@med.puc.cl NR 25 TC 11 Z9 12 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD AUG PY 2004 VL 19 IS 8 BP 1993 EP 1998 DI 10.1093/ndt/gfh301 PG 6 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 843VF UT WOS:000223114000008 PM 15161952 ER PT J AU Bartzokis, G Sultzer, D Lu, PH Neuchterlein, KH Mintz, J Cummings, JL AF Bartzokis, G Sultzer, D Lu, PH Neuchterlein, KH Mintz, J Cummings, JL TI Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's diesase SO NEUROBIOLOGY OF AGING LA English DT Article; Proceedings Paper CT 4th Annual Rural Policy Conference CY APR 28-29, 2003 CL Kansas City, MO SP Fed Reserve Bank Kansas City, Ctr Study Rural Amer DE aging; Alzheimer; myelin; oligodendrocyte; white matter; degeneration; MRI; relaxation; corpus callosum; amyloid; toxic; prevention ID T2 RELAXATION-TIME; MYELINATED NERVE-FIBERS; IN-VIVO EVALUATION; A-BETA PEPTIDES; MAGNETIC-RESONANCE; BRAIN IRON; CORPUS-CALLOSUM; RHESUS-MONKEY; DISEASE; MATURATION AB Human and non-human primate data suggest that the structural integrity of myelin sheaths deteriorates during normal aging, especially in the late-myelinating association regions and may result in "disconnection" of widely distributed neural networks. Magnetic resonance imaging (MRI) was used to assess the heterogeneity of this process and its impact on brain aging and Alzheimer's disease (AD) by evaluating early- and later-myelinating regions of the corpus callosum, the splenium (See) and genu (Gee), respectively. Calculated transverse relaxation rates (R-2), an indirect measure of white matter structural integrity for the Gee and See, were examined. The relationship between age and R2 differed in the two regions. A quadratic (inverted U) function with an accelerating rate of decline beginning at age 31 best represented the Gee pattern while the See decline was three-fold smaller, gradual, and linear. These data suggest that the severity of age-related myelin breakdown is regionally heterogeneous, consistent with the hypothesis that differences in myelin properties make later-myelinating regions more susceptible to this process. In AD this process is globally exacerbated, consistent with an extracellular deleterious process such as amyloid beta-peptide toxicity. Non-invasive measures such as R2 may be useful in primary prevention studies of AD. (C) 2003 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Dept Neurol, Lab Neuroimaging,Div Brain Mapping, Los Angeles, CA 90095 USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Bartzokis, G (reprint author), Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. EM gbar@ucla.edu RI Bartzokis, George/K-2409-2013 FU NIA NIH HHS [AG 16570]; NIMH NIH HHS [MH-30911, MH-37705, MH-51928] NR 71 TC 218 Z9 222 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD AUG PY 2004 VL 25 IS 7 BP 843 EP 851 DI 10.1016/j.neurobiolaging.2003.09.005 PG 9 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 838JQ UT WOS:000222709900002 PM 15212838 ER PT J AU Whitcomb, DC Ermentrout, GB AF Whitcomb, DC Ermentrout, GB TI A mathematical model of the pancreatic duct cell generating high bicarbonate concentrations in pancreatic juice SO PANCREAS LA English DT Article; Proceedings Paper CT 34th Meeting of the European-Pancreas-Club CY JUN 20, 2002 CL Heidelberg, GERMANY SP European Pancreas Club DE bicarbonate; chloride; pancreatitis; pancreas; secretin; sodium bicarbonate cotransporter (NBC); cystic fibrosis transmembrane conductance regulator (CFTR); antiporter; anion channel ID TRANSMEMBRANE CONDUCTANCE REGULATOR; GUINEA-PIG PANCREAS; DEPENDENT HCO3-TRANSPORT; CYSTIC-FIBROSIS; INTERLOBULAR DUCTS; EPITHELIAL-CELLS; SECRETION; COTRANSPORTER; EXPRESSION; SELECTIVITY AB Objective: To develop a simple, physiologically based mathematical model of pancreatic duct cell secretion using experimentally derived parameters that generates pancreatic fluid bicarbonate concentrations of > 140 mM after CFTR activation. Methods: A new mathematical model was developed simulating a duct cell within a proximal pancreatic duct and included a sodium-2-bicarbonate cotransporter (NBC) and sodium-potassium pump (NaK pump) on a chloride-impermeable basolateral membrane, CFTR on the luminal membrane with 0.2 to 1 bicarbonate to chloride permeability ratio. Chloride-bicarbonate antiporters (Cl-/HCO3- AP) were added or subtracted from the basolateral (AP(b)) and luminal (AP(l)) membranes. The model was integrated over time using XPPAUT. Results: This model predicts robust, NaK pump - dependent bicarbonate secretion with opening of the CFTR, generates and maintains pancreatic fluid secretion with bicarbonate concentrations > 140 mM, and returns to basal levels with CFTR closure. Limiting CFTR permeability to bicarbonate, as seen in some CFTR mutations, markedly inhibited pancreatic bicarbonate and fluid secretion. Conclusions: A simple CFTR-dependent duct cell model can explain active, high-volume, high-concentration bicarbonate secretion in pancreatic juice that reproduces the experimental findings. This model may also provide insight into why CFTR mutations that predominantly affect bicarbonate permeability predispose to pancreatic dysfunction in humans. C1 Univ Pittsburgh, UPMC Presbyterian, Dept Med, Pittsburgh, PA 15213 USA. Univ Pittsburgh, UPMC Presbyterian, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, UPMC Presbyterian, Dept Human Genet, Pittsburgh, PA 15213 USA. VA Pittsburgh Hlth Care Syst, Dept Math, Pittsburgh, PA USA. RP Whitcomb, DC (reprint author), Univ Pittsburgh, UPMC Presbyterian, Dept Med, Mezzanine Level,C Wing,200 Lothrop St, Pittsburgh, PA 15213 USA. EM whitcomb@pitt.edu NR 26 TC 31 Z9 32 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD AUG PY 2004 VL 29 IS 2 BP E30 EP E40 DI 10.1097/00006676-200408000-00016 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 861ZO UT WOS:000224458000016 PM 15257112 ER PT J AU Piqueras, L Tache, Y Martinez, V AF Piqueras, L Tache, Y Martinez, V TI Galanin inhibits gastric acid secretion through a somatostatin-independent mechanism in mice SO PEPTIDES LA English DT Article DE galanin; somatostatin; somatostatin receptors; SSTR2; acid secretion; immunoneutralization; pentagastrin ID BOMBESIN-INDUCED INHIBITION; PERFUSED RAT STOMACH; GASTROINTESTINAL-TRACT; MONOCLONAL-ANTIBODY; ANESTHETIZED RATS; HISTAMINE-RELEASE; RECEPTOR SUBTYPE; CONSCIOUS RATS; CELLS; INTESTINE AB The role of somatostatin in galanin-induced inhibition of gastric acid secretion in urethane-anesthetized mice was investigated by using immunoneutralization of endogenous somatostatin and somatostatin receptor type 2 (SSTR2) knockout mice. Intravenous galanin (10 and 20 mug/kg/h) inhibited pentagastrin-stimulated gastric acid secretion by 47 and 33%, respectively. Somatostatin antibody injected i.v. increased acid secretion by 3.5-fold over basal levels but did not modify the antisecretory effects of galanin. Urethane-anesthetized SSTR2 knockout mice had a basal secretion 14-fold higher than wild-type animals, that was inhibited by galanin (10 and 20 mug/kg/h) by 49 and 31% respectively. In mice galanin inhibits gastric acid secretion through a somatostatin-independent mechanism. (C) 2004 Elsevier Inc. All rights reserved. C1 Cardenal Herrera CEU Univ, Dept Physiol Pharmacol & Toxicol, Valencia, Spain. Univ Calif Los Angeles, VA Greater Los Angeles Hlth Care Syst, Digest Dis Res Ctr, Dept Med & Brain Res Inst, Los Angeles, CA USA. Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womans Hlth, Los Angeles, CA USA. RP Martinez, V (reprint author), AstraZeneca R&D, SE-43183 Molndal, Sweden. EM vicente.martinez@astrazeneca.com RI Martinez, Vicente/N-1189-2014 FU NIDDK NIH HHS [DK-41301] NR 38 TC 12 Z9 13 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD AUG PY 2004 VL 25 IS 8 BP 1287 EP 1295 DI 10.1016/j.peptides.2004.06.003 PG 9 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 854TQ UT WOS:000223926700008 PM 15350696 ER PT J AU Kilbourne, AM Haas, GL Mulsant, BH Bauer, MS Pincus, HA AF Kilbourne, AM Haas, GL Mulsant, BH Bauer, MS Pincus, HA TI Concurrent psychiatric diagnoses by age and race among persons with bipolar disorder SO PSYCHIATRIC SERVICES LA English DT Article ID AFRICAN-AMERICAN AB The authors characterized concurrent psychiatric diagnoses among patients with a diagnosis of bipolar disorder who were in routine care by using administrative data from a Department of Veterans Affairs facility. Of 813 patients who had a diagnosis of bipolar disorder in 2000, 21 percent were older (greater than or equal to60 years) whites, and 2 percent were older African Americans. Older African Americans were the most likely to have a diagnosis of schizophrenia documented in the medical record compared with younger African Americans, older whites, and younger whites (67 percent, 34 percent, 38 percent, and 27 percent, respectively). The results suggest that older African-American patients with bipolar disorder are more likely to receive diagnoses of mutually exclusive conditions, such as schizophrenia, and thus appear to have an elevated risk of their illness being underrecognized or misdiagnosed and receiving inappropriate treatment. C1 VA Pittsburgh Ctr Hlth Equity Res & Promot, Dept Vet Affairs, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. VA Providence Med Ctr, Providence, RI USA. Brown Univ, Dept Psychiat & Human Behav, Providence, RI 02912 USA. RAND Corp, Univ Pittsburgh, Hlth Inst, Pittsburgh, PA USA. RP Kilbourne, AM (reprint author), VA Pittsburgh Ctr Hlth Equity Res & Promot, Dept Vet Affairs, VA Pittsburgh Healthcare Syst, Mailstop 151-C,Univ Dr C, Pittsburgh, PA 15240 USA. EM amy.kilbourne@med.va.gov FU NIMH NIH HHS [MH-30915] NR 8 TC 17 Z9 17 U1 0 U2 1 PU AMER PSYCHIATRIC PRESS, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD AUG PY 2004 VL 55 IS 8 BP 931 EP 933 DI 10.1176/appi.ps.55.8.931 PG 3 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 843BX UT WOS:000223051500013 PM 15292544 ER PT J AU Cubells, JF Zabetian, CP AF Cubells, JF Zabetian, CP TI Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology SO PSYCHOPHARMACOLOGY LA English DT Review DE catecholamines; norepinephrine; quantitative trait locus; sympathetic nervous system; psychosis; depression; alcoholism; attention deficit hyperactivity disorder; Parkinson's disease; hypotension ID DEFICIT HYPERACTIVITY DISORDER; MULTIPLE SYSTEM ATROPHY; IDIOPATHIC PARKINSONS-DISEASE; PREFRONTAL CORTICAL FUNCTION; GENOTYPE-CONTROLLED ANALYSIS; PLATELET MONOAMINE-OXIDASE; EMOTIONALLY-DISTURBED BOYS; POLYMORPHIC (GT)(N) REPEAT; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE AB Rationale: Norepinephrine (NE) is a key neurotransmitter in the central and peripheral nervous systems. Dopamine beta-hydroxylase (DbetaH) catalyzes the synthesis of NE from dopamine (DA) and occurs in the plasma as a stable heritable trait. Studies of this trait have been useful in psychiatric and neurological research. Objective: To selectively and critically review the literature on plasma DbetaH, and on recent progress understanding the molecular genetic basis for its inheritance. Based on this review, directions for future research in psychiatry and neurology will be suggested. Methods: We selectively review the literature on the biochemical and molecular genetics of plasma DbetaH activity, as well as research on plasma and cerebrospinal fluid (CSF) DbetaH in psychiatric and neurological disorders. Results: Strong evidence implicates DBH, the structural locus encoding DbetaH enzyme, as the major quantitative trait locus influencing plasma DbetaH activity, with one single nucleotide polymorphism (SNP) accounting for up to 50% of the variance. Mutations at DBH appear to be responsible for the rare syndrome of DbetaH deficiency. Some biochemical and genetic studies suggest associations between low plasma or CSF DbetaH and psychotic symptoms in several psychiatric disorders. Studies combining genotyping at DBH with biochemical measurement of plasma DbetaH have proven useful in studies of schizophrenia, cocaine-induced paranoia (CIP), depression, attention deficit hyperactivity disorder, and alcoholism. Such studies may also elucidate the contribution of noradrenergic dysfunction to a variety of symptoms in Parkinson's disease and other degenerative neurological disorders. Conclusions: A model is proposed, in which lower levels of DbetaH protein may lead to elevated ratios of DA to NE. This model may explain associations between lower plasma DbetaH activity and vulnerability to psychotic symptoms. Genotype-controlled analysis of plasma DbetaH holds promise for promoting further progress in research on psychiatric and neurological disorders. C1 Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA. VA Connecticut Hlth Care Syst, West Haven, CT 06516 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Cubells, JF (reprint author), Yale Univ, Sch Med, Dept Psychiat, 950 Campbell Ave, West Haven, CT 06516 USA. EM jcubells@genetics.emory.edu FU NIDA NIH HHS [K12 DA 00089, K02 DA 15766, R01 DA 12422]; NINDS NIH HHS [K08 NS 44138] NR 138 TC 109 Z9 124 U1 0 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD AUG PY 2004 VL 174 IS 4 BP 463 EP 476 DI 10.1007/s00213-004-1840-8 PG 14 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 848NM UT WOS:000223474400004 PM 15088079 ER PT J AU Reusch, JEB Watson, PA AF Reusch, JEB Watson, PA TI Loss of CREB regulation of vascular smooth muscle cell quiescence in diabetes SO REVIEWS IN ENDOCRINE & METABOLIC DISORDERS LA English DT Article ID CAMP-RESPONSE ELEMENT; FACTOR-ALPHA-RECEPTOR; BINDING PROTEIN-DELTA; ARTERIAL-WALL THICKNESS; GROWTH-FACTOR; TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; IN-VIVO; ADIPOCYTE DIFFERENTIATION; PROMOTER ACTIVITY C1 Univ Colorado, Boulder, CO 80309 USA. Amer Federat Med Res, Denver VA Med Ctr, Denver, CO USA. RP Reusch, JEB (reprint author), Univ Colorado, Boulder, CO 80309 USA. EM Jane.Reusch@uchsc.edu FU NHLBI NIH HHS [HL56481]; NIDDK NIH HHS [DK57516] NR 69 TC 11 Z9 11 U1 0 U2 0 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1389-9155 J9 REV ENDOCR METAB DIS JI Rev. Endocr. Metab. Disord. PD AUG PY 2004 VL 5 IS 3 BP 209 EP 219 DI 10.1023/B:REMD.0000032409.13963.bc PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 840SS UT WOS:000222880500004 PM 15211092 ER PT J AU Wong, AL Harker, JO Mittman, BS Levy, GD Bulpitt, KJ Colburn, KK Liu, HH Kahn, KL Hahn, BH Paulus, HE Rubenstein, LZ AF Wong, AL Harker, JO Mittman, BS Levy, GD Bulpitt, KJ Colburn, KK Liu, HH Kahn, KL Hahn, BH Paulus, HE Rubenstein, LZ TI Development and evaluation of a patient self-report case-finding method for rheumatoid arthritis SO SEMINARS IN ARTHRITIS AND RHEUMATISM LA English DT Review DE rheumatoid arthritis; case finding; self-report; survey ID CYCLIC CITRULLINATED PEPTIDE; DISEASE-ACTIVITY SCORE; JOINT TENDERNESS; ARTICULAR INDEX; VALIDITY; QUESTIONNAIRE; INFORMATION; PREVALENCE; ANTIBODIES; CRITERIA AB Objective: To describe the development and evaluation of a patient self-report case-finding method for rheumatoid arthritis (RA) not dependent on direct contact with the treating physicians. Methods: The American College of Rheumatology criteria for RA diagnosis were adapted for patient self-report using a questionnaire, and alternative scoring algorithms were evaluated to balance case-finding sensitivity and specificity. Positive rheumatoid factor tests were used to identify 1053 individuals in 2 large healthcare organizations; 440 agreed to receive study materials. Case-finding results were validated by medical record review (MRR) for a random sample of 90 patients. Three scoring algorithms were compared with MRR for likelihood of RA diagnosis. Cases not classifiable by algorithm were flagged and reviewed by 2 expert physicians for likelihood of RA diagnosis. Results: Pilot testing demonstrated that patients comprehended the questionnaire and were willing to answer the questions. Completed questionnaires were returned by 265 (60%) of the 440 patients contacted. Following expert physician review of 16 flagged cases in the 90-patient MRR subsample, the most accurate scoring algorithm demonstrated 80% sensitivity, 67% specificity, 74% accuracy, and 77% positive predictive value for detecting early RA. Conclusion: The case-finding method represents a promising tool for identifying RA patients, with potential application in research and quality-assurance activities. C1 Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Kaiser Permanente, Bellflower, CA USA. Jerry L Pettis Mem Vet Adm Med Ctr, Loma Linda, CA USA. Univ Calif Los Angeles, Dept Med, Div Rheumatol, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA. RAND Corp, Santa Monica, CA USA. RP Wong, AL (reprint author), Olive View UCLA Med Ctr, 14445 Olive View Dr, Sylmar, CA 91342 USA. EM alunwong@ucla.edu FU NIAMS NIH HHS [P60 AR36834] NR 36 TC 7 Z9 7 U1 1 U2 2 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0049-0172 J9 SEMIN ARTHRITIS RHEU JI Semin. Arthritis Rheum. PD AUG PY 2004 VL 34 IS 1 BP 484 EP 499 DI 10.1016/j.semarthrit.2003.12.002 PG 16 WC Rheumatology SC Rheumatology GA 852DK UT WOS:000223735200005 PM 15305246 ER PT J AU Burns, SP Weaver, FM Parada, JP Evans, CT Chang, H Hampton, RY Kapur, V AF Burns, SP Weaver, FM Parada, JP Evans, CT Chang, H Hampton, RY Kapur, V TI Management of community-acquired pneumonia in persons with spinal cord injury SO SPINAL CORD LA English DT Article DE community-acquired pneumonia; spinal cord injuries; disease management; antibiotics ID PSEUDOMONAS-AERUGINOSA; HOSPITAL STAY; PROGNOSIS; OUTCOMES; CARE; SEVERITY; LENGTH; ADULTS; RISK; GUIDELINES AB Study design: Retrospective case series. Objectives: Respiratory disorders are the leading cause of death in persons with spinal cord injury (SCI), but the epidemiology and medical management of pneumonia in persons with chronic SCI is not well characterized. We describe the clinical presentation of persons with SCI with community-acquired pneumonia ( CAP), characterize its management and compare practice to recommendations for CAP in the general population. Setting: Three United States Veterans A. airs Medical Centers with specialized SCI services. Methods: Chart abstraction was performed for all persons with chronic SCI seen at participating centers for treatment of CAP during a 2-year period. Collected data included presenting signs and symptoms, laboratory and imaging results, initial antibiotic therapy, secretion mobilization techniques, in-patient vs outpatient management, length of stay, and mortality. Results: In all, 41 persons with SCI received treatment for CAP during the study period. A total of 32 (78.0%) patients were admitted for treatment; two (4.8%) required intubation and mechanical ventilation. Initial antibiotic coverage met guideline recommendations for only half of inpatients and infrequently provided adequate antipseudomonal coverage. Microbiologic testing was performed on 26 cases (63.4%) and demonstrated a specific pathogen in only five cases (12.2% of total). Three cases (7.3%) died during treatment for CAP, and 16 (42.1%) of 38 CAP survivors died within a median follow-up of 3 years. Conclusion: The majority of chronic SCI patients who present to specialized SCI centers with CAP are admitted for treatment. Short-term mortality is comparable to CAP in the general population. Sponsorship: This research was supported by the United States Department of Veterans Affairs. C1 VA Puget Sound Hlth Care Syst, Spinal Cord Injury Serv, Seattle, WA 98108 USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA. US Dept Vet Affairs, VA Edward Hines Jr Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL 60141 USA. Northwestern Univ, Inst Hlth Serv, Chicago, IL 60611 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Midwest Ctr Hlth Serv & Policy Res, Hines, IL 60141 USA. Loyola Univ, Stritch Sch Med, Dept Med, Div Infect Dis, Maywood, IL 60153 USA. Loyola Med Ctr, Maywood, IL USA. Univ Washington, Dept Med, Div Pulm & Crit Care Med, Seattle, WA USA. RP Burns, SP (reprint author), VA Puget Sound Hlth Care Syst, Spinal Cord Injury Serv, SCI 128,1660 S Columbian Way, Seattle, WA 98108 USA. RI Kapur, Vishesh/K-1054-2014 OI Kapur, Vishesh/0000-0002-5417-1097 NR 28 TC 7 Z9 7 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 J9 SPINAL CORD JI Spinal Cord PD AUG PY 2004 VL 42 IS 8 BP 450 EP 458 DI 10.1038/sj.sc.3101600 PG 9 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 843GP UT WOS:000223066900005 PM 15037861 ER PT J AU Mandal, AK Drew, N Lapidus, AA AF Mandal, AK Drew, N Lapidus, AA TI The effect of center volume on pancreas transplant outcomes SO SURGERY LA English DT Article; Proceedings Paper CT 65th Annual Meeting of the Society-of-University-Surgeons CY FEB 11-14, 2004 CL St Louis, MO SP Soc Univ Surg ID OPERATIVE MORTALITY; KIDNEY-TRANSPLANTS; SURGICAL VOLUME; HOSPITAL VOLUME; SURGEON VOLUME; UNITED-STATES; QUALITY; PROGRAM; CANCER; CARE AB Background. Caseload often correlates with improved outcomes for several surgical procedures, including, solid organ transplantation. Given the unique nature of pancreas transplantation and large variation in transplant center volumes, this study aims to determine whether center volume affects Patient and graft survival after pancreas transplantation. Methods. Registry data on all forms of whole organ pancreas transplants performed between 1995 and 2000 were obtained from the United Network for Organ Sharing. Patient and graft survival rates were followed until 2002. Center volume then was categorized as: low (< 10/year), medium (10-20/year), high (21-50/year), and very high (< 50/year). Cox proportional hazard regression models were developed to evaluate factors affecting pancreas transplant outcomes. Results. Very-high-volume centers were more likely to do pancreas after kidney transplant, pancreas transplant alone, pancreas with kidney transplant, and repeat transplants, while other centers more frequently performed simultaneous pancreas-kidney transplants (P <. 001). Very-high-volume centers were more likely to transplant older recipients and less likely to transplant minority or Medicaid patients. Low-volume centers tended to accept pancreatic allografts from younger donors and had the longest waiting times. In models adjusting for differences in patient population, there were no differences in Patient survival. However, low-volume centers had a slightly increased risk of graft loss compared to other centers. Early graft loss was similar among all centers, but medium-volume centers were at increased risk for late graft loss. Conclusions. Low center volume is not associated with increased mortality after pancreas transPlantation. Other factors appear to be more important than center volume in determining pancreas transplant outcomes. C1 Portland VA Med Ctr, Dept Surg, Portland, OR 97239 USA. Portland VA Med Ctr, Portland VA Res Fdn, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Div Liver & Pancreat Transplantat, Portland, OR 97201 USA. RP Mandal, AK (reprint author), Portland VA Med Ctr, Dept Surg, Mail Code R&D66,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. OI Mandal, Aloke/0000-0002-2245-0999 NR 21 TC 10 Z9 10 U1 0 U2 1 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0039-6060 J9 SURGERY JI Surgery PD AUG PY 2004 VL 136 IS 2 BP 225 EP 231 DI 10.1016/j.surg.2004.04.023 PG 7 WC Surgery SC Surgery GA 846LV UT WOS:000223318000017 PM 15300184 ER PT J AU Brambilla, P Soloff, PH Sala, M Nicoletti, MA Keshavan, MS Soares, JC AF Brambilla, P Soloff, PH Sala, M Nicoletti, MA Keshavan, MS Soares, JC TI Anatomical MRI study of borderline personality disorder patients SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article; Proceedings Paper CT 57th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 16-18, 2002 CL PHILADELPHIA, PA SP Soc Biol Psychiat DE neuroimaging; personality disorder; basal ganglia; hippocampus; amygdala; frontal cortex; temporal cortex; brain; magnetic resonance imaging ID POSTTRAUMATIC-STRESS-DISORDER; POSITRON-EMISSION-TOMOGRAPHY; BRAIN GLUCOSE-METABOLISM; HIPPOCAMPAL VOLUME; ORBITOFRONTAL CORTEX; SUICIDAL-BEHAVIOR; MAJOR DEPRESSION; BIPOLAR PATIENTS; CHILDHOOD ABUSE; BASAL GANGLIA AB Hippocampal volume reduction has been reported in patients with borderline personality disorder (BPD), and is hypothesized to be associated with traumatic childhood experiences. We extended this investigation to explore additional brain regions and other potential clinical correlates of structural brain changes in BPD. Ten unmedicated BPD subjects and 20 healthy controls were assessed for current and past Axis I and II comorbidities and histories of childhood abuse. All had magnetic resonance imaging (MRI) studies with a 1.5 T GE Signa Imaging System, performing three-dimensional-gradient echo imaging (SPGR) with the following parameters: TR=25 ms, TE=5 ms, and slice-thickness=1.5 mm. Compared with healthy controls, BPD subjects had significantly smaller right and left hippocampal volumes, most marked in subjects with childhood abuse, and significantly increased right and left putamen volumes, especially in subjects with substance use disorders. No significant differences between groups were found for caudate, amygdala, temporal lobes, dorsolateral prefrontal cortex and total brain volumes. This study replicated prior findings of diminished hippocampal volumes in subjects with BPD. Also, increased putamen volumes were found in BPD, a finding that has not been previously reported. Early traumatic experiences may play a role in hippocampal atrophy, whereas substance use disorders may contribute to putamen enlargement. (C) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78229 USA. Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA USA. Univ Udine, Dept Pathol & Expt & Clin Med, Sect Psychiat, I-33100 Udine, Italy. Univ Genoa, Adv Biotechnol Ctr, Genoa, Italy. Univ Pavia, Sch Med, IRCCS S Matteo, Dept Psychiat, I-27100 Pavia, Italy. Audie L Murphy Div, S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Soares, JC (reprint author), Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM soares@uthscsa.edu RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 FU NCRR NIH HHS [M01RR0056]; NIMH NIH HHS [MH 01736, MH 30915, MH48463] NR 59 TC 97 Z9 100 U1 2 U2 10 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD JUL 30 PY 2004 VL 131 IS 2 BP 125 EP 133 DI 10.1016/j.pscychresns.2004.04.003 PG 9 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 852BK UT WOS:000223730000004 PM 15313519 ER PT J AU Chin, PS Miller, JW AF Chin, PS Miller, JW TI Ictal head version in generalized epilepsy SO NEUROLOGY LA English DT Article ID LATERALIZING SIGNIFICANCE; SEIZURES AB Focal physical signs may occur with generalized seizures. The authors retrospectively reviewed video-EEG studies of 20 patients with apparent primary generalized epilepsy to assess the frequency of head version during generalized tonic-clonic seizures. Five patients (25%) demonstrated forced head version, including two with turning to the right and left on consecutive seizures. Forced head turning can occur in generalized epilepsy and may not necessarily indicate focal seizure origin. C1 Univ Washington, Reg Epilepsy Ctr, Dept Neurol, Seattle, WA 98104 USA. Univ Washington, Reg Epilepsy Ctr, Dept Neurol Surg, Seattle, WA 98104 USA. Univ Calif Los Angeles, Robert Wood Johnson VA Clin Scholars Program, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Robert Wood Johnson VA Clin Scholars Program, Dept Neurol, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Miller, JW (reprint author), Univ Washington, Reg Epilepsy Ctr, Dept Neurol, 325 9th Ave,Box 359745, Seattle, WA 98104 USA. EM millerjw@u.washington.edu NR 8 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD JUL 27 PY 2004 VL 63 IS 2 BP 370 EP 372 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 841CX UT WOS:000222908000037 PM 15277642 ER PT J AU Keil, DE Dudley, C EuDaly, JG Dempsey, J Butterworth, L Gilkeson, GS Peden-Adams, MM AF Keil, DE Dudley, C EuDaly, JG Dempsey, J Butterworth, L Gilkeson, GS Peden-Adams, MM TI Immunological and hematological effects observed in B6C3F1 mice exposed to Jp-8 jet fuel for 14 days SO JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES LA English DT Article ID HUMORAL IMMUNE-RESPONSE; LYMPHOCYTE-T ACTIVATION; CELL-MEDIATED-IMMUNITY; ANTIBODY-RESPONSE; INDUCED IMMUNOTOXICITY; DERMAL APPLICATION; HOST-RESISTANCE; RATS; VAPOR; VOLUME AB JP-8 is the primary jet fuel used by the U.S. Air Force and NATO allies. Exposure is likely to be widespread and to include both military and aviation industry personnel as well as residents living near fuel contaminated sites. This study examines the effects of JP-8 on humoral and cell-mediated and hematological parameters. A suite of immunotoxicological endpoints was evaluated in adult female B6C3F1 mice gavaged with JP-8 (in an olive oil carrier) ranging from 250-2500 mg/kg/d for 14 d. One day following the last exposure, significant increases in liver mass were detected beginning at exposure levels of 1000mg/kg/d, while thymic mass was decreased at exposure levels of 1500 mg/kg/d and above. Decreases in thymic cellularity, however, were only observed at exposure levels of 2000 mg/kg/d and above. Mean corpuscular volume was increased (1500-2500mg/kg/d), while the hematocrit, hemoglobin concentration, and red blood cell count were decreased only at the 2500 mg/kg/d exposure level. Natural killer cell (NK) activity and T- and B-cell proliferation were not altered. Decreases in the plaque forming cell (PFC) response were dose responsive at levels of 500 mg/kg/d and greater while unexpectedly, serum levels of anti-SRBC immunoglobulin M (IgM) were not altered. Alterations were detected in thymic and splenic CD4/8 subpopulations, and proliferative responses of bone marrow progenitor cells were enhanced in mice exposed to 2000 mg/kg/d of JP-8. This study establishes that humoral immune function is impaired with lower exposure levels of JP-8 than are required to affect primary and secondary immune organ weights and cellularities, CD4/8 suhpopulations, and hematological endpoints. C1 NIOSH, OD, AIG, Morgantown, WV 26505 USA. Med Univ S Carolina, Dept Hlth Profess, Charleston, SC 29425 USA. Med Univ S Carolina, Marine Biomed Ctr, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Rheumatol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pediat, Marine Biomed & Environm Sci Ctr, Charleston, SC 29425 USA. Ralph Johnson VAMC, Med Res Serv, Charleston, SC USA. RP Keil, DE (reprint author), NIOSH, OD, AIG, M-S L1119,1095 Wollowdale Dr, Morgantown, WV 26505 USA. EM dkeil@cdc.gov NR 63 TC 11 Z9 11 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1528-7394 J9 J TOXICOL ENV HEAL A JI J. Toxicol. Env. Health Part A PD JUL 23 PY 2004 VL 67 IS 14 BP 1109 EP 1129 DI 10.1080/152839049452335 PG 21 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 834WP UT WOS:000222441900004 PM 15205027 ER PT J AU Loftis, JM Socherman, RE Howell, CD Whitehead, AJ Hill, JA Dominitz, JA Hauser, P AF Loftis, JM Socherman, RE Howell, CD Whitehead, AJ Hill, JA Dominitz, JA Hauser, P TI Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C SO NEUROSCIENCE LETTERS LA English DT Article DE antidepressants; selective serotonin reuptake inhibitors; hepatitis C; depression; antiviral therapy ID THERAPY; ILLNESS AB Thirty-nine patients with hepatitis C viral infection on interferon-alpha (IFN-alpha) therapy were monitored weekly using the Beck Depression Inventory (BDI). Thirteen of thirty-nine patients (33%) developed IFN-alpha-induced major depressive disorder (MDD). During the course of IFN-alpha therapy, patients who became depressed were treated with citalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant. Results indicated that: (1) IFN-alpha response rates were significantly higher in those patients who developed IFN-alpha-induced MDD than in those who did not (end-of-treatment response (ETR) rates: 61.5% versus 26.9% and sustained viral response (SVR) rates: 38.5% versus 11.5%), (2) male patients with ETR to IFN-alpha therapy were, on average, similar to33 pounds lighter in body weight than male patients who did not respond, and (3) gender, race, past history of MDD, and past history of substance abuse were not significantly associated with ETR. In conclusion, our findings suggest that IFN-alpha-induced MDD may be a predictor of a positive response to IFN-alpha therapy, or an indication of optimal dosing. (C) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR USA. NW Hepatitis C Resource Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR USA. Univ Maryland, Sch Med, VA Med Ctr, Baltimore, MD 21201 USA. Univ Washington, Sch Med, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR USA. Portland VA Med Ctr, P3MHAdm, JENS Lab, Portland, OR 97239 USA. RP Hauser, P (reprint author), Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR USA. EM peter.hauser2@med.va.gov NR 20 TC 46 Z9 47 U1 0 U2 0 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD JUL 22 PY 2004 VL 365 IS 2 BP 87 EP 91 DI 10.1016/j.neulet.2004.04.058 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 840OR UT WOS:000222869300003 PM 15245784 ER PT J AU Donta, ST Engel, CC Collins, JF Baseman, JB Dever, LL Taylor, T Boardman, KD Kazis, LE Martin, SE Horney, RA Wiseman, AL Kernodle, DS Smith, RP Baltch, AL Handanos, C Catto, B Montalvo, L Everson, M Blackburn, W Thakore, M Brown, ST Lutwick, L Norwood, D Bernstein, J Bacheller, C Ribner, B Church, LWP Wilson, KH Guduru, P Cooper, R Lentino, J Hamill, RJ Gorin, AB Gordan, V Wagner, D Robinson, C DeJace, P Greenfield, R Beck, L Bittner, M Schumacher, HR Silverblatt, F Schmitt, J Wong, E Ryan, MAK Figueroa, J Nice, C Feussner, JR AF Donta, ST Engel, CC Collins, JF Baseman, JB Dever, LL Taylor, T Boardman, KD Kazis, LE Martin, SE Horney, RA Wiseman, AL Kernodle, DS Smith, RP Baltch, AL Handanos, C Catto, B Montalvo, L Everson, M Blackburn, W Thakore, M Brown, ST Lutwick, L Norwood, D Bernstein, J Bacheller, C Ribner, B Church, LWP Wilson, KH Guduru, P Cooper, R Lentino, J Hamill, RJ Gorin, AB Gordan, V Wagner, D Robinson, C DeJace, P Greenfield, R Beck, L Bittner, M Schumacher, HR Silverblatt, F Schmitt, J Wong, E Ryan, MAK Figueroa, J Nice, C Feussner, JR CA VA Cooperative 475 Grp TI Benefits and harms of doxycycline treatment for Gulf War veterans' illnesses SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID POLYMERASE CHAIN-REACTION; CHRONIC-FATIGUE-SYNDROME; HEALTH-STATUS; MYCOPLASMA-FERMENTANS; DESERT-STORM; DISEASE; QUESTIONNAIRE; GENITALIUM; POPULATION; EXPOSURE AB Background: It has been hypothesized that certain Mycoplasma species may cause Gulf War veterans' illnesses (GWVIs), chronic diseases characterized by pain, fatigue, and cognitive symptoms, and that affected patients may benefit from doxycycline treatment. Objective: To determine whether a 12-month course of doxycycline improves functional status in Gulf War veterans with GWVIs. Design: A randomized, double-blind, placebo-controlled clinical trial with 12 months of treatment and 6 additional months of follow-up. Setting: 26 U.S. Department of Veterans Affairs and 2 U.S. Department of Defense medical centers. Participants: 491 deployed Gulf War veterans with GWVIs and detectable Mycoplasma DNA in the blood. Intervention: Doxycycline, 200 mg, or matching placebo daily for 12 months. Measurements: The primary outcome was the proportion of participants who improved more than 7 units on the Physical Component Summary score of the Veterans Short Form-36 General Health Survey 12 months after randomization. Secondary outcomes were measures of pain, fatigue, and cognitive function and change in positivity for Mycoplasma species at 6, 12, and 18 months after randomization. Results: No statistically significant differences were found between the doxycycline and placebo groups for the primary outcome measure (43 of 238 participants [18.1%] vs. 42 of 243 participants [17.3%]; difference, 0.8 percentage point [95% CI, -6.5 to 8.0 percentage points]; P > 0.2) or for secondary outcome measures at 1 year. In addition, possible differences in outcomes at 3 and 6 months were not apparent at 9 or 18 months. Participants in the doxycycline group had a higher incidence of nausea and photosensitivity. Limitations: Adherence to treatment after 6 months was poor. Conclusion: Long-term treatment with doxycycline did not improve outcomes of GWVIs at 1 year. C1 Vet Affairs Med Ctr, Boston, MA USA. Vet Affairs Med Ctr, Milwaukee, WI USA. Vet Affairs Med Ctr, Montgomery, AL USA. Vet Affairs Med Ctr, Perry Point, MD USA. Vet Affairs Med Ctr, E Orange, NJ USA. Vet Affairs Med Ctr, White River Jct, VT USA. Vet Affairs Med Ctr, Albuquerque, NM USA. Vet Affairs Med Ctr, Bedford, MA USA. Vet Affairs Med Ctr, Nashville, TN 37212 USA. Vet Affairs Med Ctr, Albany, NY USA. Vet Affairs Med Ctr, Augusta, GA USA. Vet Affairs Med Ctr, Birmingham, AL USA. Vet Affairs Med Ctr, Bronx, NY USA. Vet Affairs Med Ctr, Brooklyn, NY USA. Vet Affairs Med Ctr, Dayton, OH USA. Vet Affairs Med Ctr, Charleston, SC 29403 USA. Vet Affairs Med Ctr, Durham, NC USA. Vet Affairs Med Ctr, Fargo, ND USA. Vet Affairs Med Ctr, Hines, IL USA. Vet Affairs Med Ctr, Houston, TX 77030 USA. Vet Affairs Med Ctr, Manchester, NH USA. Vet Affairs Med Ctr, New Orleans, LA USA. Vet Affairs Med Ctr, Oklahoma City, OK 73104 USA. Vet Affairs Med Ctr, Omaha, NE USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Vet Affairs Med Ctr, Providence, RI USA. Vet Affairs Med Ctr, Richmond, VA USA. Vet Affairs Med Ctr, San Juan, PR USA. Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. USN, Hlth Res Ctr, San Diego, CA 92152 USA. Natl Cent Off, Dept Vet Affairs, Washington, DC USA. RP Collins, JF (reprint author), Vet Affairs Maryland Healthcare Syst, Cooperat Studies Program, Coordinating Ctr 151E, POB 1010, Perry Point, MD 21902 USA. NR 39 TC 17 Z9 17 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUL 20 PY 2004 VL 141 IS 2 BP 85 EP 94 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 839BL UT WOS:000222758200001 PM 15262663 ER PT J AU Legner, VJ Doerner, D Reilly, DF McCormick, WC AF Legner, VJ Doerner, D Reilly, DF McCormick, WC TI Risk factors for nursing home placement following major nonemergent surgery SO AMERICAN JOURNAL OF MEDICINE LA English DT Article ID AFFAIRS SURGICAL RISK; NONCARDIAC SURGERY; PERIOPERATIVE COMPLICATIONS; ANESTHESIA; MORBIDITY; MORTALITY; CARE; INDICATORS; ADJUSTMENT; OUTCOMES AB PURPOSE: To determine the association between self-reported exercise tolerance and the risk of unanticipated postoperative nursing home placement in adults undergoing major surgery. METHODS: Consecutive community-dwelling adults (N 586) referred to a medical clinic for evaluation before undergoing major nonemergent surgery at a tertiary care academic medical center were prospectively followed between 1995 and 1997. The main outcome measure was unanticipated postoperative nursing home placement. RESULTS: Overall, 12% (40/324) of patients with poor preoperative exercise tolerance (inability to walk four blocks and climb two flights of stairs without symptomatic limitation) had unanticipated nursing home placement compared with 4% (10/262) of patients with good exercise tolerance. Patient and surgical characteristics associated with nursing home placement in univariate analyses included poor preoperative exercise tolerance, increasing age, living alone, history of heart failure, taking five or more preoperative medications, longer anesthesia duration, and orthopedic surgery. Patients who were married were at lower risk. After adjusting for all other patient and surgical factors, poor preoperative exercise tolerance (odds ratio [OR] 2.8; 95% confidence interval [CI]: 1.3 to 6.2). and serious postoperative complications (OR = 4.7; 95% CI: 2.1 to 10.5) remained associated with postoperative nursing home placement. CONCLUSION: Poor preoperative exercise tolerance was an independent predictor of unanticipated nursing home placement following major nonemergent Surgery. (C) 2004 by Elsevier Inc. C1 VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Univ Washington, Sch Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. RP Legner, VJ (reprint author), VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, 1660 S Columbian Way,S-182 GRECC, Seattle, WA 98108 USA. EM legner@u.washington.edu NR 25 TC 12 Z9 12 U1 1 U2 1 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD JUL 15 PY 2004 VL 117 IS 2 BP 82 EP 86 DI 10.1016/j.amjmed.2004.02.027 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 837GC UT WOS:000222615700002 PM 15234642 ER PT J AU Kwabi-Addo, B Wang, JH Erdem, H Vaid, A Castro, P Ayala, G Ittmann, M AF Kwabi-Addo, B Wang, JH Erdem, H Vaid, A Castro, P Ayala, G Ittmann, M TI The expression of sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer SO CANCER RESEARCH LA English DT Article ID FGF RECEPTORS; INTRAEPITHELIAL NEOPLASIA; DROSOPHILA-SPROUTY; OVER-EXPRESSION; PROTEINS; CELLS; ACTIVATION; PATHWAY; GENES; ADENOCARCINOMA AB A considerable body of evidence indicates that alterations of fibroblast growth factors (FGFs) and their receptors contribute to prostate cancer progression. Recently, a new family of regulators of FGF activity has been identified. The Sprouty gene family negatively regulates FGF signaling in a variety of systems and could potentially limit the biological activity of FGFs in prostate cancer. Immunohistochemical analysis of normal and neoplastic prostate tissues using tissue microarrays revealed that Sprouty1 protein is down-regulated in approximately 40% of prostate cancers when compared with matched normal prostate. By quantitative real-time PCR analysis, we found that Sprouty1 mRNA levels were significantly decreased in prostate cancers in vivo in comparison with normal prostate. In prostate cancer cell lines, there is loss of the normal upregulation of Sprouty1 mRNA and protein in response to FGFs. The decrease in Sprouty1 expression in the human prostate cancer, despite elevated levels of FGF ligands and FGF receptors, implies a loss of an important growth regulatory mechanism in prostate cancers that may potentiate the effects of increased FGF and FGF receptor expression in prostate cancer. C1 Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. Houston Dept Vet Affairs Med Ctr, Houston, TX USA. RP Ittmann, M (reprint author), Houston Vet Affairs Med Ctr, Res Serv, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM mittmann@bcm.tmc.edu RI Kwabi-Addo, Bernard/A-6993-2016 OI Kwabi-Addo, Bernard/0000-0003-3692-6350 FU NCI NIH HHS [P50 CA 058204] NR 45 TC 88 Z9 92 U1 2 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD JUL 15 PY 2004 VL 64 IS 14 BP 4728 EP 4735 DI 10.1158/0008-5472.CAN-03-3759 PG 8 WC Oncology SC Oncology GA 837XM UT WOS:000222674700009 PM 15256439 ER PT J AU Katsivas, T Sokolov, R Miller, M Hever, A Hu, B AF Katsivas, T Sokolov, R Miller, M Hever, A Hu, B TI Primary herpetic peritonitis causing intestinal perforation: Case report and review of the literature SO CLINICAL INFECTIOUS DISEASES LA English DT Review ID DIALYSIS AB Peritonitis of viral etiology is rarely reported in the literature; a prior report described a patient undergoing continuous ambulatory peritoneal dialysis who had the disease. We report a case of primary herpetic peritonitis ( the agent of which was typed by polymerase chain reaction as herpes simplex virus biotype 1), which caused intestinal perforation, and we review the current literature and provide possible pathophysiologic mechanisms. C1 Cedars Sinai Med Ctr, Dept Pathol, Los Angeles, CA 90048 USA. Cedars Sinai Med Ctr, Div Infect Dis, Los Angeles, CA 90048 USA. Greater Los Angeles Vet Affairs Med Ctr, Infect Dis Sect, Los Angeles, CA USA. Univ Calif Los Angeles, Med Ctr, Clin Labs, Los Angeles, CA 90024 USA. RP Katsivas, T (reprint author), W Los Angeles Vet Affairs Med Ctr, Infect Dis Sect, 111-F,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM tkats@prodigy.net NR 13 TC 3 Z9 3 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUL 15 PY 2004 VL 39 IS 2 BP E13 EP E16 DI 10.1086/421998 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 835HV UT WOS:000222474300030 PM 15307046 ER PT J AU Carey, KB Roberts, LJ Kivlahan, DR Carey, MP Neal, DJ AF Carey, KB Roberts, LJ Kivlahan, DR Carey, MP Neal, DJ TI Problems assessment for substance using psychiatric patients: development and initial psychometric evaluation SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE substance use; problems; psychiatric disorders; psychometrics ID SEVERE MENTAL-ILLNESS; ADDICTION SEVERITY INDEX; ALCOHOL-USE DISORDERS; IDENTIFICATION TEST AUDIT; ABUSE SCREENING-TEST; DRUG-USE DISORDERS; QUALITY-OF-LIFE; HARM REDUCTION; HEALTH SURVEY; VALIDITY AB Background: Persons with co-occurring Axis I mental disorders and substance use disorders often experience multiple negative consequences as a result of their substance use. Because no existing measure adequately assesses these population-specific problems, we developed the Problems Assessment for Substance Using Psychiatric Patients (PASUPP). This paper describes the scale development and factor structure, and provides initial reliability and validity evidence for the PASUPP. Methods: An initial pool of 54 items was assembled by reviewing existing measures for relevant items and generating new items. Then, 239 patients (90% male, 61% White) with documented Axis I psychiatric and current substance use disorders rated the lifetime and last 3-month occurrence of each problem, and completed additional measures of substance use and related functioning. Results: Lifetime endorsements ranged from 31 to 95%, whereas 3-month endorsements ranged from 24 to 78%. Item analyses reduced the set to 50 items. The PASUPP is internally consistent (alpha = 0.97) and unidimensional. Scale validity was suggested by moderate correlation with other measures of substance problem severity. Conclusions: Promising psychometric properties are reported for a population-specific measure of substance use problems. Such a measure could be useful for initial assessments and outcome evaluations with substance using psychiatric patients. (C) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Syracuse Univ, Ctr Hlth & Behav, Syracuse, NY 13244 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Carey, KB (reprint author), Syracuse Univ, Ctr Hlth & Behav, 430 Huntington Hall, Syracuse, NY 13244 USA. EM kbcarey@psych.syr.edu FU NIDA NIH HHS [K02 DA000426-05, K02 DA000426, K02-DA00426]; NIMH NIH HHS [K02-MH01582, K02 MH001582, K02 MH001582-05] NR 54 TC 8 Z9 8 U1 0 U2 3 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD JUL 15 PY 2004 VL 75 IS 1 BP 67 EP 77 DI 10.1016/j.drugalcdep.2004.01.010 PG 11 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 842TK UT WOS:000223026900007 PM 15225890 ER PT J AU Mueller, A Wallner, K Merrick, G Ford, E Sutlief, S Cavanagh, W Butler, W AF Mueller, A Wallner, K Merrick, G Ford, E Sutlief, S Cavanagh, W Butler, W TI Perirectal seeds as a risk factor for prostate brachytherapy-related rectal bleeding SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE prostatic carcinoma; brachytherapy; rectum; morbidity ID I-125; MORBIDITY; CANCER AB Purpose: To correlate rectal wall doses and perirectal seed numbers with late rectal bleeding after prostate brachytherapy. Methods and Materials: We studied 148 patients randomized to implantation with I-125 vs. Pd-103 at the VA Puget Sound HCS from 1998 through 2001 and for whom postimplant dosimetry was available. Implants were performed by standard techniques, using a modified peripheral loading pattern. A postimplant computed tomography (CT) scan (3 mm slice thickness) was obtained 1-4 h after implantation. Rectal doses were expressed as the R100, R200, and R300, defined as the rectal volume (cc) that received more than 100%, 200%, or 300% of the prescription dose, respectively. The rectum was considered to be a solid structure defined by the outer wall, without attempting to differentiate the inner wall or contents. In addition to conventional dose parameters, each patient's postimplant CT scan was reviewed for the number of seeds within 0, 0.1-2, and 2.1-4 mm of the outer rectal wall. The proximal edge of the seed was used for distance determinations from the outer rectal wall. Patients who reported Grade 1 or higher Radiation Therapy Oncology Group morbidity were contacted by telephone to obtain more details regarding their rectal bleeding. Those who reported persistent bleeding lasting for more than 1 month were categorized as Grade 2. Results: Patients had a wide range of rectal wall doses, with R100 values ranging from 0.0 to 10.4 cc (median, 0.95 cc). Similarly, the number of perirectal seeds within 0.0 to 2.0 mm of the rectum varied widely, ranging from 0 to 12 seeds (median: 1 seed). Seven patients (7 of 144 = 5%) developed persistent rectal bleeding, one of whom required a colostomy. Both rectal radiation doses and the number of perirectal seeds were higher in patients with persistent rectal bleeding. The number of perirectal seeds less than or equal to2.0 mm of the rectal wall was higher in patients with rectal bleeding (p = 0.037), but the number of seeds 2-4 mm from the wall were not related (p = 0.72). In multivariate regression analysis including prostatic D90 (the dose that covers 90% of the postimplant prostate), preimplant transrectal ultrasound volume, R300, and the number of seeds less than or equal to2 mm from the rectal wall as independent variables, only the R300 was statistically significantly associated with the likelihood of persistent rectal bleeding (p = 0.025). Conclusion: A limited number of errant perirectal sources in itself does not appear to place patients at increased risk of rectal bleeding, providing that the overall rectal wall doses are within acceptable values. (C) 2004 Elsevier Inc. C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Dept Radiat Oncol, Seattle, WA 98195 USA. Grp Hlth Cooperat Puget Sound, Seattle, WA 98121 USA. Schiffler Canc Ctr, Wheeling, WV USA. RP Wallner, K (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 174,1660 S Columbian Way, Seattle, WA 98108 USA. EM kent.wallner@med.va.gov NR 17 TC 20 Z9 21 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JUL 15 PY 2004 VL 59 IS 4 BP 1047 EP 1052 DI 10.1016/j.ijrobp.2003.12.016 PG 6 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 836FO UT WOS:000222541300015 PM 15234038 ER PT J AU Garzotto, M Mongoue-Tchokote, S Bledsoe, J Parra, RO Peters, L Park, Y Beer, TM Mori, M AF Garzotto, M Mongoue-Tchokote, S Bledsoe, J Parra, RO Peters, L Park, Y Beer, TM Mori, M TI Predictors of prostate cancer in men undergoing serial prostate biopsies: Results from 371 patients. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT 40th Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 05-08, 2004 CL New Orleans, LA SP Amer Soc Clin Oncol C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JUL 15 PY 2004 VL 22 IS 14 SU S MA 4589 BP 404S EP 404S PG 1 WC Oncology SC Oncology GA 849BL UT WOS:000223512401601 PM 28015959 ER PT J AU Janoff, D Mongoue-Tchokote, S Peterson, C Parra, RO Peters, L Park, Y Beer, TM Mori, M Garzotto, M AF Janoff, D Mongoue-Tchokote, S Peterson, C Parra, RO Peters, L Park, Y Beer, TM Mori, M Garzotto, M TI Outcomes of androgen deprivation as sole therapy for localized prostate cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT 40th Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 05-08, 2004 CL New Orleans, LA SP Amer Soc Clin Oncol C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JUL 15 PY 2004 VL 22 IS 14 SU S MA 4627 BP 413S EP 413S PG 1 WC Oncology SC Oncology GA 849BL UT WOS:000223512401639 PM 28015746 ER PT J AU Mims, MP Maran, J Leal, SM Hayes, TG Ittmann, M Wheeler, T Guan, Y Prchal, JT AF Mims, MP Maran, J Leal, SM Hayes, TG Ittmann, M Wheeler, T Guan, Y Prchal, JT TI Role of African American genetic polymorphisms in prostate cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT 40th Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 05-08, 2004 CL New Orleans, LA SP Amer Soc Clin Oncol C1 Baylor Coll Med, Houston VA Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Methodist Hosp, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JUL 15 PY 2004 VL 22 IS 14 SU S MA 4710 BP 433S EP 433S PG 1 WC Oncology SC Oncology GA 849BL UT WOS:000223512401720 PM 28016992 ER PT J AU Spurgeon, S Riavadeneira, A Peters, LM Yi-Ching, H Beer, TM Mori, M Garzotto, M AF Spurgeon, S Riavadeneira, A Peters, LM Yi-Ching, H Beer, TM Mori, M Garzotto, M TI Prediction of aggressive prostate cancer on biopsy using classification and regression tree analysis (CART). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT 40th Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 05-08, 2004 CL New Orleans, LA SP Amer Soc Clin Oncol C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JUL 15 PY 2004 VL 22 IS 14 SU S MA 4720 BP 436S EP 436S PG 1 WC Oncology SC Oncology GA 849BL UT WOS:000223512401730 PM 28016972 ER PT J AU Lubiniecki, GM Chen, Z Thompson, S Algazy, KM AF Lubiniecki, GM Chen, Z Thompson, S Algazy, KM TI Mortality from prostate cancer (PC) in Pennsylvania(PA) in civilian versus Veterans Administration (VA) populations. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT 40th Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 05-08, 2004 CL New Orleans, LA SP Amer Soc Clin Oncol C1 Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. UPA, Dept Biostat & Epidemiol, Philadelphia, PA USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JUL 15 PY 2004 VL 22 IS 14 SU S MA 4768 BP 448S EP 448S PG 1 WC Oncology SC Oncology GA 849BL UT WOS:000223512401778 PM 28017052 ER PT J AU Brouns, MC Beer, TM Ganzini, LK AF Brouns, MC Beer, TM Ganzini, LK TI Interest in physician-assisted suicide (PAS) among Oregon cancer patients. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT 40th Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 05-08, 2004 CL New Orleans, LA SP Amer Soc Clin Oncol C1 NW Canc Specialists, Vancouver, BC, Canada. OHSU, Inst Canc, Portland, OR USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JUL 15 PY 2004 VL 22 IS 14 SU S MA 8070 BP 746S EP 746S PG 1 WC Oncology SC Oncology GA 849BL UT WOS:000223512402959 PM 28015869 ER PT J AU Yeni, PG Hammer, SM Hirsch, MS Saag, MS Schechter, M Carpenter, CCJ Fischl, MA Gatell, JM Gazzard, BG Jacobsen, DM Katzenstein, DA Montaner, JSG Richman, DD Schooley, RT Thompson, MA Vella, S Volberding, PA AF Yeni, PG Hammer, SM Hirsch, MS Saag, MS Schechter, M Carpenter, CCJ Fischl, MA Gatell, JM Gazzard, BG Jacobsen, DM Katzenstein, DA Montaner, JSG Richman, DD Schooley, RT Thompson, MA Vella, S Volberding, PA TI Treatment for adult HIV infection - 2004 recommendations of the International AIDS Society-USA panel SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; STRUCTURED TREATMENT INTERRUPTION; SEQUENTIAL 3-DRUG REGIMENS; CD4(+) CELL COUNT; HIV-1-INFECTED PATIENTS; PROGNOSTIC IMPORTANCE; LOPINAVIR-RITONAVIR; COMBINATION THERAPY; PROTEASE-INHIBITOR AB Context Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection. Objective To update recommendations for physicians who provide HIV care regarding when to start antiretroviral therapy, what drugs to start with, when to change drug regimens, and what drug regimens to switch to after therapy fails. DataSources Evidence was identified and reviewed by a 16-member noncompensated panel of physicians with expertise in HIV-related basic science and clinical research, antiretroviral therapy, and HIV patient care. The panel was designed to have broad US and international representation for areas with adequate access to antiretroviral management. Study Selection Evidence considered included published basic science, clinical research, and epidemiological data (identified by experts in the field or extracted through MEDLINE searches using terms relevant to antiretroviral therapy) and abstracts from HIV-oriented scientific conferences between July 2002 and May 2004. DataExtraction Data were reviewed to identify any information that might change previous guidelines. Based on panel; discussion, guidelines were drafted by a writing committee and discussed by the panel until consensus was reached. Data Synthesis Four antiretroviral drugs recently have been made available and have broadened the options for initial and subsequent regimens. New data allow more definitive recommendations for specific drugs or regimens to include or avoid, particularly with regard to initial therapy. Recommendations are rated according to 7 evidence categories, ranging from I (data from prospective randomized clinical trials) to VII (expert opinion of the panel). Conclusion Further insights into the roles of drug toxic effects, drug resistance, and pharmacological interactions have resulted in additional guidance for strategic approaches to antiretroviral management. C1 Hop Bichat Claude Bernard, X Bichat Med Sch, Dept Infect Dis, F-75877 Paris 18, France. Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA. Harvard Univ, Sch Med, Dept Immunol & Infect Dis, Boston, MA USA. Univ Alabama, Dept Med, Birmingham, AL 35294 USA. Univ Fed Rio de Janeiro, Dept Prevent Med, Rio De Janeiro, Brazil. Brown Univ, Sch Med, Dept Biomed, Providence, RI 02912 USA. Univ Miami, Sch Med, Dept Med, Miami, FL USA. Univ Barcelona, Dept Med, Barcelona, Spain. Chelsea & Westminster Hosp, Dept HIV Med, London, England. Int AIDS Soc USA, San Francisco, CA USA. Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA. Univ British Columbia, Dept Med, Vancouver, BC, Canada. Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA. Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. San Diego VA Healthcare Syst, San Diego, CA USA. Univ Colorado, Sch Med, Dept Med, Denver, CO USA. AIDS Res Consortium Atlanta, Atlanta, GA USA. Ist Super Sanita, I-00161 Rome, Italy. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RP Yeni, PG (reprint author), Hop Bichat Claude Bernard, X Bichat Med Sch, Dept Infect Dis, 46 Rue Henri Huchard, F-75877 Paris 18, France. EM Patrick.Yeni@Bch.Ap-Hop-Paris.Fr RI Vella, Stefano/D-4912-2015 OI Vella, Stefano/0000-0003-2347-5984 NR 88 TC 413 Z9 440 U1 0 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 14 PY 2004 VL 292 IS 2 BP 251 EP 265 DI 10.1001/jama.292.2.251 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA 836TS UT WOS:000222579300031 PM 15249575 ER PT J AU Vergnes, L Peterfy, M Bergo, MO Young, SG Reue, K AF Vergnes, L Peterfy, M Bergo, MO Young, SG Reue, K TI Lamin B1 is required for mouse development and nuclear integrity SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE nuclear envelope; lamins; knockout mice; gene trapping ID HUTCHINSON-GILFORD-PROGERIA; A-TYPE; INSERTIONAL MUTATIONS; ENVELOPE PROTEINS; BUILDING-BLOCKS; MAMMALIAN-CELLS; DEFICIENT MICE; HUMAN-DISEASE; STEM-CELLS; A/C AB Lamins are key structural components of the nuclear lamina, an intermediate filament meshwork that lies beneath the inner nuclear membrane. Lamins play a role in nuclear architecture, DNA replication, and gene expression. Mutations affecting A-type lamins have been associated with a variety of human diseases, including muscular dystrophy, cardiomyopathy, lipodystrophy, and progeria, but mutations in B-type lamins have never been identified in humans or in experimental animals. To investigate the in vivo function of lamin B1, the major B-type lamin, we generated mice with an insertional mutation in Lmnb1. The mutation resulted in the synthesis of a mutant lamin B1 protein lacking several key functional domains, including a portion of the rod domain, the nuclear localization signal, and the CAAX motif (the carboxyl-terminal signal for farnesylation). Homozygous Lmnb1 mutant mice survived embryonic development but died at birth with defects in lung and bone. Fibroblasts from mutant embryos grew under standard cell-culture conditions but displayed grossly misshapen nuclei, impaired differentiation, increased polyploidy, and premature senescence. Thus, the lamin B1 mutant mice provide evidence for a broad and nonredundant function of lamin B1 in mammalian development. These mutant mice and cell lines derived from them will be useful models for studying the role of the nuclear lamina in various cellular processes. C1 Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90073 USA. Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA. RP Reue, K (reprint author), 11301 Wilshire Blvd,Bldg 113,Room 312, Los Angeles, CA 90073 USA. EM reuek@ucla.edu FU NHLBI NIH HHS [U01 HL66621, U01 HL066621] NR 41 TC 208 Z9 214 U1 0 U2 8 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD JUL 13 PY 2004 VL 101 IS 28 BP 10428 EP 10433 DI 10.1073/pnas.0401424101 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 837TR UT WOS:000222664200034 PM 15232008 ER PT J AU Wilt, TJ Bloomfield, HE MacDonald, R Nelson, D Rutks, I Ho, M Larsen, G McCall, A Pineros, S Sales, A AF Wilt, TJ Bloomfield, HE MacDonald, R Nelson, D Rutks, I Ho, M Larsen, G McCall, A Pineros, S Sales, A TI Effectiveness of statin therapy in adults with coronary heart disease SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID DENSITY-LIPOPROTEIN CHOLESTEROL; RANDOMIZED CONTROLLED TRIAL; SCANDINAVIAN SIMVASTATIN SURVIVAL; PLACEBO-CONTROLLED TRIAL; ARTERY-DISEASE; ANGIOGRAPHIC RESTENOSIS; BALLOON ANGIOPLASTY; CARDIAC EVENTS; USUAL CARE; PRAVASTATIN AB Background: We conducted a meta-analysis of patients with coronary. heart disease (CHD) to determine the effectiveness of statin therapy; whether effectiveness varied according to patient characteristics, outcomes, or pretreatment low-density lipoprotein cholesterol (LDL-C) levels; and the optimal LDL-C goal and the level at which to initiate statin therapy. Methods: Randomized trials or systematic reviews for secondary prevention of CHD with statin therapy published between January 1966 and December 2002 were identified through MEDLINE and the Cochrane Library. Studies were included if they randomly assigned adults with CHD to statin therapy or control, enrolled at least 100 individuals per arm, reported clinical outcomes and LDL-C levels, and were published as full studies in English. Two reviewers abstracted data using a prospectively designed protocol. Results: Twenty-five studies enrolling 69 511 individuals were included. Participants in 19 placebo-controlled trials had a mean age of 63 years and a mean pretreatment LDL-C level of 149 mg/dL (3.85 mmol/L); 23% were women. Statin therapy reduced CHD mortality or non-fatal myocardial infarction 25% (relative risk [RR], 0.75; 95% confidence interval [CI], 0.71-0.79), all-cause mortality 16% (RR, 0.84; 95% CI, 0.79-0.89), and CHD mortality 23% (RR, 0.77; 95% CI, 0.71-0.83). Beneficial effects were seen in women and the elderly. There were no data to determine whether lowering the LDL-C level to less than 100 mg/dL (<2.59 mmol/L) was superior to lowering it to 100 to 130 mg/dL (2.59-3.36 mmol/L) Meta-regression analyses revealed risk reductions for CHD mortality or non-fatal myocardial infarction and major vascular events across available pretreatment LDL-C levels. Conclusion: Statin therapy reduces mortality and morbidity in adults with CHD, even at pretreatment LDL-C levels as low as 100 mg/dL (2.59 mmol/L). C1 Minneapolis VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55417 USA. Denver VA Med Ctr, Denver, CO USA. Portland VA Med Ctr, Dept Cardiol, Portland, OR USA. Univ Virginia, Hlth Syst, Dept Internal Med, Charlottesville, VA USA. VA Puget Sound Hlth Care Syst, Ischem Heart Dis Qual Enhancement Res Initiat, Seattle, WA USA. RP Wilt, TJ (reprint author), Minneapolis VA Med Ctr, Ctr Chron Dis Outcomes Res, 1 Vet Dr,111-0, Minneapolis, MN 55417 USA. EM tim.wilt@med.va.gov RI Sales, Anne/D-9678-2012 OI bloomfield, hanna/0000-0002-0756-7064; Sales, Anne/0000-0001-9360-3334 NR 37 TC 150 Z9 159 U1 0 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JUL 12 PY 2004 VL 164 IS 13 BP 1427 EP 1436 DI 10.1001/archinte.164.13.1427 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 836VM UT WOS:000222583900010 PM 15249352 ER PT J AU Cao, GD Xiao, M Sun, FY Xiao, X Pei, W Li, J Graham, SH Simon, RP Chen, J AF Cao, GD Xiao, M Sun, FY Xiao, X Pei, W Li, J Graham, SH Simon, RP Chen, J TI Cloning of a novel Apaf-1-interacting protein: A potent suppressor of apoptosis and ischemic neuronal cell death SO JOURNAL OF NEUROSCIENCE LA English DT Article DE cerebral ischemia; mitochondria; AAV; Apaf-1; apoptosome; caspase-9 ID FOCAL CEREBRAL-ISCHEMIA; ADENOASSOCIATED VIRUS VECTORS; HIPPOCAMPAL CA1 NEURONS; CENTRAL-NERVOUS-SYSTEM; CYTOCHROME-C RELEASE; CASPASE ACTIVATION; SUPEROXIDE-DISMUTASE; DNA FRAGMENTATION; ENDOGENOUS INHIBITOR; BRAIN-DEVELOPMENT AB Cytochrome c-initiated activation of apoptotic protease activating factor-1 (Apaf-1) is a key step in the mitochondrial-signaling pathway for the activation of death-executing caspases in apoptosis. This signaling pathway has been implicated in the pathophysiology of various neurological disorders, including ischemic brain injury. In this study, we have cloned a novel rat gene product, designated as Apaf-1-interacting protein (AIP), which functions as a dominant-negative inhibitor of the Apaf-1-caspase-9 pathway. AIP is constitutively expressed in the brain, but at substantially lower levels than Apaf-1 and caspase-9. AIP can directly bind to Apaf-1 in vitro through its N-terminal caspase-recruiting domain, and this protein interaction was increased in cells undergoing apoptosis. Cytosolic extracts from cells overexpressing AIP were highly resistant to cytochrome c-dATP-induced activation of caspase-9 and caspase-3. Gene transfection of AIP into cell lines, including the neuronal-differentiated PC12 cells, potently suppressed apoptosis induced by various pro-apoptotic stimuli. To further investigate the functional role of AIP in primary neurons and in the brain, an adeno-associated virus (AAV) vector carrying the AIP cDNA was constructed. AAV-mediated overexpression of AIP in primary cortical-hippocampal neurons markedly reduced cell death and caspase-3 activation triggered by protein kinase C inhibition, DNA damage, or oxygen-glucose deprivation. Moreover, intracerebral infusion of the AAV vector resulted in robust AIP expression in the hippocampus and significantly promoted CA1 neuronal survival after transient global cerebral ischemia. These results suggest that molecular targeting of the Apaf-1-caspase-9 signaling pathway may be a feasible neuroprotective strategy to enhance the endogenous threshold for caspase activation and prevent neuronal loss in stroke and related disorders. C1 Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA. Fudan Univ, Sch Med, Natl Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97232 USA. Oregon Hlth Sci Univ, Dept Physiol, Portland, OR 97232 USA. Oregon Hlth Sci Univ, Dept Pharmacol, Portland, OR 97232 USA. Oregon Hlth Sci Univ, RS Dow Neurobiol Labs, Portland, OR 97232 USA. Vet Affairs Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15261 USA. RP Chen, J (reprint author), Univ Pittsburgh, Dept Neurol, S-507,Biomed Sci Tower, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu FU NINDS NIH HHS [NS35965, NS36736, NS43802, NS45048] NR 57 TC 41 Z9 44 U1 0 U2 2 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD JUL 7 PY 2004 VL 24 IS 27 BP 6189 EP 6201 DI 10.1523/JNEUROSCI.1426-04.2004 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 835NR UT WOS:000222491000017 PM 15240811 ER PT J AU Stadius, ML AF Stadius, ML TI Diminishing returns... and too many choices... the saga of pharmacologic therapy to reduce the complications of percutaneous coronary intervention SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Editorial Material ID GLYCOPROTEIN-IIB/IIIA BLOCKADE; RANDOMIZED CONTROLLED TRIAL; PLATELET-AGGREGATION; ARTERY STENTS; CLOPIDOGREL; ANGIOPLASTY; ASPIRIN; TICLOPIDINE; PRETREATMENT; HEPARIN C1 Vet Adm Med Ctr, VA Puget Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98108 USA. RP Stadius, ML (reprint author), Vet Adm Med Ctr, VA Puget Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM michael.stadius@med.va.gov NR 33 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JUL 7 PY 2004 VL 44 IS 1 BP 25 EP 27 DI 10.1016/j.jacc.2004.04.010 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 834OX UT WOS:000222421500005 PM 15234400 ER PT J AU Snow, V Barry, P Fihn, SD Gibbons, RJ Owens, DK Williams, SV Weiss, KB Mottur-Pilson, C AF Snow, V Barry, P Fihn, SD Gibbons, RJ Owens, DK Williams, SV Weiss, KB Mottur-Pilson, C CA ACP ACC Chronic Stable Angina TI Evaluation of primary care patients with chronic stable angina: Guidelines from the American College of Physicians SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID BUNDLE-BRANCH BLOCK; CORONARY-ARTERY-DISEASE; EMISSION COMPUTED-TOMOGRAPHY; DOBUTAMINE STRESS ECHOCARDIOGRAPHY; DIPYRIDAMOLE TL-201 SCINTIGRAPHY; INCREMENTAL PROGNOSTIC VALUE; ASSOCIATION TASK-FORCE; TREADMILL SCORE; EXERCISE STRESS; RISK AB In 1999, the American College of Physicians (ACP) then the American College of Physicians-American Society of Internal Medicine, and the American College of Cardiology/American Heart Association (ACC/AHA) developed joint guidelines on the management of patients with chronic stable angina. The ACC/AHA then published an updated guideline in 2002, which the ACP recognized as a scientifically valid review of the evidence and background paper. This ACP guideline summarizes the recommendations of the 2002 ACC/AHA updated guideline and underscores the recommendations most likely to be important to physicians seeing patients in the primary care setting. This guideline is the first of 2 that will provide guidance on the management of patients with chronic stable angina. This document will cover diagnosis and risk stratification for symptomatic patients who have not had an acute myocardial infarction or revascularization procedure in the previous 6 months. Sections addressing asymptomatic patients are also included. Asymptomatic refers to patients with known or suspected coronary disease based on history or on electrocardiographic evidence of previous myocardial infarction, coronary angiography, or abnormal results on noninvasive tests. A future guideline will cover pharmacologic therapy and follow-up. C1 Amer Coll Physicians, Philadelphia, PA 19106 USA. Univ Penn, Philadelphia, PA 19104 USA. Merck Inst Aging & Hlth, Washington, DC USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA. Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. Edward Hines Jr Vet Adm Hosp, Chicago, IL USA. Northwestern Univ, Chicago, IL 60611 USA. RP Snow, V (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA. EM vincenza@acponline.org NR 36 TC 29 Z9 30 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUL 6 PY 2004 VL 141 IS 1 BP 57 EP 64 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 834RF UT WOS:000222427600008 PM 15238371 ER PT J AU Ledergerber, B Lundgren, JD Walker, AS Sabin, C Justice, A Reiss, P Mussini, C Wit, F Monforte, AD Weber, R Fusco, G Staszewski, S Law, M Hogg, R Lampe, F Gill, MJ Castelli, F Phillips, AN Castelli, F Fusco, GP Gill, MJ Hogg, R Lampe, F Law, M Ledergerber, B Lundgren, JD Monforte, AD Mussini, C Phillips, AN Reiss, P Staszewski, S Walker, AS Rooney, P Taylor, S Couldwell, D Austin, D Block, M Clemons, J Finlayson, R Law, M Petoumenos, K Quan, D Smith, D O'Connor, C Gorton, C Allen, D Mulhall, B Mutimer, K Smith, D Keeffe, N Cooper, D Carr, A Miller, J Pell, C Ellis, D Baker, D Kidd, J McFarlane, R Liang, MT Brown, K Huffam, S Savage, J Morgan, S Knibbs, P Sowden, D Walker, A Orth, D Lister, G Chuah, J Fankhauser, W Dickson, B Bradford, D Wilson, C Ree, H Magon, H Anderson, J Moore, R Russell, D McGovern, G McNair, R Bal, J Fairley, K Roth, N Eu, B Strecker, S Russell, D Wood, H Mijch, A Hoy, J Pierce, A McCormack, C Watson, K Medland, N Daye, J Mallal, S French, M Skett, J Maxwel, D Cain, A Montroni, M Scalise, G Costantini, A Giacometti, A Tirelli, U Nasti, G Pastore, G Ladisa, N Perulli, ML Suter, F Arici, C Chiodo, F Gritti, FM Colangeli, V Fiorini, C Guerra, L Carosi, G Cadeo, GP Castelli, F Minardi, C Vangi, D Rizzardini, G Migliorino, G Manconi, PE Piano, P Ferraro, T Scerbo, A Pizzigallo, E Ricci, F Santoro, D Pusterla, L Carnevale, G Galloni, D Vigano, P Mena, M Ghinelli, F Sighinolfi, L Leoncini, F Mazzotta, F Pozzi, M Lo Caputo, S Angarano, G Grisorio, B Ferrara, S Grima, P Tundo, P Pagano, G Piersantelli, N Alessandrini, A Piscopo, R Toti, M Chigiotti, S Soscia, F Taccooni, L Orani, A Perini, P Scasso, A Vincenti, A Scalzini, A Fibbia, G Moroni, M Lazzarin, A Cargnel, A Vigevani, GM Caggese, L Monforte, AD Tordato, F Novati, R Galli, A Merli, S Pastecchia, C Moioli, C Esposito, R Mussini, C Abrescia, N Chirianni, A Izzo, C Piazza, M De Marco, M Montesarchio, V Manzillo, E Nappa, S Colomba, A Abbadessa, V Prestileo, T Mancuso, S Ferrari, C Pzzaferri, P Filice, G Minoli, L Bruno, R Maserati, R Pauluzzi, S Baldelli, F Petrelli, E Cioppi, A Alberici, F Ruggieri, A Menichetti, F Martinelli, C De Stefano, C La Gala, A Zauli, T Ballardini, G Magnani, G Ursitti, MA Arlotti, M Ortolani, P Ortona, L Dianzani, F Ippolito, G Antinori, A Antonucci, G D'Elia, S Narciso, P Petrosillo, N Vullo, V De Luca, A Del Forno, L Zaccarelli, M De Longis, P Ciardi, M D'Offizi, G Noto, P Lichtner, M Capobianchi, MR Girardi, E Pezzotti, P Rezza, G Mura, MS Mannazzu, M Caramello, P Sinicco, A Soranzo, ML Gennero, L Sciandra, M Salassa, B Grossi, PA Basilico, C Poggio, A Bottari, G Raise, E Pasquinucci, S De Lalla, F Tositti, G Resta, F Chimienti, A Lepri, AC Bachmann, S Battegay, M Bernasconi, E Bucher, H Burgisser, P Cattacin, S Egger, M Erb, P Fierz, W Fischer, M Flepp, M Fontana, A Francioli, P Furrer, HJ Gorgievski, M Hirschel, B Kaiser, L Kind, C Klimkait, T Ledergerber, B Lauper, U Opravil, M Paccaud, F Pantaleo, G Perrin, L Piffaretti, JC Rickenbach, M Rudin, C Schupbach, J Speck, R Tarr, P Telenti, A Trkola, A Vernazza, P Weber, R Yerly, S de Wolf, F van Sighem, AI van Valkengoed, I Gras, L Bronsveld, W Prins, JM Bos, JC Schattenkerk, JKME Godfried, MH Lange, JMA Lowe, SH van der Meer, JTM Nellen, FJB Pogany, K van der Poll, T Reiss, P Ruys, TA Sankatsing, S van der Valk, M van Vonderen, MGA Wit, FWMN van Eeden, A ten Veen, JH van Dam, PS Hillebrand-Haverkort, ME Brinkman, K Frissen, PHJ Weigel, HM Mulder, JW van Gorp, ECM Meenhorst, PL Mairuhu, ATA Veenstra, J Danner, SA Van Agtmael, MA Claessen, FAP Geerlings, SE Perenboom, RM Richter, C van der Berg, J van Leusen, R Vriesendorp, R Jeurissen, FJF Kauffmann, RH Koger, ELW Bravenboer, B ten Napel, CHH Mudrikova, T Sprenger, HG Miesen, WMAJ ten Kate, RW van Houte, DPF Leemhuis, MP Pole, M Kroon, FP Schippers, EF Schreij, G van de Geest, S Verbon, A Koopmans, PP Telgt, M van der Ven, AJAM van der Ende, ME Gyssens, IC de Marie, S Nouwen, JL Juttmann, JR Schneider, MME Bonten, MJM Borleffs, JCC Hoepelman, IM Jaspers, CAJJ Schouten, I Schurink, CAM Blok, WL Groenveld, PHP Jurriaans, S Back, NKT Cuijpers, T Rietra, PJGM Roozendaal, KJ Pauw, W van Zanten, AP Smits, PHM von Blomberg, BME Savelkoul, P Zaaijer, H Swanink, C Franck, PFH Lampe, AS Jansen, CL Hendriks, R Schirm, J Benne, D Veenendaal, D Storm, H van Zeijl, JH Kroes, ACM Claas, HCJ Bruggeman, CAMVA Goossens, VJ Galama, JMD Poort, YAGM Niesters, MG Osterhaus, ADME Schutten, M Buiting, AGM Swaans, CAM Boucher, CAB Schuurman, R Boel, E Jansz, AF Veldkamp, A Beijnen, JH Crommentuyn, KML Huitema, ADR Kappelhoff, B de Maat, MMR Burger, DM Hugen, PWH Dabis, F Thiebaut, R Chene, G Lawson-Ayayi, S Meyer, L Boufassa, F Hamouda, O Pezzotti, P Rezza, G Touloumi, G Hatzakis, A Karafoulidou, A Katsarou, O Brettle, R Del Amo, J del Romero, J van Asten, L van Benthem, B Prins, M Coutinho, R Kirk, O Pedersen, C Aguado, IH Perez-Hoyos, S Eskild, A Bruun, JN Sannes, M Sabin, C Lee, C Johnson, AM Phillips, AN Babiker, A Darbyshire, J Gill, N Porter, K Francioli, P Vanhems, P Egger, M Rickenbach, M Cooper, D Kaldor, J Ashton, L Cooper, D Kaldor, J Ashton, L Cooper, D Vizzard, J Muga, R Vanhems, P Gill, J Cayla, J de Olalla, PG Day, NE De Angelis, D Porter, K Babiker, A Walker, S Darbyshire, J Tyrer, F Beral, V Coutinho, R Darbyshire, J Del Amo, J Gill, N Lee, C Meyer, L Rezza, G Raffanti, S Becker, S Scarsella, A Braun, J Justice, A Fusco, G Most, B Balu, R Gilbert, L Fleenor, R Ising, T Dieterich, D Fusco, J Losso, M Duran, A Vetter, N Clumeck, N De Wit, S Kabeya, K Poll, B Colebunders, R Machala, L Rozsypal, H Nielsen, J Lundgren, J Kirk, O Olsen, CH Gerstoft, J Katzenstein, T Hansen, ABE Skinhoj, P Pedersen, C Zilmer, K Rauka, M Katlama, C De Sa, M Viard, JP Saint-Marc, T Vanhems, P Pradier, C Dietrich, M Manegold, C van Lunzen, J Stellbrink, HJ Miller, V Staszewski, S Goebel, FD Salzberger, B Rockstroh, J Kosmidis, J Gargalianos, P Sambatakou, H Perdios, J Panos, G Filandras, A Banhegyi, D Mulcahy, F Yust, I Burke, M Pollack, S Hassoun, J Sthoeger, Z Maayan, S Vella, S Chiesi, A Arici, C Pristera, R Mazzotta, F Gabbuti, A Esposito, R Bedini, A Chirianni, A Montesarchio, E Vullo, V Santopadre, P Narciso, P Antinori, A Franci, P Zaccarelli, M Lazzarin, A Castagna, A Monforte, AD Viksna, L Rozentale, B Chaplinskas, S Hemmer, R Staub, T Reiss, P Bruun, J Maeland, A Ormaasen, V Knysz, B Gasiorowski, J Horban, A Prokopowicz, D Wiercinska-Drapalo, A Boron-Kaczmarska, A Pynka, M Beniowski, M Trocha, H Smiatacz, T Antunes, F Mansinho, K Maltez, F Duiculescu, D Streinu-Cercel, A Mokras, M Stanekova, D Gonzalez-Lahoz, J Diaz, B Garcia-Benayas, T Martin-Carbonero, L Soriano, V Clotet, B Jou, A Conejero, J Tural, C Gatell, JM Miro, JM Zamora, L Blaxhult, A Karlsson, A Pehrson, P Ledergerber, B Weber, R Francioli, P Hirschel, B Schiffer, V Furrer, H Chentsova, N Barton, S Johnson, AM Mercey, D Phillips, A Youle, M Johnson, MA Mocroft, A Murphy, M Weber, J Scullard, G Fisher, M Brettle, R Loveday, C Clotet, B Ruiz, L Staszewski, S Helm, EB Carlebach, A Mosch, M Muller, A Haberl, A Korn, S Stephan, C Bickel, M Gute, P Locher, L Lutz, T Klauke, S Doerr, HW Sturmer, M Sabin, C Dauer, B Jennings, B Alexander, C Braitstein, P Chan, K Cote, H Gataric, N Harrigan, PR Harris, M Bonner, S Hogg, R Montaner, J O'Shaughnessy, M Wood, E Yip, B Lampe, F Chaloner, C Gumley, H Ransom, D Sabin, CA Mocroft, A Lipman, M Phillips, AN Youle, M Johnson, M Gill, J Read, R Carosi, G Castelli, F Paraninfo, G Casari, S Pan, A Patroni, A Torti, C Quiros-Roldan, E Tomasoni, L Moretti, F Nasta, P Uccelli, MC Cadeo, GP Bertelli, D Orani, A Perini, P Nigro, M Rizzardini, G Migliorino, M Abeli, C Mazzotta, F Suter, F Maggiolo, F Arici, C Ghinelli, F Sighinolfi, L Minoli, L Maserati, R Novati, S Tinelli, C Pastore, G Ladisa, N Carnevale, G Poggio, A Riccio, G Mussini, C Borghi, V Bedini, A Esposito, R AF Ledergerber, B Lundgren, JD Walker, AS Sabin, C Justice, A Reiss, P Mussini, C Wit, F Monforte, AD Weber, R Fusco, G Staszewski, S Law, M Hogg, R Lampe, F Gill, MJ Castelli, F Phillips, AN Castelli, F Fusco, GP Gill, MJ Hogg, R Lampe, F Law, M Ledergerber, B Lundgren, JD Monforte, AD Mussini, C Phillips, AN Reiss, P Staszewski, S Walker, AS Rooney, P Taylor, S Couldwell, D Austin, D Block, M Clemons, J Finlayson, R Law, M Petoumenos, K Quan, D Smith, D O'Connor, C Gorton, C Allen, D Mulhall, B Mutimer, K Smith, D Keeffe, N Cooper, D Carr, A Miller, J Pell, C Ellis, D Baker, D Kidd, J McFarlane, R Liang, MT Brown, K Huffam, S Savage, J Morgan, S Knibbs, P Sowden, D Walker, A Orth, D Lister, G Chuah, J Fankhauser, W Dickson, B Bradford, D Wilson, C Ree, H Magon, H Anderson, J Moore, R Russell, D McGovern, G McNair, R Bal, J Fairley, K Roth, N Eu, B Strecker, S Russell, D Wood, H Mijch, A Hoy, J Pierce, A McCormack, C Watson, K Medland, N Daye, J Mallal, S French, M Skett, J Maxwel, D Cain, A Montroni, M Scalise, G Costantini, A Giacometti, A Tirelli, U Nasti, G Pastore, G Ladisa, N Perulli, ML Suter, F Arici, C Chiodo, F Gritti, FM Colangeli, V Fiorini, C Guerra, L Carosi, G Cadeo, GP Castelli, F Minardi, C Vangi, D Rizzardini, G Migliorino, G Manconi, PE Piano, P Ferraro, T Scerbo, A Pizzigallo, E Ricci, F Santoro, D Pusterla, L Carnevale, G Galloni, D Vigano, P Mena, M Ghinelli, F Sighinolfi, L Leoncini, F Mazzotta, F Pozzi, M Lo Caputo, S Angarano, G Grisorio, B Ferrara, S Grima, P Tundo, P Pagano, G Piersantelli, N Alessandrini, A Piscopo, R Toti, M Chigiotti, S Soscia, F Taccooni, L Orani, A Perini, P Scasso, A Vincenti, A Scalzini, A Fibbia, G Moroni, M Lazzarin, A Cargnel, A Vigevani, GM Caggese, L Monforte, AD Tordato, F Novati, R Galli, A Merli, S Pastecchia, C Moioli, C Esposito, R Mussini, C Abrescia, N Chirianni, A Izzo, C Piazza, M De Marco, M Montesarchio, V Manzillo, E Nappa, S Colomba, A Abbadessa, V Prestileo, T Mancuso, S Ferrari, C Pzzaferri, P Filice, G Minoli, L Bruno, R Maserati, R Pauluzzi, S Baldelli, F Petrelli, E Cioppi, A Alberici, F Ruggieri, A Menichetti, F Martinelli, C De Stefano, C La Gala, A Zauli, T Ballardini, G Magnani, G Ursitti, MA Arlotti, M Ortolani, P Ortona, L Dianzani, F Ippolito, G Antinori, A Antonucci, G D'Elia, S Narciso, P Petrosillo, N Vullo, V De Luca, A Del Forno, L Zaccarelli, M De Longis, P Ciardi, M D'Offizi, G Noto, P Lichtner, M Capobianchi, MR Girardi, E Pezzotti, P Rezza, G Mura, MS Mannazzu, M Caramello, P Sinicco, A Soranzo, ML Gennero, L Sciandra, M Salassa, B Grossi, PA Basilico, C Poggio, A Bottari, G Raise, E Pasquinucci, S De Lalla, F Tositti, G Resta, F Chimienti, A Lepri, AC Bachmann, S Battegay, M Bernasconi, E Bucher, H Burgisser, P Cattacin, S Egger, M Erb, P Fierz, W Fischer, M Flepp, M Fontana, A Francioli, P Furrer, HJ Gorgievski, M Hirschel, B Kaiser, L Kind, C Klimkait, T Ledergerber, B Lauper, U Opravil, M Paccaud, F Pantaleo, G Perrin, L Piffaretti, JC Rickenbach, M Rudin, C Schupbach, J Speck, R Tarr, P Telenti, A Trkola, A Vernazza, P Weber, R Yerly, S de Wolf, F van Sighem, AI van Valkengoed, I Gras, L Bronsveld, W Prins, JM Bos, JC Schattenkerk, JKME Godfried, MH Lange, JMA Lowe, SH van der Meer, JTM Nellen, FJB Pogany, K van der Poll, T Reiss, P Ruys, TA Sankatsing, S van der Valk, M van Vonderen, MGA Wit, FWMN van Eeden, A ten Veen, JH van Dam, PS Hillebrand-Haverkort, ME Brinkman, K Frissen, PHJ Weigel, HM Mulder, JW van Gorp, ECM Meenhorst, PL Mairuhu, ATA Veenstra, J Danner, SA Van Agtmael, MA Claessen, FAP Geerlings, SE Perenboom, RM Richter, C van der Berg, J van Leusen, R Vriesendorp, R Jeurissen, FJF Kauffmann, RH Koger, ELW Bravenboer, B ten Napel, CHH Mudrikova, T Sprenger, HG Miesen, WMAJ ten Kate, RW van Houte, DPF Leemhuis, MP Pole, M Kroon, FP Schippers, EF Schreij, G van de Geest, S Verbon, A Koopmans, PP Telgt, M van der Ven, AJAM van der Ende, ME Gyssens, IC de Marie, S Nouwen, JL Juttmann, JR Schneider, MME Bonten, MJM Borleffs, JCC Hoepelman, IM Jaspers, CAJJ Schouten, I Schurink, CAM Blok, WL Groenveld, PHP Jurriaans, S Back, NKT Cuijpers, T Rietra, PJGM Roozendaal, KJ Pauw, W van Zanten, AP Smits, PHM von Blomberg, BME Savelkoul, P Zaaijer, H Swanink, C Franck, PFH Lampe, AS Jansen, CL Hendriks, R Schirm, J Benne, D Veenendaal, D Storm, H van Zeijl, JH Kroes, ACM Claas, HCJ Bruggeman, CAMVA Goossens, VJ Galama, JMD Poort, YAGM Niesters, MG Osterhaus, ADME Schutten, M Buiting, AGM Swaans, CAM Boucher, CAB Schuurman, R Boel, E Jansz, AF Veldkamp, A Beijnen, JH Crommentuyn, KML Huitema, ADR Kappelhoff, B de Maat, MMR Burger, DM Hugen, PWH Dabis, F Thiebaut, R Chene, G Lawson-Ayayi, S Meyer, L Boufassa, F Hamouda, O Pezzotti, P Rezza, G Touloumi, G Hatzakis, A Karafoulidou, A Katsarou, O Brettle, R Del Amo, J del Romero, J van Asten, L van Benthem, B Prins, M Coutinho, R Kirk, O Pedersen, C Aguado, IH Perez-Hoyos, S Eskild, A Bruun, JN Sannes, M Sabin, C Lee, C Johnson, AM Phillips, AN Babiker, A Darbyshire, J Gill, N Porter, K Francioli, P Vanhems, P Egger, M Rickenbach, M Cooper, D Kaldor, J Ashton, L Cooper, D Kaldor, J Ashton, L Cooper, D Vizzard, J Muga, R Vanhems, P Gill, J Cayla, J de Olalla, PG Day, NE De Angelis, D Porter, K Babiker, A Walker, S Darbyshire, J Tyrer, F Beral, V Coutinho, R Darbyshire, J Del Amo, J Gill, N Lee, C Meyer, L Rezza, G Raffanti, S Becker, S Scarsella, A Braun, J Justice, A Fusco, G Most, B Balu, R Gilbert, L Fleenor, R Ising, T Dieterich, D Fusco, J Losso, M Duran, A Vetter, N Clumeck, N De Wit, S Kabeya, K Poll, B Colebunders, R Machala, L Rozsypal, H Nielsen, J Lundgren, J Kirk, O Olsen, CH Gerstoft, J Katzenstein, T Hansen, ABE Skinhoj, P Pedersen, C Zilmer, K Rauka, M Katlama, C De Sa, M Viard, JP Saint-Marc, T Vanhems, P Pradier, C Dietrich, M Manegold, C van Lunzen, J Stellbrink, HJ Miller, V Staszewski, S Goebel, FD Salzberger, B Rockstroh, J Kosmidis, J Gargalianos, P Sambatakou, H Perdios, J Panos, G Filandras, A Banhegyi, D Mulcahy, F Yust, I Burke, M Pollack, S Hassoun, J Sthoeger, Z Maayan, S Vella, S Chiesi, A Arici, C Pristera, R Mazzotta, F Gabbuti, A Esposito, R Bedini, A Chirianni, A Montesarchio, E Vullo, V Santopadre, P Narciso, P Antinori, A Franci, P Zaccarelli, M Lazzarin, A Castagna, A Monforte, AD Viksna, L Rozentale, B Chaplinskas, S Hemmer, R Staub, T Reiss, P Bruun, J Maeland, A Ormaasen, V Knysz, B Gasiorowski, J Horban, A Prokopowicz, D Wiercinska-Drapalo, A Boron-Kaczmarska, A Pynka, M Beniowski, M Trocha, H Smiatacz, T Antunes, F Mansinho, K Maltez, F Duiculescu, D Streinu-Cercel, A Mokras, M Stanekova, D Gonzalez-Lahoz, J Diaz, B Garcia-Benayas, T Martin-Carbonero, L Soriano, V Clotet, B Jou, A Conejero, J Tural, C Gatell, JM Miro, JM Zamora, L Blaxhult, A Karlsson, A Pehrson, P Ledergerber, B Weber, R Francioli, P Hirschel, B Schiffer, V Furrer, H Chentsova, N Barton, S Johnson, AM Mercey, D Phillips, A Youle, M Johnson, MA Mocroft, A Murphy, M Weber, J Scullard, G Fisher, M Brettle, R Loveday, C Clotet, B Ruiz, L Staszewski, S Helm, EB Carlebach, A Mosch, M Muller, A Haberl, A Korn, S Stephan, C Bickel, M Gute, P Locher, L Lutz, T Klauke, S Doerr, HW Sturmer, M Sabin, C Dauer, B Jennings, B Alexander, C Braitstein, P Chan, K Cote, H Gataric, N Harrigan, PR Harris, M Bonner, S Hogg, R Montaner, J O'Shaughnessy, M Wood, E Yip, B Lampe, F Chaloner, C Gumley, H Ransom, D Sabin, CA Mocroft, A Lipman, M Phillips, AN Youle, M Johnson, M Gill, J Read, R Carosi, G Castelli, F Paraninfo, G Casari, S Pan, A Patroni, A Torti, C Quiros-Roldan, E Tomasoni, L Moretti, F Nasta, P Uccelli, MC Cadeo, GP Bertelli, D Orani, A Perini, P Nigro, M Rizzardini, G Migliorino, M Abeli, C Mazzotta, F Suter, F Maggiolo, F Arici, C Ghinelli, F Sighinolfi, L Minoli, L Maserati, R Novati, S Tinelli, C Pastore, G Ladisa, N Carnevale, G Poggio, A Riccio, G Mussini, C Borghi, V Bedini, A Esposito, R CA PLATO Collaboration TI Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes SO LANCET LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED INDIVIDUALS; BLIND CONTROLLED-TRIAL; CLINICAL PROGRESSION; DISEASE PROGRESSION; HAART REGIMEN; VIRAL LOAD; THERAPY; COHORT; INHIBITOR AB Background Treatment strategies for patients in whom HIV replication is not suppressed after exposure to several drug classes remain unclear. We aimed to assess the inter-relations between viral load, CD4-cell count, and clinical outcome in patients who had experienced three-class virological failure. Methods We undertook collaborative joint analysis of 13 HIV cohorts from Europe, North America, and Australia, involving patients who had had three-class virological failure (viral load >1000 copies per mL for >4 months). Regression analyses were used to quantify the associations between CD4-cell-count slope, HIV-1 RNA concentration, treatment information, and demographic characteristics. Predictors of death were analysed by Cox's proportional-hazards models. Findings 2488 patients were included. 2118 (85%) had started antiretroviral therapy with single or dual therapy. During 5015 person-years of follow-up, 276 patients died (mortality rate 5.5 per 100 person-years; 3-year mortality risk 15.3% (95% Cl 13.5-17.3). Risk of death was strongly influenced by the latest CD4-cell count with a relative hazard of 15.8 (95% CI 9.28-27.0) for counts below 50 cells per muL versus above 200 cells per muL. The latest viral load did not independently predict death. For any given viral load, patients on treatment had more favourable CD4-cell-count slopes than those off treatment. For patients on treatment and with stable viral load, CD4-cell counts tended to be increasing at times when the current viral load was below 10 000 copies per mL or 1.5 log(10) copies per mL below off-treatment values. Interpretation In patients for whom viral-load suppression to below the level of detection is not possible, achievement and maintenance of a CD4-cell count above 200 per muL becomes the primary aim. Treatment regimens that maintain the viral load below 10 000 copies per mL or at least provide 1.5 log(10) copies per mL suppression below the off-treatment value do not seem to be associated with appreciable CD4-cell-count decline. C1 Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, CH-8091 Zurich, Switzerland. Hvidovre Univ Hosp, Copenhagen HIV Programme, DK-2650 Hvidovre, Denmark. MRC, Clin Trials Unit, London, England. UCL Royal Free & Univ Coll Med Sch, London, England. VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands. Natl AIDS Therapy Evaluat Ctr, Amsterdam, Netherlands. Univ Modena, Clin Infect Dis, I-41100 Modena, Italy. Int Antiviral Therapy Evaluat Ctr, Amsterdam, Netherlands. Univ Milan, Inst Infect Dis, Milan, Italy. GlaxoSmithKline Inc, Res Triangle Pk, NC USA. Goethe Univ Frankfurt, D-6000 Frankfurt, Germany. Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Darlinghurst, NSW, Australia. Univ British Columbia, BC Ctr Excellence HIV AIDS, Vancouver, BC V5Z 1M9, Canada. So Alberta Clin, Calgary, AB, Canada. Univ Brescia, Inst Infect & Trop Dis, Brescia, Italy. RP Ledergerber, B (reprint author), Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Ramistr 100, CH-8091 Zurich, Switzerland. EM infled@usz.unizh.ch RI Klimkait, Thomas/A-1057-2008; Back, Nicole/K-3884-2013; Burger, David/C-9929-2013; Stephan, Christoph/D-1305-2014; Sabin, Caroline/C-2464-2008; Castelli, Francesco/E-7045-2010; Phillips, Andrew/B-4427-2008; Mocroft, Amanda/G-8748-2011; Panos, George/H-3944-2011; Infektiologie, USZ/A-6921-2011; SHCS, all/G-4072-2011; Hogg, Robert/B-2783-2012; Beral, Valerie/B-2979-2013; Kaldor, John /D-4545-2011; SHCS, int. coll. A/G-4083-2011; chene, genevieve/H-8665-2014; Weber, Rainer/D-5175-2012; Furrer, Hansjakob/G-6768-2013; Perez-Hoyos, Santiago/E-2370-2012; Ven, A.J.A.M./H-8102-2014; Gyssens, I.C.J./L-4343-2015; REZZA, GIOVANNI/D-4393-2016; Vella, Stefano/D-4912-2015; Gill, John/G-7083-2016; Pantaleo, Giuseppe/K-6163-2016; Rizzardini, Giuliano/K-9458-2016; Ledergerber, Bruno/B-5656-2009; DEL AMO VALERO, JULIA/M-7020-2015; van Valkengoed, Irene/B-2974-2013 OI Stephan, Christoph/0000-0003-3777-9006; Phillips, Andrew/0000-0003-2384-4807; Furrer, Hansjakob/0000-0002-1375-3146; Perez-Hoyos, Santiago/0000-0001-9797-4917; REZZA, GIOVANNI/0000-0003-0268-6790; Vella, Stefano/0000-0003-2347-5984; Gill, John/0000-0002-8546-8790; Rizzardini, Giuliano/0000-0002-5183-7818; Ledergerber, Bruno/0000-0002-6881-4401; DEL AMO VALERO, JULIA/0000-0002-3104-540X; van Valkengoed, Irene/0000-0002-9306-7831; Anderson, Jane/0000-0001-5294-8707; Tyrer, Freya/0000-0003-2877-4342; Antunes, Francisco/0000-0001-7932-1154; Lundgren, Jens/0000-0001-8901-7850; Bruno, Raffaele/0000-0002-0235-9207; petrosillo, nicola/0000-0002-2585-7567; ANGARANO, Gioacchino/0000-0003-3207-7523; Hogg, Robert/0000-0003-3463-5488; Capobianchi, Maria Rosaria/0000-0003-3465-0071; Diaz-Pollan, Beatriz/0000-0002-7241-4208; Streinu-Cercel, Adrian/0000-0001-6382-5067 FU Medical Research Council [MC_U122886351] NR 47 TC 211 Z9 216 U1 3 U2 39 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD JUL 3 PY 2004 VL 364 IS 9428 BP 51 EP 62 DI 10.1016/S0140-6736(04)16589-6 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 834DX UT WOS:000222392900031 PM 15234856 ER PT J AU Zhang, L Keane, MP Zhu, LX Sharma, S Rozengurt, E Strieter, RM Dubinett, SM Huang, M AF Zhang, L Keane, MP Zhu, LX Sharma, S Rozengurt, E Strieter, RM Dubinett, SM Huang, M TI Interleukin-7 and transforming growth factor-beta play counter-regulatory roles in protein kinase C-delta-dependent control of fibroblast collagen synthesis in pulmonary fibrosis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID RECEPTOR-GAMMA-CHAIN; GENE-EXPRESSION; MESSENGER-RNA; ACTIVATION; PATHWAY; SMAD3; CELLS; CD40; IL-2 AB Transforming growth factor-beta (TGF-beta) is a potent fibrogenic factor responsible for promoting synthesis of extracellular matrix. Interleukin-7 (IL-7) inhibits TGF-beta signaling by up-regulating Smad7, a major inhibitor of the Smad family. In a variety of cells, TGF-beta-mediated activation of target genes requires active protein kinase C-delta (PKC-delta) in addition to Smads (1). We determined the role of PKC-delta in the regulation of pulmonary fibroblast collagen synthesis in response to TGF-beta and IL-7 stimulation. Here we show that TGF-beta and IL-7 have opposing effects on PKC-delta; TGF-beta stimulates, while IL-7 inhibits, PKC-delta activity. IL-7 inhibits TGF-beta-induced PKC-delta phosphorylation at Ser-645 and Thr-505. Inhibition of PKC-delta with specific small inhibitory RNA restores TGF-beta-mediated induction of Smad7 and in parallel significantly reduces TGF-beta-mediated collagen synthesis. Thus, PKC-delta may play a critical role in the pathogenesis of pulmonary fibrosis and may serve as a molecular target for therapeutic intervention to suppress fibrosis. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. RP Huang, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. EM minhuang@mednet.ucla.edu FU NCI NIH HHS [R01 CA 085686, P50 CA 90388]; NHLBI NIH HHS [P01 HL 03906, P50 HL 67665] NR 21 TC 36 Z9 44 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JUL 2 PY 2004 VL 279 IS 27 BP 28315 EP 28319 DI 10.1074/jbc.C400115200 PG 5 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 832KC UT WOS:000222265400063 PM 15133032 ER PT J AU Satre, DD Knight, BG Dickson-Fuhrmann, E Jarvik, LF AF Satre, DD Knight, BG Dickson-Fuhrmann, E Jarvik, LF TI Substance abuse treatment initiation among older adults in the GET SMART program: effects of depression and cognitive status SO AGING & MENTAL HEALTH LA English DT Article ID MINI-MENTAL-STATE; PROBLEM DRINKERS; ALCOHOLISM-TREATMENT; BEHAVIORAL TREATMENT; CAGE QUESTIONNAIRE; EARLY-ONSET; DRINKING; SEEKING; POPULATION; VETERANS AB This study examines how individual patient characteristics predict substance abuse treatment initiation among older adults, in an investigation based on the behavioral health service use model. Analyses tested the impact of demographic factors, substance abuse symptoms, depression and cognitive status on subsequent treatment initiation. The sample included 250 older male veterans screened for substance abuse problems during inpatient medical treatment, who also participated in a clinical evaluation for substance abuse treatment. Measures included demographics and CAGE alcohol screening score. A subset of patients also completed the Michigan Alcohol Screening Test-Geriatric Version (MAST-G), Hamilton Depression Scale (HAM-D), and Folstein Mini Mental State Exam (MMSE). Patients who initiated treatment following evaluation had more years of education, better cognitive status, and more symptoms of substance abuse and depression, compared with patients who did not initiate treatment. In logistic regression analysis, CAGE and MMSE scores independently predicted treatment initiation. Findings contribute to the understanding of how clinical characteristics of older adults affect substance abuse treatment initiation. C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Kaiser Permanente Div Res, Oakland, CA USA. Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA. VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Satre, DD (reprint author), Univ Calif San Francisco, 401 Parnassus Ave,Box 0984-OVS, San Francisco, CA 94143 USA. EM dereks@lppi.ucsf.edu FU NIA NIH HHS [2-T32-AG00037]; NIDA NIH HHS [P50 DA09253, T32 DA07250] NR 37 TC 11 Z9 11 U1 1 U2 2 PU CARFAX PUBLISHING PI BASINGSTOKE PA RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND SN 1360-7863 J9 AGING MENT HEALTH JI Aging Ment. Health PD JUL PY 2004 VL 8 IS 4 BP 346 EP 354 DI 10.1080/13607860410001709692 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 839KO UT WOS:000222784200006 PM 15370050 ER PT J AU Kim, SG Kim, CM Kang, DH Kim, YJ Byun, WT Kim, SY Park, JM Kim, MJ Oslin, DW AF Kim, SG Kim, CM Kang, DH Kim, YJ Byun, WT Kim, SY Park, JM Kim, MJ Oslin, DW TI Association of functional opioid receptor genotypes with alcohol dependence in Koreans SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE alcohol dependence; mu-opioid receptor; polymorphism ID GENE POLYMORPHISMS; SUBSTANCE DEPENDENCE; BETA-ENDORPHIN; NALTREXONE; OPRM1; RISK; ETHANOL; SENSITIVITY; RESPONSES; BLOCKADE AB Background: The functional polymorphism (A118G) of the mu-opioid receptor gene (OPRM1) is thought to have clinical significance in the treatment of alcohol dependence. This study compared Koreans with one or two copies of the A118G polymorphism seeking treatment for alcohol dependence with a group of non-alcohol-dependent controls. Methods: Patients hospitalized for alcohol dependence (n = 112) and a group of non-alcohol-dependent controls (n = 140) were interviewed on aspects of drinking history and psychiatric history. Patients and controls were excluded if they met criteria for any other major psychiatric disorder. Participants were genotyped at the OPRM1 locus. Results: The allele frequency of the Asp40 allele was 0.397 in the alcohol-dependent group, which is consistent with other literature demonstrating this polymorphism to be common in Asian populations. Within the alcohol-dependent subjects, being homozygous for the Asp40 allele was associated with more days drinking than those heterozygous or homozygous for the Asn40 allele. Differences in the allele frequencies between alcohol-dependent and non-alcohol-dependent controls were not significant. Conclusions: These results suggest that having one or two copies of the A118G allele is common among Koreans and may be an important genetic factor in the etiology of alcohol dependence and the frequency of alcohol consumption. C1 Pusan Natl Univ, Sch Med, Dept Psychiat, Pusan 602739, South Korea. Pusan Natl Univ, Sch Med, Dept Biochem, Pusan 602739, South Korea. Pusan Natl Univ, Sch Med, Dept Family Med, Pusan 602739, South Korea. Haeundae Ja Myung Hosp, Pusan, South Korea. Yang San Hosp, Kyungsang Nambo, South Korea. Dong A Univ, Div Management Informat Sci, Pusan, South Korea. Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. VISN 4 MIRECC, Philadelphia, PA USA. RP Kim, SG (reprint author), Pusan Natl Univ, Sch Med, Dept Psychiat, 1 Ga 10,Ami Dong, Pusan 602739, South Korea. EM sungkim@pusan.ac.kr RI KIM, SEONG YEON/E-4164-2012 NR 32 TC 51 Z9 58 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUL PY 2004 VL 28 IS 7 BP 986 EP 990 DI 10.1097/01.ALC.0000130803.62768.AB PG 5 WC Substance Abuse SC Substance Abuse GA 840AQ UT WOS:000222829800002 PM 15252283 ER PT J AU Kliethermes, CL Cronise, K Crabbe, JC AF Kliethermes, CL Cronise, K Crabbe, JC TI Anxiety-like behavior in mice in two apparatuses during withdrawal from chronic ethanol vapor inhalation SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article ID ELEVATED PLUS-MAZE; ALCOHOL-WITHDRAWAL; ANIMAL-MODEL; PHARMACOLOGICAL CHARACTERIZATION; DAILY EXPOSURE; ZERO-MAZE; RATS; MOUSE; TRIAL; BENZODIAZEPINES AB Background: Anxiety during ethanol withdrawal may be a factor in relapse to alcohol abuse and dependence. Animal models of ethanol withdrawal have typically used forced consumption of an ethanol-containing liquid diet to induce dependence. Ethanol vapor inhalation offers an advantage over liquid diet consumption in that the onset of withdrawal can be temporally controlled more precisely, allowing studies of the development of withdrawal symptoms. Methods: The purpose of the current study was to induce ethanol dependence in mice using an inhalation procedure and to assess withdrawal anxiety symptoms behaviorally in the elevated zero maze and in the light/dark box. Male and female mice were exposed to 3 days of ethanol vapors. Anxiety-like behavior was measured on the elevated zero maze and light/dark box at multiple time points during withdrawal. Results: Mice experiencing ethanol withdrawal demonstrated increased anxiety-like behaviors relative to control animals in both apparatuses. However, this finding was specific to the procedure used with the elevated zero maze and was strongly influenced by sex in the light/dark box. Conclusions: Ethanol vapor inhalation appears to be a valid tool for the study of withdrawal-induced anxiety. C1 Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland VA Med Ctr, Portland, OR 97239 USA. VA Med Ctr, Portland Alcohol Res Ctr, Portland, OR USA. RP Kliethermes, CL (reprint author), Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland VA Med Ctr, R&D 12,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM kliether@ohsu.edu FU NIAAA NIH HHS [AA10760, AA12714, P60 AA010760, T32AA07468] NR 49 TC 40 Z9 42 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUL PY 2004 VL 28 IS 7 BP 1012 EP 1019 DI 10.1097/01.ALC.0000131976.40428.8F PG 8 WC Substance Abuse SC Substance Abuse GA 840AQ UT WOS:000222829800006 PM 15252287 ER PT J AU Schwartz, GG Bolognese, MA Tremblay, BP Caplan, R Hutchinson, H Raza, A Cressman, M AF Schwartz, GG Bolognese, MA Tremblay, BP Caplan, R Hutchinson, H Raza, A Cressman, M TI Efficacy and safety of, rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: A randomized, controlled trial SO AMERICAN HEART JOURNAL LA English DT Article ID DENSITY-LIPOPROTEIN-CHOLESTEROL; PREVENTION; EVENTS; GOALS; PRAVASTATIN; AVERAGE AB Background This double-blind, multicenter, randomized trial compared rosuvastatin and atorvastatin for reducing low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia and a high risk of coronary heart disease. Methods After a 6-week dietary lead-in period, patients with LDL-C levels greater than or equal to 160 and <250 mg/dL and triglyceride levels :5400 mg/dL were randomly assigned to 24 weeks' treatment in 1 of 3 groups, each with forced dose titrations at 12 and 18 weeks. Starting and titrated doses for each group were rosuvastatin 5, 20, and 80 mg (n = 127); rosuvastatin 10, 40, and 80 mg (n = 128); and atorvastatin 10, 40, and 80 mg (n = 128). Results At 24 weeks, LDL-C was reduced significantly more with 80 mg rosuvastatin (combined rosuvastatin group) than with atorvastatin 80 mg (60% vs 52% [P < .001]). At 12 weeks, rosuvastatin 5 and 10 mg reduced LDL-C significantly more than atorvastatin 10 mg (40% [P < .01], 47% [P < .001] vs 35%). At 18 weeks, LDL-C reductions were also significantly greater in both rosuvastatin groups than in the atorvastatin group (52% [P < .01], 59% [P < .001] vs 47%). Consequently, more patients receiving rosuvastatin achieved LDL-C goals. Total cholesterol, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, apolipoproteins B and A-1, and all lipid ratios were more favorably modified by rosuvastatin at 24 weeks (P < .01). Effects of the 2 agents on triglycerides were similar. Conclusions Rosuvastatin was more efficacious than atorvastatin in modifying lipids in patients with hypercholesterolemia and a high coronary heart disease risk. C1 Univ Colorado, Denver VA Med Ctr, Cardiol Sect, Denver, CO 80220 USA. Bethesda Hlth Res, Bethesda, MD USA. Ctr Hosp Univ, Hotel Dieu, Quebec City, PQ, Canada. AstraZeneca LP, Wilmington, DE USA. RP Univ Colorado, Denver VA Med Ctr, Cardiol Sect, 1055 Clermont St,1118, Denver, CO 80220 USA. EM Gregory.Schwartz@med.va.gov NR 21 TC 14 Z9 14 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD JUL PY 2004 VL 148 IS 1 BP 105 EP + DI 10.1016/j.ahj.2004.01.020 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 833RX UT WOS:000222357700019 ER PT J AU Gurm, HS Lincoff, AM Kleiman, NS Kereiakes, DJ Tcheng, JE Aronow, HD Askari, AT Brennan, DM Topol, EJ AF Gurm, HS Lincoff, AM Kleiman, NS Kereiakes, DJ Tcheng, JE Aronow, HD Askari, AT Brennan, DM Topol, EJ TI Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID GLYCOPROTEIN IIB/IIIA RECEPTOR; KIDNEY-FUNCTION; HEART-FAILURE; MORTALITY; REVASCULARIZATION; HEMODIALYSIS; ANGIOPLASTY; BLOCKADE AB Anemia and renal insufficiency impart an increased risk of mortality in patients with congestive heart failure. There is a paucity of data on the mortality hazard associated with anemia and renal insufficiency in patients undergoing percutoneous coronary intervention in the setting of contemporary practice. We analyzed the short- and long-term outcomes among patients enrolled in EPIC, EPILOG and EPISTENT trials according to degree of kidney dysfunction (glomerular filtration rate [GFR] <60, 60 to 75, and >75 mi/min/1.73 m(2)) and by hematocrit (<35, 35 to 39 and 40). GFR was calculated as GFR = 186 x (serum creatinine(-1.154)) X (age (-0.203)) x 1.212 (if black) or x0.742 (if female). There were 20 deaths (3.2%) among 638 patients with a hematocrit of <35, 41 deaths among 2,066 patients (2.0%) with a hematocrit of 35 to 39, and 43 deaths in 3,618 patients (1.2%) with a hematocrit >40 at 6 months (p <0.001). Similarly, a significant increase in mortality was seen with lower GFR [33 of 1,168 (2.9%) at GFR 60, 33 of 1,766 (1.9%) at GFR 60 to 75 and 37 of 3,317 (1.1%) at GFR >75, p <0.001)]. Further, GFR and anemia independently and in combination predicted mortality at 3 years. Thus, renal insufficiency and anemia are significant independent and additive predictors of short- and long-term complications in patients undergoing percutaneous coronary intervention. (C) 2004 by Excerpta Medica, Inc. C1 Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA. Methodist DeBakey Heart Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Duke Clin Res Inst, Durham, NC USA. Lindner Ctr, Cincinnati, OH USA. Ohio Heart Hlth Ctr, Cincinnati, OH USA. Case Western Reserve Univ, Cleveland, OH 44106 USA. Univ Penn, Med Ctr, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Lincoff, AM (reprint author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave,Desk F25, Cleveland, OH 44195 USA. EM lincofa@ccf.org OI Gurm, Hitinder/0000-0002-1646-0218; Topol, Eric/0000-0002-1478-4729 NR 18 TC 33 Z9 33 U1 0 U2 1 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD JUL 1 PY 2004 VL 94 IS 1 BP 30 EP 34 DI 10.1016/j.amjcard.2004.03.025 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 832QO UT WOS:000222282200006 PM 15219504 ER PT J AU Ruo, B Rumsfeld, JS Pipkin, S Whooley, MA AF Ruo, B Rumsfeld, JS Pipkin, S Whooley, MA TI Relation between depressive symptoms and treadmill exercise capacity in the heart and soul study SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID QUALITY-OF-LIFE; HEALTH-STATUS; MORTALITY; SERTRALINE; DISEASE; ANGINA AB To examine the association between depressive symptoms and exercise capacity, we performed a cross-sectional study of 944 outpatients with stable coronary artery disease and found that the presence of depressive symptoms was independently associated with poor exercise capacity (<5 MET tasks achieved; adjusted odds ratio 1.8, 95% confidence interval 1.1 to 2.7, p = 0.01). Depressive symptoms should be considered in the differential diagnosis of poor exercise capacity. (C) 2004 by Excerpta Medica, Inc. C1 Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA. Univ Calif San Francisco, Sect Gen Int Med, VA Med Ctr, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Denver Vet Affairs Med Ctr, Cardiol & Hlth Serv Res, Denver, CO USA. RP Ruo, B (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Med, 680 N St Clair, Chicago, IL 60611 USA. EM berniceruo@post.harvard.edu FU NHLBI NIH HHS [R01 HL079235-01A1, R01 HL079235] NR 20 TC 27 Z9 27 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD JUL 1 PY 2004 VL 94 IS 1 BP 96 EP 99 DI 10.1016/j.amjcard.2004.03.035 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 832QO UT WOS:000222282200017 PM 15219515 ER PT J AU Targownik, LE Spiegel, BMR Dulai, GS Karsan, HA Gralnek, IM AF Targownik, LE Spiegel, BMR Dulai, GS Karsan, HA Gralnek, IM TI The cost-effectiveness of hepatic venous pressure gradient monitoring in the prevention of recurrent variceal hemorrhage SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article; Proceedings Paper CT Digestive Disease Week Meeting/103rd Annual Meeting of the American-Gastroenterological-Association CY MAY 19-23, 2002 CL SAN FRANCISCO, CA SP Amer Gastroenterol Assoc ID PROSPECTIVE RANDOMIZED-TRIAL; BLEEDING ESOPHAGEAL-VARICES; INTRAHEPATIC PORTOSYSTEMIC SHUNT; PROPRANOLOL PLUS ISOSORBIDE-5-MONONITRATE; ENDOSCOPIC SCLEROTHERAPY; ISOSORBIDE MONONITRATE; PORTAL-HYPERTENSION; INJECTION SCLEROTHERAPY; PRIMARY PROPHYLAXIS; BANDING LIGATION AB OBJECTIVE: Recurrent variceal hemorrhage is common following an initial bleed in patients with cirrhosis. The current standard of care for secondary prophylaxis is endoscopic band ligation (EBL). Combination of beta-blocker and nitrate therapy, guided by hepatic venous pressure gradient (HVPG) monitoring, is a novel alternative strategy. We sought to determine the cost-effectiveness of these competing strategies. METHODS: Decision analysis with Markov modeling was used to calculate the cost-effectiveness of three competing strategies: (1) EBL; (2) beta-blocker and nitrate therapy without HVPG monitoring (HVPG-); and (3) beta-blocker and nitrate therapy with HVPG monitoring (HVPG+). Patients in the HVPG+ strategy who failed to achieve an HVPG decline from medical therapy were offered EBL. Cost estimates were from a third-party payer perspective. The main outcome measure was the cost per recurrent variceal hemorrhage prevented. RESULTS: Under base-case conditions, the HVPG+ strategy was the most effective yet most expensive approach, followed by EBL and HVPG-. Compared to the EBL strategy, the HVPG+ strategy cost an incremental $5,974 per recurrent bleed prevented. In a population with 100% compliance with all therapies, the incremental cost of HVPG- versus EBL fell to $5,270 per recurrent bleed prevented. The model results were sensitive to the cost of EBL, the cost of HVPG monitoring, and the probability of medical therapy producing an adequate HVPG decline. CONCLUSIONS: Compared to EBL for the secondary prophylaxis of variceal rebleeding, combination medical therapy guided by HVPG monitoring is more effective and only marginally more expensive. C1 Univ Calif Los Angeles, David Geffen Sch Med,Div Digest Dis, VA Greater Los Angeles Healthcare Syst,Div Gastro, CURE Digest Dis Res Ctr,Ctr Study Digest Healthca, Los Angeles, CA 90073 USA. Univ Manitoba, Gastroenterol Sect, Winnipeg, MB, Canada. RP Gralnek, IM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med,Div Digest Dis, VA Greater Los Angeles Healthcare Syst,Div Gastro, CURE Digest Dis Res Ctr,Ctr Study Digest Healthca, 11301 Wilshire Blvd,Bldg 115 Room 215B, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK-07180]; PHS HHS [K23 1618801] NR 51 TC 18 Z9 18 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JUL PY 2004 VL 99 IS 7 BP 1306 EP 1315 DI 10.1111/j.1572-0241.2004.30754.x PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 837NI UT WOS:000222641800020 PM 15233670 ER PT J AU Young, RC Gyulai, L Mulsant, BH Flint, A Beyer, JL Shulman, KI Reynolds, CF AF Young, RC Gyulai, L Mulsant, BH Flint, A Beyer, JL Shulman, KI Reynolds, CF TI Pharmacotherapy of bipolar disorder in old age - Review and recommendations\ SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article; Proceedings Paper CT Conference on Unmet Needs in Diagnosis and Treatment of Mood Disorders in Life CY OCT 09-10, 2001 CL Washington, DC SP Depress & Bipolar Support Alliance, Abbott Lab, AstraZeneca, Forest Lab Inc, GlaxSmithKline, Janssen Pharmaceut Ment Hlth, Organon Inc, Pfizer INC, Wyeth Ayerst Lab ID MANIC-DEPRESSIVE ILLNESS; ELDERLY PSYCHIATRIC-PATIENTS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; LITHIUM-CARBONATE; LATE-LIFE; GERIATRIC-PATIENTS; DIVALPROEX SODIUM; VALPROIC ACID; TARDIVE-DYSKINESIA AB The authors reviewed the evidence-base for pharmacological treatment of mania and bipolar (BP) depression in late life. Treatment benefits and side effects maybe modified by age-associated factors, such as neurocognitive impairments. Lithium and dival-proex have most often been studied in elderly patients, and both may be efficacious in acute treatment of mania, but there are no controlled efficacy or effectiveness trials. The role of atypical antipsychotic agents remains to be clarified. Similarly, there are no systematic studies of the treatment of BP depression in elderly patients. The authors make suggestions for management and delineate priorities for research. C1 Cornell Univ, Weill Med Coll, Inst Geriatr Psychiat, Dept Psychiat, White Plains, NY 10605 USA. Univ Penn, Philadelphia, PA 19104 USA. Univ Pittsburgh, Western Psychiat Inst, Dept Psychiat, Sch Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Western Psychiat Clin, Dept Psychiat, Sch Med, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Sst, Geriatr Res Educ & Clin CCtr, Pittsburgh, PA USA. Univ Toronto, Fac Med, Dept Psychiat, Toronto, ON M5S 1A1, Canada. Duke Univ, Dept Psychiat, Med Ctr, Durham, NC 27706 USA. RP Young, RC (reprint author), Cornell Univ, Weill Med Coll, Inst Geriatr Psychiat, Dept Psychiat, 21 Bloomingdale Rd, White Plains, NY 10605 USA. EM ryoung@med.cornell.edu FU NIMH NIH HHS [K01 MH01613, MH43832, MH37869, K02 MH067028, P30 MH52247, MH57027, MH-98-DS-001, P30 MH49762, K02 MH01192, R01 MH52763] NR 131 TC 47 Z9 49 U1 0 U2 0 PU AMER PSYCHIATRIC PRESS, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD JUL-AUG PY 2004 VL 12 IS 4 BP 342 EP 357 DI 10.1176/appi.ajgp.12.4.342 PG 16 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 835OT UT WOS:000222493800002 PM 15249272 ER PT J AU Butters, MA Bhalla, RK Mulsant, BH Mazumdar, S Houck, PR Begley, AE Dew, MA Pollock, BG Nebes, RD Becker, JT Reynolds, CF AF Butters, MA Bhalla, RK Mulsant, BH Mazumdar, S Houck, PR Begley, AE Dew, MA Pollock, BG Nebes, RD Becker, JT Reynolds, CF TI Executive functioning, illness course, and relapse/recurrence in continuation and maintenance treatment of late-life depression - Is there a relationship? SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article ID MINI-MENTAL-STATE; GERIATRIC DEPRESSION; COGNITIVE IMPAIRMENT; ELDERLY PATIENTS; RATING-SCALE; ANTIDEPRESSANT TREATMENT; TREATMENT RESPONSE; DOUBLE-BLIND; NORTRIPTYLINE; PAROXETINE AB Objective: The authors tested the hypothesis that impaired executive functioning leads to high rates of relapse and recurrence in late-life depression, Methods: They analyzed data from subjects participating in two independent intervention trials. Study I included 53 elderly depressed patients who participated in an open trial comparing the efficacy of paroxetine and nortriptyline and recurrence prevention over 18 months. Study II focused on 146 elderly depressed patients who received open treatment with paroxetine in a relapse-prevention study over 4 months of continuation treatment. They examined the effect of cognitive functioning, in general, and executive functioning, in particular, on time-to-relapse/recurrence, using baseline and post-treatment measures of neuropsychological functioning. Results: The associations between cognitive measures and both probability of, and time-to-relapse/recurrence were small and statistically nonsignificant. Conclusion: Data failed to support the hypothesis that cognitive impairment, in general, or executive dysfunction, in particular predicts relapse or recurrence of major depression in late life. Authors recommend future testing of the hypothesis with detailed, comprehensive measures over longer periods of observation during maintenance trials. C1 Univ Pittsburgh, Med Ctr, Intervent Res Ctr Late Life Mood Disorders, Western Psychiat Inst,Dept Psychiat, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Intervent Res Ctr Late Life Mood Disorders, Western Psychiat Clin,Dept Psychiat, Pittsburgh, PA USA. VA Pittsburgh Hlth Syst, GRECC, Pittsburgh, PA USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. RP Butters, MA (reprint author), WPIC E-464,3811 OHara St, Pittsburgh, PA 15213 USA. EM buttersma@upmc.edu FU NIA NIH HHS [AG05133]; NIMH NIH HHS [MH65416, MH37869, MH43832, MH01684, MH52247, MH01613] NR 28 TC 45 Z9 46 U1 0 U2 5 PU AMER PSYCHIATRIC PRESS, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD JUL-AUG PY 2004 VL 12 IS 4 BP 387 EP 394 DI 10.1176/appi.ajgp.12.4.387 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 835OT UT WOS:000222493800006 PM 15249276 ER PT J AU Pergola, PE Habiba, NM Johnson, JM AF Pergola, PE Habiba, NM Johnson, JM TI Body temperature regulation during hemodialysis in long-term patients: Is it time to change dialysate temperature prescription? SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE dialysate temperature; hemodialysis (HD); body temperature; blood temperature monitor ID ACTIVE CUTANEOUS VASODILATION; SKIN TEMPERATURE; CARDIOVASCULAR ADJUSTMENTS; VASCULAR STABILITY; ENERGY-TRANSFER; COOL DIALYSATE; HUMANS; EXERCISE; WUNDERLICH,CARL,REINHOLD,AUGUST; VASOCONSTRICTION AB During hemodialysis procedures, changes in the dialysate temperature can raise or lower body temperature because the blood Is returned to the patient in thermal equilibrium with the dialysate. Even a dialysate temperature equal to the patient's body temperature as measured from the tympanic membrane, oral cavity, or axilla can result In an increase in the patient's body temperature, leading to cutaneous vasodilation and the potential for cardiovascular instability and hypotension. This deleterious cycle of events can be prevented by suitably adjusting the dialysate temperature. Lowering the dialysate temperature from 37degreesC to 34-35.5C has Improved the cardiovascular stability of many hemodialysis patients. Continuous monitoring of blood temperature allows the practitioner to make preemptive changes in dialysate temperature because a small change in body temperature can have enormous cardiovascular implications. For example, only 0.3degreesC to 0.8degreesC separates the thresholds for skin vasodilation from that for shivering. A suggested improvement in the hemodialysis procedure is to use devices that allow continuous monitoring of arterial and venous blood temperatures and adjust the dialysate temperature automatically, keeping the patient, not the dialysate, isothermic. Less optimal solutions appear to be (1) to monitor arterial and venous temperatures while manually adjusting the dialysate temperature to maintain arterial (and hence body) temperature stability; (2) to monitor peripheral temperatures (oral, tympanic) at regular intervals and adjust dialysate temperature to maintain the body temperature constant; (3) routinely use a dialysate temperature <37.0&DEG;C in all patients unless contraindicated. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Pergola, PE (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM Pergola@UTHSCSA.edu FU NHLBI NIH HHS [HL59166] NR 44 TC 19 Z9 19 U1 0 U2 3 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD JUL PY 2004 VL 44 IS 1 BP 155 EP 165 DI 10.1053/j.ajkd.2004.03.036 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 839RK UT WOS:000222802400017 PM 15211448 ER PT J AU Volpp, KGM Buckley, E AF Volpp, KGM Buckley, E TI The effect. of increases in HMO penetration and changes in payer mix on in-hospital mortality and treatment patterns for acute myocardial infarction SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID CARE PLAN PERFORMANCE; MANAGED CARE; COMORBIDITY MEASURES; MARKET SHARE; EXPENDITURES; COMPETITION; MEDICARE; JOB AB Objective: To determine whether changes in health maintenance organization (HMO) penetration or payer mix affected in-hospital mortality and treatment patterns of patients with acute myocardial infarction (AMI). Study Design: Observational study using patient-level logistic regression analysis and hospital and year fixed effects of data from the Agency for Healthcare Research and Quality's Healthcare Cost and Utilization Project Nationwide Inpatient Sample, a geographically diverse sample of 20% of the hospitalized patients in the United States. Patients and Methods: Discharges of patients (n = 340 064) with a primary diagnosis of acute myocardial infarction who were treated in general medical or surgical hospitals that contributed at least 2 years of data to the HealthCare Cost and Utilization Project Nationwide Inpatient Sample from 1989 to 1996. In-hospital mortality and rates of cardiac catheterization, angioplasty, or coronary artery bypass grafting for Medicare patients or non-Medicare patients were the main outcome measures. Results: Among Medicare patients, increases in HMO penetration were associated with reduced odds of receiving cardiac catheterization, angioplasty, or coronary artery bypass grafting of 3% to 16%, but were not associated with any change in mortality risk. Increases in the number of HMOs within a metropolitan statistical area, our measure of HMO competition, were associated with small but significant increases in the odds of cardiac catheterization and angioplasty of about 2%. There was no pattern of changes in cardiac procedure rates or in-hospitality mortality among non-Medicare patients. Conclusion: Increases in HMO penetration reduced cardiac procedure rates by statistically significant but small amounts among Medicare patients with AMI, without affecting mortality rates. C1 Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. Univ Penn, Philadelphia Vet Hosp, Ctr Hlth Equity Res & Promot, Philadelphia, PA 19104 USA. Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Volpp, KGM (reprint author), Univ Penn, Sch Med, Dept Med, 1232 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM volpp70@mail.med.upenn.edu NR 21 TC 17 Z9 17 U1 0 U2 2 PU AMER MED PUBLISHING, M W C COMPANY PI JAMESBURG PA 241 FORSGATE DR, STE 102, JAMESBURG, NJ 08831 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD JUL PY 2004 VL 10 IS 7 BP 505 EP 512 PN 2 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 839UC UT WOS:000222809400007 PM 15298238 ER PT J AU Anaya, HD Yano, EM Asch, SM AF Anaya, HD Yano, EM Asch, SM TI Early adoption of human immunodeficiency virus quality improvement in veterans affairs medical centers: Use of organizational surveys to measure readiness to change and adapt interventions to local priorities SO AMERICAN JOURNAL OF MEDICAL QUALITY LA English DT Article DE clinical reminders; group-based quality improvement; organizations; preinterventional surveys; provider attitudes; Veterans Administration ID PHYSICIAN PERFORMANCE; HEALTH-CARE; FEEDBACK; REMINDERS; EDUCATION AB Potential delivery system responsiveness to quality improvement (QI) interventions is rarely assessed before implementation, although it might aid in interventional design. Preparing for a national initiative, we assessed Veterans Affairs (VA) human immunodeficiency virus (HIV) clinic organizational characteristics and attitudes toward QI interventions. Current QI activities and attitudes toward potential effectiveness of several techniques to improve antiretroviral and opportunistic infection prophylaxis therapy were assessed. These included computerized clinical reminders (CRs), group-based QI, expert advice, and facility and provider-level audit/feedback. Organizational characteristics were also examined. Respondents rated CRs and group-based QI (GBQI) interventions most highly. Western and complex facilities viewed CR and GBQI interventions more positively than less complex facilities or those in other regions, even controlling for organizational characteristics and perceived barriers to change. VA clinicians favored CR and GBQI over facility/ provider feedback. The persistence of regional variation should be further explored. Organizational surveys of attitudes toward potential QI interventions can assist in choosing interventions and targeting specific facilities. C1 VA Greater Los Angeles, HSR&D, Ctr Excellence Study Healthcare Provider Behav, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. RP Anaya, HD (reprint author), 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. EM henry.anaya@med.va.gov NR 25 TC 10 Z9 10 U1 0 U2 3 PU AMER COLLEGE MEDICAL QUALITY PI BETHESDA PA 4334 MONTGOMERY AVE, 2ND FL, BETHESDA, MD 20814-4402 USA SN 1062-8606 J9 AM J MED QUAL JI Am. J. Med. Qual. PD JUL-AUG PY 2004 VL 19 IS 4 BP 137 EP 144 DI 10.1177/106286060401900402 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 844EU UT WOS:000223141100002 PM 15368778 ER PT J AU Ambriz, EH Woodard, LD Kressin, NR Petersen, LA AF Ambriz, EH Woodard, LD Kressin, NR Petersen, LA TI Use of smoking cessation interventions and aspirin for secondary prevention: Are there racial disparities? SO AMERICAN JOURNAL OF MEDICAL QUALITY LA English DT Article DE aspirin; coronary artery disease; racial differences; secondary prevention; smoking ID CORONARY-REVASCULARIZATION PROCEDURES; ACUTE MYOCARDIAL-INFARCTION; MEDICARE PATIENTS; DISEASE AB We examined whether racial differences exist in the use of aspirin and smoking cessation interventions for secondary prevention in veterans with coronary artery disease (CAD). We enrolled a total of 1045 African-American and white patients with CAD at 5 Veterans Administration hospitals between 1999 and 2001. Data were obtained by chart review. Among current smokers, African-American and white patients were equally likely to receive smoking cessation interventions (55.8% versus 56.1%; P = .97). Similarly, among ideal candidates for aspirin therapy, there was no difference in overall treatment rates between the 2 groups (74.1% versus 73.4%; P = .85). However, in the subsets of ideal candidates with hypercholesterolemia and previous stroke, African-Americans were less likely than whites to receive aspirin (P < .05). In contrast, African-Americans with hypertension were more likely than whites to receive aspirin (P = .05). Our findings highlight the need for improvement in use of smoking cessation interventions and aspirin among all patients with CAD and indicate an area where future quality improvement efforts may be warranted. C1 Houston Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Sect Hypertens Clin Pharmacol, Houston, TX 77030 USA. Bedford VA Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Ctr Hlth Qual Outcomes & Econ Res, Dept Vet Affairs, Bedford, MA USA. Boston Univ, Sch Publ Hlth, Dept Hlth Serv, Bedford, MA USA. RP Petersen, LA (reprint author), Houston Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM laurap@bcm.tmc.edu FU BHP HRSA HHS [1 T32 PE 10031-01] NR 20 TC 8 Z9 8 U1 0 U2 0 PU AMER COLLEGE MEDICAL QUALITY PI BETHESDA PA 4334 MONTGOMERY AVE, 2ND FL, BETHESDA, MD 20814-4402 USA SN 1062-8606 J9 AM J MED QUAL JI Am. J. Med. Qual. PD JUL-AUG PY 2004 VL 19 IS 4 BP 166 EP 171 DI 10.1177/106286060401900405 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 844EU UT WOS:000223141100005 PM 15368781 ER PT J AU Gordon, L AF Gordon, L TI Fuch's heterochromic cyclitis: New clues regarding pathogenesis SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Editorial Material ID AQUEOUS-HUMOR; T-CELLS; UVEITIS C1 Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Ophthalmol Sect, Los Angeles, CA USA. RP Gordon, L (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM lgordon@ucla.edu NR 10 TC 3 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD JUL PY 2004 VL 138 IS 1 BP 133 EP 134 DI 10.1016/j.ajo.2004.03.031 PG 2 WC Ophthalmology SC Ophthalmology GA 836PO UT WOS:000222568200017 PM 15234292 ER PT J AU Blevins, JE Schwartz, MW Baskin, DG AF Blevins, JE Schwartz, MW Baskin, DG TI Evidence that paraventricular nucleus oxytocin neurons link hypothalamic leptin action to caudal brain stem nuclei controlling meal size SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE brain stem; adiposity; satiety; food intake ID CENTRAL-NERVOUS-SYSTEM; C-FOS EXPRESSION; REDUCES FOOD-INTAKE; SPINAL-CORD; RAT-BRAIN; GASTRIC DISTENSION; SOLITARY TRACT; BODY-WEIGHT; CHOLECYSTOKININ; VASOPRESSIN AB Hindbrain projections of oxytocin neurons in the parvocellular paraventricular nucleus (pPVN) are hypothesized to transmit leptin signaling from the hypothalamus to the nucleus of the solitary tract (NTS), where satiety signals from the gastrointestinal tract are received. Using immunocytochemistry, we found that an anorectic dose of leptin administered into the third ventricle (3V) increased twofold the number of pPVN oxytocin neurons that expressed Fos. Injections of fluorescent cholera toxin B into the NTS labeled a subset of pPVN oxytocin neurons that expressed Fos in response to 3V leptin. Moreover, 3V administration of an oxytocin receptor antagonist, [D-(CH2)5, Tyr(Me)2, Orn8]-vasotocin (OVT), attenuated the effect of leptin on food intake over a 0.5- to 4-h period (P<0.05). Furthermore, to determine whether oxytocin contributes to leptin's potentiation of Fos activation within NTS neurons in response to CCK, we counted the number of Fos-positive neurons in the medial NTS (mNTS) after 3V administration of OVT before 3V leptin and intraperitoneal CCK-8 administration. OVT resulted in a significant 37% decrease (P<0.05) in the potentiating effect of leptin on CCK activation of mNTS neuronal Fos expression. Furthermore, 4V OVT stimulated 2-h food intake by 43% (P<0.01), whereas 3V OVT at the same dose was ineffective. These findings suggest that release of oxytocin from a descending pPVN-to-NTS pathway contributes to leptin's attenuation of food intake by a mechanism that involves the activation of pPVN oxytocin neurons by leptin, resulting in increased sensitivity of NTS neurons to satiety signals. C1 Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol Metab, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA. RP Blevins, JE (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Res Serv 151, 1660 S Columbian Wy, Seattle, WA 98108 USA. EM jeblevin@u.washington.edu RI Schwartz, Michael/H-9950-2012 FU NIDDK NIH HHS [DK-12829, DK-17047, DK-52989]; NINDS NIH HHS [NS-32273] NR 52 TC 189 Z9 194 U1 1 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD JUL PY 2004 VL 287 IS 1 BP R87 EP R96 DI 10.1152/ajpregu.00604.2003 PG 10 WC Physiology SC Physiology GA 828AE UT WOS:000221944000015 PM 15044184 ER PT J AU Wolden-Hanson, T Marck, BT Matsumoto, AM AF Wolden-Hanson, T Marck, BT Matsumoto, AM TI Blunted hypothalamic neuropeptide gene expression in response to fasting, but preservation of feeding responses to AgRP in aging male Brown Norway rats SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE energy balance; food intake; proopiomelanocortin; cocaine-amphetamine-regulated transcript ID AGOUTI-RELATED PROTEIN; AMPHETAMINE-REGULATED TRANSCRIPT; THYROTROPIN-RELEASING-HORMONE; LEPTIN SIGNAL-TRANSDUCTION; NPY MESSENGER-RNA; ARCUATE NUCLEUS; FOOD-INTAKE; BODY-WEIGHT; PARAVENTRICULAR NUCLEUS; AGED RATS AB Aging mammals lose the ability to maintain energy balance, exhibiting decreased appetite ( anorexia) and impaired ability to maintain body weight. To determine the contribution of hypothalamic neuropeptides, two experiments were performed in male Brown Norway rats. To assess the hypothalamic neuropeptide response to food deprivation, young (Y; 4 mo old), middle-aged ( M; 13 mo), and old (O; 25 mo) rats were either ad libitum fed or fasted for 72 h (n = 10/group) and killed. Hypothalamic levels of agouti-related peptide ( AgRP), proopiomelanocortin ( POMC), and cocaine-amphetamine-regulated transcript ( CART) mRNA were assessed by in situ hybridization. With aging, arcuate AgRP gene expression decreased and CART mRNA increased, but POMC mRNA did not change. Fasting-induced changes in gene expression of all neuropeptides studied were attenuated with aging. To test the food intake response to appetite-stimulating neuropeptides, Y, M, O, and very old (VO; 33 mo) rats (n = 4-8/group) received one intracerebroventricular injection of each of three treatments: 0.1 nmol AgRP, 2.34 nmol NPY, and saline control. AgRP increased food intake of all groups by 10-20%, compared with saline, and this effect persisted up to 7 days after injection. VO animals were more sensitive to the effects of AgRP than younger animals. In contrast, NPY increased food intake more in Y than in older animals and its effects did not last >24 h. We conclude that the mechanisms by which arcuate nucleus neurons influence appetite are differentially affected by age and speculate that the melanocortin system may be a useful target for treatment of the anorexia of aging. C1 VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. Univ Washington, Sch Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA. RP Wolden-Hanson, T (reprint author), VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, S-182 GRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM twh@u.washington.edu FU NICHD NIH HHS [P50-HD-12629] NR 57 TC 27 Z9 28 U1 1 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD JUL PY 2004 VL 287 IS 1 BP R138 EP R146 DI 10.1152/ajpregu.00465.2003 PG 9 WC Physiology SC Physiology GA 828AE UT WOS:000221944000021 PM 15001433 ER PT J AU Tian, W Salanova, M Xu, HS Lindsley, JN Oyama, TT Anderson, S Bachmann, S Cohen, DM AF Tian, W Salanova, M Xu, HS Lindsley, JN Oyama, TT Anderson, S Bachmann, S Cohen, DM TI Renal expression of osmotically responsive cation channel TRPV4 is restricted to water-impermeant nephron segments SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE water permeability; transient receptor potential ID HEAT-EVOKED ACTIVATION; PROTEIN; KIDNEY; MOUSE; RAT; PATHWAYS; LOCALIZATION; DERIVATIVES; CELLS; MICE AB TRPV4, a nonselective cation channel of the transient receptor potential (TRP) family, is gated by hypotonicity. Expression of TRPV4 mRNA has been detected in the circumventricular organs of the brain responsible for sensing systemic tonicity and in the kidney distal convoluted tubule (DCT), among other sites. No analysis of TRPV4 expression at the protein level has been undertaken and no systematic analysis of expression of this channel has been reported in the kidney. Via RNAse protection assay and immunoblotting, abundant expression of TRPV4 was detected in the cortex, medulla, and papilla. The expression pattern of TRPV4 was characterized in both rat and mouse kidney, which revealed similar patterns of immunoreactivity. TRPV4 expression was absent from the proximal tubule (PT) and descending thin limb (DTL), whereas the strongest expression was observed in the ascending thin limb (ATL). The thick ascending limb ( TAL) was strongly positive as was the DCT and connecting tubule. Importantly, the water-permeant cells of the macula densa were unstained. Moderate TRPV4 expression was noted in all collecting duct portions and in papillary epithelium; intercalated cells ( type A) exhibited a particularly strong signal. In all positive segments, TRPV4 expression was concentrated at the basolateral membrane. Therefore, TRPV4 is expressed in only those nephron segments that are constitutively (i.e., ATL, TAL, and DCT) or conditionally (i.e., collecting duct) water impermeant and where generation of a substantial transcellular osmotic gradient could be expected. TRPV4 expression is absent from nephron segments exhibiting constitutive water permeability and unregulated apical aquaporin expression (i.e., PT and DTL). These data, although circumstantial, are consistent with a role for TRPV4 in the response to anisotonicity in the mammalian kidney. C1 Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Portland, OR 97239 USA. Charite Sch Med, Dept Anat, D-10115 Berlin, Germany. RP Cohen, DM (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Mailcode PP262,3314 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM cohend@ohsu.edu FU NIDDK NIH HHS [DK-52494] NR 27 TC 78 Z9 87 U1 1 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD JUL PY 2004 VL 287 IS 1 BP F17 EP F24 DI 10.1152/ajprenal.00397.2003 PG 8 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 827FB UT WOS:000221883500003 PM 15026302 ER PT J AU Brody, AL Olmstead, RE London, ED Farahi, J Meyer, JH Grossman, P Lee, GS Huang, J Hahn, EL Mandelkern, MA AF Brody, AL Olmstead, RE London, ED Farahi, J Meyer, JH Grossman, P Lee, GS Huang, J Hahn, EL Mandelkern, MA TI Smoking-induced ventral striatum dopamine release SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID CEREBRAL-BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; COCAINE-SEEKING BEHAVIOR; NUCLEUS-ACCUMBENS; C-11 RACLOPRIDE; HUMAN-BRAIN; CONTINUOUS-INFUSION; IN-VIVO; PARKINSONS-DISEASE; CIGARETTE SMOKERS AB Objective: Substantial evidence from animal models demonstrates that dopamine release in the ventral striatum underlies the reinforcing properties of nicotine. The authors used [C-11]raclopride bolus-plus-continuous-infusion positron emission tomography (PET) to determine smoking-induced ventral striatum dopamine release in humans. Method: Twenty nicotine-dependent smokers (who smoked greater than or equal to15 cigarettes/day) underwent a [C-11]raclopride bolus-plus-continuous-infusion PET session. During the session, subjects had a 10-minute break outside the PET apparatus during which 10 subjects smoked a cigarette and 10 did not smoke (as a control condition). Results: The group that smoked had greater reductions in [C-11]raclopride binding potential in ventral striatum regions of interest than the group that did not smoke, particularly in the left ventral caudate/nucleus accumbens and left ventral putamen (range for smoking group-25.9% to -36.6% reduction). Significant correlations were found between change from before to after the smoking break in craving ratings and change from before to after the break in binding potential for these two regions. Conclusions: Nicotine-dependent subjects who smoked during a break in PET scanning had greater reductions in [C-11]raclopride binding potential (an indirect measure of dopamine release) than nicotine-dependent subjects who did not smoke. The magnitude of binding potential changes was comparable to that found in studies that used similar methods to examine the effects of other addictive drugs. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA. Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada. Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. RP Brody, AL (reprint author), 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA. EM abrody@ucla.edu FU NIDA NIH HHS [R01 DA 15059] NR 69 TC 168 Z9 174 U1 1 U2 6 PU AMER PSYCHIATRIC PRESS, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD JUL PY 2004 VL 161 IS 7 BP 1211 EP 1218 DI 10.1176/appi.ajp.161.7.1211 PG 8 WC Psychiatry SC Psychiatry GA 835EG UT WOS:000222462700011 PM 15229053 ER PT J AU Patten, LC Awad, SS Berger, DH Fagan, SP AF Patten, LC Awad, SS Berger, DH Fagan, SP TI A novel technique for the repair of lumbar hernias after iliac crest bone harvest SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE iliac crest bone harvest; abdominal wall hernia; lumbar hernia; corkscrew suture anchor device AB Background: Lumbar hernia is a clinical entity that has been increasingly more common since the advent of iliac bone harvest for bone grafting procedures. These can be very technically difficult to repair and have a high recurrence rate. Methods: Using a corkscrew anchor suture device, we have developed a novel and simple way to repair these hernias with no recurrence. Here we present our experience with the corkscrew Suture anchor device. Results: This technique has been performed in 2 patients at our institution, and in both cases, the hernia was successfully repaired. Our I-year follow-up on this technique demonstrates intact repairs with no sign of recurrence. Conclusions: The placement of corkscrew suture anchors along the iliac crest remnant is a simple technique requiring minimal bony exposure. The anchors facilitate the long-term fixation of mesh despite the lack of fascia in this area. We conclude that this is a simple and effective approach for repair of these challenging hernias. (C) 2004 Excerpta Medica, Inc. All rights reserved. C1 Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Surg Serv VA 112, Houston, TX 77030 USA. RP Fagan, SP (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Surg Serv VA 112, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM ShawnP.Fagan@med.va.gov NR 4 TC 9 Z9 10 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD JUL PY 2004 VL 188 IS 1 BP 85 EP 88 DI 10.1016/j.amjsurg.2003.10.026 PG 4 WC Surgery SC Surgery GA 832NY UT WOS:000222275400016 PM 15219491 ER PT J AU Zhang, L Plotkin, RC Wang, G Sandel, ME Lee, S AF Zhang, L Plotkin, RC Wang, G Sandel, ME Lee, S TI Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE acetylcholine; brain injuries; cognition disorders; rehabilitation ID PLACEBO-CONTROLLED TRIAL; DIFFUSE AXONAL INJURY; ALZHEIMERS-DISEASE; HEAD-INJURY; DOUBLE-BLIND; REHABILITATION; SYSTEMS; ACETYLCHOLINE; SCALE; RAT AB Objective: To examine effects of donepezil on short-term memory and sustained attention in postacute patients with traumatic brain injury (TBI). Design: A 24-week, randomized, placebo-controlled, double-blind crossover trial. Setting: Outpatient clinics in 2 teaching hospitals. Participants: Eighteen postacute TBI patients with cognitive impairment. Intervention: Patients were randomly assigned to group A or group B. Patients in group A received donepezil for the first 10 weeks and then a placebo for another 10 weeks. The 2 treatment phases were separated by a washout period of 4 weeks. Patients in group B received the preparations in the opposite order. Main Outcome Measures: Short-term memory and sustained attention were assessed by 2 indexes (Auditory Immediate Index [All], Visual Immediate Index [VII]) of the Wechsler Memory Scale-III and the Paced Auditory Serial Addition Test (PASAT), at baseline, week 10, and week 24 of the trial. Results: Intragroup comparison of different phases of the trial in both groups showed that donepezil significantly increased the testing scores of the All and VII, as well as PASAT scores, compared with baseline. There was no significant change in the testing scores between assessment at baseline and the end of the placebo phase in group B. Intergroup comparison at the 10-week assessment showed significantly improved testing scores in group A with donepezil over group B with the placebo. The improved testing scores with donepezil in group A were sustained after the washout period and placebo phase, suggesting a carry-over effect of the medication. Conclusions: Donepezil increased neuropsychologic testing scores in short-term memory and sustained attention in post-acute TBI patients. Cholinergic augmentation may be a viable approach to restore memory and attention after TBI. (C) 2004 by the American Congress of Rehabilitation Medici. ne and the American Academy of Physical Medicine and Rehabilitation. C1 Univ Texas, Hlth Sci Ctr, Dept Rehabil Med, San Antonio, TX 78285 USA. Dept Vet Affairs Med Ctr, San Antonio, TX USA. Univ Penn, Ctr Med, Philadelphia, PA 19104 USA. SUNY Syracuse, Upstate Med Univ, Syracuse, NY 13210 USA. Kaiser Fdn Rehabil Ctr, Vallejo, CA USA. RP Zhang, L (reprint author), San Antonio Brain & Spine Consultants, 19114 La Verita, San Antonio, TX 78258 USA. EM neurorehab@yahoo.com NR 38 TC 88 Z9 91 U1 0 U2 7 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUL PY 2004 VL 85 IS 7 BP 1050 EP 1055 DI 10.1016/j.apmr2003.10.014 PG 6 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 835XU UT WOS:000222519600002 PM 15241749 ER PT J AU Bodenheimer, CF Roig, RL Worsowicz, GM Cifu, DX AF Bodenheimer, CF Roig, RL Worsowicz, GM Cifu, DX TI Geriatric rehabilitation. 5. The societal aspects of disability in the older adult SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE automobile driving; ethics; geriatrics; rehabilitation; sexuality; vocations ID ELDER ABUSE; DEMENTIA; STROKE; RESTRICTIONS; DYSFUNCTION; WOMEN; RISK AB This self-directed learning module highlights the societal aspects of disability and the older adult. It is part of the study guide on geriatric rehabilitation in the Self-Directed Physiatric Education Program for practitioners and trainees in physical medicine and rehabilitation and geriatric medicine. This article specifically focuses on ethical issues, including capacity, psychodynamics, sexuality, community integration, work, leisure skills, and the issue of driving a motor vehicle. Overall Article Objective: To summarize the societal aspects of disability and the older adult. C1 Philadelphia VA Med Ctr, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA. Northlake Rehabil Profess, Hammond, LA USA. Univ Missouri, Dept Phys Med & Rehabil, Columbia, MO USA. Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA. RP Bodenheimer, CF (reprint author), Philadelphia VA Med Ctr, Dept Phys Med & Rehabil, RMS 117,Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM Carol.Bodenheimer2@med.va.gov NR 35 TC 2 Z9 2 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUL PY 2004 VL 85 IS 7 SU 3 BP S23 EP S26 DI 10.1016/j.apmr.2004.03.009 PG 4 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 837ZG UT WOS:000222679600006 PM 15221719 ER PT J AU Phillips, EM Bodenheimer, CF Roig, RL Cifu, DX AF Phillips, EM Bodenheimer, CF Roig, RL Cifu, DX TI Geriatric rehabilitation. 4. Physical medicine and rehabilitation interventions for common age-related disorders and geriatric syndromes SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE activities of daily living; behavior; bladder; bowel; cognition; disability; exercise; geriatrics; osteoporosis; rehabilitation ID HEALTHY POSTMENOPAUSAL WOMEN; RANDOMIZED CONTROLLED TRIAL; ESTROGEN PLUS PROGESTIN; BONE-MINERAL DENSITY; URINARY-INCONTINENCE; HIP FRACTURE; FECAL INCONTINENCE; OSTEOPOROSIS; RISK; CONSTIPATION AB This self-directed learning module highlights physical medicine and rehabilitation (PM&R) interventions for age-related physiologic changes. It is part of the study guide on geriatric rehabilitation in the Self-Directed Physiatric Education Program for practitioners and trainees in PM&R and geriatric medicine. This article specifically focuses on PM&R interventions (including exercise) for mobility alterations, activities of daily living alterations, osteoporosis, cognitive and behavioral changes, bladder changes, and bowel changes. Overall Article Objective: To summarize the physical medicine and rehabilitation interventions for age-related physiologic changes. C1 Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA. Philadelphia VA Med Ctr, Dept Phys Med & Rehabil, Philadelphia, PA USA. Northlake Rehabil Profess, Dept Phys Med & Rehabil, Hammond, LA USA. Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA. RP Phillips, EM (reprint author), Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA 02114 USA. EM ephillips1@partners.org NR 42 TC 3 Z9 3 U1 1 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUL PY 2004 VL 85 IS 7 SU 3 BP S18 EP S22 DI 10.1016/j.apmr.2004.03.008 PG 5 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 837ZG UT WOS:000222679600005 PM 15221718 ER PT J AU Stewart, DG Phillips, EM Bodenheimer, CF Cifu, DX AF Stewart, DG Phillips, EM Bodenheimer, CF Cifu, DX TI Geriatric rehabilitation. 2. Physiatric approach to the older adult SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE falls; geriatrics; pain; pharmacology; prevention; rehabilitation ID EVIDENCE-BASED MEDICINE; PAIN MANAGEMENT; VULNERABLE ELDERS/; QUALITY INDICATORS; PATIENT SAFETY; IMPROVE; COMMUNITY; FALLS; CARE; RELIABILITY AB This self-directed learning module highlights the physiatric approach to the older adult. It is part of the study guide on geriatric rehabilitation in the Self-Directed Physiatric Education Program for practitioners and trainees in physical medicine and rehabilitation (PM&R) and geriatric medicine. This article specifically focuses' on the advantages of the physiatric approach, PM&R training in geriatric rehabilitation, metrics in geriatric assessment, prevention, symptom management, medical management, falls, pain, and pharmacology. Overall Article Objective: To summarize the physiatric approach to the older adult. C1 Brooks Hlth Syst Adm, Jacksonville, FL USA. Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA. Philadelphia VA Med Ctr, Dept Phys Med & Rehabil, Philadelphia, PA USA. Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA. RP Stewart, DG (reprint author), Brooks Rehabil Hosp, 3599 Univ Blvd, Jacksonville, FL 32216 USA. EM deborah.stewart@brookshealth.org NR 41 TC 2 Z9 2 U1 3 U2 4 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUL PY 2004 VL 85 IS 7 SU 3 BP S7 EP S11 DI 10.1016/j.apmr.2004.03.006 PG 5 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 837ZG UT WOS:000222679600003 PM 15221716 ER PT J AU Gorin, Y Ricono, JM Wagner, B Kim, NH Bhandari, B Choudhury, GG Abboud, HE AF Gorin, Y Ricono, JM Wagner, B Kim, NH Bhandari, B Choudhury, GG Abboud, HE TI Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells SO BIOCHEMICAL JOURNAL LA English DT Article DE angiotensin II; arachidonic acid; extracellular-signal-regulated kinase 1 and 2 (ERK1/ERK2); hypertrophy; Nox4 NADPH oxidase; reactive oxygen species ID SMOOTH-MUSCLE-CELLS; TUBULAR EPITHELIAL-CELLS; ARACHIDONIC-ACID; NAD(P)H OXIDASE; GROWTH-FACTOR; CELLULAR MECHANISMS; SIGNALING PATHWAYS; PHOSPHOLIPASE A(2); KINASE; HYPERTROPHY AB Angiotensin II (Ang II) stimulates hypertrophy of glomerular mesangial cells. The signalling mechanism by which Ang II exerts this effect is not precisely known. Downstream potential targets of Ang II are the extracellular-signal-regulated kinases 1 and 2 (ERK1/ERK2). We demonstrate that Ang II activates ERK1/ERK2 via the AT, receptor. Arachidonic acid (AA) mimics the action of Ang II on ERK1/ERK2 and phospholipase A(2) inhibitors blocked Ang II-induced ERK1/ERK2 activation. The antioxidant N-acetylcysteine as well as the NAD(P)H oxidase inhibitors diphenylene iodonium and phenylarsine oxide abolished both Ang II- and AA-induced ERK1/ERK2 activation. Moreover, dominant-negative Rac1 (N17Rac1) blocks activation of ERK1/ERK2 in response to Ang II and AA, whereas constitutively active Rac1 resulted in an increase in ERK1/ERK2 activity. Antisense oligonucleotides for Nox4 NAD(P)H oxidase significantly reduce activation of ERK1/ERK2 by Ang II and AA. We also show that protein synthesis in response to Ang II and AA is inhibited by N17Rac1 or MEK (mitogen-activated protein kinase/ERK kinase) inhibitor. These results demonstrate that Ang II stimulates ERK1/ ERK2 by AA and Nox4-derived reactive oxygen species, suggesting that these molecules act as downstream signal transducers of Ang II in the signalling pathway linking the Ang II receptor AT, to ERK1/ERK2 activation. This pathway involving AA, Rac1, Nox4, reactive oxygen species and ERK1/ERK2 may play an important role in Ang II-induced mesangial cell hypertrophy. C1 Univ Texas, Hlth Sci Ctr, Div Nephrol, Dept Med, San Antonio, TX 78229 USA. Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. Audie L Murphy Mem Vet Adm Med Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. RP Gorin, Y (reprint author), Univ Texas, Hlth Sci Ctr, Div Nephrol, Dept Med, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM gorin@uthscsa.edu OI Gorin, Yves/0000-0003-4048-6925; Wagner, Brent/0000-0002-7063-0142 FU NIDDK NIH HHS [DK 55815, DK 33665, DK 43988, R01 DK033665, R01 DK055815, R37 DK033665] NR 43 TC 92 Z9 100 U1 0 U2 0 PU PORTLAND PRESS PI LONDON PA 59 PORTLAND PLACE, LONDON W1N 3AJ, ENGLAND SN 0264-6021 J9 BIOCHEM J JI Biochem. J. PD JUL 1 PY 2004 VL 381 BP 231 EP 239 DI 10.1042/BJ20031614 PN 1 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 838PB UT WOS:000222724200027 PM 15027896 ER PT J AU Atwood, CW McCrory, D Garcia, JGN Abman, SH Ahearn, GS AF Atwood, CW McCrory, D Garcia, JGN Abman, SH Ahearn, GS TI Pulmonary artery hypertension and sleep-disordered breathing - ACCP evidence-based clinical practice guidelines SO CHEST LA English DT Article DE clinical guideline; continuous positive airway pressure therapy; evidenced-based review; hypoxemia; pulmonary arterial hypertension; sleep-disordered breathing ID POSITIVE AIRWAY PRESSURE; APNEA SYNDROME; PARALLEL TRIAL; LUNG-DISEASE; HEMODYNAMICS; HYPOXEMIA; OXYGEN AB The objective of this article is to review the available data on the relationship between sleep-disordered breathing (SDB) and pulmonary arterial hypertension (PAH), with a focus on the prevalence of SDB in patients with idiopathic PAH (IPAH); the prevalence of PAH in patients with SDB; and the effects of SDB treatment on PAH. The evidence to date suggests that PAH may occur in the setting of SDB, although the prevalence is low. However, pulmonary hypertension (PH) in SDB is most strongly associated with other risk factors, such as left-sided heart disease, parenchymal lung disease, nocturnal desaturation, and obesity. The limited data available also suggest that SDB is uncommon in patients with IPAH. Treatment of SDB with continuous positive airway pressure may lower pulmonary artery pressures when the degree of PH is mild. C1 Univ Pittsburgh, Med Ctr, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Duke Univ, Med Ctr, Duke Ctr Clin Hlth Res, Dept Med, Durham, NC USA. Johns Hopkins Univ Hosp, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21287 USA. Univ Colorado, Childrens Hosp, Hlth Sci Ctr, Denver, CO 80202 USA. RP Atwood, CW (reprint author), UPMC, Montefiore PACCM, MUH, NW 628, Pittsburgh, PA 15213 USA. EM atwoodcw@upmc.edu RI Garcia, Joe/E-8862-2010 NR 27 TC 67 Z9 71 U1 0 U2 1 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD JUL PY 2004 VL 126 IS 1 SU S BP 72S EP 77S DI 10.1378/chest.126.1_suppl.72S PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 843EB UT WOS:000223057600007 PM 15249496 ER PT J AU Hecht, DW AF Hecht, DW TI Prevalence of antibiotic resistance in anaerobic bacteria: Worrisome developments SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID BACTEROIDES-FRAGILIS GROUP; CARBAPENEMASE GENE CFIA; BETA-LACTAM RESISTANCE; 5-NITROIMIDAZOLE RESISTANCE; ANTIMICROBIAL SUSCEPTIBILITY; FLUOROQUINOLONE RESISTANCE; INTRAABDOMINAL INFECTIONS; SEQUENCE-ANALYSIS; GYRA MUTATIONS; INSERTION AB Antibiotic-resistant anaerobic bacteria have become increasingly recognized as a confounding factor in the selection of therapeutic agents. The use of potent, broad-spectrum antibiotics as empirical therapy, along with appropriate adjunctive measures, has, in some ways, masked the magnitude of the antibiotic resistance problem that parallels that observed for nonanaerobic pathogens. The use of standardized testing methods that recognize resistance and an understanding of resistance mechanisms have become essential for the treatment of patients and the development of new agents. C1 Loyola Univ, Med Ctr, Dept Med, Maywood, IL 60153 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. RP Hecht, DW (reprint author), Loyola Univ, Med Ctr, Dept Med, Bldg 54,Rm 101,2160 S 1st Ave, Maywood, IL 60153 USA. EM dhecht@lumc.edu FU NIAID NIH HHS [AI050122] NR 47 TC 69 Z9 72 U1 2 U2 6 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUL 1 PY 2004 VL 39 IS 1 BP 92 EP 97 DI 10.1086/421558 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 829YJ UT WOS:000222087800016 PM 15206059 ER PT J AU Weems, SA Zaidel, E Berman, S Mandelkern, MA AF Weems, SA Zaidel, E Berman, S Mandelkern, MA TI Asymmetry in alpha power predicts accuracy of hemispheric lexical decision SO CLINICAL NEUROPHYSIOLOGY LA English DT Article DE alpha; laterality; electroencephalography; hemispheric specialization ID TERM-MEMORY TASK; BILATERAL PRESENTATIONS; BRAIN ACTIVITY; EEG; GAMMA; HUMANS; PERFORMANCE; SCALES AB Objective: Previous work has shown that individual differences in resting alpha asymmetry are associated with efficacy on a variety of cognitive tasks. Still unresolved is how ongoing alpha asymmetry relates to behavioral asymmetry, explored here using lateralized lexical decision. Methods: Alpha power immediately preceding lexical decision trials was measured to assess cognitive engagement during word recognition. This was compared with behavioral performance for the task, measured by accuracy and latency of the lexical decision response. Results: Greater relative left hemisphere alpha power (i.e. higher asymmetry) immediately before presentation of a word led to reduced likelihood for its successful identification. Greater alpha asymmetry was also associated with reduced performance for identifying stimuli lateralized to the right visual field. Conclusions: Word recognition is facilitated by decreased asymmetry in cognitive engagement in the two cerebral hemispheres, particularly when the stimuli are lateralized to the left hemisphere (right visual field). Significance: Results address the role of cognitive engagement in the two cerebral hemispheres, and its relationship with lexical access. (C) 2004 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved. C1 Univ Maryland, Dept Comp Sci, College Pk, MD 20742 USA. W Los Angeles Vet Adm Hosp, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. Univ Calif Irvine, Irvine, CA USA. RP Weems, SA (reprint author), Univ Maryland, Dept Comp Sci, AV Williams Bldg, College Pk, MD 20742 USA. EM sweems@cs.umd.edu FU NIDCD NIH HHS [F31 DC 04916-01]; NINDS NIH HHS [NS 20187] NR 30 TC 4 Z9 5 U1 2 U2 2 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 1388-2457 J9 CLIN NEUROPHYSIOL JI Clin. Neurophysiol. PD JUL PY 2004 VL 115 IS 7 BP 1575 EP 1582 DI 10.1016/j.clinph.2004.02.020 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 839WE UT WOS:000222814800010 PM 15203058 ER PT J AU Chao, LL Lindgren, JA Flenniken, DL Weiner, MW AF Chao, LL Lindgren, JA Flenniken, DL Weiner, MW TI ERP evidence of impaired central nervous system function in virally suppressed HIV patients on antiretroviral therapy SO CLINICAL NEUROPHYSIOLOGY LA English DT Article DE human immunodeficiency virus; P3a; P3b; viral load; antiretroviral therapy ID EVENT-RELATED POTENTIALS; AIDS DEMENTIA COMPLEX; P3 LATENCY; INTRACEREBRAL POTENTIALS; VISUAL-STIMULI; TEMPORAL-LOBE; RARE TARGET; INFECTION; DEPRESSION; LESIONS AB Objective: To examine the effects of human immunodeficiency virus (HIV) on central nervous system (CNS) function in patients receiving antiretroviral therapy (ART) who have suppressed viral loads. Methods: Event-related brain potentials (ERPs) were recorded from 15 virally suppressed HIV patients and 15 age-, sex-, and education-matched controls while they performed a 3-stimulus auditory oddball task. The amplitude and latency of the P3a, P3b, and early auditory components were examined in HIV patients and controls. Results: Virally suppressed HIV patients on ART were more depressed than controls, as determined by the Beck Depression Inventory (BDI). After controlling for the effects of depression, HIV patients had smaller P2, P3a, and P3b amplitudes and longer P3a and P3b latency than control subjects. BDI scores correlated positively with NI latency in HIV patients and negatively with P3b amplitude in all subjects. Conclusions: These electrophysiological results suggest that, even in the absence of detectable levels of HIV in the peripheral blood, viral replication persists in the CNS and continues to cause disease in HIV patients on ART. (C) 2004 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved. C1 San Francisco Vet Affairs Med Ctr, Dept Radiol, Magnet Resonance Unit, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. RP Chao, LL (reprint author), San Francisco Vet Affairs Med Ctr, Dept Radiol, Magnet Resonance Unit, 4150 Clement St,116R, San Francisco, CA 94121 USA. EM llchao@itsa.ucsf.edu FU NIA NIH HHS [P50 AG023501, P50 AG023501-059004]; NIAAA NIH HHS [P01 AA011493, P01 AA11493] NR 59 TC 15 Z9 18 U1 0 U2 2 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 1388-2457 J9 CLIN NEUROPHYSIOL JI Clin. Neurophysiol. PD JUL PY 2004 VL 115 IS 7 BP 1583 EP 1591 DI 10.1016/j.clinph.2004.02.015 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 839WE UT WOS:000222814800011 PM 15203059 ER PT J AU George, MS Nahas, Z Bohning, DE Mu, QW Kozel, FA Borckhardt, J Denslow, S AF George, MS Nahas, Z Bohning, DE Mu, QW Kozel, FA Borckhardt, J Denslow, S TI Mechanisms of action of vagus nerve stimulation (VNS) SO CLINICAL NEUROSCIENCE RESEARCH LA English DT Article; Proceedings Paper CT 83rd Conference on Convulsants and AntiConvulsants in Psychiatry and Neurology CY NOV 14-15, 2003 CL New York, NY SP Assoc Res Nervous & Ment Dis DE vagus nerve; VNS; locus ceruleus; anticonvulsant; antidepressant; brain stimulation; fMRI ID TREATMENT-RESISTANT DEPRESSION; PARTIAL SEIZURES; SOLITARY TRACT; NORADRENERGIC FUNCTION; ANTIANXIETY TREATMENT; REFRACTORY EPILEPSY; VAGAL-STIMULATION; BRAIN; NUCLEUS; RAT AB In 1992, Dr Jake Zabara discovered in a canine model that repeated stimulation of the vagus nerve in the neck could stop seizures. Since that time, repeated stimulation of the vagus nerve has been FDA approved as an anticonvulsant. Zabara's work is built on a 50-year-old theme in the literature where scientists had sought to exploit the fact that the vagus nerve is composed of 80% afferent fibers. Thus vagus stimulation might potentially provide a 'window' into the brain. This manuscript reviews the basic science and brain imaging work done to date with VNS, attempting to understand how VNS affects the brain. This research is crucial to perfecting VNS as an anticonvulsant, and for determining other neuropsychiatric conditions that might be helped by VNS. (C) 2004 Elsevier B.V. All rights reserved. C1 Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC USA. Med Univ S Carolina, Ctr Adv Imaging Res, Charleston, SC USA. Ralph H Johson Vet Hosp, Charleston, SC USA. RP George, MS (reprint author), Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, 67 President St,Room 502, Charleston, SC USA. EM georgem@musc.edu RI Kozel, Frank/I-5366-2012 NR 56 TC 3 Z9 3 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1566-2772 J9 CLIN NEUROSCI RES JI Clin. Neurosci. Res. PD JUL PY 2004 VL 4 IS 1-2 BP 71 EP 79 DI 10.1016/j.cnr.2004.06.006 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 861EU UT WOS:000224399700007 ER PT J AU Mularski, RA AF Mularski, RA TI Pain management in the intensive care unit SO CRITICAL CARE CLINICS LA English DT Review ID END-OF-LIFE; CRITICALLY-ILL PATIENTS; CLINICAL-PRACTICE GUIDELINES; MECHANICAL VENTILATION; HOSPITALIZED-PATIENTS; EPIDURAL ANALGESIA; NATIONAL-SURVEY; CANCER PAIN; ICU; SEDATIVES AB Pain management is an essential component of quality care delivery for the critically ill patient. Because outcomes are difficult to predict in the intensive care unit (ICU), high-quality pain management and palliative therapy should be a goal for every patient. For those patients actively dying, palliation may be among the main benefits offered by the health care team. Appropriate palliation of pain begins with the use of effective strategies for recognizing, evaluating, and monitoring pain. Skill in pain management requires knowledge of both pharmacologic and nonpharmacologic therapies. This article focuses on expertise in the use of opiates to facilitate confident and appropriate pain therapy To optimize palliative therapy, symptoms are best addressed by interdisciplinary care teams guided by models that acknowledge a continuum of curative therapies and palliative care. C1 Univ Calif Los Angeles, Sch Publ Hlth, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Hlth Sci,Div Pulm & Crit Care Med, Los Angeles, CA 90073 USA. RP Mularski, RA (reprint author), Univ Calif Los Angeles, Sch Publ Hlth, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Hlth Sci,Div Pulm & Crit Care Med, 11301 Wilshire Blvd,Mail Code G111, Los Angeles, CA 90073 USA. EM rmularsk@ucla.edu NR 115 TC 22 Z9 22 U1 1 U2 2 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0749-0704 J9 CRIT CARE CLIN JI Crit. Care Clin. PD JUL PY 2004 VL 20 IS 3 BP 381 EP + DI 10.1016/j.ccc.2004.03.010 PG 22 WC Critical Care Medicine SC General & Internal Medicine GA 848IK UT WOS:000223460700005 PM 15183209 ER PT J AU Nelson, JE Meier, DE Litke, A Natale, DA Siegel, RE Morrison, RS AF Nelson, JE Meier, DE Litke, A Natale, DA Siegel, RE Morrison, RS TI The symptom burden of chronic critical illness SO CRITICAL CARE MEDICINE LA English DT Article DE ventilator weaning; respiration; artificial; palliative care; critical illness ID PROLONGED MECHANICAL VENTILATION; INTENSIVE-CARE UNIT; CONFUSION ASSESSMENT METHOD; ILL PATIENTS; BONE HYPERRESORPTION; ASSESSMENT SCALE; LUNG-CANCER; EXPERIENCE; SURVIVAL; PAIN AB Objective. To assess self-reported symptom burden of chronic critical illness. Design: Prospective cohort study. Setting. Respiratory care unit for treatment of chronically critically ill patients at an academic, tertiary-care, urban medical center. Patients: Fifty patients who underwent elective tracheotomy and transfer from an adult intensive care unit to the respiratory care unit for weaning from mechanical ventilation. Interventions. Assessment of physical and psychological symptoms through patients' self-reports using a modification of the Condensed Form of the Memorial Symptom Assessment Scale. Measurements and Main Results: We measured self-reported symptom burden, ventilator outcomes, and vital status and functional status at discharge and 3 and 6 months after discharge. Half of the patients were successfully liberated from mechanical ventilation, but most hospital survivors were discharged to skilled nursing facilities and more than half of the cohort was dead at 3 months after discharge. Seventy-two percent (36 of 50) of patients were able to self-report symptoms during the period of respiratory care unit treatment. Among patients responding to symptom assessment, approximately 90% were symptomatic. Forty-four percent of patients reported pain at the highest levels. More than 60% reported psychological symptoms at these levels, and approximately 90% of patients reported severe distress due to difficulty communicating. Conclusions: Physical and psychological symptom distress is common and severe among patients receiving treatment for chronic critical illness. The majority of these patients die soon after hospital discharge. Given the level of distress in our study patients and the high mortality rate that we and others have observed, greater attention should be given to relief of pain and other distressing symptoms and to assessment of burdens and benefits of treatment for the chronically critically ill. C1 Mt Sinai Sch Med, Div Pulm & Crit Care Med, Dept Med, New York, NY 10029 USA. Mt Sinai Sch Med, Hertzberg Palliat Care Inst, Dept Geriatr & Adult Dev, New York, NY 10029 USA. Crit Care Ctr, Bronx, NY USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. RP Nelson, JE (reprint author), Mt Sinai Sch Med, Div Pulm & Crit Care Med, Dept Med, Box 1232,1 Gustave L Levy Pl, New York, NY 10029 USA. EM Judith.nelson@mountsinai.org FU NIA NIH HHS [AG021172, K07 AG00903-03, K08AG00833-01] NR 56 TC 115 Z9 117 U1 6 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD JUL PY 2004 VL 32 IS 7 BP 1527 EP 1534 DI 10.1097/01.CCM.0000129485.08835.5A PG 8 WC Critical Care Medicine SC General & Internal Medicine GA 837QZ UT WOS:000222651800010 PM 15241097 ER PT J AU Chanin, TD Merrick, DT Franklin, WA Hirsch, FR AF Chanin, TD Merrick, DT Franklin, WA Hirsch, FR TI Recent developments in biomarkers for the early detection of lung cancer: perspectives based on publications 2003 to present SO CURRENT OPINION IN PULMONARY MEDICINE LA English DT Article DE lung cancer; biomarkers; proteomics; gene analysis ID ATYPICAL ADENOMATOUS HYPERPLASIA; BRONCHIAL PRECANCEROUS LESIONS; ABERRANT PROMOTER METHYLATION; K-RAS; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; PROTEOMIC PATTERNS; TISSUE MICROARRAYS; SPUTUM CYTOLOGY; EXPRESSION; MARKERS AB Purpose of review Given the poor prognosis associated with lung cancer, the ability to diagnose lung cancer in its early stages is considered crucial to achieving decreased lung cancer mortality. Herein, we discuss recent advances in biomarker discovery and evaluation of their potential application in the clinical setting. Recent findings Novel potential biomarkers have been identified via new techniques including cDNA microarray analysis, comparative genomic hybridization, and proteomics. These factors have been evaluated in various validation studies including tissue microarrays, RT-PCR, and assays of bioactivity. The characterization of these potential biomarkers through analysis of pathways that have been associated with neo-plastic transformation may help to identify the precursor lesions that are associated with subsequent progression to invasive carcinoma. In addition, the past year has also produced intriguing results regarding the detection of biomarkers in easily accessible screening specimens such as sputa, serum, and exhaled breath. Recent advances in these aspects of biomarker identification for the early detection of lung cancer are reviewed. Summary Identification of new candidate biomarkers and improved applications of previously detected biomarkers show great promise for the ultimate establishment of practical lung cancer screening. While recent studies engender optimism for the creation of clinically applicable screening tests, the biomarkers that have been identified need larger, follow-up validational studies and further characterization as to their biologic importance. C1 Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA. Univ Colorado, Ctr Canc, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Dept Pathol, Denver, CO USA. RP Hirsch, FR (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Pathol, B216,4200 E 9th Ave, Denver, CO 80262 USA. EM fred.hirsch@uchsc.edu FU NCI NIH HHS [P50-CA58187, U01-CA85070] NR 63 TC 35 Z9 37 U1 3 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1070-5287 J9 CURR OPIN PULM MED JI Curr. Opin. Pulm. Med. PD JUL PY 2004 VL 10 IS 4 BP 242 EP 247 DI 10.1097/01.mcp.0000130321.11513.13 PG 6 WC Respiratory System SC Respiratory System GA 835BS UT WOS:000222455500002 PM 15220746 ER PT J AU Maciejewski, ML Reiber, GE Smith, DG Wallace, C Hayes, S Boyko, EJ AF Maciejewski, ML Reiber, GE Smith, DG Wallace, C Hayes, S Boyko, EJ TI Effectiveness of diabetic therapeutic footwear in preventing reulceration SO DIABETES CARE LA English DT Review ID ULCERS; SHOES; MANAGEMENT; MEDICARE; PATIENT; TRIALS; COHORT; COSTS; RISK AB OBJECTIVE - To review the evidence for the effectiveness of therapeutic footwear in preventing foot reulceration in individuals with diabetes and foot risk factors. RESEARCH DESIGN AND METHODS - We conducted a structured literature review based on a Medline search for studies of therapeutic footwear that examined prevention of reulceration. Nine published articles were identified. Characteristics of the study population, components of the intervention, and level of adherence were evaluated. U.S. preventive Services Task Force criteria for evaluating research were applied to rate each study on study design and internal validity. RESULTS - Risk ratios in all studies assessing the association between therapeutic footwear and reulceration were below 1.0, suggesting some protective footwear benefit. However, in the most rigorous experimental study, no statistically significant benefit was observed between control patients wearing their own footwear and intervention patients wearing study footwear. Annual reulceration in these studies control groups ranged from 8.4 to 59.3%. In patients with severe foot deformity or prior toe or ray amputation, observational studies suggested a significant protective benefit from therapeutic footwear. CONCLUSIONS - Therapeutic footwear has been used for decades as one of many strategies to prevent reulceration in patients with diabetes and foot risk factors. The findings of several studies reporting statistically significant protective effects from therapeutic footwear may have been influenced by several design issues. When considering the appropriateness of therapeutic footwear recommendations for moderate-risk patients, clinicians and patients should jointly explore individual strategies to decrease events that lead to foot ulcers. C1 VA Puget Sound Hlth Care Syst HSR&D 152, Hlth Serv Res & Dev, Dept Vet Affairs, Seattle, WA 98108 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Orthoped Surg, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Maciejewski, ML (reprint author), VA Puget Sound Hlth Care Syst HSR&D 152, Hlth Serv Res & Dev, Dept Vet Affairs, 1660 S Columbian Way, Seattle, WA 98108 USA. EM mlmaciej@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X NR 36 TC 42 Z9 46 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JUL PY 2004 VL 27 IS 7 BP 1774 EP 1782 DI 10.2337/diacare.27.7.1774 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 834FN UT WOS:000222397100043 PM 15220265 ER PT J AU Williams, R Ehde, D Smith, D Czerniecki, J Hoffman, A Robinson, L AF Williams, R Ehde, D Smith, D Czerniecki, J Hoffman, A Robinson, L TI A two-year longitudinal study of social support following amputation SO DISABILITY AND REHABILITATION LA English DT Article ID LOWER-LIMB AMPUTATION; CHRONIC PAIN; LIFE SCALE; ADJUSTMENT; REHABILITATION; SATISFACTION; DEPRESSION; STRESS; DISABILITY; MORTALITY AB Purpose : (1) To describe one aspect of social support, social integration, longitudinally for 2 years following lower limb amputation and (2) to explore the impact of social support on depression, pain interference, life satisfaction, mobility, and occupational functioning. Method : Eighty-nine adults recruited from consecutive admissions to an orthopaedic surgery service completed telephone interviews 1, 6, 12 and 24 months following amputation surgery. Dependent variables included the Social Integration (SI) sub-scale of the Craig Handicap Assessment and Reporting Technique (CHART) and the Multidimensional Scale of Perceived Social Support (MSPSS). Results : There was a high level of SI among most persons following lower limb amputations that was relatively unchanged in the 2 years following surgery. However, mean levels of SI were lower in this group compared to a sample without disabilities. MSPSS scores were highly variable, ranging from almost no support to the maximum amount of support. MSPSS was an important concurrent predictor of pain interference, life satisfaction, and mobility, controlling for demographic and amputation-related factors. Baseline MSPSS predicted mobility and occupational functioning 6 months post-amputation, controlling for demographic and amputation-related factors. Conclusions : Findings suggest that interventions aimed at improving the quality of social relationships after amputation may facilitate participation in activities. C1 Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Sch Med, Seattle, WA 98104 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. VA Ctr Amputat Prosthet & Limb Loss Prevent, Seattle, WA USA. RP Ehde, D (reprint author), Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Sch Med, Box 359740,325 9th Ave, Seattle, WA 98104 USA. EM ehde@u.washington.edu RI Robinson , Lawrence/D-8455-2013 FU NICHD NIH HHS [P01 HD/NS33988]; PHS HHS [MM-0127-02/02] NR 52 TC 32 Z9 32 U1 1 U2 10 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1464-5165 J9 DISABIL REHABIL JI Disabil. Rehabil. PD JUL-AUG PY 2004 VL 26 IS 14-15 BP 862 EP 874 DI 10.1080/09638280410001708878 PG 13 WC Rehabilitation SC Rehabilitation GA 835ZJ UT WOS:000222524200005 PM 15497915 ER PT J AU Madison, DL Bliziotes, M AF Madison, DL Bliziotes, M TI Severe dystrophic calcification confounded by secondary hyperparathyroidism in a patient with thyroid lymphoma and CREST syndrome SO ENDOCRINOLOGIST LA English DT Article DE calcinosis; vitamin D; hyperparathyroidism; extraskeletal calcification ID TUMORAL CALCINOSIS; SYSTEMIC-SCLEROSIS; PARATHYROIDECTOMY; DILTIAZEM; HEMODIALYSIS; REGRESSION; PATHOGENESIS; SCLERODERMA AB The extraskeletal calcific disorders represent a wide variety of metabolic, genetic, and autoimmune diseases causing abnormal calcium salt deposition. Sequelae resulting from calcifications can be severe, causing dermal breakdown, superinfection, and restriction of joint mobility with a significant decrease in patient quality of life.. The pathophysiology and extent of extraskeletal calcification is directly dependent on the causative disease process, and therefore the determination of the etiology of extraskeletal calcification can lead to early treatment and significant reduction in comorbidities related to the underlying clinical condition. We discuss a case of extreme subcutaneous extraskeletal calcification resulting from an autoimmune inflammatory process that is confounded by secondary hyperparathyroidism. C1 Oregon Hlth Sci Univ, Div Endocrinol, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Div Endocrinol Diabet & Clin Nutr, Dept Med, Portland, OR 97239 USA. Portland VA Med Ctr, Endocrinol Sect, Portland, OR USA. RP Madison, DL (reprint author), Oregon Hlth Sci Univ, Div Endocrinol, L-607,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM madisond@ohsu.edu NR 27 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1051-2144 J9 ENDOCRINOLOGIST JI Endocrinologist PD JUL-AUG PY 2004 VL 14 IS 4 BP 195 EP 198 DI 10.1097/01.ten.0000134719.42806.64 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 840YJ UT WOS:000222896200004 ER PT J AU Wiren, KM Zhang, XW Toombs, AR Kasparcova, V Gentile, MA Harada, SI Jepsen, KJ AF Wiren, KM Zhang, XW Toombs, AR Kasparcova, V Gentile, MA Harada, SI Jepsen, KJ TI Targeted overexpression of androgen receptor in osteoblasts: Unexpected complex bone phenotype in growing animals SO ENDOCRINOLOGY LA English DT Article ID NORMAL ELDERLY MEN; I COLLAGEN; BIOCHEMICAL MARKERS; OSTEOGENESIS IMPERFECTA; POSTMENOPAUSAL WOMEN; ORCHIECTOMIZED RAT; CANCELLOUS BONE; DEFICIENT MICE; GROWTH-PLATE; ESTROGEN AB The androgen receptor (AR), as a classic steroid receptor, generally mediates biologic responses to androgens. In bone tissue, both AR and the estrogen receptor ( ER) are expressed in a variety of cell types. Because androgens can be converted into estrogen via aromatase activity, the specific role of the AR in maintenance of skeletal homoeostasis remains controversial. The goal of this study was to use skeletally targeted overexpression of AR as a means of elucidating the specific role(s) for AR transactivation in bone homeostasis. Rat AR cDNA was cloned downstream of a 3.6-kb alpha1(I)-collagen promoter fragment and used to create AR-transgenic mice. AR-transgenic males gain less weight and body and femur length is shorter than wild-type controls, whereas females are not different. AR-transgenic males also demonstrate thickened calvaria and increased periosteal but reduced endosteal labeling by fluorescent labeling and reduced osteocalcin levels. High-resolution micro-computed tomography shows normal mineral content in both male and female AR-transgenic mice, but male AR-transgenics reveal a reduction in cortical area and moment of inertia. Male AR-transgenics also demonstrate an altered trabecular morphology with bulging at the metaphysis. Histomorphometric analysis of trabecular bone parameters confirmed the increased bone volume comprised of more trabeculae that are closer together but not thicker. Biomechanical analysis of the skeletal phenotype demonstrate reduced stiffness, maximum load, post-yield deflection, and work-to-failure in male AR-transgenic mice. Steady-state levels of selected osteoblastic and osteoclastic genes are reduced in tibia from both male and female transgenics, with the exception of increased osteoprotegerin expression in male AR-transgenic mice. These results indicate that AR action is important in the development of a sexually dimorphic skeleton and argue for a direct role for androgen transactivation of AR in osteoblasts in modulating skeletal development and homeostasis. C1 Portland Vet Affairs Med Ctr, Bone & Mineral Res Unit, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Merck Res Labs, Dept Mol Endocrinol Bone Biol, W Point, PA 19486 USA. CUNY Mt Sinai Sch Med, Dept Orthopaed, New York, NY 10029 USA. RP Wiren, KM (reprint author), Portland Vet Affairs Med Ctr, Bone & Mineral Res Unit, P3-R&D39,3710 SW Vet Hosp Rd, Portland, OR 97239 USA. EM wirenk@ohsu.edu OI Wiren, Kristine/0000-0002-6159-4450 NR 60 TC 53 Z9 54 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD JUL PY 2004 VL 145 IS 7 BP 3507 EP 3522 DI 10.1210/en.2003-1016 PG 16 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 829JI UT WOS:000222043900056 PM 15131013 ER PT J AU Jensen, DM Chaves, DM Grund, KE AF Jensen, DM Chaves, DM Grund, KE TI Endoscopic diagnosis and treatment of watermelon stomach SO ENDOSCOPY LA English DT Article ID ANTRAL VASCULAR ECTASIA; ARGON PLASMA COAGULATION; LASER THERAPY; GAVE AB The aim of the Expert Approach section is to contribute to the dissemination and standardization of new endoscopic procedures. Authors from three distinct geographic areas combine forces, sharing their experience to form a consensus of opinion. Readers' comments are welcome and will be published in the Mailbox which appears at the end of each Expert Approach article. C1 Univ Calif Los Angeles, CURE, Los Angeles VA Med Ctr, Los Angeles, CA 90073 USA. Univ Sao Paulo, Sch Med, Endoscopy Serv, Sao Paulo, Brazil. Univ Hosp, Dept Gen Surg, Tubingen, Germany. RP Jensen, DM (reprint author), Univ Calif Los Angeles, CURE, Los Angeles VA Med Ctr, 11301 Wilshire Blvd,Bldg 115,Room 318, Los Angeles, CA 90073 USA. EM djensen@mednet.ucla.edu FU NCRR NIH HHS [M01 RR 008658]; NIDDK NIH HHS [DK 02650] NR 19 TC 13 Z9 14 U1 0 U2 0 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0013-726X J9 ENDOSCOPY JI Endoscopy PD JUL PY 2004 VL 36 IS 7 BP 640 EP 647 DI 10.1055/s-2004-814525 PG 8 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 835LG UT WOS:000222484000012 PM 15243889 ER PT J AU Alam, MN McGinty, D Bashir, T Kumar, S Imeri, L Opp, MR Szymusiak, R AF Alam, MN McGinty, D Bashir, T Kumar, S Imeri, L Opp, MR Szymusiak, R TI Interleukin-1 beta modulates state-dependent discharge activity of preoptic area and basal forebrain neurons: role in sleep regulation SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE cytokine; extracellular unit recording; interleukin-1 receptor antagonist; microdialysis; rat ID RECEPTOR MESSENGER-RNA; EYE-MOVEMENT SLEEP; NF-KAPPA-B; CEREBRAL-CORTEX; CHOLINERGIC NEURONS; BRAIN TEMPERATURE; GABAERGIC NEURONS; RAT-BRAIN; ACTIVATION; ADENOSINE AB Interleukin-1beta (IL-1) is a pro-inflammatory cytokine that has been implicated in the regulation of nonrapid eye movement (nonREM) sleep. IL-1, IL-1 receptors and the IL-1 receptor antagonist (ra) are present normally in discrete brain regions, including the preoptic area (POA) of the hypothalamus and the adjoining magnocellular basal forebrain (BF). The POA/BF have been implicated in the regulation of sleep-wakefulness. We hypothesized that IL-1 promotes nonREM sleep, in part by altering the state-dependent discharge activity of POA/BF neurons. We recorded the sleep-wake discharge profiles of 83 neurons in the lateral POA/BF and assessed the effects of IL-1, IL-1ra, and IL-ra + IL-1 delivered through a microdialysis probe on state-dependent neuronal discharge activity. IL-1 decreased the discharge rate of POA/BF neurons as a group (n = 55) but wake-related and sleep-related neurons responded differently. IL-1 significantly decreased the discharge rate of wake-related neurons. Of 24 wake-related neurons studied, 19 (79%) neurons exhibited a greater than 20% change in their discharge in the presence of IL-1 during waking. IL-1 suppressed the discharge activity of 18 of 19 responsive neurons. Of 13 sleep-related neurons studied, IL-1 increased the discharge activity of five and suppressed the discharge activity of four neurons. IL-1ra increased the discharge activity of four of nine neurons and significantly attenuated IL-1-induced effects on neuronal activity of POA/BF neurons (n = 19). These results suggest that the sleep-promoting effects of IL-1 may be mediated, in part, via the suppression of wake-related neurons and the activation of a subpopulation of sleep-related neurons in the POA/BF. C1 Vet Affairs Greater Los Angeles Hlth Care Syst, North Hills, CA 91343 USA. Univ So Calif, Dept Psychol, Los Angeles, CA 90033 USA. Univ So Calif, Dept Med, Los Angeles, CA 90033 USA. Univ Milan, Inst Human Physiol 2, Milan, Italy. Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48109 USA. Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA. RP Szymusiak, R (reprint author), Vet Affairs Greater Los Angeles Hlth Care Syst, 16111 Plummer St, North Hills, CA 91343 USA. EM rszym@ucla.edu FU NHLBI NIH HHS [HL60296]; NIMH NIH HHS [MH64843, MH61354, MH63323, MH47480] NR 59 TC 49 Z9 52 U1 0 U2 3 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0953-816X J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD JUL PY 2004 VL 20 IS 1 BP 207 EP 216 DI 10.1111/j.1460-9568.2004.03469.x PG 10 WC Neurosciences SC Neurosciences & Neurology GA 835YQ UT WOS:000222522000020 PM 15245493 ER PT J AU El-Serag, HB Everhart, JE AF El-Serag, HB Everhart, JE TI Is diabetes a risk factor for hepatocellular carcinoma? - Reply SO GASTROENTEROLOGY LA English DT Letter ID LIVER-DISEASE; HEPATITIS-C; VIRUS C1 Houston Dept Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA. Houston Dept Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. NIDDKD, Bethesda, MD 20892 USA. RP El-Serag, HB (reprint author), Houston Dept Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA. NR 5 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JUL PY 2004 VL 127 IS 1 BP 361 EP 362 DI 10.1053/j.gastro.2004.05.046 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 836HE UT WOS:000222545700050 ER PT J AU Gralnek, IM Dulai, GS AF Gralnek, IM Dulai, GS TI Incremental value of upper endoscopy for triage of patients with acute non-variceal upper-GI hemorrhage SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID UPPER-GASTROINTESTINAL HEMORRHAGE; LOW-RISK PATIENTS; RANDOMIZED CONTROLLED-TRIAL; OUTPATIENT MANAGEMENT; TRACT HEMORRHAGE; CARE; DISCHARGE; COMMUNITY AB Background: Risk scores for triage of patients with acute upper-GI hemorrhage that incorporate endoscopic variables (e.g., the complete Rockall Score) may have better test characteristics for identification of "low-risk" bleeding episodes than those (e.g., Blatchford Score, clinical Rockall Score) that rely solely on clinical variables. An endoscopy-based risk score was compared with two clinically based risk scores in a large cohort of patients hospitalized for treatment of acute upper-GI hemorrhage to quantify the incremental value of endoscopy in the identification of low-risk bleeding. Methods: ICD-9-CMcodes for discharge diagnosis were used to identify a cohort of patients(n=175) hospitalized at a university medical center with acute non-variceal upper-GI hemorrhage. Medical record data were abstracted by two data abstractors blinded to the study intent by using a standardized data collection instrument. Blatchford and Rockall Scores were generated for each case. Low risk was defined as a Blatchford Score of 0, a clinical Rockall Score of 0, or complete Rockall Score of 2 or less. Results: The Blatchford Score risk stratified only 14 of 175 (8%) patients with acute, non-variceal upper-GI hemorrhage as "low risk," while the clinical Rockall Score identified 12%. However, the complete Rockall Score identified the greatest number of low-risk cases, 53/175 (30%) (p<0.0001), when compared with either the Blatchford or clinical Rockall Score. Conclusions: The complete Rockall Score identified significantly more low-risk patients with acute upper-GI hemorrhage than either the clinical Rockall Score or the Blatchford Score. Identification of additional low-risk patients via this endoscopy-based score could lead to decreases in the use of hospital-based services, iatrogenic complications, and time lost from work or usual activity, while improving quality of care. Use of the clinical and complete Rockall Scores sequentially, with consideration of outpatient care for patients at identified as low risk, is recommended. C1 Univ Calif Los Angeles, David Geffen Sch Med ,CURE Digest Dis Res Ctr, VA Greater Los Angeles Healthcare Syst,Dept Med, Ctr Study Digest Healthcare Qual & Outcomes, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Dept Med, Div Gastroenterol & Hepatol, Los Angeles, CA USA. RP Gralnek, IM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med ,CURE Digest Dis Res Ctr, VA Greater Los Angeles Healthcare Syst,Dept Med, Ctr Study Digest Healthcare Qual & Outcomes, 11301 Wilshire Blvd,Bldg 115,Rm 215, Los Angeles, CA 90073 USA. FU NCRR NIH HHS [K23 RR1618801] NR 22 TC 45 Z9 48 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JUL PY 2004 VL 60 IS 1 BP 9 EP 14 AR PII S0016-5107(04)01524-X DI 10.1016/S0016-5107(04)01524-X PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 835SN UT WOS:000222505900002 PM 15229418 ER PT J AU Abraham, NS Wieczorek, P Huang, J Mayrand, S Fallone, CA Barkun, AN AF Abraham, NS Wieczorek, P Huang, J Mayrand, S Fallone, CA Barkun, AN TI Assessing clinical generalizability in sedation studies of upper GI endoscopy SO GASTROINTESTINAL ENDOSCOPY LA English DT Article; Proceedings Paper CT Digestive Disease Week Meeting/104th Annual Meeting of the American-Gastroenterological-Association CY MAY 17-22, 2003 CL ORLANDO, FL SP Amer Gastroenterol Assoc ID UPPER GASTROINTESTINAL ENDOSCOPY; CONSCIOUS SEDATION; RANDOMIZED-TRIAL; TOLERANCE AB Background: Prior endoscopic studies evaluating conscious sedation have recruited only a small proportion of the patients actually approached. The generalizability of such results to an unselected adult ambulatory care population is thus questionable. The objectives of this study were to determine the characteristics of patients who refused inclusion in a randomized controlled trial of sedation and to compare these characteristics to those of patients who agreed to participate. Methods: Patients who refused participation in a randomized controlled trial of sedation completed standardized questionnaires addressing demographic data and possible confounding variables, and they also completed a validated anxiety questionnaire. Characteristics associated with refusal to participate in the randomized controlled trial were assessed by using uni- and multivariate analysis. Exploratory comparisons of outcomes between both groups included self-reported satisfaction with level of comfort and technical adequacy. Results: Of 302 patients screened, 203 refused to participate in the randomized controlled trial. The most common reason for refusal was the request for no sedation (135/203). A total of 163 were enrolled in this synchronous study. Patients who refused to participate exhibited 3 distinguishing characteristics: prior treatment for an anxiety disorder (risk difference 9.4%: 95% CI[3%,17%]), use of analgesic medication (risk difference 10.4%: 95% CI[2%, 19%]), and prior experience with EGD (risk difference 17.9: 95% CI[5%, 30%]). Only upper endoscopy experience was predictive of refusal to participate in the randomized controlled trial. No differences in outcomes existed between patients randomized to sedation and those refusing the randomized controlled trial who chose to receive sedative medication. Patients who refused participation in the randomized controlled trial and who underwent upper endoscopy without sedation were more satisfied than patients randomized to placebo (1.33 vs. 2.58; risk difference -1.25: 95% CI[-0.385 -2.1]). Moreover, the procedure in these patients was more adequate technically (4.86 vs. 4.18; risk difference 0.68: 95% CI[0.21, 1.13]). Conclusions: Characteristics of patients accepting and refusing randomization were highly similar, differing only with regard to upper endoscopy experience. An exploratory analysis of outcomes suggests that randomized controlled trial results may be biased in a direction that may underestimate the benefits of not administering sedative medication in a real-life setting. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. McGill Univ, Ctr Hlth, Div Gastroenterol, Montreal, PQ, Canada. RP Abraham, NS (reprint author), Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. NR 16 TC 3 Z9 3 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JUL PY 2004 VL 60 IS 1 BP 28 EP 33 AR PII S0016-5107(04)01307-0 DI 10.1016/S0016-5107(04)01307-0 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 835SN UT WOS:000222505900005 PM 15229421 ER PT J AU Flynn, HA Davis, M Marcus, SM Cunningham, R Blow, FC AF Flynn, HA Davis, M Marcus, SM Cunningham, R Blow, FC TI Rates of maternal depression in pediatric emergency department and relationship to child service utilization SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE maternal depression; depression screening; child health outcomes ID HEALTH-CARE USE; PRESCHOOL-CHILDREN; DOMESTIC VIOLENCE; BEHAVIOR PROBLEMS; SUBSTANCE-ABUSE; YOUNG-CHILDREN; MOTHERS; SYMPTOMS; DISORDERS; PARENTS AB This cross-sectional study aimed to (a) identify rates and correlates of untreated elevated depression in mothers of young children in a pediatric emergency department (ED) setting and (b) examine the association of depression and other key variables to child healthcare use. Mothers (n=176) bringing their child (1.5 or <-1.5 fold change; P less than or equal to .05), of which 140 genes were suppressed and only 18 genes were up-regulated. These altered genes encode for leukocyte-specific markers and receptors, histocompatibility complex, cytokines/receptors, chemokines/receptors, adhesion molecules, components of the complement cascade, cellular activation, and transcription factors and signal transduction-related molecules. Interestingly, T(H)2 phenotype cytokines such as interleukin-4, interleukin-10, and transforming growth factor-beta1 and transcription factors such as peroxisome proliferator-activated receptor (PPAR)-gamma were upregulated in LSC by LOV treatment as further revealed by real-time PCR and immunoblotting. These findings indicate that PPARs may be mediating the anti inflammatory and immunomodulatory effects of LOV. Together, these findings provide new insight into the molecular events associated with the protection provided by statins during treatment of demyelinating diseases such as multiple sclerosis. (C) 2004 Wiley-Liss, Inc. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, 96 Jonathan Lucas St,CSB-316, Charleston, SC 29425 USA. EM singhi@musc.edu OI Paintlia, Ajaib/0000-0003-4525-5333 FU NINDS NIH HHS [NS-40144, NS-34741, NS-22576, NS-37766] NR 43 TC 60 Z9 64 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD JUL 1 PY 2004 VL 77 IS 1 BP 63 EP 81 DI 10.1002/jnr.20130 PG 19 WC Neurosciences SC Neurosciences & Neurology GA 834KW UT WOS:000222411000007 PM 15197739 ER PT J AU Matejuk, A Bakke, AC Hopke, C Dwyer, J Vandenbark, AA Offner, H AF Matejuk, A Bakke, AC Hopke, C Dwyer, J Vandenbark, AA Offner, H TI Estrogen treatment induces a novel population of regulatory cells, which suppresses experimental autoimmune encephalomyelitis SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE CD45; EAE; suppression; estrogen ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; T-CELLS; MULTIPLE-SCLEROSIS; GENDER-DIFFERENCES; IMMUNE PATHOLOGY; GENE-EXPRESSION; TNF-ALPHA; MICE; PREGNANCY AB Multiple sclerosis (MS) is a debilitating neurological disease characterized by a progressive loss of motor and sensory function, eventually leading to paralysis and death. The primary cause of neurological impairment is demyelination of the central nervous system (CNS) caused by an inflammatory autoimmune response. Previous studies have shown that the severity of MS is reduced during pregnancy, suggesting that the increased level of sex hormones may reduce the autoimmune response. Recently, we have shown that estrogen treatment confers protection from experimental autoimmune encephalomyelitis (EAE), which is an animal model for MS. However, the cellular basis of estrogen's action remains unknown. In the current study, we demonstrate that estrogen treatment led to the induction of a novel subpopulation of regulatory cells in spleen and CNS, which also occurs naturally in pregnant mice. These previously uncharacterized cells display a low level expression of CD45 (CD45 dim) and no detectable expression of many cell surface markers related to TCR signaling, including CD3 and TCR. However, these cells retained expression of VLA-4, an extracellular protein involved in cellular migration. Several lines of evidence suggest that these novel cells, defined as CD45(dim)VLA-4(+) cells, may play a role in the protective effects of estrogen in EAE. Injection of purified CD45(dim)VLA-4(+) cells conferred protection from spontaneous EAE (Sp-EAE). In contrast, injection of CD45(high)VLA-4(+) cells exacerbated the disease course. CD45(dim)VLA-4(+) cells also suppressed antigen-specific proliferation of primed lymphocytes in coculture. A better understanding of how CD45(dim)VLA-4(+) cells suppress the harmful immune response of EAE may help in explaining the induction of immune tolerance during pregnancy and lead to novel therapeutic approaches to combat MS and other autoimmune diseases. (C) 2004 Wiley-Liss, Inc. C1 Portland VA Med Ctr, Neuroimmunol Res, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR USA. Polish Acad Sci, L Hirszfeld Inst Immunol & Expt Therapy, Wroclaw, Poland. Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR USA. RP Matejuk, A (reprint author), Portland VA Med Ctr, Neuroimmunol Res, R&D 31,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM matejuka@ohsu.edu FU NIAID NIH HHS [AI42376]; NINDS NIH HHS [NS23444, NS23221] NR 32 TC 26 Z9 30 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD JUL 1 PY 2004 VL 77 IS 1 BP 119 EP 126 DI 10.1002/jnr.20145 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 834KW UT WOS:000222411000013 PM 15197745 ER PT J AU Valente, SM Bullough, V AF Valente, SM Bullough, V TI Sexual harassment of nurses in the workplace SO JOURNAL OF NURSING CARE QUALITY LA English DT Article DE evaluation; legal issues; sexual harassment ID BEHAVIOR AB Nurses who are sexually harassed at work face frustration and emotional and economic consequences. Historically before the 1970s, nurses had little legal recourse and tolerated sexual harassment as a necessary "evil" associated with working. The Civil Rights Act of 1964 created the option for legal remedies for sexual harassment/discrimination cases. Successful court cases established the legal criteria for sexual harassment. This article discusses the history, definition, high profile cases, research, consequences, and prevention of sexual harassment. Although research is scant and little is known of how nurses respond to harassing behavior, prevention requires coordinated activities of employers, individual employees, and the healthcare profession. Sexual harassment at work increases anxiety and undermines the nurse's ability to focus on the delivery of safe and competent care. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ So Calif, Los Angeles, CA USA. RP Valente, SM (reprint author), 346 N Bowling Green Way, Los Angeles, CA 90049 USA. EM Sharon.Valente@med.va.gov NR 27 TC 8 Z9 10 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1057-3631 J9 J NURS CARE QUAL JI J. Nurs. Care Qual. PD JUL-SEP PY 2004 VL 19 IS 3 BP 234 EP 241 PG 8 WC Nursing SC Nursing GA 831SD UT WOS:000222215500009 PM 15326993 ER PT J AU Singh, JA Pando, JA Tomaszewski, J Schumacher, HR AF Singh, JA Pando, JA Tomaszewski, J Schumacher, HR TI Quantitative analysis of immunohistologic features of very early rheumatoid synovitis in disease modifying antirheumatic drug- and corticosteroid-naive patients SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE rheumatoid arthritis; very early synovitis; quantitative immunohistochemistry ID MORPHOMETRIC ANALYSIS; BLOOD-VESSELS; KNEE JOINTS; ARTHRITIS; MEMBRANE; DURATION; TISSUE AB Objective. To describe the immunohistochemical features of very early rheumatoid synovitis in disease modifying antirheumatic drug- and corticosteroid-naive patients. Methods. Eight patients presenting with oligoarthritis or polyarthritis, who later met American Rheumatism Association criteria for rheumatoid arthritis (RA), underwent needle synovial biopsies of a knee joint within the first 6 weeks after onset of disease symptoms. Using antibodies to CD3, CD8, L26, CD68, and von Willebrand factor, a detailed quantitative immunohistochemical analysis was done. Results. CD3+ T lymphocytes, CD8+ T lymphocytes, L26+ B lymphocytes, and CD68+ macrophages were seen in 8/8 (100%), 7/8 (87%), 4/8 (50%), and 6/6 (100%) of synovial biopsies stained with the respective marker. There was a wide variation in number of positive cells between patients. CD3+ and CD8+ T cells were seen predominantly in perivascular areas, less often in a diffuse distribution, and not in aggregates. L26+ B lymphocytes were found in much smaller numbers compared with T lymphocytes. A mean of 67 vessels/mm(2) was noted. No lymphoid aggregates were seen. In all cases, infiltration of macrophages and lymphocytes was limited mainly to relatively superficial parts of synovium, i.e., within 1 to 2 high power fields of the surface. Conclusion. An absence of lymphoid aggregates or dramatic vascularity and a predominantly superficial infiltrate consisting mainly of perivascular T cell's with few B cells characterized our patients with very early RA of < 6 weeks' duration. Thus, there appear to be some potentially important differences from findings reported in well established disease. C1 Univ Minnesota, Div Rheumatol, Minneapolis, MN USA. Beebe Hosp, Lewes, DE USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Arthrit Res 151 K, Philadelphia, PA 19104 USA. RP Schumacher, HR (reprint author), Philadelphia VA Med Ctr, Arthrit Res 151 K, Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM schumacr@mail.med.upenn.edu OI singh, jasvinder/0000-0003-3485-0006 NR 24 TC 11 Z9 11 U1 0 U2 0 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD JUL PY 2004 VL 31 IS 7 BP 1281 EP 1285 PG 5 WC Rheumatology SC Rheumatology GA 835KK UT WOS:000222481600009 PM 15229944 ER PT J AU Gariti, P Alterman, AI Lynch, KG Kampman, K Whittingham, T AF Gariti, P Alterman, AI Lynch, KG Kampman, K Whittingham, T TI Adding a nicotine blocking agent to cigarette tapering SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article; Proceedings Paper CT 65th Annual Scientific Meeting of the College-on-Problems-of-Drug-Dependence CY JUN 14-19, 2003 CL Bal Harbour, FL SP Coll Problems Drug Dependence DE nicotine fading; cigarette tapering; Accu Drop; smoking cessation; motivational interviewing ID SMOKING CESSATION; PATCH THERAPY; RELIABILITY; WITHDRAWAL; ABSTINENCE; DEPENDENCE; VALIDITY AB A non-pharmacologic nicotine-blocking agent (Accu Drop; AD) was preliminarily tested in combination with cigarette tapering and brief counseling (C) in a random assignment, double-blind, placebo controlled, 6-week smoking cessation study (n=60). It was hypothesized that the AD&C group would have higher rates of treatment completion and smoking abstinence than the placebo drop group plus counseling (PD&C). The participants were 37 women and 23 men averaging 24 cigarettes per day along with high Fagerstrom nicotine dependence scores (FTQsimilar to7) and high plasma cotinine levels (>250ng/ml). There were no significant differences between groups for withdrawal scores, treatment completion (55%), or average number of sessions attended. Point prevalence followup evaluations were obtained 1 week, 1 month, and 6 months post projected treatment completion. Biochemically confirmed abstinence rates at followups did not differ between treatment groups (AD&C=10%, 13%, 10% vs. PD&C=3%, 10%, 13%). There is not enough evidence to suggest a Stage II trial. (C) 2004 Elsevier Inc. All rights reserved. C1 Univ Penn, Sch Med, Treatment Res Ctr, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. RP Gariti, P (reprint author), Univ Penn, Sch Med, Treatment Res Ctr, Philadelphia, PA 19104 USA. EM gariti_p@mail.trc.upenn.edu FU NIDA NIH HHS [DA 11645] NR 26 TC 1 Z9 1 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD JUL PY 2004 VL 27 IS 1 BP 17 EP 25 DI 10.1016/j.jsat.2004.03.005 PG 9 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 836AZ UT WOS:000222528400003 PM 15223089 ER PT J AU Chodosh, J Petitti, DB Elliott, M Hays, RD Crooks, VC Reuben, DB Buckwalter, JG Wenger, N AF Chodosh, J Petitti, DB Elliott, M Hays, RD Crooks, VC Reuben, DB Buckwalter, JG Wenger, N TI Physician recognition of cognitive impairment: Evaluating the need for improvement SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE dementia; cognitive impairment; physician behavior; documentation ID PRIMARY-CARE PHYSICIANS; MINI-MENTAL-STATE; PLACEBO-CONTROLLED TRIAL; ALZHEIMERS-DISEASE; DEMENTIA QUESTIONNAIRE; MEMORY IMPAIRMENT; US MULTICENTER; DISORDERS; DONEPEZIL; DIAGNOSIS AB OBJECTIVES: To assess physician recognition of dementia and cognitive impairment, compare recognition with documentation, and identify physician and patient factors associated with recognition. DESIGN: Survey of physicians and review of medical records. SETTING: Health maintenance organization in southern California. PARTICIPANTS: Seven hundred twenty-nine physicians who provided care for women participating in a cohort study of memory (Women's Memory Study). MEASUREMENTS: Percentage of patients with dementia or cognitive impairment (using the Telephone Interview of Cognitive Status supplemented by the Telephone Dementia Questionnaire) recognized by physicians. Relationship between physician recognition and patient characteristics and physician demographics, practice characteristics, training, knowledge, and attitudes about dementia. RESULTS Physicians (n=365) correctly identified 81% of patients with dementia and 44% of patients with cognitive impairment without definite dementia. Medical records documented cognitive impairment in 83% of patients with dementia and 26% of patients with cognitive impairment without definite dementia. In a multivariable model, physicians with geriatric credentials (defined as geriatric fellowship experience and/or the certificate of added qualifications) recognized cognitive impairment more often than did those without (risk ratio (RR)=1.56, 95% confidence interval (CI)=1.04-1.66). Physicians were more likely to recognize cognitive impairment in patients with a history of depression treatment (RR=1.3, 95% CI=1.03-1.45) or stroke (RR=1.37, 95% CI=1.04-1.45) and less likely to recognize impairment in patients with cognitive impairment without definite dementia than in those with dementia (RR=0.46, 95% CI=0.23-0.72) and in patients with a prior hospitalization for myocardial infarction (RR=0.37, 95% CI=0.09-0.88) or cancer (RR=0.49, 95% CI=0.18-0.90). CONCLUSION: Medical record documentation reflects physician recognition of dementia, yet physicians are aware of, but have not documented, many patients with milder cognitive impairment. Physicians are unaware of cognitive impairment in more than 40% of their cognitively impaired patients. Additional geriatrics training may promote recognition, but systems solutions are needed to improve recognition critical to provision of emerging therapies for early dementia. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RAND Hlth, Santa Monica, CA USA. So Calif Permanente Med Grp, Dept Res & Evaluat, Pasadena, CA USA. RP Chodosh, J (reprint author), Univ Calif Los Angeles Geriatr, 10945 Le Conte 2339, Los Angeles, CA 90095 USA. EM jchodosh@mednet.ucla.edu RI Hays, Ronald/D-5629-2013 OI Chodosh, Joshua/0000-0001-7784-4306 FU NIA NIH HHS [AG10415] NR 45 TC 116 Z9 117 U1 1 U2 4 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUL PY 2004 VL 52 IS 7 BP 1051 EP 1059 DI 10.1111/j.1532-5415.2004.52301.x PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 829SV UT WOS:000222070900002 PM 15209641 ER PT J AU Penrod, JD Boockvar, KS Litke, A Magaziner, J Hannan, EL Halm, EA Silberzweig, SB Sean Morrison, R Orosz, GM Koval, KJ Siu, AL AF Penrod, JD Boockvar, KS Litke, A Magaziner, J Hannan, EL Halm, EA Silberzweig, SB Sean Morrison, R Orosz, GM Koval, KJ Siu, AL TI Physical therapy and mobility 2 and 6 months after hip fracture SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE hip fractures; physical therapy; mobility; disability ID FUNCTIONAL INDEPENDENCE; MORTALITY; ADMISSION; OUTCOMES; PAIN; COMPLICATIONS; DELIRIUM; RECOVERY; SYSTEM; CARE AB OBJECTIVES: To examine the relationship between early physical therapy (PT), later therapy, and mobility 2 and 6 months after hip fracture. DESIGN: Prospective, multisite observational study. SETTING: Four hospitals in the New York City area. PARTICIPANTS: Four hundred forty-three hospitalized older patients discharged after surgery for hip fracture in 1997-98. MEASUREMENTS: Patient demographics, fracture type, comorbidities, dementia, number of new impairments at discharge, amount of PT between day of surgery and postoperative day (POD) 3, amount of therapy between POD4 and 8 weeks later, and prefracture, 2-, and 6-month mobility measured using the Functional Independence Measure. RESULTS: More PT immediately after hip fracture surgery was associated with significantly better locomotion 2 months later. Each additional session from the day of surgery through POD3 was associated with an increase of 0.4 points (P=.032) on the 14-point locomotion scale, but the positive relationship between early PT and mobility was attenuated by 6 months postfracture. There was no association between later therapy and 2- or 6-month mobility. CONCLUSION: PT immediately after hip fracture surgery is beneficial. The effects of later therapy on mobility were difficult to assess because of limitations of the data. Well-designed randomized, controlled trials of the effect of varying schedules and amounts of therapy on functional status after hip fracture would be informative. C1 Bronx Vet Affairs Med Ctr, Program Res Serious Phys & Mental Illness, New York, NY USA. Bronx Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, New York, NY USA. Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA. SUNY Albany, Sch Publ Hlth, Dept Hlth Policy Management & Behav, Rensselaer, NY USA. NYU, Sch Med, Dept Orthoped Surg, New York, NY USA. RP Penrod, JD (reprint author), CUNY Mt Sinai Sch Med, Brookdale Dept Geriatr, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM joan.penrod@mssm.edu OI Boockvar, Kenneth/0000-0003-1165-5558 FU AHRQ HHS [U18 HS009459, U18HS09459]; NIA NIH HHS [R01 AG021992, K24 AG000918] NR 29 TC 33 Z9 33 U1 1 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUL PY 2004 VL 52 IS 7 BP 1114 EP 1120 DI 10.1111/j.1532-5415.2004.52309.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 829SV UT WOS:000222070900010 PM 15209649 ER PT J AU Jensen, DM Machicado, GA Hirabayashi, K AF Jensen, DM Machicado, GA Hirabayashi, K TI Randomized double-blind studies of polysaccharide gel compared with glue and other agents for hemostasis of large veins and bleeding canine esophageal or gastric varices SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article; Proceedings Paper CT Symposium on Clinical Activity and Mode of Action of the Hemostatic Agent Poly-N-Acetyl Glucosamine CY FEB 25, 2003 CL Harvard, Boston, MA HO Harvard DE abdominal varices; venous collaterals; esophageal varices; gastric varices; hemostatic agents ID ENDOSCOPIC INJECTION; FUNDIC VARICES; SCLEROTHERAPY; N-BUTYL-2-CYANOACRYLATE; CLASSIFICATION; CYANOACRYLATE; BUCRYLATE; MODEL AB Background. The safety and efficacy of poly-N-acetyl glucosamine (p-GlcNAc) gels were compared with standard agents in three different dog studies to assess abdominal venous collaterals, bleeding esophageal varices, and bleeding gastric varices. Methods: Adult dogs with prehepatic portal hypertension and large abdominal venous collaterals, esophageal varices, or gastric varices were studied. Results: Significantly higher sclerosis rates were seen with F2 or F4 p-GlcNAc gels and standard sclerosants. F2 and F4 gels had high rates of permanent hemostasis, low rates of secondary ulceration, and significant reductions in esophageal and gastric variceal size. These results were either equivalent to or significantly better than the most commonly used gastric varix hemostatic agent (glue) or other sclerosing agents. Conclusion. F2 and F4 poly-N-acetyl glucosantine gels are promising therapeutic agents for venous and variceal hemostasis. C1 VA Greater Los Angles Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA USA. RP Jensen, DM (reprint author), VA Greater Los Angles Healthcare Syst, CURE Digest Dis Res Ctr, Bldg 115,Room 318,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM djensen@mednet.ucla.edu FU NIDDK NIH HHS [K24 DK02650] NR 21 TC 6 Z9 6 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD JUL PY 2004 VL 57 IS 1 SU S BP S33 EP S37 DI 10.1097/01.TA.0000136748.42934.AB PG 5 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 860YP UT WOS:000224380900009 PM 15280749 ER PT J AU Bazan, HA Schanzer, H AF Bazan, HA Schanzer, H TI Transposition of the brachial vein: A new source for autologous arteriovenous fistulas SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID UNITED-STATES; BASILIC VEIN; HEMODIALYSIS; GRAFTS AB Increasing the prevalence of arteriovenous fistula over arteriovenous synthetic graft is critical for decreasing the morbidity and costs of dialysis patients. This is highlighted in the guidelines set forth by The National Kidney Foundation-Dialysis Outcomes Quality Initiative (NKF-DOQI), which encourage the increased use of autogenous vein in fistula creation. In addition to the basilic and cephalic veins, another source of autogenous vein is the brachial vein, a deep vein of the upper arm. Here we describe 2 patients with absence of adequate superficial veins, in whom a transposed brachial vein was used for the creation of an arteriovenous fistula. C1 Mt Sinai Sch Med, Dept Surg, New York, NY 10028 USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. RP Bazan, HA (reprint author), Mt Sinai Sch Med, Dept Surg, Box 1259,1 Gustave L Levy Pl, New York, NY 10028 USA. EM hernan.bazan@mssm.edu RI Bazan, Hernan/D-4923-2011 NR 12 TC 28 Z9 30 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUL PY 2004 VL 40 IS 1 BP 184 EP 186 DI 10.1016/j.jvs.2004.03.044 PG 3 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 835YT UT WOS:000222522300032 PM 15218484 ER PT J AU Blutt, SE Crawford, SE Warfield, KL Lewis, DE Estes, MK Conner, ME AF Blutt, SE Crawford, SE Warfield, KL Lewis, DE Estes, MK Conner, ME TI The VP7 outer capsid protein of rotavirus induces polyclonal B-cell activation SO JOURNAL OF VIROLOGY LA English DT Article ID VESICULAR STOMATITIS-VIRUS; RESPIRATORY SYNCYTIAL VIRUS; MAMMARY-TUMOR VIRUS; MONOCLONAL-ANTIBODIES; INFLUENZA-VIRUS; IN-VIVO; T-CELLS; 3-DIMENSIONAL STRUCTURE; HETEROLOGOUS ROTAVIRUS; LIPOPOLYSACCHARIDE LPS AB The early response to a homologous rotavirus infection in mice includes a T-cell-independent increase in the number of activated B lymphocytes in the Peyer's patches. The mechanism of this activation has not been previously determined. Since rotavirus has a repetitively arranged triple-layered capsid and repetitively arranged antigens can induce activation of B cells, one or more of the capsid proteins could be responsible for the initial activation of B cells during infection. To address this question, we assessed the ability of rotavirus and virus-like particles to induce B-cell activation in vivo and in vitro. Using infectious rotavirus, inactivated rotavirus, noninfectious but replication-competent virus, and virus-like particles, we determined that neither infectivity nor RNA was necessary for B-cell activation but the presence of the rotavirus outer capsid protein, VP7, was sufficient for murine B-cell activation. Preincubation of the virus with neutralizing VP7 antibodies inhibited B-cell activation. Polymyxin B treatment and boiling of the virus preparation were performed, which ruled out possible lipopolysaccharide contamination as the source of activation and confirmed that the structural conformation of VP7 is important for B-cell activation. These findings indicate that the structure and conformation of the outer capsid protein, VP7, initiate intestinal B-cell activation during rotavirus infection. C1 Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Med Res Serv, Houston, TX 77030 USA. RP Conner, ME (reprint author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA. EM mconner@bcm.tmc.edu FU NIAID NIH HHS [R21 AI024998, R01 AI024998, AI24998, P30 AI036211, F32 AI010604, AI36211, AI10604]; NIDDK NIH HHS [DK56338, P30 DK056338] NR 62 TC 30 Z9 33 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JUL PY 2004 VL 78 IS 13 BP 6974 EP 6981 DI 10.1128/JVI.78.13.6974-6981.2004 PG 8 WC Virology SC Virology GA 830WC UT WOS:000222153800030 PM 15194774 ER PT J AU Mulky, A Sarafianos, SG Arnold, E Wu, XY Kappes, JC AF Mulky, A Sarafianos, SG Arnold, E Wu, XY Kappes, JC TI Subunit-specific analysis of the human immunodeficiency virus type 1 reverse transcriptase in vivo SO JOURNAL OF VIROLOGY LA English DT Article ID DNA-SYNTHESIS; MUTATIONAL ANALYSIS; POLYMERASE-ACTIVITY; PRECURSOR PROTEIN; CRYSTAL-STRUCTURE; HIV-1; MUTAGENESIS; DIMERIZATION; INHIBITOR; COMPLEX AB The human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is a heterodimer comprised of two structurally distinct subunits (p51 and p66). Since p51 and p66 are derived from the same coding region, subunit-specific structure-function studies of RT have been conducted exclusively by in vitro biochemical approaches. To study RT subunit function in the context of infectious virus, we constructed an LTR-vpr-p51IRES-p66 expression cassette in which the HIV-1 vpr gene was fused in frame with p51, followed by an internal ribosome entry site (IRES) sequence and the p66 coding region. By coexpression with RT-deficient proviral DNA, we demonstrated that the p66 subunit is specifically and selectively packaged into virions as a Vpr-p51/ p66 complex. Our analysis showed that cleavage by the viral protease liberates Vpr and generates functional heterodimeric RT (p51/p66) that supports HIV-1 reverse transcription and virus infection. By exploiting this novel trans-complementation approach, we demonstrated, for the first time with infectious virions, that the YMDD aspartates of p66 are both required and sufficient for RT polymerase function. Mutational analyses of the p51 YMDD aspartates indicated that they play an important structural role in p51 folding and subunit interactions that are required for the formation of an active RT heterodimer within infected cells. Understanding the role of the individual RT subunits in RNA- and DNA-dependent DNA synthesis is integral to our understanding of RT function. Our findings will lead to important new insights into the role of the p51 and p66 subunits in HIV-1 reverse transcription. C1 Univ Alabama, Dept Med, Birmingham, AL 35294 USA. Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA. Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA. Rutgers State Univ, Dept Chem, Piscataway, NJ 08854 USA. Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL 35233 USA. RP Kappes, JC (reprint author), Univ Alabama, Dept Med, LHRB 613,701 S 19th St, Birmingham, AL 35294 USA. EM kappesjc@uab.edu OI Sarafianos, Stefan G/0000-0002-5840-154X FU NCI NIH HHS [CA73470]; NIAID NIH HHS [R01 AI047714, P30 AI027767, AI47714, P30-AI-27767] NR 51 TC 19 Z9 21 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JUL PY 2004 VL 78 IS 13 BP 7089 EP 7096 DI 10.1128/JVI.78.13.7089-7096.2004 PG 8 WC Virology SC Virology GA 830WC UT WOS:000222153800041 PM 15194785 ER PT J AU Liu, J Wolfe, D Hao, SL Huang, SH Glorioso, JC Mata, M Fink, DJ AF Liu, J Wolfe, D Hao, SL Huang, SH Glorioso, JC Mata, M Fink, DJ TI Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain SO MOLECULAR THERAPY LA English DT Article DE gene therapy; spinal cord injury; neuropathic pain; HSV; GABA; GAD ID SUPERFICIAL DORSAL HORN; NEUROPATHIC PAIN; INTRATHECAL BACLOFEN; CENTRAL SENSITIZATION; EVOKED ALLODYNIA; NERVE INJURY; RAT; GABA; INHIBITION; MECHANISMS AB Neuropathic pain after spinal cord injury (SCI) represents a difficult problem that is commonly refractory to conventional medical management. To determine if spinal release of gamma-amino butyric acid (GABA) could reduce below-level central neuropathic pain after SCI, we constructed a replication-incompetent herpes simplex virus (HSV)-based vector encoding one isoform of human glutamic acid decarboxylase (GAD67). Dorsal root ganglion (DRG) neurons transduced in vitro or in vivo by subcutaneous inoculation produced GAD and released GABA constitutively. T13 spinal cord hemisection resulted in central neuropathic pain manifested by mechanical allodynia and thermal hyperalgesia. Subcutaneous inoculation of the vector into both feet reduced both manifestations of below-level SCI pain; the vector-mediated effect was partially reversed by intrathecal bicuculline or phaclofen at doses that did not affect thresholds in normal or injured uninoculated animals. Vector-mediated GABA release attenuated the increase in spinal calcitonin gene-related peptide immunoreactivity caused by cord hemisection. These results suggest that HSV-mediated gene transfer to DRG could be used to treat below-level central neuropathic pain after incomplete SCI. C1 Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA. GRECC, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA. Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA. Ann Arbor VA Med Ctr, Ann Arbor, MI 48109 USA. RP Fink, DJ (reprint author), Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. EM djfink@umich.edu NR 43 TC 92 Z9 102 U1 1 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-0016 J9 MOL THER JI Mol. Ther. PD JUL PY 2004 VL 10 IS 1 BP 57 EP 66 DI 10.1016/j.ymthe.2004.04.017 PG 10 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 843SF UT WOS:000223106100011 PM 15233942 ER PT J AU Puskovic, V Wolfe, D Goss, J Huang, SH Mata, M Glorios, JC Fink, DJ AF Puskovic, V Wolfe, D Goss, J Huang, SH Mata, M Glorios, JC Fink, DJ TI Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo SO MOLECULAR THERAPY LA English DT Article DE gene therapy; herpes simplex virus; latency; Parkinson disease; glial cell-derived neurotrophic factor; 6-hydroxydopamine; MPTP; rat; mouse ID HERPES-SIMPLEX-VIRUS; LATENCY-ASSOCIATED TRANSCRIPT; MEDIATED GENE-TRANSFER; CENTRAL-NERVOUS-SYSTEM; TYPE-1 LATENCY; PARKINSONS-DISEASE; FUNCTIONAL RECOVERY; TRIGEMINAL GANGLIA; STAIRCASE TEST; MESSENGER-RNA AB Herpes simplex virus (HSV) naturally establishes a life-long latent state in neurons, characterized by the expression of latency-associated transcripts (LATs) in the absence of viral lytic functions, and the latency-associated promoter (LAP2) has been identified as a moveable element responsible for the expression of LATs from latent HSV genomes. Prolonged transgene expression will be required for the treatment of chronic diseases of the CNS using HSV vectors. We therefore examined the ability of LAP2 to drive prolonged expression of a biologically active transgene from latent HSV vector genomes in brain in vivo using the 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) models of Parkinson disease. A replication-incompetent HSV vector containing the glial cell-derived neurotrophic factor (GDNF) under the control of LAP2 was injected into the substantia nigra and 5 and a half months later 6-OHDA was injected into the striatum. GDNF expression from the vector preserved dopaminergic function measured by histology and behavior 6 months after vector inoculation. Mice inoculated with the LAP2-GDNF replication-incompetent HSV vector followed by 3 months of daily low-dose MPTP injections were substantially protected against the consequences of that treatment measured by weekly behavioral testing and histologic measures at the conclusion of the experiment. These studies using subacute and chronic models of neurodegeneration demonstrate that the HSV LAP2 promoter element provides prolonged expression of relevant amounts of a transgene to produce significant biological effects in brain in vivo over the course of many months. C1 Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA. Ann Arbor VA Healthcare Syst, Ann Arbor, MI 48109 USA. RP Fink, DJ (reprint author), Taubman Ctr, MD1914,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA. EM djfink@umich.edu NR 53 TC 33 Z9 36 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-0016 J9 MOL THER JI Mol. Ther. PD JUL PY 2004 VL 10 IS 1 BP 67 EP 75 DI 10.1016/j.ymthe.2004.04.004 PG 9 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 843SF UT WOS:000223106100012 PM 15233943 ER PT J AU Breitner, JCS Zandi, PP Li, G Rea, TD Psaty, BM AF Breitner, JCS Zandi, PP Li, G Rea, TD Psaty, BM TI Can statins prevent AD, or are they just prescribed less often to those with cognitive disorders? SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 GRECC, VA Puget Sound HCS, Seattle, WA USA. Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. Univ Washington, Seattle, WA 98195 USA. EM jcsb@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S5 EP S5 DI 10.1016/S0197-4580(04)80016-2 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058700017 ER PT J AU Duda, JE Moberg, PJ Balderston, C Roalf, DR Doty, RL Stern, MB AF Duda, JE Moberg, PJ Balderston, C Roalf, DR Doty, RL Stern, MB TI Meta-analysis of olfactory dysfunction in Alzheimer's, Parkinson's and Huntington's Diseases SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Penn, Philadelphia, PA 19104 USA. EM john.duda@med.va.gov RI Doty, Richard/B-7623-2012; Doty, Richard/G-1602-2013 NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S95 EP S95 DI 10.1016/S0197-4580(04)80320-8 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058700318 ER PT J AU Hale, C Baker, LD Reger, M Rhoads, K Cholerton, B Watson, GS Craft, S AF Hale, C Baker, LD Reger, M Rhoads, K Cholerton, B Watson, GS Craft, S TI Agraphic changes in mild cognitive impairment SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 Univ Puget Sound, Tacoma, WA 98416 USA. Univ Washington, Seattle, WA 98195 USA. GRECC, VA Puget Sound HCS, Seattle, WA USA. EM hale@ups.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S338 EP S338 DI 10.1016/S0197-4580(04)81112-6 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058701110 ER PT J AU Hayden, KM Norton, MC Tschanz, JT Zandi, PP Lyketsos, CG Khachaturian, AS Pieper, CF Welsh-Bohmer, KA Breitner, JC AF Hayden, KM Norton, MC Tschanz, JT Zandi, PP Lyketsos, CG Khachaturian, AS Pieper, CF Welsh-Bohmer, KA Breitner, JC TI The complex role of cardiovascular risk factors, cerebrovascular disease, and gender, with the incidence of Alzheimer's disease: Findings from the Cache County Study SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 Duke Univ, Med Ctr, Ctr Study Aging, Durham, NC 27706 USA. Utah State Univ, Dept Family Consumer & Hlth Dev, Logan, UT 84322 USA. Utah State Univ, Ctr Epidemiol Studies, Logan, UT 84322 USA. Utah State Univ, Dept Psychol, Logan, UT 84322 USA. Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD USA. Khachaturian & Associates Inc, Potomac, MD USA. Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27706 USA. Duke Univ, Med Ctr, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC 27706 USA. Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. EM khayden@duke.edu RI Norton, Maria/E-6994-2013; Hayden, Kathleen/B-6442-2012 OI Hayden, Kathleen/0000-0002-7745-3513 NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S388 EP S388 DI 10.1016/S0197-4580(04)81268-5 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058701266 ER PT J AU Hirschman, KB James, BD Joyce, CM Karlawish, JH Casarett, D AF Hirschman, KB James, BD Joyce, CM Karlawish, JH Casarett, D TI Do Alzheimer's disease patients want to participate in an AD treatment decision and will their family let them? SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 Univ Penn, Dept Sociol, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equit Res & Promot, Philadelphia, PA USA. Ctr Bioeth, Dept Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA USA. EM hirschk@mail.med.upenn.edu NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S21 EP S22 DI 10.1016/S0197-4580(04)80070-8 PG 2 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058700071 ER PT J AU Johnson, SC Schmitz, TW Kawahara-Baccus, TN Jahn, NM Gleason, CE Carlsson, CM Sager, MA Rowley, HA Moritz, CH Meyerand, EM Asthana, S AF Johnson, SC Schmitz, TW Kawahara-Baccus, TN Jahn, NM Gleason, CE Carlsson, CM Sager, MA Rowley, HA Moritz, CH Meyerand, EM Asthana, S TI MCI patients with better RAVLt learning performance have greater FMRI activation in the anterior hippocampus during an encoding task SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. Univ Wisconsin, Madison, WI 53706 USA. EM scj@medicine.wisc.edu NR 0 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S275 EP S275 DI 10.1016/S0197-4580(04)80918-7 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058700916 ER PT J AU Khachaturian, AS Zandi, PP Hayden, KM Lyketsos, CG Mayer, LS Skoog, I Tschanz, JT Norton, MC Welsh-Bohmer, KA Breitner, JCS AF Khachaturian, AS Zandi, PP Hayden, KM Lyketsos, CG Mayer, LS Skoog, I Tschanz, JT Norton, MC Welsh-Bohmer, KA Breitner, JCS TI Anti-hypertensive medication use may reduce risk of incident Alzheimer's disease. The cache county study SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 Khachaturian & Associates Inc, Potomac, MD USA. Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. Duke Univ, Med Ctr, Ctr Study Aging & Human Dev, Durham, NC USA. Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA. Univ Gothenburg, Inst Clin Neurosci, Unit Neuropsychiat Epidemiol, Gothenburg, Sweden. Utah State Univ, Dept Psychol, Logan, UT 84322 USA. Utah State Univ, Ctr Epidemiol Studies, Logan, UT 84322 USA. Utah State Univ, Dept Family Consumer & Human Dev, Logan, UT 84322 USA. Utah State Univ, Ctr Epidemiol Studies, Logan, UT 84322 USA. Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. Duke Univ, Med Ctr, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC USA. Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RI Norton, Maria/E-6994-2013; Hayden, Kathleen/B-6442-2012 OI Hayden, Kathleen/0000-0002-7745-3513 NR 0 TC 1 Z9 1 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S53 EP S53 DI 10.1016/S0197-4580(04)80181-7 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058700181 ER PT J AU Kuller, LH Lopez, OL Jagust, WJ Becker, JT DeKosky, ST Lyketsos, C Kawas, C Breitner, JCS Fitzpatrick, A Dulberg, B AF Kuller, LH Lopez, OL Jagust, WJ Becker, JT DeKosky, ST Lyketsos, C Kawas, C Breitner, JCS Fitzpatrick, A Dulberg, B TI Clinical and MRI factors for vascular dementia in the Cardiovascular Health Study Cognition Study SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA. Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA. Univ Pittsburgh, Dept Neurol & Psychiat, Pittsburgh, PA 15260 USA. Johns Hopkins Univ, Div Geriatr Psychiat & Neuropsychiat, Baltimore, MD 21218 USA. Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA. VA Puget Sound Hlth Care Syst, Div Geriatr Psychiat Psychiat & Behav Sci, Seattle, WA USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. EM kullerl@edc.pitt.edu NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S483 EP S484 DI 10.1016/S0197-4580(04)81597-5 PG 2 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058701594 ER PT J AU Kulstad, J Green, PS Cook, DG Watson, GS Reger, M Cholerton, B Baker, LD Plymate, SR Asthana, S Fishel, M Kahn, SE Craft, S AF Kulstad, J Green, PS Cook, DG Watson, GS Reger, M Cholerton, B Baker, LD Plymate, SR Asthana, S Fishel, M Kahn, SE Craft, S TI Effects of rosiglitazone treatment on serum amyloid-beta 1-40 and 1-42 in patients with early Alzheimer's disease SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 Univ Washington, Seattle, WA 98195 USA. VA Med Ctr, Seattle, WA USA. Univ Wisconsin, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. EM jkulstad@u.washington.edu NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S354 EP S355 DI 10.1016/S0197-4580(04)81167-9 PG 2 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058701165 ER PT J AU Li, GG Kukull, WA Peskind, E Moore, KV Higdon, R Tsuang, D van Belle, G McCormick, W Bowen, JD Teri, L Schellenberg, GD Larson, EB AF Li, GG Kukull, WA Peskind, E Moore, KV Higdon, R Tsuang, D van Belle, G McCormick, W Bowen, JD Teri, L Schellenberg, GD Larson, EB TI Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 Univ Washington, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Grp Hlth Cooperat Puget Sound, Seattle, WA 98121 USA. EM gli@u.washington.edu NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S388 EP S389 DI 10.1016/S0197-4580(04)81269-7 PG 2 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058701267 ER PT J AU Li, GG Cherrier, M Tsuang, D Petrie, E Colasurdo, EPE Charles, WW Peskind, E Raskind, M AF Li, GG Cherrier, M Tsuang, D Petrie, E Colasurdo, EPE Charles, WW Peskind, E Raskind, M TI Salivary cortisol associated with cognitive decline in normal elderly SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. EM gli@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S357 EP S357 DI 10.1016/S0197-4580(04)81177-1 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058701175 ER EF